PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Javitch, JA; Fu, DY; Liapakis, G; Chen, JY				Javitch, JA; Fu, DY; Liapakis, G; Chen, JY			Constitutive activation of the beta(2) adrenergic receptor alters the orientation of its sixth membrane-spanning segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; TRANSMEMBRANE HELICES; PROLINE RESIDUES; BINDING; CHANNEL; RHODOPSIN; CYSTEINES; DOMAIN	The binding site of the beta(2) adrenergic receptor, like that of other homologous G-protein-coupled receptors, is contained within a water-accessible crevice formed among its seven membrane spanning segments. Methanethiosulfonate ethylammonium (MTSEA), a charged, hydrophilic, lipophobic, sulfhydryl-specific reagent, had no effect on the binding of agonist or antagonist to wild type beta(2) receptor expressed in HEK 293 cells. This suggested that no endogenous cysteines are accessible in the binding site crevice. In contrast, in a constitutively active beta(2) receptor, MTSEA significantly inhibited antagonist binding, and isoproterenol slowed the rate of reaction of MTSEA. This implies that at least one endogenous cysteine becomes accessible in the binding site crevice of the constitutively active beta(2) receptor, Cys-285, in the sixth membrane-spanning segment, is responsible for the inhibitory effect of MTSEA on ligand binding to the constitutively active mutant. The acquired accessibility of Cys-285 in the constitutively active mutant may result from a rotation and/or tilting of the sixth membrane-spanning segment associated with activation of the receptor. This rearrangement could bring Cys-285 to the margin of the binding site crevice where it becomes accessible to MTSEA.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032	Columbia University; Columbia University; New York State Psychiatry Institute	Javitch, JA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR MOL RECOGNIT,P&S 11-401,630 W 168TH ST,NEW YORK,NY 10032, USA.			Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER; NIMH NIH HHS [MH54137, MH01030] Funding Source: Medline; NINDS NIH HHS [NS07258] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; DEMPSEY CE, 1991, FEBS LETT, V281, P240, DOI 10.1016/0014-5793(91)80402-O; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; Javitch JA, 1996, MOL PHARMACOL, V49, P692; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P1035; KARLE IL, 1991, P NATL ACAD SCI USA, V88, P5307, DOI 10.1073/pnas.88.12.5307; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; LUO XC, 1994, PROTEIN ENG, V7, P1441, DOI 10.1093/protein/7.12.1441; OPRIAN DD, 1992, J BIOENERG BIOMEMBR, V24, P211, DOI 10.1007/BF00762679; Rees S, 1996, BIOTECHNIQUES, V20, P102; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021	27	184	186	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18546	18549		10.1074/jbc.272.30.18546	http://dx.doi.org/10.1074/jbc.272.30.18546			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228019	hybrid			2022-12-25	WOS:A1997XM34200010
J	Olive, M; Krylov, D; Echlin, DR; Gardner, K; Taparowsky, E; Vinson, C				Olive, M; Krylov, D; Echlin, DR; Gardner, K; Taparowsky, E; Vinson, C			A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; C-JUN; DIMERIZATION SPECIFICITY; INDUCED TRANSFORMATION; COILED COILS; GENE FAMILY; T-CELLS; FOS; TRANSCRIPTION; GROWTH	We describe a dominant negative (DN) to activation protein-1 (AP1) that inhibits DNA binding in an equimolar competition, AP1 is a heterodimer of the oncogenes Fos and Jun, members of the bZIP family of transcription factors. The DN, termed A-Fos, consists of a newly designed acidic amphipathic protein sequence appended onto the N-terminus of the Fos leucine zipper, replacing the normal basic region critical for DNA binding. The acidic extension and the Jun basic region form a heterodimeric coiled coil structure that stabilizes the complex over 3000-fold and prevents the basic region of Jun from binding to DNA. Gel shift assays indicate that A Fos can inactivate the DNA binding of a Fos:Jun heterodimer in an equimolar competition. Transient transfection assays indicate that A-Pos inhibits Jun-dependent transactivation. Both the acidic extension and the Fos leucine zipper are critical for this inhibition. Expression of A-Fos in mouse fibroblasts inhibits focus formation more than colony formation, reflecting the ability of A-Fos to interfere with the AP1 biological functions in mammalian cells. This reagent is more potent than a deletion of either the Fos or Jun transactivation domain, which has been used previously as a dominant negative to AP1 activity.	NCI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA; NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Purdue University System; Purdue University; Purdue University West Lafayette Campus								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GARDNER K, 1994, J BIOL CHEM, V269, P32963; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Olive M, 1996, J BIOL CHEM, V271, P2040, DOI 10.1074/jbc.271.4.2040; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WICK M, 1992, ONCOGENE, V7, P859; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	49	236	241	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18586	18594		10.1074/jbc.272.30.18586	http://dx.doi.org/10.1074/jbc.272.30.18586			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228025	hybrid			2022-12-25	WOS:A1997XM34200016
J	Sekine, T; Watanabe, N; Hosoyamada, M; Kanai, Y; Endou, H				Sekine, T; Watanabe, N; Hosoyamada, M; Kanai, Y; Endou, H			Expression cloning and characterization of a novel multispecific organic anion transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; PROTEIN; SECRETION; TUBULE	Numerous drugs and endogenous compounds are efficiently excreted from the renal proximal tubule via carrier-mediated pathways. Transepithelial excretion of organic anions occurs via their accumulative transport from the blood into the proximal tubule cells across the basolateral membrane and subsequent secretion into the urine through the apical membrane. Here we report on the isolation of a novel complementary DNA from rat kidney that encodes a 551-amino acid residue protein (OAT1) with 12 putative membrane-spanning domains. When expressed in Xenopus laevis oocytes, OAT1 mediated sodium-independent para-aminohippurate (PAH) uptake (K-m = 14.3 +/- 2.9 mu M). The uptake rate of PAH was increased by the outwardly directed dicarboxylate gradient, consisting with the idea that OAT1 is an organic anion/dicarboxylate exchanger, OAT1 displayed remarkably wide substrate selectivity, covering endogenous substrates such as cyclic nucleotides, a prostaglandin and uric acid, and a variety of drugs with different structures (e.g. antibiotics, a nonsteroidal antiinflammatory drug, diuretics, an antineoplastic drug, and a uricosuric drug). The Northern blot analysis and in situ hybridization revealed that OAT1 is exclusively expressed in the particular segment of the proximal tubule in the kidney. These data suggest that OAT1 is a multispecific organic anion transporter at the basolateral membrane of the proximal tubule. Isolation of OAT1 will facilitate elucidation of the molecular basis of drug kinetics and the development of new drugs lacking unwanted side effects.	KYORIN UNIV,SCH MED,DEPT PHARMACOL & TOXICOL,MITAKA,TOKYO 181,JAPAN	Kyorin University								Adkison KDK, 1996, J PHARMACOL EXP THER, V276, P1189; BOELSTERLI UA, 1995, AM J PHYSIOL-GASTR L, V268, pG797, DOI 10.1152/ajpgi.1995.268.5.G797; Bossuyt X, 1996, J PHARMACOL EXP THER, V276, P891; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Horz JA, 1996, BBA-LIPID LIPID MET, V1300, P114, DOI 10.1016/0005-2760(95)00239-1; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; Moller J. V., 1983, PHARMACOL REV, V34, P315; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PETZINGER E, 1994, REV PHYSIOL BIOCH P, V123, P47, DOI 10.1007/BFb0030903; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SIMONSON GD, 1994, J CELL SCI, V107, P1065; ULLRICH KJ, 1988, AM J PHYSIOL, V254, pF453, DOI 10.1152/ajprenal.1988.254.4.F453; WALKER RJ, 1992, KIDNEY PHYSL PATHOPH, P3571; WEINMAN SA, 1994, HEPATOLOGY, V20, P1642, DOI 10.1002/hep.1840200641; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	25	524	552	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18526	18529		10.1074/jbc.272.30.18526	http://dx.doi.org/10.1074/jbc.272.30.18526			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228014	hybrid			2022-12-25	WOS:A1997XM34200005
J	Paire, A; BernierValentin, F; SelmiRuby, S; Rousset, B				Paire, A; BernierValentin, F; SelmiRuby, S; Rousset, B			Characterization of the rat thyroid iodide transporter using anti-peptide antibodies - Relationship between its expression and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING HORMONE; CELLS; CULTURE	Anti-peptide antibodies directed against the C-terminal portion (amino acids 603-618) of the rat thyroid iodide transporter (rTIT) have been produced to characterize the molecular forms of rTIT in the rat thyroid and in the functional rat thyroid cell line, FRTL-5. rTIT is located on the basolateral membrane of rat thyroid follicular cells and randomly distributed on the plasma membrane of FRTL-5 cells that do not exhibit cell polarity, The major rTIT component corresponds to an 80-90kDa glycosylated protein, After treatment of cell membrane fractions with N-glycosidase F or incubation of FRTL-5 cells with tunicamycin, rTIT has an apparent molecular mass of about 55 kDa, FRTL-5 cells cultured in the presence of TSH exhibit a high rTIT content and a high iodide uptake activity (IUA), Upon either removal of TSH or addition of cycloheximide, IUA declines more rapidly than rTIT. The half-life of rTIT was about 4 days, Re-exposure of 7-day TSH-deprived FRTL-5 cells to TSH causes a rapid synthesis of the glycosylated rTIT but a delayed re-induction of IUA, Tunicamycin totally prevents the TSH-dependent re-expression and activity of rTIT, Our data bring basic information on the location, structure, and turnover of rTIT and suggest that its activity is subjected to diverse control mechanisms including regulatory proteins.	FAC MED LYON, RTH LAENNEC, INSERM, U369, F-69372 LYON 08, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			selmi-ruby, Samia/L-3509-2016; RUBY, Samia/T-1131-2019	RUBY, Samia/0000-0001-9491-9285				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; CHAMBARD M, 1983, J CELL BIOL, V96, P1172, DOI 10.1083/jcb.96.4.1172; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; EKHOLM R, 1990, INT REV CYTOL, V120, P243; Endo T, 1996, BIOCHEM BIOPH RES CO, V224, P92, DOI 10.1006/bbrc.1996.0989; Endo T, 1996, BIOCHEM BIOPH RES CO, V228, P199, DOI 10.1006/bbrc.1996.1639; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; KNOPP J, 1970, J BIOL CHEM, V245, P4403; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCOCCI C, 1984, ENDOCRINOLOGY, V115, P2123, DOI 10.1210/endo-115-6-2123; Rajas F, 1996, J BIOL CHEM, V271, P29882, DOI 10.1074/jbc.271.47.29882; Weber K., 1975, PROTEINS, VI, P179; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090; WOLFF J, 1964, PHYSIOL REV, V44, P45, DOI 10.1152/physrev.1964.44.1.45	16	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18245	18249		10.1074/jbc.272.29.18245	http://dx.doi.org/10.1074/jbc.272.29.18245			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218462	hybrid			2022-12-25	WOS:A1997XL73500052
J	Qian, XB; Balestra, ME; Innerarity, TL				Qian, XB; Balestra, ME; Innerarity, TL			Two distinct TATA-less promoters direct tissue-specific expression of the rat apo-B editing catalytic polypeptide 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTOR; APOLIPOPROTEIN-B; RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; BINDING PROTEIN; LIVER; COMPLEMENTATION; LOCALIZATION; MODULATION; SECRETION	The species and tissue specificity of apolipoprotein (ape) B mRNA editing is determined by the expression of apoB editing catalytic polypeptide 1 (APOBEC-1), the cytidine deaminase that catalyzes apoB mRNA editing. To understand the molecular mechanisms that regulate the transcription of APOBEC-1, we characterized Fat APOBEC-1 cDNA and genomic DNA. cDNA cloning and RNase protection analysis showed two alternative promoters for the tissue-specific expression of APBBEC-1. in the liver and intestine, P-liv and P-int. Both promoters lack a TATA box, and P-int belongs to the MED-1 class of promoters, which initiate transcription at multiple sites. We also identified two allelic forms of the APOBEC-1 gene from the characterization of two rat APOBEC-1 P1 genomic clones, RE4 and RE5. The RE4 allele is 18 Kilobases long and contains six exons and five introns, whereas the RE5 allele contains an additional similar to 8 Kilobases of intron sequences and an extra exon encoding a 5'-untranslated region; however, the APOBEC-1. transcripts from the two alleles appear to have similar, If not identical, functions, Transgenic mouse studies showed that P-liv was preferentially used in the liver, kidney, brain, and adipose tissues, whereas P-int was preferentially used in the small intestine, stomach, and lung. Our results suggest that the tissue-specific expression of APOBEC-1 is governed by multiple regulatory elements exerting control over at single coding sequence, The presence car absence of these regulatory elements may determine the tissue-specific expression of APOBEC-1 in other mammalian species.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco	Qian, XB (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,POB 419100,SAN FRANCISCO,CA 94141, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUM CL, 1990, J BIOL CHEM, V265, P19263; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FUNAHASHI T, 1995, J LIPID RES, V36, P414; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GIANNONI F, 1995, J LIPID RES, V36, P1664; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; INNERARITY TL, 1990, J LIPID RES, V31, P1337; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; INUI Y, 1994, J LIPID RES, V35, P1477; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THORNGATE FE, 1994, P NATL ACAD SCI USA, V91, P5392, DOI 10.1073/pnas.91.12.5392; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483	33	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18060	18070		10.1074/jbc.272.29.18060	http://dx.doi.org/10.1074/jbc.272.29.18060			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218436	hybrid			2022-12-25	WOS:A1997XL73500026
J	Read, RD; Lionberger, JM; Smithgall, TE				Read, RD; Lionberger, JM; Smithgall, TE			Oligomerization of the Fes tyrosine kinase - Evidence for a coiled-coil domain in the unique N-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID DIFFERENTIATION; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; LEUKEMIA-CELLS; GROWTH-FACTORS; PROTEIN; BCR; EXPRESSION; ABL; RECEPTOR	The c-fes proto-oncogene encodes a non-receptor tyrosine kinase (Fes) that has been implicated in cytokine receptor signal transduction and myeloid differentiation. Previous work from our laboratory has shown that Fes autophosphorylates via an intermolecular mechanism more commonly associated with growth factor receptor tyrosine kinases. Analysis of the Fes amino acid sequence with the COILS algorithm indicates that the N-terminal region of the protein has a very high probability of forming coiled-coil structures often associated with oligomeric proteins. These findings suggest that oligomerization may be a prerequisite for trans-auto-phosphorylation and activation of Fes. To establish whether the active form of Fes is oligomeric, we performed gel-filtration experiments with recombinant Fes and found that it eluted as a single symmetrical peak of approximately 500 kDa. No evidence of the monomeric, 93-kDa form of the protein was observed. Deletion of the unique N-terminal domain (amino acids 1-450, including the coiled-coil homology region) completely abolished the formation of oligomers. Furthermore, co-precipitation assays demonstrated that an immobilized glutathione S-transferase fusion protein containing the Fes N-terminal region bound to full-length Fes but not to a mutant lacking the N-terminal region. Similarly, a recombinant Fes N-terminal domain protein was readily cross-linked in vitro, whereas the SH2 and kinase domains were refractory to cross-linking. Incubation of wild-type Fes with a kinase-inactive Fes mutant or with the isolated N-terminal region suppressed Fes autophosphorylation in vitro, suggesting that oligomerization may be essential for autophosphorylation of full-length Fes. The presence of an oligomerization function iu the Fes family of tyrosine kinases suggests a novel mechanism for non-receptor protein-tyrosine kinase regulation.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [P30 CA36727, CA58667] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA058667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; CARE A, 1994, ONCOGENE, V9, P739; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FANG F, 1993, BIOCHEMISTRY-US, V32, P6995, DOI 10.1021/bi00078a026; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KIM L, 1995, MOL CELL BIOL, V15, P4553; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1989, ONCOGENE, V4, P759; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1992, CANCER SURV, V15, P37; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; YU G, 1989, J BIOL CHEM, V264, P10276; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	40	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18498	18503		10.1074/jbc.272.29.18498	http://dx.doi.org/10.1074/jbc.272.29.18498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218495	hybrid			2022-12-25	WOS:A1997XL73500085
J	Ma, ZM; Landt, M; Bohrer, A; Ramanadham, S; Kipnis, DM; Turk, J				Ma, ZM; Landt, M; Bohrer, A; Ramanadham, S; Kipnis, DM; Turk, J			Interleukin-1 reduces the glycolytic utilization of glucose by pancreatic islets and reduces glucokinase mRNA content and protein synthesis by a nitric oxide-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; BETA-CELLS; INSULIN-SECRETION; MESSENGER-RNA; OXIDATIVE-METABOLISM; RAT PANCREAS; LANGERHANS; GENE; RELEASE; EXPRESSION	Culture of rat pancreatic islets with interleukin-l (IL-1) results in up-regulation of the inducible isoform of nitric oxide synthase and overproduction of nitric oxide (NO), This is associated with reversible inhibition of both glucose-induced insulin secretion and islet glucose oxidation, and these effects are prevented by the inducible nitric oxide synthase inhibitor N-G-monomethylarginine. IL-1 also induces accumulation of nonesterified arachidonic acid in islets by an NO dependent mechanism, and one potential explanation for that effect would involve an IL-l-induced enhancement of islet glycolytic flux. We have therefore examined effects of IL-1 on islet glycolytic utilization of glucose and find that culture of islets with IL-1 in medium containing 5.5 mM glucose results in suppression of islet glucose utilization subsequently measured at glucose concentrations between 6 and 18 mM. The IL-1-induced suppression of islet glucose utilization is associated with a decline in islet glucokinase mRNA content, as determined by competitive reverse transcriptase polymerase chain reaction, and in glucokinase protein synthesis, as determined by immuoprecipitation experiments, and all of these effects are prevented by N-G-monomethylarginine. These findings suggest that IL-1 can down-regulate islet glucokinase, which is the primary component of the islet glucose-sensor apparatus, by an NO-dependent mechanism, Because reductions in islet glucokinase levels are known to cause a form of type II diabetes mellitus, these observations raise the possibility that factors which increase islet NO levels might contribute to development of glucose intolerance.	WASHINGTON UNIV, SCH MED,DEPT MED,MASS SPECTROMETRY RESOURCE, DIV ENDOCRINOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV DIABET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV METAB, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV LAB MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [R37-DK-34388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BEDOYA FJ, 1986, DIABETES, V35, P61, DOI 10.2337/diabetes.35.1.61; BEDOYA FJ, 1986, J BIOL CHEM, V261, P760; BEGGS M, 1990, FEBS LETT, V267, P217, DOI 10.1016/0014-5793(90)80928-C; COMENS PG, 1987, DIABETES, V36, P963, DOI 10.2337/diabetes.36.8.963; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; DAVIS L, 1994, BASIC METHODS MOL BI, P669; Davis LG, 1994, BASIC METHODS MOL BI; DELANEY CA, 1993, FEBS LETT, V333, P291, DOI 10.1016/0014-5793(93)80673-I; EIZIRIK DL, 1988, ACTA ENDOCRINOL-COP, V119, P321, DOI 10.1530/acta.0.1190321; EIZIRIK DL, 1988, ENDOCRINOLOGY, V123, P1001, DOI 10.1210/endo-123-2-1001; EIZIRIK DL, 1989, ENDOCRINOLOGY, V125, P752, DOI 10.1210/endo-125-2-752; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GENG YJ, 1994, BBA-GENE STRUCT EXPR, V1218, P421, DOI 10.1016/0167-4781(94)90196-1; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HAKAN LA, 1979, BIOCHEM J, V182, P797; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; HUGHES JH, 1990, J CLIN INVEST, V86, P856, DOI 10.1172/JCI114785; HUGHES JH, 1989, DIABETES, V38, P1251, DOI 10.2337/diabetes.38.10.1251; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KORANYI LI, 1991, DIABETES, V40, P401, DOI 10.2337/diabetes.40.3.401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG Y, 1990, J BIOL CHEM, V265, P16863; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MALAISSE WJ, 1976, ACTA DIABETOL LAT, V13, P202, DOI 10.1007/BF02581118; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MCDANIEL ML, 1988, DIABETES, V37, P1311, DOI 10.2337/diabetes.37.10.1311; MCDANIEL ML, 1974, DIABETOLOGIA, V10, P303; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MONCADA S, 1991, PHARMACOL REV, V43, P109; PACE CS, 1975, DIABETES, V24, P476, DOI 10.2337/diabetes.24.5.476; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILKIS SJ, 1994, J BIOL CHEM, V269, P21925; RABINOVITCH A, 1993, DIABETES REV, V1, P215; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; SANDLER S, 1989, ENDOCRINOLOGY, V124, P1492, DOI 10.1210/endo-124-3-1492; SANDLER S, 1987, ENDOCRINOLOGY, V121, P1424, DOI 10.1210/endo-121-4-1424; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; SHIMA K, 1987, HORM METAB RES, V19, P395, DOI 10.1055/s-2007-1011835; SHIMIZU T, 1988, DIABETES, V37, P1524, DOI 10.2337/diabetes.37.11.1524; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN F, 1993, J CLIN INVEST, V92, P1174, DOI 10.1172/JCI116687; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; TAKEDA J, 1993, J BIOL CHEM, V268, P15200; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WEIR GC, 1993, NEW ENGL J MED, V328, P729, DOI 10.1056/NEJM199303113281012; WELSH N, 1991, DIABETES, V40, P290, DOI 10.2337/diabetes.40.2.290; YIN L, 1992, DIABETES, V41, P792; ZAWALICH WS, 1979, DIABETOLOGIA, V16, P115, DOI 10.1007/BF01225460; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1	75	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17827	17835		10.1074/jbc.272.28.17827	http://dx.doi.org/10.1074/jbc.272.28.17827			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211938	hybrid			2022-12-25	WOS:A1997XK16500081
J	Malaney, S; Trumpower, BL; Deber, CM; Robinson, BH				Malaney, S; Trumpower, BL; Deber, CM; Robinson, BH			The N terminus of the Qcr7 protein of the cytochrome bc(1) complex is not essential for import into mitochondria in Saccharomyces cerevisiae but is essential for assembly of the complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C REDUCTASE COMPLEX; ELECTRON-TRANSFER; 14-KDA SUBUNIT; POLYPEPTIDE SUBUNITS; RESPIRATORY-CHAIN; UBIQUINOL; YEAST; GENE; OXIDOREDUCTASE; SEQUENCE	Subunit 7 of the yeast cytochrome be, complex is encoded by the nuclear QCR7 gene and is essential for respiration, This protein does not contain a cleavable N-terminal mitochondrial targeting sequence, and it is not understood how the Qcr7 protein is imported into mitochondria and assembled into the compiler, To test the role of the N terminus of the Qcr7 protein in mitochondrial import, assembly of the complex, and proton translocation, we inactivated the endogenous QCR7 gene and expressed mutated qcr7 genes capable of synthesizing proteins truncated by 7, 10, 14, and 20 residues (Qcr7p-Delta 7, Qcr7p-Delta 10, Qcr7p-Delta 14, and Qcr7p-Delta 20, respectively) from the N terminus. In addition, we studied two mutants containing Qcr7 proteins with point mutations in addition to a Delta 7 truncation, Qcr7p-Delta 7(D13V) and Qcr7p-Delta 7(R10K). All the mutant proteins with the exception of Qcr7p-Delta 10 were present in the mitochondria at 30 degrees C, although most at lower steady-state levels than the Qcr7p from the strain overexpressing wild type QCR7, The absence of the Qcr7p-Delta 10 may be the result of an unstable protein or a decrease in the efficiency of mitochondrial import due to its compromised amphipathic a-helix and the presence of a negative charge exposed at the N terminus, Cytochrome c reductase activities and the amounts of ATP synthesized were comparable with the wild type in the strain expressing Qcr7p-Delta 7. The strain expressing Qcr7p-Delta 7(R10K) had an identical phenotype to the one containing the Qcr7p-Delta 7, whereas strains expressing the Qcr7p-Delta 10, Qcr7p-Delta 14, Qcr7p-Delta 20, and Qcr7p-Delta 7(D13V) were all respiration-deficient, Examination of the steady-state levels of complex III subunits showed that core protein 2, cytochrome c(1), the iron-sulfur protein, and the Il-kDa subunit are reduced in respiration-deficient mutant strains, Results from deletion analyses indicate that the N-terminal 20 residues (after Met-1) of the Qcr7 protein are not essential for import into mitochondria and that the N-terminal seven residues (after Met-1) are not involved in proton translocation. The results of this work show, however, that the N terminus of the Qcr7 protein is essential for the biosynthesis of ubiquinol-cytochrome c reductase.	HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,RES INST,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,RES INST,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; Dartmouth College					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BRANDT U, 1994, J BIOL CHEM, V269, P12947; COCCO T, 1991, EUR J BIOCHEM, V195, P731, DOI 10.1111/j.1432-1033.1991.tb15760.x; DEHAAN M, 1984, EUR J BIOCHEM, V138, P169; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Fourney R.M., 1988, FOCUS, V10, P5; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GRAHAM LA, 1992, FEBS LETT, V313, P251, DOI 10.1016/0014-5793(92)81203-X; Guthrie C, 1991, GUIDE YEAST GENETICS; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HEMRIKA W, 1994, EUR J BIOCHEM, V220, P569, DOI 10.1111/j.1432-1033.1994.tb18657.x; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; JAPA S, 1989, J BIOL CHEM, V264, P13994; LINK TA, 1987, CYTOCHROME SYSTEMS M, P289; LORUSSO M, 1989, EUR J BIOCHEM, V179, P535, DOI 10.1111/j.1432-1033.1989.tb14580.x; MAARSE AC, 1988, EUR J BIOCHEM, V172, P179, DOI 10.1111/j.1432-1033.1988.tb13870.x; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; ROBINSON BH, 1986, J CLIN INVEST, V77, P1422, DOI 10.1172/JCI112453; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOPPINK PJ, 1989, EUR J BIOCHEM, V181, P475, DOI 10.1111/j.1432-1033.1989.tb14749.x; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; WALLACE DC, 1982, MICROBIOL REV, V46, P208, DOI 10.1128/MMBR.46.2.208-240.1982; YANG MJ, 1994, J BIOL CHEM, V269, P1270; YANG XH, 1986, METHOD ENZYMOL, V126, P316	27	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17495	17501		10.1074/jbc.272.28.17495	http://dx.doi.org/10.1074/jbc.272.28.17495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211895	hybrid			2022-12-25	WOS:A1997XK16500038
J	Haynes, RL; Zheng, TL; Nicchitta, CV				Haynes, RL; Zheng, TL; Nicchitta, CV			Structure and folding of nascent polypeptide chains during protein translocation in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBILIZED ROUGH MICROSOMES; SECRETORY PROTEINS; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-TRANSPORT; DISULFIDE BONDS; MESSENGER-RNA; ER-MEMBRANE; BIP; COMPLEX	To investigate the role of protein folding and chaperone-nascent chain interactions in translocation across the endoplasmic reticulum membrane, the translocation of wild type and mutant forms of preprolactin were studied in vivo and in vitro, The preprolactin mutant studied contains an 18-amino acid substitution at the amino terminus of the mature protein, eliminating a disulfide-bonded loop domain. In COS-7 cells, mutant prolactin accumulated in the endoplasmic reticulum as stable protein-protein and disulfide-bonded aggregates, whereas wild type prolactin was efficiently secreted. In vitro, wild type and mutant preprolactin translocated with equal efficiency although both translation products were recovered as heterogeneous aggregates. Studies with translocation intermediates indicated that aggregation occurred co-translationally. To evaluate the contribution of lumenal chaperones to translocation and folding, in vitro studies were performed with native and reconstituted, chaperone-deficient membranes, The absence of lumenal chaperones was associated with a decrease in translocation efficiency and pronounced aggregation of the translation products. These studies suggest that chaperone-nascent chain interactions significantly enhance translocation and indicate that in the absence of such interactions, aggregation can serve as the predominant in vitro protein folding end point. The ramifications of these observations on investigations into the mechanism of translocation are discussed.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University			Haynes, Robin L/M-4401-2016	Haynes, Robin L/0000-0003-4909-9585	NIDDK NIH HHS [DK47897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DONEEN BA, 1979, BIOCHEMISTRY-US, V18, P4851, DOI 10.1021/bi00589a013; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Horst M, 1996, PROTEIN SCI, V5, P759; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; Lord JM, 1996, CURR BIOL, V6, P1067, DOI 10.1016/S0960-9822(02)70666-0; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA C, 1991, METHOD CELL BIOL, V34, P263; Nicchitta CV, 1996, SEMIN CELL DEV BIOL, V7, P497, DOI 10.1006/scdb.1996.0062; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; REDICK SD, 1995, J CELL SCI, V108, P1761; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797	62	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17126	17133		10.1074/jbc.272.27.17126	http://dx.doi.org/10.1074/jbc.272.27.17126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202031	hybrid			2022-12-25	WOS:A1997XH44600063
J	Kolman, MF; Egelhoff, TT				Kolman, MF; Egelhoff, TT			Dictyostelium myosin heavy chain kinase A subdomains - Coiled-coil and WD repeat roles in oligomerization and substrate targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MOTILITY; PURIFICATION; PROTEINS; REPLACEMENT; DISCOIDEUM; SUBUNIT; FAMILY; GENE	Myosin heavy chain kinase A (MHCK A) participates in the regulation of cytoskeletal myosin assembly in Dictyostelium, driving filament disassembly via phosphorylation of sites in the myosin tail. MHCK A contains an amino-terminal coiled-coil domain, a novel central catalytic domain, and a carboxyl-terminal domain containing a 7-fold WD repeat motif, We have overexpressed MHCK A truncation constructs to clarify the roles of each of these domains, Recombinant full-length MHCK A, MHCK A lacking the predicted coiled-coil domain, and MHCK A lacking the WD repeat domain were expressed at high levels in Dictyostelium cells lacking endogenous MHCK A, Biochemical analysis of the purified proteins demonstrates that the putative coiled-coil domain is responsible for the oligomerization of the MHCK A holoenzyme. Removal of the WD repeat domain had no effect on catalytic activity toward a synthetic peptide, hut did result in a 95% loss of protein kinase activity when native myosin filaments were used as the substrate. Cellular analysis confirms that the same severe loss of activity against myosin occurs in vivo when the WD repeat domain is eliminated. These results suggest that the WD repeat domain of MHCK A serves to target this enzyme to its physiological substrate.			Kolman, MF (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA.				NHLBI NIH HHS [HL07653] Funding Source: Medline; NIGMS NIH HHS [GM50009] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050009, R29GM050009] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; COTE GP, 1987, J BIOL CHEM, V262, P1065; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; JAY PY, 1995, J CELL SCI, V108, P387; Kolman MF, 1996, J CELL BIOL, V132, P101, DOI 10.1083/jcb.132.1.101; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; MEDLEY QG, 1992, BIOCHIM BIOPHYS ACTA, V1175, P7, DOI 10.1016/0167-4889(92)90003-T; MEDLEY QG, 1991, METHOD ENZYMOL, V196, P23; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Thanos CD, 1996, PROTEIN SCI, V5, P782; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818	32	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16904	16910		10.1074/jbc.272.27.16904	http://dx.doi.org/10.1074/jbc.272.27.16904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201999	hybrid			2022-12-25	WOS:A1997XH44600031
J	Morel, P; Cherny, D; Ehrlich, SD; Cassuto, E				Morel, P; Cherny, D; Ehrlich, SD; Cassuto, E			Recombination-dependent repair of DNA double-strand breaks with purified proteins from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED BRANCH MIGRATION; HELICASE-II UVRD; RECA PROTEIN; GENETIC-RECOMBINATION; ILLEGITIMATE RECOMBINATION; DUPLEX DNA; EXCHANGE; BINDING	We have developed an in vitro system in which repair of DNA double-strand breaks is performed by purified proteins of Escherichia coli, A segment was deleted from a circular duplex DNA molecule by restriction at two sites, 3' single-stranded overhangs were introduced at both ends of the remaining linear fragment, In a first step, RecA protein catalyzed the formation of a D-loop between one single-stranded tail and a homologous undeleted supercolied DNA molecule, In a second step, E. coli DNA polymerase II or III used the 3' end in the D-loop as a primer to copy the missing sequences of the linear substrate on one strand of the supercolied template, Under proper conditions, the integrity of the deleted substrate was restored, as shown by analysis of the products by electrophoresis, restriction, and transformation, In this reaction, DNA synthesis is strictly dependent on recombination, and repair is achieved without formation of a Holliday junction.	INRA, F-78352 JOUY EN JOSAS, FRANCE; INST GUSTAVE ROUSSY, F-94805 VILLEJUIF, FRANCE; RUSSIAN ACAD SCI, INST MOL GENET, ELECTRON MICROSCOPY LAB, MOSCOW 123182, RUSSIA	INRAE; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Russian Academy of Sciences			Ehrlich, S./Y-2423-2019	Ehrlich, S./0000-0002-7563-4046; morel, patrice/0000-0003-1690-8032				BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; Canceill D, 1996, P NATL ACAD SCI USA, V93, P6647, DOI 10.1073/pnas.93.13.6647; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CASSUTO E, 1986, NUCLEIC ACIDS RES, V14, P1149, DOI 10.1093/nar/14.3.1149; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; CUNNINGHAM RP, 1979, NATURE, V281, P191, DOI 10.1038/281191a0; Delain E, 1995, VISUALIZATION NUCL A, P35; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; KODADEK T, 1991, J BIOL CHEM, V266, P9712; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KUHN B, 1982, EUR J BIOCHEM, V125, P63, DOI 10.1111/j.1432-1033.1982.tb06651.x; LANGLEY KE, 1975, P NATL ACAD SCI USA, V72, P1254, DOI 10.1073/pnas.72.4.1254; LIN FL, 1984, MOL CELL BIOL, V10, P103; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; MORTIMER RK, 1958, RADIAT RES, V9, P3312; Mosig Gisela, 1994, P54; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; POLLARD EC, 1981, MOL GEN GENET, V184, P421, DOI 10.1007/BF00352516; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; Sambrook J., 2002, MOL CLONING LAB MANU; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; SHIBATA T, 1980, P NATL ACAD SCI-BIOL, V77, P2606, DOI 10.1073/pnas.77.5.2606; Skaliter R, 1996, J BIOL CHEM, V271, P2478, DOI 10.1074/jbc.271.5.2478; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1988, ANNU REV GENET, V22, P168; THURING RWJ, 1975, ANAL BIOCHEM, V66, P213, DOI 10.1016/0003-2697(75)90739-3; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451	39	5	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17091	17096		10.1074/jbc.272.27.17091	http://dx.doi.org/10.1074/jbc.272.27.17091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202026	Green Published, hybrid			2022-12-25	WOS:A1997XH44600058
J	Bhat, A; Kolibaba, K; Oda, T; OhnoJones, S; Heaney, C; Druker, BJ				Bhat, A; Kolibaba, K; Oda, T; OhnoJones, S; Heaney, C; Druker, BJ			Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE-PHOSPHORYLATED PROTEIN; COLONY-STIMULATING FACTOR; C-CBL; PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN	The Philadelphia chromosome, detected in virtually all cases of chronic myelogenous leukemia (CML), is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR-encoded sequences upstream of exon 2 of c-ABL, The BCR-ABL fusion creates a gene whose protein product, p210BCR-ABL, has been implicated as the cause of the disease, Although ABL kinase activity has been shown to be required for the transforming abilities of BCR-ABL and numerous substrates of the BCR-ABL tyrosine kinase have been identified, the requirement of most of these substrates for the transforming function of BCR-ABL is unknown, In this study we mapped a direct binding site of the c-CBL proto-oncogene to the SH2 domain of BCR-ABL. This interaction only occurs under conditions where c-CBL is tyrosine-phosphorylated. Despite the direct interaction of c-CBL with the SH2 domain of BCR-ABL, deletion of the SH2 domain of BCR-ABL did not result in an alteration in the complex formation of BCR-ABL and c-CBL, suggesting that another site of direct interaction between c-CBL and BCR-ABL exists or that another protein mediates an indirect interaction of c-CBL and BCR-ABL, Since CRKL, an SH2, SH3 domain-containing adapter protein is known to bind directly to BCR-ABL and also binds to tyrosine-phosphorylated c-CBL, the ability of CRKL to mediate a complex between c-CBL and BCR-ABL was examined.	OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,DEPT DEV & CELL BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			Oda, Tsukasa/ABI-1855-2020	Druker, Brian/0000-0001-8331-8206; Oda, Tsukasa/0000-0002-8941-161X	NATIONAL CANCER INSTITUTE [R37CA065823, R01CA065823] Funding Source: NIH RePORTER; NCI NIH HHS [CA65823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P32; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DRUKER B, 1992, BLOOD, V79, P2215; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20402; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; KANAKURA Y, 1990, BLOOD, V76, P706; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU D, 1993, BLOOD, V82, P1257; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; NOWELL PC, 1960, SCIENCE, V132, P1497; ODA T, 1994, J BIOL CHEM, V269, P22925; ODA T, 1995, LEUKEMIA, V9, P295; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TENHOEVE J, 1994, CANCER RES, V54, P2563; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	54	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16170	16175		10.1074/jbc.272.26.16170	http://dx.doi.org/10.1074/jbc.272.26.16170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195915	hybrid			2022-12-25	WOS:A1997XG01900019
J	Ko, BCB; Ruepp, B; Bohren, KM; Gabbay, KH; Chung, SSM				Ko, BCB; Ruepp, B; Bohren, KM; Gabbay, KH; Chung, SSM			Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPEROSMOTIC STRESS; ORGANIC OSMOLYTES; HYPERTONIC STRESS; CELLS; KIDNEY; EXPRESSION; ACCUMULATION; PURIFICATION; INDUCTION; CLONING	Aldose reductase (AR) has been implicated in osmoregulation in the kidney because it reduces glucose to sorbitol, which can serve as an osmolite. Under hyperosmotic stress, transcription of this gene is induced to increase the enzyme level. This mode of osmotic regulation of AR, gene expression has been observed in a number of nonrenal cells as well, suggesting that this is a common response to hyperosmotic stress. We have identified a 132-base pair sequence similar to 1 kilobase pairs upstream of the transcription start site of the AR gene that enhances the transcription activity of the AR promoter as well as that of the SV40 promoter when the cells are under hyperosmotic stress. Within this 132-base pair sequence, there are three sequences that resemble TonE, the tonicity response element of the canine betaine transporter gene, and the osmotic response element of the rabbit AR gene, suggesting that the mechanism of osmotic regulation of gene expression in these animals is similar. However, our data indicate that cooperative interaction among the three TonE-like sequence's in the human AR may be necessary for their enhancer function.	UNIV HONG KONG,INST MOL BIOL,POKFULAM,HONG KONG; BAYLOR COLL MED,DEPT PEDIAT,MOL DIABET & METAB SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of Hong Kong; Baylor College of Medicine; Baylor College of Medicine			Ko, Chi-bun/ACH-7514-2022	Bohren, Kurt/0000-0002-3183-4118; Ko, Ben Chi Bun/0000-0003-2027-5899	NATIONAL EYE INSTITUTE [R01EY011018] Funding Source: NIH RePORTER; NEI NIH HHS [EY11018] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BURG MB, 1988, KIDNEY INT, V33, P635, DOI 10.1038/ki.1988.46; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CHUNG S, 1989, J BIOL CHEM, V264, P14775; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; DAS B, 1985, ARCH BIOCHEM BIOPHYS, V238, P670, DOI 10.1016/0003-9861(85)90213-9; FERRARETTO A, 1993, BIOCHIM BIOPHYS ACTA, V1175, P283, DOI 10.1016/0167-4889(93)90218-E; FERRARIS JD, 1994, P NATL ACAD SCI USA, V91, P10742, DOI 10.1073/pnas.91.22.10742; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; GREENE DA, 1985, DIABETES CARE, V8, P290, DOI 10.2337/diacare.8.3.290; GULLANS SR, 1988, AM J PHYSIOL, V255, pF626, DOI 10.1152/ajprenal.1988.255.4.F626; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KADOR PF, 1985, AM J MED, V79, P8, DOI 10.1016/0002-9343(85)90504-2; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KING TE, 1959, PROC R SOC SER B-BIO, V151, P226, DOI 10.1098/rspb.1959.0061; KO BCB, 1995, DIABETES, V44, P727, DOI 10.2337/diabetes.44.7.727; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; OHTA M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P395, DOI 10.1016/0167-4838(91)90162-S; PETRASH JM, 1992, BIOCHEM BIOPH RES CO, V187, P201, DOI 10.1016/S0006-291X(05)81479-2; PETRASH JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P105, DOI 10.1016/0167-4838(82)90402-2; Ruepp B, 1996, P NATL ACAD SCI USA, V93, P8624, DOI 10.1073/pnas.93.16.8624; RUSSELL P, 1990, ARCH BIOCHEM BIOPHYS, V276, P259, DOI 10.1016/0003-9861(90)90036-X; SIEVENS MJ, 1993, AM J PHYSIOL, V265, pE428; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SRIVASTAVA SK, 1984, LENS RES, V2, P309; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; TERADA Y, 1994, J BIOL CHEM, V269, P31296; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; WANG K, 1993, J BIOL CHEM, V268, P16052; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	39	176	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16431	16437		10.1074/jbc.272.26.16431	http://dx.doi.org/10.1074/jbc.272.26.16431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195951	hybrid			2022-12-25	WOS:A1997XG01900055
J	Mortensen, ER; Marks, PA; Shiotani, A; Merchant, JL				Mortensen, ER; Marks, PA; Shiotani, A; Merchant, JL			Epidermal growth factor and okadaic acid stimulate Sp1 proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PITUITARY-CELLS; TRANSCRIPTION FACTOR SP1; NF-KAPPA-B; SP1-MEDIATED TRANSCRIPTION; GASTRIN PROMOTER; C-FOS; PROTEIN; EXPRESSION; INHIBITION; BINDING	Sp1 nuclear levels have been shown to directly correlate with the proliferative state of the cell. We therefore studied changes in the abundance of Sp1 in a rat pituitary cell line GH(4) whose growth rate is regulated by epidermal growth factor (EGF). Nuclear extracts from GH, cells treated with 10 nM EGF for at least 16 h showed a 50% decrease in Sp1 binding to a GC-rich element present in the gastrin promoter. The decrease in binding correlated with a decrease in cell proliferation, a loss of nuclear Sp1 protein and a 50-60% decrease in Sp1-mediated transactivation through an Sp1 enhancer element in transfection assays. Okadaic acid, a phosphatase inhibitor, was synergistic with the effect of EGF on Sp1 protein levels suggesting that the loss of Sp1 was mediated by phosphorylation events. This result was confirmed by showing a 2-fold increase in orthophosphate-labeled Sp1 with EGF and okadaic acid, Cycloheximide prevented the expected loss of Sp1 mediated by EGF and okadaic acid suggesting that the synthesis of a protease may mediate these events. This hypothesis was tested directly by showing that the cysteine protease inhibitor leupeptin prevented Sp1 degradation. Using the PEST-FIND computer program, the computed PEST score for human and rat Sp1 is 10.4 and 13.7, respectively, indicating that Sp1 has a domain with a high concentration of proline, glutamic acid, serine, and threonine residues as reported for a number of proteins with inducible rates of degradation. Collectively, these results indicate that sustained stimulation of GH(4) cells by EGF initiates a cascade of phosphorylation events that promotes Sp1 proteolysis, decreased Sp1 nuclear levels and decreased cellular proliferation.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109; HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute			Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045729, R01DK045729] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR-00042] Funding Source: Medline; NIDDK NIH HHS [DK-45729] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON LK, 1980, P NATL ACAD SCI-BIOL, V77, P394, DOI 10.1073/pnas.77.1.394; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; OSBORNE R, 1981, ENDOCRINOLOGY, V108, P1164, DOI 10.1210/endo-108-4-1164; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PARK K, 1992, J BIOL CHEM, V267, P10810; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; SCHONBRUNN A, 1980, J CELL BIOL, V85, P786, DOI 10.1083/jcb.85.3.786; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANDOLAH FM, 1992, J CELL PHYSIOL, V152, P190, DOI 10.1002/jcp.1041520124; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	45	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16540	16547		10.1074/jbc.272.26.16540	http://dx.doi.org/10.1074/jbc.272.26.16540			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195964	hybrid			2022-12-25	WOS:A1997XG01900068
J	Uesono, Y; Tohe, A; Kikuchi, Y				Uesono, Y; Tohe, A; Kikuchi, Y			Ssd1p of Saccharomyces cerevisiae associates with RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE FUNCTIONS; COLI RIBONUCLEASE-II; BINDING-PROTEIN; NEUROSPORA MITOCHONDRIA; CELL-GROWTH; CYCLIC-AMP; KINASE-C; YEAST; GENE; EXORIBONUCLEASE	The SSD1 gene has been isolated as a single copy suppressor of many mutants, such as sit4, slk1/bck1, pde2, and rpc31, in the yeast Saccharomyces cerevisiae. Ssd1p has domains showing weak but significant homology with RNase II-related proteins, Cyt4p, Dss1p, VacB, and RNase II, which are involved in the modification of RNA. We found that Ssd1p had the ability to bind RNA, preferably poly(rA), as well as single-stranded DNA, Interestingly, the most conserved domain among the RNase II-related proteins was not necessary for interaction with RNA. Indirect immunofluorescence staining with anti-Ssd1p antibody revealed that Ssd1p was detected mainly in the cytoplasm. Furthermore, sucrose gradient sedimentation analysis demonstrated that Ssd1p was not cofractionated with polyribosomes, suggesting that Ssd1p is not particularly bound to a translationally active subpopulation of mRNA in the cytoplasm.	UNIV TOKYO, DEPT BIOL SCI, GRAD SCH SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BEUF L, 1995, PLANT MOL BIOL, V27, P779, DOI 10.1007/BF00020230; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DMOCHOWSKA A, 1995, CURR GENET, V28, P108, DOI 10.1007/BF00315775; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; GARRIGA G, 1984, CELL, V36, P623, DOI 10.1016/0092-8674(84)90342-8; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KENNA M, 1993, MOL CELL BIOL, V13, P341, DOI 10.1128/MCB.13.1.341; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KRAIG E, 1980, J BACTERIOL, V144, P1098, DOI 10.1128/JB.144.3.1098-1112.1980; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LEE FJS, 1993, J BIOL CHEM, V268, P15080; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Liang S, 1996, MOL CELL BIOL, V16, P5139; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; MATSUURA A, 1990, EMBO J, V9, P3225, DOI 10.1002/j.1460-2075.1990.tb07521.x; MATUNIS MJ, 1993, MOL CELL BIOL, V13, P6114, DOI 10.1128/MCB.13.10.6114; MIN JJ, 1993, J BACTERIOL, V175, P6245, DOI 10.1128/JB.175.19.6245-6253.1993; MIN JJ, 1993, J BIOL CHEM, V268, P7350; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; PIEDADE J, 1995, FEMS MICROBIOL LETT, V127, P187; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Rose MD., 1990, METHODS YEAST GENETI; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; STETTLER S, 1993, MOL GEN GENET, V239, P169, DOI 10.1007/BF00281615; STEVENS A, 1980, J BIOL CHEM, V255, P3080; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TANAKA K, 1988, EMBO J, V7, P495, DOI 10.1002/j.1460-2075.1988.tb02837.x; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; TURCQ B, 1992, P NATL ACAD SCI USA, V89, P1676, DOI 10.1073/pnas.89.5.1676; UESONO Y, 1994, GENE, V143, P135; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; WILSON RB, 1991, MOL CELL BIOL, V11, P3369, DOI 10.1128/MCB.11.6.3369; ZILHAO R, 1993, MOL MICROBIOL, V8, P43, DOI 10.1111/j.1365-2958.1993.tb01201.x	46	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16103	16109		10.1074/jbc.272.26.16103	http://dx.doi.org/10.1074/jbc.272.26.16103			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195905	hybrid			2022-12-25	WOS:A1997XG01900009
J	Zhu, CX; Roche, CJ; TseDinh, YC				Zhu, CX; Roche, CJ; TseDinh, YC			Effect of Mg(II) binding on the structure and activity of Escherichia coli DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL FRAGMENT; PROTEIN-OMEGA; COMPLEX	Escherichia coli DNA topoisomerase I requires Mg(II) as a cofactor for the relaxation of negatively supercoiled DNA. Mg(II) binding to the enzyme was shown by fluorescence spectroscopy to affect the tertiary structure of the enzyme. Addition of 2 mM MgCl2 resulted in a 30% decrease in the maximum emission of tryptophan fluorescence of the enzyme. These Mg(II)-induced changes in fluorescence properties were reversible by the addition of EDTA and not obtained with other divalent cations. After incubation with Mg(II) and dialysis, inductively coupled plasma (ICP) analysis showed that each enzyme molecule could form a complex with 1-2 Mg(II) bound to each enzyme molecule. Such Mg(II) enzyme complexes were found to be active in the relaxation of negatively supercoiled DNA in the absence of additional Mg(II). Results from ICP analysis after equilibrium dialysis and relaxation assays with limiting Mg(II) concentrations indicated that both Mg(ZI) binding sites had to be occupied for the enzyme to catalyze relaxation of negatively supercoiled DNA.	NEW YORK MED COLL,DEPT BIOCHEM & MOL BIOL,VALHALLA,NY 10595	New York Medical College					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054226] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54226] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; DOMANICO PL, 1988, BIOCHEMISTRY-US, V27, P6365, DOI 10.1021/bi00417a026; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Tse-Dinh Y C, 1994, Adv Pharmacol, V29A, P21; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J BIOL CHEM, V261, P931; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; ZHU CX, 1995, BIOCHEM MOL BIOL INT, V35, P375	15	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16206	16210		10.1074/jbc.272.26.16206	http://dx.doi.org/10.1074/jbc.272.26.16206			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195920	hybrid			2022-12-25	WOS:A1997XG01900024
J	Eliopoulos, AG; Stack, M; Dawson, CW; Kaye, KM; Hodgkin, L; Sihota, S; Rowe, M; Young, LS				Eliopoulos, AG; Stack, M; Dawson, CW; Kaye, KM; Hodgkin, L; Sihota, S; Rowe, M; Young, LS			Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappa B pathway involving TNF receptor-associated factors	ONCOGENE			English	Article						LMP1; CD40; TRAF; IL6; NF-kappa B; keratinocytes	LATENT MEMBRANE-PROTEIN; ZINC-FINGER PROTEIN; TRANSFORMING PROTEIN; TRANSCRIPTION FACTOR; ACTIVATION MOLECULE; CYTOPLASMIC DOMAIN; INTERLEUKIN-6 GENE; T-LYMPHOCYTES; UP-REGULATION; IN-VITRO	Expression of the Epstein-Barr virus (EBV) transforming LMP1 in B cells activates the transcription factor NF-kappa B and induces phenotypic changes through two distinct domains in the cytoplasmic C-terminus of the protein, The aa 187-231 domain of LMP1, which is important for growth transformation, binds tumour necrosis factor (TNF) receptor associated factor (TRAF) 1 and TRAF3 and this interaction mediates subsequent signalling events, The TRAFs also associate with CD40, a member of the TNFR family, which upon ligation activates NF-kappa B and induces phenotypic changes similar to those mediated by LMP1. This study demonstrates that LMP1 expression in carcinoma cell lines and SV40-transformed keratinocytes results in induction of the pleiotropic cytokine interleukin 6 (IL6), an effect which is also observed upon CD40 Ligation. The mechanism by which either LMP1 expression or CD40 ligation induces IL6 production was found to be NF-kappa B-dependent. Mutational analysis identified domains in the C-terminus of LMP1 which are important for NF-KB activation and IL6 secretion, LMP1 and CD40 share a common PxQxT core TRAF binding motif and mutations in or adjacent to this sequence impaired the ability of LMP1 or CD40 to induce NF-kappa B activation and IL6 secretion, The importance of TRAF interactions in mediating these effects was confirmed using dominant negative TRAF2 and TRAF3 mutants which also identified differences in the signalling events mediated by the two NF-kappa B activating domains of LMP1. A20, an anti-apoptotic protein which interacts with TRAF2 and blocks CD40-mediated NF-kappa B activity, also blocked NF-kappa B and IL6 secretion in LMP1-transfected epithelial cells, These results suggest that LMP1 regulates IL6 production in epithelial cells in a manner similar to CD40 ligation and implicate TRAFs as common mediators in the transduction of signals generated via the CD40 and LMP1 pathways, As a role for IL6 in regulating epithelial cell growth has previously been suggested, the control of IL6 secretion via the CD4O and LMP1 pathways may have implications for the growth of both normal and transformed epithelial cells.	UNIV BIRMINGHAM,SCH MED,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	University of Birmingham; Cardiff University; Harvard University; Brigham & Women's Hospital; Harvard Medical School			ELIOPOULOS, ARISTIDES/ABI-6632-2020; Rowe, Martin/B-2880-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; Young, Lawrence S/B-7213-2009	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Rowe, Martin/0000-0003-4139-7326; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Young, Lawrence S/0000-0003-3919-4298				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1990, J IMMUNOL, V145, P1400; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; GAJEWSKI TF, 1995, J IMMUNOL, V154, P5637; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENDERSON SA, 1994, SEMIN VIROL, V5, P391, DOI 10.1006/smvy.1994.1043; HESS S, 1995, J IMMUNOL, V155, P4588; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Jaattela M, 1996, J IMMUNOL, V156, P1166; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KATIRA A, 1995, LEUKOCYTE TYPING, V5; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liebowitz David, 1993, P107; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; STADNYK AW, 1994, FASEB J, V8, P1041, DOI 10.1096/fasebj.8.13.7926369; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TAKIZAWA H, 1993, CANCER RES, V53, P4175; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209, DOI 10.1002/jlb.58.2.209; Young L S, 1992, Semin Cancer Biol, V3, P273; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	65	225	230	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2899	2916		10.1038/sj.onc.1201258	http://dx.doi.org/10.1038/sj.onc.1201258			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205097				2022-12-25	WOS:A1997XF55500004
J	Coleman, KG; Wautlet, BS; Morrissey, D; Mulheron, J; Sedman, SA; Brinkley, P; Price, S; Webster, KR				Coleman, KG; Wautlet, BS; Morrissey, D; Mulheron, J; Sedman, SA; Brinkley, P; Price, S; Webster, KR			Identification of CDK4 sequences involved in cyclin D1 and p16 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; ALANINE-SCANNING MUTAGENESIS; CELL-CYCLE; PROTEIN-KINASE; G1 PHASE; PHOSPHORYLATION; ACTIVATION; G(1); CDC2; PROGRESSION	Activation of CDK4 is regulated, in part, by its association with a D-type cyclin. Conversely, CDK4 activity is inhibited when it is bound to the cyclin-dependent kinase inhibitor, p16(INK4A). TO investigate the molecular basis of the interactions between CDK4 and cyclin D1 or p16(INK4A) we performed site-directed mutagenesis of CDK4. The interaction was examined using in vitro translated wild type and mutant CDK4 proteins and bacterially expressed cyclin D1 and pig fusion proteins. As mutational analysis of CDC2 suggests that its cyclin binding domain is primarily located near its amino terminus, the majority of the mutations constructed in CDK4 were located near its amino terminus. In addition, CDK4 residues homologous to CDCS sites involved in Suc1 binding were also mutated. Our analysis indicates that cyclin D1 and pie binding sites are overlapping and located primarily near the amino terminus. All CDK4 mutations that resulted in decreased pig binding capability also diminished cyclin D1 binding. In contrast, amino-terminal sequences were identified, including the PSTAIRE region, that are important for cyclin D1 binding but are not involved in p16 binding.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT BIOMOL DRUG DISCOVERY ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; GOUBIN F, 1995, ONCOGENE, V10, P2281; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	37	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18869	18874		10.1074/jbc.272.30.18869	http://dx.doi.org/10.1074/jbc.272.30.18869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228064	hybrid			2022-12-25	WOS:A1997XM34200055
J	Fajas, L; Auboeuf, D; Raspe, E; Schoonjans, K; Lefebvre, AM; Saladin, R; Najib, J; Laville, M; Fruchart, JC; Deeb, S; VidalPuig, A; Flier, J; Briggs, MR; Staels, B; Vidal, H; Auwerx, J				Fajas, L; Auboeuf, D; Raspe, E; Schoonjans, K; Lefebvre, AM; Saladin, R; Najib, J; Laville, M; Fruchart, JC; Deeb, S; VidalPuig, A; Flier, J; Briggs, MR; Staels, B; Vidal, H; Auwerx, J			The organization, promoter analysis, and expression of the human PPAR gamma gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; ADIPOSE-CELL-DIFFERENTIATION; PEROXISOME PROLIFERATOR; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; FATTY-ACIDS; ENHANCER; INCREASE	PPAR gamma is a member of the PPAR subfamily of nuclear receptors. In this work, the structure of the human PPAR gamma cDNA and gene was determined, and its promoters and tissue-specific expression were functionally characterized. Similar to the mouse, two PPAR isoforms, PPAR gamma 1 and PPAR gamma 2, were detected in man. The relative expression of human PPAR gamma was studied by a newly developed and sensitive reverse transcriptase-competitive polymerase chain reaction method, which allowed us to distinguish between PPAR gamma 1 and gamma 2 mRNA. In all tissues analyzed, PPAR gamma 2 was much less abundant than PPAR gamma 1. Adipose tissue and large intestine have the highest levels of PPAR gamma mRNA; kidney, liver, and small intestine have intermediate levels; whereas PPAR gamma is barely detectable in muscle. This high level expression of PPAR gamma in colon warrants further study in view of the well established role of fatty acid and arachidonic acid derivatives in colonic disease. Similarly as mouse PPAR gamma s, the human PPAR gamma s are activated by thiazolidinediones and prostaglandin J and bind with high affinity to a PPRE. The human PPAR gamma gene has nine exons and extends over more than 100 kilobases of genomic DNA. Alternate transcription start sites and alternate splicing generate the PPAR gamma 1 and PPAR gamma 2 mRNAs, which differ at their 6'-ends. PPAR gamma 1 is encoded by eight exons, and PPAR gamma 2 is encoded by seven exons. The 5'-untranslated sequence of PPAR gamma 1 is comprised of exons A1 and A2, whereas that of PPAR gamma 2 plus the additional PPAR gamma 2-specific N-terminal amino acids are encoded by exon B, located between exons A2 and A1. The remaining six exons, termed 1 to 6, are common to the PPAR gamma 1 and gamma 2. Knowledge of the gene structure will allow screening for PPAR gamma mutations in humans with metabolic disorders, whereas knowledge of its expression pattern and factors regulating its expression could be of major importance in understanding its biology.	INST PASTEUR,DEPT ATHEROSCLEROSE,INSERM,U325,F-59019 LILLE,FRANCE; UNIV LYON 1,FAC MED RENE LAENNEC,INSERM,U449,F-69373 LYON,FRANCE; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121; UNIV WASHINGTON,DEPT MED & GENET,SEATTLE,WA 98195; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ligand Pharmaceuticals; University of Washington; University of Washington Seattle; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Coll, Lluis Fajas/C-8567-2014; Auboeuf, Didier/M-4610-2014; Staels, Bart/N-9497-2016; Vidal, Hubert/M-6674-2017; Flier, jeffrey/AAG-6223-2019	Staels, Bart/0000-0002-3784-1503; Vidal, Hubert/0000-0002-9467-0317; Lefebvre, Anne-Marie/0000-0001-5644-0441; Auboeuf, Didier/0000-0002-3757-0002; Fajas, Lluis/0000-0002-1283-9503; Vidal-Puig, Antonio/0000-0003-4220-9577; Auwerx, Johan/0000-0002-5065-5393; Schoonjans, Kristina/0000-0003-1247-4265				AMRI EZ, 1991, J LIPID RES, V32, P1449; APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; Aubert J, 1996, FEBS LETT, V397, P117, DOI 10.1016/S0014-5793(96)01152-0; Auwerx J, 1996, J MOL MED, V74, P347, DOI 10.1007/BF00210629; Auwerx J, 1996, ATHEROSCLEROSIS, V124, pS29, DOI 10.1016/0021-9150(96)05854-6; Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; BRANDES R, 1987, LIFE SCI, V40, P935, DOI 10.1016/0024-3205(87)90312-2; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GHARBICHIHI J, 1993, BIOCHIM BIOPHYS ACTA, V1177, P8, DOI 10.1016/0167-4889(93)90150-N; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; Greene M. E., 1995, Gene Expression, V4, P281; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hulin B, 1996, CURR PHARM DESIGN, V2, P85; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; NEGREL R, 1989, BIOCHEM J, V257, P399, DOI 10.1042/bj2570399; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Sambrook J., 2002, MOL CLONING LAB MANU; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1996, J LIPID RES, V37, P907; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STENSON WF, 1992, ANN INTERN MED, V116, P609, DOI 10.7326/0003-4819-116-8-609; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Vidal H, 1996, J CLIN INVEST, V98, P251, DOI 10.1172/JCI118786; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; WU Z, 1996, GENE DEV, V16, P4128; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xue JC, 1996, MOL CELL BIOL, V16, P1567; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	57	1011	1045	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18779	18789		10.1074/jbc.272.30.18779	http://dx.doi.org/10.1074/jbc.272.30.18779			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228052	hybrid			2022-12-25	WOS:A1997XM34200043
J	Nisimoto, Y; Freeman, JLR; Motalebi, SA; Hirshberg, M; Lambeth, JD				Nisimoto, Y; Freeman, JLR; Motalebi, SA; Hirshberg, M; Lambeth, JD			Rac binding to p67(phox) - Structural basis for interactions of the Rac1 effector region and insert region with components of the respiratory burst oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL NADPH OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; PLASMA-MEMBRANE; POLYMORPHONUCLEAR LEUKOCYTES; SUPEROXIDE PRODUCTION; RECOMBINANT P47-PHOX; GUANINE-NUCLEOTIDES; ANIONIC AMPHIPHILE; EXCHANGE PROTEINS	Activation of the respiratory burst oxidase involves the assembly of the membrane associated flavocyto chrome b(558) with the cytosolic components p47(phox), p67(phox), and the small GTPase Rac. Herein, the interaction between Rac and p67(phox) is explored using functional and physical methods. Mutually facilitated binding (EC50) of Rac1 and p67(phox) within the NADPH oxidase complex was demonstrated using steady state kinetic methods measuring NADPH-dependent superoxide generation. Direct binding of Rac1 and Rac2 to p67(phox) was shown using a fluorescent analog of GTP (methylanthraniloyl guanosine-5'-[beta,gamma-imido]triphosphate) bound to Rac as a reporter group. An increase in the methylanthraniloyl fluorescence was seen with added p67(phox) but not p47(phox), and the emission maximum shifted from 445 to 440 nm. Rac1 and Rac2 bound to p67(phox) with a 1:1 stoichiometry and with k(d) values of 120 and 60 nM, respectively. Mutational studies (Freeman, J., Kreck, M., Uhlinger, D. J., and Lambeth, J. D. (1994) Biochemistry 33, 13431-13435; Freeman, J. L., Abo, A, and Lambeth, J. D. (1996) J. Biol. Chem. 271, 19794-19801) previously identified two regions in Rac1 that are important for activity: the ''effector region'' (residues 26-45) and the ''insert region'' (residues 124-135). Proteins mutated in the effector region (Rac1(N26H), Rac1(133N), and Rac1(D38N)) showed a marked increase in both the K-d and the EC50, indicating that mutations in this region affect activity by inhibiting Rac binding to p67(phox). Insert region mutations (Rac1(K132E) and L134R), while showing markedly elevated EC50 values, bound with normal affinity to p67(phox). The structure of Rac1 determined by x-ray crystallography reveals that the effector region and the insert region are located in defined sectors on the surface of Rac1. A model is discussed in which the Rac1 effector region binds to p67(phox), the C terminus binds to the membrane, and the insert region interacts with a different protein component, possibly cytochrome b(558).	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; AICHI MED UNIV,DEPT BIOCHEM,NAGAKUTE,AICHI 48011,JAPAN; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Emory University; Aichi Medical University; MRC National Institute for Medical Research					NIAID NIH HHS [AI22809] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; ANDO S, 1992, J BIOL CHEM, V267, P25709; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ESCRIOU V, 1994, J BIOL CHEM, V269, P14007; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; KLEINBERG ME, 1994, BIOCHEMISTRY-US, V33, P2490, DOI 10.1021/bi00175a018; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LUTTER R, 1985, J BIOL CHEM, V260, P2237; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; NAKAMURA M, 1988, BLOOD, V72, P1550; NISHIMOTO Y, 1995, J BIOL CHEM, V270, P16428; NOMANBHOY TK, 1996, J BIOL CHEM, V271, P10003; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEMBER SO, 1983, BLOOD, V61, P1105; PHILIPS MR, 1995, J BIOL CHEM, V270, P11514, DOI 10.1074/jbc.270.19.11514; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; XU XM, 1994, J BIOL CHEM, V269, P23569	64	112	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18834	18841		10.1074/jbc.272.30.18834	http://dx.doi.org/10.1074/jbc.272.30.18834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228059	hybrid			2022-12-25	WOS:A1997XM34200050
J	Gabai, VL; Meriin, AB; Mosser, DD; Caron, AW; Rits, S; Shifrin, VI; Sherman, MY				Gabai, VL; Meriin, AB; Mosser, DD; Caron, AW; Rits, S; Shifrin, VI; Sherman, MY			Hsp70 prevents activation of stress kinases - A novel pathway of cellular thermotolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TUMOR-CELLS; PHOSPHORYLATION; NECROSIS; CASCADE; OVEREXPRESSION; ACCUMULATION; DENATURATION; FIBROBLASTS; AGGREGATION	Harmful conditions including heat shock, oxidative stress, UV, and so forth cause programmed cell death, whose triggering requires activation of the Jun N-terminal kinase, JNK, High levels of Hsp72, a heat-inducible member of Hsp70 family, protect cells against a variety of stresses by a mechanism that is unclear at present. Here we report that elevated levels of Hsp72. inhibit a signal transduction pathway leading to programmed cell death by preventing stress-induced activation of JNK. Stress-induced activation of another stress-kinase, p38 (HOG1), is also blocked when the level of Hsp72 is increased, Similarly, addition of a purified recombinant Hsp72 to a crude cell lysate reduced p38 kinase activation, while depletion of the whole family of Hsp70 proteins with a monoclonal antibody enhanced such activation, In addition, we have found that accumulation of abnormal proteins in cells upon incubation with amino acid analogs causes activation of JNK and p38 kinases, which can be prevented by overproduction of Hsp72, Taken together, these data suggest that, in regulation of JNK and p38 kinases, Hsp70 serves as a ''sensor'' of the build-up of abnormal proteins after heat shock and other stresses, The inhibitory effect of an increased level of Hsp70 on JNK appears to be a major contributor to acquired thermotolerance in mammalian cells.	BOSTON BIOMED RES INST,BOSTON,MA 02114; MED RADIOL RES CTR,OBNINSK 249020,RUSSIA; BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA; DANA FARBER CANC INST,BOSTON,MA 02115	Boston Biomedical Research Institute; National Research Council Canada; Harvard University; Dana-Farber Cancer Institute			Gabai, Vladimir L/I-1650-2013; Mosser, Dick D/A-7391-2008	Gabai, Vladimir L/0000-0003-4505-4718; Mosser, Richard/0000-0002-9183-2288; Meriin, Anatoli/0000-0003-0087-814X	PHS HHS [R01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANDERSON RL, 1989, MOL CELL BIOL, V9, P3509, DOI 10.1128/MCB.9.8.3509; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J IMMUNOL, V151, P4286; KABAKOV AE, 1995, EXP CELL RES, V217, P15, DOI 10.1006/excr.1995.1058; KAMPINGA HH, 1993, J CELL SCI, V104, P11; KAMPINGA HH, 1995, EXP CELL RES, V219, P536, DOI 10.1006/excr.1995.1262; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	35	448	498	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18033	18037		10.1074/jbc.272.29.18033	http://dx.doi.org/10.1074/jbc.272.29.18033			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218432	hybrid			2022-12-25	WOS:A1997XL73500022
J	Oda, M; Farukawa, K; Ogata, K; Sarai, A; Ishii, S; Nishimura, Y; Nakamura, H				Oda, M; Farukawa, K; Ogata, K; Sarai, A; Ishii, S; Nishimura, Y; Nakamura, H			Investigation sf the pyrimidine preference by the c-Myb DNA-binding domain at the initial base of the consensus sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-TURN-HELIX; REPRESSOR-OPERATOR INTERACTION; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; RECOGNITION HELICES; ONCOGENE PRODUCT; PROTO-ONCOGENE; CRO REPRESSOR; ZINC FINGERS; COMPLEX	The principal determinant of the pyrimidine preference by the c-Myb DNA-binding domain at the initial base of the consensus sequence was investigated by mutation of both the protein and the DNA base pairs, with analysis by a filter binding assay. Amino acid residue 187 was revealed to interact with the pyrimidine base position, as estimated from our previous complex structure. Unexpectedly, since the pyrimidine preference is retained even in the Gly(187) mutant, the principal origin of the base specificity should no occur via the direct-readout mechanism, but by an indirect-readout mechanism, namely in the intrinsic ''bendability'' of the pyrimidine-purine step of the DNA duplex. A significant but rather small positive base pair roll is detectable in the conformation of DNA in complex with the C-Myb DNA-binding domain. Following the conventional chemical rules of the direct-readout mechanism, amino acid mutagenesis at position 187 yielded several new base preferences for the protein.	BIOMOL ENGN RES INST,SUITA,OSAKA 565,JAPAN; KANAGAWA ACAD SCI & TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL STRUCT,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Kanagawa Academy Science & Technology; Yokohama City University; RIKEN; Yokohama City University			Nakamura, Haruki/O-4028-2014; Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478; Oda, Masayuki/0000-0002-8568-4223; Nishimura, Yoshifumi/0000-0002-5148-3458				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BABCOCK MS, 1994, J MOL BIOL, V237, P98, DOI 10.1006/jmbi.1994.1212; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; CALLADINE CR, 1984, J MOL BIOL, V178, P773, DOI 10.1016/0022-2836(84)90251-1; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; LAWSON CL, 1993, NATURE, V366, P178, DOI 10.1038/366178a0; LEHMING N, 1990, EMBO J, V9, P615, DOI 10.1002/j.1460-2075.1990.tb08153.x; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; REBER EJ, 1994, SCIENCE, V263, P671; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RODGERS DW, 1993, STRUCTURE, V1, P227, DOI 10.1016/0969-2126(93)90012-6; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAIKUMAR P, 1994, ONCOGENE, V9, P1279; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHIMON LJW, 1993, J MOL BIOL, V232, P826, DOI 10.1006/jmbi.1993.1434; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI M, 1994, P NATL ACAD SCI USA, V91, P12357, DOI 10.1073/pnas.91.26.12357; SUZUKI M, 1995, PROTEIN ENG, V8, P329, DOI 10.1093/protein/8.4.329; SUZUKI M, 1993, EMBO J, V12, P3221, DOI 10.1002/j.1460-2075.1993.tb05991.x; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	60	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17966	17971		10.1074/jbc.272.29.17966	http://dx.doi.org/10.1074/jbc.272.29.17966			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218422	hybrid			2022-12-25	WOS:A1997XL73500012
J	Bruhat, A; Jousse, C; Wang, XZ; Ron, D; Ferrara, M; Fafournoux, P				Bruhat, A; Jousse, C; Wang, XZ; Ron, D; Ferrara, M; Fafournoux, P			Amino acid limitation induces expression of CHOP, a CCAAT/enhancer binding protein-related gene, at both transcriptional and post-transcriptional levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; MESSENGER-RNA; ASPARAGINE SYNTHETASE; (C/EBP)-RELATED GENE; METABOLIC-REGULATION; ENERGY-METABOLISM; DNA DAMAGE; GADD153; PROMOTER; C/EBP	In mammals, plasma concentrations of amino acids are affected by nutritional or pathological conditions, Here we examined the role of amino acid limitation in regulating the expression of CHOP, a CCAAT/enhancer binding protein (C/EBP)-related gene, CHOP protein is capable of interacting with other C/EBPs to modify their DNA binding activities and may function as a negative regulator of these transcription factors, Our data show that leucine limitation in human cell lines leads to induction of CHOP mRNA and protein in a dose-dependent manner, CHOP mRNA induction is rapidly reversed by leucine replenishment, Elevated mRNA levels result from both an increase in the rate of CHOP transcription and an increase in the CHOP mRNA stability, Using a transient expression assay, we show that a promoter fragment, when linked to a reporter gene, is sufficient to mediate the regulation of CROP expression by leucine starvation in HeLa cells. In addition, we found that decreasing amino acid concentration by itself can induce CHOP expression independently of a cellular stress due to protein synthesis inhibition, Moreover, CHOP expression is induced at leucine concentrations in the range of those observed in blood of protein-restricted animals suggesting that amino acids can participate, in concert with hormones, in the regulation of gene expression.	INRA,UNITE NUTR CELLULAIRE & MOL,F-63122 ST GENES CHAMPANE,FRANCE; NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016	INRAE; New York University				Ron, David/0000-0002-3014-5636				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Battey, 1986, BASIC METHODS MOL BI; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; CYNOBER L, 1989, JPEN-PARENTER ENTER, V13, P196, DOI 10.1177/0148607189013002196; FAFOURNOUX P, 1990, AM J PHYSIOL, V259, pE614, DOI 10.1152/ajpendo.1990.259.5.E614; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOLTER R, 1982, ANNU REV GENET, V16, P113, DOI 10.1146/annurev.ge.16.120182.000553; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAINE RO, 1994, J BIOL CHEM, V269, P9693; Liu YL, 1996, NUCLEIC ACIDS RES, V24, P2718, DOI 10.1093/nar/24.14.2718; LUETHY JD, 1992, CANCER RES, V52, P5; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; NAIR KS, 1987, AM J CLIN NUTR, V46, P557, DOI 10.1093/ajcn/46.4.557; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; TRIENZENBERG SJ, 1992, CURRENT PROTOCOLS MO; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	50	161	195	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17588	17593		10.1074/jbc.272.28.17588	http://dx.doi.org/10.1074/jbc.272.28.17588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211906	hybrid, Green Published			2022-12-25	WOS:A1997XK16500049
J	Krump, E; Nikitas, K; Grinstein, S				Krump, E; Nikitas, K; Grinstein, S			Induction of tyrosine phosphorylation and Na+/H+ exchanger activation during shrinkage of human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; CELL-VOLUME; SIGNAL-TRANSDUCTION; BINDING PROTEINS; MAMMALIAN-CELLS; ISOFORM-1 NHE1; OKADAIC ACID; H+ EXCHANGE; ANTIPORTER	The ubiquitous isoform of the Na+/H+ exchanger (NHE1) is essential for the regulation of cellular volume, The underlying molecular mechanism, which is poorly understood, was studied in human polymorphonuclear leukocytes (PMN). Suspension of PMN in hypertonic media induced rapid cellular shrinkage and activation of NHE1, which is measurable as a cytosolic alkalinization. Concomitantly, hypertonic stress also induced extensive tyrosine phosphorylation of several proteins, Pretreatment of PMN with genistein, a tyrosine kinase inhibitor, prevented not only the tyrosine phosphorylation in response to a hypertonic shock but also the activation of NHE1, The signal elicited by hyperosmolarity that induces activation of tyrosine kinases and NHE1 was investigated, Methods were devised to change medium osmolarity without altering cell volume and vice versa, Increasing medium and intracellular osmolarity in normovolemic cells failed to activate tyrosine kinases or NHE1, However, shrinkage of cells under iso-osmotic conditions stimulated both tyrosine phosphorylation and NHE1 activity, These findings imply that cells detect alterations in cell size but not changes in osmolarity or ionic strength, The identity of the proteins that were tyrosine-phosphorylated in response to cell shrinkage was also investigated, Unexpectedly, the mitogen activated protein kinases SAPK, p38, erk1, and erk2 were not detectably phosphorylated or activated, In contrast, the tyrosine kinases p59(fgr) and p56/59(hck) were phosphorylated and activated upon hypertonic challenge. We propose that cells respond to alterations in cell size, but not to changes in osmolarity, with increased tyrosine phosphorylation, which in turn leads to the activation of NHE1. The resulting changes in ion content and cytosolic pH contribute to the restoration of cell volume in shrunken cells.	HOSP SICK CHILDREN,DIV CELL BIOL,RES INST,TORONTO,ON M5G 1X8,CANADA; HOWARD HUGHES MED INST,COCONUT GROVE,FL 33133; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Howard Hughes Medical Institute; University of Toronto								Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; CASS A, 1973, NATURE-NEW BIOL, V244, P47, DOI 10.1038/newbio244047a0; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; Fukushima T, 1996, J CELL BIOL, V132, P1037, DOI 10.1083/jcb.132.6.1037; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Goss G, 1996, AM J PHYSIOL-CELL PH, V270, pC1493, DOI 10.1152/ajpcell.1996.270.5.C1493; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRINSTEIN S, 1988, AM J PHYSIOL, V254, pC272, DOI 10.1152/ajpcell.1988.254.2.C272; GRINSTEIN S, 1986, J CELL PHYSIOL, V128, P33, DOI 10.1002/jcp.1041280107; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; NACCACHE PH, 1990, BLOOD, V76, P2098; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; NOBES CD, 1995, J CELL SCI, V108, P225; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SARDET C, 1991, J BIOL CHEM, V266, P19166; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHRODE LD, 1995, AM J PHYSIOL-CELL PH, V269, pC257, DOI 10.1152/ajpcell.1995.269.1.C257; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; TORRES M, 1993, J IMMUNOL, V150, P1563; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WORTHEN GS, 1994, AM J RESP CELL MOL, V10, P1; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553	49	118	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17303	17311		10.1074/jbc.272.28.17303	http://dx.doi.org/10.1074/jbc.272.28.17303			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211867	hybrid			2022-12-25	WOS:A1997XK16500010
J	Laccotripe, M; Makrides, SC; Jonas, A; Zannis, VI				Laccotripe, M; Makrides, SC; Jonas, A; Zannis, VI			The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; FUNCTIONAL-PROPERTIES; PLASMA; PROTEIN; ACTIVATION; VARIANTS; DOMAIN; DNA; PHOSPHATIDYLCHOLINES; SUBSTITUTIONS	We performed a series of mutations in the human apolipoprotein A-I (apoA-I) gene designed to alter specific amino acid residues and domains implicated in lecithin: cholesterol acyltransferase (LCAT) activation or lipid binding. We used the mutant apoA-I forms to establish nine stable cell lines, and developed strategies for the large scale production and purification of the mutated apoA-I proteins from conditioned media. HDL and dimyristoyl phosphatidylcholine binding assays using the variant apoA-I forms have shown that replacement of specific carboxyl-terminal hydrophobic residues Leu(222), Phe(225), and Phe(229) with lysines, as well as replacement of Leu(211), Leu(214), Leu(218), and Leu(219) with valines, diminished the ability of apoA-I to bind to HDL and to lyse dimyristoyl phosphatidylcholine liposomes. The findings indicate that Leu(222), and Phe(225), Phe(229) located in the putative random coil region, and Leu(211), Leu(214), Leu(218), and Leu(219) located in the putative helix 8, are important for lipid binding. In contrast, substitutions of alanines for specific charged residues in putative helices 7, 8, or 9 as well as various point mutations in other regions of apoA-I, did not affect the ability of the variant apoA-I forms to bind to HDL or to lyse dimyristoyl phosphatidylcholine liposomes. Cross-linking experiments confirmed that the carboxyl-terminal domain of apoA-I participates in the self-association of the protein, as demonstrated by the inability of the carboxyl-terminal deletion mutants Delta 185-243 and Delta 209-243 to form higher order aggregates in solution. Lecithin:cholesterol acyltransferase analysis, using reconstituted HDL particles prepared by the sodium cholate dialysis method, has shown that mutants (Pro(165) --> Ala,Gln(173) --> Glu) (Leu(311) --> Val,Leu(214) --> Val,Leu(318) --> Val,Leu(319) --> Val), Leu(222) --> Lys,Phe(255) --> Lys,Phe(290) --> Lys) and Delta 209-243 reduced LCAT activation (38-68%). Mutant (Glu(191) --> Ala,His(195) --> Ala,Lys(196) --> Ala) enhanced LCAT activation (131%), and mutant (Ala(162) --> Leu,Leu(189) --> Trp) exhibited normal LCAT activation as compared with the wild type proapoA-I and plasma apoA-I forms. The apparent catalytic efficiency (V-max(app)/K-m(app)) of the apoA-I mutants ranged from 17.8 to 107.2% of the control and was the result of variations in both the K-m and the V-max in the different mutants. These findings indicate that putative helices 6 and 7, and the carboxyl-terminal helices 8 and 9 contribute to the optimum activation of lecithin:cholesterol acyltransferase. In addition to their use in the present study, the variant apoA-I forms generated will serve as valuable reagents for the identification of the domains and residues of apoA-I involved in binding the scavenger receptor BI, and facilitating cholesterol efflux from cells as well as aid in the structural analysis of apoA-I.	BOSTON UNIV,MED CTR,DEPT MED,CTR ADV BIOMED RES,SECT MOL GENET,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT BIOCHEM,BOSTON,MA 02118; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801	Boston University; Boston University; University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL48739, HL16059] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016059, R01HL048739] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albers J J, 1986, Methods Enzymol, V129, P763; ALLAN CM, 1993, BIOCHEM J, V290, P449, DOI 10.1042/bj2900449; BAKRIA A, 1991, ATHEROSCLEROSIS, V87, P135; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARKER WC, 1977, COMP BIOCHEM PHYS B, V57, P309, DOI 10.1016/0305-0491(77)90060-8; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; Cleland W W, 1979, Methods Enzymol, V63, P103; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; DEEB SS, 1991, J BIOL CHEM, V266, P13654; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; FRANCESCHINI G, 1990, BIOCHIM BIOPHYS ACTA, V1043, P1, DOI 10.1016/0005-2760(90)90102-4; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; GHISELLI G, 1985, J BIOL CHEM, V260, P5662; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; HUSSAIN MM, 1991, ELECTROPHORESIS, V12, P273, DOI 10.1002/elps.1150120408; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JONAS A, 1993, BIOCHIM BIOPHYS ACTA, V1166, P202, DOI 10.1016/0005-2760(93)90098-T; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1984, J BIOL CHEM, V259, P6369; JONAS A, 1987, PLASMA LIPOPROTEINS, P299; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI WH, 1988, J LIPID RES, V29, P245; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENG QH, 1993, J BIOL CHEM, V268, P16966; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PALIAKASIS CD, 1992, PROTEIN ENG, V5, P739, DOI 10.1093/protein/5.8.739; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROGHANI A, 1988, BIOCHEMISTRY-US, V27, P7428, DOI 10.1021/bi00419a038; SCHMITZ G, 1990, EUR HEART J, V11, P197, DOI 10.1093/eurheartj/11.suppl_E.197; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; Sparrow J T, 1980, Ann N Y Acad Sci, V348, P187, DOI 10.1111/j.1749-6632.1980.tb21300.x; Steinmetz A, 1984, Agents Actions Suppl, V16, P217; UTERMANN G, 1984, EUR J BIOCHEM, V144, P325, DOI 10.1111/j.1432-1033.1984.tb08467.x; VONECKARDSTEIN A, 1989, J CLIN INVEST, V84, P1722, DOI 10.1172/JCI114355; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; WALD JH, 1990, J BIOL CHEM, V265, P20037; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; ZANNIS VI, 1982, J BIOL CHEM, V257, P536; ZANNIS VI, 1993, ADV HUM GENET, V21, P145; ZANNIS VI, 1980, J BIOL CHEM, V255, P8612; ZANNIS VI, 1986, METHOD ENZYMOL, V128, P823	59	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17511	17522		10.1074/jbc.272.28.17511	http://dx.doi.org/10.1074/jbc.272.28.17511			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211897	hybrid			2022-12-25	WOS:A1997XK16500040
J	McCoy, KD; Ahmed, N; Tan, AS; Berridge, MV				McCoy, KD; Ahmed, N; Tan, AS; Berridge, MV			The hemopoietic growth factor, interleukin-3, promotes glucose transport by increasing the specific activity and maintaining the affinity for glucose of plasma membrane glucose transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MOUSE 3T3-L1 CELLS; RAT ADIPOSE-CELLS; INTRINSIC ACTIVITY; HEXOSE-TRANSPORT; GLUT-4 PHOSPHORYLATION; SUGAR-TRANSPORT; INSULIN ACTION; CLONE-9 CELLS; PHORBOL ESTER	Most mammalian cells rely on an external supply of glucose for survival, proliferation, and function, Glucose enters cells through specific transporter molecules at the plasma membrane by a facilitative process that does not expend energy, Regulation of glucose transport into cells is thought to occur largely through transporter expression at the cell surface, but the extent to which the intrinsic properties of glucose transporters are regulated is at present controversial, Using a bone marrow-derived cell line that responds to the hemopoietic growth factor, interleukin-3 (IL-3), we investigated IL-3 regulation of glucose transport, IL-3 significantly increased 2-deoxyglucose (2-DOG) uptake within 1 h (26 +/- 8.0%, n = 11) with a maximum 73% increase after 6 h, Withdrawal of IL-3 resulted in decreased uptake within 1 h rand this continued to decline to 43% of initial uptake by 16 h, To determine whether these changes in 2-DOG uptake were associated with corresponding changes in glucose transporter expression, subtype-specific antisera against. Glut-1 and Glut-3 were used, Little change in membrane expression of these transporters was observed prior to 16 h, Fractionation of cell membranes on Nycodenz gradients showed that the majority of each transporter subtype was associated with the plasma membrane (63-93%) and that transporter distribution did not change markedly in response to addition or withdrawal of IL-3, These results demonstrate that IL-3 regulates glucose uptake by modulating the: intrinsic transporting ability of glucose transporters, Decreased transporter affinity for 2-DOG and 3-8-methylglucose was observed following IL-3 withdrawal, Similar affinity changes were observed with 2-DOG following exposure of IL-3-stimulated cells to the protein kinase inhibitors, genistein and staurosporine, In contrast, the tyrosine phosphatase inhibitor, vanadate, acted hire IL-3 to increase transporter affinity for glucose, Together these results demonstrate that IL-3 acts to maintain the intrinsic transport properties of glucose transporters without markedly affecting their expression or translocation.	MALAGHAN INST MED RES, WELLINGTON SCH MED, WELLINGTON 6002, NEW ZEALAND	Malaghan Institute; University of Otago; Victoria University Wellington			Berridge, Michael V/I-3969-2013; McCoy, Kathy/ABD-5814-2021	Berridge, Michael/0000-0003-2619-7473				ASANO T, 1992, BIOCHEM J, V288, P189, DOI 10.1042/bj2880189; BEGUM N, 1993, J BIOL CHEM, V268, P3352; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; BILAN PJ, 1992, BIOCHEM BIOPH RES CO, V186, P1129, DOI 10.1016/0006-291X(92)90864-H; BILAN PJ, 1992, FEBS LETT, V298, P285, DOI 10.1016/0014-5793(92)80078-U; BIRD TA, 1990, J BIOL CHEM, V265, P13578; CHAKRABARTI R, 1994, J IMMUNOL, V152, P2660; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DIAMOND DL, 1993, J BIOL CHEM, V268, P6437; Fisher MD, 1996, J BIOL CHEM, V271, P11806, DOI 10.1074/jbc.271.20.11806; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUILLETDENIAU I, 1994, J CELL SCI, V107, P487; HAMILTON JA, 1988, J CELL PHYSIOL, V134, P405, DOI 10.1002/jcp.1041340311; HARRINGTON CR, 1990, ANAL BIOCHEM, V186, P285, DOI 10.1016/0003-2697(90)90081-J; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JOOST HG, 1986, J BIOL CHEM, V261, P33; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MERCADO CL, 1989, AM J PHYSIOL, V257, pC19; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; SHI YW, 1995, J BIOL CHEM, V270, P21772, DOI 10.1074/jbc.270.37.21772; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKAGI H, 1994, INVEST OPHTH VIS SCI, V35, P170; THOMAS HM, 1993, BIOCHEM J, V290, P707, DOI 10.1042/bj2900707; TOYODA N, 1987, J BIOL CHEM, V262, P2737; WHETTON AD, 1985, J CELL PHYSIOL, V123, P73, DOI 10.1002/jcp.1041230112; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; WHITESELL RR, 1985, J BIOL CHEM, V260, P2894; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	40	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17276	17282		10.1074/jbc.272.28.17276	http://dx.doi.org/10.1074/jbc.272.28.17276			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211864	hybrid			2022-12-25	WOS:A1997XK16500007
J	Widlak, P; Gaynor, RB; Garrard, WT				Widlak, P; Gaynor, RB; Garrard, WT			In vitro chromatin assembly of the HIV-1 promoter - ATP-dependent polar repositioning of nucleosomes by Sp1 and NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; I-HYPERSENSITIVE SITES; TRANSCRIPTIONAL ACTIVATION; REMODELING FACTOR; GENE-EXPRESSION; DNA-REPLICATION; BINDING; DISRUPTION; ENHANCER; INVITRO	Nuclease hypersensitive sites exist in vivo in the chromatin of the integrated human immunodeficiency virus (HIV)-1 proviral genome, in the 5'-long terminal repeat (LTR) within the promoter/enhancer region near Spl and NF kappa B binding sites, Previous studies from the Kadonaga and Jones laboratories have shown that Spl and NF kappa B can establish hypersensitive sites in a truncated form of this LTR when added before in vitro chromatin assembly with Drosophiba extracts, thus facilitating subsequent transcriptional activation of a linked reporter gene upon the association of additional factors (Pazin, M. J,, Sheridan, P, L,, Cannon, Ii., Cao, Z,, Keck, J, G,, Kadanaga, J, T., and Jones, Ii, A, (1996) Genes & Dev. 10, 37-49), Here we assess the role of a full-length LTR and 1 kilobase pair of downstream flanking HIV sequences in chromatin remodeling when these transcription factors are added after chromatin assembly. Using Xenopus laevis oocyte extracts to assemble chromatin in vitro, we have confirmed that Spl and NF kappa B can indeed induce sites hypersensitive to DNase I, micrococcal nuclease, or restriction enzymes on either side of factor binding sites in chromatin but not naked DNA, We extend these earlier studies by demonstrating that the process is ATP-dependent when the factors are added after chromatin assembly and that histone H1, API, TBP, or Tat had no effect on hypersensitive site formation, Furthermore, we have found that nucleosomes upstream of NF kappa B sites are rotationally positioned prior to factor binding and that their translational frame is registered after binding-NF kappa B, On the other hand, binding of Spl positions adjacent downstream nucleosome(s), We term this polar repositioning because each factor aligns nucleosomes only on one side of its binding sites, Mutational analysis and oligonucleotide competition each demonstrated that this remodeling required Spl and NF kappa B binding sites.	UNIV TEXAS, SW MED CTR, DEPT MOL BIOL & ONCOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Widlak, Piotr/AAL-8075-2021	Widlak, Piotr/0000-0001-5099-4726	NIAID NIH HHS [AI25288] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; ELKHARROUBI A, 1994, J BIOL CHEM, V269, P19916; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARCIAMARTINEZ LF, 1995, J MOL BIOL, V254, P350; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; Hoover T, 1996, NUCLEIC ACIDS RES, V24, P1895, DOI 10.1093/nar/24.10.1895; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1988, NUCLEIC ACIDS RES, V16, P6677, DOI 10.1093/nar/16.14.6677; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LUSE D, 1995, CHROMATIN STRUCTURE, P105; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Nagano M, 1997, BIOCHEM BIOPH RES CO, V231, P561, DOI 10.1006/bbrc.1997.6120; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Potter KN, 1996, J IMMUNOL, V157, P2982; RAZVI F, 1983, GENE, V23, P175, DOI 10.1016/0378-1119(83)90049-5; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SHIMAMURA A, 1989, METHOD ENZYMOL, V170, P603; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; STEFFY K, 1991, MICROBIOL REV, V55, P193, DOI 10.1128/MMBR.55.2.193-205.1991; STEGER DJ, 1996, EMBO J, V18, P875; Strouboulis J, 1996, J CELL SCI, V109, P1991; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VANHOLDE KE, 1988, CHROMATIN, P1; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696	50	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17654	17661		10.1074/jbc.272.28.17654	http://dx.doi.org/10.1074/jbc.272.28.17654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211915	hybrid			2022-12-25	WOS:A1997XK16500058
J	Artigues, A; Iriarte, A; MartinezCarrion, M				Artigues, A; Iriarte, A; MartinezCarrion, M			Refolding intermediates of acid-unfolded mitochondrial aspartate aminotransferase bind to hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE TRANSLATION SYSTEM; MOLTEN GLOBULE STATE; HEAT-SHOCK; ESCHERICHIA-COLI; STRUCTURAL FEATURES; HOMOLOGOUS PROTEINS; PRECURSOR PROTEIN; FOLDING PATHWAY; IMPORT; LYSOZYME	The cytosolic (cAAT) and mitochondrial (mAAT) isozymes of eukaryotic aspartate aminotransferase share a high degree of sequence identity and almost identical three-dimensional structure, The rat liver proteins can be refolded and reassembled into active dimers after unfolding at low pH. However, refolding of the mitochondrial form after unfolding at pH 2.0 is arrested in the presence of hsp70, whereas this chaperone does not affect the refolding of the cytosolic isozyme unfolded under similar conditions. To elucidate the nature of the differential interaction between hsp70 and the two transaminase forms, eve have characterized their refolding from their acid-unfolded states, The recovery of activity of the cytosolic enzyme is monophasic and can be adequately described by a single first-order reaction, By contrast, two sequential first-order rate-limiting stops can be detected for the refolding and reactivation of the mitochondrial protein, The overall refolding pathway of mAAT includes a very fast collapse to an intermediate with 80% of the secondary structure of the active dimer, This is followed by a slow isomerization to form assembly-competent monomers that rapidly associate to form an inactive dimer and a final structural rearrangement of the dimer to the native conformation. Analysis of the interaction of hsp70 with intermediates along the folding pathway of mAAT shows that the polypeptide loses its ability to bind to the chaperone after it has proceeded through the first isomerization/fast dimerization steps, Thus it appears that only the first collapsed intermediate states in the folding of mAAT bind hsp70. By contrast a faster refolding of cAAT from this, collapsed state could explain, at least in part,the inability of hsp70 to bind this isozyme.	UNIV MISSOURI, SCH BIOL SCI, DIV MOL BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City					NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTIGUES A, 1994, J BIOL CHEM, V269, P21990; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOND S, 1985, J MOL BIOL, V182, P597, DOI 10.1016/0022-2836(85)90245-1; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOETTCHER B, 1975, BIOCHEMISTRY-US, V14, P4528, DOI 10.1021/bi00691a030; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; CHIEN JY, 1948, J AM CHEM SOC, V70, P2256, DOI 10.1021/ja01186a078; COURNIL I, 1975, J BIOL CHEM, V250, P8564; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Endo T, 1996, J BIOL CHEM, V271, P4161; FELISS N, 1970, BIOCHEM BIOPH RES CO, V40, P932, DOI 10.1016/0006-291X(70)90993-9; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; JAENICKE R, 1988, PROTEIN STRUCTURE PR, P191; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAIN B, 1994, J BIOL CHEM, V269, P15588; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MARTINEZCARRION M, 1970, BIOCHEMISTRY-US, V9, P2574, DOI 10.1021/bi00815a004; MARTINEZCARRION M, 1967, J BIOL CHEM, V242, P2397; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1995, J BIOL CHEM, V270, P1138, DOI 10.1074/jbc.270.3.1138; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; PUIG A, 1994, J BIOL CHEM, V269, P25889; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; REYES AM, 1993, J BIOL CHEM, V268, P22281; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; TERADA K, 1995, MOL CELL BIOL, V15, P3708; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; TSAI MY, 1994, J BIOL CHEM, V269, P5958; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WU T, 1994, THESIS U MISSOURI KA; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	65	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16852	16861		10.1074/jbc.272.27.16852	http://dx.doi.org/10.1074/jbc.272.27.16852			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201992	hybrid			2022-12-25	WOS:A1997XH44600024
J	Desseyn, JL; Aubert, JP; VanSeuningen, I; Porchet, N; Laine, A				Desseyn, JL; Aubert, JP; VanSeuningen, I; Porchet, N; Laine, A			Genomic organization of the 3' region of the human mucin gene MUC5B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VONWILLEBRAND-FACTOR; IN-SITU HYBRIDIZATION; VON-WILLEBRAND-FACTOR; HUMAN GASTRIC MUCIN; INTESTINAL MUCIN; GALLBLADDER MUCIN; MOLECULAR-CLONING; CHOLESTEROL GALLSTONES; EXPRESSION CLONING; AMINO-ACIDS	MUC5B, mapped clustered with MUC6, MUC2, and MUC5AC to chromosome 11p15.5, is a human mucin gene of which the genomic organization is being elucidated. We have recently published the sequence and the peptide organization of its huge central exon, 10,713 base pairs (bp) in length, We present here the genomic organization of its 3' region, which encompasses 10,690 bp. The genomic sequence has been completely determined, The 3' region of MUC5B is composed of 18 exons ranging in size from 32 to 781 bp, contrasting thus with the very large central exon, The sizes of the 18 introns range from 114 to 1118 bp, Some repetitive sequences were identified in four introns, The peptide deduced from the sequence of the 18 exons consists of an 808-amino acid peptide. This carboxyl-terminal region exhibits extensive sequence similarity to MUGS, MUC5AC, and von Willebrand factor, particularly the number and the positions of the cysteine residues, suggesting that this domain may be derived from a common ancestral gene, The presence in these components of a cystine knot also found in growth factors such as transforming growth factor-beta is of particular interest, Moreover, one part of this peptide is identical to the 196-amino acid sequence deduced from the cDNA clone pSM2-1, which codes for a part of the high molecular weight mucin MG1 isolated from human sublingual gland, Considering the expression pattern of MUC5B and the origin of MG1, we can thus conclude that MUC5B encodes MG1.	INSERM U377, F-59045 LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, HOP HURIEZ, LAB BIOCHIM & BIOL MOL, F-59037 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille			VAN SEUNINGEN, Isabelle/N-6176-2016; Desseyn, Jean-Luc/M-5070-2018	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Desseyn, Jean-Luc/0000-0001-6876-8049				AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; AUDIE JP, 1995, HUM REPROD, V10, P98, DOI 10.1093/humrep/10.1.98; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BAKER ME, 1988, BIOCHEM J, V256, P1059, DOI 10.1042/bj2561059; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953, DOI 10.1016/0016-5085(95)90406-9; BANSIL R, 1995, ANNU REV PHYSIOL, V57, P635, DOI 10.1146/annurev.ph.57.030195.003223; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Bobek LA, 1996, GENOMICS, V31, P277, DOI 10.1006/geno.1996.0049; BORK P, 1992, CURR OPIN STRUC BIOL, V4, P383; Buisine MP, 1996, GASTROENTEROLOGY, V110, P84, DOI 10.1053/gast.1996.v110.pm8536891; CAMPION JP, 1995, HEPATOLOGY, V21, P223, DOI 10.1002/hep.1840210135; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CONG NV, 1990, HUM GENET, V86, P167; CREPIN M, 1990, BIORHEOLOGY, V27, P471; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; Hoffmann W, 1995, BIOCHEM SOC T, V23, P805, DOI 10.1042/bst0230805; HOFFMANN W, 1993, COMP BIOCHEM PHYS B, V105, P465, DOI 10.1016/0305-0491(93)90075-G; KALINER M, 1986, AM REV RESPIR DIS, V134, P612; KAWAGISHI S, 1990, ARCH ORAL BIOL, V35, P265, DOI 10.1016/0003-9969(90)90041-8; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLINKSPOOR JH, 1993, EUR J GASTROEN HEPAT, V5, P226, DOI 10.1097/00042737-199304000-00007; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LAN MS, 1990, J BIOL CHEM, V265, P15294; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LEE SP, 1981, J CLIN INVEST, V67, P1712, DOI 10.1172/JCI110209; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; LOOMIS RE, 1987, ARCH BIOCHEM BIOPHYS, V258, P452, DOI 10.1016/0003-9861(87)90366-3; LYNCH DC, 1983, P NATL ACAD SCI-BIOL, V80, P2738, DOI 10.1073/pnas.80.9.2738; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; Pigny P, 1996, BIOCHEM BIOPH RES CO, V220, P186, DOI 10.1006/bbrc.1996.0378; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROBERTON AM, 1989, BIOCHEM J, V261, P637, DOI 10.1042/bj2610637; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH BF, 1985, J CLIN INVEST, V76, P439, DOI 10.1172/JCI111991; SMITH BF, 1984, J BIOL CHEM, V259, P2170; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Troxler RF, 1995, BIOCHEM BIOPH RES CO, V217, P1112, DOI 10.1006/bbrc.1995.2884; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; VERMA M, 1994, CANCER BIOCHEM BIOPH, V14, P151; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320	67	99	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16873	16883		10.1074/jbc.272.27.16873	http://dx.doi.org/10.1074/jbc.272.27.16873			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201995	hybrid			2022-12-25	WOS:A1997XH44600027
J	Upchurch, GR; Welch, GN; Fabian, AJ; Freedman, JE; Johnson, JL; Keaney, JF; Loscalzo, J				Upchurch, GR; Welch, GN; Fabian, AJ; Freedman, JE; Johnson, JL; Keaney, JF; Loscalzo, J			Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL INJURY; POSSIBLE RISK FACTOR; SMOOTH-MUSCLE CELLS; MYOCARDIAL-INFARCTION; HOMOCYSTEINE; DISEASE; SELENIUM; ATHEROSCLEROSIS; HOMOCYSTINURIA; PLASMA	Hyperhomocyst(e)inemia is believed to injure endothelial cells in vivo through a number of mechanisms, including the generation of hydrogen peroxide (H2O2), Earlier in vitro studies demonstrated that homocyst(e)ine (Hcy) decreases the biological activity of endothelium-derived relaxing factor and that this decrease can be reversed by preventing the generation of hydrogen peroxide, Here we show that Hcy treatment of bovine aortic endothelial cells leads to a dose-dependent decrease in NOx (p = 0.001 by one-way analysis of variance) independent of endothelial nitric-oxide synthase activity or protein levels and nos3 transcription, suggesting that Hcy affects the bioavailability of NO, not its production, We hypothesized that, in addition to increasing the generation of H2O2, Hcy decreases the cell's ability to detoxify H2O2 by impairing intracellular antioxidant enzymes, specifically the intracellular isoform of glutathione peroxidase (GPx), To test this hypothesis, confluent bovine aortic endothelial cells were treated with a range of concentrations of Hcy, and intracellular GPx activity was determined, Compared with control cells, cells treated with Hcy showed a significant reduction in GPx activity (up to 81% at 250 mu M Hcy), In parallel with the decrease in GPx activity, steady-state GPx mRNA levels were also significantly decreased compared with control levels after exposure to Hcy, which appeared not to be a consequence of message destabilization, These data suggest; a novel mechanism by which Hcy, in addition to increasing the generation of hydrogen peroxide, may selectively impair the endothelial cells ability to detoxify H2O2, thus rendering NO more susceptible to oxidative inactivation.	BOSTON UNIV,SCH MED,WHITAKER CARDIOVASC INST,BOSTON,MA 02118; BOSTON UNIV,SCH MED,EVANS DEPT MED,BOSTON,MA 02118; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02115	Boston University; Boston University; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Loscalzo, Joseph/ABD-8980-2021	Keaney, John/0000-0002-0866-1837	NHLBI NIH HHS [HL47416, HL48743, P50 HL55993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055993, P01HL048743] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON A, 1995, CLIN CHEM, V41, P361; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; AVISSAR N, 1989, BLOOD, V73, P318; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM L, 1989, THESIS U LUND LUND; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUCZYNSKI A, 1993, ATHEROSCLEROSIS, V100, P223, DOI 10.1016/0021-9150(93)90208-C; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; FREEDMAN JE, 1995, J CLIN INVEST, V96, P394, DOI 10.1172/JCI118047; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; FUKUO K, 1995, J CLIN INVEST, V95, P669, DOI 10.1172/JCI117712; GABRIELSEN BO, 1980, J NUTR, V110, P1096, DOI 10.1093/jn/110.6.1096; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HAUDENSCHILD CC, 1976, EXP CELL RES, V98, P175, DOI 10.1016/0014-4827(76)90477-8; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1988, OXYRADICALS MOL BIOL; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; LENTZ SR, 1991, J CLIN INVEST, V88, P1936; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MUDD SH, 1972, BIOCHEM BIOPH RES CO, V46, P905; MUDD SH, METABOLIC BASIS INHE, P1279; NISHINAGA M, 1994, JPN J CLIN PATHOL, V42, P340; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; SALONEN JT, 1982, LANCET, V2, P175; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SMOLIN LA, 1983, J NUTR, V113, P2022, DOI 10.1093/jn/113.10.2022; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WALCH GN, 1996, METHOD ENZYMOL, V268, P293; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9	42	577	618	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17012	17017		10.1074/jbc.272.27.17012	http://dx.doi.org/10.1074/jbc.272.27.17012			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202015	hybrid, Green Published			2022-12-25	WOS:A1997XH44600047
J	Blakesley, VA; BeitnerJohnson, D; VanBrocklyn, JR; Rani, S; ShenOrr, Z; Stannard, BS; Spiegel, S; LeRoith, D				Blakesley, VA; BeitnerJohnson, D; VanBrocklyn, JR; Rani, S; ShenOrr, Z; Stannard, BS; Spiegel, S; LeRoith, D			Sphingosine 1-phosphate stimulates tyrosine phosphorylation of Crk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEOTIDE EXCHANGE FACTOR; PHOSPHATIDIC-ACID LEVELS; SRC HOMOLOGY-3 DOMAIN; 2ND MESSENGER; PC12 CELLS; C-CRK; V-CRK; CERAMIDE; PATHWAY	The proto-oncogene molecule c-Crk plays a role in growth factor-induced activation of Pas. Sphingosine 1-phosphate (SPP), a metabolite of cellular sphingolipids, has previously been shown to play a role in growth factor receptor signaling (Olivera, A., and Spiegel, S. (1993) Nature 365, 557-560), SPP was found to strongly induce tyrosine phosphorylation of Crk, but not She, in NIH-3T3 parental, insulin-like growth factor-I receptor-overexpressing and Crk-overexpressing (3T3-Crk) fibroblasts. Sphingosine, a metabolic precursor of SPP, also produced a slight increase in tyrosine phosphorylation of Crk. In contrast, other sphingolipid metabolites including ceramide did not alter Crk tyrosine phosphorylation. Furthermore, Crk enhanced SPP-induced mitogenesis, as measured by SPP-stimulated [H-3]thymidine incorporation in a manner proportional to the level of Crk expression in 3T3-Crk cells. This stimulation appears to be Ras dependent, whereas SPP stimulation of MAP kinase activity is Ras independent. These data indicate that SPP activates a tyrosine kinase that phosphorylates Crk and that Crk is a positive effector of SPP-induced mitogenesis.	NIDDK,DIABET BRANCH,NATL INST HLTH,BETHESDA,MD 20892; GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Georgetown University			Van Brocklyn, Jim/A-9733-2010		NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAO CP, 1994, J BIOL CHEM, V269, P5849; DESAI NN, 1992, J BIOL CHEM, V267, P23122; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAVIE Y, 1990, BIOCHEM BIOPH RES CO, V167, P607; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAINES MA, 1993, J BIOL CHEM, V268, P14572; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG H, 1990, J BIOL CHEM, V265, P21309	39	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16211	16215		10.1074/jbc.272.26.16211	http://dx.doi.org/10.1074/jbc.272.26.16211			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195921	hybrid			2022-12-25	WOS:A1997XG01900025
J	Lackmann, M; Mann, RJ; Kravets, L; Smith, FM; Bucci, TA; Maxwell, KF; Howlett, GJ; Olsson, JE; Bos, TV; Cerretti, DP; Boyd, AW				Lackmann, M; Mann, RJ; Kravets, L; Smith, FM; Bucci, TA; Maxwell, KF; Howlett, GJ; Olsson, JE; Bos, TV; Cerretti, DP; Boyd, AW			Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SURFACE-PLASMON RESONANCE; BINDING CONSTANTS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; KINETIC-ANALYSIS; GROWTH-FACTOR; CELL LINES; FAMILY; EXPRESSION	HEK is a member of the EPH-like receptor tyrosine kinase family, which appear to have roles in development and oncogenesis. Recently, we purified a soluble HEK ligand which is also a ligand (AL1) for the HEK-related receptor EHK1. Promiscuity appears to be a characteristic feature of interactions between the EPH-like receptors and their ligands, termed ligands for EPH-related kinases (LERKs). This prompted us to analyze the interactions between the HER exodomain and fusion proteins comprising candidate LERKs and the Fc portion of human IgG(1) (Fc) or a FLAG(TM)-peptide tag by surface plasmon resonance, size exclusion high performance liquid chromatography, sedimentation equilibrium, and transphosphorylation. Our results indicate that AL1/LERK7 is the preferred high-affinity ligand for HEK, forming a stable 1:1 complex with a dissociation constant of 12 nM. As expected the apparent affinities of bivalent fusion proteins of LERKs and the Fc portion of human IgG(1) had significantly reduced dissociation rates compared with their monovalent, FLAG(TM)-tagged derivatives. High-avidity binding of monovalent ligands can be achieved by antibody-mediated cross-linking of monovalent ligands and with LERK7 results in specific phosphorylation of the receptor. By extrapolation, our findings indicate that some of the reported LERK-receptor interactions are a consequence of the use of bivalent ligand or receptor constructs and may be functionally irrelevant.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,LUDWIG INST CANC RES,MELBOURNE BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,LIONS CANC RES LAB,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,RUSSELL GRIMWADE SCH BIOCHEM & MOL BIOL,PARKVILLE,VIC 3052,AUSTRALIA; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; ROYAL BRISBANE HOSP,BANCROFT CTR,QUEENSLAND INST MED RES,HERSTON,QLD 4029,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Lackmann, M (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,COOPERAT RES CTR CELLULAR GROWTH FACTORS,MELBOURNE,VIC 3050,AUSTRALIA.		Boyd, Andrew/G-2083-2010					ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BIOSENSOR P, 1995, BIATECHNOLOGY HDB; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOYD AW, 1992, J BIOL CHEM, V267, P3262; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Cerretti DP, 1996, GENOMICS, V35, P376, DOI 10.1006/geno.1996.0371; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; Chatellier J, 1996, J MOL RECOGNIT, V9, P39, DOI 10.1002/(SICI)1099-1352(199601)9:1<39::AID-JMR239>3.0.CO;2-V; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOGG PJ, 1987, BIOCHEMISTRY-US, V26, P1867, DOI 10.1021/bi00381a012; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KARLSSON R, 1992, STRUCTURE ANTIGENS; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; MARU Y, 1990, ONCOGENE, V5, P445; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PELLEQUER JL, 1993, J IMMUNOL METHODS, V166, P133, DOI 10.1016/0022-1759(93)90337-7; POSNER RG, 1991, BIOCHEMISTRY-US, V30, P2348, DOI 10.1021/bi00223a008; SALVARIS E, 1992, LEUKEMIA RES, V16, P655, DOI 10.1016/0145-2126(92)90016-Z; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SIMPSON RJ, 1986, EUR J BIOCHEM, V157, P497, DOI 10.1111/j.1432-1033.1986.tb09694.x; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2901, DOI 10.1021/bi00009a021; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6	49	63	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16521	16530		10.1074/jbc.272.26.16521	http://dx.doi.org/10.1074/jbc.272.26.16521			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195962	hybrid			2022-12-25	WOS:A1997XG01900066
J	Matsuo, N; Ogawa, S; Takagi, T; Wanaka, A; Mori, T; Matsuyama, T; Pinsky, DJ; Stern, DM; Tohyama, M				Matsuo, N; Ogawa, S; Takagi, T; Wanaka, A; Mori, T; Matsuyama, T; Pinsky, DJ; Stern, DM; Tohyama, M			Cloning of a putative vesicle transport-related protein, RA410, from cultured rat astrocytes and its expression in ischemic rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MEDIATED INDUCTION; FREE-RADICALS; GENE; SURVIVAL; HYPOXIA/REOXYGENATION; INTERLEUKIN-6; ENDOTHELIUM; METABOLISM; MECHANISM	To elucidate the role of astrocytes in the stress response of the central nervous system to ischemia, early gene expression was evaluated in cultured rat astrocytes subjected to hypoxia/reoxygenation. Using differential display, a novel putative vesicle transport-related factor (RA410) was cloned from reoxygenated astrocytes. Analysis of the deduced amino acid sequence showed RA410 to be composed of domains common to vesicle transport-related proteins of the Sec1/Unc18 family, including Sly1p and Sec1p (yeast), Rop (Drosophila), Unc18 (Caenorhabditis elegans), and Munc18 (mammalian), suggesting its possible role in vesicular transport. Northern analysis of normal rat tissues showed the highest expression of RA410 transcripts in testis. When astrocyte cultures were subjected to a period of hypoxia followed by reoxygenation, induction of RA410 mRNA was observed within 15 min of reoxygenation, reaching a maximum by 60 min. At the start of reoxygenation, the addition of diphenyl iodonium, an NADPH oxidase inhibitor, blocked in parallel astrocyte generation of reactive oxygen intermediates and expression of RA410 message. In contrast, cycloheximide did not affect RA410 mRNA levels, indicating that RA410 is an immediate-early gene in the setting of reoxygenation. Using polyclonal antibody raised against an RA410-derived synthetic peptide, Western blotting of lysates from reoxygenated astrocytes displayed an immunoreactive band of approximate to 70 kDa, the expression of which followed induction of the mRNA. Fractionation of astrocyte lysates on sucrose gradients showed RA410 antigen to be predominantly in the plasma membrane. Immunoelectron microscopic analysis demonstrated RA410 in large vesicles associated with the Golgi, but not in the Golgi apparatus itself, consistent with its participation in post-Golgi transport. Consistent with these in vitro data, RA410 expression was observed in rat brain astrocytes following transient occlusion of the middle cerebral artery. These data provide insight into a new protein (RA410) that participates in the ischemia-related stress response in astrocytes.	OSAKA UNIV, SCH MED, DEPT ANAT & NEUROSCI, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MOL NEUROBIOL TANABE, SUITA, OSAKA 565, JAPAN; FUKUSHIMA MED COLL, DEPT CELL SCI, INST BIOMED SCI, FUKUSHIMA 96012, JAPAN; HYOGO MED UNIV, DEPT MED 5, NISHINOMIYA, HYOGO 663, JAPAN; DAINIPPON PHARMACEUT CO LTD, SUITA, OSAKA 564, JAPAN; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS & SURG, NEW YORK, NY 10032 USA	Osaka University; Osaka University; Fukushima Medical University; Hyogo College of Medicine; University of Hyogo; Dainippon Sumitomo Pharmaceutical Company; Columbia University			Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/ABE-4671-2020; Wanaka, Akio/GPW-8926-2022	Wanaka, Akio/0000-0001-9951-9862; 	NHLBI NIH HHS [HL50629, HL42507] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042507, R01HL050629] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALATO MK, 1991, YEAST, V7, P643; ARTHUR FE, 1987, DEV BRAIN RES, V36, P155, DOI 10.1016/0165-3806(87)90075-7; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLES CR, 1994, J CELL SCI, V107, P3449; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HENN FA, 1972, BRAIN RES, V43, P435; HORI O, 1994, J NEUROCHEM, V62, P1489; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hori O, 1996, J NEUROCHEM, V66, P973; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; JANECZKO K, 1991, BRAIN RES, V564, P86, DOI 10.1016/0006-8993(91)91355-5; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; KUBOTA Y, 1987, BRAIN RES, V413, P179, DOI 10.1016/0006-8993(87)90167-3; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHOUSBOE A, 1977, NEUROCHEM RES, V2, P217, DOI 10.1007/BF00964098; SHRECK R, 1991, EMBO J, V10, P2247; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; SWANSON RA, 1993, J CEREBR BLOOD F MET, V13, P162, DOI 10.1038/jcbfm.1993.19; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	42	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16438	16444		10.1074/jbc.272.26.16438	http://dx.doi.org/10.1074/jbc.272.26.16438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195952	Green Published, hybrid			2022-12-25	WOS:A1997XG01900056
J	Cappellen, D; deMedina, SGD; Chopin, D; Thiery, JP; Radvanyi, F				Cappellen, D; deMedina, SGD; Chopin, D; Thiery, JP; Radvanyi, F			Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder	ONCOGENE			English	Article						bladder; human; transitional cell carcinoma; tumour progression; chromosome 10; loss of heterozygosity	SUPPRESSOR LOCI; ALLELIC LOSS; PROSTATE-CANCER; MXI1 GENE; LONG ARM; DELETION; IDENTIFICATION; PROGRESSION; REGION; HYBRIDIZATION	Loss of heterozygosity (LOH) on chromosome 10 has been observed in several human cancers including glioblastomas, meningiomas, melanomas and endometrial and prostate carcinomas, We have investigated the incidence of LOH on chromosome 10 in 36 human transitional cell carcinomas (TCCs) of the bladder, three upper urinary tract TCCs and one lymph node metastasis, using a panel of 27 highly polymorphic markers spanning 10p (short arm) and 10q (long arm), Fourteen bladder tumours (39%), the three upper urinary tract tumours and the lymph node metastasis showed LOH for at least one locus on chromosome 10, Remarkably, LOH on chromosome 10 was observed mainly in muscle-invasive (P=0.01) and high grade tumours (P=0.03). For five tumours and the lymph node metastasis, LOH was found at all informative loci, indicating monosomy or isodisomy of chromosome 10, The deletion mapping of the tumours with partial loss delineated two minimal regions of loss on chromosome 10q, One region, the most telomeric, was bounded by markers D10S214 and D10S169 and the other, the most proximal, was bounded by markers D10S222 and D10S531, Our results demonstrate that chromosome 10q LOH is common in muscle-invasive bladder cancers and that two potential tumour suppressor loci, at 10q24.1-q24.3 and 10q26.1-q26.2, may contribute to the malignant progression of these tumours. Localization of the smallest common regions of loss in bladder tumours provides a starting point for the identification of the genes involved.	INST CURIE,CNRS,UMR 144,SECT RECH,F-75248 PARIS 05,FRANCE; CHU HENRI MONDOR,GRP ETUD TUMEURS UROL,F-94010 CRETEIL,FRANCE; CHU HENRI MONDOR,UROL SERV,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP			Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424	NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAROSA R, 1995, HUM GENET, V95, P709; ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1991, ONCOGENE, V6, P2305; CHANG WYH, 1995, CANCER RES, V55, P3246; COOMBS LM, 1990, ANAL BIOCHEM, V188, P338, DOI 10.1016/0003-2697(90)90617-I; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIBAS Z, 1984, CANCER RES, V44, P1257; GRAY IC, 1995, CANCER RES, V55, P4800; HABUCHI T, 1995, ONCOGENE, V11, P1671; HERBST RA, 1994, CANCER RES, V54, P3111; Ittmann M, 1996, CANCER RES, V56, P2143; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mostofi FK, 1973, INT HISTOLOGICAL CLA; OLUMI AF, 1990, CANCER RES, V50, P7081; PEIFFER SL, 1995, CANCER RES, V55, P1922; POLASCIK TJ, 1995, CANCER RES, V55, P5396; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; ROSIN MP, 1995, CANCER RES, V55, P5213; RUPPERT JM, 1993, CANCER RES, V53, P5093; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SIMON M, 1995, CANCER RES, V55, P4696; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SPIESSL B, 1992, TNM ATLAS ILLUSTRATE, P214; SPRUCK CH, 1994, CANCER RES, V54, P784; Trybus TM, 1996, CANCER RES, V56, P2263; TSAI YC, 1990, CANCER RES, V50, P44; WANG MR, 1994, CANCER GENET CYTOGEN, V73, P8, DOI 10.1016/0165-4608(94)90175-9; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	47	99	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3059	3066		10.1038/sj.onc.1201154	http://dx.doi.org/10.1038/sj.onc.1201154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223669				2022-12-25	WOS:A1997XG10000008
J	Berner, JM; MezaZepeda, LA; Kools, PFJ; Forus, A; Schoenmakers, EFPM; VandeVen, WJM; Fodstad, O; Myklebost, O				Berner, JM; MezaZepeda, LA; Kools, PFJ; Forus, A; Schoenmakers, EFPM; VandeVen, WJM; Fodstad, O; Myklebost, O			HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas	ONCOGENE			English	Article						chromosome 12q13-15; amplicon; MAR; MDM2; HMGIC	GENOMIC HYBRIDIZATION ANALYSIS; MULTIPLE-ABERRATION REGION; SOFT-TISSUE SARCOMAS; MESSENGER-RNA; SOLID TUMORS; AMPLIFICATION; PROTEIN; MDM2; EXPRESSION; GLI	Amplified segments of the long arm of chromosome 12 are frequently observed in human sarcomas, In most cases there are separate amplified regions around the MDM2 and CDK4 genes, Here we show recurrent amplification of a third region encompassing HMGIC, a human architectural transcription factor gene, Reduced amplification frequency of sequences flanking the gene was observed, indicating that inclusion of this third region in the amplicons is also selected for, In three samples only the 5' part of HMGIC was amplified, suggesting preferential loss of the 3' part of the gene preceding or during amplification, In several other samples rearrangement of the gene was observed, Expression analysis showed transcripts of aberrant sizes, lacking 3' sequences, and 3' RACE of one sample revealed replacement of exons 4 and 5 with ectopic sequences, This truncation of HMGIC resembles that reported for translocations of HMGIC in benign tumors, including Lipomas, and it is striking that the gene was frequently amplified or rearranged in web differentiated Liposarcomas, the malignant counterpart of lipomas, It seems conceivable that high levels of either full length or truncated hmgic could be relevant for the etiology of these tumors.	NORWEGIAN RADIUM HOSP, DEPT TUMOR BIOL, B-3000 OSLO, NORWAY; CATHOLIC UNIV LEUVEN VIB, CTR HUMAN GENET, MOL ONCOL LAB, LOUVAIN, BELGIUM	Flanders Institute for Biotechnology (VIB); KU Leuven			Meza-Zepeda, Leonardo Andres/CAG-5229-2022; Myklebost, Ola/E-9335-2010	Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Myklebost, Ola/0000-0002-2866-3223				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; FORUS A, 1994, CANCER GENET CYTOGEN, V78, P165, DOI 10.1016/0165-4608(94)90085-X; FORUS A, 1991, CYTOGENET CELL GENET, V58, P1977; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; Kazmierczak B, 1996, ONCOGENE, V12, P515; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kools PFJ, 1996, CANCER GENET CYTOGEN, V91, P1, DOI 10.1016/S0165-4608(96)00109-4; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROBERTS WM, 1989, CANCER RES, V49, P5407; SCHAJOWICH F, 1993, HISTOLOGICAL TYPING; SCHOENMAKERS EFPM, 1995, GENOMICS, V29, P665, DOI 10.1006/geno.1995.9952; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SMITH SH, 1992, CANCER RES, V52, P3746; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; WANSCHURA S, 1995, GENE CHROMOSOME CANC, V14, P68, DOI 10.1002/gcc.2870140112; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	35	86	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2935	2941		10.1038/sj.onc.1201135	http://dx.doi.org/10.1038/sj.onc.1201135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205100				2022-12-25	WOS:A1997XF55500007
J	Korchev, YE; Bashford, CL; Alder, GM; Apel, PY; Edmonds, DT; Lev, AA; Nandi, K; Zima, AV; Pasternak, CA				Korchev, YE; Bashford, CL; Alder, GM; Apel, PY; Edmonds, DT; Lev, AA; Nandi, K; Zima, AV; Pasternak, CA			A novel explanation for fluctuations of ion current through narrow pores	FASEB JOURNAL			English	Article						PETP membrane; alpha toxin channel; Staphylococcus aureus	AUREUS ALPHA-TOXIN; CONDUCTANCE STATES; DIVALENT-CATIONS; VOLUME CHANGES; CHANNEL; MEMBRANES; MODULATION; MECHANISM; TRANSPORT; BILAYERS	Fluctuation of ion current, between a high conductance and a low conductance state, through biological ion channels changes between an ''open'' and a ''closed'' configuration. Here we offer an additional mechanism that arises from changes in ionization of fixed charges within, or at the mouth of, a channel or pore. Our hypothesis, which is based on measurements of ion selectivity alongside ion current, applies to pores through some synthetic membranes and through channels--such as those created by certain toxins--that remain (at least partially) open in the low conductance state. It may also explain the phenomena of ''open channel noise'' and ''sub-state behavior'' that characterize several endogenous ion channels and should be considered when modeling the behavior of such channels.	UNIV LONDON, ST GEORGES MED SCH, DEPT CELLULAR & MOL SCI, LONDON SW17 0RE, ENGLAND; UNIV LONDON, CHARING CROSS & WESTMINSTER MED SCH, DEPT PHYSIOL, LONDON W6 8RF, ENGLAND; JOINT INST NUCL RES, DUBNA 141980, MOSCOW REGION, RUSSIA; RUSSIAN ACAD SCI, INST CYTOL, ST PETERSBURG 194064, RUSSIA; UNIV OXFORD, CLARENDON LAB, OXFORD OX1 3PU, ENGLAND	St Georges University London; University of London; Imperial College London; University of London; Joint Institute for Nuclear Research - Russia; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; University of Oxford			Apel, Pavel Yu./D-4133-2009; babakinejad, babak/G-2674-2012; Korchev, Yuri/D-2498-2009	Apel, Pavel Yu./0000-0003-1259-163X; Korchev, Yuri/0000-0002-4872-8696	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APEL PY, 1985, COLLOID J USSR+, V47, P1; BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BASHFORD CL, 1988, J MEMBRANE BIOL, V103, P79, DOI 10.1007/BF01871934; BASHFORD CL, 1996, CELL MOL BIOL LETT, V1, P213; BEZRUKOV SM, 1993, PHYS REV LETT, V70, P2352, DOI 10.1103/PhysRevLett.70.2352; CESCATTI L, 1991, J MEMBRANE BIOL, V119, P53, DOI 10.1007/BF01868540; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; DAWSON RMC, 1969, DATA BIOCH RES, P426; FOX JA, 1987, J MEMBRANE BIOL, V97, P1, DOI 10.1007/BF01869609; GUTMAN M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P391, DOI 10.1016/0005-2728(90)90073-D; HILLE B, 1992, IONIC CHANNELS EXCIT, P472; HOWARD RE, 1986, SCIENCE, V231, P346, DOI 10.1126/science.231.4736.346; KORCHEV YE, 1995, J MEMBRANE BIOL, V147, P233; KRASILNIKOV OV, 1989, GEN PHYSIOL BIOPHYS, V8, P213; Lakshminarayanaiah N., 1969, TRANSPORT PHENOMENA; LEV AA, 1993, P ROY SOC B-BIOL SCI, V252, P187, DOI 10.1098/rspb.1993.0064; MEARES P, 1974, P ROY SOC LOND A MAT, V339, P513, DOI 10.1098/rspa.1974.0136; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; MEVES H, 1989, BIOCHIM BIOPHYS ACTA, V988, P99, DOI 10.1016/0304-4157(89)90005-1; NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700; PASTERNAK CA, 1995, RADIAT MEAS, V25, P675, DOI 10.1016/1350-4487(95)00220-9; PASTERNAK CA, 1993, COLLOID SURFACE A, V77, P119, DOI 10.1016/0927-7757(93)80108-Q; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; ROSTOVTSEVA T, 1996, BIOPHYS J, V70, pA1; Rostovtseva TK, 1996, J MEMBRANE BIOL, V151, P29, DOI 10.1007/s002329900055; SACHS F, 1993, BIOPHYS J, V65, P1101, DOI 10.1016/S0006-3495(93)81149-4; SIGWORTH FJ, 1985, BIOPHYS J, V47, P709, DOI 10.1016/S0006-3495(85)83968-0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SPOHR R, 1990, ION TRACKERS MICROTE; STEIN WD, 1986, TRANSPORT DIFFUSION, P134; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VLACHY V, 1986, J PHYS CHEM-US, V90, P3248, DOI 10.1021/j100405a039; WOLF A, 1995, GSI NACHR 5 OCT 1995; YEOMANS L, 1993, J CHEM PHYS, V98, P1436, DOI 10.1063/1.464308; ZAMBROWICZ EB, 1993, BIOPHYS J, V65, P1093, DOI 10.1016/S0006-3495(93)81148-2; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIMMERBERG J, 1990, BIOPHYS J, V57, P1049, DOI 10.1016/S0006-3495(90)82623-0	37	59	60	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					600	608		10.1096/fasebj.11.7.9212084	http://dx.doi.org/10.1096/fasebj.11.7.9212084			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212084				2022-12-25	WOS:A1997XH34200012
J	Makino, K; Kuwahara, H; Masuko, N; Nishiyama, Y; Morisaki, T; Sasaki, J; Nakao, M; Kuwano, A; Nakata, M; Ushio, Y; Saya, H				Makino, K; Kuwahara, H; Masuko, N; Nishiyama, Y; Morisaki, T; Sasaki, J; Nakao, M; Kuwano, A; Nakata, M; Ushio, Y; Saya, H			Cloning and characterization of NE-dlg: A novel human homolog of the Drosophila discs large (dlg) tumor suppressor protein interacts with the APC protein	ONCOGENE			English	Article						tumor suppressor genes; two-hybrid screening; chromosome Xq13; EST	MOLECULAR CHARACTERIZATION; GENE-PRODUCT; HUMAN GENOME; TIGHT; ZO-1; ASSOCIATION; JUNCTIONS; SEPTATE; SAP90	We have cloned a cDNA for a novel human homolog of the Dvosophila discs large (dig) tumor suppressor protein, termed NE-dlg (neuronal and endocrine dig). Northern blot analysis revealed that the gene is highly expressed in neuronal and endocrine tissues. Fluorescence in situ hybridization (FISH) and radiation hybrid mapping studies localized the NE-dlg gene to chromosome Xq13. We also found that the NE-dlg gene encoded a 100 kDa protein. Immunolocalization studies using an NE-dlg antibody showed that the protein tended to be expressed in non-proliferating cells, such as neurons, cells in Langerhans islets of the pancreas, myocytes of the heart muscles, and the prickle and functional layer cells of the esophageal epithelium. Proliferative cells, including various cultured cancer cell lines and basal cells in the esophageal epithelium, showed little expression of the NE-dlg protein. In addition, yeast true-hybrid screening and in vitro binding assays revealed that the NE-dlg interacted with the carboxyl-terminal region of the APC tumor suppressor protein. These data suggest that NE-dlg negatively regulates cell proliferation through its interaction with the APC protein.	KUMAMOTO UNIV, SCH MED, DEPT TUMOR GENET & BIOL, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT NEUROSURG, KUMAMOTO 860, JAPAN; EHIME UNIV, SCH MED, DEPT HYG EHIME, SHIGENOBU, EHIME 79102, JAPAN; SUMITOMO ELECT IND LTD, BIOMED R&D DEPT, YOKOHAMA, KANAGAWA 244, JAPAN	Kumamoto University; Kumamoto University; Ehime University; Sumitomo Electric Industries			Saya, Hideyuki/J-4325-2013					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUWANO A, 1991, AM J HUM GENET, V49, P707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MONROE KR, 1995, NAT MED, V1, P827, DOI 10.1038/nm0895-827; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; WATSON KL, 1994, J CELL SCI, P19; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	34	53	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2425	2433		10.1038/sj.onc.1201087	http://dx.doi.org/10.1038/sj.onc.1201087			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188857				2022-12-25	WOS:A1997WZ68000006
J	Hammad, SM; Ranganathan, S; Loukinova, E; Twal, WO; Argraves, WS				Hammad, SM; Ranganathan, S; Loukinova, E; Twal, WO; Argraves, WS			Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2 megalin - A mechanism to prevent pathological accumulation of amyloid beta-peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; ALPHA(2)-MACROGLOBULIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; MEDIATES ENDOCYTOSIS; ORGAN DISTRIBUTION; PRECURSOR PROTEIN; GLYCOPROTEIN-330; EXPRESSION; IDENTIFICATION; PURIFICATION	Apolipoprotein J (apoJ) has been shown to be the predominant amyloid beta-peptide (A beta)-binding protein in cerebrospinal fluid. We have previously demonstrated that the endocytic receptor low density lipoprotein receptor-related protein-2/megalin (LRP-2), which is expressed by choroid plexus epithelium and ependymal cells lining the brain ventricles and neural tube, binds and mediates cellular uptake of apoJ (Kounnas, M. Z., Loukinova, E. B., Stefansson, S., Harmony, J. A., Brewer, B., Strickland, D. K., and Argraves, W. S. (1995) J. Biol. Chem. 270, 13070-13075). In the present study, we evaluated the ability of apoJ to mediate binding of A beta(1-40)-apoJ complex to LRP-2 in vitro. Immunoblot analysis showed that incubation of apoJ with A beta(1-40) resulted in the formation of A beta(1-40)-apoJ complex and the inhibition of the formation of A beta(1-40) aggregates. Using an enzyme-linked immunosorbent assay, an estimated dissociation constant (K-d) of 4.8 nM was derived for the interaction between A beta(1-40) and apoJ. Enzyme-linked immunosorbent assay was also used to study the interaction of the A beta(1-40)-apoJ complex with LRP-2. The results showed that A beta alone did not bind directly to LRP-2; however, when A beta(1-40) was combined with apoJ to form a complex, binding to LRP-2 took place. The binding interaction could be blocked by inclusion of the receptor-associated protein, an antagonist of apoJ binding to LRP-2. When LRP-2-expressing cells were given I-125-A beta(1-40), cellular uptake of the radiolabeled peptide was promoted by co-incubation with apoJ. When the cells were provided purified I-125-A beta(1-40)-apoJ complex, the complex was internalized and degraded, and both processes were inhibited with polyclonal LRP-2 antibodies. Furthermore, chloroquine treatment inhibited the cellular degradation of the complex. The data indicate that apoJ facilitates A beta(1-40) binding to LRP-2 and that the receptor mediates cellular clearance of A beta(1-40)-apoJ complex leading to lysosomal degradation of A beta(1-40). The findings support the possibility that LRP-2 can act in vivo to mediate clearance of the complex from biological fluids such as cerebrospinal fluid and thereby play a role in the regulation of A beta accumulation.	MED UNIV S CAROLINA,DEPT CELL BIOL & ANAT,CHARLESTON,SC 29425	Medical University of South Carolina				Hammad, Samar/0000-0002-1313-2542	NIDDK NIH HHS [DK45598] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHUJA HS, 1994, BIOCHEM CELL BIOL, V72, P523, DOI 10.1139/o94-070; ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; ASSMANN KJM, 1986, VIRCHOWS ARCH A, V408, P541, DOI 10.1007/BF00705307; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BU GJ, 1994, J BIOL CHEM, V269, P18521; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; ODA T, 1994, BIOCHEM BIOPH RES CO, V204, P1131, DOI 10.1006/bbrc.1994.2580; PIKE CJ, 1993, J NEUROSCI, V13, P1676; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEFANSSON S, 1995, J CELL SCI, V108, P2361; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TSUZUKI K, 1994, BRAIN RES, V659, P213, DOI 10.1016/0006-8993(94)90881-8; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V205, P1431, DOI 10.1006/bbrc.1994.2825; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	36	173	180	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18644	18649		10.1074/jbc.272.30.18644	http://dx.doi.org/10.1074/jbc.272.30.18644			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228033	hybrid			2022-12-25	WOS:A1997XM34200024
J	NikolovaKarakashian, M; Morgan, ET; Alexander, C; Liotta, DC; Merrill, AH				NikolovaKarakashian, M; Morgan, ET; Alexander, C; Liotta, DC; Merrill, AH			Bimodal regulation of ceramidase by interleukin-1 beta - Implications for the regulation of cytochrome P450 2C11 (CYP2C11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT HEPATOCYTES; TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; CONSTITUTIVE EXPRESSION; CELL-DIFFERENTIATION; SIGNAL-TRANSDUCTION; LIVER MICROSOMES; FREE SPHINGOSINE; PROTEIN-KINASES; FATTY-ACID	Interleukin 1 beta (IL-1 beta) induces the hydrolysis of sphingomyelin (SM) to ceramide (Cer) in primary cultures of rat hepatocytes, and Cer has been proposed to play a role in the down-regulation of cytochrome P450 2C11 (CYP2C11) and induction of alpha(1)-acid glycoprotein (AGP) by this cytokine (Chen, J., Nikolova-Karakashian, M., Merrill, A. H. & Morgan, E. T. (1995) J. Biol. Chem. 270, 25235-25238). Nonetheless, some of the features of the down regulation of CYPSC11 do not fit a simple model of Cer as a second messenger as follows: N-acetylsphinganine (C2-DHCer) is as potent as RT-acetylsphingosine (C2-Cer) in suppression of CYP2C11; the IL-1 beta concentration dependence for SM turnover is different from that for the increase in Cer; and the increase in Cer mass is not equivalent to the amount of SM hydrolyzed nor the time course of SM hydrolysis. In this article, we report that these discrepancies are due to activation of ceramidase by the low concentrations of IL-1 beta (similar to 2.5 ng/ml) that maximally down-regulate CYP2C11 expression, whereas higher IL-1 beta concentrations (that induce AGP) do not activate ceramidase and allow Cer accumulation, This bimodal concentration dependence is demonstrated both by in vitro ceramidase assays and in intact hepatocytes using a fluorescence Cer analog, 6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-Cer (NBD-Cer), and following release of the NBD-fatty acid, IL-1 beta increases both acid and neutral ceramidase activities, which appear to be regulated by tyrosine phosphorylation because pretreatment of hepatocytes with sodium vanadate increases (and 25 mu M genistein reduces) the basal and IL-1 beta-stimulated ceramidase activities, Since these findings suggested that sphingosine (and, possibly, subsequent metabolites) is the primary mediator of the down regulation of CYP2C11 by IL-1 beta, the effects of exogenous sphingosine and Ca-Cer on expression of this gene were compared, Sphingosine was more potent than C2-Cer in down-regulation of CYP2C11 when added alone or with fumonisin B-1 to block acylation of the exogenous sphingosine. Furthermore, the suppression of CYP2C11 by C2-Cer (and C2-DHCer) is probably mediated by free sphingoid bases, rather than the short chain Cer directly, because both are hydrolyzed by hepatocytes and increase cellular levels of sphingosine and sphinganine. From these observations we conclude that sphingosine, possibly via sphingosine 1-phosphate, is a mediator of the regulation of CYP2C11 by IL-1 beta in rat hepatocytes and that ceramidase activation provides a ''switch'' that determines which sphingolipids are elevated by this cytokine to produce multiple intracellular responses.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ROLLINS RES CTR,ATLANTA,GA 30322; EMORY UNIV,DEPT PHARMACOL,ATLANTA,GA 30322; EMORY UNIV,DEPT CHEM,ATLANTA,GA 30322	Emory University; Emory University; Emory University				Morgan, Edward/0000-0003-4273-2261; Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM 46897, GM 46368] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368, R01GM046897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BABIA T, 1993, INT J CANCER, V54, P839, DOI 10.1002/ijc.2910540519; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHEN JQ, 1995, MOL PHARMACOL, V47, P940; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; Ching KZ, 1996, DRUG METAB DISPOS, V24, P542; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DBAIBO GS, 1995, BIOCHEM J, V310, P453, DOI 10.1042/bj3100453; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KIM MY, 1991, J BIOL CHEM, V266, P484; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; KOHIRA T, 1993, J BIOCHEM-TOKYO, V114, P658, DOI 10.1093/oxfordjournals.jbchem.a124233; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIDDLE C, 1992, ARCH BIOCHEM BIOPHYS, V298, P159, DOI 10.1016/0003-9861(92)90107-8; MARTIN OC, 1986, ANAL BIOCHEM, V159, P101, DOI 10.1016/0003-2697(86)90313-1; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCCORMACK M, 1987, BIOCHEM J, V244, P717, DOI 10.1042/bj2440717; MERRILL AH, 1988, ANAL BIOCHEM, V171, P337; MERRILL AH, 1996, HANDB LIP R, V8, P205; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Oral H, 1997, J BIOL CHEM, V272, P4836, DOI 10.1074/jbc.272.8.4836; PATCHINSKY T, 1982, P NATL ACAD SCI USA, V79, P973; PUSHKAREVA MY, 1993, BIOCHEM J, V294, P699, DOI 10.1042/bj2940699; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Smith ER, 1997, J BIOL CHEM, V272, P5640, DOI 10.1074/jbc.272.9.5640; SPENCE MW, 1986, BIOCHEM CELL BIOL, V64, P400, DOI 10.1139/o86-056; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SPINAS GA, 1988, ACTA ENDOCRINOL-COP, V119, P307, DOI 10.1530/acta.0.1190307; STRUM JC, 1994, J BIOL CHEM, V269, P15493; SU Y, 1994, J BIOL CHEM, V269, P16512; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	50	137	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18718	18724		10.1074/jbc.272.30.18718	http://dx.doi.org/10.1074/jbc.272.30.18718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228043	hybrid			2022-12-25	WOS:A1997XM34200034
J	Saftig, P; Hartmann, D; LullmannRauch, R; Wolff, J; Evers, M; Koster, A; Hetman, M; vonFigura, K; Peters, C				Saftig, P; Hartmann, D; LullmannRauch, R; Wolff, J; Evers, M; Koster, A; Hetman, M; vonFigura, K; Peters, C			Mice deficient in lysosomal acid phosphatase develop lysosomal storage in the kidney and central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC TAIL; TARTRATE-RESISTANT; CELLS; GENE; SIGNAL; INTERNALIZATION; LOCALIZATION; ANTAGONISTS; PROTEINS; BINDING	Lysosomal acid phosphatase (LAP) is a tartrate-sensitive enzyme with ubiquitous expression. Neither the physiological substrates nor the functional significance is known. Mice with a deficiency of LAP generated by targeted disruption of the LAP gene are fertile and develop normally. Microscopic examination of various peripheral organs revealed progredient lysosomal storage in podocytes and tubular epithelial cells of the kidney, with regionally different ultrastructural appearance of the stored material. Within the central nervous system, lysosomal storage was detected to a regionally different extent in microglia, ependymal cells, and astroglia concomitant with the development of a progressive astrogliosis and microglial activation. Whereas behavioral and neuromotor analyses were unable to distinguish between control and deficient mice, similar to 7% of the deficient animals developed generalized seizures. From the age of 6 months onward, conspicuous alterations of bone structure became apparent, resulting in a kyphoscoliotic malformation of the lower thoracic vertebral column. We conclude from these findings that LAP has a unique function in only a subset of cells, where its deficiency causes the storage of a heterogeneously appearing material in lysosomes. The causal relationship of the enzyme defect to the clinical manifestations remains to be determined.	CHRISTIAN ALBRECHTS UNIV KIEL,INST ANAT,D-24118 KIEL,GERMANY; UNIV GOTTINGEN,ZENTRUM ANAT,D-37075 GOTTINGEN,GERMANY	University of Kiel; University of Gottingen	Saftig, P (corresponding author), UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOL ZELLBIOL,BIOCHEM ABT 2,GOSSLERSTR 12D,D-37073 GOTTINGEN,GERMANY.		Saftig, Paul/A-7966-2010					ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SA, 1989, J BONE MINER RES, V4, P399; DANYSZ W, 1994, PHARMACOL BIOCHEM BE, V48, P111, DOI 10.1016/0091-3057(94)90506-1; de Duve C., 1969, LYSOSOME RETROSPECT, P3; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; DREXLER HG, 1994, LEUKEMIA, V8, P359; GEIER C, 1992, J HISTOCHEM CYTOCHEM, V40, P1275, DOI 10.1177/40.9.1506664; GEIER C, 1991, BIOL CHEM H-S, V372, P301, DOI 10.1515/bchm3.1991.372.1.301; GIESELMANN V, 1995, BBA-MOL BASIS DIS, V1270, P103, DOI 10.1016/0925-4439(94)00075-2; GIESELMANN V, 1984, H-S Z PHYSIOL CHEM, V365, P651, DOI 10.1515/bchm2.1984.365.1.651; Giulian Dana, 1995, P671; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Heinemann Uwe, 1995, P936; HILLE A, 1992, EUR J CELL BIOL, V59, P106; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ISBRANDT D, 1994, AM J HUM GENET, V54, P454; KERSTENS HMJ, 1995, J HISTOCHEM CYTOCHEM, V43, P347, DOI 10.1177/43.4.7897179; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MARLEY RJ, 1987, LIFE SCI, V40, P2215, DOI 10.1016/0024-3205(87)90056-7; MCKUSICK VA, 1983, METABOLIC BASIS INHE, P2465; NADLER HL, 1970, NEW ENGL J MED, V282, P302, DOI 10.1056/NEJM197002052820604; NADLER HL, 1973, LYSOSOMES STORAGE DI, P475; PARSONS CG, 1995, NEUROPHARMACOLOGY, V34, P1239, DOI 10.1016/0028-3908(95)00092-K; PETERS C, 1989, BIOL CHEM H-S, V370, P177, DOI 10.1515/bchm3.1989.370.1.177; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RAAB AK, 1995, HUM MOL GENET, V4, P529; REHKOP DM, 1975, H-S Z PHYSIOL CHEM, V356, P1775, DOI 10.1515/bchm2.1975.356.2.1775; RESNICK D, 1988, DIAGNOSIS BONE JOINT, V4, P2022; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WAHEED A, 1985, BIOCHEM GENET, V23, P309, DOI 10.1007/BF00504327; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; YU O, 1986, BRAIN RES, V399, P374, DOI 10.1016/0006-8993(86)91531-3	45	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18628	18635		10.1074/jbc.272.30.18628	http://dx.doi.org/10.1074/jbc.272.30.18628			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228031	hybrid			2022-12-25	WOS:A1997XM34200022
J	Schneider, P; Bodmer, JL; Holler, N; Mattmann, C; Scuderi, P; Terskikh, A; Peitsch, MC; Tschopp, J				Schneider, P; Bodmer, JL; Holler, N; Mattmann, C; Scuderi, P; Terskikh, A; Peitsch, MC; Tschopp, J			Characterization of Fas (Apo-1, CD95)-Fas ligand interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR-BINDING; FACTOR-ALPHA; CD40 LIGAND; LYMPHOPROLIFERATIVE SYNDROME; CYTOTOXIC ACTIVITY; INDUCED APOPTOSIS; T-LYMPHOCYTES; CD95 LIGAND; CELL-DEATH	The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Pas Ligand (FasL). When human soluble FasL (sFasL, containing the extracellular portion) was expressed in human embryo kidney 293 cells, the three N-linked glycans of each FasL monomer were found to be essential for efficient secretion. Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods. Point mutations of amino acid residues predicted to affect the receptor-ligand interaction were introduced at three sites. The F275L mutant, mimicking the loss of function murine gld mutation, exhibited a high propensity for aggregation and was unable to bind to Fas. Mutants P206R, P206D, and P206F displayed reduced cytotoxicity toward Fas-positive cells with a concomitant decrease in the binding affinity for the recombinant Fas-immunoglobulin Fc fusion proteins. Although the cytotoxic activity of mutant Y218D was unaltered, mutant Y218R was inactive, correlating with the prediction that Tyr-218 of FasL interacts with a cluster of three basic amino acid side chains of Fas. Interestingly, mutant Y218F could induce apoptosis in murine, but not human cells.	GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline	Schneider, P (corresponding author), UNIV LAUSANNE,INST BIOCHEM,BIL MED RES CTR,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.		Terskikh, Alexey/U-8407-2019; Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X; Schneider, Pascal/0000-0003-0677-9409				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BANNER DW, 1993, CELL, V73, P481; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BENJAMIN D, 1992, LYMPHOKINE CYTOK RES, V11, P45; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Estaquier J, 1996, BLOOD, V87, P4959, DOI 10.1182/blood.V87.12.4959.bloodjournal87124959; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; GOH CR, 1991, PROTEIN ENG, V4, P785; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JUMPER MD, 1995, J IMMUNOL, V155, P2369; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KINGSTON RE, 1995, CURRENT PROTOCOLS MO; KOYAMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P188, DOI 10.1016/0167-4781(92)90010-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LUETHY R, 1992, Nature (London), V356, P83; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Mariani SM, 1996, J IMMUNOL METHODS, V193, P63, DOI 10.1016/0022-1759(96)00051-8; MartinezLorenzo MJ, 1996, IMMUNOLOGY, V89, P511, DOI 10.1046/j.1365-2567.1996.d01-782.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PEITSCH MC, 1995, MOL IMMUNOL, V32, P761, DOI 10.1016/0161-5890(95)00016-8; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sato K, 1996, BRIT J HAEMATOL, V94, P379, DOI 10.1046/j.1365-2141.1996.d01-1799.x; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Starling GC, 1997, J EXP MED, V185, P1487, DOI 10.1084/jem.185.8.1487; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsutsui H, 1996, J IMMUNOL, V157, P3967; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; Via CS, 1996, J IMMUNOL, V157, P5387; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	64	152	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18827	18833		10.1074/jbc.272.30.18827	http://dx.doi.org/10.1074/jbc.272.30.18827			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228058	hybrid, Green Published			2022-12-25	WOS:A1997XM34200049
J	Besra, GS; Morehouse, CB; Rittner, CM; Waechter, CJ; Brennan, PJ				Besra, GS; Morehouse, CB; Rittner, CM; Waechter, CJ; Brennan, PJ			Biosynthesis of mycobacterial lipoarabinomannan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; GLYCOPROTEIN-BIOSYNTHESIS; STRUCTURAL DEFINITION; MANNOSYL DONOR; BOVIS BCG; TUBERCULOSIS; SMEGMATIS; OLIGOSACCHARIDE; MACROPHAGES; ETHAMBUTOL	The mycobacterial lipoglycans, lipomannan (LM) and lipoarabinomannan (LAM), are potent immunomodulators in tuberculosis and leprosy. Little is known of their biosynthesis, other than being based on phosphatidylinositol (PI), and they probably originate in the phosphatidylinositol mannosides (PIMs; PIMans). A novel form of cell-free incubation involving in vitro and in situ labeling with GDP-[(14)]Man of the polyprenyl-P-mannoses (C35C50-P-Man) and the simpler PIMs of mycobacterial membranes, reisolation of the [C-14]Man-labeled membranes, and in situ chase demonstrated the synthesis of a novel ru(1 --> 6)-linked linear form of LM at the expense of the C-33/C-50-P-Man. There was little or no synthesis under these conditions of PIMan(5) with its terminal. alpha(1 --> 6)Man unit or the mature LM or LAM with copious alpha(1 --> 2)Man branching. Synthesis of the linear LM, but not of the simpler PIMan(2), was susceptible to amphomycin, a lipopeptide antibiotic that specifically inhibits polyprenyl-P-requiring translocases. A mixture of P[H-3]I and P[H-3]IMan(2) was incorporated into the linear LM, supporting other evidence that, like the PIMs, LM and LAM, it is a lipid-linked mannooligosaccharide and a new member of the mycobacterial glycosylphosphatidylinositol lipoglycan/glycolipid class. Hence, the simpler PIMs originate in PI and GDP-Man, but further growth of the linear backbone emanates from C-35-/C-50-P-Man and is amphomycin-sensitive. The origin of the alpha(1 --> 1)Man branches of mature PIMan(5), LM, and LAM is not known at this time but is probably GDP-IMan.	COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,LEXINGTON,KY 40536	Colorado State University; University of Kentucky				Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R01AI018357, R37AI018357, U19AI038087] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-38087, AI-18357] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMANY AM, 1975, J BIOL CHEM, V250, P2842; AZUMA I, 1968, J BACTERIOL, V95, P263, DOI 10.1128/JB.95.2.263-271.1968; BALLOU CE, 1963, J BIOL CHEM, V238, P69; BALLOU CE, 1972, METHOD ENZYMOL, V28, P493; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; Besra Gurdyal S., 1994, P285; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; DELL A, 1994, METHOD ENZYMOL, V230, P108; DITTMER JC, 1964, J LIPID RES, V5, P126; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HILL DL, 1966, J BIOL CHEM, V241, P895; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; KANG MS, 1978, J BIOL CHEM, V253, P8860; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; LEE YC, 1964, J BIOL CHEM, V239, P1316; LEE YC, 1965, BIOCHEMISTRY-US, V4, P1395, DOI 10.1021/bi00883a026; LUCAS JJ, 1975, J BIOL CHEM, V250, P1992; MAITRA SK, 1976, BIOCHEM BIOPH RES CO, V73, P1101, DOI 10.1016/0006-291X(76)90236-9; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; PANGBORN MC, 1966, J LIPID RES, V7, P627; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; RATLEDGE C, 1976, ADV MICROB PHYSIOL, V13, P115, DOI 10.1016/S0065-2911(08)60039-9; ROACH TIA, 1993, J IMMUNOL, V150, P1886; ROBBINS PW, 1977, J BIOL CHEM, V252, P1780; RUSH JS, 1993, J BIOL CHEM, V268, P13110; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SCHULTZ J, 1974, ARCH BIOCHEM BIOPHYS, V160, P311, DOI 10.1016/S0003-9861(74)80039-1; SCHULTZ JC, 1975, BIOCHIM BIOPHYS ACTA, V381, P175, DOI 10.1016/0304-4165(75)90199-3; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SLAKOTOS AN, 1965, J AM OIL CHEM SOC, V42, P913; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1971, FEBS LETT, V18, P67, DOI 10.1016/0014-5793(71)80408-8; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V136, P217; TANAKA H, 1977, BIOCHIM BIOPHYS ACTA, V496, P633; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21621	50	144	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18460	18466		10.1074/jbc.272.29.18460	http://dx.doi.org/10.1074/jbc.272.29.18460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218490	hybrid			2022-12-25	WOS:A1997XL73500080
J	Gurnett, CA; Felix, R; Campbell, KP				Gurnett, CA; Felix, R; Campbell, KP			Extracellular interaction of the voltage-dependent Ca2+ channel alpha(2)delta and alpha(1) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; NA,K-ATPASE BETA-SUBUNIT; SKELETAL-MUSCLE; DIHYDROPYRIDINE-BINDING; STRUCTURAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; HIGH-AFFINITY; DOMAIN; IDENTIFICATION; RECEPTOR	The role of the extracellular domain of the voltage-dependent Ca2+ channel alpha(2) delta subunit in assembly with the alpha(1C) subunit was investigated. Transiently transfected tsA201 cells processed the alpha(2) delta subunit properly as disulfide linkages and cleavage sites between the alpha(2) and delta subunits were shown to be similar to native channel protein. Coimmunoprecipitation experiments demonstrated that in the absense of delta subunits, alpha(2) subunits do not assemble with alpha(1) subunits. Furthermore, the transmembrane and cytoplasmic sequences in delta can be exchanged with those of an unrelated protein without any effect on the association between the alpha(2) delta and alpha(1) proteins. Extracellular domains of the alpha(2) delta subunits are also shown to be responsible for increasing the binding affinity of [H-3]PN200-11- (isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-5-([H-3]methoxycarbonyl)-pyridine-3-carboxylate) for the alpha(1C) subunit. Investigation of the corresponding interaction site on the alpha(1) subunit revealed that although tryptic peptides containing repeat III of native alpha(1S) subunit remain in association with the alpha(2) delta subunit during wheat germ agglutinin chromatography, repeat III by itself is not sufficient for assembly with the alpha(2) delta subunit likely interacts with more than one extracellular loop of the alpha(1) subunit.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT NEUROL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa			Felix, Ricardo/A-6989-2008	Felix, Ricardo/0000-0002-5383-7176; Gurnett, Christina/0000-0001-9129-315X; Campbell, Kevin/0000-0003-2066-5889				Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; BRICKLEY K, 1995, FEBS LETT, V364, P129, DOI 10.1016/0014-5793(95)00371-F; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; COOPER CL, 1987, J BIOL CHEM, V262, P509; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GURNETT CA, 1995, J BIOL CHEM, V270, P9035, DOI 10.1074/jbc.270.16.9035; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; JAY SD, 1991, J BIOL CHEM, V266, P3287; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Makita N, 1996, CIRC RES, V78, P244, DOI 10.1161/01.RES.78.2.244; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SHEN V, 1995, NEURON, V14, P625; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TOKUMARU H, 1995, J NEUROCHEM, V65, P831; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106; Wiser O, 1996, FEBS LETT, V379, P15, DOI 10.1016/0014-5793(95)01475-6; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	31	82	87	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18508	18512		10.1074/jbc.272.29.18508	http://dx.doi.org/10.1074/jbc.272.29.18508			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218497	hybrid			2022-12-25	WOS:A1997XL73500087
J	Taguchi, H; Amada, K; Murai, N; Yamakoshi, M; Yoshida, M				Taguchi, H; Amada, K; Murai, N; Yamakoshi, M; Yoshida, M			ATP-, K+-dependent heptamer exchange reaction produces hybrids between GroEL and chaperonin from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THERMOANAEROBACTER-BROCKII; BACTERIUM; PURIFICATION; HYDROLYSIS; PROTEINS; RING; HB8	Chaperonin from Thermus thermophilus (Tcpn60(14).Tcpn10(7)) splits at the plane between two Tcpn60(7) rings into two parts in a solution containing ATP and K+ (Ishii, N., Taguchi, H., Sasabe, H., and Yoshida, M. (1995) FEBS Lett. 362, 121-125). When Escherichia coli GroEL(14) was additionally included in the solution described above, hybrid chaperonins GroEL(7).Tcpn60(7) and GroEL(7).Tcpn60(7).Tcpn10(7) were formed rapidly (<20 s) at 37 degrees C. The hybrid was also formed from Tcpn60(14) and GroEL(14) but not from a mutant GroEL(14) lacking ATPase activity. The hybrid formation was saturated at similar to 300 mu M ATP and similar to 300 mM K+. These results imply that GroEL(14) also splits and undergoes a heptamer exchange reaction with Thermus chaperonin under nearly physiological conditions, Similar to parent chaperonins, the isolated hybrid chaperonins exhibited ATPase activity that was susceptible to inhibition by Tcpn10(7) or GroES(7) and mediated folding of other proteins, Once formed, the hybrid chaperonins were stable, and the parent chaperonins were not regenerated from the isolated hybrids under the same conditions in which the hybrids had been formed, Only under conditions in which GroEL in the hybrids was selectively destroyed, such as incubation at 70 degrees C, Thermus chaperonin, but not GroEL(14), was regenerated from the hybrid. Therefore, the split reaction may not be an obligatory event repeated in each turnover of the chaperonin functional cycles but an event that occurs only when chaperonin is first exposed to ATP/K+.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			MURAI, NORIYUKI/V-5747-2018; Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021	MURAI, NORIYUKI/0000-0002-1552-5104; Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339				AMADA K, 1995, J BIOCHEM-TOKYO, V118, P347, DOI 10.1093/oxfordjournals.jbchem.a124913; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; ELLIS RJ, 1996, CHAPERONINS; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ISHII N, 1995, FEBS LETT, V362, P121, DOI 10.1016/0014-5793(95)00222-U; ISHII N, 1992, FEBS LETT, V299, P69; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MILLER SG, 1990, J MOL BIOL, V214, P407, DOI 10.1016/0022-2836(90)90190-W; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TAGUCHI H, 1997, IN PRESS METHODS ENZ; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; TRUSCOTT KN, 1994, EUR J BIOCHEM, V222, P277, DOI 10.1111/j.1432-1033.1994.tb18866.x; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; YAMADA T, 1990, J BIOCHEM-TOKYO, V108, P449, DOI 10.1093/oxfordjournals.jbchem.a123220; YAMAKOSHI M, 1997, IN PRESS STRUCTURE F; YOSHIDA M, 1993, PHILOS T ROY SOC B, V339, P305, DOI 10.1098/rstb.1993.0029	30	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18155	18160		10.1074/jbc.272.29.18155	http://dx.doi.org/10.1074/jbc.272.29.18155			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218450	hybrid			2022-12-25	WOS:A1997XL73500040
J	vanGinkel, PR; Hsiao, KM; Schjerven, H; Farnham, PJ				vanGinkel, PR; Hsiao, KM; Schjerven, H; Farnham, PJ			E2F-mediated growth regulation requires transcription factor cooperation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING PROTEINS; CELL-CYCLE; DIHYDROFOLATE-REDUCTASE; GENE-EXPRESSION; IN-VIVO; RETINOBLASTOMA PROTEIN; DNA-BINDING; E2F FAMILY; PROMOTER; MOUSE	Previous studies have indicated that the presence of an E2F site is not sufficient for G(1)/S phase transcriptional regulation, For example, the E2F sites in the E2F1 promoter are necessary, but not sufficient, to mediate differential promoter activity in G(0) and S phase, We have now utilized the E2F1 minimal promoter to test several hypotheses that could account for these observations, To test the hypothesis that G(1)/S phase regulation is achieved via E2F-mediated repression of a strong promoter, a variety of transactivation domains were brought to the E2F1 minimal promoter, Although many of these factors caused increased promoter activity, growth regulation was not observed, suggesting that a general repression model is incorrect. However, constructs having CCAAT or YY1 sites or certain GC boxes cloned upstream of the E2F1 minimal promoter displayed E2F site-dependent regulation, Further analysis of the promoter activity suggested that E2F requires cooperation with another factor to activate transcription in S phase, However, we found that the requirement for E2F to cooperate with additional factors to achieve growth regulation could be relieved by bringing the E2F1 activation domain to the promoter via a Gal4 DNA binding domain, Our results suggest a model that explains why some, but not all, promoters that contain E2F sites display growth regulation.	UNIV WISCONSIN,MCARDLE LAB CANC RES,SCH MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Schjerven, Hilde/I-1437-2013	Schjerven, Hilde/0000-0001-9287-3375; Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [R29CA045240, P30CA007175, R01CA045240, T32CA009681] Funding Source: NIH RePORTER; NCI NIH HHS [CA09681, CA07175, CA45240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Blau J, 1996, MOL CELL BIOL, V16, P2044; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARTINELLI R, 1994, MOL CELL BIOL, V14, P8322, DOI 10.1128/MCB.14.12.8322; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; PANG JH, 1993, J BIOL CHEM, V268, P2909; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHILLING LJ, 1995, CELL GROWTH DIFFER, V6, P541; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SLANSKY J, 1995, THESIS U WISCONSIN M; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLANSKY JE, 1996, TRANSCRIPTIONAL CONT, V208, P1; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU CL, 1995, MOL CELL BIOL, V15, P2536	40	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18367	18374		10.1074/jbc.272.29.18367	http://dx.doi.org/10.1074/jbc.272.29.18367			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218478	hybrid			2022-12-25	WOS:A1997XL73500068
J	Gruhler, A; Arnold, I; Seytter, T; Guiard, B; Schwarz, E; Neupert, W; Stuart, RA				Gruhler, A; Arnold, I; Seytter, T; Guiard, B; Schwarz, E; Neupert, W; Stuart, RA			N-terminal hydrophobic sorting signals of preproteins confer mitochondrial hsp70 independence for import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; INNER MEMBRANE; MATRIX ATP; INTERMEMBRANE SPACE; MOLECULAR CHAPERONES; CYTOCHROME B(2); SUBUNIT VA; TRANSLOCATION; REQUIREMENT; PRECURSOR	The requirement of mitochondrial hsp70 (mt-hsp70) for the import of a series af preproteins containing hydrophobic sorting signals into isolated yeast mitochondria was investigated. Here we demonstrate that the presence of such a sorting signal in proximity to the N-terminal matrix-targeting sequence of 21 preprotein can secure a translocating polypeptide chain in the fashion channel in a manner that does nea; require mt-hsp70 activity. Trapping the translocating chain in this fashion leads to efficient processing by the mitochondrial processing peptidase and to complete translocation across the outer mitochondrial membrane into the inner membrane space. These mt-hsp70-independent effects appear to be exerted at the level of the inner membrane through an interaction of the hydrophobic core of the sorting signal with component(s) of the translocase of the inner membrane. Hydrophobic sorting signals of inner membrane proteins inserted into the membrane from the matrix, as well as those of intermembrane space proteins, are capable of causing this mt-hsp70-independent stabilization, demonstrating that this phenomenon is not unique to those preproteins normally sorted to the intermembrane space.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich								BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CYR DM, 1993, J BIOL CHEM, V268, P23751; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MILLER BR, 1993, J CELL BIOL, V121, P1021, DOI 10.1083/jcb.121.5.1021; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1995, CURR BIOL, V5, P132; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x	37	17	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17410	17415		10.1074/jbc.272.28.17410	http://dx.doi.org/10.1074/jbc.272.28.17410			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211883	hybrid			2022-12-25	WOS:A1997XK16500026
J	Spurway, TD; Morland, C; Cooper, A; Sumner, I; Hazlewood, GP; ODonnell, AG; Pickersgill, RW; Gilbert, HJ				Spurway, TD; Morland, C; Cooper, A; Sumner, I; Hazlewood, GP; ODonnell, AG; Pickersgill, RW; Gilbert, HJ			Calcium protects a mesophilic xylanase from proteinase inactivation and thermal unfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; ACTIVE-SITE; CELLULOMONAS-FIMI; CRYSTAL-STRUCTURE; BINDING SITES; SEQUENCE; FAMILY; ARCHITECTURE; CELLULASES; GLYCANASES	Crystal structure analysis of Pseudomonas fluorescens subsp, cellulosa xylanase A (XYLA) indicated that the enzyme contained a single calcium binding site that did not exhibit structural features typical of the EF-hand motif, Isothermal titration calorimetry revealed that XYLA binds calcium with a K-a of 4.9 x 10(4) M-1 and a stoichiometry consistent with one calcium binding site per molecule of enzyme. Occupancy of the calcium binding domain with its ligand protected XYLA from proteinase and thermal inactivation and increased the melting temperature of the enzyme from 60.8 to 66.5 degrees C, However, the addition of calcium or EDTA did not influence the catalytic activity of the xylanase, Replacement of the calcium binding domain, which is located within loop 7 of XYLA, with the corresponding short loop from Cex (a Cellulomonas fimi xylanase/exoglucanase), did not significantly alter the biochemical properties of the enzyme, These data suggest that the primary function of the calcium binding domain is to increase the stability of the enzyme against thermal unfolding and proteolytic attack, To understand further the nature of the calcium binding domain of XYLA, four variants of the xylanase, D256A, N261A, D262A, and XYLA''', in which Asp-256, Asn-261, and Asp-262 had all been changed to alanine, were constructed, These mutated enzymes did not show any significant binding to Ca2+, indicating that Asp-256, Asn-261, and Asp-262 play a pivotal role in the affinity of XYLA for the divalent cation, In the presence or absence of calcium, XYLA''' exhibited thermal stability similar to that of the native enzyme bound to Ca2+ ions, although the variant was sensitive to proteinase inactivation, The role of the calcium binding domain in vivo and the possible mechanism by which the domain evolved are discussed.	UNIV NEWCASTLE UPON TYNE, DEPT BIOL & NUTR SCI, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT AGR & ENVIRONM SCI, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND; UNIV GLASGOW, DEPT CHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND; INST FOOD RES, DEPT FOOD MACROMOL SCI, READING RG6 2EF, BERKS, ENGLAND; BABRAHAM INST, DEPT CELLULAR PHYSIOL, CAMBRIDGE CB2 4AT, ENGLAND	Newcastle University - UK; Newcastle University - UK; University of Glasgow; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute			Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343; O'Donnell, Tony/0000-0003-2001-4533				BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; CHAUVAUX S, 1995, J BIOL CHEM, V270, P9757, DOI 10.1074/jbc.270.17.9757; Cooper A, 1994, Methods Mol Biol, V22, P125; Cooper A, 1994, Methods Mol Biol, V22, P137; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; FONTES CMGA, 1995, APPL MICROBIOL BIOT, V43, P52, DOI 10.1007/BF00170622; GILBERT HJ, 1993, J GEN MICROBIOL, V139, P187, DOI 10.1099/00221287-139-2-187; HALL J, 1993, BIO-TECHNOL, V11, P376, DOI 10.1038/nbt0393-376; HALL J, 1989, MOL MICROBIOL, V3, P1211, DOI 10.1111/j.1365-2958.1989.tb00271.x; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HENRISSAT B, 1996, BIOCHEM J, V316, P395; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MILLWARDSADLER SJ, 1995, BIOCHEM J, V312, P39, DOI 10.1042/bj3120039; REID RE, 1980, J THEOR BIOL, V84, P401, DOI 10.1016/S0022-5193(80)80013-0; RUSSELL EW, 1988, SOIL CONDITIONS PLAN, P151; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TULL D, 1991, J BIOL CHEM, V266, P15621; WELFLE K, 1995, EUR J BIOCHEM, V229, P726, DOI 10.1111/j.1432-1033.1995.tb20520.x; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; [No title captured]	31	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17523	17530		10.1074/jbc.272.28.17523	http://dx.doi.org/10.1074/jbc.272.28.17523			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211898	hybrid			2022-12-25	WOS:A1997XK16500041
J	Duff, SMG; Wittenberg, JB; Hill, RD				Duff, SMG; Wittenberg, JB; Hill, RD			Expression purification, and properties of recombinant barley (Hordeum sp.) hemoglobin - Optical spectra and reactions with gaseous ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCARIS HEMOGLOBIN; CARBON-MONOXIDE; OXYGEN; LEGHEMOGLOBIN; MYOGLOBIN; PLANTS; AUTOOXIDATION; REACTIVITY; KINETICS; GLOBIN	A cDNA encoding barley hemoglobin (Hb) has been cloned into pUC 19 and expressed in Escherichia coli, The resulting fusion protein has five extra amino acids at the N terminus compared with the native protein, resulting in a protein of 168 amino acids (18.5 kDa), The recombinant Hb is expressed constitutively, Extracts made from the bacteria containing the. recombinant fusion construct contain a protein with a subunit molecular mass of approximately 18.5 kDa comprising approximately 5% total soluble protein. Recombinant Rb was purified to homogeneity according to SDS-polyacrylamide gel electrophoresis by sequential polyethylene glycol precipitation and fast protein liquid chromatography, Its native molecular mass as assessed by fast protein liquid chromatography-size exclusion was 40 kDa suggesting that it is a dimer. Ligand binding experiments demonstrate that 1) barley Hb has a very slow oxygen dissociation rate constant (0.0272 s(-1)) relative to other Hbs, and 2) the heme of ferrous and ferric forms of the barley Hb is low spin sis-coordinate, The subunit structure, optical spectrum, and oxygen dissociation rate of native barley hemoglobin are indistinguishable from those obtained for the recombinant protein. The implications of these kinetic data on the in vivo function of barley Hb are discussed.	UNIV MANITOBA,DEPT PLANT SCI,WINNIPEG,MB R3T 2N2,CANADA	University of Manitoba	Duff, SMG (corresponding author), ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461, USA.							Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P1; APPLEBY CA, 1973, P NATL ACAD SCI USA, V70, P564, DOI 10.1073/pnas.70.2.564; APPLEBY CA, 1992, SCI PROG, V76, P365; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; APPLEBY CA, 1976, J BIOL CHEM, V251, P6090; APPLEBY CA, 1973, J BIOL CHEM, V248, P3183; BOFFI A, 1994, J BIOL CHEM, V269, P20437; BOGUSZ D, 1988, NATURE, V331, P178, DOI 10.1038/331178a0; BOGUSZ D, 1990, PLANT CELL, V2, P633, DOI 10.1105/tpc.2.7.633; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN GG, 1984, J MOL EVOL, V21, P19, DOI 10.1007/BF02100624; CARVER TE, 1992, J BIOL CHEM, V267, P14443; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; DOELLER JE, 1988, BIOL BULL, V174, P67, DOI 10.2307/1541760; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; KEILIN J, 1966, HEMES HEMOPROTEINS, P173; KENNEDY D, 1960, J GEN PHYSIOL, V44, P277, DOI 10.1085/jgp.44.2.277; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KRAUS DW, 1990, J BIOL CHEM, V265, P16043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb D. C., 1997, Biophysical Journal, V72, pA425; PEISACH J, 1968, J BIOL CHEM, V243, P1871; Sambrook J., 2002, MOL CLONING LAB MANU; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Wittenberg JB, 1996, PLANT SOIL, V178, P161, DOI 10.1007/BF00011579; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WITTENBERG JB, 1986, J BIOL CHEM, V261, P3624	32	151	159	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16746	16752		10.1074/jbc.272.27.16746	http://dx.doi.org/10.1074/jbc.272.27.16746			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201978	hybrid			2022-12-25	WOS:A1997XH44600010
J	KasusJacobi, A; Perdereau, D; TartareDeckert, S; VanObberghen, E; Girard, J; Burnol, AF				KasusJacobi, A; Perdereau, D; TartareDeckert, S; VanObberghen, E; Girard, J; Burnol, AF			Evidence for a direct interaction between insulin receptor substrate-1 and Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; BINDING-SITES; I-RECEPTOR; DOMAIN; PROTEINS; RAS; ASSOCIATION; ACTIVATION	Insulin receptor substrate-1 (IRS-I) and She are two proteins implicated ill intracellular signal transduction. They are activated by an increasing number of extracellular signals, mediated by receptor tyrosine kinases, cytokine receptors, and G protein-coupled receptors, In this study we demonstrate that She interacts directly with IRS-1, using the yeast two-hybrid system and an in. vitro interaction assay. Deletion analysis of the proteins to map the domains implicated in this interaction shows that the phosphotyrosine binding domain of She binds to the region of IRS-1 comprising amino acids 583-661. An irt vitro association assay, performed with or without activation of tyrosine kinases, gives evidence that tyrosine phosphorylation of IRS-1 and She drastically improves the interaction. Site-directed mutagenesis on IRS-I 583-693 shows that the asparagine, hut not the tyrosine residue of the N(625)GDY(628)motif domain, is implicated in the IRS-1-Shc-phosphotyrosine binding interaction. Mutation of another tyrosine residue, Tyr(608) also induced a 40% decrease in the interaction. This study, describing a phosphotyrosine-dependent interaction between IRS-1 and She, suggests that this association might be important in signal transduction.	CNRS,CTR RECH ENDOCRINOL MOL & DEV,UPR 1511,F-92190 MEUDON,FRANCE; INSERM,U145,F-06107 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			TARTARE-DECKERT, Sophie/P-6057-2015; KASUS-JACOBI, Anne/V-7799-2019; Burnol, Anne-Francoise/P-2181-2017	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; KASUS-JACOBI, Anne/0000-0003-3844-0450; 				Bartel P. L., 1993, CELLULAR INTERACTION, P153; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Borg JP, 1996, MOL CELL BIOL, V16, P6229; CASE RD, 1994, J BIOL CHEM, V269, P10467; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25243; HARPER JW, 1993, CELL, V75, P805; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Keegan K, 1996, ONCOGENE, V12, P1537; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MILLER JH, 1972, EXPT MOL GENETICS, P153; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; Myers MG, 1996, MOL CELL BIOL, V16, P4147; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Raffel GD, 1996, J BIOL CHEM, V271, P4640; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	42	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17166	17170		10.1074/jbc.272.27.17166	http://dx.doi.org/10.1074/jbc.272.27.17166			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202037	hybrid			2022-12-25	WOS:A1997XH44600069
J	Nowak, G; PesticDragovich, L; Hozak, P; Philimonenko, A; Simerly, C; Schatten, G; deLanerolle, P				Nowak, G; PesticDragovich, L; Hozak, P; Philimonenko, A; Simerly, C; Schatten, G; deLanerolle, P			Evidence for the presence of myosin I in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-LIKE POLYPEPTIDE; ACTIN-BINDING-PROTEIN; INTERPHASE NUCLEI; ACANTHAMOEBA MYOSIN; MUSCLE MYOSIN; SMOOTH-MUSCLE; LOCALIZATION; IDENTIFICATION; CELLS; FAMILY	We produced and affinity-purified polyclonal antibodies to adrenal myosin I, These antibodies recognize adrenal myosin I by Western blot analysis (116 kDa) and inhibit the actin-activated ATPase activity of purified adrenal myosin I. They also recognize a 120-kDa protein in extracts prepared from many different cell lines, Fluorescence microscopy demonstrated the presence of immunoreactive material in the perinuclear region, the leading edges, and the nuclei of 3T3 cells. Fluorescence microscopy also demonstrated nuclear staining in mouse oocytes at the germinal vesicle stage and in the pronuclei during fertilization, Confocal and immuno-electron microscopy confirmed the intranuclear localization, Electron microscopy also demonstrated staining of structures in nucleoli that are thought to be associated with rDNA transcription, Western blot analyses revealed the presence of the 120-kDa protein in extracts prepared from nuclei that are apparently free of cytosolic contamination, The same nuclear protein binds I-125-calmodulin and is photoaffinity labeled with [alpha-P-32]ATP. The 120-kDa protein was partially purified from twice washed nuclei using ammonium sulfate fractionation and gel filtration chromatography. Column fractions containing 120-kDa protein as revealed by Western blot analysis also contain K+-EDTA ATPase activity. The 120-kDa protein was also shown to bind actin in the absence, but not the presence, of ATP, Since K+-EDTA ATPase activity, actin, and ATP binding are defining features of the members of the myosin superfamily of proteins, we propose that the 120-kDa protein is a previously undescribed myosin I isoform that is an intranuclear actin-based molecular motor.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612; ACAD SCI CZECH REPUBL,INST EXPT MED,DEPT CELL ULTRASTRUCT & MOL BIOL,PRAGUE 14220 4,CZECH REPUBLIC; UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT OBSTET & GYNECOL,MADISON,WI 53706	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			simerly, Calvin/AAC-9564-2021; Hozak, Pavel/AAB-5359-2021; Schatten, Gerald/B-3253-2009; Hozak, Pavel/J-4182-2014	Hozak, Pavel/0000-0003-1901-1394; Schatten, Gerald/0000-0001-5206-7782; Hozak, Pavel/0000-0003-1901-1394	NHLBI NIH HHS [HI 32887, HL 02411] Funding Source: Medline; NICHD NIH HHS [HD 12912] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; AMANKWAH KS, 1994, EXP CELL RES, V210, P315, DOI 10.1006/excr.1994.1044; ANKENBAUER T, 1989, NATURE, V342, P822, DOI 10.1038/342822a0; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; BERRIOS M, 1991, P NATL ACAD SCI USA, V88, P219, DOI 10.1073/pnas.88.1.219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECKLER J, 1994, CELL MOTIL CYTOSKEL, V29, P312, DOI 10.1002/cm.970290404; BREMER JW, 1981, BIOCHEMISTRY-US, V20, P2013, DOI 10.1021/bi00510a042; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEAN WL, 1989, DEVELOPMENT, V106, P325; DELANEROLLE P, 1981, P NATL ACAD SCI-BIOL, V78, P4738; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; DUNDR M, 1993, EXP CELL RES, V208, P275, DOI 10.1006/excr.1993.1247; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GLENNEY JR, 1983, METHOD ENZYMOL, V102, P204; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HOZAK P, 1994, J CELL SCI, V107, P639; KOSLOVSKY JS, 1993, FEBS LETT, V320, P121, DOI 10.1016/0014-5793(93)80075-6; LI DQ, 1992, J NEUROCHEM, V59, P1344, DOI 10.1111/j.1471-4159.1992.tb08446.x; MARUTA H, 1981, J BIOL CHEM, V256, P499; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MILANKOV K, 1993, EXP CELL RES, V209, P189, DOI 10.1006/excr.1993.1301; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIMM DL, 1989, J CELL BIOL, V109, P585, DOI 10.1083/jcb.109.2.585; RUNGGER D, 1979, NATURE, V282, P320, DOI 10.1038/282320a0; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SAHLAS DJ, 1993, J CELL SCI, V105, P347; SANGER JW, 1975, P NATL ACAD SCI USA, V72, P2451, DOI 10.1073/pnas.72.6.2451; SAUMAN I, 1994, EUR J CELL BIOL, V64, P348; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4727, DOI 10.1073/pnas.82.14.4727; SHCEER U, 1984, CELL, V39, P111; SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405; SIMERLY C, 1993, METHOD ENZYMOL, V225, P516; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163	48	103	105	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17176	17181		10.1074/jbc.272.27.17176	http://dx.doi.org/10.1074/jbc.272.27.17176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202039	hybrid			2022-12-25	WOS:A1997XH44600071
J	Gibson, RM; JiBuechler, Y; Taylor, SS				Gibson, RM; JiBuechler, Y; Taylor, SS			Interaction of the regulatory and catalytic subunits of cAMP-dependent protein kinase - Electrostatic sites on the type I alpha regulatory subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HEAT-STABLE INHIBITOR; ESCHERICHIA-COLI; HOLOENZYME FORMATION; RABBIT SKELETAL; BINDING; EXPRESSION; MUTATIONS; DELETION; DOMAINS	Since a basic surface on the catalytic (C) subunit of cAMP-dependent protein kinase is important for binding to the regulatory (R) subunit, acidic residues in R were sought that might contribute to R-C interaction. Using differential labeling by a water-soluble carbodiimide (Buechler, T. A., and Taylor, S. S. (1990) Biochemistry 29, 1937-1943), seven specific carboxylates in RI alpha were identified that were protected from chemical modification in the holoenzyme; each was then replaced with Ala. Of these, rRI(E15A/E106A/D107A)), rRI(E105A), rRI(D140A), rRI(E143A), and rRI(D258A) all were defective in holoenzyme formation and define negative electrostatic surfaces on RI alpha. An additional conserved car boxylate, Glu(101) in RI alpha and the equivalent, Glu(99) in RII alpha were mutated to Ala. Replacement of Glu(101) had no effect while rRII(E99A) was very defective. RI alpha and RII alpha thus differ in the molecular details of how they recognize C. Unlike wild-type RI, two additional mutants, rRI(D170A) and rRI(K242A), inhibited C-subunit stoichiometrically in the presence of cAMP and show increases in both on- and off-rates. Asp(170), which contributes directly to the hydrogen bonding network in cAMP-binding site A, thus contributes also to holoenzyme stability.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego			Gibson, Robin/A-6841-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA0952223-08] Funding Source: Medline; NIGMS NIH HHS [GM34921] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; BUILDER SE, 1980, J BIOL CHEM, V255, P2350; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEON DA, 1991, BIOCHEMISTRY-US, V30, P3035, DOI 10.1021/bi00226a008; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; OGREID D, 1989, EUR J BIOCHEM, V181, P19; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; RINGHEIM GE, 1990, J BIOL CHEM, V265, P19472; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SARASWAT LD, 1988, METHOD ENZYMOL, V159, P325; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SLICE LW, 1989, J BIOL CHEM, V264, P20940; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; WALSH DA, 1990, CRC CRIT REV BIOCH, P43; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WELDON SL, 1985, J BIOL CHEM, V260, P4203; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	38	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16343	16350		10.1074/jbc.272.26.16343	http://dx.doi.org/10.1074/jbc.272.26.16343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195940	hybrid			2022-12-25	WOS:A1997XG01900044
J	Flick, MB; Sapi, E; Perrotta, PL; Maher, MG; Halaban, R; Carter, D; Kacinski, BM				Flick, MB; Sapi, E; Perrotta, PL; Maher, MG; Halaban, R; Carter, D; Kacinski, BM			Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody	ONCOGENE			English	Article						c-fms proto-oncogene; phosphotyrosine; immunohistochemistry; tyrosine kinase; breast carcinoma	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; MACROPHAGE CELL-LINE; FMS PROTO-ONCOGENE; SIGNAL-TRANSDUCTION; PHOSPHORYLATED PROTEINS; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN MELANOCYTES	The macrophage colony stimulating factor receptor (CSF-1R), the product of the c-fms proto-oncogene, plays an important role in regulating the normal proliferation and differentiation of macrophages and trophoblasts. However, the abnormal expression of CSF-1R transcripts and protein by human breast carcinomas has been shown to correlate with advanced stage and poor prognosis. Ligand activated CSF-1R dimers transphosphorylate several tyrosines in their cytoplasmic domains which provide recognition sites for various effector proteins in multiple signal transduction pathways. In cells transformed by the c-fms oncogene, one of the major CSF-1R phosphotyrosines, pTyr723 is important for phenotypic expression of anchorage-independent growth and metastasis. In order to investigate the relationship between receptor activation/phosphorylation and cellular phenotypes in vitro and in vivo, we prepared a CSF-1R phosphorylation-state specific antibody raised against a specific phosphopeptide of CSF-1R, which included phosphorylated tyrosine 723. On immunoblots of lysates from cells expressing CSF-1R, this antibody recognizes phosphorylated CSF-1R in CSF-1 stimulated cells but not in unstimulated cells. As an immunohistochemical reagent, this antibody stained 52% of invasive human breast tumors (72% of CSF-1R positive cases) in a sample of 114 cases and 38% of carcinoma in situ. This data represents the first direct evidence of in vivo phosphorylation of CSF-1R in human breast carcinomas.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT OBSTET & GYNECOL, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Yale University	Flick, MB (corresponding author), YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.				PHS HHS [CF47292] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Bacus SS, 1996, AM J PATHOL, V148, P549; BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO;2-8; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; BRUCKNER A, 1992, CANCER RES, V52, P3043; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMBERS SK, 1995, CANCER RES, V55, P1578; COMOGLIO PM, 1990, AM REV RESPIR DIS, V142, pS16, DOI 10.1164/ajrccm/142.6_Pt_2.S16; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; HALABAN R, 1992, ONCOGENE, V7, P2195; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1989, CANCER CEL, V7, P333; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KACINSKI BM, 1990, MOL CELLULAR BIOL CY, P393; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEATING MT, 1988, J BIOL CHEM, V263, P12805; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; MARCUSSEN J, 1991, ANAL BIOCHEM, V198, P318, DOI 10.1016/0003-2697(91)90432-S; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PANNEERSELVAM K, 1995, J BIOL CHEM, V270, P7975, DOI 10.1074/jbc.270.14.7975; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROHRSCHNEIDER LR, 1994, GUIDEBOOK CYTOKINES, P168; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; Sapi E, 1996, CANCER RES, V56, P5704; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STERN DF, 1991, METHOD ENZYMOL, V198, P494; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WANG JYJ, 1988, ANAL BIOCHEM, V172, P1, DOI 10.1016/0003-2697(88)90403-4; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	39	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2553	2561		10.1038/sj.onc.1201092	http://dx.doi.org/10.1038/sj.onc.1201092			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191055				2022-12-25	WOS:A1997XA94900007
J	Lengyel, E; Wang, H; Gum, R; Simon, C; Wang, Y; Boyd, D				Lengyel, E; Wang, H; Gum, R; Simon, C; Wang, Y; Boyd, D			Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade	ONCOGENE			English	Article						urokinase receptor; extracellular signal regulated kinase; mitogen activated protein kinase; invasion	FIBROBLAST GROWTH-FACTOR; VASCULAR ENDOTHELIAL-CELLS; MAP KINASE-KINASE; PROTEIN-KINASE; C-JUN; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL ACTIVATION; MATRIX INVASION; STROMAL CELLS; MUSCLE CELLS	The urokinase-type plasminogen activator receptor (u-PAR) facilitates extracellular matrix degradation in part by accelerating plasmin formation at the cell surface. We previously reported that u-PAR expression is elevated in colon cancer cell lines characterized by their in vitro invasive capacity. Since, u-PAR expression is increased by a variety of growth factors, which signal through the extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2), we determined if these mitogen-activated protein kinases (MAPKs) regulate u-PAR expression in two cultured colon cancer cell lines, An in-gel kinase assay showed that ERK1 activity was considerably higher in RKO cells, which display greater than or equal to 10(4) receptors/cell, than the GEO cells which have similar or equal to 10(4) urokinase receptors per cell. The expression of either an ERK-inactivating phosphatase (CL100), or a kinase-defective ERK1, decreased the activity of a u-PAR promoter-driven CAT reporter in RKO cells. Immune complex kinase assays indicated that the constitutive ERK1 activity in RKO cells was largely a result of an activated MEK1. Further, treatment of RKO cells with a specific inhibitor (PD 098059) of MEK1 activation, which diminished ERK1 activity, reduced the amount of urokinase specifically bound to the cell surface and this was associated with reduced laminin degradation. The expression of a dominant negative c-Raf-l also reduced u-PAR promoter activity suggesting that MEK1 activation involved an activator at, or upstream, of this serine-threonine kinase, Transfection of the u-PAR-deficient GEO cells with a constitutively activated MEK1 expression construct upregulated u-PAR promoter activity. Similarly treatment of GEO cells,vith a phosphatase inhibitor (sodium vanadate) caused a dose-dependent increase in ERK1 activity which paralleled increased cell surface binding of urokinase. Taken together, these data suggest that elevated u-PAR expression, in at least a sub-population of colon cancer, is partly a consequence of a constitutively activated ERK-1-dependent signaling cascade.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL HEAD & NECK SURG,HOUSTON,TX; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV MOL MED,MUCOSAL INFLAMMAT & CANC GRP,CANBERRA,ACT 2601,AUSTRALIA	University of Texas System; UTMD Anderson Cancer Center; Australian National University; John Curtin School of Medical Research			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGARWAL S, 1995, ONCOGENE, V11, P427; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOS JL, 1989, CANCER RES, V49, P4682; BOYD D, 1988, CANCER RES, V48, P3112; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; CASEY JR, 1994, BLOOD, V84, P1151; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HOLLAS W, 1991, CANCER RES, V51, P3690; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKUN J, 1991, CANCER RES, V51, P1221; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JONES LG, 1994, J BIOL CHEM, V269, P23790; KARIKO K, 1993, CANCER RES, V53, P3109; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lengye E, 1995, ONCOGENE, V11, P2639; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Muda M, 1996, J BIOL CHEM, V271, P4319; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; OHagan RC, 1996, ONCOGENE, V13, P1323; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OKA H, 1995, CANCER RES, V55, P4182; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1991, AM J PATHOL, V138, P1059; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; RAO VN, 1993, CANCER RES, V53, P3449; RIDANPAA M, 1993, HUM MOL GENET, V2, P639, DOI 10.1093/hmg/2.6.639; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROMER J, 1994, INT J CANCER, V57, P553, DOI 10.1002/ijc.2910570419; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SHIRAKABE K, 1992, J BIOL CHEM, V207, P16685; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; SOZERI O, 1992, ONCOGENE, V7, P2259; STACEY DW, 1991, ONCOGENE, V6, P2297; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TSAI PS, 1995, ENDOCRINOLOGY, V136, P3831, DOI 10.1210/en.136.9.3831; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI J, 1982, J CELL BIOL, V100, P86; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	86	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2563	2573		10.1038/sj.onc.1201098	http://dx.doi.org/10.1038/sj.onc.1201098			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191056				2022-12-25	WOS:A1997XA94900008
J	deMedeiros, SRB; Krey, G; Hihi, AK; Wahli, W				deMedeiros, SRB; Krey, G; Hihi, AK; Wahli, W			Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 io promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; RNA-POLYMERASE-II; GENE-EXPRESSION; INVITRO TRANSCRIPTION; MAMMALIAN-CELLS; CTF/NF-I; SUPERFAMILY; COMPLEX; DOMAINS; FAMILY	Two distinct, TATA box-containing promoters regulate the transcriptional activity of the Xenopus vitellogenin Al gene. These two promoters are of different strength and are separated by 1.8 kilobase pairs of untranslated sequence. Estrogen receptor (ER) and its ligand, 17 beta-estradiol, induce the activity of both promoters. The estrogen response elements (EREs) are located a proximal to the downstream i promoter while no ERE-like sequences have been identified in the vicinity of the upstream io promoter. We show here, that transcriptional activity of the upstream io promoter is Sp1-dependent. Moreover, we demonstrate that estrogen inducibility of the io promoter results from functional interactions between the io bound Sp1 and the ER bound at the proximity of i. Functional interactions between Sp1 and ER do not require the presence of a TATA box for transcriptional activation, as is demonstrated using the acyl-CoA oxidase promoter. The relative positions that ER and Sp1 occupy with respect to the initiation site determines whether these two transcription activators can synergize for transcription initiation.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne			Batistuzzo de Medeiros, Silvia/H-2117-2015; Wahli, Walter/B-1398-2009; DE MEDEIROS, SILVIA REGINA BATISTUZZO/ABC-2811-2020; Wahli, Walter/I-3194-2019	Batistuzzo de Medeiros, Silvia/0000-0003-2431-0479; Wahli, Walter/0000-0002-5966-9089; DE MEDEIROS, SILVIA REGINA BATISTUZZO/0000-0003-2431-0479; 				Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BONFANTI M, 1991, NUCLEIC ACIDS RES, V19, P5739, DOI 10.1093/nar/19.20.5739; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLARET FX, 1994, J BIOL CHEM, V269, P14047; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1988, SCIENCE, V239, P1137, DOI 10.1126/science.2830672; CORTHESY B, 1989, DNA PROTEIN ENG TECH, V2, P68; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER M, 1990, J BIOL CHEM, V265, P22243; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; KUWAHARA J, 1993, BIOCHEMISTRY-US, V32, P5994, DOI 10.1021/bi00074a010; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maniatis T., 1982, MOL CLONING; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Maxam A M, 1980, Methods Enzymol, V65, P499; OSUMI T, 1987, J BIOL CHEM, V262, P8138; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; TREMEA F, 1989, MOL ENDOCRINOL, V3, P1596, DOI 10.1210/mend-3-10-1596; WAHLI W, 1981, SCIENCE, V212, P298, DOI 10.1126/science.7209528; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WUPENG XS, 1992, MOL ENDOCRINOL, V6, P231, DOI 10.1210/me.6.2.231; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	47	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18250	18260		10.1074/jbc.272.29.18250	http://dx.doi.org/10.1074/jbc.272.29.18250			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218463	hybrid			2022-12-25	WOS:A1997XL73500053
J	Edwards, AS; Newton, AC				Edwards, AS; Newton, AC			Phosphorylation at conserved carboxyl-terminal hydrophobic motif regulates the catalytic and regulatory domains of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMISSIVE ACTIVATION; HIGH-AFFINITY; AUTOPHOSPHORYLATION; PHOSPHATIDYLSERINE; DIACYLGLYCEROL; INACTIVATION; MEMBRANES; SITE	Mature protein kinase C is phosphorylated at a conserved carboxyl-terminal motif that contains a Ser (or Thr) bracketed by two hydrophobic residues; in protein kinase C beta II, this residue is Ser-660 (Keranen, L. M., Dutil, E. M., and Newton, A. C. (1995) Curr. Biol. 5, 1394-1403), This contribution examines how negative charge at this position regulates the function of protein kinase C. Specifically, Ser-660 in protein kinase C beta II was mutated to Ala or Glu and the enzyme's stability, membrane interaction, Ca2+ regulation, and kinetic parameters were compared with those of wild-type protein phosphorylated at residue 660, Negative charge at this position had no significant effect on the enzyme's diacylglycerol-stimulated membrane interaction nor the conformational change accompanying membrane binding. In contrast, phosphate caused a 10-fold increase in the enzyme's affinity for Ca2+ and a comparable increase in its affinity for phosphatidylserine, two interactions that are mediated by the C2 domain, Negative charge also increased the protein's thermal stability and decreased its K-m, for ATP and peptide substrate. These data indicate that phosphorylation at the extreme carboxyl terminus of protein kinase C structures the active site so that it binds ATP and substrate with higher affinity and structures determinants in the regulatory region enabling higher affinity binding of Ca2+. The motif surrounding Ser-660 in protein kinase C beta II is found in a number of other kinases, suggesting interactions promoted by phosphorylation of the carboxyl terminus may provide a general mechanism for stabilizing kinase structure.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NIGMS NIH HHS [GM 43154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CONRAD R, 1994, J BIOL CHEM, V269, P32051; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KREBS EG, 1959, J BIOL CHEM, V234, P2867; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; YONEMOTO W, 1997, IN PRESS PROTEIN ENG; ZHANG J, 1994, J BIOL CHEM, V269, P19578	35	128	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18382	18390		10.1074/jbc.272.29.18382	http://dx.doi.org/10.1074/jbc.272.29.18382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218480	hybrid			2022-12-25	WOS:A1997XL73500070
J	Kelly, CR; Dickinson, CD; Ruf, W				Kelly, CR; Dickinson, CD; Ruf, W			Ca2+ binding to the first epidermal growth factor module of coagulation factor VIIa is important for cofactor interaction and proteolytic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; HUMAN TISSUE FACTOR; FACTOR-X; CALCIUM-BINDING; PROTEASE DOMAIN; GLA DOMAIN; SITE; SUBSTRATE; RESIDUES; AFFINITY	Epidermal growth factor-like (EGF) domain Ca2+ binding sites in the homologous coagulation factors VII, IX, and X stabilize the structural orientation of the gamma-carboxyglutamic acid-rich (Cia) domain relative to EGF-1. Site directed mutagenesis was employed here to analyze the functional importance of Ca2+ binding to EGF-1 in factor VIIa (VIIa), which initiates coagulation in complex with its cofactor, tissue factor (TF). Ala replacements for Asp(63) Or Gln(49) resulted in reduced TF affinity concordant with the number of eliminated Ca2+-coordinating oxygen atoms in the respective side chains, Ca2+ binding to EGF-1 had no major direct effect on contacts with TF residue Gln(110) or on interactions of VIIa residues Arg(79) and Phe(40), suggesting that the stabilized Gla-EGF-1 orientation affects overall docking, Gly, Ala, and Glu replacements at Asp(46), which is a Ca2+-coordinating residue at the Gla aromatic stack carboxyl terminus, are consistent with the notion that an increased flexibility of the Gla domain relative to EGF-1 contributes significantly to loss of function, Certain mutants in the EGF-1 Ca2+ site had reduced proteolytic function, suggesting the importance of the high affinity Ca2+ binding site for macromolecular substrate interaction.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Dittmar S, 1997, BIOCHEM J, V321, P787, DOI 10.1042/bj3210787; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; Monroe D M, 1990, Blood Coagul Fibrinolysis, V1, P633; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1991, J BIOL CHEM, V266, P15719; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; SUNNERHAGEN MS, 1993, J BIOL CHEM, V268, P23339; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016	33	35	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17467	17472		10.1074/jbc.272.28.17467	http://dx.doi.org/10.1074/jbc.272.28.17467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211891	hybrid			2022-12-25	WOS:A1997XK16500034
J	Roos, RS; Loetscher, M; Legler, DF; ClarkLewis, I; Baggiolini, M; Moser, B				Roos, RS; Loetscher, M; Legler, DF; ClarkLewis, I; Baggiolini, M; Moser, B			Identification of CCR8, the receptor for the human CC chemokine I-309	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHEMOKINE; BIOLOGIC ACTIVITIES; INTERLEUKIN-8; EXPRESSION; LEUKOCYTE; CLONING; TCA3; LYMPHOCYTES; NEUTROPHILS; PROTEINS	The nucleotide sequence for a putative chemokine receptor, termed TER1, ChemR1, or CKR-L1, was recently obtained by a polymerase chain reaction-based cloning technique. It encodes a protein of 355 amino acids that shows 32-45% sequence identity with human chemokine receptors. The gene was localized on human chromosome 3p21-24, the site for the genes for the five known CC chemokine receptors, suggesting that the natural ligand may be a CC chemokine, We have stably expressed this receptor in murine pre-B cells 300-19 and have tested their responsiveness to 20 human chemokines and some other potential agonists, The CC chemokine I-309 was the only agonist that selectively induced intracellular Ca2+ mobilization and chemotaxis in receptor-transfected 300-19 cells, Stromal cell-derived factor 1, which binds to murine CXCR4 expressed in parental as well as transfected 300-19 cells, served as positive control in the functional screening, The interaction of I-309 with TER1 was of high affinity as shown by I-125-I-309 binding (K-d of 1.2 nM) and transient [Ca2+](i) changes at subnanomolar concentrations of agonist, Migration responses in receptor-transfected 300-19 cells was typically bimodal with maximal activity at 10 nM of I-309, These data demonstrate that TER1 (ChemR1 or CKR-L1) is the receptor for I-309, and we propose to call this receptor CCR8 in agreement with the current nomenclature for chemokine receptors. The expression of CCR8 in blood leukocytes and lymphocytes was analyzed by Northern blot. No transcripts were found in RNA from freshly isolated blood neutrophils, monocytes, cultured macrophages, and phytohemagglutinin-stimulated T lymphocytes, and a faint hybridization signal corresponding to the RNA species of 4 kb was obtained only with RNA from interleukin-2-treated T lymphocytes, CCR8 is unusual for its selectivity for a single chemokine, previously shown only for CXCR1 and CXCR4, which bind interleukin-8 and stromal cell-derived factor 1, respectively, Identification of the receptor for I-309 represents a significant progress in determining the function of I-309 in inflammation and disease.	UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN 9,SWITZERLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA	University of Bern; University of British Columbia				Moser, Bernhard/0000-0002-4354-4572; Legler, Daniel F./0000-0001-8610-4764				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARELLA L, 1995, BIOCHEM J, V309, P773, DOI 10.1042/bj3090773; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BURD PR, 1987, J IMMUNOL, V139, P3126; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; DEVI S, 1995, J IMMUNOL, V154, P5376; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; LANING J, 1994, J IMMUNOL, V153, P4625; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Loetscher P, 1996, J IMMUNOL, V156, P322; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Luo Y, 1996, J IMMUNOL, V156, P742; Luo Y, 1996, J IMMUNOL, V157, P2143; LUO Y, 1994, J IMMUNOL, V153, P4616; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAPOLITANO M, 1996, J IMMUNOL, V157, P259; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; Samson M, 1996, EUR J IMMUNOL, V26, P3021, DOI 10.1002/eji.1830261230; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; VanSnick J, 1996, J IMMUNOL, V157, P2570; Vicari AP, 1996, IMMUNOL TODAY, V17, P71, DOI 10.1016/0167-5699(96)80582-2; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; Zaballos A, 1996, BIOCHEM BIOPH RES CO, V227, P846, DOI 10.1006/bbrc.1996.1595	34	152	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17251	17254		10.1074/jbc.272.28.17251	http://dx.doi.org/10.1074/jbc.272.28.17251			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211859	hybrid			2022-12-25	WOS:A1997XK16500002
J	YamaguchiIwai, Y; Serpe, M; Haile, D; Yang, WM; Kosman, DJ; Klausner, RD; Dancis, A				YamaguchiIwai, Y; Serpe, M; Haile, D; Yang, WM; Kosman, DJ; Klausner, RD; Dancis, A			Homeostatic regulation of copper uptake in yeast via direct binding of MAC1 protein to upstream regulatory sequences of FRE1 and CTR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; MOLECULAR CHARACTERIZATION; TRANSPORT PROTEIN; FERRIC REDUCTASE; METABOLISM; RESISTANCE; ACE1	Copper deprivation of Saccharomyces cerevisiae induces transcription of the FRE1 and CTR1 genes, FRE1 encodes a surface reductase capable of reducing and mobilizing copper chelates outside the cell, and CTR1 encodes a protein mediating copper uptake at the plasma membrane, In this paper, the protein encoded by MAC1 is identified as the factor mediating this homeostatic control. A novel dominant allele of MAC1, MAC1(up2), is mutated in a Cys-rich domain that may function in copper sensing (a G to A change of nucleotide 812 resulting in a Cys-271 to Tyr substitution), This mutant is functionally similar to the MAC1(up1) allele in which His-279 in the same domain has been replaced by Gin. Both mutations confer constitutive copper-independent expression of FRE1 and CTR1. A sequence including the palindrome TTTGCTCA,, TGAGCAAA, appearing within the 5'-flanking region of the CTR1 promoter, is necessary and sufficient for the copper- and MAC1-dependent CTR1 transcriptional regulation. An identical sequence appears as a direct repeat in the FRE1 promoter, The data indicate that the signal resulting from copper deprivation is transduced via the Cys-rich motif of MAC1 encompassing residues 264-279, MAC1 then binds directly and specifically to the CTR1 and FRE1 promoter elements, inducing transcription of those target genes, This model defines the homeostatic mechanism by which yeast regulates the cell acquisition of copper in response to copper scarcity or excess.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA; NCI, BIOCHEM LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Serpe, Michael/T-4176-2019	Serpe, Michael/0000-0002-0161-1087; Serpe, Mihaela/0000-0002-9205-8589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; DAMERON CT, 1993, BIOCHEMISTRY-US, V32, P7294, DOI 10.1021/bi00079a028; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HALLIWELL B, 1988, FREE RADICAL BIO MED, P31; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; Johns DR, 1996, NAT MED, V2, P1065, DOI 10.1038/nm1096-1065; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; Kelly EJ, 1996, NAT GENET, V13, P219, DOI 10.1038/ng0696-219; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KNIGHT SA, 1996, GENE DEV, V10, P1947; Koch KA, 1996, MOL CELL BIOL, V16, P724; KOSMAN DJ, 1991, METAL IONS FUNGI, P1; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; Lesuisse Emmanuel, 1994, V11, P149; LINDER MC, 1991, BIOCH COPPER, P1; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; POUNTNEY DJ, 1995, BIOCHEM SOC T, V23, pS140, DOI 10.1042/bst023140s; Rose MD., 1990, METHODS YEAST GENETI; ROSEN DR, 1993, NATURE, V362, P20; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1994, BIOCHEMISTRY-US, V33, P9566, DOI 10.1021/bi00198a024; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; ZHOU B, 1996, AM J HUM GENET S, V59	41	137	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17711	17718		10.1074/jbc.272.28.17711	http://dx.doi.org/10.1074/jbc.272.28.17711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211922	hybrid			2022-12-25	WOS:A1997XK16500065
J	Ohshima, K; Wells, RD				Ohshima, K; Wells, RD			Hairpin formation during DNA synthesis primer realignment in vitro in triplet repeat sequences from human hereditary disease genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REVERSE-TRANSCRIPTASE; MISMATCH REPAIR; STRANDED-DNA; BASE-PAIRS; IN-VITRO; REPLICATION; SPECIFICITY; INSTABILITY; INVITRO	Genetic expansion of DNA triplet repeat sequences (TRS) found in neurogenetic disorders may be due to abnormal DNA replication. We have previously observed strong DNA synthesis pausings at specific loci within the long tracts (>similar to 70 repeats) of CTG.CAG and CGG.CCG as well as GTC.GAC by primer extensions in vitro using DNA polymerases (the Klenow fragment of Escherichia call DNA polymerase I, the modified T7 DNA polymerase (Sequenase), and human DNA polymerase beta). Herein, we have isolated and analyzed the products of stalled synthesis found at similar to 30-40 triplets from the beginning of the TRS, DNA sequence analyses revealed that. the stalled products contained short tracts of homogeneous TRS (6-12 repeats) in the middle of the sequence corresponding to the flanking region of the primer-template sequence, The sequence at the 3'-side terminated at the end of the primer, indicating that the primer molecule had served as a template. In addition, chemical probe and polyacrylamide gel electrophoretic analyses revealed that the stalled products existed in hairpin structures. WE postulate that these products of the DNA polymerases are caused by the existence of an unusual DP JA conformation(s) within the TRS, during the in vitro DNA synthesis, enhancing the DNA slippages and the hairpin formations in the TRS due to primer realignment. The consequence of these steps is DNA synthesis to the end of the primer and termination. Primer realignment including hairpin formation may play an important intermediate role in the replication of TRS in vivo to elicit genetic expansions.	TEXAS A&M UNIV,TEXAS MED CTR,INST BIOSCI & TECHNOL,CTR GENOME RES,HOUSTON,TX 77030; TEXAS A&M UNIV,TEXAS MED CTR,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Texas A&M University System; Baylor College of Medicine; Texas A&M University System					NIGMS NIH HHS [GM 52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BEDINGER P, 1989, J BIOL CHEM, V264, P16880; BIERNE H, 1991, EMBO J, V10, P2699, DOI 10.1002/j.1460-2075.1991.tb07814.x; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; GAO XL, 1995, J AM CHEM SOC, V117, P8883, DOI 10.1021/ja00139a035; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P11019; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P784, DOI 10.1093/nar/24.4.784; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P775, DOI 10.1093/nar/24.4.775; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCLEAN MJ, 1987, NUCLEIC ACIDS RES, V15, P6917, DOI 10.1093/nar/15.17.6917; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Mytelka DS, 1996, NUCLEIC ACIDS RES, V24, P2774, DOI 10.1093/nar/24.14.2774; OHSHIMA A, 1992, P NATL ACAD SCI USA, V89, P1016, DOI 10.1073/pnas.89.3.1016; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; PAPANICOLAOU C, 1991, J MOL BIOL, V221, P805, DOI 10.1016/0022-2836(91)80177-V; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; SHIBATA D, 1994, NAT GENET, V6, P213; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SKELLY JV, 1993, P NATL ACAD SCI USA, V90, P804, DOI 10.1073/pnas.90.3.804; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAUTZ D, 1994, CURR OPIN GENET DEV, V4, P832, DOI 10.1016/0959-437X(94)90067-1; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; YU A, 1995, NUCLEIC ACIDS RES, V23, P4055, DOI 10.1093/nar/23.20.4055; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706	59	78	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16798	16806		10.1074/jbc.272.27.16798	http://dx.doi.org/10.1074/jbc.272.27.16798			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201985	hybrid			2022-12-25	WOS:A1997XH44600017
J	Wolberg, AS; Stafford, DW; Erie, DA				Wolberg, AS; Stafford, DW; Erie, DA			Human factor IX binds to specific sites on the collagenous domain of collagen IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; AMINO-ACID-SEQUENCE; ENDOTHELIAL-CELLS; CRO REPRESSOR; OPERATOR DNA; PEPTIDE; RECOGNITION; PROTEIN; HEPARIN; CHAIN	The primary region of factor IX that mediates binding to bovine aortic endothelial cells resides in residues 3-11 of the N-terminal region known as the Gla domain, Recently, it was proposed that the observed binding to endothelial cells is actually a measure of the interaction between factor IX and collagen IV (Cheung, W. F., van den Born, J., Kuhn, K., Kjellen, L., Hudson, B. G., and Stafford, D. W. (1996) Proc, Natl, Acad, Sci, U. S. A. 93, 11068-11073), To confirm that factor M binds to collagen IV and to examine the specificity of this interaction, we used scanning force microscopy to examine factor M binding to collagen IV, We imaged collagen IV in the presence and the absence of factor IX and observed specific interactions between factor IX and collagen IV, Our results demonstrate that factor IX binds to collagen IV at specific sites in the collagenous domain similar to 98 and similar to 50 nm from the C-terminal pepsin-cleaved end.	UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054136] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL06350] Funding Source: Medline; NIGMS NIH HHS [R29 GM54136] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BRAZEL D, 1988, EUR J BIOCHEM, V172, P35, DOI 10.1111/j.1432-1033.1988.tb13852.x; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Bustamante C, 1996, ANNU REV BIOPH BIOM, V25, P395; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ERIE DA, 1994, SCIENCE, V266, P1562, DOI 10.1126/science.7985026; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; FRAZIER D, 1989, BLOOD, V74, P971; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; GLANVILLE RW, 1979, EUR J BIOCHEM, V95, P383, DOI 10.1111/j.1432-1033.1979.tb12976.x; HEIMARK RL, 1983, BIOCHEM BIOPH RES CO, V111, P723, DOI 10.1016/0006-291X(83)90365-0; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; KELLER KM, 1986, BIOCHIM BIOPHYS ACTA, V882, P1, DOI 10.1016/0304-4165(86)90047-4; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; SCHWARZ U, 1986, EUR J BIOCHEM, V157, P49, DOI 10.1111/j.1432-1033.1986.tb09636.x; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; SIXMA JJ, 1995, THROMB HAEMOSTASIS, V74, P454; SOININEN R, 1987, FEBS LETT, V225, P188; STERN DM, 1983, P NATL ACAD SCI-BIOL, V80, P4119, DOI 10.1073/pnas.80.13.4119; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; YANG J, 1993, J MICROSC-OXFORD, V171, P183, DOI 10.1111/j.1365-2818.1993.tb03375.x	38	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16717	16720		10.1074/jbc.272.27.16717	http://dx.doi.org/10.1074/jbc.272.27.16717			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201971	hybrid, Green Published			2022-12-25	WOS:A1997XH44600003
J	Jorgensen, S; Vorgias, CE; Antranikian, G				Jorgensen, S; Vorgias, CE; Antranikian, G			Cloning, sequencing, characterization, and expression of an extracellular alpha-amylase from the hyperthermophilic archaeon Pyrococcus furiosus in Escherichia coli and Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; NUCLEOTIDE-SEQUENCE; AMYLOLYTIC ENZYME; SP-NOV; ARCHAEBACTERIUM; GENE; DNA; STRAINS; WOESEI	A gene encoding a highly thermostable extracellular alpha-amylase from the hyperthermophilic archaeon Pyrococcus furiosus was identified, The gene was cloned, sequenced, and expressed in Escherichia coli and Bacillus subtilis. The gene is 1383 base pairs long and encodes a protein of 461 amino acids, The open reading frame of the gene was Verified by microsequencing of the recombinant purified enzyme. The deduced amino acid sequence is 25 amino acids longer at the N terminus than that determined by sequencing of the purified protein, suggesting that a leader sequence is removed during transport of the enzyme across the membrane. The recombinant alpha-amylase was biochemically characterized and shows an activity optimum at pH 4.5, whereas the optimun temperature for enzymatic activity is close to 100 degrees C. alpha-Amylase shows sequence homology to the other known alpha-amylases and belongs to family 13 of glycosyl hydrolases. This extracellular alpha-amylase is not homologous to the subcellular alpha-amylase previously isolated from the same organism.	TECH UNIV HAMBURG,INST BIOTECHNOL,DEPT TECH MICROBIOL,D-21071 HAMBURG,GERMANY; NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK; UNIV ATHENS,DEPT BIOL,DIV BIOCHEM & MOL BIOL,ATHENS 15071,GREECE	Hamburg University of Technology; Novo Nordisk; National & Kapodistrian University of Athens								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1983, METHODS ENZYMATIC AN; ANTRANIKIAN G, 1990, FEMS MICROBIOL LETT, V75, P201, DOI 10.1111/j.1574-6968.1990.tb04095.x; BROWN SH, 1990, APPL ENVIRON MICROB, V56, P1985, DOI 10.1128/AEM.56.7.1985-1991.1990; DIDERICHSEN B, 1990, J BACTERIOL, V172, P4315, DOI 10.1128/jb.172.8.4315-4321.1990; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Fritsch EF, 1986, MOL CLONING LAB MANU, V2nd; FUJITA M, 1989, J BACTERIOL, V171, P1333, DOI 10.1128/jb.171.3.1333-1339.1989; FUKUSUMI S, 1988, EUR J BIOCHEM, V174, P15, DOI 10.1111/j.1432-1033.1988.tb14056.x; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUANG N, 1990, PLANT MOL BIOL, V14, P655, DOI 10.1007/BF00016499; KIESER T, 1984, PLASMID, V12, P19, DOI 10.1016/0147-619X(84)90063-5; KOCH R, 1990, FEMS MICROBIOL LETT, V71, P21, DOI 10.1111/j.1574-6968.1990.tb03792.x; LADERMAN KA, 1993, J BIOL CHEM, V268, P24402; LADERMAN KA, 1993, J BIOL CHEM, V268, P24394; LEUSCHNER C, 1995, WORLD J MICROB BIOT, V11, P95, DOI 10.1007/BF00339139; NAKAJIMA R, 1986, APPL MICROBIOL BIOT, V23, P355; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; RAHA M, 1992, J BACTERIOL, V174, P6644, DOI 10.1128/JB.174.20.6644-6652.1992; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YASBIN RE, 1975, J BACTERIOL, V121, P296, DOI 10.1128/JB.121.1.296-304.1975; YUUKI T, 1985, J BIOCHEM-TOKYO, V98, P1147, DOI 10.1093/oxfordjournals.jbchem.a135381; ZILLIG W, 1987, SYST APPL MICROBIOL, V9, P62, DOI 10.1016/S0723-2020(87)80057-7; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	27	96	113	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16335	16342		10.1074/jbc.272.26.16335	http://dx.doi.org/10.1074/jbc.272.26.16335			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195939	hybrid			2022-12-25	WOS:A1997XG01900043
J	Stranick, KS; Zambas, DN; Uss, AS; Egan, RW; Billah, MM; Umland, SP				Stranick, KS; Zambas, DN; Uss, AS; Egan, RW; Billah, MM; Umland, SP			Identification of transcription factor binding sites important in the regulation of the human interleukin-5 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE PROMOTER ELEMENTS; CELL RECEPTOR STIMULATION; LYMPHOCYTE-T ACTIVATION; NUCLEAR FACTOR; DIFFERENTIAL REGULATION; INDUCIBLE ENHANCER; MOLECULAR-CLONING; NF-Y; EXPRESSION; PROTEINS	This study identifies three regions of the human interleukin (IL)-5 promoter involved in binding nuclear factors from activated T cells. DNase I footprinting and mobility shift assays with nuclear proteins from the human T cell clone, SP-B21, demonstrated protein interactions with each of these response elements (REs), located between positions -79 and -45 (RE-I), -123 and -92 (RE-II), and -170 and -130 (RE-III). Two of these regions, RE-II and RE-III, have not previously been described to regulate IL-5 expression in T cells. The RE-II site was shown to be critical for inducible IL-5 promoter activity in transient transfection assays in D10.G4.1 T cells, while the RE-III site functions as a negative regulatory element. The activity of the RE-II site was specifically inhibited by cyclosporin A, and transfection assays with IL-5 constructs containing mutations in the RE-II site showed greatly reduced reporter gene activity. We have defined the sequence involved in stimulation-dependent transcription and have identified constitutive as well as inducible DNA-binding protein complexes that bind to RE-II. Antibodies against at least two members of the nuclear factor of activated T cells (NFAT) family of transcription factors are capable of binding to the IL-5 RE-II complexes, although they can be distinguished from previously identified NFAT-specific complexes by several characteristics.			Stranick, KS (corresponding author), SCHERING PLOUGH CORP,RES INST,DEPT ALLERGY,2015 GALLOPING HILL RD,KENILWORTH,NJ 07033, USA.							Ausubel FM., 2006, ENZYMATIC MANIPULATI; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOURKE PF, 1995, BLOOD, V85, P2069, DOI 10.1182/blood.V85.8.2069.bloodjournal8582069; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JENKINS F, 1995, J IMMUNOL, V155, P1240; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; KITA H, 1992, J IMMUNOL, V149, P629; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEE HJ, 1993, J IMMUNOL, V151, P6135; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Mori A, 1996, J IMMUNOL, V156, P2400; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nagai Hiroichi, 1993, Life Sciences, V53, P243; NAORA H, 1995, EXP HEMATOL, V23, P597; NAORA H, 1994, J IMMUNOL, V152, P5691; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PARK JH, 1993, J BIOL CHEM, V268, P6299; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; RONCAROLO MG, 1988, J EXP MED, V168, P2139, DOI 10.1084/jem.168.6.2139; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Sambrook J., 2002, MOL CLONING LAB MANU; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; STRANICK KS, 1995, J BIOL CHEM, V270, P20575, DOI 10.1074/jbc.270.35.20575; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; Tsuruta L, 1995, J ALLERGY CLIN IMMUN, V96, P1126, DOI 10.1016/S0091-6749(95)70197-4; VANDERPOUWKRAAN T, 1992, EUR J IMMUNOL, V22, P1237, DOI 10.1002/eji.1830220519; WARREN DJ, 1988, J IMMUNOL, V140, P94; WATANABE S, 1994, INT IMMUNOL, V6, P523, DOI 10.1093/intimm/6.4.523; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WOLFF CHJ, 1993, J IMMUNOL, V151, P1337; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	62	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16453	16465		10.1074/jbc.272.26.16453	http://dx.doi.org/10.1074/jbc.272.26.16453			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195954	hybrid			2022-12-25	WOS:A1997XG01900058
J	Hockerman, GH; Johnson, BD; Abbott, MR; Scheuer, T; Catterall, WA				Hockerman, GH; Johnson, BD; Abbott, MR; Scheuer, T; Catterall, WA			Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the alpha(1) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CA2+ CHANNELS; RECEPTOR; IDENTIFICATION; EXPRESSION; VERAPAMIL; MECHANISM; MEMBRANE; D600	Recent studies of the phenylalkylamine binding site in the alpha(1C) subunit of L-type Ca2+ channels have revealed three amino acid residues in transmembrane segment IVS6 that are critical for high affinity block and are unique to L-type channels, We have extended this analysis of the phenylalkylamine binding site to amino acid residues in transmembrane segment IIIS6 and the pore region. Twenty-two consecutive amino acid residues in segment IIIS6 were mutated to alanine and the conserved Glu residues in the pore region of each homologous domain were mutated to Gln. Mutant channels were expressed in tsA-201 cells along with the beta(1b) and alpha(2) delta auxiliary subunits, Assay for block of Ba2+ current by (-)-D888 at -60 mV revealed that mutation of five amino acid residues in segment IIIS6 and the pore region that are conserved between L-type and non-L-type channels (Tyr(1152), Phe(1164), Val(1165) Glu(1118) and Glu(1419)) and one L-type-specific amino acid (Ile(1153)) decreased affinity for (-)-D888 from 10-20 fold. Combination of the four mutations in segment IIIS6 increased the IC50 for block by (-)-D888 to approximately 9 mu M, similar to the affinity of non-L-type Ca2+ channels for this drug. These results indicate that there are important determinants of phenylalkylamine binding in both the S6 segments and the pore regions of domains III and IV, same of which are conserved across the different classes of voltage-gated Ca2+ channels. A model of the phenylalkylamine receptor site at the interface between domains III and IV of the alpha(1) subunit is presented.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; DECOURSEY TE, 1995, J GEN PHYSIOL, V106, P745, DOI 10.1085/jgp.106.4.745; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; EHARA T, 1978, J PHARMACOL EXP THER, V207, P49; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Fleckenstein A, 1980, Eur Heart J, V1, P15; GLOSSMANN H, 1984, J CARDIOVASC PHARM S, V6, P508; GOULD RJ, 1983, COLD SPRING HARB SYM, V48, P355, DOI 10.1101/SQB.1983.048.01.039; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Johnson BD, 1996, MOL PHARMACOL, V50, P1388; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCDONALD TF, 1984, J PHYSIOL-LONDON, V352, P217, DOI 10.1113/jphysiol.1984.sp015288; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; PELZER D, 1982, PFLUG ARCH EUR J PHY, V394, P97, DOI 10.1007/BF00582909; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; WIT AL, 1974, CIRC RES, V35, P413, DOI 10.1161/01.RES.35.3.413; YANG J, 1993, NATURE, V366, P109	33	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18759	18765		10.1074/jbc.272.30.18759	http://dx.doi.org/10.1074/jbc.272.30.18759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228049	hybrid			2022-12-25	WOS:A1997XM34200040
J	Nichols, JC; Matthews, KS				Nichols, JC; Matthews, KS			Combinatorial mutations of lac repressor - Stability of monomer-monomer interface is increased by apolar substitution at position 84	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; AMINO-ACID SEQUENCE; LACTOSE REPRESSOR; ESCHERICHIA-COLI; OPERATOR DNA; BOUNDARY ANALYSIS; BINDING; PROTEIN; INDUCER; TETRAMER	To examine the monomer-monomer subunit interface in the lac repressor, a mutation that generates dimeric protein (deletion of C-terminal amino acids to disrupt the dimer-dimer interface) has been combined with amino acid substitutions that alter the monomer-monomer interface (substitution at Lys(84) or Tyr(282)). Dimeric proteins with significantly increased stability to urea denaturation were formed by the introduction of the apolar amino acids Ala or Leu in lieu of Lys(84) in concert with the deletion of 11 C-terminal amino acids. K84A/-11 deletion protein retained wild-type affinity for operator DNA, while K84L/-11 deletion protein displayed operator affinity similar to its parent tetramer, To assess further the influence of monomer-monomer interface stability on assembly and DNA binding, triple mutants were generated with Y282D, an alteration that disrupts assembly completely in the wild-type background, The triple mutants were dimeric, but they exhibited diminished dimer stability to urea denaturation and decreased operator affinity compared with the double mutations. These results demonstrate directly the stabilizing influence of apolar substitution at position 84 on the monomer monomer interface.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NIGMS NIH HHS [GM22441, 5T32GM08362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441, T32GM008362] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BEYREUTHER K, 1978, NATURE, V274, P767, DOI 10.1038/274767a0; BEYREUTHER K, 1975, EUR J BIOCHEM, V59, P491, DOI 10.1111/j.1432-1033.1975.tb02477.x; BEYREUTHER K, 1973, P NATL ACAD SCI USA, V70, P3576, DOI 10.1073/pnas.70.12.3576; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; BUTLER AP, 1977, BIOCHEMISTRY-US, V16, P4757, DOI 10.1021/bi00641a001; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1994, J BIOL CHEM, V269, P12482; CHEN J, 1992, GENE, V111, P145, DOI 10.1016/0378-1119(92)90618-Y; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHEN J, 1994, BIOCHEMISTRY-US, V33, P8728, DOI 10.1021/bi00195a014; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FRIEDMAN BE, 1977, J MOL BIOL, V111, P27; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; GREENE RF, 1974, J BIOL CHEM, V249, P5388; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; JOBE A, 1972, J MOL BIOL, V69, P397, DOI 10.1016/0022-2836(72)90253-7; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LI L, 1995, J BIOL CHEM, V270, P10640, DOI 10.1074/jbc.270.18.10640; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MILLER JH, 1978, OPERON; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; OHSHIMA Y, 1972, BIOCHEM BIOPH RES CO, V47, P1444, DOI 10.1016/0006-291X(72)90234-3; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PLATT T, 1973, J BIOL CHEM, V248, P110; Ralston G., 1993, INTRO ANAL ULTRACENT; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	58	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18550	18557		10.1074/jbc.272.30.18550	http://dx.doi.org/10.1074/jbc.272.30.18550			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228020	hybrid			2022-12-25	WOS:A1997XM34200011
J	Paton, VG; Shackelford, JE; Krisans, SK				Paton, VG; Shackelford, JE; Krisans, SK			Cloning and subcellular localization of hamster and rat Isopentenyl diphosphate dimethylallyl diphosphate isomerase - A PTS1 motif targets the enzyme to peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PEROXISOMES; MEVALONATE KINASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ACETOACETYL-COA; ACETYL-COA; DISORDERS; STEP	To date, isopentenyl diphosphate:dimethylallyl diphosphate isomerase (IPP isomerase; EC 5.3.3.2) is presumed to have a cytosolic localization, However, we have recently shown that in permeabilized cells lacking cytosolic components, mevalonate can be converted to cholesterol, implying that all of the enzymes required for the conversion of mevalonate to farnesyl diphosphate are found in the peroxisome. To provide unequivocal evidence for the subcellular localization of IPP isomerase, in this study, we have cloned the rat and hamster homologues of IPP isomerase and identified the signal that targets this enzyme to peroxisomes. In addition, we also demonstrate that IPP isomerase is regulated at the mRNA level.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032852] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32852] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432-1033.1989.tb15142.x; Biardi L, 1996, J BIOL CHEM, V271, P1784, DOI 10.1074/jbc.271.3.1784; BIARDI L, 1994, J BIOL CHEM, V269, P1197; CHAMBLISS LL, 1996, J BIOL CHEM, V271, P17330; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Hahn FM, 1996, ARCH BIOCHEM BIOPHYS, V332, P30, DOI 10.1006/abbi.1996.0312; HOVIK R, 1991, J LIPID RES, V32, P993; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; KRISANS SK, 1988, J CELL BIOL, V107, P122; MUEHLBACHER M, 1985, J AM CHEM SOC, V107, P8307, DOI 10.1021/ja00312a107; PARKER RA, 1989, J BIOL CHEM, V264, P4877; POPJAK G, 1970, NATURAL SUBSTANCES F, P17; Purdue PE, 1996, ANN NY ACAD SCI, V804, P775, DOI 10.1111/j.1749-6632.1996.tb18699.x; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Sambrook J., 2002, MOL CLONING LAB MANU; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SPURGEON SL, 1981, BIOSYNTHESIS ISOPREN, V1, P2; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOTH JM, 1996, J BIOL CHEM, V271, P7895; XUAN J, 1994, GENOMICS, V20, P128	27	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18945	18950		10.1074/jbc.272.30.18945	http://dx.doi.org/10.1074/jbc.272.30.18945			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228075	hybrid			2022-12-25	WOS:A1997XM34200066
J	Bisaillon, M; Bergeron, J; Lemay, G				Bisaillon, M; Bergeron, J; Lemay, G			Characterization of the nucleoside triphosphate phosphohydrolase and helicase activities of the reovirus lambda 1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE; PUTATIVE HELICASES; ESCHERICHIA-COLI; MESSENGER-RNA; VIRUS; AFFINITY; ATPASE; MOTIF; CORE; POLYMERASE	Previous studies have shown that the reovirus lambda 1 core protein harbors a putative nucleotide-binding motif and exhibits an affinity for nucleic acids, In addition, a nucleoside triphosphate phosphohydrolase activity present in reovirus cores has been recently assigned to hi using gene reassortment analysis. In this study, it was demonstrated that the recombinant lambda 1 protein, expressed in the yeast Pichia pastoris, is able to hydrolyze nucleoside 5'-biphosphates or deoxynucleoside 5'-triphosphates. This activity was absolutely dependent on the presence of a divalent cation, Mg2+ or Mn2+. The protein can also unwind double-stranded nucleic acid molecules in the presence of a nucleoside 5'-triphosphate or deoxynucleoside 5'-triphosphate. These results provide the first biochemical evidence that the reovirus lambda 1 protein is a nucleoside triphosphate phosphohydrolase/helicase and strongly support the idea that lambda 1 participates in transcription of the viral genome.	UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal			Lemay, Guy/B-2165-2008	Lemay, Guy/0000-0002-0402-1285				ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; BARTLETT JA, 1988, VIROLOGY, V167, P31, DOI 10.1016/0042-6822(88)90051-7; Bayliss CD, 1996, J VIROL, V70, P794, DOI 10.1128/JVI.70.2.794-800.1996; BORSA J, 1970, J VIROL, V6, P295, DOI 10.1128/JVI.6.3.295-302.1970; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; CASHDOLLAR LW, 1994, RES VIROLOGY, V145, P277, DOI 10.1016/S0923-2516(07)80032-X; CLERTANT P, 1984, J BIOL CHEM, V259, P5196; COOMBS KM, 1994, J VIROL, V68, P177, DOI 10.1128/JVI.68.1.177-186.1994; Coombs KM, 1996, J VIROL, V70, P4237, DOI 10.1128/JVI.70.7.4237-4245.1996; DRAYNA D, 1982, J VIROL, V41, P110, DOI 10.1128/JVI.41.1.110-118.1982; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FAUST M, 1975, NUCLEIC ACIDS RES, V2, P1329, DOI 10.1093/nar/2.8.1329; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P362, DOI 10.1073/pnas.72.1.362; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; JINDAL HK, 1994, J BIOL CHEM, V269, P3283; KAPULER AM, 1970, BIOCHEMISTRY-US, V9, P4453, DOI 10.1021/bi00824a029; KAPULER AM, 1970, NATURE, V225, P1209, DOI 10.1038/2251209a0; LEMAY G, 1994, J GEN VIROL, V75, P3261, DOI 10.1099/0022-1317-75-11-3261; LI JP, 1988, J VIROL, V62, P4016, DOI 10.1128/JVI.62.11.4016-4021.1988; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; Nibert Max L., 1996, P691; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STARNES MC, 1993, VIROLOGY, V193, P356, DOI 10.1006/viro.1993.1132; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TAMURA JK, 1993, VIROLOGY, V193, P1, DOI 10.1006/viro.1993.1097; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016	44	63	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18298	18303		10.1074/jbc.272.29.18298	http://dx.doi.org/10.1074/jbc.272.29.18298			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218469	hybrid			2022-12-25	WOS:A1997XL73500059
J	Johansson, JS				Johansson, JS			Binding of the volatile anesthetic chloroform to albumin demonstrated using tryptophan fluorescence quenching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE-FREQUENCY PHASE; HUMAN SERUM-ALBUMIN; QUANTITATIVE-DETERMINATION; MODULATION DATA; PROTEINS; HALOTHANE; STABILITY; TITRATION; CHEMISTRY; KINETICS	The site(s) of action of the volatile general anesthetics remain(s) controversial, but evidence in favor of specific protein targets is accumulating. The techniques to measure directly volatile anesthetic binding to proteins are still under development. Further experience with the intrinsic protein fluorescence quenching approach to monitor anesthetic-protein complexation is reported using chloroform. Chloroform quenches the steady state tryptophan fluorescence of bovine serum albumin (ESA) in a concentration-dependent, saturable manner with a K-d = 2.7 +/- 0.2 mM. Tryptophan fluorescence lifetime analysis reveals that the majority of the quenching is due to a static mechanism, indicative of anesthetic binding. The ability of chloroform to quench BSA tryptophan fluorescence was decreased markedly in the presence of 50% 2,2,2-trifluoroethanol, which causes loss of tertiary structural contacts in BSA, indicating that protein conformation is crucial for anesthetic binding. Circular dichroism spectroscopy revealed no measurable effect of chloroform on the secondary structure of BSA. The results suggest that chloroform binds to subdomains IB and IIA in ESA, each of which contains a single tryptophan. Earlier work has shown that these sites are also occupied by halothane. The present study therefore provides experimental support for the theory that structurally distinct general anesthetics may occupy the same domains on protein targets.	UNIV PENN, DEPT ANESTHESIA, PHILADELPHIA, PA 19104 USA; UNIV PENN, JOHNSON RES FDN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM055876] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01-GM55876] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM MH, 1987, CHROMATOGRAPHIA, V23, P243, DOI 10.1007/BF02311772; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; Chen Y, 1996, J AM CHEM SOC, V118, P9271, DOI 10.1021/ja961307u; COWAN DO, 1970, J AM CHEM SOC, V92, P6281, DOI 10.1021/ja00724a029; DUBOIS BW, 1993, P NATL ACAD SCI USA, V90, P6478, DOI 10.1073/pnas.90.14.6478; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; EBERSON L, 1982, ACTA CHEM SCAND B, V36, P533, DOI 10.3891/acta.chem.scand.36b-0533; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 1996, P NATL ACAD SCI USA, V93, P2807, DOI 10.1073/pnas.93.7.2807; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EGER EI, 1969, ANESTHESIOLOGY, V30, P129; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; Gibney BR, 1997, BIOCHEMISTRY-US, V36, P2798, DOI 10.1021/bi9618225; GRATTON E, 1984, BIOPHYS J, V46, P479, DOI 10.1016/S0006-3495(84)84044-8; HARRIS RA, 1995, FASEB J, V9, P1454, DOI 10.1096/fasebj.9.14.7589987; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; Johansson JS, 1996, J PHARMACOL EXP THER, V279, P56; Johansson JS, 1996, BBA-GEN SUBJECTS, V1290, P63, DOI 10.1016/0304-4165(95)00187-5; Johansson JS, 1997, BIOPHYS J, V72, pTH406; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; KARON BS, 1995, BIOPHYS J, V68, P936, DOI 10.1016/S0006-3495(95)80269-9; KAUFMAN RD, 1977, ANESTHESIOLOGY, V46, P49, DOI 10.1097/00000542-197701000-00010; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAKOWICZ JR, 1980, BIOPHYS J, V32, P591, DOI 10.1016/S0006-3495(80)84992-7; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; Laskowski RA, 1996, PROTEIN SCI, V5, P2438; LEE AG, 1991, PROG LIPID RES, V30, P323, DOI 10.1016/0163-7827(91)90002-M; MCDONAGH AF, 1992, EXPERIENTIA, V48, P246, DOI 10.1007/BF01930465; MILES JL, 1962, J BIOL CHEM, V237, P1319; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; POSTNIKOVA GB, 1991, EUR J BIOCHEM, V198, P223, DOI 10.1111/j.1432-1033.1991.tb16005.x; RAINES DE, 1995, ANESTHESIOLOGY, V82, P276, DOI 10.1097/00000542-199501000-00033; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; STEINER RF, 1969, J PHYS CHEM-US, V73, P4130, DOI 10.1021/j100846a015; STEINHARDT J, 1971, BIOCHEMISTRY-US, V10, P4005, DOI 10.1021/bi00798a001; TAHERI S, 1991, ANESTH ANALG, V72, P627; WASYLEWSKI Z, 1988, EUR J BIOCHEM, V172, P719, DOI 10.1111/j.1432-1033.1988.tb13948.x; Xu Y, 1996, BIOPHYS J, V70, P532, DOI 10.1016/S0006-3495(96)79599-1; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	45	114	116	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17961	17965		10.1074/jbc.272.29.17961	http://dx.doi.org/10.1074/jbc.272.29.17961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218421	hybrid			2022-12-25	WOS:A1997XL73500011
J	Qin, SF; Minami, Y; Kurosaki, T; Yamamura, H				Qin, SF; Minami, Y; Kurosaki, T; Yamamura, H			Distinctive functions of Syk and Lyn in mediating osmotic stress- and ultraviolet C irradiation-induced apoptosis in chicken B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ABL TYROSINE KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MAMMALIAN-CELLS; BCR-ABL; HA-RAS; ACTIVATION; JUN; PHOSPHORYLATION	By taking advantage of the established chicken B cell line, DT40 cells, which do not express tyrosine kinase Syk or Lyn, functional soles or Syk and kyn in apoptotic response elicited by cellular stress were investigated, DT40 cells underwent apoptosis after hyperosmostic stress, In Syk-deficient DT40 cells, this apoptotic process was significantly enhanced, Ectopic expression of wild type, but not kinase-inactive, porcine Syk in Syk-deficient cells rescued cells from osmotic stress-induced apoptosis, demonstrating that the presence of functionally active? Syk is necessary to protect cells from osmotic stress-induced apoptosis. In comparison these was no effect on osmotic stress-induced apoptosis in Lyn-deficency DT40 cells, Interestingly, while Syk, was not involved in ultraviolet C (UVC)-induced apoptosis, a a deficiency of Lyn rendered cells resistant to UVC irradiation, These observations defined Syk and Lyn as important mediators of apoptosis in DT40 cells in response to osmotic stress and UVC irradiation, respectively, Furthermore, osmotic stress, but not UVC irradiation, could activate c-Jun N-terminal kinase (JNK) in DT40 cells. A deficiency in either Syk or Lyn did not affect the osmotic stress-induced activation of JNK. Wet therefore, concluded that Syk and Lyn regulate the apoptotic responses to osmotic stress and UVC irradiation independently of the JNK pathway in DT40 cells.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE,HYOGO 650,JAPAN; FUKUI MED SCH,DEPT BIOCHEM,FUKUI 91011,JAPAN; KANSAI MED UNIV,DEPT BIOCHEM,MORIGUCHI,OSAKA 570,JAPAN	Kobe University; University of Fukui; Kansai Medical University			Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Qin, Suofu/0000-0002-3323-8846				BEDI A, 1994, BLOOD, V83, P2038; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P9575, DOI 10.1073/pnas.92.21.9575; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Qin SF, 1997, J BIOL CHEM, V272, P2098; Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHIEVEN GL, 1995, J BIOL CHEM, V270, P20824, DOI 10.1074/jbc.270.35.20824; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	38	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17994	17999		10.1074/jbc.272.29.17994	http://dx.doi.org/10.1074/jbc.272.29.17994			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218426	hybrid			2022-12-25	WOS:A1997XL73500016
J	AbuSoud, HM; Gachhui, R; Raushel, FM; Stuehr, DJ				AbuSoud, HM; Gachhui, R; Raushel, FM; Stuehr, DJ			The ferrous-dioxy complex of neuronal nitric oxide synthase - Divergent effects of L-arginine and tetrahydrobiopterin on its stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; MACROPHAGE NO SYNTHASE; ELECTRON-TRANSFER; HEME COORDINATION; OXYGENATED FORM; LOW-TEMPERATURE; CALMODULIN; ENZYME; MECHANISM; BINDING	Nitric oxide synthases (NOS) are hemeproteins that catalyze oxidation of L-arginine to nitric oxide (NO) and citrulline. The NOS heme iron is expected to participate in oxygen activation during catalysis, but its interac tions with O-2 are not characterized. We utilized the heme-containing oxygenase domain of neuronal NOS (nNOSoxy) and stopped-flow methods to study forma tion and autooxidative decomposition of the nNOSoxy oxygenated complex at 10 degrees C. Mixing ferrous nNOSoxy with air-saturated buffer generated a transient species with absorption maxima at 427 and similar to 560 nm. This species decayed within 1 s to form ferric nNOSoxy. Its formation was first order with respect to O-2, monophasic, and gave rate constants for k(on) = 9 x 10(5) M-1 s(-1) and k(off) = 108 s(-1) for an L-arginine- and tetrahydrobiopterin (H4B)-saturated nNOSoxy. Omission of L-arginine and/or H4B did not greatly effect O-2 binding and dissociation rates. Decomposition of the oxygenated intermediate was independent of O-2 concentration and was either biphasic or monophasic depending on sample conditions, L-Arginine stabilized the oxygenated intermediate (decay rate = 0.14 s(-1)), while H4B accelerated its decay by a factor of 70 irrespective of L-arginine. The spectral and kinetic properties of the intermediate identify it as the (FeO2)-O-II complex of nNOSoxy. Destabilization of a metallo-oxy species by H4B is unprecedented and may be important regarding the role of this cofactor in NO synthesis.	TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station	AbuSoud, HM (corresponding author), CLEVELAND CLIN,RES INST,DEPT IMMUNOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BONFILS C, 1979, BIOCHEM BIOPH RES CO, V88, P1301, DOI 10.1016/0006-291X(79)91122-7; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; EISENSTEIN L, 1977, BIOCHEM BIOPH RES CO, V77, P1377, DOI 10.1016/S0006-291X(77)80131-9; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GUENGERICH FP, 1976, BIOCHEM BIOPH RES CO, V70, P951; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MOMENTEAU M, 1994, CHEM REV, V94, P659, DOI 10.1021/cr00027a006; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; POU S, 1992, J BIOL CHEM, V267, P24173; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SLIGAR SG, 1974, BIOCHEM BIOPH RES CO, V61, P290, DOI 10.1016/0006-291X(74)90565-8; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; TYSON CA, 1972, J BIOL CHEM, V247, P5777; VINCENT SR, 1994, PROG NEUROBIOL, V42, P129, DOI 10.1016/0301-0082(94)90023-X; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	49	156	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17349	17353		10.1074/jbc.272.28.17349	http://dx.doi.org/10.1074/jbc.272.28.17349			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211873	hybrid			2022-12-25	WOS:A1997XK16500016
J	Asano, S; Matsuda, S; Tega, Y; Shimizu, K; Sakamoto, S; Takeguchi, N				Asano, S; Matsuda, S; Tega, Y; Shimizu, K; Sakamoto, S; Takeguchi, N			Mutational analysis of putative SCH 28080 binding sites of the gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; AMINO-ACID-SEQUENCE; DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; DISTAL COLON; CDNA CLONING; K+-ATPASE; NA+,K+-ATPASE	A compound, SCH 28080 (2-methyl-8-(phenylmethoxy) imidazo[1,2-a]pyridine-3-acetonitrile) reversibly inhibits gastric and renal ouabain-insensitive H+,K+-ATPase, but not colonic ouabain-sensitive H+,H+-ATPase, By using the functional expression system and site-directed mutagenesis, we analyzed the putative binding sites of SCH 28080 in gastric H+,K+-ATPase alpha-subunit, It was previously reported that the binding site of SCH 28080, which is a K+-site inhibitor specific for gastric H+,K+-ATPase, was in the first extracellular loop between the first and second transmembrane segments of the alpha-subunit; Phe-126 and Asp-138 were putative binding sites, However, we found that all the mutants in the first extracellular loop including Phe-126 and Asp-ISS retained H+,K+-ATPase activity and sensitivity to SCH 28080, Therefore, amino acid residues in the first extracellular loop are not directly involved in the SCH 28080 binding nor indispensable for the H+,K+-ATPase activity. Here rye propose a candidate residue that is important for the binding with SCH 28080, Glu-822 in the sixth transmembrane segment. Mutations of Glu-822 to Asp and Ala (mutants termed E822D and E822A, respectively) decreased the ATPase activity to about 45% and 35% of the wild-type enzyme, respectively, while the mutations to Gin and Leu abolished the activity, Mutant E822A showed a significantly lower affinity for K+ than the wild-type enzyme, indicating that Glu-822 is involved in determining the affinity for K+, The sensitivity of mutant E822D to SCH 28080 was 8 times lower than that of the wild-type enzyme, The counterpart of Glu-822 in gastric H+,K+-ATPase is Asp in Na+,K+-ATPase and other colonic ouabain-sensitive H+,K+-ATPase, which are insensitive to SCN 28080, These results suggest that Glu-822 is one of important sites that bind with SCH 28080.	TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,TOYAMA 93001,JAPAN	University of Toyama	Asano, S (corresponding author), TOYAMA MED & PHARMACEUT UNIV,MOL GENET RES CTR,2630 SUGITANI,TOYAMA 93001,JAPAN.			Asano, Shinji/0000-0003-1443-8970				ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; ASANO S, 1988, J BIOCHEM-TOKYO, V103, P672, DOI 10.1093/oxfordjournals.jbchem.a122327; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; Burns EL, 1996, J BIOL CHEM, V271, P15879, DOI 10.1074/jbc.271.27.15879; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CHEVAL L, 1991, AM J PHYSIOL, V260, pF800, DOI 10.1152/ajprenal.1991.260.6.F800; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORMACK B, 1991, CURRENT PROTOCOLS MO; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FORTE JG, 1975, GASTROENTEROLOGY, V69, P175; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; MORII M, 1989, GASTROENTEROLOGY, V96, P1453, DOI 10.1016/0016-5085(89)90512-X; MORII M, 1995, BIOCHEM PHARMACOL, V49, P1729, DOI 10.1016/0006-2952(95)00090-M; Morii M, 1996, J BIOL CHEM, V271, P4068; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCOTT CK, 1985, EUR J PHARMACOL, V112, P268, DOI 10.1016/0014-2999(85)90508-4; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SONG I, 1993, BIOCHEM BIOPH RES CO, V196, P1240, DOI 10.1006/bbrc.1993.2385; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKEGUCHI M, 1990, GASTROENTEROLOGY, V99, P1339, DOI 10.1016/0016-5085(90)91159-4; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	45	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17668	17674		10.1074/jbc.272.28.17668	http://dx.doi.org/10.1074/jbc.272.28.17668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211917	hybrid			2022-12-25	WOS:A1997XK16500060
J	Balestrieri, ML; Servillo, L; Lee, TC				Balestrieri, ML; Servillo, L; Lee, TC			The role of platelet-activating factor-dependent transacetylase in the biosynthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by stimulated endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPLEEN MICROSOMES; ALKYL ETHER ANALOG; FACTOR PAF; 1-ALKYL-2-LYSO-SN-GLYCERO-3-PHOSPHOCHOLINE-ACETYL-COA ACETYLTRANSFERASE; FACTOR 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; INDEPENDENT TRANSACYLASE; FACTOR ACETYLHYDROLASE; HUMAN NEUTROPHILS; PROTEIN-KINASE; HL-60 CELLS	Acyl analogs of platelet-activating factor (PAF) (1-acyl-2-acetyl-sn-glycero-3-phosphocholine, acylacetyl-GPC) are the predominant products synthesized during thrombin or ionophore A23187-mediated activation of endothelial cells, However, the biosynthetic pathway responsible for the production of acylacetyl-GPC is not well understood, In the present investigation, we have demonstrated that the acyl analogs of PAF are also the major products from calf pulmonary artery endothelial cells in response to a time-dependent stimulation of ATP (10(-3) M), bradykinin (10(-8) M), or ionophore A23187 (2 mu M) In addition, we have found that the CoA-independent PAF:acyllyso-GPC transacetylase recently identified by us is concurrently and transiently induced with maximal 4-fold enhancement at 5 min and returned to near basal level by 10 min treatment of endothelial cells with ATP. Acid phosphatase reduces the increased PAF:acyllyso-GPC transacetylase activity from the homogenates of ATP-activated endothelial cells, Reduced PAF:acyllyso-GPC transacetylase activity can be restored by incubating the acid phosphatase-treated homogenates with ATP (5 mM) and Mg2+ (10 mM), Furthermore, okadaic acid, a protein phosphatase I and 2A inhibitor, incubated with endothelial cells in a dose-dependent manner (1-100 nM) for 10-min potentiates and sustained the stimulation of PAF:acyllyso-GPC transacetylase activity by ATP. On the other hand, genistein, tyrphostin-25 (inhibitors of tyrosine-specific protein kinase), and calphostin C (an inhibitor of protein kinase C) block the activation of PAF:acyllyso-GPC transacetylase by ATP, These results are consistent with the notion that ATP regulates the transacetylase activity by reversible activation and inactivation via the phosphorylation and dephosphorylation cycle, ATP also augments the activities of alkyllyso-GPC/acyllyso-GPC:acetyl-CoA acetyltransferase, However, the activation of the acetyltransferases precedes that of the transacetylase with peak activation occurring at 1-2 min of the ATP treatment, In addition, sodium vanadate, also an inhibitor of protein phosphatase, stimulates the increase in the incorporation of [H-3]acetate into acyl[H-3]acetyl-GPC of the ATP-treated endothelial cells, Collectively, our data show that both acetyltransferases and transacetylase participate in and contribute to the biosynthesis of acyl analogs of PAF in a coordinate fashion in endothelial cells.	OAK RIDGE ASSOCIATED UNIV, ENVIRONM & HLTH SCI DIV, OAK RIDGE, TN 37831 USA; UNIV NAPLES, DEPT BIOCHEM & BIOPHYS F CEDRANGOLO, I-80138 NAPLES, ITALY	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Naples Federico II				Balestrieri, Maria Luisa/0000-0001-6001-1789	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052492] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52492] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BLANK ML, 1982, RES COMMUN CHEM PATH, V38, P3; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BLANK ML, 1990, J CHROMATOGR, V508, P382, DOI 10.1016/S0021-9673(00)91281-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CLAY KL, 1991, BIOCHIM BIOPHYS ACTA, V1094, P43, DOI 10.1016/0167-4889(91)90024-R; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLUMBO M, 1993, J ALLERGY CLIN IMMUN, V92, P325, DOI 10.1016/0091-6749(93)90176-G; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DOEBBER TW, 1987, P NATL ACAD SCI USA, V84, P7557, DOI 10.1073/pnas.84.21.7557; DOMENECH C, 1987, J BIOL CHEM, V262, P5671; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; GARCIA MC, 1991, BIOCHIM BIOPHYS ACTA, V1083, P37, DOI 10.1016/0005-2760(91)90122-X; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; GOMEZCAMBRONERO J, 1987, BIOCHEM J, V245, P893, DOI 10.1042/bj2450893; HOLLAND MR, 1992, J BIOL CHEM, V267, P22883; LEE TC, 1985, J BIOL CHEM, V260, P952; LEE TC, 1994, J LIPID MEDIAT CELL, V9, P267; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; LEE TC, 1992, METHOD ENZYMOL, V209, P396; LEE TC, 1992, J BIOL CHEM, V267, P19992; LEE TC, 1987, PLATELET ACTIVATING, P115; LENIHAN DJ, 1984, BIOCHEM BIOPH RES CO, V120, P834, DOI 10.1016/S0006-291X(84)80182-5; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAZIERE C, 1994, BBA-LIPID LIPID MET, V1210, P233, DOI 10.1016/0005-2760(94)90126-0; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MUELLER HW, 1991, BIOCHEM BIOPH RES CO, V176, P1557, DOI 10.1016/0006-291X(91)90465-J; NAKAGAWA Y, 1992, BIOCHIM BIOPHYS ACTA, V1126, P277, DOI 10.1016/0005-2760(92)90241-M; NIETO ML, 1991, J BIOL CHEM, V266, P18699; NINIO E, 1983, BIOCHIM BIOPHYS ACTA, V751, P298, DOI 10.1016/0005-2760(83)90287-4; NINIO E, 1987, J IMMUNOL, V139, P154; PINCKARD RN, 1992, J IMMUNOL, V148, P3528; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, THROMB HAEMOSTASIS, V64, P99; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; STURK A, 1989, BIOCHIM BIOPHYS ACTA, V993, P148, DOI 10.1016/0304-4165(89)90157-8; TORDAI A, 1994, J IMMUNOL, V152, P566; TRIGGIANI M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P41, DOI 10.1016/0005-2760(91)90053-K; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; TRIGGIANI M, 1992, BIOCHEM J, V286, P497, DOI 10.1042/bj2860497; TRIGGIANI M, 1991, J BIOL CHEM, V266, P6928; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VANDENBOSCH H, 1991, LIPIDS, V26, P967, DOI 10.1007/BF02536486; VENABLE ME, 1993, J LIPID RES, V34, P691; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WHATLEY RE, 1988, ARTERIOSCLEROSIS, V8, P321, DOI 10.1161/01.ATV.8.3.321; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WYKLE RL, 1980, J BIOL CHEM, V255, P256	58	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17431	17437		10.1074/jbc.272.28.17431	http://dx.doi.org/10.1074/jbc.272.28.17431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211886	hybrid			2022-12-25	WOS:A1997XK16500029
J	deWeerd, WFC; LeebLundberg, LMF				deWeerd, WFC; LeebLundberg, LMF			Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled G alpha subunits G alpha(q) and G alpha(i) in caveolae in DDT1 MF-2 smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; ROUS-SARCOMA VIRUS; SIGNAL-TRANSDUCTION; PROTEIN-COMPONENT; ANCHORED PROTEINS; PLASMA-MEMBRANE; KININ RECEPTORS; GROWTH-FACTOR; EXPRESSION; TYROSINE	In this report, we show that the vasoactive peptide agonist bradykinin (BK) when bound to B2 BK receptors on DDT1 MF-2 smooth muscle. cells promotes the recruitment and sequestration of the occupied receptors and the receptor-coupled G-protein alpha subunits G alpha(q) and G alpha(i) in caveolae, Association of ligand receptor complexes and G alpha subunits with caveolae was indicated by their co-enrichment on density gradients with caveolin, a marker protein for caveolae. Caveolin and G alpha subunits were monitored by immunoblotting, whereas receptors were monitored as ligand receptor complexes formed by labeling receptors with the agonist BK or the antagonist NPC17731 prior to cell disruption and caveolae enrichment, These complexes were detected with radioligand and by immunoblotting with BR antibodies. A direct interaction of G alpha subunits with caveolin was also indicated by their co-immunoprecipitation, Immunoelectron microscopy revealed that the enriched caveolin, Ga subunits, and BK receptor complexes were present in structures of 0.1-0.2 mu m. At 4 degrees C, BH and NPC17731 receptor complexes were detected in caveolae, and both complexes were sensitive to acid washing prior to cell disruption and caveolae enrichment. Elevation of the temperature to 37 degrees C increased the amount of BK receptor complexes in caveolae with a maximal response at 10 min (continuous labeling or 20 min (single-round labelling), and the complexes became acid-resistant, These conditions also increased the amount of G alpha(q), and G alpha(i) in caveolae with a maximal response at 5-10 min, In contrast, the NPC17731 receptor complexes remained acid-sensitive and dissociated at this temperature, and antagonists did not increase the amount of Get subunits in caveolae, These results show that some agonists that act through G-protein-coupled receptors promote the association of their receptors and receptor-coupled Get subunits with caveolae.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Anderson RM, 1991, INFECT DIS HUMANS DY, P13; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LI S, 1995, J BIOL CHEM, V27, P15693; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PAGE E, 1994, CIRC RES, V75, P949, DOI 10.1161/01.RES.75.5.949; PALADE GE, 1953, J APPL PHYS, V24, P1424; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; REGOLI D, 1980, PHARMACOL REV, V32, P1; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROPEA MM, 1992, CAN J PHYSIOL PHARM, V70, P1360, DOI 10.1139/y92-191; WALLACE H, 1969, ANAL BIOCHEM, V32, P334, DOI 10.1016/0003-2697(69)90094-3; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WILKBLASZCZAK MA, 1994, NEURON, V12, P109, DOI 10.1016/0896-6273(94)90156-2; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	59	235	236	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17858	17866		10.1074/jbc.272.28.17858	http://dx.doi.org/10.1074/jbc.272.28.17858			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211942	hybrid			2022-12-25	WOS:A1997XK16500085
J	Li, SL; Valente, AJ; Zhao, SJ; Clark, RA				Li, SL; Valente, AJ; Zhao, SJ; Clark, RA			PU.1 is essential for p47(phox) promoter activity in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; COLONY-STIMULATING FACTOR-1; CCAAT DISPLACEMENT PROTEIN; TRANSCRIPTION FACTOR PU.1; TUMOR-NECROSIS-FACTOR; RNA-POLYMERASE-II; NADPH OXIDASE; CD11B PROMOTER; GENE PROMOTER	Expression of the phagocyte cytosolic protein p47(phox), a component of NADPH oxidase, is restricted mainly to myeloid cells. To study the cis elements and trans acting factors responsible for its gene expression, we have cloned and characterized the p47(phox) promoter, A predominant transcriptional start site was identified 21 nucleotides upstream of the translation initiation codon, To identify the gene promoter sequences, transient transfections of HL-60 human myeloid cells were performed with a series of 5'-deletion p47(phox)-luciferase reporter constructs that extended as far upstream as -3050 bp relative to the transcriptional start site, The -224 and -86 constructs had the strongest p47(phax) promoter activity, whereas the -46 construct showed a major reduction in activity and the -36 construct a complete loss of activity. DNase I footprint analysis identified a protected region from -57 to -53. This region containing a consensus PU.1 site bound specifically both PU,I present in nuclear extracts from myeloid cells and PU.1 synthesized in vitro. Mutations of this site eliminated PU.1 binding and abolished the ability of the p47(phox) promoter to direct expression of the reporter gene, The p47(phox) promoter was active in all myeloid cell Lines tested (HL-60, THP-1, U937, PLB-985), but not in non-myeloid cells (HeLa, HEK293). Finally, PU.1 transactivated the p47(phox)-luciferase constructs in HeLa cells, We conclude that, similar to certain other myeloid specific genes, p47(phox) promoter activity in myeloid cells requires PU.1.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; S TEXAS VET HLTH CARE SYST,AUDIE L MURPHY DIV,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital			Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020866, R01AI020866] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52665] Funding Source: Medline; NIAID NIH HHS [R37 AI020866, R01 AI020866, AI20866] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHNE B, 1994, J BIOL CHEM, V269, P17794; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; AUSTIN GE, 1995, LEUKEMIA, V9, P848; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRUGGEMAN LA, 1992, ONCOGENE, V7, P1497; CASIMIR CM, 1991, P NATL ACAD SCI USA, V88, P2753, DOI 10.1073/pnas.88.7.2753; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1983, ADV INFLAMMAT RES, V5, P107; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2, DOI 10.1006/clin.1993.1078; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; Friedman AD, 1996, CURR TOP MICROBIOL, V211, P149; Gorlach A., 1995, Blood, V86, p260A; GREEN SP, 1994, J LEUKOCYTE BIOL, V55, P530, DOI 10.1002/jlb.55.4.530; GUPTA JW, 1992, CANCER RES, V52, P2530; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMALAINEN ER, 1993, GENOMICS, V17, P544, DOI 10.1006/geno.1993.1369; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kuga S, 1996, EXP HEMATOL, V24, P151; LEONE TC, 1995, J BIOL CHEM, V270, P16308, DOI 10.1074/jbc.270.27.16308; LEVY R, 1991, J IMMUNOL, V147, P3066; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; Mink S, 1996, MOL CELL BIOL, V16, P1316; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; OBERMEIER H, 1995, BBA-MOL CELL RES, V1269, P25, DOI 10.1016/0167-4889(95)00095-A; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; ORKIN SH, 1992, BLOOD, V80, P575; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; REDEKE HH, 1991, J BIOL CHEM, V266, P21025; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; Roos D, 1996, BLOOD, V87, P1663; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1992, BLOOD, V79, P2598; ROUET P, 1992, BIOTECHNIQUES, V13, P700; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Segal AW, 1996, MOL MED TODAY, V2, P129, DOI 10.1016/1357-4310(96)88723-5; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; STEINBECK MJ, 1994, J CELL BIOL, V126, P767; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WANG YB, 1994, J BIOL CHEM, V269, P9137; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhao WG, 1996, LEUKEMIA, V10, P1089; ZULUETA JJ, 1995, AM J RESP CELL MOL, V12, P41, DOI 10.1165/ajrcmb.12.1.7529030	70	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17802	17809		10.1074/jbc.272.28.17802	http://dx.doi.org/10.1074/jbc.272.28.17802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211934	hybrid			2022-12-25	WOS:A1997XK16500077
J	Lisitsky, I; Kotler, A; Schuster, G				Lisitsky, I; Kotler, A; Schuster, G			The mechanism of preferential degradation of polyadenylated RNA in the chloroplast - The exoribonuclease 100RNP/polynucleotide phosphorylase displays high binding affinity for poly(A) sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' INVERTED REPEATS; MESSENGER-RNA; ESCHERICHIA-COLI; GENE-EXPRESSION; SPINACH CHLOROPLAST; NUCLEOTIDE-SEQUENCE; PROTEIN; RIBONUCLEOPROTEIN; POLYADENYLYLATION; IDENTIFICATION	Polyadenylation of mRNA in the chloroplast has recently been shown to target the RNA molecule for rapid exonucleolytic degradation. A model has been suggested in which the degradation of chloroplast mRNA is initiated by endonucleolytic cleavage(s) followed by the addition of poly(A)-rich sequences and rapid exonucleolytic degradation. When in vitro transcribed RNAs were incubated with chloroplast protein extract, competition between polyadenylated and non-polyadenylated RNAs for degradation resulted in the rapid degradation of the polyadenylated molecules and stabilization of their nonpolyadenylated counterparts, To elucidate the molecular mechanism governing this effect, we determined whether the chloroplast exoribonuclease 100RNP/polynucleotide phosphorylase (PNPase) preferably degrades polyadenylated RNA, When separately incubated with each molecule, isolated 100RNP/PNPase degraded polyadenylated and non-polyadenylated RNAs at the same rate, However, when both molecules were mixed together, the polyadenylated RNA was degraded, whereas the non-polyadenylated RNA was stabilized, In RNA binding experiments, 100RNP/PNPase bound the poly(A) sequence with much higher affinity than other RNA molecules, thereby defining the poly(ii)-rich RNA as a preferential substrate for the enzyme, 100RNP/PNPase may therefore be involved in a mechanism in which post-transcriptional addition of poly(A)-rich sequence targets the chloroplast RNA for rapid exonucleolytic degradation.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology			Schuster, Gadi/AAE-2010-2019					Baker EJ, 1993, CONTROL MESSENGER RN, P367; Belasco J, 1993, CONTROL MESSENGER RN, P3; Brawerman G., 1993, CONTROL MESSENGER RN, P149; BURKARD G, 1974, P NATL ACAD SCI USA, V71, P389, DOI 10.1073/pnas.71.2.389; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1996, J BIOL CHEM, V271, P15776, DOI 10.1074/jbc.271.26.15776; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; Drager RG, 1996, RNA, V2, P652; GRUISSEM W, 1989, CELL, V56, P161, DOI 10.1016/0092-8674(89)90889-1; GRUISSEM W, 1986, METHOD ENZYMOL, V118, P253; GRUISSEM W, 1985, EMBO J, V4, P1637, DOI 10.1002/j.1460-2075.1985.tb03831.x; Gruissem W., 1993, CONTROL MRNA STABILI, P329; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HaugelNielsen J, 1996, EMBO J, V15, P3144, DOI 10.1002/j.1460-2075.1996.tb00677.x; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; JAJACKSON RJ, 1990, CELL, V62, P15; Klaff P, 1995, NUCLEIC ACIDS RES, V23, P4885, DOI 10.1093/nar/23.23.4885; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; Li QS, 1996, J BIOL CHEM, V271, P19831, DOI 10.1074/jbc.271.33.19831; LISITSKY I, 1995, NUCLEIC ACIDS RES, V23, P2506, DOI 10.1093/nar/23.13.2506; LISITSKY I, 1994, NUCLEIC ACIDS RES, V22, P4719, DOI 10.1093/nar/22.22.4719; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; LISITSKY I, 1995, ANAL BIOCHEM, V224, P603, DOI 10.1006/abio.1995.1094; LISITSKY I, 1995, PLANT PHYSIOL, V107, P933, DOI 10.1104/pp.107.3.933; LITTAUER UZ, 1982, ENZYMES, V15, P517; MANLEY JL, 1995, P NATL ACAD SCI USA, V92, P1800, DOI 10.1073/pnas.92.6.1800; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PY P, 1996, NATURE, V381, P169; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; SACHS A, 1993, J BIOL CHEM, V268, P22955; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; STERN DB, 1989, PLANT MOL BIOL, V13, P615, DOI 10.1007/BF00016017; STERN DB, 1989, J BIOL CHEM, V264, P18742; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P7699, DOI 10.1073/pnas.79.24.7699	39	60	62	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17648	17653		10.1074/jbc.272.28.17648	http://dx.doi.org/10.1074/jbc.272.28.17648			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211914	hybrid			2022-12-25	WOS:A1997XK16500057
J	Malgaretti, N; Pozzoli, O; Bosetti, A; Corradi, A; Ciarmatori, S; Panigada, M; Bianchi, ME; Martinez, S; Consalez, GG				Malgaretti, N; Pozzoli, O; Bosetti, A; Corradi, A; Ciarmatori, S; Panigada, M; Bianchi, ME; Martinez, S; Consalez, GG			Mmot1, a new helix-loop-helix transcription factor gene displaying a sharp expression boundary in the embryonic mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DIFFERENTIATION; SEQUENCE; NEURONS; MICE; PCR; FOREBRAIN; HOMEOBOX; DELETION; PROTEIN; CLONING	Several genetic factors have been proven to contribute to the specification of the metencephalic-mesencephalic territory, a process that sets the developmental foundation for prospective morphogenesis of the cerebellum and mesencephalon, However, evidence stemming from genetic and developmental studies performed in man and various model organisms suggests the contribution of many additional factors in determining the fine subdivision and differentiation of these central nervous system regions, In man, the cerebellar ataxias/aplasias represent a large and heterogeneous family of genetic disorders. Here, we describe the identification by differential screening and the characterization of Mmot1, a new gene encoding a DNA-binding protein strikingly similar to the helix-leap-helix factor Ebf/Olf1, Throughout midgestation embryogenesis, Mmot1 is expressed at high levels in the metencephalon, mesencephalon, and sensory neurons of the nasal cavity. In vitro DNA binding data suggest some functional equivalence of Mmot1 and Ebf/Olf1, possibly accounting for the reported lack of olfactory or neural defects in Ebf(-/-) knockout mutants, The isolation of Mmot1 and of an additional homolog in the mouse genome defines a novel, phylogenetically conserved mammalian family of transcription factor genes of potential relevance in studies of neural development and its aberrations.	DIBIT,HSR,I-20132 MILAN,ITALY; UNIV MILAN,SCH BIOL,DEPT GENET & MICROBIOL,I-20132 MILAN,ITALY; UNIV MURCIA,SCH MED,INST MORPHOL SCI,E-30071 MURCIA,SPAIN	University of Milan; University of Murcia			Corradi, Anna/AAC-5209-2022; Bianchi, Marco Emilio/K-3417-2018; Consalez, Giacomo/AAA-2146-2019	Bianchi, Marco Emilio/0000-0002-5329-6445; Consalez, Giacomo/0000-0003-4594-6273	Telethon [E.0501] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS MD, 1995, NATURE, V377, P3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Consalez GG, 1996, TRENDS GENET, V12, P455; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crozatier M, 1996, CURR BIOL, V6, P707, DOI 10.1016/S0960-9822(09)00452-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; HURST J, 1987, CYTOGENET CELL GENET, V45, P30, DOI 10.1159/000132421; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789; MCCLELLAND M, 1994, PCR METH APPL, V4, pS66; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILATOVICH A, 1994, MAMM GENOME, V5, P211, DOI 10.1007/BF00360547; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; Moore DD, 1995, GLOB MOB SURV; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SAMBROOK J, 1989, MOL LAB MANUAL; SOMERVILLE MJ, 1988, GENOME, V30, P499, DOI 10.1139/g88-083; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WELSH J, 1995, MUTAT RES-DNAGING G, V338, P215, DOI 10.1016/0921-8734(95)00026-3; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; WILKINSON DG, 1992, IN SITU HYDBRIDIZATI; WURST W, 1994, DEVELOPMENT, V120, P2065	42	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17632	17639		10.1074/jbc.272.28.17632	http://dx.doi.org/10.1074/jbc.272.28.17632			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211912	hybrid			2022-12-25	WOS:A1997XK16500055
J	Roman, BB; Wieringa, B; Koretsky, AP				Roman, BB; Wieringa, B; Koretsky, AP			Functional equivalence of creatine kinase isoforms in mouse skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; MICE DEFICIENT; RAT MUSCLE; LOCALIZATION; COMPARTMENTATION; ISOENZYMES; ENERGY; PHOSPHOCREATINE; PHOSPHOKINASE; METABOLISM	Creatine kinase (CK) is a highly conserved enzyme abundant in skeletal muscle that has a key role in high energy phosphate metabolism, The localization of the muscle isoenzyme of CK (MM-CK) to the M line and the sarcoplasmic reticulum of myofibrils has been suggested to be important for proper force development in skeletal muscle, The importance of this subcellular compartmentation has not been directly tested in vivo. To test the role of myofibrilar localization of CR, the consequences of a complete CR isoform switch from MM-CII to the brain (BE-CIT) isoform, which does not localize to the M Line, was studied in transgenic mouse skeletal muscle, in RIM-CK knockout mice there are large contractile defects, When MM-CK was replaced by BE-CK, the aberrant contractile phenotypes seen in MIM-CH knockout mice were returned to normal despite the lack of myofibrillar localization, These results indicate that CK compartmentation to the myofibril of skeletal muscle is not essential for contractile function and that there is functional equivalence of creatine kinase isoforms in supporting cellular energy metabolism.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,PITTSBURGH NMR CTR BIOMED RES,PITTSBURGH,PA 15213; UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,NL-6500 AB NIJMEGEN,NETHERLANDS	Carnegie Mellon University; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Radboud University Nijmegen			Koretsky, Alan P/C-7940-2015; Wieringa, Berend/A-5346-2011	Koretsky, Alan P/0000-0002-8085-4756; Wieringa, Berend/0000-0001-9192-8020	NHLBI NIH HHS [R01-HL40354, 5 K04 HL-02847, F32-HL08985] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002847, R01HL040354, F32HL008985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACERENZA L, 1993, J THEOR BIOL, V165, P63, DOI 10.1006/jtbi.1993.1177; BASKIN RJ, 1970, J BIOL CHEM, V245, P1345; BEEKMANS S, 1993, J MOL RECOGNIT, V6, P195; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V299, P116, DOI 10.1016/0003-9861(92)90252-R; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BIERMANS W, 1989, BIOCHIM BIOPHYS ACTA, V974, P74, DOI 10.1016/S0005-2728(89)80167-7; BROSNAN MJ, 1993, AM J PHYSIOL, V264, pC151, DOI 10.1152/ajpcell.1993.264.1.C151; CANDE WZ, 1983, NATURE, V304, P557, DOI 10.1038/304557a0; CUNEO P, 1992, BIOCHEM J, V281, P507, DOI 10.1042/bj2810507; DANG CV, 1982, FEBS LETT, V142, P1, DOI 10.1016/0014-5793(82)80206-8; DEHAAN A, 1995, EXP PHYSIOL, V80, P491, DOI 10.1113/expphysiol.1995.sp003863; FITCH CD, 1975, AM J PHYSIOL, V228, P1123, DOI 10.1152/ajplegacy.1975.228.4.1123; GELLERICH F, 1982, BIOCHEM BIOPH RES CO, V105, P1473, DOI 10.1016/0006-291X(82)90954-8; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1140, P327, DOI 10.1016/0005-2728(93)90073-O; KORGE P, 1993, EUR J BIOCHEM, V213, P973, DOI 10.1111/j.1432-1033.1993.tb17842.x; LEVITSKY DO, 1978, MEMBRANE BIOCHEM, V2, P81, DOI 10.3109/09687687809063859; LYNCH RM, 1987, AM J PHYSIOL, V252, pC328, DOI 10.1152/ajpcell.1987.252.3.C328; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MEYER RA, 1986, AM J PHYSIOL, V250, pC264, DOI 10.1152/ajpcell.1986.250.2.C264; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; Roman BB, 1996, AM J PHYSIOL-CELL PH, V270, pC1236, DOI 10.1152/ajpcell.1996.270.4.C1236; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SAVABI F, 1994, MOL CELL BIOCHEM, V133, P145, DOI 10.1007/BF01267953; SAVABI F, 1986, BIOCHEM MED METAB B, V35, P227, DOI 10.1016/0885-4505(86)90078-2; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SHAROV VG, 1977, BIOCHIM BIOPHYS ACTA, V468, P495, DOI 10.1016/0005-2736(77)90299-1; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P79, DOI 10.1016/0167-4889(84)90039-9; SILVER RB, 1983, J BIOL CHEM, V258, P3287; SRERE PA, 1995, ADV MOL CEL, V11, P125; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; STEEGHS K, 1995, BBA-BIOENERGETICS, V1230, P130, DOI 10.1016/0005-2728(95)00044-J; SUMEGI B, 1991, BIOCHEM SOC T, V4, P1002; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1994, P NATL ACAD SCI USA, V91, P9091, DOI 10.1073/pnas.91.19.9091; VANDORSTEN FA, 1996, THESIS U UTRECHT NET; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; Wallimann T, 1985, Cell Muscle Motil, V6, P239; Watchko JF, 1997, J APPL PHYSIOL, V82, P1416, DOI 10.1152/jappl.1997.82.5.1416; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; WILSON IA, 1995, BIOCHEM J, V308, P599, DOI 10.1042/bj3080599; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	47	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17790	17794		10.1074/jbc.272.28.17790	http://dx.doi.org/10.1074/jbc.272.28.17790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211932	hybrid, Green Submitted, Green Published			2022-12-25	WOS:A1997XK16500075
J	Wang, BL; Golemis, EA; Kruh, GD				Wang, BL; Golemis, EA; Kruh, GD			ArgBP2, a multiple Src homology 3 domain-containing, Arg/Abl-interacting protein, is phosphorylated in v-Abl-transformed cells and localized in stress fibers and cardiocyte Z-disks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; TYROSINE KINASE; C-ABL; SIGNAL-TRANSDUCTION; GENE-PRODUCT; MYOSIN-I; CYCLE; CRK; MUSCLE; ACTIVATION	Arg and c-Abl represent the mammalian members of the Abelson family of protein-tyrosine kinases. A novel Arg/Abl-binding protein, ArgBP2, is as isolated using a segment of the Arg COOH-terminal domain as bait in the yeast two-hybrid system. ArgBP2 contains three COOH-terminal Src homology 3 domains, a serine/threonine-rich domain, and several potential Abl phosphorylation sites. ArgBP2 associates with and is a substrate of Arg and v-Abl, and is phosphorylated on tyrosine in v-Abl-transformed cells, ArgBP2 is widely expressed in human tissues and extremely abundant in heart. In epithelial cells ArgBP2 is located in stress fibers and the nucleus, similar to the reported localization of c-Abl. In cardiac muscle cells ArgBP2 is located in the Z-disks of sarcomeres, These observations suggest that ArgBP2 functions as an adapter protein to assemble signaling complexes in stress fibers, and that ArgBP2 is a potential link between Abl family kinases and the actin cytoskeleton. In addition, the localization of ArgBP2 to Z-disks suggests that ArgBP2 may influence the contractile or elastic properties of cardiac sarcomeres and that the Z-disk is a target of signal transduction cascades.	FOX CHASE CANC CTR, DIV BASIC SCI, PHILADELPHIA, PA 19111 USA; FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; University of Pennsylvania				Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [CA63366, CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA057273, R01CA057273, R01CA063366, R29CA063366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOLL DE, 1991, J BIOL CHEM, V266, P8501; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hobert O, 1996, ONCOGENE, V12, P1577; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; KELLER CS, 1995, CURR OPIN CELL BIOL, V7, P32, DOI 10.1016/0955-0674(95)80042-5; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOTELIANSKY VE, 1986, EUR J BIOCHEM, V156, P619, DOI 10.1111/j.1432-1033.1986.tb09622.x; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; LAEMMLI UK, 1968, MOL GEN GENET, V101, P333, DOI 10.1007/BF00436231; Law SF, 1996, MOL CELL BIOL, V16, P3327; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MITTAL B, 1987, CELL MOTIL CYTOSKEL, V8, P345, DOI 10.1002/cm.970080407; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; MORRIS JF, 1991, ONCOGENE, V6, P2339; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PEREGO R, 1991, ONCOGENE, V6, P1899; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, ONCOGENE, V11, P1149; SANGER JM, 1986, J CELL SCI, P17; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; VAGNEDESCROIX M, 1991, EUR J BIOCHEM, V201, P53, DOI 10.1111/j.1432-1033.1991.tb16254.x; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1996, ONCOGENE, V12, P1921; Wang BL, 1996, ONCOGENE, V13, P1379; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	55	105	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17542	17550		10.1074/jbc.272.28.17542	http://dx.doi.org/10.1074/jbc.272.28.17542			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211900	hybrid			2022-12-25	WOS:A1997XK16500043
J	Gunther, MR; Hsi, LC; Curtis, JF; Gierse, JK; Marnett, LJ; Eling, TE; Mason, RP				Gunther, MR; Hsi, LC; Curtis, JF; Gierse, JK; Marnett, LJ; Eling, TE; Mason, RP			Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; ACUTE LUNG INJURY; RIBONUCLEOTIDE REDUCTASE; ENDOPEROXIDE SYNTHASE-2; PEROXYNITRITE; KINETICS; ENZYME; QUANTITATION; EXPRESSION; INHIBITION	The determination of protein nitrotyrosine content has become a frequently used technique for the detection of oxidative tissue damage, Protein nitration has been suggested to be a final product of the production of highly reactive nitrogen oxide intermediates (e.g. peroxynitrite) formed in reactions between nitric oxide (NO.) and oxygen-derived species such as superoxide. The enzyme prostaglandin H synthase-2 (PHS-2) forms one or more tyrosyl radicals duping its enzymatic catalysis of prostaglandin formation, In the presence of She NO.-generator diethylamine nonoate, the electron spin resonance spectrum of the PHS-a-derived tyrosyl radical is replaced by the spectrum of another free radical containing a nitrogen atom. The magnitude of the nitrogen hyperfine coupling constant in the latter species unambiguously identifies it as an iminoxyl radical, which is likely formed by the oxidation of nitrosotyrosine, a stable product of the addition of NO. to tyrosyl radical. Addition of superoxide dismutase did not alter the spectra, indicating that peroxynitrite was not involved. Western blot analysis of PHS-2 after exposure to the NO.-generator revealed nitrotyrosine formation. The results provide a mechanism for nitric oxide-dependent tyrosine nitration that does not require formation of more highly reactive nitrogen oxide intermediates such as peroxynitrite or nitrogen dioxide.	NIEHS,NIH,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; GD SEARLE & CO,ST LOUIS,MO 63167; VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University	Gunther, MR (corresponding author), NIEHS,LAB PHARMACOL & CHEM,NIH,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				ABE K, 1995, NEUROSCI LETT, V199, P152, DOI 10.1016/0304-3940(95)12039-7; Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BEAKE BD, 1994, J CHEM SOC PERK T 2, P957, DOI 10.1039/p29940000957; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROKENSHIRE JL, 1972, J AM CHEM SOC, V94, P7040, DOI 10.1021/ja00775a030; Buttery LDK, 1996, LAB INVEST, V75, P77; CASTRO A, 1987, B SOC CHIM FR, P83; EISERICH JP, 1994, FEBS LETT, V353, P53, DOI 10.1016/0014-5793(94)01011-0; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; FISCHER V, 1986, CHEM-BIOL INTERACT, V57, P129, DOI 10.1016/0009-2797(86)90033-5; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Good PF, 1996, AM J PATHOL, V149, P21; GREEN RG, 1975, J CHEM SOC PERK T 2, P1380, DOI 10.1039/p29750001380; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; LOW W, 1957, PHYS REV, V105, P801, DOI 10.1103/PhysRev.105.801; Mannick EE, 1996, CANCER RES, V56, P3238; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MILLER MJS, 1995, GASTROENTEROLOGY, V109, P1475, DOI 10.1016/0016-5085(95)90633-9; OURY TD, 1995, FREE RADICAL RES, V23, P537, DOI 10.3109/10715769509065275; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; Sanakis Y, 1997, BIOCHEMISTRY-US, V36, P1411, DOI 10.1021/bi9622074; Schulz JB, 1995, J NEUROSCI, V15, P8419; STREIDER S, 1992, J BIOL CHEM, V267, P13870; THOMAS JR, 1964, J AM CHEM SOC, V86, P1446, DOI 10.1021/ja01061a043; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Viner RI, 1996, FEBS LETT, V379, P286, DOI 10.1016/0014-5793(95)01530-2	46	153	155	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17086	17090		10.1074/jbc.272.27.17086	http://dx.doi.org/10.1074/jbc.272.27.17086			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202025	hybrid			2022-12-25	WOS:A1997XH44600057
J	Guo, XQ; Becker, PL				Guo, XQ; Becker, PL			Cyclic ADP-ribose-gated Ca2+ release in sea urchin eggs requires an elevated [Ca2+]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; RYANODINE RECEPTOR; INOSITOL TRISPHOSPHATE; IONIC-STRENGTH; FERTILIZATION; EGTA; TEMPERATURE; PHOTOLYSIS; AFFINITY; TISSUES	Cyclic ADP-ribose (cADPr) has been shown to release intracellular Ca2+ from sea urchin eggs and a variety of vertebrate cell types, although its mechanism of action remains elusive, We employed the caged version of cADPr to study the [Ca2+] transient kinetics in intact sea urchin eggs for insights into how cADPr gates Ca2+ release. Ca2+ release triggered by photolytic production of cADPr was initially slow, with an effective delay of several hundred milliseconds before the onset of a rapid. Ca2+ release phase, in contrast, Ca2+ release induced by photolysis of caged inositol 1,4,5-trisphosphate was immediate in onset and roughly an order of magnitude faster. The delay before cADPr-induced Ca2+ release was eliminated when the [Ca2+] was step-elevated coincident with the photoliberation of cADPr and greatly prolonged in the presence of exogenous Ca2+ buffers. Thus, the slow onset of Ca2+ release does not reflect an intrinsically slow rate by which cADPr gates release channels, Rather, a [Ca2+] rise from resting levels is needed to achieve more than minimal cADPr activity, Fun release of Ca2+ by cADPr in intact sea urchin eggs requires a positive Ca2+ feedback.	EMORY UNIV,SCH MED,DEPT PHYSIOL,ATLANTA,GA 30322	Emory University								AARHUS R, 1995, J BIOL CHEM, V270, P7745, DOI 10.1074/jbc.270.13.7745; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUCK WR, 1994, DEV BIOL, V163, P1, DOI 10.1006/dbio.1994.1118; Chini EN, 1996, BIOCHEM J, V316, P709, DOI 10.1042/bj3160709; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; FRUEN BR, 1994, FEBS LETT, V352, P123, DOI 10.1016/0014-5793(94)00931-7; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1997, J BIOL CHEM, V272, P7669, DOI 10.1074/jbc.272.12.7669; Guo XQ, 1996, CIRC RES, V79, P147, DOI 10.1161/01.RES.79.1.147; HARRISON SM, 1989, AM J PHYSIOL, V256, pC1250, DOI 10.1152/ajpcell.1989.256.6.C1250; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; Lee HC, 1996, RECENT PROG HORM RES, V51, P355; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1995, J BIOL CHEM, V270, P90060; MCCRAY JA, 1992, BIOCHEMISTRY-US, V31, P8856, DOI 10.1021/bi00152a023; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MOHRI T, 1991, CELL STRUCT FUNCT, V16, P157, DOI 10.1247/csf.16.157; MORRISSETTE J, 1993, FEBS LETT, V330, P270, DOI 10.1016/0014-5793(93)80886-Y; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SHEN SS, 1979, NATURE, V282, P87, DOI 10.1038/282087a0; SITSAPESAN R, 1995, AM J PHYSIOL-CELL PH, V268, pC1235, DOI 10.1152/ajpcell.1995.268.5.C1235; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; TANAKA Y, 1995, P NATL ACAD SCI USA, V92, P3244, DOI 10.1073/pnas.92.8.3244; UKHANOV KY, 1995, J GEN PHYSIOL, V105, P95, DOI 10.1085/jgp.105.1.95; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Willmott N, 1996, J BIOL CHEM, V271, P3699	35	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16984	16989		10.1074/jbc.272.27.16984	http://dx.doi.org/10.1074/jbc.272.27.16984			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202011	hybrid			2022-12-25	WOS:A1997XH44600043
J	Ho, GY; Broze, GJ; Schwartz, AL				Ho, GY; Broze, GJ; Schwartz, AL			Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; CELL-SURFACE; PLASMINOGEN-ACTIVATOR; CARBOXY-TERMINUS; HEPATOMA-CELLS; IN-VIVO; LIPOPROTEIN; METABOLISM; BINDING; INTERNALIZATION	Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of blood coagulation factor Xa. (fXa) and factor VIIa. We have recently shown that fXa binding stimulates the uptake and degradation of cell surface-bound I-125-TFPI (He, G., Toomey, J. pg., Broze, G. J., Jr., and Schmartz, A. L. (1996) J. Biol. Chem. 271, 9497-9502). in the present study ave examined the role of cell surface glycosaminoglycans (GAGs) in this process, Removal of cell surface GAG chains by treatment of Cells with heparinase or heparitinase but not chondroitinase markedly reduced fXa-stimulated I-125-TFPI uptake and degradation, Inhibition of GAG sulfation by growth of cells in chlorate-containing medium similarly decreased fXa-stimulated I-125-TFPI degradation. These results suggest that heparan sulfate proteoglycans (HSPGs) are required fur the uptake and degradation of I-125-TFPI.fXa complexes. Chemical cross-linking/immunoprecipitation analyses revealed that I-125-TFPI was directly associated with HSPGs on the cell surface and that fXa binding increased the amount of I-125-TFPI bound, Of the several cell lines evaluated, bend endothelial cells demonstrated the greatest fXa stimulation of I-125-TFPI uptake and degradation, Cross-linking/immunoprecipitation analyses on bend cells also revealed that HSPGs were specifically associated with TFPI and fXa. These data suggest that HSPGs may directly act as the uptake and degradation receptor for TFPI.fXa complexes.	WASHINGTON UNIV,SCH MED,DEPT BIOL MOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,DIV HEMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital	Ho, GY (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,BOX 8116,ST LOUIS,MO 63110, USA.							BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROZE GJ, 1994, BLOOD COAGUL FIBRIN, V5, P551; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BU G, 1994, CELL BIOL LAB HDB, P199; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1993, J BIOL CHEM, V268, P13002; COLBURN P, 1982, BIOCHEM BIOPH RES CO, V104, P220, DOI 10.1016/0006-291X(82)91962-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Ho GY, 1996, J BIOL CHEM, V271, P9497, DOI 10.1074/jbc.271.16.9497; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JI ZS, 1994, J BIOL CHEM, V269, P2764; KAZAMA Y, 1993, BLOOD, V81, P676; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NOVOTNY WF, 1991, BLOOD, V78, P394; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OTOTANI N, 1981, CARBOHYD RES, V88, P291, DOI 10.1016/S0008-6215(00)85542-1; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; SANSET PM, 1988, THROMB RES, V50, P803; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILLNOW TE, 1994, J CELL SCI, V107, P719; WUN TC, 1988, J BIOL CHEM, V263, P6001; WUN TC, 1992, BLOOD, V79, P430; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270	39	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16838	16844		10.1074/jbc.272.27.16838	http://dx.doi.org/10.1074/jbc.272.27.16838			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201990	hybrid			2022-12-25	WOS:A1997XH44600022
J	Kasahara, M; Shimoda, E; Maeda, M				Kasahara, M; Shimoda, E; Maeda, M			Amino acid residues responsible for galactose recognition in yeast Gal2 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT1 GLUCOSE-TRANSPORTER; SUBSTRATE RECOGNITION; CYTOCHALASIN-B; LOCALIZATION; EXPRESSION; PROTEINS; CLONING	A novel, systematic approach was used to identify amino acid residues responsible for substrate recognition in the transmembrane 10 region of the Gal2 galactose transporter of Saccharomyces cerevisiae, A mixture of approximately 25,000 distinct plasmids that encode all the combinations of 12 amino acids in transmembrane 10 that are different in Gal2 and the homologous glucose transporter Hxt2 was synthesized. Selection of galactose transport-positive clones on galactose limited agar plates yielded 19 clones, all of which contained the Tyr(446) residue found in Gal2. 14 of the 19 clones contained Trp(455) found in Gal2, whereas the other 5 contained Cys(455), a residue not found in either Gal2 or Hxt2. When Tyr(446) Of Gal2 was replaced with any of the other 19 amino acids, no galactose transport activity was observed in the resulting transporters, indicating that Tyr(446) plays an essential role in the transport of this sugar. Replacement of 2 amino acids of Hxt2 with the corresponding Tyr(446) and Trp(455) Of Gal2 allowed the modified Hxt2 to transport galactose, The K-m of galactose transport for the modified transporter was 8- fold higher than that of Gal2. These results and other evidence unequivocally show that Tyr(446) is essential and Trp(455) is important for the discrimination of galactose versus glucose.			Kasahara, M (corresponding author), TEIKYO UNIV,SCH MED,BIOPHYS LAB,HACHIOJI,TOKYO 19203,JAPAN.							Arbuckle MI, 1996, BIOCHEMISTRY-US, V35, P16519, DOI 10.1021/bi962210n; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; CAIRNS MT, 1991, J BIOL CHEM, V266, P8176; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GIROS B, 1994, J BIOL CHEM, V269, P15985; HILL DE, 1989, CURRENT PROTOCOLS MO, V1; INUKAI K, 1994, BIOCHEM J, V302, P355, DOI 10.1042/bj3020355; KABACK HR, 1992, INT REV CYTOL, V137A, P97; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; LUCKIE DB, 1991, FEBS LETT, V281, P231, DOI 10.1016/0014-5793(91)80400-W; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P12; MATEUCCI MD, 1983, NUCLEIC ACIDS RES, V11, P3113; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SHERMAN F, 1986, METHODS YEAST GENETI, P164; SHURMANN A, 1993, BIOCHEM J, V290, P497; SKELLY PJ, 1994, J BIOL CHEM, V269, P4247; STADLER R, 1995, PLANT PHYSIOL, V107, P33, DOI 10.1104/pp.107.1.33; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; Will A, 1996, FEBS LETT, V381, P127, DOI 10.1016/0014-5793(96)00097-X	24	30	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16721	16724		10.1074/jbc.272.27.16721	http://dx.doi.org/10.1074/jbc.272.27.16721			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201972	hybrid			2022-12-25	WOS:A1997XH44600004
J	Romey, G; Attali, B; Chouabe, C; Abitbol, I; Guillemare, E; Barhanin, J; Lazdunski, M				Romey, G; Attali, B; Chouabe, C; Abitbol, I; Guillemare, E; Barhanin, J; Lazdunski, M			Molecular mechanism and functional significance of the MinK control of the KvLQT1 channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+-CURRENT; XENOPUS-OOCYTES; POTASSIUM CURRENT; ACTION-POTENTIALS; MEMBRANE PATCHES; MESSENGER-RNA; EXPRESSION; CLONING; PROTEIN; BLOCK	The very slowly activating delayed rectifier K+ channel I-Ks is essential for controlling the repolarization phase of cardiac action potentials and K+ homeostasis in the inner ear. The I-Ks channel is formed via the assembly of two transmembrane proteins, KvLQT1 and MinK. Mutations in KvLQT1 are associated with a long QT syndrome that causes syncope and sudden death and also with deafness. Here, we show a new mode of association between ion channel forming subunits in that the cytoplasmic C-terminal end of MinK interacts directly with the pore region of KvLQT1. This interaction reduces KvLQT1 channel conductance from 7.6 to 0.58 picosiemens. However, because MinK also reveals a large number of previously silent KvLQT1 channels (x 60), the overall effect is a large increase (x 4) in the macroscopic K+ current. Conformational changes associated with the KvLQT1/MinK association create very slow and complex activation kinetics without much alteration in the deactivation process. Changes induced by MinK have an essential regulatory role in the development of this K+ channel activity upon repetitive electrical stimulation with a particular interest in tachycardia.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Weizmann Institute of Science								ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; CUI J, 1994, J GEN PHYSIOL, V104, P87, DOI 10.1085/jgp.104.1.87; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUSWIRTH O, 1972, J PHYSIOL-LONDON, V222, P27, DOI 10.1113/jphysiol.1972.sp009786; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; MARCUS DC, 1994, AM J PHYSIOL, V267, pC857, DOI 10.1152/ajpcell.1994.267.3.C857; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TOHSE N, 1990, AM J PHYSIOL, V258, pH1200, DOI 10.1152/ajpheart.1990.258.4.H1200; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WALSH KB, 1991, AM J PHYSIOL, V260, pH1390, DOI 10.1152/ajpheart.1991.260.4.H1390; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; YEH JZ, 1978, NATURE, V273, P387, DOI 10.1038/273387a0; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	28	115	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16713	16716		10.1074/jbc.272.27.16713	http://dx.doi.org/10.1074/jbc.272.27.16713			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201970	hybrid			2022-12-25	WOS:A1997XH44600002
J	Wan, Y; Bence, K; Hata, A; Kurosaki, T; Veillette, A; Huang, XY				Wan, Y; Bence, K; Hata, A; Kurosaki, T; Veillette, A; Huang, XY			Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RAS-DEPENDENT ACTIVATION; FOCAL ADHESION KINASE; B-CELL DEVELOPMENT; MAP KINASE; GROWTH-FACTOR; PERTUSSIS TOXIN; ANGIOTENSIN-II; LYSOPHOSPHATIDIC ACID; COUPLED RECEPTORS	The signal transduction pathway from heterotrimeric G proteins to the mitogen-activated protein kinase (MAPK) cascade is best understood in the yeast mating pheromone response, in which a serine/threonine protein kinase (STE20) serves as the critical linking component, Little is known in metazoans on how G proteins and the MAPK cascade are coupled, Here we provide genetic and biochemical evidence that a tyrosine kinase cascade bridges G proteins and the MAPK pathway in vertebrate cells, Targeted deletion of tyrosine kinase Csk in avian B lymphoma cells blocks the stimulation of MAPK by G(q), but not G(i)-, coupled receptors, In cells deficient in Bruton's tyrosine kinase (Btk), G(i)-coupled receptors failed to activate MAPK, while G(q)-coupled receptor-mediated stimulation is unaffected. Taken together with our previous data on tyrosine kinases Lyn and Syk, the G(q)-coupled pathway requires tyrosine kinases Csk, Lyn, and Syk, while the G(i)-coupled pathway requires tyrosine kinases Btk and Syk to feed into the MAPK cascade in these cells, The central role of Syk is further strengthened by data showing that Syk can bind to purified Lyn, Csk, or Btk.	CORNELL UNIV,COLL MED,DEPT PHYSIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021; KANSAI MED UNIV,DEPT MOL GENET,MORIGUCHI,OSAKA 570,JAPAN; MCGILL UNIV,CTR CANC,MONTREAL,PQ H3G 1Y6,CANADA	Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Kansai Medical University; McGill University			Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Bence, Kendra/0000-0002-5879-4726				AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; ASAHI M, 1992, FEBS LETT, V309, P10, DOI 10.1016/0014-5793(92)80728-Y; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; Satterthwaite A, 1996, ANNU REV IMMUNOL, V14, P131, DOI 10.1146/annurev.immunol.14.1.131; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	77	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17209	17215		10.1074/jbc.272.27.17209	http://dx.doi.org/10.1074/jbc.272.27.17209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202044	hybrid			2022-12-25	WOS:A1997XH44600076
J	Herr, AB; Ornitz, DM; Sasisekharan, R; Venkataraman, G; Waksman, G				Herr, AB; Ornitz, DM; Sasisekharan, R; Venkataraman, G; Waksman, G			Heparin-induced self-association of fibroblast growth factor-alpha - Evidence for two oligomerization processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; CRYSTAL-STRUCTURE; BINDING DOMAIN; CELL-SURFACE; ACTIVATION; SULFATE; DIMERIZATION; MOLECULES; MECHANISM; PRODUCE	Fibroblast growth factor-2 (FGF-2), a potent angiogenic factor, requires heparin for dimerization and activation of the FGF receptor tyrosine kinase. The binding of multiple fibroblast growth factors by heparin may be necessary for dimerization of the FGF receptor, Analytical ultracentrifugation of FGF-2 in the presence of heparin-derived saccharides shows that both an active heparin octasaccharide and an inactive heparin-like disaccharide induce fibroblast growth factor-2 self-association, Analysis of the data indicates that the heparin octasaccharide induces a monomer-dimer-tetramer assembly of FGF-2 while the disaccharide induces a monomer-dimer equilibrium. Evidence is presented indicating that the dimer conformation induced by the heparin octasaccharide is a side by side dimer with the FGF-2 molecules cis to the heparin, while the disaccharide-induced dimer is a head to head dimer in which FGF-2 molecules are trans to the ligand. These results, combined with previous studies, support the model that formation of a specific side by side heparin-induced FGF-2 dimer is required for activation of the FGF receptor.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOL BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Massachusetts Institute of Technology (MIT)			Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK051207, R44DK051207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008492] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline; NIDDK NIH HHS [DK51207] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM08492-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA T, 1993, J PROTEIN CHEM, V12, P689, DOI 10.1007/BF01024927; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Burz DS, 1996, BIOCHEMISTRY-US, V35, P3341, DOI 10.1021/bi952055x; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Schlessinger J., 1979, PHYSICAL CHEM ASPECT, P89; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	41	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16382	16389		10.1074/jbc.272.26.16382	http://dx.doi.org/10.1074/jbc.272.26.16382			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195945	hybrid			2022-12-25	WOS:A1997XG01900049
J	Ho, YS; Magnenat, JL; Bronson, RT; Cao, J; Gargano, M; Sugawara, M; Funk, CD				Ho, YS; Magnenat, JL; Bronson, RT; Cao, J; Gargano, M; Sugawara, M; Funk, CD			Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENIUM DEFICIENCY; NUCLEOTIDE-SEQUENCE; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; BOVINE LYMPHOCYTES; SELENOPROTEIN-P; MESSENGER-RNA; HUMAN-PLASMA; ACTIVE-SITE; GSHPX-GI	Glutathione peroxidase, a selenium-containing enzyme, is believed to protect cells from the toxicity of hydroperoxides. The physiological role of this enzyme has previously been implicated mainly using animals fed with a selenium-deficient diet. Although selenium deficiency also affects the activity of several other cellular selenium-containing enzymes, a dramatic decrease of glutathione peroxidase activity has been postulated to play a role in the pathogenesis of a number of diseases, particularly those whose progression is associated with an overproduction of reactive oxygen species, found in selenium-deficient animals. To further clarify the physiological relevance of this enzyme, a model of mice deficient in cellular glutathione peroxidase (GSHPx-1), the major isoform of glutathione peroxidase ubiquitously expressed In all types of cells, was generated by gene-targeting technology. Mice deficient in this enzyme were apparently healthy and fertile and showed no increased sensitivity to hyperoxia. Their tissues exhibited neither a retarded rate in consuming extracellular hydrogen peroxide nor an increased content of protein carbonyl groups and lipid peroxidation compared with those of wild-type mice. However, platelets from GSHPx-1-deficient mice incubated with arachidonic acid generated less 12-hydroxyeicosatetraenoic acid and more polar products relative to control platelets at a higher concentration of arachidonic acid, presumably reflecting a decreased ability to reduce the 12-hydroperoxyeicosatetraenoic acid intermediate. These results suggest that the contribution of GSHPx-1 to the cellular antioxidant mechanism under normal animal development and physiological conditions and to the pulmonary defense against hyperoxic insult is very limited. Nevertheless, the potential antioxidant role of this enzyme in protecting cells and animals against the pathogenic effect of reactive oxygen species in other disorders remains to be defined. The knockout mouse model described in this report will also provide a new tool for future study to distinguish the physiological role of this enzyme from other selenium-containing proteins in mammals under normal and disease states.	WAYNE STATE UNIV, DEPT BIOCHEM, DETROIT, MI 48201 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; UNIV PENN, CTR EXPT THERAPEUT, PHILADELPHIA, PA 19104 USA	Wayne State University; Tufts University; University of Pennsylvania	Ho, YS (corresponding author), WAYNE STATE UNIV, INST CHEM TOXICOL, 2727 2ND AVE, RM 4000, DETROIT, MI 48201 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056421, R01HL053558] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; Arthur John R., 1993, American Journal of Clinical Nutrition, V57, p236S, DOI 10.1093/ajcn/57.2.236S; BEDWAL RS, 1994, EXPERIENTIA, V50, P626, DOI 10.1007/BF01952862; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Borg D. C., 1993, OXYGEN FREE RADICALS, P12; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRYANT RW, 1980, BIOCHEM BIOPH RES CO, V92, P268, DOI 10.1016/0006-291X(80)91548-X; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; CAO YZ, 1992, J NUTR, V122, P2121, DOI 10.1093/jn/122.11.2121; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chiu D, 1982, FREE RADICAL BIO MED, V5, P115; CHU FF, 1993, J BIOL CHEM, V268, P2571; CHU FF, 1995, ARCH BIOCHEM BIOPHYS, V323, P288, DOI 10.1006/abbi.1995.9962; COHEN G, 1963, BIOCHEMISTRY-US, V2, P1420, DOI 10.1021/bi00906a038; Crapo J D, 1978, Methods Enzymol, V53, P382; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; David M., 1965, METHOD ENZYMAT AN, P875; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; ESKEW ML, 1993, PROSTAG OTH LIPID M, V46, P319, DOI 10.1016/0090-6980(93)90097-Q; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; Forman H.J., 1982, OXYGEN LIVING PROCES, P235; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRAMPTON J, 1987, NUCLEIC ACIDS RES, V15, P3671, DOI 10.1093/nar/15.9.3671; FREEMAN BA, 1984, ENVIRON HEALTH PERSP, V56, P51; FREEMAN BA, 1982, LAB INVEST, V47, P412; GAETANI G F, 1989, Blood, V73, P334; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; HAWKER FH, 1993, EUR RESPIR J, V6, P1317; HILL KE, 1991, J BIOL CHEM, V266, P10050; HO YS, 1988, NUCLEIC ACIDS RES, V16, P5207, DOI 10.1093/nar/16.11.5207; HONG Y, 1989, J BIOL CHEM, V264, P13793; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; JONES DP, 1981, ARCH BIOCHEM BIOPHYS, V210, P505, DOI 10.1016/0003-9861(81)90215-0; KIM CH, 1988, NUTR RES, V8, P767, DOI 10.1016/S0271-5317(88)80157-X; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LOHR GW, 1974, METHOD ENZYMAT AN, P636; MADDIPATI KR, 1987, ARCH BIOCHEM BIOPHYS, V254, P9, DOI 10.1016/0003-9861(87)90075-0; MADDOX JF, 1991, BIOCHEM BIOPH RES CO, V181, P389, DOI 10.1016/S0006-291X(05)81431-7; MAKINO N, 1994, J BIOL CHEM, V269, P1020; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MIROCHNITCHENKO O, 1995, P NATL ACAD SCI USA, V92, P8120, DOI 10.1073/pnas.92.18.8120; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEVE J, 1985, CLIN ENDOCRINOL META, V14, P629, DOI 10.1016/S0300-595X(85)80010-4; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V279, P306, DOI 10.1016/0304-4165(72)90147-X; OCHI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P407, DOI 10.1016/0003-9861(92)90704-Z; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; REDDY AP, 1988, NUCLEIC ACIDS RES, V16, P5557, DOI 10.1093/nar/16.12.5557; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TAPPEL AL, 1984, CURR TOP CELL REGUL, V24, P87; THOMAS JP, 1990, J BIOL CHEM, V265, P454; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMCENKOYOUSSEF L, 1985, J BIOL CHEM, V260, P3355; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; WENDEL A, 1980, ENZYMATIC BASIS DETO, P333, DOI DOI 10.1016/B978-0-12-380001-5.50022-0; Yoshida T, 1996, J MOL CELL CARDIOL, V28, P1759, DOI 10.1006/jmcc.1996.0165; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2; ZAROWSKI J, 1978, BIOCHIM BIOPHYS ACTA, V526, P65	70	465	479	1	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16644	16651		10.1074/jbc.272.26.16644	http://dx.doi.org/10.1074/jbc.272.26.16644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195979	hybrid			2022-12-25	WOS:A1997XG01900083
J	Ogilvie, I; Aggeler, R; Capaldi, RA				Ogilvie, I; Aggeler, R; Capaldi, RA			Cross-linking of the delta subunit to one of the three alpha subunits has no effect on functioning, as expected if delta is a part of the stator that links the F-1 and F-0 parts of the Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; EPSILON-SUBUNIT; CRYOELECTRON MICROSCOPY; PROTON-ATPASE; H+-ATPASE; F1-ATPASE; BINDING; NUCLEOTIDE; MEMBRANE; COMPLEX	A mutant of the Escherichia coli F1F0-ATPase has been generated (alpha Q2C) in which the glutamine at position 2 of the alpha subunit has been replaced with a cysteine residue. Cu2+ treatment of ECF1 from this mutant crosslinked an alpha subunit to the delta subunit in high yield. Two different sites of disulfide bond formation were involved, i.e. between Cys(90) (or the closely spaced Cys(47)) of alpha with Cys(140) of delta, and between Cys(2) of alpha and Cys140 of delta. Small amounts of other cross-linked products, including alpha-alpha, delta internal, and alpha-alpha-delta were obtained. In ECF1F0, there was no cross-linking between the intrinsic Cys of alpha and Cys140. Instead, the product generated between Cys(2) of alpha and Cys140 of delta was obtained at near 90% yield. Small amounts of alpha-alpha and delta internal were present, and under high Cu2+ concentrations, alpha-alpha-delta was also formed. The ATPase activity of ECF1 and ECF1F0 was not significantly affected by the presence of these cross-links, When Cys(140) of delta was first modified with N-ethylmaleimide in ECF1F0, an alpha-delta cross-link was still produced, although in lower yield, between Cys(64) of delta and Cys(2) of alpha. ATP hydrolysis-linked proton pumping of inner membranes from the mutant alpha B2C was only marginally affected by cross-linking of the alpha to the delta subunit. These results indicate that Cys(140) and Cys(64) of the delta subunit and Cys(2) of the alpha subunit are in close proximity. This places the delta subunit near the top of the alpha-beta hexagon and not in the stalk region. As fixing the delta to the alpha by cross-linking does not greatly impair either the ATPase function of the enzyme, or coupled proton translocation, we argue that the delta subunit forms a portion of the stator linking F-1 to F-0.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DAVIES LG, 1986, BASIC METHODS MOL BI; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1980, J BIOL CHEM, V255, P6891; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GOGOL EP, 1987, FEBS LETT, V219, P276; HUNDAL T, 1983, FEBS LETT, V162, P5, DOI 10.1016/0014-5793(83)81038-2; Joshi S, 1996, BIOCHEMISTRY-US, V35, P12094, DOI 10.1021/bi9612327; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; Maniatis T., 1982, MOL CLONING; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANN REV BIOPHYS, V19, P17; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P272, DOI 10.1006/abbi.1993.1210; STANLOTTER H, 1986, FEBS LETT, V197, P121, DOI 10.1016/0014-5793(86)80310-6; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; WILKENS S, 1997, IN PRESS BIOPHYS CHE; WISE JG, 1981, J BIOL CHEM, V256, P383; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	49	137	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16652	16656		10.1074/jbc.272.26.16652	http://dx.doi.org/10.1074/jbc.272.26.16652			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195980	hybrid			2022-12-25	WOS:A1997XG01900084
J	Zhang, L; Dresser, MJ; Chun, JK; Babbitt, PC; Giacomini, KM				Zhang, L; Dresser, MJ; Chun, JK; Babbitt, PC; Giacomini, KM			Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; BASOLATERAL MEMBRANE; CIMETIDINE TRANSPORT; MOLECULAR-CLONING; MESSENGER-RNAS; VESICLES; KIDNEY; PROTEIN; MECHANISMS; EXPRESSION	Polyspecific organic cation transporters in the renal proximal tubule mediate the secretion of many clinically used drugs as well as endogenous metabolites. Recently, two organic cation transporters (rOCT1 and rOCT2) were cloned from rat kidney. In this study, we report the cloning and functional expression of an rOCT1 isoform, rOCT1A, from rat kidney. Genomic DNA cloning and sequencing demonstrated that rOCT1A is an alternatively spliced variant of rOCT1 with a deletion of 104 base pairs near the 5'-end. The uptake of [C-14]tetraethylammonium (TEA) in oocytes injected with the cRNA-encoding rOCT1A was increased 10-fold over that in water-injected oocytes (29 +/- 2.8 pmol/oocyte/h versus 1.8 +/- 0.13 pmol/oocyte/h, mean +/- S.E., p < 0.05). [C-14]TEA uptake in the cRNA-injected oocytes was saturable (K-m = 42 +/- 11 mu M) and was inhibited significantly by organic cations, including cimetidine and N-1-methylnicotinamide. The amino acid sequence was deduced from the cDNA after examination of all three reading frames. Two overlapping open reading frames were found. Studies with synthetic constructs suggest that a functional organic cation transporter is encoded by the larger open reading frame. The larger open reading frame encodes a 430-amino acid protein (termed rOCT1A) that is 92% identical to rOCT1 and 57% identical to rOCT2. From hydropathy analysis, rOCT1A is predicted to have 10 transmembrane domains with both amino and carboxyl termini intracellular. RNase protection assays demonstrate the presence of rOCT1A mRNA transcripts in rat kidney cortex, medulla, and intestine. These studies demonstrate the presence of a functional, alternatively spliced organic cation transporter (rOCT1A) in rat kidney.	UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Giacomini, Kathleen/AEF-2452-2022		NIGMS NIH HHS [GM 36780, GM 26691] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM026691, R01GM036780] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; CACINI W, 1982, J PHARMACOL EXP THER, V221, P342; Canton H, 1996, MOL PHARMACOL, V50, P799; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; DANTZLER WH, 1989, AM J PHYSIOL, V256, pF290, DOI 10.1152/ajprenal.1989.256.2.F290; GIACOMINI KM, 1994, PFLUG ARCH EUR J PHY, V427, P381, DOI 10.1007/BF00374549; GISCLON L, 1987, AM J PHYSIOL, V253, pF141, DOI 10.1152/ajprenal.1987.253.1.F141; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HOLOHAN PD, 1980, J PHARMACOL EXP THER, V215, P191; HSYU PH, 1988, AM J PHYSIOL, V254, pF56, DOI 10.1152/ajprenal.1988.254.1.F56; HSYU PH, 1987, J BIOL CHEM, V262, P3964; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KATSURA T, 1993, BIOCHIM BIOPHYS ACTA, V1146, P197, DOI 10.1016/0005-2736(93)90356-5; Koehler MR, 1996, MAMM GENOME, V7, P247, DOI 10.1007/s003359900074; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCKINNEY TD, 1987, AM J PHYSIOL, V252, pF525, DOI 10.1152/ajprenal.1987.252.3.F525; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; OTT RJ, 1991, AM J PHYSIOL, V261, pF443, DOI 10.1152/ajprenal.1991.261.3.F443; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Preiano BS, 1996, BIOCHEMISTRY-US, V35, P7946; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Roch-Ramel F., 1992, HDB PHYSL 8, P2189; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SOKOL PP, 1985, J PHARMACOL EXP THER, V233, P694; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; TAKANO M, 1985, LIFE SCI, V37, P1579, DOI 10.1016/0024-3205(85)90476-X; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1995, BIOESSAYS, V17, P25, DOI 10.1002/bies.950170107; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; ZHANG L, 1997, IN PRESS MOL PHARM	40	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16548	16554		10.1074/jbc.272.26.16548	http://dx.doi.org/10.1074/jbc.272.26.16548			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195965	hybrid			2022-12-25	WOS:A1997XG01900069
J	Roschke, V; Kopantzev, E; Dertzbaugh, M; Rudikoff, S				Roschke, V; Kopantzev, E; Dertzbaugh, M; Rudikoff, S			Chromosomal translocations deregulating c-myc are associated with normal immune responses	ONCOGENE			English	Article						c-myc; chromosomal translocation; B cell malignancy; tumor susceptibility	MURINE PLASMACYTOMAS; MOLECULAR ANALYSIS; CHOLERA-TOXIN; CELLS; LYMPHOMA; MICE; ONCOGENE; SUSCEPTIBILITY; DNA; DIFFERENTIATION	Plasmacytomas induced in BALB/c mice by pristane consistently evidence chromosomal translocations involving the c-myc gene and one of the Ig loci. This obervation has lead to the suggestion that c-myc deregulation is a critical event in the generation of such tumors, However, it is not clear whether c-myc translocation is related to pristane treatment or occurs in normal lymphocyte populations nor whether such translocations occur normally, and at similar frequencies, in strains genetically resistant to plasmacytoma development, such as DBA/2, In order to address these questions, a Long Distance PCR assay with single copy sensitivity was employed to assess the frequency of c-myc/IgA translocations in normal and immunized mice of both plasmacytoma resistant and susceptible lineages in the absence of pristane treatment. Our data demonstrate that spontaneous translocations occur in normal DBA/2 and BALB/c mice with no significant differences in frequency, A 3-5-fold increase in translocation frequency was observed in mice immunized with cholera toxin, a strong stimulator of IgA responses, We conclude that c-myc deregulation by chromosomal translocation is associated with normal physiological processes of B-cell differentiation and, as such, can not be the determining factor leading to malignancy.	NCI,GENET LAB,NIH,BETHESDA,MD 20892; USA,MED RES INST INFECT DIS,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; CHENG S, 1994, NATURE, V369, P684, DOI 10.1038/369684a0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; GARBE C, 1991, J AM ACAD DERMATOL, V24, P584, DOI 10.1016/0190-9622(91)70088-J; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; HILBERT DM, 1993, ONCOGENE, V8, P1993; Husband A J, 1977, Ciba Found Symp, P29; HUSBAND AJ, 1978, J EXP MED, V148, P1146, DOI 10.1084/jem.148.5.1146; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1993, TOXICOL LETT, V67, P237, DOI 10.1016/0378-4274(93)90059-7; JI WZ, 1995, CANCER RES, V55, P2876; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; LYCKE N, 1989, J IMMUNOL, V142, P3781; LYCKE N, 1986, IMMUNOLOGY, V59, P301; Magrath I, 1992, Semin Cancer Biol, V3, P285; MOCK BA, 1993, P NATL ACAD SCI USA, V90, P9499, DOI 10.1073/pnas.90.20.9499; Muller JR, 1996, CANCER RES, V56, P419; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; PAVLIDIS NA, 1992, MED PEDIATR ONCOL, V20, P279, DOI 10.1002/mpo.2950200403; POTTER M, 1994, J NATL CANCER I, V86, P1058, DOI 10.1093/jnci/86.14.1058; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; POTTER M, 1994, CANCER RES, V54, P969; POTTER M, 1984, CANCER SURV, V3, P247; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; Sokal RR, 1995, BIOMETRY; SOULIER J, 1995, BLOOD, V86, P1131; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STROBER W, 1991, IMMUNOL RES, V10, P386, DOI 10.1007/BF02919726; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904	43	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3011	3016		10.1038/sj.onc.1201156	http://dx.doi.org/10.1038/sj.onc.1201156			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223664				2022-12-25	WOS:A1997XG10000003
J	Yayon, A; Ma, YS; Safran, M; Klagsbrun, M; Halaban, R				Yayon, A; Ma, YS; Safran, M; Klagsbrun, M; Halaban, R			Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: Evidence for the involvement of Src-family kinases	ONCOGENE			English	Article						FGF2; dominant-negative receptor; receptor tyrosine kinase; melanocytes	ACTIVATED PROTEIN-KINASE; HUMAN-MALIGNANT MELANOMA; MULTIPLE HUMAN CANCERS; TYROSINE KINASES; HUMAN MELANOCYTES; SIGNAL-TRANSDUCTION; C-SRC; FACTORS STIMULATE; CYCLE REGULATOR; EXPRESSION	Basic Fibroblast Growth Factor (bFGF/FGF2) is thought to play a decisive role in malignant progression. Aberrant expression of bFGF causes constitutive autocrine activation of its cognate receptor and autonomous growth of human melanoma cells or bFGF transformed fibroblasts in culture, It remains to be determined, however, whether the endogenous bFGF confers growth advantage to tumors and what are the downstream targets of the activated FGF receptor critical for its transforming capacity, We therefore transfected metastatic melanoma cells and bFGF transformed mouse fibroblasts with a dominant-negative mutant of the murine FGF receptor 1 (fgfr1/flg), comprising the extracellular and transmembrane domains but lacking the intracellular kinase domain (dnflg), Reverse transcriptase-PCR, I-125-bFGF binding and affinity labeling analyses show that the truncated receptor is targeted to the membrane and is expressed at much higher levels than the endogenous receptor in all of the selected clones, Expression of the dnflg dramatically reduces the basal as well as bFGF induced growth of these cells in vitro and also suppresses their tumorigenic potential in nude mice, The expression of the dnflg does not significantly alter the general level of tyrosyl-phosphorylated proteins in the transduced melanoma cells. Rather, a major downstream affected target is a Src-family kinase, whose activity, determined by an in vitro immune kinase assay, is stimulated in normal melanocytes by exogenous bFGF, and is markedly reduced in the dnflg-expressing melanoma cells, The present study demonstrates that direct interference with the activity of FGF receptors has a deleterious effect on cell proliferation and survival in vitro and in vivo leading to the suppression of melanoma tumor progression possibly through the inactivation of a Src-family kinase.	YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; HARVARD UNIV,SCH MED,BOSTON,MA 02115; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115	Yale University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Yayon, A (corresponding author), WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL.		Fu, Da/GXF-2656-2022		NCI NIH HHS [CA44542] Funding Source: Medline; NIAMS NIH HHS [AR39848, AR41942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044542, R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942, R01AR039848] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINO AP, 1991, CANCER RES, V51, P4815; AMAYA E, 1993, DEVELOPMENT, V118, P477; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; COWAN JM, 1991, MELANOMA RES GENETIC, V3; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EASTY DJ, 1995, CANCER RES, V55, P2528; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; Halaban R, 1996, J INVEST DERMATOL, V106, P1266, DOI 10.1111/1523-1747.ep12348972; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1992, BIOLOGY OF THE EPIDERMIS : MOLECULAR AND FUNCTIONAL ASPECTS, P133; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1988, ONCOGENE RES, V3, P177; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HALABAN R, 1993, EPIDERMAL GROWTH FAC, P273; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAMB A, 1994, COLD SPRING HARB SYM, V59, P39, DOI 10.1101/SQB.1994.059.01.007; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI LY, 1994, BIOCHEMISTRY-US, V33, P10999, DOI 10.1021/bi00202a020; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LIU L, 1995, ONCOGENE, V11, P405; LOGANZO F, 1993, ONCOGENE, V8, P2637; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REED JA, 1994, AM J PATHOL, V144, P329; REYMOND A, 1995, ONCOGENE, V11, P1173; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1992, J BIOL CHEM, V267, P1470; WALKER GJ, 1994, ONCOGENE, V9, P819; WELLBROCK C, 1995, ONCOGENE, V10, P2135; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360; ZAKUT R, 1993, ONCOGENE, V8, P2221; ZHAN X, 1994, J BIOL CHEM, V269, P20221	65	66	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					2999	3009		10.1038/sj.onc.1201159	http://dx.doi.org/10.1038/sj.onc.1201159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223663				2022-12-25	WOS:A1997XG10000002
J	Takaoka, A; Adachi, M; Okuda, H; Sato, S; Yawata, A; Hinoda, Y; Takayama, S; Reed, JC; Imai, K				Takaoka, A; Adachi, M; Okuda, H; Sato, S; Yawata, A; Hinoda, Y; Takayama, S; Reed, JC; Imai, K			Anti-cell death activity promotes pulmonary metastasis of melanoma cells	ONCOGENE			English	Article						BCL-2; BAG-1; melanoma; pulmonary metastasis	HUMAN FOLLICULAR LYMPHOMA; CANCER METASTASIS; BCL-2; PROTEIN; APOPTOSIS; EXPRESSION; LECTINS; MATRIX; GENE	Bcl-2 inhibits apoptosis from a variety of stimuli, and a Bcl-2-binding protein BAG-1 also functions in protection from apoptosis in concert with Bcl-2, Here, we provide evidence that prolonged cell survival introduced by overexpression of Bcl-2 or BAG-1 proteins strongly promotes experimental pulmonary metastasis of melanoma B16-BL6 cells, In murine melanoma cell line B16-BL6, gene transfer-mediated expression of the Bcl-2 or BAG-1 led to prolonged cell survival against serum-starved apoptosis in vitro, The Bcl-2-expressing B16 cells, B16-Bcl-2 and the BAG-1-expressing B16 cells, B16-BAG-1 strongly enhanced pulmonary metastasis in allogenic BALB/c nude mice and whole lung weights were increased by 2.4-fold and 1.4-fold, respectively, compared with control transfectants, suggesting that Bcl-2 is a stronger positive modulator of metastasis, When the viable B16-Bcl-2 and control transfectants were injected subcutaneously into BALB/c nude mice, the colony numbers of pulmonary metastasis of the B16-Bcl-2 transfectant increased by 5.6-fold compared with the control transfectants, These enhanced metastatic potentials in the B16-Bcl-2 and the B16-BAG-1 transfectants were well correlated with anti-cell death activity against serum-starvation and enhanced cell viability on limiting dilution, Analysis of the transfectants however revealed that their growth rates, invasive ability and cell motility were not significantly altered by overexpression of either Bcl-2 or BAG-1 proteins, Taken together, these studies demonstrate that prolonged cell survival is a crucial factor to promote metastasis of melanoma, thereby contributing to tumor progression.	SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,HOKKAIDO 060,JAPAN; BURNHAM INST,CTR CANC RES,LA JOLLA,CA 92037	Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; ALBRECHTBUEHLER G, 1977, CELL, V11, P359; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; COLLINS KA, 1995, AM J DERMATOPATH, V17, P429, DOI 10.1097/00000372-199510000-00001; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIDLER IJ, 1990, CANCER RES, V50, P6130; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEROMSKY L, 1986, CANCER RES, V46, P5270; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254; POSTE G, 1980, CANCER RES, V40, P1636; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAENZSANTAMARIA MC, 1994, J CUTAN PATHOL, V21, P393; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TRON VA, 1995, AM J PATHOL, V146, P643; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	29	109	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2971	2977		10.1038/sj.onc.1201147	http://dx.doi.org/10.1038/sj.onc.1201147			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205104				2022-12-25	WOS:A1997XF55500011
J	Zhang, HT; Zhang, X; Zhao, HZ; Kajino, Y; Weber, BL; Davis, JG; Wang, Q; ORourke, DM; Zhang, HB; Kajino, K; Greene, MI				Zhang, HT; Zhang, X; Zhao, HZ; Kajino, Y; Weber, BL; Davis, JG; Wang, Q; ORourke, DM; Zhang, HB; Kajino, K; Greene, MI			Relationship of p215(BRCA1) to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells	ONCOGENE			English	Article						BRCA1; neu; EGFR; transformation	BREAST-CANCER; GROWTH-FACTOR; DNA-BINDING; BRCA1; PROTEIN; PHOSPHORYLATION; COMMON; LOCALIZATION; EXPRESSION; ONCOGENE	We have analysed the relationship of the products of two genes, neu and BRCA1, known to be important in human breast cancer, Highly specific antibodies that recognized both the rodent and human form of the BRCA1 gene product (M-r 215 kDa, p215(BRCA1)) were developed to facilitate these efforts, p215(BRCA1) was identified as a tyrosine phosphorylated protein primarily localized in the nucleus of several breast cancer cell lines, In transformed murine and human cells, levels of p215(BRCA1) tyrosine phosphorylation were inversely correlated with the activity of the erbB family receptor-tyrosine-kinases and with the transformed growth features of these cells, Regulation of p215(BRCA1) tyrosine phosphorylation was also related to events in the cell cycle, Increased levels of p215(BRCA1) phosphotyrosine content were observed in NIH3T3 cells arrested at the G(2)/M transition, These findings indicate that the products of BRCA1, neu, and erbB breast cancer genes participate in a common or shared signaling pathway important in cell growth and its regulation.	UNIV PENN,SCH MED,DEPT PATHOL & LAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Kajino, Kiichi/F-6873-2012; O'Rourke, Donald/AAC-3376-2021; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049; O'Rourke, Donald/0000-0002-8479-7314				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; ALTSCHUL SF, 1990, J MOL BIOL, V215, P195; Bennett L. M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P514; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davis JG, 1997, P NATL ACAD SCI USA, V94, P707, DOI 10.1073/pnas.94.2.707; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EASTON DF, 1995, AM J HUM GENET, V56, P265; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Ormerod M.G., 1994, FLOW CYTOMETRY PRACT, P119; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Qian XL, 1996, ONCOGENE, V13, P2149; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Rao VN, 1996, ONCOGENE, V12, P523; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924	35	24	24	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2863	2869		10.1038/sj.onc.1201140	http://dx.doi.org/10.1038/sj.onc.1201140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205094				2022-12-25	WOS:A1997XF55500001
J	Wang, MS; Liu, YLE; Greene, J; Sheng, SJ; Fuchs, A; Rosen, EM; Shi, YE				Wang, MS; Liu, YLE; Greene, J; Sheng, SJ; Fuchs, A; Rosen, EM; Shi, YE			Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4	ONCOGENE			English	Article						TIMP; MMP; mammary carcinoma; nude mice; angiogenesis	INVASIVE TUMORS; IV COLLAGENASES; MESSENGER-RNAS; STROMAL CELLS; UP-REGULATION; CHICK-EMBRYO; IN-VIVO; EXPRESSION; TIMP-2; ANGIOGENESIS	We recently identified, cloned, and characterized a novel human tissue inhibitor of metalloproteinases-4, TIMP-4 (Greene et al., 1996), To determine if TIMP-4 can modulate the in vivo growth of human breast cancers, Ne transfected a full-length TIMP-4 cDNA into MDA-MB-435 human breast cancer cells and studied the orthotopic growth of TIMP-4-transfected (TIMP4-435) versus control (neo-435) clones in the mammary fat pad of athymic nude mice, TIMP4-435 clones expressed TIMP-4 mRNA and produced anti-metalloproteinase (MMP) activity, while neo-435 clones did not express TIMP-4 mRNA or produce detectable anti-MMP activity. Overexpression of TIMP-4 inhibited the invasion potential of the cells in the in vitro invasion assay, When injected orthotopically into nude mice, TIMP-4 transfectants were significantly inhibited in tumor growth by 4-10-fold in primary tumor volumes; and in an axillary lymph node and lung metastasis as compared with controls. These results suggest the therapeutic potential of TIMP-4 in treating cancer malignant progression.	LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,NEW HYDE PK,NY 11040; LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,NEW HYDE PK,NY 11040; LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT RADIAT ONCOL,NEW HYDE PK,NY 11040; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115	Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; GlaxoSmithKline; Human Genome Sciences Inc; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BARSKY SH, 1983, LAB INVEST, V49, P140; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BASSET P, 1994, CANCER-AM CANCER SOC, V74, P1045, DOI 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0.CO;2-7; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERRETTONI BA, 1986, J BONE JOINT SURG AM, V68A, P308, DOI 10.2106/00004623-198668020-00021; DECLERCK YA, 1992, CANCER RES, V52, P701; Denhardt D T, 1992, Matrix Suppl, V1, P281; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HARAN EF, 1994, CANCER RES, V54, P5511; Heppner KJ, 1996, AM J PATHOL, V149, P273; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; HLATKY L, 1994, CANCER RES, V54, P6083; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; Imren S, 1996, CANCER RES, V56, P2891; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KHOKHA R, 1992, CLIN EXP METASTAS, V10, P365, DOI 10.1007/BF00133464; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LAMSZUS K, 1997, IN PRESS LAB INVEST; Lund LR, 1996, DEVELOPMENT, V122, P181; MATSUZAWA K, 1996, NEUROPATHOL EXP NEUR, V55, P88; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; POLETTE M, 1993, PATHOL RES PRACT, V189, P1052; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; PYKE C, 1993, AM J PATHOL, V142, P359; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi Y. E., 1995, V74, P215; SHI YE, 1993, CANCER RES, V53, P1409; SHI YE, 1993, CLIN EXP METASTAS, V11, P251, DOI 10.1007/BF00121168; SPYRATOS F, 1989, LANCET, V2, P1115; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WOLFF JEA, 1993, BRAIN RES, V604, P79, DOI 10.1016/0006-8993(93)90354-P	47	132	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2767	2774		10.1038/sj.onc.1201245	http://dx.doi.org/10.1038/sj.onc.1201245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190892				2022-12-25	WOS:A1997XD64300004
J	Ivanov, VN; Lee, RK; Podack, ER; Malek, TR				Ivanov, VN; Lee, RK; Podack, ER; Malek, TR			Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: A potential role for transcription factor NF-kappa B	ONCOGENE			English	Article						apoptosis; T lymphocyte; NF-kappa B; Fas ligand	PROTEIN-KINASE-A; IMMUNE-SYSTEM; REL FAMILY; C-MYC; DEATH; INHIBITION; EXPRESSION; BCL-2; HYBRIDOMAS; LIGAND	TCR-mediated activation of T cell hybridomas induces programmed cell death by a Fas-dependent pathway. We now show that costimulation of 2B4 cells, in the absence or presence of transgenic Bcl-2, with anti-CD3 epsilon and forskolin, an activator of cAMP signaling, resulted in antagonism of Fas-dependent activation-induced cell death that was always accompanied by selective down-regulation of the nuclear levels of NF-kappa B p65-p50 (RelA-p50) transcription factor. Forskolin not only inhibited activation-induced cell death and NF-kappa B activation, but also suppressed expression of Fas and Fas ligand (Fast). Furthermore, NF-kappa B p65 antisense oligonucleotide down-regulated nuclear levels of NF-kappa B, inhibited cell surface expression of Fas-L and apoptosis of 2B4. Collectively, these finding demonstrate a potential role of NF-kappa B in the regulation of activation-induced apoptosis in T lymphocytes.	UNIV MIAMI, SCH MED, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33101 USA; RUSSIAN ACAD SCI, INST GENE BIOL, MOSCOW, RUSSIA	University of Miami; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences			Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774	NCI NIH HHS [R01-CA4609] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ASHWELL JD, 1994, HDB B T LYMPHOCYTES, P63; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BRIDLE PK, 1992, CURR OPIN GENET DEV, V2, P199; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; CODIAS EK, 1990, J IMMUNOL, V145, P1407; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; IVANOV V, 1994, J IMMUNOL, V153, P2394; IVANOV V, 1993, J IMMUNOL, V151, P4694; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JONDAL M, 1995, APOPTOSIS IMMUNOLOGY, P67; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEE MR, 1993, J IMMUNOL, V151, P5208; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams MS, 1996, J IMMUNOL, V157, P2395; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WU HY, 1994, J BIOL CHEM, V269, P20067; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	59	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2455	2464		10.1038/sj.onc.1201088	http://dx.doi.org/10.1038/sj.onc.1201088			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188860	Green Published			2022-12-25	WOS:A1997WZ68000009
J	Schuit, F; DeVos, A; Farfari, S; Moens, K; Pipeleers, D; Brun, T; Prentki, M				Schuit, F; DeVos, A; Farfari, S; Moens, K; Pipeleers, D; Brun, T; Prentki, M			Metabolic fate of glucose in purified islet cells - Glucose-regulated anaplerosis in beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; INSULIN RELEASE; B-CELLS; PYRUVATE-DEHYDROGENASE; GENE-EXPRESSION; MALONYL-COA; A-CELLS; CARBOXYLASE; SECRETION; GLUCOKINASE	Previous studies in rat islets have suggested that anaplerosis plays an important role in the regulation of pancreatic beta cell function and growth. However, the relative contribution of islet beta cells versus non-beta cells to glucose-regulated anaplerosis is not known. Further more, the fate of glucose carbon entering the Krebs cycle of islet cells remains to be determined. The present study has examined the anaplerosis of glucose carbon in purified rat beta cells using specific C-14-labeled glucose tracers. Between 5 and 20 mM glucose, the oxidative production of CO2 from [3,4-C-14]glucose represented close to 100% of the total glucose utilization by the cells. Anaplerosis, quantified as the difference between (CO2)-C-14 production from [3,4-C-14]glucose and [6-C-14]glucose, was strongly influenced by glucose, particularly between 5 and 10 mM. The dose dependence of glucose-induced insulin secretion correlated with the accumulation of citrate and malate in beta(INS-1) cells, All glucose carbon that was not oxidized to CO2 was recovered from the cells after extraction in trichloroacetic acid. This indirectly indicates that lactate output is minimal in beta cells. From the effect of cycloheximide upon the incorporation of C-14-glucose into the acid-precipitable fraction, it could be calculated that 25% of glucose carbon entering the Krebs cycle via anaplerosis is channeled into protein synthesis. In contrast, non-beta cells (approximately 80% glucagon producing alpha cells) exhibited rates of glucose oxidation that were 1/3 to 1/6 those of the total glucose utilization and no detectable anaplerosis from glucose carbon, This difference between the two cell types was associated with a 7-fold higher expression of the anaplerotic enzyme pyruvate carboxylase in beta cells, as well as a 4-fold lower ratio of lactate dehydrogenase to FAD-linked glycerol phosphate dehydrogenase in beta cells versus alpha cells. Finally, glucose caused a dose-dependent suppression of the activity of the pentose phosphate pathway in beta cells. In conclusion, rat beta cells metabolize glucose essentially via aerobic glycolysis, whereas glycolysis in alpha cells is largely anaerobic. The results support the view that anaplerosis is an essential pathway implicated in beta cell activation by glucose.	UNIV MONTREAL, DEPT NUTR, MOL NUTR UNIT, MONTREAL, PQ H2L 4M1, CANADA; INST CANC RES, CTR RECH LC SIMARD, MONTREAL, PQ H2L 4M1, CANADA	Universite de Montreal; Universite de Montreal	Schuit, F (corresponding author), FREE UNIV BRUSSELS, FAC MED, DIABET RES CTR, LAARBEEKLAAN 103, B-1090 BRUSSELS, BELGIUM.		; Glaser, Benjamin/F-8411-2017	BRUN, Thierry/0000-0002-1659-4283; De Vos, Anick/0000-0001-5311-1589; Glaser, Benjamin/0000-0003-4711-5000; Pipeleers, Daniel/0000-0002-6440-2485				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; BRUN T, 1993, J BIOL CHEM, V268, P18905; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; DEVOS A, 1991, BIOCHEM INT, V24, P117; DIONNE KE, 1993, DIABETES, V42, P12, DOI 10.2337/diabetes.42.1.12; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GOODRIDGE AG, 1972, J BIOL CHEM, V247, P6946; GORUS FK, 1984, J BIOL CHEM, V259, P1196; GRODSKY GM, 1963, AM J PHYSIOL, V205, P638, DOI 10.1152/ajplegacy.1963.205.4.638; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; HEDESKOV CJ, 1975, BIOCHEM J, V152, P571, DOI 10.1042/bj1520571; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; HELLMAN B, 1971, BIOCHIM BIOPHYS ACTA, V241, P147, DOI 10.1016/0005-2736(71)90312-9; HENQUIN JC, 1994, JOSLINS DIABETES MEL, P56; KATZ J, 1963, J BIOL CHEM, V238, P517; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MALAISSE WJ, 1993, J CLIN INVEST, V91, P432, DOI 10.1172/JCI116219; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; SCHUIT FC, 1991, BIOCHEM BIOPH RES CO, V178, P1182, DOI 10.1016/0006-291X(91)91017-7; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SENER A, 1987, BIOCHEM J, V246, P89, DOI 10.1042/bj2460089; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; YIN L, 1992, DIABETES, V41, P792; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394	50	347	353	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18572	18579		10.1074/jbc.272.30.18572	http://dx.doi.org/10.1074/jbc.272.30.18572			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228023	Green Published, hybrid			2022-12-25	WOS:A1997XM34200014
J	Huet, J; Conesa, C; Carles, C; Sentenac, A				Huet, J; Conesa, C; Carles, C; Sentenac, A			A cryptic DNA binding domain at the COOH terminus of TFIIIB70 affects formation, stability, and function of preinitiation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; FACTOR-TFIIB; INITIATION-FACTOR; 2 COMPONENTS; FACTOR RAP30; GENE; TBP; IDENTIFICATION; SUFFICIENT	TFIIIC-dependent assembly of yeast TFIIIB on class III genes unmasks a high avidity of TFIIIB for DNA. TFIIIB contains TATA-binding protein (TBP), TFIIIB90/B '', and TFIIIB70/Brf1, which is homologous to TFIIB. Using limited proteolysis, we have found that the COOH terminus of TFIIIB70 (residues 510-596) forms a protease-resistant domain that binds DNA tightly as seen by Southwestern, DNase I footprinting, and gel shift assays. Consistent with a role for this DNA binding activity, preinitiation complexes were formed less efficiently with truncated TFIIIB70 lacking the COOH-terminal domain and displayed an increased sensitivity to heparin, B' (TFIIIB70 + TBP).TFIIIC.DNA complexes were also particularly unstable, In addition, TFIIIB.TFIIIC.DNA complexes containing truncated TFIIIB70 were im paired in promoting transcription initiation.	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BAKER RE, 1982, EMBO J, V1, P291, DOI 10.1002/j.1460-2075.1982.tb01162.x; BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BRAUN BR, 1992, J BIOL CHEM, V267, P22562; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GABRIELSEN OS, 1987, NUCLEIC ACIDS RES, V15, P5699, DOI 10.1093/nar/15.14.5699; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V1, P247; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HUET J, 1985, J BIOL CHEM, V260, P5304; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IBORRA F, 1979, J BIOL CHEM, V254, P920; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TAN SY, 1994, P NATL ACAD SCI USA, V91, P9808, DOI 10.1073/pnas.91.21.9808; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITE RJ, 1994, RNA POLYMERASE 3 TRA; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	61	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18341	18349		10.1074/jbc.272.29.18341	http://dx.doi.org/10.1074/jbc.272.29.18341			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218475	hybrid			2022-12-25	WOS:A1997XL73500065
J	Krupnick, JG; Gurevich, VV; Benovic, JL				Krupnick, JG; Gurevich, VV; Benovic, JL			Mechanism of quenching of phototransduction - Binding competition between arrestin and transducin for phosphorhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; 48-KDA PROTEIN; RHODOPSIN KINASE; VISUAL ARRESTIN; PHOSPHODIESTERASE ACTIVATION; BETA-2-ADRENERGIC RECEPTOR; PHOTOEXCITED RHODOPSIN; CHOLINERGIC RECEPTORS; BOVINE RHODOPSIN; WILD-TYPE	Quenching of phototransduction in retinal rod cells involves phosphorylation of photoactivated rhodopsin by the enzyme rhodopsin kinase followed by binding of the protein arrestin, Although it has been proposed that the mechanism of arrestin quenching of visual transduction is via steric exclusion of transducin binding to phosphorylated light-activated rhodopsin (P-Rh*), direct evidence for this mechanism is lacking, In this study, we investigated both the role of rhodopsin phosphorylation in modulating its interaction with arrestin and transducin and the proposed binding competition between arrestin and transducin for P-Rh*. While the beta-adrenergic receptor kinase promotes significant arrestin binding to rhodopsin at a phosphorylation stoichiometry of greater than or equal to 2 mol/mol, rhodopsin kinase promotes arrestin binding at a stoichiometry of similar to 0.9 mol/mol, Moreover, while beta-adrenergic receptor kinase phosphorylation of rhodopsin only modestly decreases transducin binding and activation, rhodopsin kinase phosphorylation of rhodopsin significantly decreases transducin binding and activation, Finally, arrestin competes effectively with transducin for binding to P-Rh* (50% inhibition at similar to 1:1 molar ratio of arrestin:transducin) but has no effect on transducin binding to nonphosphorylated light activated rhodopsin (Rh*), paralleling the functional inhibition by arrestin on P-Rh*-stimulated transducin activation (50% inhibition at similar to 1.7:1 molar ratio of arrestin:transducin). These results demonstrate that a major role of rhodopsin phosphorylation is to promote high-affinity arrestin binding and decrease transducin binding thus allowing arrestin to effectively compete with transducin for binding to photoactivated rhodopsin.	THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107	Jefferson University	Krupnick, JG (corresponding author), THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MOL PHARMACOL & BIOCHEM,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.		Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NIDDK NIH HHS [T32-DK07705] Funding Source: Medline; NIGMS NIH HHS [GM44944, GM47419] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, NATURE, V322, P869; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; DODD LR, 1996, INVEST OPTHALM VIS S, V37, P55; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7227; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HARGRAVE PA, 1992, FASEB J, V6, P2328; KIM CM, 1993, RECEPTOR, V3, P39; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; PUIG J, 1995, FEBS LETT, V362, P1854; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	39	144	146	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18125	18131		10.1074/jbc.272.29.18125	http://dx.doi.org/10.1074/jbc.272.29.18125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218446	hybrid			2022-12-25	WOS:A1997XL73500036
J	Sudakin, V; Shteinberg, M; Ganoth, D; Hershko, J; Hershko, A				Sudakin, V; Shteinberg, M; Ganoth, D; Hershko, J; Hershko, A			Binding of activated cyclosome to p13(suc1) - Use for affinity purification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 PROTEIN-KINASE; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASE; M-PHASE; MITOSIS; COMPLEX; YEAST; DESTRUCTION; PROTEOLYSIS	Previous studies have indicated that a similar to 1,500-kDa complex, designated the cyclosome or anaphase-promoting complex, has a regulated cyclin-ubiquitin ligase activity that targets cyclin B for degradation at the end of mitosis. The cyclosome is inactive in the interphase of the embryonic cell cycle and is converted to the active form in late mitosis in a phosphorylation-dependent process initiated by protein kinase Cdc2-cyclin B. We show here that the active, phosphorylated form of the cyclosome from clam oocytes binds to p13(suc1), a protein known to associate with Cdc2, The following evidence indicates that the binding of the cyclosome to p13(suc1) is not mediated via the Cdc2-cyclin B complex: (a) activated cyclosome binds to p13(suc1)-Sepharose following its separation from Cdc2-cyclin B by gel filtration chromatography; (b) cyclosome from interphase extracts, activated by a kinase in which cyclin B has been replaced by an N-terminally truncated derivative fused to glutathione S-transferase, binds well to p13(suc1) Sepharose but not to glutathione-agarose. An alternative possibility, that the phosphorylated cyclosome binds directly to a phosphate-binding site of p13(suc1), is supported by the observation that the cyclosome is efficiently eluted from p13(suc1)-Sepharose by phosphate-containing compounds. This information was utilized to develop a procedure for the affinity purification of the cyclosome. A factor abundant in the fraction not adsorbed to p13(suc1)-Sepharose stimulates the activity of purified cyclosome. It is suggested that binding of Suc1 may have a role in the regulation of cyclosome activity.	FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, BIOCHEM UNIT, IL-31096 HAIFA, ISRAEL; TECHNION ISRAEL INST TECHNOL, RAPPORT INST RES MED SCI, IL-31096 HAIFA, ISRAEL	Fox Chase Cancer Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology								Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; EDINCOTT JA, 1995, EMBO J, V14, P1004; EDINCOTT JA, 1995, STRUCTURE, V3, P321; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; ODONNELL KL, 1991, J CELL SCI, V99, P711; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	36	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18051	18059		10.1074/jbc.272.29.18051	http://dx.doi.org/10.1074/jbc.272.29.18051			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218435	hybrid			2022-12-25	WOS:A1997XL73500025
J	Branstrom, R; Corkey, BE; Berggren, PO; Larsson, O				Branstrom, R; Corkey, BE; Berggren, PO; Larsson, O			Evidence for a unique long chain acyl-CoA ester binding site on the ATP-regulated potassium channel in mouse pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; SULFONYLUREA RECEPTOR; ISLETS; RELEASE; ADENINE; TRYPSIN; KATP; ADP	The mechanism by which long chain acyl-CoA (LC-CoA) esters affect the ATP-regulated potassium channel (K-ATP channel) was studied in inside-out patches isolated from mouse pancreatic beta cells, Addition of LC-CoA esters dramatically increased K-ATP, channel activity. The stimulatory effect of the esters could be explained by the induction of a prolonged open state of the channel and did not involve alterations in single channel unitary conductance. Under central conditions, absence of adenine nucleotides, the distribution of K-ATP channel open time could be described by a single exponential, with a time constant of about 25 ms, Exposing the same patch to LC-CoA esters resulted in the appearance of an additional component with a time constant of >150 ms, indicating a conformational change of the channel protein, LC-CoA esters were also able to potently activate channel activity at different ratios of ATP/ADP. Simultaneous additions of MgADP and LC-CoA esters resulted in a supra-additive effect on channel mean open time, characterized by openings of very long duration. Following modification of the K-ATP channel by a short exposure of the patch rep the protease trypsin, the stimulatory effect of ADP oil channel activity was lost while activation by LC-CoA testers still persisted, This indicates that LC-CoA esters and MgADP do not bind to the same site, We conclude that LC-CoA esters may play an important role in the physiological regulation of the K-ATP channel in the pancreatic beta cell by binding to a unique site and thereby inducing repolarization of the beta cell-membrane potential.	KAROLINSKA INST,DEPT MOL MED,ROLF LUFT CTR DIABET RES,S-17176 STOCKHOLM,SWEDEN; BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,BOSTON,MA 02118	Karolinska Institutet; Boston University			Corkey, Barbara/E-7712-2015	Corkey, Barbara/0000-0002-5467-1630; Berggren, Per-Olof/0000-0001-8991-413X; Branstrom, Robert/0000-0001-6245-7223	NIDDK NIH HHS [DK35914, DK50662] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R01DK050662, R56DK035914, R01DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Benyon RJ, 1989, PROTEOLYTIC ENZYMES; BOYLAN JG, 1992, BIOCHEMISTRY-US, V31, P557, DOI 10.1021/bi00117a037; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; DEAN PM, 1968, NATURE, V219, P389, DOI 10.1038/219389a0; GHOSH A, 1991, J BIOL CHEM, V266, P22887; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HESCHELER J, 1988, J PHYSIOL-LONDON, V404, P259, DOI 10.1113/jphysiol.1988.sp017289; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; Larsson O, 1996, P NATL ACAD SCI USA, V93, P5161, DOI 10.1073/pnas.93.10.5161; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; OHTA M, 1991, BIOCHEM PHARMACOL, V42, P593; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PROKS P, 1993, PFLUG ARCH EUR J PHY, V424, P63, DOI 10.1007/BF00375103; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SCHWANSTECHER M, 1991, N-S ARCH PHARMACOL, V343, P83; TRUBE G, 1989, SECRETION ITS CONTRO, P83	29	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17390	17394		10.1074/jbc.272.28.17390	http://dx.doi.org/10.1074/jbc.272.28.17390			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211879	hybrid			2022-12-25	WOS:A1997XK16500022
J	Jacoby, T; Flanagan, H; Faykin, A; Seto, AG; Mattison, C; Ota, I				Jacoby, T; Flanagan, H; Faykin, A; Seto, AG; Mattison, C; Ota, I			Two protein-tyrosine phosphatases inactivate the osmotic stress response pathway in yeast by targeting the mitogen-activated protein kinase, Hog1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; GENE; GROWTH; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION; CASCADE; VECTORS	Protein phosphatases inactivate mitogen-activated protein kinase (MAPK) signaling pathways by dephosphorylating components of the MAPK cascade. Two genes encoding protein-tyrosine phosphatases, PTP2, and a new phosphatase, PTP3, have been isolated in a genetic selection for negative regulators of an osmotic stress response pathway called HOG, for high osmolarity glycerol, in budding yeast. PTP2 and PTP3 were isolated as multicopy suppressors of a severe growth defect due to hyperactivation of the HOG: pathway. Phosphatase activity is required for suppression since mutation of the catalytic Cys residue in Ptp2 and Ptp3, destroys suppressor function and biochemical activity. The substrate of these phosphatases is likely to be the MAPK, Hog1. Catalytically inactive Ptp2 and Ptp3 coprecipitate with Hog1 from yeast extracts. In addition, strains lacking PTP2 and PTP3 do not dephosphorylate Hog1-phosphotyrosine as well as wild type. The latter suggests that PTP2 and PTP3 play a role in adaptation. Consistent with this role, osmotic stress induces expression of PTP2 and PTP3 transcripts in a Hog1-dependent manner. Thus Ptp2 and Ptp3 likely act in a negative feedback loop to inactivate Hog1.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM07135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Degols G, 1996, MOL CELL BIOL, V16, P2870; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUAN KL, 1992, J BIOL CHEM, V267, P10024; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAMES P, 1992, GENE, V122, P101, DOI 10.1016/0378-1119(92)90037-P; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3632; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SHERMAN F, 1986, METHODS YEAST GENETI, P177; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	52	126	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17749	17755		10.1074/jbc.272.28.17749	http://dx.doi.org/10.1074/jbc.272.28.17749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211927	hybrid			2022-12-25	WOS:A1997XK16500070
J	Shrimpton, CN; Glucksman, MJ; Lew, RA; Tullai, JW; Margulies, EH; Roberts, JL; Smith, AI				Shrimpton, CN; Glucksman, MJ; Lew, RA; Tullai, JW; Margulies, EH; Roberts, JL; Smith, AI			Thiol activation of endopeptidase EC 3.4.24.15 - A novel mechanism for the regulation of catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-CONTAINING PEPTIDES; PROTEIN DISULFIDE-ISOMERASE; DNA-BINDING ACTIVITY; PZ-PEPTIDASE; SOLUBLE METALLOENDOPEPTIDASE; THIMET OLIGOPEPTIDASE; RAT TESTES; DEPENDENT METALLOENDOPEPTIDASE; NATURAL PEPTIDES; REDOX CHANGES	Endopeptidase EC 3.4.24.15 (EP24,15) is a thermolysin-like metalloendopeptidase involved in the regulated metabolism of a number of neuropeptides. Unlike other thermolysin-like peptidases EP24.15 displays a unique thiol activation, a mechanism that is not clearly understood, In this study we show that both recombinant and tissue-derived EP24,15 are activated up to 8-fold by low concentrations (0.1 mM) of dithiothreitol, Additionally, under non-reducing conditions, recombinant and native EP24,15 forms multimers that can be returned to the monomeric form by reduction, We have also shown that competitive inhibitor binding occurs only to the monomeric form, which indicates that catalytic site access is restricted in the multimeric forms, Through systematic site-directed mutagenesis we have identified that cysteine residues 246, 253, and possibly 248 are involved in the formation of these multimers, Furthermore, both a double mutant (C246S/C253S) and a triple mutant (C246S/C248S/C253S) are fully active in the absence of reducing agents, as measured by both inhibitor binding and hydrolysis, The formation and disruption of disulfide bonds involving these cysteine residues may be a mechanism by which EP24,15 activity is regulated through changes in intra- and extracellular redox potential.	BAKER MED RES INST,PEPTIDE BIOL LAB,PRAHRAN,VIC 3181,AUSTRALIA; CUNY MT SINAI SCH MED,DR ARTHUR M FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	Baker Heart and Diabetes Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Lew, Rebecca A/C-5454-2008	Smith, Ian/0000-0002-4143-2892	NIDDK NIH HHS [DK45493, T32-DK07645] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007645, R29DK045493] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BARRETT AJ, 1990, BIOCHEM J, V271, P701, DOI 10.1042/bj2710701; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHU TG, 1984, BIOCHEMISTRY-US, V23, P3598, DOI 10.1021/bi00311a005; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; GLUCKSMAN MJ, 1995, METHODS NEUROSCI, V43, P296; GOMORI G, 1955, METHOD ENZYMOL, V1, P138, DOI 10.1016/0076-6879(55)01020-3; Issakidis E, 1996, FEBS LETT, V392, P121, DOI 10.1016/0014-5793(96)00801-0; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; LEW RA, 1995, BIOCHEM BIOPH RES CO, V209, P788, DOI 10.1006/bbrc.1995.1569; MARTIN H, 1991, BIOCHEM BIOPH RES CO, V175, P123, DOI 10.1016/S0006-291X(05)81209-4; MCDERMOTT JR, 1992, BIOCHEM BIOPH RES CO, V185, P746, DOI 10.1016/0006-291X(92)91689-N; MORALES TI, 1977, J BIOL CHEM, V252, P4855; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PAPASTOITSIS G, 1994, BIOCHEMISTRY-US, V33, P192, DOI 10.1021/bi00167a025; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PIEROTTI A, 1994, BIOCHEMISTRY-US, V33, P622, DOI 10.1021/bi00168a600; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; TISLJAR U, 1990, BIOCHEM J, V267, P531, DOI 10.1042/bj2670531; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; TISLJAR U, 1990, ANAL BIOCHEM, V186, P112, DOI 10.1016/0003-2697(90)90582-T; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	31	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17395	17399		10.1074/jbc.272.28.17395	http://dx.doi.org/10.1074/jbc.272.28.17395			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211880	hybrid			2022-12-25	WOS:A1997XK16500023
J	Choi, CY; Choi, BH; Park, GT; Rho, HM				Choi, CY; Choi, BH; Park, GT; Rho, HM			Activating transcription factor 2 (ATF2) down-regulates hepatitis B virus X promoter activity by the competition for the activating protein I binding site and the formation of the ATF2-Jun heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ENHANCER ELEMENT; GENE PRODUCT; TAX PROTEIN; EF-C; CELLS; REPLICATION; INTERACT; REGION; TRANSACTIVATION	The hepatitis B viral X promoter is known to be positively autoregulated by its own HBx protein, which also interacts with many cellular regulatory proteins, We investigated the effect of activating transcription factor 2, (ATF2) on the activity of the PL promoter. Cotransfection of the ATF2 expression vector with a X promoter-chloramphenicol acetyltransferase plasmid repressed the X promoter activity in HepG2 cells, HBx activated activating protein 1 (AP-1)-mediated transcription through the hepatitis B virus E element by 35-fold, while its activation activity was inhibited in the presence of ATF2, suggesting that ATF2 inhibited the autoactivation of X promoter by HBx and basal transcription mediated by AP-1. Since the binding sites of AP-1 and ATF2 in the hepatitis B virus E element overlap, the repression of X promoter activity by ATF2 is everted by the competition for the AP-1 binding site and the formation of the ATF2-Jun heterodimer as in the casa of the consensus AP-1 element. However, the small X promoter had a ATF2 binding site and was activated by ATF2. These results suggest that the syntheses of X proteins are differentially regulated by ATF2.	SEOUL NATL UNIV,DEPT MOL BIOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,RES CTR CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHEN M, 1994, VIROLOGY, V205, P127, DOI 10.1006/viro.1994.1627; Choi CY, 1996, EUR J BIOCHEM, V239, P579, DOI 10.1111/j.1432-1033.1996.0579u.x; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUO WT, 1991, J VIROL, V65, P6686, DOI 10.1128/JVI.65.12.6686-6692.1991; GUSTIN K, 1993, VIROLOGY, V193, P653, DOI 10.1006/viro.1993.1173; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM SH, 1992, J GEN VIROL, V73, P2421, DOI 10.1099/0022-1317-73-9-2421; KIM SK, 1994, J GEN VIROL, V75, P917, DOI 10.1099/0022-1317-75-4-917; KWEE L, 1992, J VIROL, V66, P4382, DOI 10.1128/JVI.66.7.4382-4389.1992; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; ORI A, 1994, VIROLOGY, V204, P600, DOI 10.1006/viro.1994.1574; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; Park GT, 1996, J GEN VIROL, V77, P2775, DOI 10.1099/0022-1317-77-11-2775; RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124; RIGGS P, 1992, SHORT PROTOCOLS MOL; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SCHEK N, 1991, MOL BIOL HEPATITIS B, P181; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SHIN HJ, 1995, J BIOL CHEM, V270, P11047, DOI 10.1074/jbc.270.19.11047; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOGNONI A, 1985, NUCLEIC ACIDS RES, V13, P7457, DOI 10.1093/nar/13.20.7457; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; YUH CH, 1990, J VIROL, V64, P4281, DOI 10.1128/JVI.64.9.4281-4287.1990; ZHANG P, 1993, J VIROL, V67, P1472, DOI 10.1128/JVI.67.3.1472-1481.1993; ZHENG YW, 1994, J BIOL CHEM, V269, P22593	50	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16934	16939		10.1074/jbc.272.27.16934	http://dx.doi.org/10.1074/jbc.272.27.16934			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202004	hybrid			2022-12-25	WOS:A1997XH44600036
J	Giannakakou, P; Sackett, DL; Kang, YK; Zhan, ZR; Buters, JTM; Fojo, T; Poruchynsky, MS				Giannakakou, P; Sackett, DL; Kang, YK; Zhan, ZR; Buters, JTM; Fojo, T; Poruchynsky, MS			Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; BINDING-SITE; EXCHANGEABLE GTP; MAMMALIAN-CELLS; BREAST-CANCER; ALPHA-TUBULIN; AMINO-ACIDS; TAXOL; MICROTUBULE; MECHANISM	Acquired resistance to paclitaxel can be mediated by P-glycoprotein or by alterations involving tubulin. We report two paclitaxel-resistant sublines derived from 1A9 human ovarian carcinoma cells. Single-step paclitaxel selection with verapamil yielded two clones that are resistant to paclitaxel and collaterally sensitive to vinblastine. The resistant sublines are not paclitaxel-dependent, and resistant remained stable after 3 years of drug-free culture. All cell lines accumulate [H-3]paclitaxel equally, and no MDR-1 mRNA was detected by polymerase chain reaction following reverse transcription. Total tubulin content is similar, but the polymerized fraction increased in parental but not in resistant cells following the paclitaxel addition. Purified tubulin from parental cells demonstrated paclitaxel-driven increased polymerization, in contrast to resistant cell tubulin, which did not polymerize under identical conditions. In contrast, epothilone B, an agent to which the resistant cells retained sensitivity, increased assembly. Comparable expression of beta-tubulin isotypes was found in parental and resistant cells, with predominant expression of the M40 and beta 2 isotypes. Sequence analysis demonstrated acquired mutations in the M40 isotype at nucleotide 810 (T --> G; Phe(270) --> Val) in 1A9PTX10 cells and nucleotide 1092 (G --> A; Ala(364) --> Thr) in 1A9PTX22 cells. These results identify residues beta 270 and beta 364 as important modulators of paclitaxel's interaction with tubulin.	NCI,MED BRANCH,DIV CLIN SCI,NIH,BETHESDA,MD 20892; KOREA CANC CTR HOSP,DIV HEMATOL ONCOL,SEOUL 139240,SOUTH KOREA; NCI,MOL CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Korea (NCC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Buters, Jeroen T/G-5070-2011; BUTERS, JEROEN/AAF-6949-2020	Buters, Jeroen/0000-0003-3581-5472				BAI R, 1990, J BIOL CHEM, V265, P17141; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BOLLAG DM, 1995, CANCER RES, V55, P2325; CABRAL F, 1989, FASEB J, V3, P1593, DOI 10.1096/fasebj.3.5.2646163; CABRAL F, 1981, P NATL ACAD SCI-BIOL, V78, P4388, DOI 10.1073/pnas.78.7.4388; CABRAL FR, 1986, ANN NY ACAD SCI, V466, P745, DOI 10.1111/j.1749-6632.1986.tb38456.x; CHAUDHARY AG, 1994, J AM CHEM SOC, V116, P4097, DOI 10.1021/ja00088a063; CHEN YN, 1990, J BIOL CHEM, V265, P10073; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Dumontet C, 1996, CANCER RES, V56, P1091; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; Haber M, 1995, J BIOL CHEM, V270, P31269, DOI 10.1074/jbc.270.52.31269; HAMEL E, 1992, PHARMACOL THERAPEUT, V55, P31, DOI 10.1016/0163-7258(92)90028-X; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Horwitz Susan Band, 1993, Journal of the National Cancer Institute Monographs, V0, P55; Hyams J. S, 1993, MICROTUBULES; Jaffrezou JP, 1995, ONCOL RES, V7, P517; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; LEWIS SA, 1987, CELL, V49, P539, DOI 10.1016/0092-8674(87)90456-9; LEWIS SA, 1985, J MOL BIOL, V182, P11, DOI 10.1016/0022-2836(85)90023-3; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OHTA S, 1994, JPN J CANCER RES, V85, P290, DOI 10.1111/j.1349-7006.1994.tb02096.x; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PRATT WB, 1994, ANTI-CANCER DRUG, P50; Rai SS, 1996, J BIOL CHEM, V271, P14707, DOI 10.1074/jbc.271.25.14707; Ranganathan S, 1996, CANCER RES, V56, P2584; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SACKETT DL, 1995, BIOCHEMISTRY-US, V34, P7010, DOI 10.1021/bi00021a012; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; Sackett DL, 1997, CANCER CHEMOTH PHARM, V40, P228, DOI 10.1007/s002800050651; SACKETT DL, 1986, J BIOL CHEM, V261, P9070; SACKETT DL, 1995, ANAL BIOCHEM, V228, P343, DOI 10.1006/abio.1995.1361; SACKETT DL, 1995, PROTEIN-STRUCT FUNCT, P255; SAWADA T, 1993, BIOCHEM PHARMACOL, V45, P1387; SCHIBLER MJ, 1989, FASEB J, V3, P163, DOI 10.1096/fasebj.3.2.2563346; SCHIBLER MJ, 1986, J CELL BIOL, V102, P1522, DOI 10.1083/jcb.102.4.1522; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WILDE CD, 1982, NATURE, V297, P83, DOI 10.1038/297083a0	53	626	661	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17118	17125		10.1074/jbc.272.27.17118	http://dx.doi.org/10.1074/jbc.272.27.17118			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202030	Green Published, hybrid			2022-12-25	WOS:A1997XH44600062
J	Marhin, WW; Chen, SJ; Facchini, LM; Fornace, AJ; Penn, LZ				Marhin, WW; Chen, SJ; Facchini, LM; Fornace, AJ; Penn, LZ			Myc represses the growth arrest gene gadd45	ONCOGENE			English	Article						gadd45; Myc; cell cycle; p53; growth arrest	HUMAN C-MYC; ENHANCER-BINDING-PROTEIN; DNA-DAMAGING AGENTS; CELL-CYCLE ARREST; LARGE T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; MAMMALIAN-CELLS; IN-VIVO; EXPRESSION	The c-Myc protein strongly stimulates cellular proliferation, inducing cells to exit G0/G1 and enter the cell cycle. At a molecular level, Myc prevents growth arrest and drives cell cycle progression through the transcriptional regulation of Myc-target genes. Expression of the growth arrest and DNA damage inducible gene 45 (gadd45) is elevated in response to DNA damaging agents, such as ionizing radiation via a p53-dependent mechanism, upon nutrient deprivation, or during differentiation. Gadd35 holds a vital role in growth arrest as ectopic expression confers a strong block to proliferation. Exposure of quiescent cells to mitogen stimulates a rapid increase in c-Myc expression which is followed by the subsequent reduction in gadd45 expression. The kinetics of these two regulatory events suggest that Myc suppresses the expression of gadd45, contributing to G0/G1 phase exit of the cell cycle. Indeed, ectopic Myc expression in primary and immortalized fibroblasts results in the suppression of gadd45 mRNA levels, by a mechanism which is independent of cell cycle progression. Using an inducible MycER(TM) system, rapid suppression of gadd45 mRNA is first evident approximately 0.5 h following Myc activation. The reduction in gadd45 mRNA. expression occurs at the transcriptional level and is mediated by a p53-independent pathway. Moreover, Myc suppression and p53 induction of gadd45 following exposure to ionizing radiation are noncompetitive co-regulatory events. Myc suppression of gadd45 defines a novel pathway through which Myc promotes cell cycle entry and prevents growth arrest of transformed cells.	UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Penn, Linda/0000-0001-8133-5459				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ANTONSON P, 1995, EUR J BIOCHEM, V232, P397, DOI 10.1111/j.1432-1033.1995.tb20824.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CHEN IT, 1995, ONCOGENE, V11, P1931; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Constance CM, 1996, MOL CELL BIOL, V16, P3878; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DEAN M, 1986, J BIOL CHEM, V261, P9161; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HALL PA, 1995, ONCOGENE, V10, P2427; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JACKMAN J, 1994, CANCER RES, V54, P5656; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG D, 1993, ONCOGENE, V8, P2805; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANIA L, 1980, VIROLOGY, V101, P217, DOI 10.1016/0042-6822(80)90497-3; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lenahan MK, 1996, ONCOGENE, V12, P1847; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUCAS JM, 1993, BIOCHEM BIOPH RES CO, V194, P1446, DOI 10.1006/bbrc.1993.1987; MARHIN MW, 1996, ONCOGENE, V12, P43; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Papathanasiou M A, 1991, Cancer Treat Res, V57, P13; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; Vairapandi M, 1996, ONCOGENE, V12, P2579; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WATERS CM, 1991, ONCOGENE, V6, P797; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WEIR L, 1995, J BIOL CHEM, V270, P5457, DOI 10.1074/jbc.270.10.5457; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	83	133	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2825	2834		10.1038/sj.onc.1201138	http://dx.doi.org/10.1038/sj.onc.1201138			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190899				2022-12-25	WOS:A1997XD64300011
J	Sachdev, S; Diehl, JA; McKinsey, TA; Hans, A; Hannink, M				Sachdev, S; Diehl, JA; McKinsey, TA; Hans, A; Hannink, M			A threshold nuclear level of the v-Rel oncoprotein is required for transformation of avian lymphocytes	ONCOGENE			English	Article						Rel/NF-kappa B transcription factors; I kappa B; nuclear import; nuclear export; oncogenesis	NF-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-NECROSIS-FACTOR; CHICKEN SPLEEN-CELLS; TATA-BINDING PROTEIN; RETICULOENDOTHELIOSIS VIRUS; DNA-BINDING; C-REL; TRANSCRIPTIONAL ACTIVATION; CYTOPLASMIC RETENTION	The net distribution of eukaryotic transcription factors between the cytoplasm and the nucleus provides an effective mechanism for controlling gene expression. We have utilized cis-acting signals for both nuclear import and nuclear export to experimentally manipulate the distribution of the v-Rel oncoprotein between the nucleus and the cytoplasm. The respective abilities of the v-Rel oncoprotein to localize to the nucleus in chicken embryo fibroblasts, to activate kappa B-dependent transcription in yeast, and to transform avian lymphoid cells were each markedly reduced by the fusion of a cis-acting nuclear export signal onto v-Rel. Our results demonstrate that a threshold nuclear function of v-Rel is required for manifestation of its oncogenic properties. In contrast, while increased expression of the avian I kappa B-alpha protein was able to prevent nuclear localization of v-Rel in chicken embryo fibroblasts, coexpression of I kappa B-alpha with v-Rel in the target cell for v-Rel mediated transformation did not reduce the ability of v-Rel to transform avian lymphoid cells or alter the distribution of v-Rel between the nucleus and the cytoplasm in v-Rel-transformed cells. Our results suggest that the ability of I kappa B-alpha to inhibit nuclear localization of v-Rel is affected by cell-type specific differences between fibroblasts and lymphoid cells.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NCI NIH HHS [CA55027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GELINAS C, 1988, ONCOGENE, V3, P349; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1996, IN PRESS ONCOGENE; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MICHAEL WM, 1995, CELL, V83, P415; MILLER CK, 1988, J VIROL, V62, P1219, DOI 10.1128/JVI.62.4.1219-1226.1988; MILLER CK, 1986, J VIROL, V58, P75, DOI 10.1128/JVI.58.1.75-80.1986; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; SACHDEV S, 1995, ONCOGENE, V11, P811; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TZEN CY, 1994, EXP CELL RES, V211, P6; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	66	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2585	2594		10.1038/sj.onc.1201108	http://dx.doi.org/10.1038/sj.onc.1201108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191058				2022-12-25	WOS:A1997XA94900010
J	Lubec, B; Marx, M; HerreraMarschitz, M; Labudova, O; Hoeger, H; Gille, L; Nohl, H; Mosgoeller, W; Lubec, G				Lubec, B; Marx, M; HerreraMarschitz, M; Labudova, O; Hoeger, H; Gille, L; Nohl, H; Mosgoeller, W; Lubec, G			Decrease of heart protein kinase C and cyclin-dependent kinase precedes death in perinatal asphyxia of the rat	FASEB JOURNAL			English	Article						neonatal; oxidative stress; antioxidant enzymes; superoxide dismutase; catalase; glutathione peroxidase; lipid peroxidation; malondialdehyde; protein carbonyls; electron spin resonance	TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; BRAIN ISCHEMIA; IN-VITRO; PHOSPHORYLATION; OXIDATION; ACIDOSIS; CELL; DYSFUNCTION	Acidosis, energy depletion, overstimulation by excitatory amino acids, and free radical-mediated reactions are the major current concepts for the explanation of damage and death resulting from asphyxia. Impaired phosphorylation by protein kinase C (PKC) represents another mechanism incriminated for cell death. We used an unsophisticated perinatal asphyxia model to study heart protein kinases PKC and cyclin dependent kinase (CDK). Tissue pH, ATP, the antioxidant enzymes superoxide dismutase, catalase, and glutathion peroxidase, Lipid peroxidation products, carbonyls, and aromatic hydroxylation were also tested. Electron spin resonance was applied to demonstrate the possible presence of radical adducts. An ELISA method was used to determine cell death. PKC activity and mRNA decreased with the length of the asphyctic periods and were paralleled by CDK and pH, whereas cell death gradually increased. No evidence was found for the involvement of active oxygen species or a radical adduct, and no energy depletion was observed. We conclude that impaired protein phosphorylation and/or acidosis may play a role in the pathobiochemistry of death from perinatal asphyxia in the rat.	UNIV VIENNA,DEPT PEDIAT,DIV NEONATOL,A-1090 VIENNA,AUSTRIA; KAROLINSKA INST,DEPT PHARMACOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST ANIM BREEDING,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT PHARMACOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT HISTOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna; University of Vienna				Lubec, Gert/0000-0002-6333-9461; Mosgoller, Wilhelm/0000-0003-1436-1504				ARONOWSKI J, 1992, J NEUROCHEM, V58, P1743, DOI 10.1111/j.1471-4159.1992.tb10049.x; Baran H, 1996, LIFE SCI, V58, P1891, DOI 10.1016/0024-3205(96)00173-7; BARKS JDE, 1992, BRAIN PATHOL, V2, P235, DOI 10.1111/j.1750-3639.1992.tb00697.x; BATIST G, 1989, CIRCULATION, V80, P10; BJELKE B, 1991, BRAIN RES, V543, P1, DOI 10.1016/0006-8993(91)91041-X; BOLLI R, 1987, AM J PHYSIOL, V253, pH1372, DOI 10.1152/ajpheart.1987.253.6.H1372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUSTO R, 1994, J NEUROCHEM, V63, P1095; CARDELL M, 1990, NEUROSCI LETT, V119, P228, DOI 10.1016/0304-3940(90)90840-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Cohen MV, 1996, ANNU REV MED, V47, P21, DOI 10.1146/annurev.med.47.1.21; COVA D, 1992, FREE RADICAL RES COM, V15, P353, DOI 10.3109/10715769209049151; DELLANNA E, 1995, EXP NEUROL, V131, P279, DOI 10.1016/0014-4886(95)90050-0; DELLANNA E, IN PRESS EXP BRAIN R; DELLANNA ME, 1995, EXP NEUROL, V131, P144, DOI 10.1016/0014-4886(95)90016-0; DOMANSKAJANIK K, 1992, J NEUROCHEM, V58, P1432, DOI 10.1111/j.1471-4159.1992.tb11360.x; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; GOPLERUD JM, 1995, BRAIN RES, V696, P161, DOI 10.1016/0006-8993(95)00861-J; HARA H, 1990, NEUROSCI LETT, V120, P120, DOI 10.1016/0304-3940(90)90183-A; Hayn M, 1996, LIFE SCI, V59, P537, DOI 10.1016/0024-3205(96)00334-7; Henry P, 1996, CIRC RES, V78, P161, DOI 10.1161/01.RES.78.1.161; HERRERAMARSCHITZ M, 1994, MOL NEUROBIOL, V9, P171, DOI 10.1007/BF02816117; Hu KL, 1996, CIRC RES, V78, P492, DOI 10.1161/01.RES.78.3.492; HU YRF, 1993, NEUROCHEM RES, V18, P1003; INGWALL JS, 1975, P NATL ACAD SCI USA, V72, P2809, DOI 10.1073/pnas.72.7.2809; JAHNEL U, 1992, N-S ARCH PHARMACOL, V346, P665; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Kwak BR, 1996, MOL CELL BIOCHEM, V157, P93; LEIST M, 1994, J IMMUNOL, V153, P1778; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1993, FASEB J, V7, P1242, DOI 10.1096/fasebj.7.13.8405809; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOUIS JC, 1988, J BIOL CHEM, V263, P19282; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lubec B, 1996, FREE RADICAL BIO MED, V21, P219, DOI 10.1016/0891-5849(96)00018-4; Lubec B, 1996, CIRCULATION, V94, P2620, DOI 10.1161/01.CIR.94.10.2620; LUBEC G, 1994, FASEB J, V8, P1166, DOI 10.1096/fasebj.8.14.7958623; Lubec G, 1996, J INVEST MED, V44, P324; MAYER RJ, 1987, CELL MOL BIOL, P259; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MELLONI E, 1985, P NATL ACAD SCI USA, V82, P6435, DOI 10.1073/pnas.82.19.6435; MITCHELL MB, 1995, CIRC RES, V76, P73, DOI 10.1161/01.RES.76.1.73; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ODONNELL BR, 1994, STROKE, V25, P171, DOI 10.1161/01.STR.25.1.171; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PUCEAT M, 1996, MOL CELL BIOCHEM, V157, P655; QU Y, 1992, CAN J PHYSIOL PHARM, V70, P1230, DOI 10.1139/y92-171; REHNCRONA S, 1980, ACTA PHYSIOL SCAND, V110, P435, DOI 10.1111/j.1748-1716.1980.tb06692.x; Rehring TF, 1996, J SURG RES, V63, P324, DOI 10.1006/jsre.1996.0269; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Shuba LM, 1996, BRIT J PHARMACOL, V117, P1395, DOI 10.1111/j.1476-5381.1996.tb15298.x; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIESJO BK, 1990, STROKE, V21, P194; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPEECHLYDICK ME, 1995, CIRC RES, V77, P1030, DOI 10.1161/01.RES.77.5.1030; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; TSAO PS, 1990, AM J PHYSIOL, V259, pH1660, DOI 10.1152/ajpheart.1990.259.6.H1660; WALTHER FJ, 1985, J PEDIATR-US, V107, P781, DOI 10.1016/S0022-3476(85)80417-0; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WIELOCH T, 1991, J NEUROCHEM, V56, P1227, DOI 10.1111/j.1471-4159.1991.tb11415.x; WONG SHY, 1987, CLIN CHEM, V33, P214	65	29	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					482	492		10.1096/fasebj.11.6.9194529	http://dx.doi.org/10.1096/fasebj.11.6.9194529			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194529				2022-12-25	WOS:A1997XE40400011
J	Babichuk, CK; Bleackley, RC				Babichuk, CK; Bleackley, RC			Mutational analysis of the murine granzyme B gene promoter in primary T cells and a T cell clone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; CORE-BINDING-FACTOR; C-JUN; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; REGULATORY ELEMENTS; BETA-SUBUNITS; ACTIVATION; EXPRESSION	The granzyme B gene is induced in cytotoxic T lymphocytes in response to antigenic stimulation. Previous studies have identified several distinct regions in the granzyme B promoter which may be important in either the induction or the T cell specificity of the gene. These regions contain the canonical transcription factor binding sites AP1, cyclic AMP-responsive element (CRE), Ikaros, and core-binding factor (CBF/PEBP2). Each protein binding site was disrupted by site-directed mutagenesis to investigate its role in granzyme B promoter function. Mutations were introduced alone, or in various combinations, within the context of a 243-base pair promoter fragment known to confer high levels of reporter gene expression. Transfection assays revealed that all of the single binding site mutant promoters were capable of sustaining moderate to high levels of transcriptional activity in primary activated T lymphocytes, whereas certain mutants were more impeded in a T cell clone. A quadruple mutant promoter, with only the CRE binding site intact, showed background expression levels. This drop in expression was found to be mostly due to mutations in AP1 and the 3' CBF binding sites. Their close proximity and requirement in promoter function suggest an important role for protein-protein interaction between these two factors.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								Atkinson EA, 1995, CRIT REV IMMUNOL, V15, P359, DOI 10.1615/CritRevImmunol.v15.i3-4.90; Babichuk CK, 1996, J BIOL CHEM, V271, P16485, DOI 10.1074/jbc.271.28.16485; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BLEACKLEY RC, 1982, J IMMUNOL, V128, P758; CHIEN YH, 1993, IMMUNOL TODAY, V14, P597, DOI 10.1016/0167-5699(93)90199-U; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; FREGEAU CJ, 1991, NUCLEIC ACIDS RES, V19, P5583; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; HADDAD P, 1993, EUR J IMMUNOL, V23, P625, DOI 10.1002/eji.1830230307; HANSON RD, 1993, BLOOD, V9, P2749; HAVELE C, 1986, J IMMUNOL, V137, P1448; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIU CC, 1995, IMMUNOL TODAY, V16, P194, DOI 10.1016/0167-5699(95)80121-9; LIU CC, 1989, J EXP MED, V170, P2105, DOI 10.1084/jem.170.6.2105; LU J, 1995, MOL CELL BIOL, V15, P1651; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1666; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SMYTH MJ, 1990, J EXP MED, V171, P1269, DOI 10.1084/jem.171.4.1269; Taylor DS, 1996, J BIOL CHEM, V271, P14020, DOI 10.1074/jbc.271.24.14020; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	38	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18564	18571		10.1074/jbc.272.30.18564	http://dx.doi.org/10.1074/jbc.272.30.18564			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228022	hybrid			2022-12-25	WOS:A1997XM34200013
J	Kaplan, MD; Olschowka, JA; OBanion, MK				Kaplan, MD; Olschowka, JA; OBanion, MK			Cyclooxygenase-1 behaves as a delayed response gene in PC12 cells differentiated by nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; MESSENGER-RNA; NEURONAL DIFFERENTIATION; PHORBOL ESTER; INDUCTION; EXPRESSION; TRANSCRIPTION; GLUCOCORTICOIDS; SYNTHASE-2; CLONING	Treatment of PC12 cells with nerve growth factor (NGF) results in a differentiation program characterized by expression of immediate early and delayed response genes. In this program, morphological changes such as neurite extension are accompanied by phenotypic changes in enzyme expression, including an in creased capacity for prostaglandin synthesis. Cyclooxygenase (COX), the enzyme responsible for prostanoid production, exists as two isoforms: constitutive COX-1 and inducible COX-2. We report that COX-1 behaves as a delayed response gene in PC12 cells exposed to NGF. Six hours following NGF treatment, COX-1 mRNA levels were elevated in PC12 cells, reaching nearly B-fold above basal levels at 12 h. This increase was blocked by cycloheximide and was accompanied by concomitant increases in COX-1 protein and enzyme activity, COX-1 protein remained elevated for at least 10 days and localized to the cytoplasm and neurites of NGF-differentiated PC12 cells. Moreover, basic fibroblast growth factor, but not epidermal growth factor, caused similar increases in COX-1, which is consistent with expression characteristics of other delayed response genes in PC12 cells. This is the first example of neurotrophic factor regulation of cyclooxygenase and may have important implications for determination of the differentiated phenotype in PC12 cells.	UNIV ROCHESTER, SCH MED & DENT, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT NEUROL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				O'Banion, M. Kerry/0000-0003-1246-3363	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K16DE000159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG009016] Funding Source: NIH RePORTER; NIA NIH HHS [LEAD AG09016] Funding Source: Medline; NIDCR NIH HHS [K16 DE00159] Funding Source: Medline; NINDS NIH HHS [R29 NS33553] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DEGEORGE JJ, 1988, J NEUROSCI RES, V21, P323, DOI 10.1002/jnr.490210225; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; HERSCHMAN HR, 1995, ADV PROSTAG THROMB L, V23, P23; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; KUJUBU DA, 1987, ONCOGENE, V1, P257; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LI XM, 1994, NEUROCHEM RES, V19, P591, DOI 10.1007/BF00971335; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; OBanion MK, 1996, J NEUROCHEM, V66, P2532; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SALTON SRJ, 1991, MOL CELL BIOL, V11, P2335, DOI 10.1128/MCB.11.5.2335; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; VANE JR, 1995, ADV PROSTAG THROMB L, V23, P41; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	30	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18534	18537		10.1074/jbc.272.30.18534	http://dx.doi.org/10.1074/jbc.272.30.18534			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228016	hybrid			2022-12-25	WOS:A1997XM34200007
J	Ni, L; Sheikh, S; Weiner, H				Ni, L; Sheikh, S; Weiner, H			Involvement of glutamate 399 and lysine 192 in the mechanism of human liver mitochondrial aldehyde dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; PURIFICATION; RAT; EXPRESSION; MG-2+	Mutation to the conserved Glu(399) Or Lys(192) caused the rate-limiting step of human liver mitochondrial aldehyde dehydrogenase (ALDH2) to change from deacylation to hydride transfer (Sheikh, S., Ni, L., Hurley, T, D,, and Weiner, H. (1997) J. Biol. Chem. 272, 18817-18822), Here we further investigated the role of these two NAD(+)-ribose-binding residues. The E399Q/K/H/D and K192Q mutants had lower dehydrogenase activity when compared with the native enzyme, No pre-steady state burst of NADH formation was found with the E399Q/K and R192Q enzymes when propionaldehyde was used as the substrate; furthermore, each mutant oxidized chloroacetaldehyde slower than propionaldehyde, and a primary isotope effect was observed for each mutant when [H-2]acetaldehyde was used as a substrate, However, no isotope effect was observed for each mutant when alpha-[H-2]benzaldehyde was the substrate, A pre-steady state burst of NADH formation was observed for the E399Q/H and R192Q mutants with benzaldehyde, and p-nitrobenzaldehyde was oxidized faster than benzaldehyde. Hence, when aromatic aldehydes were used as substrates, the rate-limiting step remained deacylation for all these mutants, The rate-limiting step remained deacylation for the E399H/D mutants when either aliphatic or aromatic aldehydes were used as substrates, The K192Q mutant displayed a change in substrate specificity, with aromatic aldehydes becoming better substrates than aliphatic aldehydes.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; FARRES J, 1994, J BIOL CHEM, V269, P13854; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FELDMAN RI, 1972, J BIOL CHEM, V247, P260; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; GUAN KL, 1988, ALCOHOL CLIN EXP RES, V12, P713, DOI 10.1111/j.1530-0277.1988.tb00270.x; JENG JJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P214, DOI 10.1016/0003-9861(91)90464-T; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4457, DOI 10.1021/bi9521102; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sheikh S, 1997, J BIOL CHEM, V272, P18817, DOI 10.1074/jbc.272.30.18817; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P2720, DOI 10.1021/bi00513a003; TAKAHASHI K, 1980, J BIOL CHEM, V255, P8206; VALLARI RC, 1984, J BIOL CHEM, V259, P4927; VALLARI RC, 1984, J BIOL CHEM, V259, P4922; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	18	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18823	18826		10.1074/jbc.272.30.18823	http://dx.doi.org/10.1074/jbc.272.30.18823			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228057	hybrid			2022-12-25	WOS:A1997XM34200048
J	Che, WY; Asahi, M; Takahashi, M; Kaneto, H; Okado, A; Higashiyama, S; Taniguchi, N				Che, WY; Asahi, M; Takahashi, M; Kaneto, H; Okado, A; Higashiyama, S; Taniguchi, N			Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells - The involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; DIPHTHERIA-TOXIN RECEPTOR; FACTOR MESSENGER-RNA; GLYOXALASE SYSTEM; MAILLARD REACTION; FACTOR EXPRESSION; N-ACETYLCYSTEINE; ANGIOTENSIN-II; PROTEIN-KINASE; FREE-RADICALS	Methylglyoxal (MG) and 3-deoxyglucosone (3-DG), reactive dicarbonyl metabolites in the glyoxalase system and glycation reaction, respectively, selectively induced heparin-binding epidermal growth factor (HB-EGF)-like growth factor mRNA in a dose- and time-dependent manner in rat aortic smooth muscle cells (RASMC). A nuclear run-on assay revealed that the dicarbonyl may regulate expression of HB-EGF at the transcription level. The dicarbonyl also increased the secretion of HB-EGF from RASMC. However, platelet-derived growth factor, another known growth factor of smooth muscle cells (SMC), was not induced by both dicarbonyls. The dicarbonyl augmented intracellular peroxides prior to the induction of HB-EGF mRNA as judged by flow cytometric analysis using 2',7'-dichlorofluorescin diacetate. N-acetyl-L-cysteine and aminoguanidine suppressed both dicarbonyl-increased HB-EGF mRNA and intracellular peroxide levels in RASMC. DL-Buthionine-(S,R)-sulfoximine increased the levels of 3-DG-induced HB-FGF mRNA. Furthermore, hydrogen peroxide alone also induced HB-EGF mRNA in RASMC. These results indicate that MG and 3-DG induce HB-EGF by increasing the intracellular peroxide levels. In addition, the pretreatment with 12-O-tetra-decanoylphorbol-13-acetate failed to alter dicarbonyl-induced HB-EGF mRNA expression in RASMC, suggesting that the signal transducing mechanism is not mediated by protein kinase C. Since HB-EGF is known as a potent mitogen for smooth muscle cells and is abundant in atherosclerotic plaques, the induction of HB-EGF by MG and 3-DG, as well as the concomitant increment of intracellular peroxides, may trigger atherogenesis during diabetes.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University			Taniguchi, Naoyuki/I-4182-2014; Takahashi, Motoko/I-3154-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Takahashi, Motoko/0000-0002-2112-6142				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BASS DA, 1983, J IMMUNOL, V130, P1910; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD D, 1988, ONCOGENE, V3, P27; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; FUKUDA K, 1995, ARTERIOSCL THROM VAS, V15, P1680, DOI 10.1161/01.ATV.15.10.1680; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; KALAPOS MP, 1993, ARCH TOXICOL, V67, P369, DOI 10.1007/BF01973710; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KHADEM HE, 1971, CARBOHYD RES, V17, P183; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LIBBY P, 1991, LAB INVEST, V64, P5; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LYLES GA, 1992, BIOCHEM PHARMACOL, V43, P1409, DOI 10.1016/0006-2952(92)90196-P; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; MEISTER A, 1986, J AM COLL NUTR, V5, P137; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; NAKANO T, 1993, J BIOL CHEM, V268, P22941; NIWA T, 1993, BIOCHEM BIOPH RES CO, V196, P837, DOI 10.1006/bbrc.1993.2325; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; Okado A, 1996, BIOCHEM BIOPH RES CO, V225, P219, DOI 10.1006/bbrc.1996.1157; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; Phillips Susan A., 1993, Biochemical Society Transactions, V21, p163S; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Selwood Trevor, 1993, Biochemical Society Transactions, V21, p170S; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI M, 1993, GENE, V127, P249, DOI 10.1016/0378-1119(93)90728-L; Taniguchi N, 1996, DIABETES, V45, pS81, DOI 10.2337/diab.45.3.S81; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; VALENTE AJ, 1988, J CELL PHYSIOL, V136, P479, DOI 10.1002/jcp.1041360312; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; YAMADA H, 1994, J BIOL CHEM, V269, P20275; YIM HS, 1995, J BIOL CHEM, V270, P28228	57	99	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18453	18459		10.1074/jbc.272.29.18453	http://dx.doi.org/10.1074/jbc.272.29.18453			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218489	hybrid			2022-12-25	WOS:A1997XL73500079
J	Clark, AF; Sharp, MGF; Morley, SD; Fleming, S; Peters, J; Mullins, JJ				Clark, AF; Sharp, MGF; Morley, SD; Fleming, S; Peters, J; Mullins, JJ			Renin-1 is essential for normal renal juxtaglomerular cell granulation and macula densa morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED SECRETORY PATHWAY; PITUITARY ATT-20 CELLS; ANGIOTENSIN-II; DEFICIENT MICE; BLOOD-PRESSURE; MOUSE; GENE; EXPRESSION; GLAND; HYPOTENSION	The secretion of renin from granules stored in renal juxtaglomerular cells plays a key role in blood pressure homeostasis. The synthesis and release of renin and the extent of granulation is regulated by several mechanisms including signaling from the macula densa, neuronal input, and blood pressure. Through the use of a gene-targeting vector containing homology arms generated using the polymerase chain reaction, we have inactivated the Ren-1(d) gene, one of two mouse genes encoding renin, and report that lack of renin-1(d) results in altered morphology of the macula densa of the kidney distal tubule and complete absence of juxtaglomerular cell granulation. Furthermore, Ren-1(d-/-) mice exhibit sexually dimorphic hypotension. The altered growth morphology of the macula densa in Ren-1(d)-null mice should provide a tool for the investigation of the JG cell-macula densa signaling. Furthermore, the current data indicate that expression of the Ren-1(d) gene is a prerequisite for the formation of storage granules, even though the related protein renin-2 is present in these mice, suggesting that renin-1(d) and renin-2 are secreted by distinct pathways in vivo.	UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV HEIDELBERG,DEPT PHARMACOL,D-69120 HEIDELBERG,GERMANY	University of Edinburgh; University of Edinburgh; Ruprecht Karls University Heidelberg			Morley, Steve/AAY-9985-2020	Morley, Steven/0000-0002-7355-3349				ABEL KJ, 1990, GENETICS, V124, P937; BING J, 1980, J HISTOCHEM CYTOCHEM, V28, P874, DOI 10.1177/28.8.7003007; Briggs JP, 1996, KIDNEY INT, V49, P1724, DOI 10.1038/ki.1996.255; CHIDGEY MAJ, 1990, EUR J BIOCHEM, V190, P139, DOI 10.1111/j.1432-1033.1990.tb15556.x; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; DICKINSON DP, 1984, GENETICS, V108, P651; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; HERMANN K, 1988, CLIN CHEM, V34, P1046; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KING JA, 1993, AM J PHYSIOL, V265, pC305, DOI 10.1152/ajpcell.1993.265.2.C305; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; LADENHEIM RG, 1991, EUR J BIOCHEM, V198, P535, DOI 10.1111/j.1432-1033.1991.tb16047.x; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0; Matsusaka T, 1996, J CLIN INVEST, V98, P1867, DOI 10.1172/JCI118988; MILLER CCJ, 1992, P NATL ACAD SCI USA, V89, P5020, DOI 10.1073/pnas.89.11.5020; MILLER CCJ, 1989, NUCLEIC ACIDS RES, V17, P3117, DOI 10.1093/nar/17.8.3117; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; PETERS J, 1993, J CLIN INVEST, V91, P742, DOI 10.1172/JCI116292; PRATT RE, 1987, P NATL ACAD SCI USA, V84, P7837, DOI 10.1073/pnas.84.22.7837; PRATT RE, 1988, J BIOL CHEM, V263, P3137; PRATT RE, 1988, ENDOCRINOLOGY, V123, P1721, DOI 10.1210/endo-123-4-1721; SCHELLING P, 1980, NEUROENDOCRINOLOGY, V31, P297, DOI 10.1159/000123092; SHARP MGF, 1996, HYPERTENSION, V26, P1126; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SKOTT O, 1987, SCIENCE, V237, P1618, DOI 10.1126/science.3306925; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Taugner R, 1989, JUXTAGLOMERULAR APPA; VILLARD E, 1994, J BIOL CHEM, V269, P30307	34	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18185	18190		10.1074/jbc.272.29.18185	http://dx.doi.org/10.1074/jbc.272.29.18185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218454	hybrid			2022-12-25	WOS:A1997XL73500044
J	Flanagan, SA; MecklingGill, KA				Flanagan, SA; MecklingGill, KA			Characterization of a novel Na+-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; INTESTINAL EPITHELIAL-CELLS; CHORIOCARCINOMA BEWO CELLS; PROTEIN-KINASE-C; NUCLEOSIDE-TRANSPORT; URIDINE-TRANSPORT; HL-60 LEUKEMIA; MAMMALIAN-CELLS; MONOCYTIC DIFFERENTIATION; HUMAN-ERYTHROCYTES	NB4 cells are the only bona fide in vitro model of human acute promyelocytic leukemia. We have examined cytidine and guanosine transport in this cell fine and characterized a novel guanosine-specific transporter. Cytidine transport occurred predominately by equilibrative nitrobenzylthioinosine (NBMPR)-sensitive (es) transport, In the presence of Na+, guanosine at various concentrations accumulated at lease 6-fold above equilibrium. Th initial rate of guanosine transport in Na+ buffer decreased by 75% with the addition of 1 mu M NBMPR and the IC50 for NBMPR inhibition was 0.7 +/- 0.1 mM. Replacement of Na+ with choline also resulted in a 75% decrease in total guanosine transport, Tbe potent inhibition of guanosine transport by NBMPR and the loss of transport in choline suggested that a Na+-dependent NBMPR-sensitive transporter was responsible for the majority of guanosine uptake, This concentrative, sensitive transporter is Na+ dependent with a stoichiometric coupling ratio of 1:1. This novel transporter, referred to as csg, is guanosine-specific with total guanosine transport inhibited by only 50% in the presence of 1 mM competing nucleosides, HL-60, acute myelocytic leukemia cells, do not exhibit csg activity while L1210, murine acute lymphocytic leukemia cells, exhibit csg transport, The presence of the csg transporter suggests an important role for guanosine in particular forms of leukemia and may provide a new target for cytotoxic therapy.	UNIV GUELPH, DEPT HUMAN BIOL & NUTR SCI, GUELPH, ON N1G 2W1, CANADA	University of Guelph								BELT JA, 1983, MOL PHARMACOL, V24, P479; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131; BHATIA M, 1994, LEUKEMIA, V8, P1744; BOUMAH CE, 1992, BIOCHEM J, V288, P987, DOI 10.1042/bj2880987; BURRES NS, 1986, J CELL PHYSIOL, V128, P375, DOI 10.1002/jcp.1041280305; CARVER JD, 1995, J NUTR BIOCHEM, V6, P58, DOI 10.1016/0955-2863(94)00019-I; CASS CE, 1974, BIOCHIM BIOPHYS ACTA, V345, P1, DOI 10.1016/0005-2736(74)90239-9; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHEN SF, 1986, CANCER RES, V46, P3449; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; DALTON WT, 1988, BLOOD, V71, P242; FIDEU MD, 1993, CELL MOL NEUROBIOL, V13, P493, DOI 10.1007/BF00711458; FOX IH, 1978, ANNU REV BIOCHEM, V47, P655, DOI 10.1146/annurev.bi.47.070178.003255; GATI WP, 1989, BIOCHEM J, V263, P957, DOI 10.1042/bj2630957; GATI WP, 1989, RED BLOOD CELL MEMBR, P635; GOH LB, 1993, BIOCHEM J, V294, P693, DOI 10.1042/bj2940693; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; JACKSON RC, 1980, CANCER RES, V40, P1286; JAKOBS ES, 1990, J BIOL CHEM, V265, P22210; JARVIS SM, 1982, BIOCHEM J, V208, P83, DOI 10.1042/bj2080083; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; JARVIS SM, 1980, BIOCHEM J, V190, P377, DOI 10.1042/bj1900377; JARVIS SM, 1989, BIOCHEM SOC T, V17, P448, DOI 10.1042/bst0170448; JONES KW, 1994, BRAIN RES, V660, P104, DOI 10.1016/0006-8993(94)90844-3; LANOTTE M, 1991, BLOOD, V77, P1080; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LEE CW, 1994, BIOCHEM J, V300, P407, DOI 10.1042/bj3000407; LEE CW, 1988, BIOCHIM BIOPHYS ACTA, V942, P139, DOI 10.1016/0005-2736(88)90283-0; MECKLINGGILL KA, 1992, BIOCHEM J, V282, P147, DOI 10.1042/bj2820147; MECKLINGGILL KA, 1993, J CELL PHYSIOL, V155, P530, DOI 10.1002/jcp.1041550311; Paterson A. R. P., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P14; PATERSON ARP, 1984, BIOCHEM J, V224, P1001, DOI 10.1042/bj2241001; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; Plagemann P.G.W., 1980, CURR TOP MEMBR TRANS, P225; PLAGEMANN PGW, 1984, BIOCHIM BIOPHYS ACTA, V773, P39, DOI 10.1016/0005-2736(84)90548-0; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; Roovers KI, 1996, J CELL PHYSIOL, V166, P593, DOI 10.1002/(SICI)1097-4652(199603)166:3<593::AID-JCP14>3.0.CO;2-8; Segel I.H., 1975, ENZYME KINETICS; SOKOLOSKI JA, 1986, CANCER RES, V46, P2314; SOKOLOSKI JA, 1991, BIOCHEM J, V280, P515, DOI 10.1042/bj2800515; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TRICOT GJ, 1987, CANCER RES, V47, P4988; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; VOET D, 1990, BIOCHEMISTRY-US, P740; WEBER G, 1988, ADV ENZYME REGUL, V27, P405, DOI 10.1016/0065-2571(88)90029-5; WILLIAMS TC, 1991, BIOCHEM J, V274, P27, DOI 10.1042/bj2740027; WOFFENDIN C, 1987, BIOCHIM BIOPHYS ACTA, V903, P18, DOI 10.1016/0005-2736(87)90151-9; WRIGHT DG, 1987, BLOOD, V69, P334; WU XC, 1992, J BIOL CHEM, V267, P8813; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	53	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18026	18032		10.1074/jbc.272.29.18026	http://dx.doi.org/10.1074/jbc.272.29.18026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218431	hybrid			2022-12-25	WOS:A1997XL73500021
J	Fraaije, MW; vanBerkel, WJH				Fraaije, MW; vanBerkel, WJH			Catalytic mechanism of the oxidative demethylation of 4-(methoxymethyl)phenol by vanillyl-alcohol oxidase - Evidence for formation of a p-quinone methide intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE OXIDASE; PENICILLIUM-SIMPLICISSIMUM; SUBSTRATE; CRESOL	The catalytic mechanism for the oxidative demethylation of 4-(methoxymethyl)phenol by the covalent flavoprotein vanillyl-alcohol oxidase was studied, Using (H2O)-O-18, it was found that the carbonylic oxygen atom from the product 4-hydroxybenzaldehyde originates from a water molecule. Oxidation of vanillyl alcohol did not result in any incorporation of O-18. Enzyme-monitored turnover experiments revealed that for both substrates a process involving flavin reduction is rate determining, During anaerobic reduction of vanillyl-alcohol oxidase by 4-(methoxymethyl)phenol, a relatively stable spectral intermediate is formed, Deconvolution of its spectral characteristics showed a typical ps-independent absorption maximum at 364 nm (epsilon(364 nm) = 46 mM(-1) cm(-1)). A similar transient species was observed upon anaerobic reduction by vanillyl alcohol. The rate of flavin reduction and synchronous intermediate formation by 4-(methoxymethyl)phenol is 3.3 s(-1) and is fast enough to account for turnover (3.1 s(-1)). The anaerobic decay of the intermediate was too slow (0.01 s(-1)) to be of catalytical relevance, The reduced binary complex is rapidly reoxidized (1.5 x 10(5) M-1 s(-1)) and is accompanied with formation and release of product. Oxidation of free-reduced enzyme is an even faster process (3.1 x 10(5) M-1 s(-1)). The kinetic data for the oxidative demethylation of 4-(methoxymethyl)phenol are in accordance with a ternary complex mechanism in which the reduction rate is rate-limiting. It is proposed that, upon reduction, a binary complex is produced composed of the p-quinone methide of 4-(methoxymethyl)phenol and reduced enzyme.	AGR UNIV WAGENINGEN,DEPT BIOCHEM,NL-6703 HA WAGENINGEN,NETHERLANDS	Wageningen University & Research			Fraaije, Marco/E-8421-2014; van Berkel, Willem J.H./O-2431-2014	van Berkel, Willem J.H./0000-0002-6551-2782; Fraaije, Marco/0000-0001-6346-5014				DEJONG E, 1992, EUR J BIOCHEM, V208, P651; DIAO L, 1995, J AM CHEM SOC, V117, P5369, DOI 10.1021/ja00124a024; FILAR LJ, 1960, TETRAHEDRON LETT, V25, P9; FRAAIJE MW, 1995, EUR J BIOCHEM, V234, P271, DOI 10.1111/j.1432-1033.1995.271_c.x; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; Fraaije MW, 1997, FEBS LETT, V402, P33, DOI 10.1016/S0014-5793(96)01494-9; FRAAIJE MW, 1997, FLAVINS FLAVOPROTEIN, V12; GEISSLER J, 1986, EUR J BIOCHEM, V160, P93, DOI 10.1111/j.1432-1033.1986.tb09944.x; GHISLA S, 1979, J BIOL CHEM, V254, P662; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; HOPPER DJ, 1976, BIOCHEM BIOPH RES CO, V69, P462, DOI 10.1016/0006-291X(76)90544-1; LEARY G, 1972, J CHEM SOC PERK T 2, P640, DOI 10.1039/p29720000640; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Mattevi A, 1997, PROTEINS, V27, P601, DOI 10.1002/(SICI)1097-0134(199704)27:4<601::AID-PROT12>3.0.CO;2-O; MENON V, 1995, BIOORG CHEM, V23, P42, DOI 10.1006/bioo.1995.1004; Palmer G, 1968, BIOL OXIDATIONS, P263; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13850; TAN AK, 1993, BIOCHEMISTRY-US, V32, P2137, DOI 10.1021/bi00060a003; THOMPSON D, 1989, J BIOL CHEM, V264, P1016; THOMPSON DC, 1995, BIOCHEM BIOPH RES CO, V209, P6, DOI 10.1006/bbrc.1995.1462; THOMPSON DC, 1995, CHEM RES TOXICOL, V8, P55, DOI 10.1021/tx00043a007; VANBERKEL WJH, 1997, Patent No. 0710289	27	72	72	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18111	18116		10.1074/jbc.272.29.18111	http://dx.doi.org/10.1074/jbc.272.29.18111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218444	Green Published, hybrid			2022-12-25	WOS:A1997XL73500034
J	Larrain, J; CizmeciSmith, G; Troncoso, V; Stahl, RC; Carey, DJ; Brandan, E				Larrain, J; CizmeciSmith, G; Troncoso, V; Stahl, RC; Carey, DJ; Brandan, E			Syndecan-1 expression is down-regulated during myoblast terminal differentiation - Modulation by growth factors and retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; HEPARAN-SULFATE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; FACTOR-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; MYOGENIC DIFFERENTIATION; MESENCHYMAL INTERACTIONS; MUSCLE DEVELOPMENT; SODIUM-BUTYRATE; BASAL LAMINA	Syndecan-1 is an integral membrane proteoglycan involved in the interaction of cells with extracellular matrix proteins and growth factors. It is transiently expressed in several condensing mesenchymal tissues after epithelial induction. In this study we evaluated the expression of syndecan-1 during skeletal muscle differentiation. The expression of syndecan-1 as determined by Northern blot analyses and immunofluorescence microscopy is down-regulated during differentiation. The transcriptional activity of a syndecan-1 promoter construct is also down-regulated in differentiating muscle cells. The decrease in syndecan-1 gene expression is not dependent on the presence of E-boxes, binding sites for the MyoD family of transcription factors in the promoter region, or myogenin expression. Deletion of the region containing the E-boxes or treatment of differentiating cells with sodium butyrate, an inhibitor of myogenin expression, had no effect on syndecan-1 expression. Basic fibroblast growth factor and transforming growth factor type beta, which are inhibitors of myogenesis, had little effect on syndecan-1 expression. When added together, however, they induced syndecan-1 expression. Retinoic acid, an inducer of myogenesis, inhibited syndecan-1 expression and abolished the effect of the growth factors. These results indicate that syndecan-1 expression is down-regulated during myogenesis and that growth factors and retinoic acid modulate syndecan-1 expression by a mechanism that is independent of myogenin.	PONTIFICIA UNIV CATOLICA CHILE, FAC CIENCIAS BIOL, DEPT BIOL CELULAR & MOL, SANTIAGO, CHILE; WEIS CTR RES, DANVILLE, PA 17822 USA	Pontificia Universidad Catolica de Chile			Brandan, Enrique/A-7063-2017	Brandan, Enrique/0000-0002-6820-5059	FIC NIH HHS [TW 00093] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOUTIN EL, 1991, DEV BIOL, V148, P63, DOI 10.1016/0012-1606(91)90317-V; BRANDAN E, 1991, EUR J CELL BIOL, V55, P209; Brandan E, 1996, EUR J CELL BIOL, V71, P170; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; CAMPOS A, 1993, EUR J BIOCHEM, V216, P587, DOI 10.1111/j.1432-1033.1993.tb18178.x; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FISZMAN MY, 1980, EXP CELL RES, V126, P31, DOI 10.1016/0014-4827(80)90467-X; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; Kainulainen V, 1996, J BIOL CHEM, V271, P18759, DOI 10.1074/jbc.271.31.18759; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; LARRAIN J, 1997, IN PRESS EXP CELL RE; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LIEBERSBACH BF, 1994, J BIOL CHEM, V269, P20013; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LUNDOLPH DC, 1995, FASEB J, V9, P1595; Melo F, 1996, J CELL BIOCHEM, V62, P227, DOI 10.1002/(SICI)1097-4644(199608)62:2<227::AID-JCB11>3.0.CO;2-I; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; MOORE JW, 1991, DEVELOPMENT, V111, P741; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAIRIO S, 1992, DEV BIOL, V152, P221; VAIRIO S, 1991, DEV BIOL, V147, P322; VANSWEARINGEN J, 1995, DEV BIOL, V170, P321, DOI 10.1006/dbio.1995.1218; Vihinen T, 1996, J BIOL CHEM, V271, P12532, DOI 10.1074/jbc.271.21.12532; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	60	69	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18418	18424		10.1074/jbc.272.29.18418	http://dx.doi.org/10.1074/jbc.272.29.18418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218485	hybrid			2022-12-25	WOS:A1997XL73500075
J	McCarthy, TL; Ji, CH; Shu, H; Casinghino, S; Crothers, K; Rotwein, P; Centrella, M				McCarthy, TL; Ji, CH; Shu, H; Casinghino, S; Crothers, K; Rotwein, P; Centrella, M			17 beta-estradiol potently suppresses cAMP-induced insulin-like growth factor-I gene activation in primary rat osteoblast cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; ESTROGEN-RECEPTOR GENE; PARATHYROID-HORMONE; OVARIECTOMIZED RATS; BONE LOSS; CANCELLOUS BONE; ENRICHED CULTURES; INTERLEUKIN-6 PRODUCTION; TRANSCRIPTIONAL CONTROL; HYPOPHYSECTOMIZED RATS	Insulin-like growth factor-I (IGF-I) is a key factor in bone remodeling. In osteoblasts, IGF-I synthesis is enhanced by parathyroid hormone and prostaglandin E-2 (PGE(2)) through cAMP-activated protein kinase. In rats, estrogen loss after ovariectomy leads to a rise in serum IGF-I and an increase in bone remodeling, both of which are reversed by estrogen treatment, To examine estrogen-dependent regulation of IGF-P expression at the molecular level, primary fetal rat osteoblasts were co-transfected with the estrogen receptor (hER, to ensure active ER expression), and luciferase reporter plasmids controlled by promoter I of the rat IGF-I gene (HGF-P PP), used exclusively in these cells, Bs reported, 1 mu M PGE(2) increased IGF-I P1 activity by 5-fold. 17 beta-Estradiol alone had no effect, but dose-dependently suppressed the stimulatory effect of PGE(2) by up to 90% (ED50 similar to-0.1 nM). This occurred within 3 In, persisted for at least 16 h, required ER, and appeared specific, since 17 alpha-estradiol was 100-300-fold less effective, By contrast, 17 beta-Estradiol stimulated estrogen response element (ERE)dependent reporter expression by up to 10-fold, 17 beta-Estradiol also suppressed an HGF-I PP. construct retaining only minimal promoter sequence required for cAMP-dependent gene activation, but did not affect the 60-fold increase in cAMP induced by PGE(2). There is no consensus ERE in rat HGF-H P1, suggesting novel downstream interactions in the cAMP pathway that normally enhances IGF-I expression ist skeletal cells, To explore this, nuclear extract from osteoblasts expressing hER were examined by electrophoretic mobility shift assay using the atypical cAMP response element in IGF-I P1. Estrogen alone did not cause DNA-protein binding, while PGE(2) induced a characteristic gel shift complex. eo-treatment with both hormones caused a gel shift greatly diminished in intensity, consistent with their combined effects on IGF-H promoter activity. Nonetheless, hER did not bind IGF-I cAMP response element or any adjacent sequences,These results provide new molecular evidence that estrogen may temper the biological effects of hormones acting through cAMP to regulate skeletal IGF-I expression and activity,.	OREGON HLTH SCI UNIV,DIV MOL MED,PORTLAND,OR 97201	Oregon Health & Science University	McCarthy, TL (corresponding author), YALE UNIV,SECT PLAST SURG,SCH MED,333 CEDAR ST,POB 208041,NEW HAVEN,CT 06520, USA.		Rotwein, Peter/R-5783-2019	Crothers, Kristina/0000-0001-9702-0371; Rotwein, Peter/0000-0002-9505-1817	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037449, R01DK047421] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37449, DK47421] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BAGI C, 1995, BONE, V16, P559, DOI 10.1016/8756-3282(95)00078-R; BAGI CM, 1994, J BONE MINER RES, V9, P1301; Baron Roland E., 1996, P3; BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; Borski RJ, 1996, ENDOCRINOLOGY, V137, P3253, DOI 10.1210/en.137.8.3253; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CANTATORE FP, 1995, CLIN RHEUMATOL, V14, P157, DOI 10.1007/BF02214935; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; DEMPSTER DW, 1995, BONE, V16, P157, DOI 10.1016/S8756-3282(94)00024-7; Diamond T, 1996, OSTEOPOROSIS INT, V6, P329, DOI 10.1007/BF01623394; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HILL PA, 1995, ENDOCRINOLOGY, V136, P124, DOI 10.1210/en.136.1.124; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; HSUEH AJW, 1989, ENDOCRINOLOGY, P1929; JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756-3282(90)90078-D; JEE WSS, 1992, BONE, V13, P153, DOI 10.1016/8756-3282(92)90005-H; Kaji H, 1996, ENDOCRINOLOGY, V137, P2217, DOI 10.1210/en.137.6.2217; KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I; KALU DN, 1994, BONE MINER, V25, P135, DOI 10.1016/S0169-6009(08)80255-3; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, V313, P36; KIMBLE RB, 1994, J CLIN INVEST, V93, P1959, DOI 10.1172/JCI117187; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MURPHY LJ, 1988, ENDOCRINOLOGY, V122, P325, DOI 10.1210/endo-122-1-325; OLDHAM SB, 1992, OSTEOPOROSIS INT, V2, P174, DOI 10.1007/BF01623923; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; RAY A, 1994, J BIOL CHEM, V269, P12940; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RUSSELL SM, 1985, ENDOCRINOLOGY, V116, P2563, DOI 10.1210/endo-116-6-2563; SALIH MA, 1993, BONE MINER, V23, P285, DOI 10.1016/S0169-6009(08)80104-3; SATO F, 1993, CALCIFIED TISSUE INT, V53, P111, DOI 10.1007/BF01321888; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; SHEN V, 1992, CALCIFIED TISSUE INT, V50, P214, DOI 10.1007/BF00296285; SHEWMON DA, 1994, ARTERIOSCLER THROMB, V14, P1586, DOI 10.1161/01.ATV.14.10.1586; SKOTTNER A, 1987, J ENDOCRINOL, V112, P123, DOI 10.1677/joe.0.1120123; SLOOTWEG MC, 1992, J ENDOCRINOL, V132, P433, DOI 10.1677/joe.0.1320433; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEPAN JJ, 1987, BONE, V8, P279; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; TURNER RT, 1992, ENDOCRINOLOGY, V131, P883, DOI 10.1210/en.131.2.883; TURNER RT, 1993, J BONE MINER RES, V8, P359; TURNER RT, 1991, MODERN CONCEPTS INSU, P143; TURNER RT, 1994, ENDOCR REV, V15, P129; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WRONSKI TJ, 1993, ENDOCRINOLOGY, V132, P823, DOI 10.1210/en.132.2.823; Zofkova I, 1996, BONE, V19, P227	68	63	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18132	18139		10.1074/jbc.272.29.18132	http://dx.doi.org/10.1074/jbc.272.29.18132			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218447	hybrid			2022-12-25	WOS:A1997XL73500037
J	Notarnicola, SM; Mulcahy, HL; Lee, J; Richardson, CC				Notarnicola, SM; Mulcahy, HL; Lee, J; Richardson, CC			The acidic carboxyl terminus of the bacteriophage T7 gene 4 helicase/primase interacts with T7 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; LAGGING STRAND SYNTHESIS; NUCLEOTIDE-BINDING SITE; DEOXYRIBONUCLEIC-ACID; REPLICATION INVITRO; TEMPLATE RECOGNITION; T7-DNA POLYMERASE; RNA PRIMER; PROTEIN; PRIMASE	The gene 4 proteins of bacteriophage T7 provide both primase and helicase activities at the replication fork. Efficient DNA replication requires that the functions of the gene 4 protein be coordinated with the movement of the T7 DNA polymerase. We show that a carboxyl-terminal domain of the gene 4 protein is required for interaction with T7 DNA polymerase during leading strand DNA synthesis. The carboxyl terminus of the gene 4 protein is highly acidic: of the 17 carboxyl-terminal amino acids 7 are negatively charged. Deletion of the coding region for these 17 residues results in a gene 4 protein that cannot support the growth of T7 phage. The purified mutant gene 4 protein has wild-type levels of both helicase and primase activities; however, DNA synthesis catalyzed by T7 DNA polymerase on a duplex DNA substrate is stimulated by this mutant protein to only about 5% of the level of synthesis obtained with wildtype protein. The mutant gene 4 protein can form hexamers and bind single-stranded DNA, but as determined by native PAGE analysis, the protein cannot form a stable complex with the DNA polymerase. The mutant gene 4 protein can prime DNA synthesis normally, indicating that for lagging strand synthesis a different set of helicase/primase-DNA polymerase interactions are involved. These findings have implications for the mechanisms coupling leading and lagging strand DNA synthesis at the T7 replication fork.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; SUFFOLK UNIV,DEPT BIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Suffolk University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KIM S, 1996, CELL, V84, P343; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MODRICH P, 1975, J BIOL CHEM, V250, P5515; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1993, J BIOL CHEM, V268, P10668; RICHARDSON CC, 1987, UCLA S MOL CELL BIOL, V47, P151; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; Yang XM, 1997, J BIOL CHEM, V272, P6599, DOI 10.1074/jbc.272.10.6599; Yang XM, 1996, J BIOL CHEM, V271, P24207, DOI 10.1074/jbc.271.39.24207	50	81	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18425	18433		10.1074/jbc.272.29.18425	http://dx.doi.org/10.1074/jbc.272.29.18425			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218486	Green Published, hybrid			2022-12-25	WOS:A1997XL73500076
J	Sullivan, PM; Mezdour, H; Aratani, Y; Knouff, C; Najib, J; Reddick, RL; Quarfordt, SH; Maeda, N				Sullivan, PM; Mezdour, H; Aratani, Y; Knouff, C; Najib, J; Reddick, RL; Quarfordt, SH; Maeda, N			Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-ARGININE INTERCHANGE; RECEPTOR-BINDING ACTIVITY; TRANSGENIC MICE; LIPOPROTEIN RECEPTOR; PLASMA-LIPOPROTEINS; E POLYMORPHISM; C-I; HYPERLIPOPROTEINEMIA; EXPRESSION; IDENTIFICATION	Apolipoprotein (apo) E, a constituent of several lipoproteins, is a ligand for the low density lipoprotein receptor, and this interaction is important for maintaining cholesterol and triglyceride homeostasis. We have use a gene replacement strategy to generate mice that express the human apoE3 isoform in place of the mouse protein. The levels of apoE mRNA in various tissues are virtually the same in the human apoE3 homozygous (3/3) mice and their littermates having the wild type mouse allele (+/+). Total cholesterol and triglyceride levels in fasted plasma from the 3/3 mice were not different from those in the +/+ mice, when maintained on a normal (low fat) chow diet. We found, however, notable differences in the distribution of plasma lipoproteins and apo-lipoprotein E between the two groups: beta-migrating lipoproteins and plasma apoB100 levels are decreased in the 3/3 mice, and the apoE distribution is shifted from high density lipoproteins to larger lipoprotein particles. In addition, the fractional catabolic rate of exogenously administered remnant particles without apoE was 6-fold slower in the 3/3 mice compared with the +/+ mice. When the 3/3 and +/+ animals were fed a high fat/high cholesterol diet, the 3/3 animals responded with a dramatic increase (5-fold) in total cholesterol compared with the +/+ mice (1.5-fold), and after 12 weeks on this same diet the 3/3 animals developed significantly (at least 13-fold) larger atherosclerotic plaques in the aortic sinus area than the +/+ animals. Thus the structural differences between human APOE3 and mouse ApoE proteins are sufficient to cause an increased susceptibility to dietary-induced hypercholesterolemia and atherosclerosis in the 3/3 mice.	UNIV N CAROLINA, DEPT PATHOL & LAB MED, CHAPEL HILL, NC 27599 USA; INST PASTEUR, LILLE, FRANCE; DURHAM VA HOSP, DEPT MED, DURHAM, NC 27705 USA; DUKE UNIV, MED CTR, DURHAM, NC 27705 USA	University of North Carolina; University of North Carolina Chapel Hill; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Duke University					NHLBI NIH HHS [HL42630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630, R37HL042630] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1982, J BIOL CHEM, V257, P9788; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOERWINKLE E, 1987, AM J MED GENET, V27, P567, DOI 10.1002/ajmg.1320270310; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESILVA HV, 1994, J LIPID RES, V35, P1297; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; FAZIO S, 1994, J LIPID RES, V35, P408; GREEN EK, 1991, CLIN CHEM, V37, P1263; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IMAIZUMI K, 1978, J LIPID RES, V19, P712; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LANDIS BA, 1987, AM J PHYSIOL, V252, pG805, DOI 10.1152/ajpgi.1987.252.6.G805; LEROY A, 1988, J IMMUNOASSAY, V9, P309, DOI 10.1080/01971528808053219; MAHLEY R W, 1978, P181; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1977, J BIOL CHEM, V252, P3980; MORTIMER BC, 1994, ARTERIOSCLER THROMB, V14, P1542, DOI 10.1161/01.ATV.14.10.1542; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; PAIK YK, 1988, J BIOL CHEM, V263, P13340; QUARFORDT SH, 1995, J LIPID RES, V36, P1227; RALL SC, 1982, J BIOL CHEM, V257, P4171; ROBINSON SF, 1978, BIOCHIM BIOPHYS ACTA, V541, P492, DOI 10.1016/0304-4165(78)90158-7; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SMITH JD, 1990, J BIOL CHEM, V265, P14709; TAYLOR JM, 1991, CURR OPIN LIPIDOL, V2, P73; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UTERMANN G, 1982, RES CLIN LAB, V12, P23; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; vanVlijmen BJM, 1996, J BIOL CHEM, V271, P30595, DOI 10.1074/jbc.271.48.30595; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; YANG YW, 1991, J MOL EVOL, V32, P469, DOI 10.1007/BF02102649; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	47	382	394	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17972	17980		10.1074/jbc.272.29.17972	http://dx.doi.org/10.1074/jbc.272.29.17972			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218423	Green Published, hybrid			2022-12-25	WOS:A1997XL73500013
J	Eguchi, H; Ikuta, T; Tachibana, T; Yoneda, Y; Kawajiri, K				Eguchi, H; Ikuta, T; Tachibana, T; Yoneda, Y; Kawajiri, K			A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator hypoxia-inducible factor 1 beta is a novel bipartite type recognized by the two components of nuclear pore-targeting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED TRANSCRIPTION FACTOR; PROTEIN IMPORT; AH-RECEPTOR; FUNCTIONAL DOMAINS; CYTOSOLIC FACTORS; DIOXIN RECEPTOR; DNA-BINDING; IDENTIFICATION; TRANSPORT; SEQUENCE	Aryl hydrocarbon receptor nuclear translocator (ARNT) is a component of the transcription factors, aryl hydrocarbon receptor (AhR) and hypoxia-inducible factor 1, which transactivate their target genes, such as CYP1A1 and erythropoietin, in response to xenobiotic aromatic hydrocarbons and to low O-2 concentration, respectively, Since ARNT was isolated as a factor required for the nuclear translocation of AhR from the cytoplasm in response to xenobiotics, the subcellular localization of ARNT has been of great interest, In this investigation, we analyzed the subcellular distribution of ARNT using transient expression of a fusion gene with P-galactosidase and microinjection of recombinant proteins containing various fragments of ARNT in the linker region of glutathione S-transferase/green fluorescent protein, We found a clear nuclear localization of ARNT in the absence of exogenous li,bands to AhR, and identified the nuclear localization signal (NLS) of amino acid residues 39-61, The characterized NLS consists of 23 amino acids, and can be classified as a novel variant of the bipartite type on the basis of having tyro separate regions responsible for efficient nuclear translocation activity, but considerable deviation of the sequence from the consensus of the classical bipartite type. NLSs. Like the well characterized NLS of the SV40 T-antigen, this variant bipartite type of ARNT NLS was also mediated by the two components of nuclear pore targeting complex, PTAC58 and PTAC97, to target to the nuclear rim in an in vitro nuclear transport assay.	SAITAMA CANC CTR, RES INST, DEPT BIOCHEM, INA, SAITAMA 362, JAPAN; OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN	Osaka University								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FUJIIKURIYAMA Y, 1994, EXP CLIN IMMUNOGENET, V11, P65; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kawajiri K., 1996, CYTOCHROMES P450 MET, P77; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	51	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17640	17647		10.1074/jbc.272.28.17640	http://dx.doi.org/10.1074/jbc.272.28.17640			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211913	hybrid			2022-12-25	WOS:A1997XK16500056
J	Acker, J; deGraaff, M; Cheynel, I; Khazak, V; Kedinger, C; Vigneron, M				Acker, J; deGraaff, M; Cheynel, I; Khazak, V; Kedinger, C; Vigneron, M			Interactions between the human RNA polymerase II subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; STRESS SURVIVAL; YEAST; TRANSCRIPTION; MOLECULES; SEQUENCE; ENCODES; PORTION; COMMON	As an initial approach to characterizing the molecular structure of the human RNA polymerase II (hRPB), we systematically investigated the protein-protein contacts that the subunits of this enzyme may establish with each other, To this end, we applied a glutathione S-transferase-pulldown assay to extracts from Sf9 insect cells, which were coinfected with all possible combinations of recombinant baculoviruses expressing hRPB subunits, either as untagged polypeptides or as glutathione S-transferase fusion proteins, This is the first comprehensive study of interactions between eukaryotic RNA polymerase subunits; among the 116 combinations of hRPB subunits tested, 56 showed significant to strong interactions, whereas 60 were negative, Within the intricate network of interactions, subunits hRPB3 and hRPB5 play a central role in polymerase organization, These subunits, which are able to homodimerize and to interact, may constitute the nucleation center for polymerase assembly, by providing a large interface to most of the other subunits.	ULP,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Acker, Joël/F-5138-2010	Acker, Joël/0000-0002-0855-875X				ACKER J, 1994, DNA SEQUENCE, V4, P329, DOI 10.3109/10425179409020860; ACKER J, 1993, NUCLEIC ACIDS RES, V21, P5345, DOI 10.1093/nar/21.23.5345; ACKER J, 1992, J MOL BIOL, V226, P1295, DOI 10.1016/0022-2836(92)91071-V; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; ARCHAMBAULT J, 1990, MOL CELL BIOL, V10, P6123, DOI 10.1128/MCB.10.12.6123; BOCCO JL, 1993, ONCOGENE, V8, P2977; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEONG J, 1994, EMBO J, V14, P143; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fanciulli M, 1996, FEBS LETT, V384, P48, DOI 10.1016/0014-5793(96)00277-3; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; Klinger C, 1996, EMBO J, V15, P4643, DOI 10.1002/j.1460-2075.1996.tb00841.x; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Luban Jeremy, 1995, Current Opinion in Biotechnology, V6, P59, DOI 10.1016/0958-1669(95)80010-7; MCKUNE K, 1994, MOL CELL BIOL, V14, P4155, DOI 10.1128/MCB.14.6.4155; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PATI UK, 1990, J BIOL CHEM, V265, P8400; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; PATI UK, 1989, J BIOL CHEM, V264, P13114; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; SCHULTZ P, 1990, J MOL BIOL, V216, P353, DOI 10.1016/S0022-2836(05)80326-2; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; Sentenac A., 1992, TRANSCRIPTIONAL REGU, V1, P27; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; Treich Isabelle, 1992, Gene Expression, V2, P31; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; WINTZERITH M, 1992, NUCLEIC ACIDS RES, V20, P910, DOI 10.1093/nar/20.4.910; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	44	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16815	16821		10.1074/jbc.272.27.16815	http://dx.doi.org/10.1074/jbc.272.27.16815			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201987	hybrid			2022-12-25	WOS:A1997XH44600019
J	Boumans, H; vanGaalen, MCM; Grivell, LA; Berden, JA				Boumans, H; vanGaalen, MCM; Grivell, LA; Berden, JA			Differential inhibition of the yeast bc(1) complex by phenanthrolines and ferroin - Implications for structure and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; PROTONMOTIVE Q-CYCLE; PHOTOSYNTHETIC REACTION CENTER; 17-KDA SUBUNIT-VI; SACCHAROMYCES-CEREVISIAE; UBIQUINONE OXIDOREDUCTASE; RHODOPSEUDOMONAS-VIRIDIS; BC1 COMPLEX; MITOCHONDRIA; PROTEIN	o-Phenanthroline and m-phenanthroline both inhibit the electron transfer activity of lauryl maltoside-solubilized yeast be, complex progressively with time, Presteady state kinetics indicate that these compounds bind to the complex on the intermembrane space side, thereby blocking reduction of cytochrome b via the ubiquinol oxidation site, o-Phenanthroline is additionally capable of chelating an iron atom derived from the Rieske Fe-S cluster, thereby distorting the structure of the Rieske protein, EPR analysis shows that the secondary effect of o-phenanthroline occurs after initial inactivation and that m-phenanthroline, which lacks chelating activity, does not affect the Rieske Fe-S cluster, Spectral analysis shows that the b and c(1) cytochromes are still dithionite-reducible after inactivation by o-phenanthroline, indicating that they remain intact, Inactivation by o-phenanthroline can be prevented by the addition of Fe2+, Surprisingly, ferroin, the o-phenanthroline-ferrous sulfate complex, also inhibits the bc(1) complex activity, In contrast to o-phenanthroline, this effect is instantaneous, The two types of inhibition are clearly distinguishable by pre-steady-state reduction kinetics, Interestingly, ferroin can only inhibit electron transfer activity by about 50%, This behavior is discussed in relation to the dimeric structure of the bc(1) complex, and we conclude that ferroin binds to only one of the two protomers, The rate of inactivation by o-phenanthroline is dependent on the incubation temperature and can be quantitated in terms of the half-life for a certain temperature, the time at which the be, activity is reduced to 50%. In contrast to the solubilized form, the bc(1) complex in intact mitochondria is insensitive to o-phenanthroline, suggesting that the inactivation rate by o-phenanthroline is dependent on accessibility of the complex to the agent. Reaction with o-phenanthroline is thus a useful technique for study of structural stability of the bc(1) complex under different conditions and should provide a sensitive tool for determination of the relative stability of mutant enzymes.	UNIV AMSTERDAM, EC SLATER INST BIOCHEM RES, NL-1018 TV AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, BIOCTR, DEPT MOL CELL BIOL, MOL BIOL SECT, NL-1018 TV AMSTERDAM, NETHERLANDS	University of Amsterdam; University of Amsterdam								ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BOWYER JR, 1981, FEBS LETT, V126, P93, DOI 10.1016/0014-5793(81)81041-1; BRANDT U, 1994, J BIOL CHEM, V269, P12947; Brandt U, 1996, BBA-BIOENERGETICS, V1275, P41, DOI 10.1016/0005-2728(96)00048-5; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; COOPER CE, 1991, BIOCHEM CELL BIOL, V69, P586, DOI 10.1139/o91-089; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; ENGEL WD, 1983, EUR J BIOCHEM, V132, P395, DOI 10.1111/j.1432-1033.1983.tb07376.x; FINEL M, 1994, FEBS LETT, V339, P142, DOI 10.1016/0014-5793(94)80402-8; GIESSLER A, 1994, EUR J BIOCHEM, V222, P147, DOI 10.1111/j.1432-1033.1994.tb18852.x; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; LANCASTER CRD, 1997, IN PRESS REACTION CT; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; Link TA, 1996, BBA-BIOENERGETICS, V1275, P54, DOI 10.1016/0005-2728(96)00050-3; LJUNGDAHL PO, 1986, METHOD ENZYMOL, V126, P181; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRES CAM, 1991, BIOCHIM BIOPHYS ACTA, V1057, P51, DOI 10.1016/S0005-2728(05)80083-0; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; NAKAI T, 1994, J BIOCHEM-TOKYO, V116, P752, DOI 10.1093/oxfordjournals.jbchem.a124592; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; NIEBOER P, 1992, BIOCHIM BIOPHYS ACTA, V1101, P90, DOI 10.1016/0167-4838(92)90472-P; OHNISHI T, 1985, J BIOL CHEM, V260, P2782; PFISTER K, 1981, P NATL ACAD SCI-BIOL, V78, P981, DOI 10.1073/pnas.78.2.981; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; SINNING I, 1992, TRENDS BIOCHEM SCI, V17, P150, DOI 10.1016/0968-0004(92)90324-3; SINNING I, 1989, BIOCHEMISTRY-US, V28, P5544, DOI 10.1021/bi00439a031; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; van Gelder B F, 1978, Methods Enzymol, V53, P125; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; YASUHARA T, 1994, J BIOCHEM-TOKYO, V115, P1166, DOI 10.1093/oxfordjournals.jbchem.a124474; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7	44	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16753	16760		10.1074/jbc.272.27.16753	http://dx.doi.org/10.1074/jbc.272.27.16753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201979	hybrid, Green Published			2022-12-25	WOS:A1997XH44600011
J	Lange, Y; Ye, J; Chin, J				Lange, Y; Ye, J; Chin, J			The fate of cholesterol exiting lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN FIBROBLASTS; PLASMA-MEMBRANE; INTRACELLULAR-TRANSPORT; CELLS; PROGESTERONE; HOMEOSTASIS; SUPPRESSION; INHIBITION; METABOLISM	Cholesterol released from ingested low density lipoproteins in lysosomes moves both to the plasma membrane and to the endoplasmic reticulum (ER) where it is re-esterified, Whether cholesterol can move directly from lysosomes to ER or first must traverse the plasma membrane has not been established, To examine this question, the endocytic pathway of rat hepatoma cells was loaded at 18 degrees C with low density lipoproteins (LDL) labeled with [H-3]cholesteryl linoleate, and the label then was chased at 37 degrees C, The hydrolysis of the accumulated ester proceeded linearly for several hours, Almost all of the released [H-3]cholesterol moved to the plasma membrane rapidly and without a discernable lag, In contrast, the re-esterification in the ER of the released [H-3]cholesterol showed a characteristic lag of 0.5-1 h, These data are inconsistent with direct cholesterol transfer from lysosomes to ER; rather, they suggest movement through the plasma membrane. Furthermore, we found that progesterone, imipramine and 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one (U18666A) strongly inhibited the re-esterification of lysosomal cholesterol in the ER, However, contrary to previous reports, they did not block transfer of [H-3]cholesterol from lysosomes to the cell surface, Therefore, the site of action of these agents was not at the lysosomes. We suggest instead that their known ability to block cholesterol movement from the plasma membrane to the ER accounts for the inhibition of lysosomal cholesterol esterification. These findings are consistent with the hypothesis that cholesterol released from lysosomes passes through the plasma membrane or, its way to the ER rather than proceeding there directly, As a result, ingested cholesterol is subject to the same homeostatic regulation as the bulk of cell cholesterol, which is located in the plasma membrane.	RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT BIOCHEM, CHICAGO, IL 60612 USA	Rush University	Lange, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT PATHOL, 1653 W CONGRESS PKWY, CHICAGO, IL 60612 USA.		Lange, Yvonne/A-7794-2009		NHLBI NIH HHS [HL 28448] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL028448, R01HL028448] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; FIELDING CJ, 1985, BIOCH LIPIDS MEMBRAN, P404; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1991, J BIOL CHEM, V266, P21439; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; ROFF CF, 1991, DEV NEUROSCI-BASEL, V13, P315, DOI 10.1159/000112179; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SUCKLING KE, 1985, J LIPID RES, V26, P647; Underwood KW, 1996, J LIPID RES, V37, P1556	24	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17018	17022		10.1074/jbc.272.27.17018	http://dx.doi.org/10.1074/jbc.272.27.17018			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202016	hybrid			2022-12-25	WOS:A1997XH44600048
J	Ottilie, S; Diaz, JL; Chang, J; Wilson, G; Tuffo, KM; Weeks, S; McConnell, M; Wang, Y; Oltersdorf, T; Fritz, LC				Ottilie, S; Diaz, JL; Chang, J; Wilson, G; Tuffo, KM; Weeks, S; McConnell, M; Wang, Y; Oltersdorf, T; Fritz, LC			Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DEFICIENT MICE; HOMOLOG BAK; PROTEIN; APOPTOSIS; FAMILY; SURVIVAL; GENE; HETERODIMERIZATION; DISTINCT	Interactions among proteins in the Bcl-2 family regulate the onset of programmed cell death. Previous work has shown that the death-inhibiting family members Bcl-2 and Bcl-x(L) form heterodimers with the death-promoting homologue Bax and that certain site-directed mutants of Bcl-2 and Bcl-x(L) lose both biological activity and the ability to bind Bax. To better understand the structural basis of heterodimer formation, we have used a yeast two-hybrid assay to screen for mutants of Bax that regain the ability to bind to these inactive Bcl-2(G145A) and Bcl-x(L)(G138A) mutants. This screen identified a series of C-terminally truncated Fax molecules that contain complete BH3 (Bcl-2 homology domain 3) domains but that have lost BH1 and BH2 sequences. These results indicate that while the Bcl-2 and Bcl-x(L) mutants fail to bind full-length Bax, they still retain a binding site for the critical BH3 domain. This suggests that conformational constraints in full-length Pax regulate its ability to bind to other Bcl-2 family members. Furthermore, we demonstrate that the normally inert Bcl-2(G145A) mutant effectively blocks apoptosis induced by a C-terminally truncated Fax molecule, but does not block apoptosis induced by wild-type Bax. This demonstrates that cell protection can be effected by directly binding pro-apoptotic members of the Bcl-2 family.			Ottilie, S (corresponding author), IDUN PHARMACEUT INC, 11085 N TORREY PINES RD, SUITE 300, LA JOLLA, CA 92037 USA.							BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DIAZ JL, 1997, J BIOL CHEM, V272, P11650; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gibson L, 1996, ONCOGENE, V13, P665; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Han J, 1996, MOL CELL BIOL, V16, P5857; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG H, 1995, BIOCHEM BIOPH RES CO, V208, P920	37	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16955	16961		10.1074/jbc.272.27.16955	http://dx.doi.org/10.1074/jbc.272.27.16955			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202007	hybrid			2022-12-25	WOS:A1997XH44600039
J	Tortosa, P; Aymerich, S; Lindner, C; Saier, MH; Reizer, J; LeCoq, D				Tortosa, P; Aymerich, S; Lindner, C; Saier, MH; Reizer, J; LeCoq, D			Multiple phosphorylation of SacY, a Bacillus subtilis transcriptional antiterminator negatively controlled by the phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDE UTILIZATION; ESCHERICHIA-COLI; GENE-EXPRESSION; BGL OPERON; PROTEIN; PHOSPHOENOLPYRUVATE; LEVANSUCRASE; MODULATION; INDUCTION; BACTERIA	The Bacillus subtilis SacY transcriptional antiterminator is a regulator involved in sucrose-promoted induction of the sacB gene, SacY activity is negatively controlled by enzyme I and HPr, the general energy coupling proteins of the phosphoenolpyruvate:sugar phosphotransferase system (PTS), and by SacX, a membranal protein homologous to SacP, the B. subtilis sucrose-specific PTS-permease. Previous studies suggested that the negative control exerted by the PTS oil bacterial antiterminators of the SacY family involves phosphoenolpyruvate-dependent phosphorylation by the sugar-specific PTS-permeases. However, data reported herein show direct phosphorylation of SacY by HPr(His similar to P) with no requirement for SacX, Experiments were carried out to determine the phosphorylatable residues in SacY, In silico analyses of SacY and its homologues revealed the modular structure of these proteins as well as four conserved histidines within two homologous domains (here designated P1 and P2), present in 14 distinct mRNA- and DNA-binding bacterial transcriptional regulators, Single or multiple substitutions of these histidyl residues were introduced in SacY by site-directed mutagenesis, and their effects on phosphorylation and antitermination activity were examined. In vitro phosphorylation experiments showed that SacY was phosphorylated on three of the conserved histidines. Nevertheless, in vivo studies using cells bearing a sacB'-lacZ reporter fusion, as well as SacY mutants lacking the phosphorylatable histidyls, revealed that only His-99 is directly involved in regulation of SacY antitermination activity.	INRA, CNRS ERS 567, LAB GENET MICROORGANISMES, F-78850 THIVERVAL GRIGNON, FRANCE; INST BIOL & CHIM PROT, CNRS UPR 412, F-69367 LYON 07, FRANCE; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Diego				Tortosa, Pablo/0000-0002-7928-7264; Le Coq, Dominique/0000-0001-5756-2280	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055434] Funding Source: NIH RePORTER; NIAID NIH HHS [5RO1 AI21702] Funding Source: Medline; NIGMS NIH HHS [9K01 GM55434] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPERT CA, 1985, BIOCHEMISTRY-US, V24, P959, DOI 10.1021/bi00325a023; AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Arnaud M, 1996, J BIOL CHEM, V271, P18966, DOI 10.1074/jbc.271.31.18966; AYMERICH S, 1987, MOL GEN GENET, V208, P114, DOI 10.1007/BF00330431; AYMERICH S, 1992, P NATL ACAD SCI USA, V89, P10410, DOI 10.1073/pnas.89.21.10410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; FENG DF, 1990, METHOD ENZYMOL, V183, P375; GONZYTREBOUL G, 1987, J BACTERIOL, V169, P2287, DOI 10.1128/jb.169.5.2287-2290.1987; KRUGER S, 1995, J BACTERIOL, V177, P5590; Kruger S, 1996, J BACTERIOL, V178, P2637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOQ D, 1995, J BACTERIOL, V177, P1527, DOI 10.1128/jb.177.6.1527-1535.1995; MADADEVAN S, 1987, CELL, V50, P485; MANIVAL X, 1997, IN PRESS EMBO J; Miller J.H., 1972, EXPT MOL GENETICS; PIGGOT PJ, 1987, J BACTERIOL, V169, P1260, DOI 10.1128/jb.169.3.1260-1266.1987; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reizer Aiala, 1994, V25, P319; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; Reizer J, 1996, RES MICROBIOL, V147, P458, DOI 10.1016/0923-2508(96)84000-9; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; SCHNETZ K, 1988, EMBO J, V7, P3271, DOI 10.1002/j.1460-2075.1988.tb03194.x; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; SHIMOTSU H, 1986, J BACTERIOL, V168, P380, DOI 10.1128/jb.168.1.380-388.1986; STEINMETZ M, 1986, ANN INST PASTEUR MIC, V137A, P3, DOI 10.1016/S0769-2609(86)80001-1; STEINMETZ M, 1994, GENE, V142, P79, DOI 10.1016/0378-1119(94)90358-1; STULKE J, 1995, J BACTERIOL, V177, P6928; Tobisch S, 1997, J BACTERIOL, V179, P496, DOI 10.1128/jb.179.2.496-506.1997; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439; ZUKOWSKI MM, 1990, GENE, V90, P153, DOI 10.1016/0378-1119(90)90453-X	40	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17230	17237		10.1074/jbc.272.27.17230	http://dx.doi.org/10.1074/jbc.272.27.17230			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202047	Green Published, hybrid			2022-12-25	WOS:A1997XH44600079
J	Bianchi, V; Borella, S; Rampazzo, C; Ferraro, P; Calderazzo, F; Bianchi, LC; Skog, S; Reichard, P				Bianchi, V; Borella, S; Rampazzo, C; Ferraro, P; Calderazzo, F; Bianchi, LC; Skog, S; Reichard, P			Cell cycle-dependent metabolism of pyrimidine deoxynucleoside triphosphates in CEM cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; DEOXYRIBONUCLEOSIDE TRIPHOSPHATES; RIBONUCLEOTIDE REDUCTASE; MOUSE FIBROBLASTS; THYMIDINE KINASE; MAMMALIAN-CELLS; POOLS; DEOXYCYTIDINE; REPLICATION; DYNAMICS	We incorporated H-3-labeled thymidine, deoxycytidine, or cytidine into dNTPs and DNA of exponentially growing CEM cells. G(1) and S phase cells were separated by centrifugal elutriation, and the size and specific activity of dNTP pools were determined to study the cell cycle-dependent regulation of specific dNTP synthesizing enzymes in their metabolic context. With [H-3]thymidine, we confirm the earlier demonstrated S phase specificity of thymidine kinase. Incorporation of radioactivity from [5-H-3]deoxycytidine into dCTP occurred almost exclusively in G(1) cells, During S phase, de novo synthesis by ribonucleotide reductase was switched on, resulting in a 70-fold dilution of [H-3]dCTP, confirming that ribonucleotide reductase is an S phase-specific enzyme, whereas deoxycytidine kinase is not, [5-H-3]Cytidine appeared in dCTP almost to the same extent in G(1) as in S phase, despite the S phase specificity of ribonucleotide reductase, During S phase, DNA replication greatly increased the turnover of dCTP, requiring a corresponding increase in ribonucleotide reductase activity. During G(1), the enzyme maintained activity to provide dNTPs for DNA repair and mitochondrial DNA synthesis, The poor incorporation of isotope from deoxycytidine into DNA earlier led to the suggestion that the nucleoside is used only for DNA repair (Xu, Y-Z., Peng, H., and Plunkett, W. (1995) J. Biol. Chem. 270, 631-637). The poor phosphorylation of deoxycytidine in S phase provides a better explanation.	UNIV PADUA,DEPT BIOL,I-35121 PADUA,ITALY; DEPT ONCOL & SURG SERV,ONCOL SECT,I-35128 PADUA,ITALY; KAROLINSKA INST,DEPT MED RADIOBIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MED NOBEL INST,S-17177 STOCKHOLM,SWEDEN	University of Padua; Karolinska Institutet; Karolinska Institutet								ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BIANCHI V, 1994, J BIOL CHEM, V269, P16677; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FERRARO P, 1992, EXP CELL RES, V199, P349, DOI 10.1016/0014-4827(92)90444-D; HELLGREN D, 1979, BIOCHEM BIOPH RES CO, V88, P16, DOI 10.1016/0006-291X(79)91690-5; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KAUFFMAN MG, 1990, ANAL BIOCHEM, V191, P41, DOI 10.1016/0003-2697(90)90384-L; LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532; LEEDS JM, 1985, MOL CELL BIOL, V5, P3442; Mikulits W, 1996, J BIOL CHEM, V271, P853, DOI 10.1074/jbc.271.2.853; NICANDER B, 1985, J BIOL CHEM, V260, P5376; NICANDER B, 1983, P NATL ACAD SCI-BIOL, V80, P1347, DOI 10.1073/pnas.80.5.1347; PLUCINSKI TM, 1990, MOL PHARMACOL, V38, P114; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; REDDY GPV, 1983, NATURE, V303, P86; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1951, J BIOL CHEM, V188, P839; RODE W, 1980, J BIOL CHEM, V255, P1305; Sanderson R J, 1977, Methods Cell Biol, V15, P1, DOI 10.1016/S0091-679X(08)60206-X; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SPASOKUKOTSKAJA T, 1988, BIOCHEM BIOPH RES CO, V155, P923, DOI 10.1016/S0006-291X(88)80584-9; SPYROU G, 1988, MUTAT RES, V200, P37, DOI 10.1016/0027-5107(88)90069-3; SPYROU G, 1989, J BIOL CHEM, V264, P960; TANAKA K, 1984, ANAL BIOCHEM, V139, P35, DOI 10.1016/0003-2697(84)90386-5; XU YZ, 1995, J BIOL CHEM, V270, P631, DOI 10.1074/jbc.270.2.631	31	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16118	16124		10.1074/jbc.272.26.16118	http://dx.doi.org/10.1074/jbc.272.26.16118			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195907	hybrid			2022-12-25	WOS:A1997XG01900011
J	Ryden, M; Hempstead, B; Ibanez, CF				Ryden, M; Hempstead, B; Ibanez, CF			Differential modulation of neuron survival during development by nerve growth factor binding to the p75 neurotrophin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY NGF RECEPTOR; TRK PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; SYMPATHETIC NEURONS; PC12 CELLS; EXPRESSION; BRAIN; DEATH; RAT; COEXPRESSION	Nerve growth factor (NGF) supports the survival and differentiation of distinct populations of peripheral and central neurons, NGF binds to two classes of cell-surface receptors, the protein tyrosine kinase TrkA and the smaller p75 receptor lacking intrinsic catalytic activity. It has been suggested that both receptors are required for NGF high affinity binding, although TrkA appears to be sufficient for transducing most of the biological effects of NGF. Some evidence suggests that p75 could play a modulatory role on TrkA activation by an as yet unknown mechanism, In this study, we have investigated functional roles of p75 using a purified triple mutant NGF (triNGF) deficient in p75 binding but retaining significant TrkA binding and activation, The mutant was found to be as potent as wild type NGF at promoting survival of serum-deprived TrkA-expressing fibroblasts, On developing chick sensory neurons, survival responses to mutant and native NGF were indistinguishable when assayed at nanomolar concentrations, However, triNGF was 3- to 4-fold less potent than wild type NGF at lower concentrations (i.e. 10(-11)M). Interestingly, in PC12 cells coexpressing TrkA and p75, no high affinity binding sites for triNGF could be detected, The reduced responsiveness to triNGF in sensory neurons was increasingly evident at later developmental stages; late embryonic neurons did not respond at all to concentrations of triNGF that were saturating at earlier developmental stages, Likewise, although no difference could be seen between wild type and mutant NGF on the survival responses of embryonic rat superior cervical ganglion sympathetic neurons, the mutant was much less potent than native NGF on postnatal sympathetic neurons, In sensory neurons, the decrease in responsiveness to triNGF correlated with a developmental reduction in the expression of both p75 and TrkA. Thus, NGF binding to p75 enhances responsiveness to ligand, particularly when this is present at limiting concentrations, During development, p75 modulates responsiveness to NGF so that binding to p75 becomes increasingly important in neurons undergoing a down-regulation of NGF receptors. These results support a ligand-dependent modulatory role for p75 in NGF-mediated neuron survival consistent with p75 functioning as a TrkA regulator and/or signaling receptor.	KAROLINSKA INST,MOL NEUROBIOL LAB,DIV MOL NEUROBIOL,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN; CORNELL UNIV,COLL MED,DEPT MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021	Karolinska Institutet; Cornell University					NINDS NIH HHS [NS 3081] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; Frade JM, 1996, NATURE, V383, P166; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1987, J NEUROSCI, V7, P923; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, DEVELOPMENT, V120, P1027; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Ross AH, 1996, J CELL BIOL, V132, P945, DOI 10.1083/jcb.132.5.945; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; Ryden M, 1996, J BIOL CHEM, V271, P5623, DOI 10.1074/jbc.271.10.5623; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderZee CEEM, 1996, SCIENCE, V274, P1729, DOI 10.1126/science.274.5293.1729; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WRIGHT LL, 1983, J NEUROCYTOL, V12, P727, DOI 10.1007/BF01258147; WYATT S, 1995, J CELL BIOL, V130, P1435, DOI 10.1083/jcb.130.6.1435	51	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16322	16328		10.1074/jbc.272.26.16322	http://dx.doi.org/10.1074/jbc.272.26.16322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195937	hybrid			2022-12-25	WOS:A1997XG01900041
J	Silverstein, AM; Galigniana, MD; Chen, MS; OwensGrillo, JK; Chinkers, M; Pratt, WB				Silverstein, AM; Galigniana, MD; Chen, MS; OwensGrillo, JK; Chinkers, M; Pratt, WB			Protein phosphatase 5 is a major component of glucocorticoid receptor hsp90 complexes with properties of an FK506-binding immunophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TETRATRICOPEPTIDE REPEAT DOMAIN; HAMSTER OVARY CELLS; STEROID-RECEPTOR; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; CYCLOSPORINE-A; SERINE/THREONINE PHOSPHATASE; POLYCLONAL ANTIBODY; MOLECULAR-CLONING	Steroid receptors are recovered from hormone-free cells in multiprotein complexes containing hsp90, p23, an immunophilin, and often some hsp70, The immunophilin, which can be of the FK506- or cyclosporin A-binding class, binds to hsp90 via its tetratricopeptide repeat (TPR) domain, and different receptor heterocomplexes exist depending upon which immunophilin occupies the TPR-binding region of hsp90, We have recently reported that a protein serine/threonine phosphatase that is designated PP5 and contains four TPRs binds to hsp90 and is co-purified with the glucocorticoid receptor (GR) (Chen, M.-S., Silverstein, A. M., Pratt, W. B., and Chinkers, M. (1996) J. Biol. Chem. 271, 32315-32320). In this work, we show that PP5 is recovered with both GR that is nuclear and GR that is cytoplasmic in hormone-free cells. Approximately one-half of the GR hsp90 heterocomplexes in L cell cytosol contains an immunophilin with high affinity FK506 binding activity, such as FKBP51 or FKBP52, and similar to 35% contains PP5. Only a small (but undetermined) fraction of the native GR hsp90 heterocomplexes contain the cyclosporin A-binding immunophilin CyP-40. PP5, FKBP52, and CyP-40 exist in separate heterocomplexes with hsp90, and competition binding experiments with the PP5 TPR domain suggest that the three proteins occupy a common binding site on hsp90. A 55-residue connecting region between the N-terminal TPR domain of human PP5 and its C-terminal phosphatase domain has 50% amino acid homology and 22% identity with the central portion of the peptidylprolyl isomerase domain of human FKBP52, Of the 9 residues in this portion of FKBP52 involved in high affinity interactions with FK506, 3 residues are retained and 4 have homologous substitutions in PP5, Although immunoadsorbed PP5 did not bind [H-3]FK506, we found that both rabbit PP5 in reticulocyte lysate and purified rat PP5 were specifically retained by an FK506 affinity matrix. Thus, we propose that PP5 possesses properties of an immunophilin with low affinity FK506 binding activity and that it determines a major portion of the native GR heterocomplexes in L cell cytosol.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	University of Michigan System; University of Michigan; Oregon Health & Science University				GALIGNIANA, MARIO/0000-0002-9130-8574	NCI NIH HHS [CA28010] Funding Source: Medline; NHLBI NIH HHS [HL47063] Funding Source: Medline; NICHD NIH HHS [HD30236] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD030236] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER W, 1994, J BIOL CHEM, V269, P22586; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GEHRING U, 1995, GLUCOCORTICOID RECEP, P35; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; OwensGrillo JK, 1996, BIOCHEMISTRY-US, V35, P15249, DOI 10.1021/bi9615349; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; REXIN M, 1991, J BIOL CHEM, V266, P24601; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WALSH CT, 1992, J BIOL CHEM, V267, P13115; YEM AW, 1992, J BIOL CHEM, V267, P2868	62	204	221	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16224	16230		10.1074/jbc.272.26.16224	http://dx.doi.org/10.1074/jbc.272.26.16224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195923	hybrid			2022-12-25	WOS:A1997XG01900027
J	Halachmy, S; Bern, O; Schreiber, L; Carmel, M; Sharabi, Y; Shoham, J; Nir, U				Halachmy, S; Bern, O; Schreiber, L; Carmel, M; Sharabi, Y; Shoham, J; Nir, U			p94(fer) facilitates cellular recovery of gamma irradiated pre-T cells	ONCOGENE			English	Article						ionizing-radiation; nuclear; p94(fer); T cell; tyrosine kinase	PROTEIN-TYROSINE KINASE; FES-ENCODED PROTEIN; ABL MESSENGER-RNAS; C-ABL; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAY; TRANSCRIPT FERT; TRANSGENIC MICE; LYMPHOID-CELLS; MOUSE-TISSUES	p94(fer) is a ubiquitous, nuclear and cytoplasmic tyrosine kinase, whose accumulation has been demonstrated in all mammalian cell Lines analysed. In the present work, the p94(fer) expression profile was determined in cell lines which were not tested before. While being present in several hematopoietic and non hematopoietic cell lines including thymic stromal cells, the p94(fer) kinase could not be detected in pre-T and T cell lines. p94(fer) was also absent in pre-B line, but accumulated in these cells upon their induced development to antibody producing cells. This is in agreement with the absence of p94(fer) in primary th,mic and splenic T lymphocytes and its induced accumulation in stimulated B cells. Relatively high p94(fer) levels were detected in primary thymic and splenic stromal cells. Ectopic expression of p94(fer) in pre-T cells slightly affected their cell cycle profile but it did not affect their apoptotic death which was induced by ionizing radiation. However, p94(fer) facilitated dramatically, the cellular recovery of gamma irradiated pre-T cells which have escaped the apoptotic death. The enhanced recovery of the irradiated, p94(fer) expressing pre-T cells, resulted most probably from their increased survival, rather than from a prominent change in their proliferation rate. The absence of p94(fer) from pre-B and pre-T cells, may thus contribute to the relative sensitivity of these cells to ionizing radiation and to their dependence on the functioning of other nuclear tyrosine kinasese.	BAR ILAN UNIV,DEPT LIFE SCI,IL-52900 RAMAT GAN,ISRAEL	Bar Ilan University								BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; CARE A, 1994, ONCOGENE, V9, P739; COFFER PJ, 1995, ONCOGENE, V11, P561; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ESHEL I, 1990, J IMMUNOL, V144, P1554; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; GLIMCHER LH, 1983, SCAND J IMMUNOL, V17, P1, DOI 10.1111/j.1365-3083.1983.tb00759.x; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; IRLIN Y, 1992, IMMUNOL LETT, V33, P233, DOI 10.1016/0165-2478(92)90067-X; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KIM L, 1995, MOL CELL BIOL, V15, P4553; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LETWIN K, 1988, ONCOGENE, V3, P621; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARKS PA, 1983, P NATL ACAD SCI-BIOL, V80, P2281, DOI 10.1073/pnas.80.8.2281; MCWHIRTER JR, 1993, EMBO J, V12, P1523; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAMBROOK J, 1989, MOL CLONE LAB MANUAL; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SCHREIBER L, 1996, IN PRESS SCAND J IMM; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SOKAGUCHI N, 1980, J IMMUNOL, V125, P2654; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WADSWORTH SA, 1995, J IMMUNOL, V154, P2125; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WILKS AF, 1988, ONCOGENE, V3, P289; YAFFE A, 1996, IN PRESS CELL GROWTH; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; YATES KE, 1995, ONCOGENE, V10, P1239	52	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2871	2880		10.1038/sj.onc.1201145	http://dx.doi.org/10.1038/sj.onc.1201145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205095				2022-12-25	WOS:A1997XF55500002
J	Chernov, MV; Stark, GR				Chernov, MV; Stark, GR			The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate	ONCOGENE			English	Article						p53 accumulation; transcriptional activation; DNA binding; mouse (12)1/CA cells; DNA damaging agents	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; NF-KAPPA-B; BINDING FUNCTION; IN-VITRO; GAMMA-IRRADIATION; SODIUM-SALICYLATE; GENE-EXPRESSION; KINASE-C	Treatment of mouse (12)1/CA cells with adriamycin or irradiation with U.V.C. induces p53-dependent transcription of a beta-galactosidase reporter and the endogenous p21/Waf1/Cip1 gene. Despite the induction of Waf1, the cells arrest only transiently in G(1) or G(2), then resume growth and eventually undergo apoptosis. In situ analysis of beta-galactosidase activity in U.V.C.-irradiated cells revealed a much higher level of p53-dependent transcription in cells undergoing apoptosis compared to transiently arrested cells. Incubation of the treated cells with salicylate, which inhibits the activation of protein kinases and transcription factors involved in stress responses, inhibits both p53-dependent transcription and apoptosis. The inhibition of transcription is due mainly to impairment of the ability of p53 to bind to DNA. The treated cells resume their p53-dependent programs whenever the salicylate is removed, even after as long as 60 h after the DNA has been damaged. Therefore, the p53-activating signals generated by adriamycin or U.V.C. are very long lived. The resumption of p53-dependent transcription is not accompanied by additional accumulation of the p53 protein, indicating that the activation of p53 is regulated by a separate pathway.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; GUILLOUF C, 1995, ONCOGENE, V10, P2263; Harlow E., 1988, ANTIBODIES LAB MANUA; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOMAROVA EA, 1996, IN PRESS EMBO J; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maki CG, 1996, CANCER RES, V56, P2649; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PRICE BD, 1995, ONCOGENE, V11, P73; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Soddu S, 1996, MOL CELL BIOL, V16, P487; STEWART N, 1995, ONCOGENE, V10, P109; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TISCHLER RB, 1993, CANCER RES, V53, P2212; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHAN QM, 1994, ONCOGENE, V9, P3743	61	42	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2503	2510		10.1038/sj.onc.1201104	http://dx.doi.org/10.1038/sj.onc.1201104			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191050				2022-12-25	WOS:A1997XA94900002
J	Liu, QJ; Huang, SS; Huang, JS				Liu, QJ; Huang, SS; Huang, JS			Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; II RECEPTOR; AUTOCRINE TRANSFORMATION; KINASE; EXPRESSION; IDENTIFICATION; RESPONSIVENESS; SPECIFICITY; COMPLEXES; MECHANISM	The type V transforming growth factor beta (TGF-beta) is a 400-kDa nonproteoglycan membrane protein that co-expresses with the type I, type II, and type III TGF-beta receptors in most cell types, The type V TGF-beta receptor exhibits a Ser/Thr-specific protein kinase activity with distinct substrate specificity (Liu, Q., Huang, S. S., and Huang, J. (1994) J. Biol. Chem. 269, 9221-9226). In mink lung epithelial cells, the type V TGF-beta receptor was found to form heterocomplexes with the type I TGF-beta receptor by immunoprecipitation with antiserum to the type V TGF-beta receptor after I-125-TGF-beta affinity labeling or Trans(35)S-label metabolic labeling of the cells, The kinase activity of the type V TGF-beta receptor was stimulated after treatment of mink lung epithelial cells with TGF-beta. TGF-beta stimulation resulted in the growth inhibition of wild-type mink lung epithelial cells and to a lesser extent of the type I and type II TGF-beta receptor-defective mutants, although higher concentrations of TGF-beta were required for the growth inhibition of these mutants, TGF-beta was unable to induce growth inhibition in human colorectal carcinoma cells lacking the type V TGF-beta receptor but expressing the type I and type II TGF-beta receptors, These results suggest that the type V TGF-beta receptor can mediate the TGF-beta-induced growth inhibitory response in the absence of the type I or type II TGF-beta receptor, These results also support the hypothesis that loss of the type V TGF-beta receptor may contribute to the malignancy of certain carcinoma cells.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; HUANG SS, 1988, J BIOL CHEM, V263, P12608; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU QJ, 1994, J BIOL CHEM, V269, P9221; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LUO KX, 1995, P NATL ACAD SCI USA, V92, P11761, DOI 10.1073/pnas.92.25.11761; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OGRADY P, 1992, J BIOL CHEM, V267, P21035; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P410; SHAH M, 1995, J CELL SCI, V108, P985; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	27	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18891	18895		10.1074/jbc.272.30.18891	http://dx.doi.org/10.1074/jbc.272.30.18891			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228067	hybrid			2022-12-25	WOS:A1997XM34200058
J	Nair, D; Misra, RP; Sallis, JD; Cheung, HS				Nair, D; Misra, RP; Sallis, JD; Cheung, HS			Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; HYDROXYAPATITE; GROWTH; PHOSPHORYLATION; TRANSCRIPTION; INDUCTION; PROSTAGLANDIN-E2; PROTOONCOGENES; CHONDROCYTES; COLLAGENASE	Calcium deposition diseases caused by calcium pyrophosphate dihydrate (CPPD) and basic calcium phosphate (BCP) crystals are a significant source of morbidity in the elderly, We have shown previously that both types of crystals can induce mitogenesis, as well as metalloproteinase synthesis and secretion by fibroblasts and chondrocyte, These responses may promote degradation of articular tissues, We have also shown previously that both CPPD and BCP crystals activate expression of the c-fos and c-jun proto oncogenes. Phosphocitrate (PC) can specifically block mitogenesis and proto-oncogene expression induced by either BCP or CPPD crystals in 3T3 cells and human fibroblasts, suggesting that PC may be an effective therapy for calcium deposition diseases, To understand how PC inhibits BCP and CPPD-mediated cellular effects, we have investigated the mechanism by which BCP and CPPD transduce signals to the nucleus, Here we demonstrate that BCP and CPPD crystals activate a protein kinase signal transduction pathway involving p42 and p44 mitogen activated protein (MAP) kinases (ERK 2 and ERK 1). BCP and CPPD also cause phosphorylation of a nuclear transcription factor, cyclic AMP response element-binding protein (CREB), on serine 133, a residue essential for CREB's ability to transactivate. Treatment of cells with PC at concentrations of 10(-3) to 10(-5) M blocked both the activation of p42/p44 MAP kinases, and CREB serine 133 phosphorylation, in a dose-dependent fashion, At 10(-3) M, a PC analogue, n-sulfo-2-aminotricarballylate and citrate also modulate this signal transduction pathway, Inhibition by PC is specific for BCP- and CPPD-mediated signaling, since all three compounds had no effect on serum-induced p42/P44 or interleukin-1 beta induced p38 MAP kinase activities. Treatment of cells with an inhibitor of MEK1, an upstream activator of MAPKs, significantly inhibited crystal-induced cell proliferation, suggesting that the MAPK pathway is a significant mediator of crystal-induced signals.	UNIV MIAMI,SCH MED,DEPT MED ARTHRIT,MIAMI,FL 33135; VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,MIAMI,FL 33135; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; UNIV TASMANIA,DEPT BIOCHEM,HOBART,TAS 7001,AUSTRALIA	University of Miami; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical College of Wisconsin; University of Tasmania					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051856] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38421] Funding Source: Medline; NIGMS NIH HHS [R55GM/OD51856] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETT JAS, 1967, J AM CHEM SOC, V89, P5535, DOI 10.1021/ja00998a003; BROWN MR, 1985, UROLITHIASIS RELATED, P891; Cheung HS, 1996, BBA-MOL BASIS DIS, V1315, P105, DOI 10.1016/0925-4439(95)00106-9; CHEUNG HS, 1989, CANCER RES, V49, P134; CHEUNG HS, 1988, RHEUM DIS CLIN N AM, V14, P365; CHEUNG HS, 1986, J CELL PHYSIOL, V128, P143, DOI 10.1002/jcp.1041280202; Cheung HS, 1996, J BIOL CHEM, V271, P28082, DOI 10.1074/jbc.271.45.28082; CHEUNG HS, 1983, P SOC EXP BIOL MED, V173, P181; CHEUNG HS, 1993, BASIC CLIN ASPECTS I, P209; CURRAN T, 1988, COLD SPRING HARB SYM, V53, P769, DOI 10.1101/SQB.1988.053.01.087; DAYER JM, 1987, ARTHRITIS RHEUM, V30, P1372, DOI 10.1002/art.1780301208; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALVERSON PB, 1992, ARTHRITIS ALLIED CON, P1737; HOWARD JE, 1976, JOHNS HOPKINS MED J, V139, P239; JOHNSSON M, 1991, CALCIFIED TISSUE INT, V49, P134, DOI 10.1007/BF02565136; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KRUG HE, 1993, ARTHRITIS RHEUM, V36, P1603, DOI 10.1002/art.1780361116; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY GM, 1992, J CELL PHYSIOL, V153, P140, DOI 10.1002/jcp.1041530118; MCCARTY DJ, 1979, ARTHRITIS RHEUM, V22, P718, DOI 10.1002/art.1780220705; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MITCHELL PG, 1989, J BIOL CHEM, V264, P14071; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; PANKOWSKI AH, 1994, TETRAHEDRON LETT, V35, P227; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROTHENBERG RJ, 1987, ARTHRITIS RHEUM, V30, P266, DOI 10.1002/art.1780300304; ROTHENBERG RJ, 1988, AM J PHYSIOL-CELL PH, V23, pC554; RYAN LM, 1992, ARTHRITIS ALLIED CON, P1711; SALLIS JD, 1995, SCANNING MICROSCOPY, V9, P127; SHANKAR R, 1985, ATHEROSCLEROSIS, V50, P191; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; TEW WP, 1981, P NATL ACAD SCI-BIOL, V78, P5528, DOI 10.1073/pnas.78.9.5528; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WIERZBICKI A, 1995, CALCIFIED TISSUE INT, V56, P297, DOI 10.1007/BF00318050; WILLIAMS G, 1982, CALCIFIED TISSUE INT, V34, P169, DOI 10.1007/BF02411229; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	36	62	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18920	18925		10.1074/jbc.272.30.18920	http://dx.doi.org/10.1074/jbc.272.30.18920			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228071	hybrid			2022-12-25	WOS:A1997XM34200062
J	Schlador, ML; Nathanson, NM				Schlador, ML; Nathanson, NM			Synergistic regulation of m2 muscarinic acetylcholine receptor desensitization and sequestration by G protein-coupled receptor kinase-2 and beta-arrestin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT-PHOSPHORYLATION; MEDIATED GENE-TRANSCRIPTION; EMBRYONIC CHICK HEART; GTP-BINDING-PROTEIN; CHOLINERGIC RECEPTORS; WILD-TYPE; ADENYLYL-CYCLASE; RAT-BRAIN; EXPRESSION; CLONING	The m2 muscarinic acetylcholine receptor (m2 mAChR) belongs to the superfamily of G protein coupled receptors and is regulated by many processes that attenuate signaling following prolonged stimulation by agonist, We used a heterologous expression system to examine the ability of G protein-coupled receptor kinase-2 (GRK2) and beta-arrestin-1 to regulate the phosphorylation state and to promote desensitization and sequestration of the m2 mAChR. Treatment of JEG-3 cells transiently expressing the m2 mAChR with a muscarinic agonist induced an similar to 4- or 8-fold increase in receptor phosphorylation in the absence or presence of cotransfected GRK2, respectively, compared with untreated cells transfected with receptor alone. Using the expression of a cAMP-regulated reporter gene to measure receptor function, we found that transiently transfected m2 mAChRs underwent functional desensitization following exposure to agonist, Transfected GRK2 enhanced agonist-induced functional desensitization in a manner that was synergistically enhanced by cotransfection of beta-arrestin-1, which had no effect on m2 mAChR function when coexpressed in the absence of GRK2. Finally, GRK2 and beta-arrestin-1 synergistically enhanced both the rate and extent of agonist-induced m2 mAChR sequestration. These results are the first to demonstrate that agonist-induced desensitization and sequestration of the m2 mAChR in the intact cell can be enhanced by the presence of GRK2, and beta-arrestin-1 and show that these molecules have multiple actions on the m2 mAChR.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL44948] Funding Source: Medline; NIGMS NIH HHS [GM07270] Funding Source: Medline; NINDS NIH HHS [NS26920] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HUNTER DD, 1986, J NEUROSCI, V6, P3739; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MCKINNON LA, 1995, J BIOL CHEM, V270, P20636, DOI 10.1074/jbc.270.35.20636; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4871; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; MIGEON JC, 1994, J BIOL CHEM, V269, P29146; MORO O, 1993, J BIOL CHEM, V268, P6862; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NATHANSON NM, 1989, MUSCARINIC RECEPTORS, P419; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Sambrook J., 2002, MOL CLONING LAB MANU; Tiberi M, 1996, J BIOL CHEM, V271, P3771; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VILARO MT, 1992, NEUROSCIENCE, V47, P367, DOI 10.1016/0306-4522(92)90253-X; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	54	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18882	18890		10.1074/jbc.272.30.18882	http://dx.doi.org/10.1074/jbc.272.30.18882			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228066	hybrid			2022-12-25	WOS:A1997XM34200057
J	White, JA; BeckettJones, B; Guo, YD; Dilworth, FJ; Bonasoro, J; Jones, G; Petkovich, M				White, JA; BeckettJones, B; Guo, YD; Dilworth, FJ; Bonasoro, J; Jones, G; Petkovich, M			cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450 (CYP26)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; CELLS; RESISTANCE; RECEPTORS; PROTEIN; HAMSTER; CANCER	Retinoids, including all-trans retinoic acid (RA) and its stereoisomer 9-cis-RA play important roles in regulating gene expression, through interactions with nuclear receptors, during embryonic development and in the maintenance of adult epithelial tissues (Chambon, P. (1995) Rec. Prog. Horm. Res. 50, 317-32; Mangelsdorf, D. J., and Evans, R. M. (1995) Cell 83, 841-850; Petkovich, M. (1992) Annu. Rev. Nutr. 12, 443-471). Evidence suggests that 4-hydroxylation of RA inside the target cell limits its biological activity and initiates a degradative process of RA leading to its eventual elimination. However, 18-hydroxylation and glucuronidation may also be important steps in this process. In this paper, we describe the cloning and characterization of the first mammalian retinoic acid-inducible retinoic acid-metabolizing cytochrome P450 (hP450RAI), which belongs to a novel class of cytochromes (CYP26). We demonstrate that hP450RAI is responsible for generation of several hydroxylated forms of RA, including 4-OH-RA, 4-oxo-RA, and 18-OH-RA. We also show that hP450RAI mRNA expression is highly induced by RA in certain human tumor cell lines and further show that RA-inducible RA metabolism may correlate with P450RAI expression. We conclude that this enzyme plays a key role in RA metabolism, functioning in a feedback loop where RA levels are controlled in an autoregulatory manner.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada				Dilworth, F. Jeffrey/0000-0002-6265-8102				Blaner William S., 1994, P229; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRENTANO ST, 1992, ENDOCRINOLOGY, V131, P3010, DOI 10.1210/en.131.6.3010; CAMPLING BG, 1995, CANCER, V75, P2442, DOI 10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; DeCoster R, 1996, J STEROID BIOCHEM, V56, P133, DOI 10.1016/0960-0760(95)00230-8; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUBLER ML, 1990, METHOD ENZYMOL, V189, P525; Han IS, 1996, J CLIN ENDOCR METAB, V81, P2069, DOI 10.1210/jc.81.6.2069; JONES BB, 1995, MOL CELL BIOL, V15, P5226; Kurlandsky SB, 1996, J BIOL CHEM, V271, P15346, DOI 10.1074/jbc.271.26.15346; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANOTTE M, 1991, BLOOD, V77, P1080; LEO MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P305, DOI 10.1016/0003-9861(84)90353-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MOASSER MM, 1994, ONCOGENE, V9, P833; MUINDEL JR, 1994, LEUKEMIA BALTIMORE, P1807; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; ROBERTS AB, 1979, J BIOL CHEM, V254, P6303; SEBAG M, 1992, J BIOL CHEM, V267, P12162; Taimi M, 1997, BIOCHEM BIOPH RES CO, V232, P432, DOI 10.1006/bbrc.1997.6309; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WOUTERS W, 1992, CANCER RES, V52, P2841; Zheng WL, 1996, ENDOCRINOLOGY, V137, P5028, DOI 10.1210/en.137.11.5028	27	328	348	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18538	18541		10.1074/jbc.272.30.18538	http://dx.doi.org/10.1074/jbc.272.30.18538			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228017	hybrid			2022-12-25	WOS:A1997XM34200008
J	Watson, F; Gasmi, L; Edwards, SW				Watson, F; Gasmi, L; Edwards, SW			Stimulation of intracellular Ca2+ levels in human neutrophils by soluble immune complexes - Functional activation of Fc gamma RIIIb during priming	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNOVIAL-FLUID; TYROSINE PHOSPHORYLATION; RHEUMATOID-ARTHRITIS; RESPIRATORY BURST; MEDIATED PHAGOCYTOSIS; SIGNAL TRANSDUCTION; RECEPTOR EXPRESSION; OXIDASE ACTIVITY; NADPH OXIDASE; MECHANISMS	Soluble immune complexes bind to unprimed neutrophils and generate intracellular Ca2+ transients but fail to activate the NADPH oxidase. Following priming of the neutrophils with either tumor necrosis factor alpha of granulocyte-macrophage colony-stimulating factor, stimulation of the cells with the soluble immune complexes leads to an enhanced Ca2+ signal and significant secretion of reaction oxidants. The enhanced Ca2+ signal observed in primed neutrophils results from the influx of Ca2+ from the external environment and is partly sensitive to tyrosine kinase inhibitors. This is in contrast to the Ca2+ signal observed in unprimed neutrophils, which arises from the mobilization of intracellular stores. When the surface expression of Fc gamma RIIIb on primed neutrophils was decreased wither through incubation with Pronase of phosphoinositide-specific phospholipase C, the extra enhanced Ca2+ mobilization seen in primed cells was significantly lowered, while the initial rise in intracellular Ca2+ was unaffected. Depletion of Fc gamma RIIIb had no significant effect on the Ca2+ transients in unprimed neutrophils. Cross-linking Fc gamma RII, but not Fc gamma RIIIb, induced increase in intracellular Ca2+ in unprimed neutrophils, while cross-linking either of these receptors increased Ca2+ levels in primed neutrophils. The Fc gamma RII-dependent intracellular Ca2+ rise in primed cells was unaffected by incubation in Ca2+-free medium, whereas the Fc gamma RIIIb-dependent transient was significantly decreased when Ca2+ influx was prevented in Ca2+-free medium supplemented with EGTA. Cross-linking wither Fc gamma RII or Fc gamma RIIIb in primed or unprimed cells failed to stimulate substantial levels of inositol 1,4,5-trisphosphate production. These results indicate that following stimulation of primed neutrophils with soluble immune complexes the enhanced Ca2+ mobilization observed is the result of a functional activation of the glycosylphosphatidylinositol-linked Fc gamma RIIIb.	UNIV LIVERPOOL,SCH BIOL SCI,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool				Edwards, Steven/0000-0002-7074-0552				ABRAHAM JS, 1993, NATURAL IMMUNE SYSTE; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BRUNKHORST BA, 1992, J BIOL CHEM, V267, P20659; CROCKETTTORABI E, 1990, J IMMUNOL, V145, P3026; DEHAAS M, 1995, BLOOD, V86, P2403, DOI 10.1182/blood.V86.6.2403.bloodjournal8662403; Dularay B, 1988, Autoimmunity, V1, P159, DOI 10.3109/08916938808997161; DUSI S, 1994, BIOCHEM BIOPH RES CO, V201, P30, DOI 10.1006/bbrc.1994.1665; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; Edwards Steven W., 1996, Methods (Orlando), V9, P563, DOI 10.1006/meth.1996.0064; EDWARDS SW, 1990, BIOSCIENCE REP, V10, P393, DOI 10.1007/BF01117239; EDWARDS SW, 1995, TRENDS BIOCHEM SCI, V20, P362, DOI 10.1016/S0968-0004(00)89077-5; EDWARDS SW, 1987, J CLIN LAB IMMUNOL, V22, P35; EDWARDS SW, 1990, FREE RADICAL RES COM, V256, P333; EMERY P, 1991, ANN RHEUM DIS, V47, P34; FEARON DT, 1983, J IMMUNOL, V130, P370; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; HENSON PM, 1972, AM J PATHOL, V68, P593; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KUIJPERS TW, 1991, BLOOD, V78, P1105; MACKENZIE SJ, 1995, BIOCHEM J, V306, P519, DOI 10.1042/bj3060519; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MERRY P, 1989, ANN RHEUM DIS, V48, P864, DOI 10.1136/ard.48.10.864; NAZIRUDDIN B, 1992, J IMMUNOL, V149, P3702; NURCOMBE HL, 1991, ANN RHEUM DIS, V50, P147, DOI 10.1136/ard.50.3.147; NURCOMBE HL, 1991, ANN RHEUM DIS, V50, P237, DOI 10.1136/ard.50.4.237; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RICHARD S, 1994, BIOCHEM BIOPH RES CO, V199, P653, DOI 10.1006/bbrc.1994.1278; ROBINSON J, 1992, BIOCHEM J, V286, P345, DOI 10.1042/bj2860345; ROBINSON JJ, 1992, EUR J CLIN INVEST, V22, P314, DOI 10.1111/j.1365-2362.1992.tb01468.x; ROBINSON JJ, 1993, ANN RHEUM DIS, V52, P347, DOI 10.1136/ard.52.5.347; ROBINSON JJ, 1994, FEMS IMMUNOL MED MIC, V8, P247; ROSALES C, 1991, J IMMUNOL, V146, P3937; ROSALES C, 1992, J BIOL CHEM, V267, P5265; SALMON JE, 1991, J IMMUNOL, V146, P997; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; VEYS PA, 1991, BLOOD, V78, P852, DOI 10.1182/blood.V78.3.852.bloodjournal783852; VOSSEBELD PJM, 1995, J BIOL CHEM, V270, P10671, DOI 10.1074/jbc.270.18.10671; WALKER BAM, 1991, J IMMUNOL, V146, P735; WATSON F, 1991, J BIOL CHEM, V266, P7432; WATSON F, 1992, BIOSCIENCE REP, V12, P123, DOI 10.1007/BF02351217; WATSON F, 1993, ANN RHEUM DIS, V52, P353; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407	48	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17944	17951		10.1074/jbc.272.29.17944	http://dx.doi.org/10.1074/jbc.272.29.17944			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218419	hybrid			2022-12-25	WOS:A1997XL73500009
J	Matsuguchi, T; Zhao, YM; Lilly, MB; Kraft, AS				Matsuguchi, T; Zhao, YM; Lilly, MB; Kraft, AS			The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha subunit is essential for both GM-CSF-mediated growth and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BETA-SUBUNIT; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; TRANSCRIPTIONAL ACTIVATION; EXPRESSION CLONING; BONE-MARROW; CELL-GROWTH; C-JUN; PROTEINS; INTERLEUKIN-3	Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates differentiation, survival, and proliferation of colony-forming unit-granulocyte-macrophage progenitor cells. The biologic actions of GM-CSF are mediated by binding to a specific receptor consisting of two chains designated as alpha and beta subunits. We have demonstrated that the murine FDC-P1-derived cell line WT-19 transfected with the human GM-CSF receptor alpha and beta subunits (GM-CSFR alpha and beta) can be induced to differentiate by the addition of human GM-CSF (hGM-CSF). By expressing a series of GM-CSFR alpha cytoplasmic domain that regulate cell differentiation, proliferation, and survival. We found that the membrane proximal proline-rich domain and adjacent 16 residues are essential for both hGM-CSF-dependent cell proliferation and differentiation. In contrast, the C-terminal region of the GM-CSFR alpha cytoplasmic domain was not necessary for cell differentiation mediated by hGM-CSF, but the removal of this region severely impaired the ability of hGM-CSF to support cell survival. While the activation of JAK2, Shc, Erk, and STAT5 proteins correlated with hGM-CSF-mediated cell growth, cellular differentiation occurred in the absence of activation of these signal transduction pathways.	UNIV COLORADO,HLTH SCI CTR,DIV MED ONCOL,DENVER,CO 80262; UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40536; UNIV WASHINGTON,DIV MED ONCOL,SEATTLE,WA 98108; VET ADM MED CTR,SEATTLE,WA 98108	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Kentucky; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA045672, R01CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEXTER TM, 1980, J EXP MED, V152, P1026; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EMERSON SG, 1989, BLOOD, V74, P49; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HO MK, 1983, J BIOL CHEM, V258, P636; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI JM, 1994, CELL GROWTH DIFFER, V5, P743; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; PARK LS, 1986, J BIOL CHEM, V261, P4177; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAINES MA, 1991, P NATL ACAD SCI USA, V88, P8203, DOI 10.1073/pnas.88.18.8203; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SIEFF CA, 1985, SCIENCE, V230, P1171, DOI 10.1126/science.3877981; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Till KJ, 1996, BLOOD, V88, P479, DOI 10.1182/blood.V88.2.479.bloodjournal882479; TOMONAGA M, 1986, BLOOD, V67, P31; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WEISS M, 1993, BLOOD, V82, P3298; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOKOTA T, 1993, LEUKEMIA, V7, pS102; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	51	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17450	17459		10.1074/jbc.272.28.17450	http://dx.doi.org/10.1074/jbc.272.28.17450			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211889	hybrid			2022-12-25	WOS:A1997XK16500032
J	Arribas, J; LopezCasillas, F; Massague, J				Arribas, J; LopezCasillas, F; Massague, J			Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; T-LYMPHOCYTES; TNF RECEPTOR; TGF-ALPHA; MEMBRANE; CLEAVAGE; INHIBITOR; BETAGLYCAN; PROTEOGLYCAN	Although regulated ectodomain shedding is a well known process that affects a large group of transmembrane molecules, it is not clear how the shedding system selects its substrates. Here we investigate the structural requirements for the regulated shedding of two substrates of the general shedding system, the transforming growth factor-alpha precursor, pro-TGF-alpha and the beta-amyloid precursor protein, beta-APP. The ability of different regions of pro-TGF-alpha or beta-APP to confer susceptibility to the shedding system was tested using as a reporter a transmembrane molecule that is not a substrate of this shedding system. For this purpose we chose the TGF-beta accessory receptor, betaglycan, since genetic and biochemical evidence showed that betaglycan is not a substrate of the shedding system, We determined that replacement of the 14 extracellular amino acids adjacent to the transmembrane region of betaglycan with the corresponding regions of TGF-alpha or beta-APP rendered betaglycan susceptible to ectodomain shedding, These domain swap constructs were cleaved ill response to protein kinase C stimulation, and cleavage. was prevented by the metalloprotease inhibitor TAPI, both effects being characteristic of the general shedding system, Domain swap constructs containing the transmembrane and/or the cytoplasmic domains of pro-TGF-alpha did not undergo regulated ectodomain cleavage. We conclude that despite a lack of sequence similarity, the extracellular regions of pro-TGF-alpha and beta-APP immediately preceding their transmembrane domains are key determinants of ectodomain shedding.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; NATL AUTONOMOUS UNIV MEXICO,INST FISIOL CELULAR,MEXICO CITY 04510,DF,MEXICO	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Universidad Nacional Autonoma de Mexico			Arribas, Joaquin/M-4482-2014; Arribas, Jose/A-1595-2015	Arribas, Joaquin/0000-0002-0504-0664; Massague, Joan/0000-0001-9324-8408; Arribas, Jose/0000-0002-7410-9450				ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CROWE PD, 1993, J IMMUNOL, V151, P6882; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Deng P, 1996, J BIOL CHEM, V271, P16338, DOI 10.1074/jbc.271.27.16338; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; XU H, 1996, J BIOL CHEM, V270, P23243	29	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17160	17165		10.1074/jbc.272.27.17160	http://dx.doi.org/10.1074/jbc.272.27.17160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202036	hybrid			2022-12-25	WOS:A1997XH44600068
J	Kim, JK; Palaniappan, C; Wu, WM; Fay, PJ; Bambara, RA				Kim, JK; Palaniappan, C; Wu, WM; Fay, PJ; Bambara, RA			Evidence for a unique mechanism of strand transfer from the transactivation response region of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 NUCLEOCAPSID PROTEIN; RNA ANNEALING ACTIVITIES; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; TAT GENE-PRODUCT; REVERSE-TRANSCRIPTASE; INTERNAL REGIONS; RETROVIRAL RECOMBINATION; TEMPLATES	We previously found that strand transfer by human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is promoted at sites where RT pauses during synthesis, In this report, strand transfer is measured within the 5' transactivation response region (TAR) of HIV-1 RNA, We hypothesized that the stable hairpin structure of TAR would induce RT pausing, promoting RNase II-directed cleavage of the template and subsequent transfer at that site, We further predicted that HIV-1 nucleocapsid protein (NC), known to melt secondary structures, would decrease transfer, We show that TAR created a strong pause site for RT, but NC significantly promoted strand transfer, The effect of NC is specific, since other single strand binding proteins failed to stimulate transfer, In another unexpected outcome, preferred positions of internal transfer were not at the pause site but were in the upper stem and loop of TAR, Thus, we propose a new mechanism for transfer within TAR described by an interactive hairpin model, in which association between the donor and the acceptor templates within the TAR stem promotes transfer, The model is consistent with the observed stimulation of strand transfer by NC, The model is applicable to internal and replicative end transfer.	UNIV ROCHESTER,MED CTR,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUISER RG, 1993, BIOCHIM BIOPHYS ACTA, V1216, P20, DOI 10.1016/0167-4781(93)90033-A; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOWELL RM, 1991, AIDS RES HUM RETROV, V7, P869, DOI 10.1089/aid.1991.7.869; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KHAN R, 1992, J BIOL CHEM, V267, P6689; KLAVER B, 1994, NUCLEIC ACIDS RES, V22, P137, DOI 10.1093/nar/22.2.137; KORNBERG A, 1992, DNA REPLICATION, P323; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Sambrook J., 2002, MOL CLONING LAB MANU; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491	36	98	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16769	16777		10.1074/jbc.272.27.16769	http://dx.doi.org/10.1074/jbc.272.27.16769			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201981	hybrid			2022-12-25	WOS:A1997XH44600013
J	Mark, MD; Storm, DR				Mark, MD; Storm, DR			Coupling of epidermal growth factor (EGF) with the antiproliferative activity of cAMP induces neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; G1 CYCLIN EXPRESSION; PROTEIN-KINASE; AMP; INHIBITION; ENCODES; PROLIFERATION; TRIGGERS; YEAST; GENE	Nerve growth factor (NGF) functions as a progression factor with both mitogenic and antimitogenic activities. When PC12 cells are treated with NGF, they advance to the G(1) stage of the cell cycle before they differentiate, The correlation between cessation of proliferation and differentiation suggests that the antimitotic activity of NGF may be obligatory for differentiation Although epidermal growth factor- (EGF) and NGF-treated PC12 cells share several common properties, including activation of the mitogen-activated protein (MAP) kinase pathway and induction of immediate early genes, EGF is mitogenic for PC12 cells and does not normally stimulate differentiation However, combinations of EGF and low levels of cAMP stimulate differentiation even though neither agent alone does (Mark, M. D., Liu, Y., Wong, S. T., Hinds, T. R., and Storm, D.R. (1995) J. Cell Biol. 130, 701-710), Since EGF is mitogenic for PC12 cells and differentiation may not occur until proliferation is inhibited, differentiation caused by cAMP and EGF may be due to the antiproliferative activity of cAMP, To test this hypothesis, we examined the effect of EGF or combinations of EGF and cAMP on PC12 cell proliferation. EGF alone stimulated proliferation of PC12 cells and increased the levels of several cell cycle progression factors including cdk2, cdk4, and cyclin B1, Cyclic AMP inhibited the EGF-stimulated increases in cell cycle progression factors as well as proliferation, Other antiproliferative agents including rapamycin, mimosine, and nitric oxide agonists also synergized with EGF to stimulate differentiation, These data indicate that the coupling of antiproliferative signals with EGF modifies the biological properties of EGF and converts it to a differentiating growth factor.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Mark, Melanie/ABF-9102-2020	Mark, Melanie/0000-0002-2788-6003	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020498] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20498] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchkovich K, 1994, MOL BIOL CELL, V5, P1226; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COHEN STANLEY, 1965, DEVELOP BIOL, V12, P394, DOI 10.1016/0012-1606(65)90005-9; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; GAGELIN C, 1994, BIOCHEM BIOPH RES CO, V205, P923, DOI 10.1006/bbrc.1994.2753; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2421; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HARTWELL L, 1994, NATURE, V371, P286, DOI 10.1038/371286a0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; HUFFAKER T, 1984, J CELL PHYSIOL, V120, P188, DOI 10.1002/jcp.1041200212; IGNATIUS MJ, 1985, J NEUROSCI, V5, P343; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SEWING A, 1993, J CELL SCI, V104, P545; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, 1993, ONCOGENE, V8, P174; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VALVERDE AM, 1995, EXP CELL RES, V218, P305, DOI 10.1006/excr.1995.1159; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VITTET D, 1995, J CELL PHYSIOL, V163, P645, DOI 10.1002/jcp.1041630327; YAN GZ, 1995, J NEUROSCI, V15, P6200	39	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17238	17244		10.1074/jbc.272.27.17238	http://dx.doi.org/10.1074/jbc.272.27.17238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202048	hybrid			2022-12-25	WOS:A1997XH44600080
J	Wu, MY; Hsu, TL; Lin, WW; Campbell, RD; Hsieh, SL				Wu, MY; Hsu, TL; Lin, WW; Campbell, RD; Hsieh, SL			Serine/threonine kinase activity associated with the cytoplasmic domain of the lymphotoxin-beta receptor in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR TNF RECEPTOR; PROTEIN-KINASE; HETEROMERIC COMPLEX; 33-KDA GLYCOPROTEIN; SIGNAL-TRANSDUCTION; SURFACE; MICE; FAMILY; IDENTIFICATION	The lymphotoxin-beta receptor (LT-beta R) has been shown to be the receptor for the membrane-bound lymphotoxin heterotrimers LT alpha 1/beta 2 and LT alpha 2/beta 1. The extracellular domain of LT-beta R shows extensive similarity with members of the turner necrosis factor receptor family, while its cytoplasmic domain is distinct and lacks any inherent enzymatic activity. This suggests that the interaction of LT-beta R with other molecules might be important for signal transduction, Here we demonstrate the asso ciation of a fusion protein, comprising glutathione S-transferase and the cytoplasmic domain of LT-beta R (GST-LT-beta R(GD)), with several proteins in the size range 29-80 kDa from HepG2 cell lysates, We present evidence that two of these proteins are serine/threonine kinases, which associate with amino acids 324-377 of the cytoplasmic domain of LT-beta R and phosphorylate this receptor. The characteristics of these novel kinases indicate that they are distinct from the previously described tumor necrosis factor receptor-associated kinases, This suggests the presence of novel signal transduction pathway(s) for LT-beta R.	NATL YANG MING UNIV,DEPT MICROBIOL & IMMUNOL,SCH MED,TAIPEI 11221,TAIWAN; NATL YANG MING UNIV,SCH MED,IMMUNOL RES CTR,TAIPEI 11221,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PHARMACOL,TAIPEI 100,TAIWAN; UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taiwan University; University of Oxford			Hsu, Tsui-Ling/AAE-8821-2019; Hsieh, Shie-Liang Edmond/ABA-9184-2021; Hsu, Tsui-Ling/H-6704-2015	Hsu, Tsui-Ling/0000-0002-2912-3261; Lin, Wan Wan/0000-0002-3207-734X				ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BANKS TA, 1995, J IMMUNOL, V155, P1685; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1991, J IMMUNOL, V147, P1230; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DE TP, 1994, SCIENCE, V264, P703; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; GUO H, 1993, J BIOL CHEM, V268, P11193; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Mackay F, 1996, J BIOL CHEM, V271, P24934, DOI 10.1074/jbc.271.40.24934; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SONG HY, 1994, J BIOL CHEM, V269, P22492; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TOTPAL K, 1994, J IMMUNOL, V153, P2248; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211	38	9	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17154	17159		10.1074/jbc.272.27.17154	http://dx.doi.org/10.1074/jbc.272.27.17154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202035	hybrid			2022-12-25	WOS:A1997XH44600067
J	Burke, SA; Krzycki, JA				Burke, SA; Krzycki, JA			Reconstitution of monomethylamine:Coenzyme M methyl transfer with a corrinoid protein and two methyltransferases purified from Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; IRON-SULFUR PROTEIN; CO DEHYDROGENASE; CLOSTRIDIUM-THERMOACETICUM; METHIONINE SYNTHASE; ENZYME COMPLEX; ACETYL-COA; METHANOGENESIS; CENTERS; TRIMETHYLAMINE	Methanogenesis from methylamines requires the intermediate methylation of 2-mercaptoethanesulfonate (CoM). In vitro reconstitution of CoM methylation with monomethylamine was achieved with three purified proteins: a monomethylamine corrinoid protein (MMCP), the ''A'' isozyme of methylcobamide:CoM methyltransferase (MTS-A), and a newly isolated protein termed monomethylamine methyltransferase (MMAMT). MMAMT is a 170-kDa protein with 52-kDa subunits. The MMAMT polypeptide was rate-limiting for methyl transfer until at a 2-fold molar excess over MMCP. MMAMT is a monomethylamine:MMCP methyltransferase, since methylation of MMCP required MMAMT but not MTS-A. MMCP and MMAMT formed a complex detectable by size exclusion high pressure liquid chromatography. Methyl group transfer from methyl-MMCP to CoM was mediated by MTS-A since methyl iodide:CoM methyl transfer by MMCP and MTS-A did not require MMAMT. MTS-M, an isozyme of MTS-A, was inactive in MMCP-dependent methyl transfer. Immunodepletion of MMCP from the extract inhibited CoM methylation with monomethylamine but mot dimethylamine. Purified MMCP reconstituted activity in immunodepleted extracts. These results show that MMCP is the major corrinoid protein for methanogenesis from monomethylamine detectable in extracts and that it interacts with two methyltransferases. MMAMT functions as a MMA: MMCP methyltransferase, while MTS-A functions as a methyl-MMCP:CoM methyltransferase.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University								BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; Blaut Michael, 1993, P171; Boone David R., 1993, P35; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; CAO XJ, 1991, J BACTERIOL, V173, P5439, DOI 10.1128/jb.173.17.5439-5448.1991; Daas PJH, 1996, J BIOL CHEM, V271, P22346, DOI 10.1074/jbc.271.37.22346; DAAS PJH, 1993, J BACTERIOL, V175, P1278, DOI 10.1128/JB.175.5.1278-1283.1993; Daas PJH, 1996, J BIOL CHEM, V271, P22339, DOI 10.1074/jbc.271.37.22339; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Ferguson DJ, 1997, J BACTERIOL, V179, P846, DOI 10.1128/jb.179.3.846-852.1997; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; GRAHAME DA, 1993, BIOCHEMISTRY-US, V32, P10786, DOI 10.1021/bi00091a033; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; Harlow E, 1988, ANTIBODIES LAB MANUA, P564; Harms U, 1996, EUR J BIOCHEM, V235, P653, DOI 10.1111/j.1432-1033.1996.00653.x; HIPPE H, 1979, P NATL ACAD SCI USA, V76, P494, DOI 10.1073/pnas.76.1.494; JABLONSKI PE, 1993, J BIOL CHEM, V268, P325; KREMER JD, 1993, J BACTERIOL, V175, P4824, DOI 10.1128/JB.175.15.4824-4833.1993; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeClerc GM, 1996, J BIOL CHEM, V271, P18725, DOI 10.1074/jbc.271.31.18725; LU WP, 1990, J BIOL CHEM, V265, P3124; LU WP, 1995, J BACTERIOL, V177, P2245, DOI 10.1128/jb.177.9.2245-2250.1995; MCLACHLAN KL, 1990, J ELECTROANAL CHEM, V295, P113, DOI 10.1016/0022-0728(90)85009-T; NAUMANN E, 1984, ARCH MICROBIOL, V138, P79, DOI 10.1007/BF00425412; Paul L, 1996, J BACTERIOL, V178, P6599, DOI 10.1128/jb.178.22.6599-6607.1996; POL A, 1982, BIOCHEM BIOPH RES CO, V108, P731, DOI 10.1016/0006-291X(82)90890-7; POL A, 1984, BIOCHIM BIOPHYS ACTA, V797, P83, DOI 10.1016/0304-4165(84)90385-4; RAYBUCK SA, 1991, J BACTERIOL, V173, P929, DOI 10.1128/jb.173.2.929-932.1991; Sauer K, 1997, EUR J BIOCHEM, V243, P670, DOI 10.1111/j.1432-1033.1997.t01-1-00670.x; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tallant TC, 1996, J BACTERIOL, V178, P1295, DOI 10.1128/jb.178.5.1295-1301.1996; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; Wassenaar RW, 1996, J BACTERIOL, V178, P6937, DOI 10.1128/jb.178.23.6937-6944.1996; WEISS DS, 1993, CELL, V72, P819, DOI 10.1016/0092-8674(93)90570-G; Wolfe Ralph S., 1993, P1; YELISEEV A, 1993, ARCH MICROBIOL, V159, P530, DOI 10.1007/BF00249031; ZINDER SH, 1993, METHANOGENESIS ECOLO, P129	44	77	84	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16570	16577		10.1074/jbc.272.26.16570	http://dx.doi.org/10.1074/jbc.272.26.16570			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195968	hybrid			2022-12-25	WOS:A1997XG01900072
J	Ma, WL; Lehner, PJ; Cresswell, P; Pober, JS; Johnson, DR				Ma, WL; Lehner, PJ; Cresswell, P; Pober, JS; Johnson, DR			Interferon-gamma rapidly increases peptide transporter (TAP) subunit expression and peptide transport capacity in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-CLASS-I; MAJOR HISTOCOMPATIBILITY COMPLEX; MHC CLASS-I; TUMOR-NECROSIS-FACTOR; ANTIGEN PRESENTATION; ENDOPLASMIC-RETICULUM; PROTEASOME SUBUNITS; T-CELLS; UP-REGULATION; MUTANT MICE	Human cytotoxic T lymphocytes (CTL) recognize specific complexes of HLA class I molecules and peptides, which assemble when nascent class I molecules bind peptides transported from the cytoplasm into the endoplasmic reticulum by the heterodimeric transporter associated with antigen processing (TAP). Increased class I molecule expression on the cell surface increases the efficiency of CTL lysis. The kinetics of interferon (IFN)-gamma induction of TAP, peptide transport capacity, and HLA class I molecule expression was determined in endothelial cells, which are targets of CTL following transplantation or viral infection, TAP mRNAs are induced rapidly, increasing 20-fold (TAP1) or 10-fold (TAP2) by 12 h, whereas HLA class I mRNA is induced more slowly, increasing 10-fold in 24 h. TAP1 and TAP2 proteins are also induced rapidly, increasing 10-fold in 24 h, whereas HLA class I heavy chain proteins and surface expression increase more slowly. Peptide transport capacity in endothelial and HeLa cells increases within 6 h of IFN-gamma treatment, suggesting that the IFN-gamma-induced TAP heterodimers are functional. Therefore, the IFN-gamma-induced increase in TAP proteins is accompanied by an increased peptide transport capacity, which may be important in supporting the subsequent rise in HLA class I protein expression.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,MOL CARDIOBIOL PROGRAM,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University				Lehner, Paul Joseph/0000-0001-9383-1054	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035099] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL36003] Funding Source: Medline; NIAID NIH HHS [R29-AI35099] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; EPPERSON DE, 1994, J IMMUNOL, V153, P5402; EPPERSON DE, 1992, J IMMUNOL, V149, P3297; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; GABATHULER R, 1994, J EXP MED, V180, P1415, DOI 10.1084/jem.180.4.1415; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P5183, DOI 10.1073/pnas.87.13.5183; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOENIG S, 1990, J IMMUNOL, V145, P127; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MASHESHWARI R, 1980, NATURE, V287, P454; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Min W, 1996, J IMMUNOL, V156, P3174; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MULLBACHER A, 1995, IMMUNITY, V3, P207, DOI 10.1016/1074-7613(95)90090-X; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OLDEN K, 1982, NATURE, V300, P290, DOI 10.1038/300290a0; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Ozato Keiko, 1995, P80, DOI 10.1017/CBO9780511525339.005; PARHAM P, 1995, IMMUNOL REV, V143, P141, DOI 10.1111/j.1600-065X.1995.tb00674.x; POBER JS, 1987, J IMMUNOL, V138, P3319; REALINI C, 1994, J BIOL CHEM, V269, P20727; ROSENBERG AS, 1986, NATURE, V322, P829, DOI 10.1038/322829a0; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; YANG B, 1995, J IMMUNOL, V155, P3889; YEWDELL J, 1994, J IMMUNOL, V152, P1163; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	62	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16585	16590		10.1074/jbc.272.26.16585	http://dx.doi.org/10.1074/jbc.272.26.16585			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195970	hybrid			2022-12-25	WOS:A1997XG01900074
J	MarieCardine, A; Bruyns, E; Eckerskorn, C; Kirchgessner, H; Meuer, SC; Schraven, B				MarieCardine, A; Bruyns, E; Eckerskorn, C; Kirchgessner, H; Meuer, SC; Schraven, B			Molecular cloning of SKAP55, a novel protein that associates with the protein tyrosine kinase p59(fyn) in human T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; CROSS-LINKING; ACTIVATION; P59(FYN); BINDING; DOMAIN; DISTINCT; P59FYN; CELLS; TCR	In human T-lymphocytes the Src family protein tyrosine kinase p59(fyn) associates with three phosphoproteins of 43, 55, and 85 kDa (pp43, pp55, and pp85), Employing a GST-Fyn-Src homology 2 (SH2) domain fusion protein pp55 was purified from lysates of Jurkat T-cells, Molecular cloning of the pp55 cDNA reveals that the pp55 gene codes for a so far nondescribed polypeptide of 359 amino acids that comprises a pleckstrin homology domain, a C-terminal SH3 domain, as well as several potential tyrosine phosphorylation sites, among which one fulfills the criteria to bind Src-like SH2 domains with high affinity, Consistent with this observation, pp55 selectively binds to isolated SH2 domains of Lck, Lyn, Src, and Fyn but not to the SH2 domains of ZAP70, Syk, Shc, SLP-76, Grb2, phosphatidylinositol 3-kinase, and c-abl in vitro, Based on these properties the protein was termed SKAP55 (src kinase-associated phosphoprotein of 55 kDa). Northern blot analysis shows that SKAP55 mRNA is preferentially expressed in lymphatic tissues, SKAP55 is detected in resting human T-lymphocytes as a constitutively tyrosine phosphorylated protein that selectively interacts with p59(fyn). These data suggest that SKAP55 represents a novel adaptor protein likely involved in Fyn-mediated signaling in human T-lymphocytes.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society	MarieCardine, A (corresponding author), UNIV HEIDELBERG, INST IMMUNOL, NEUENHEIMER FELD 305, D-69120 HEIDELBERG, GERMANY.							APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARNI S, 1993, ONCOGENE, V8, P2485; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Fusaki N, 1996, J IMMUNOL, V156, P1369; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEE SK, 1994, INT IMMUNOL, V6, P1621, DOI 10.1093/intimm/6.10.1621; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; MarieCardine A, 1995, EUR J IMMUNOL, V25, P3290, DOI 10.1002/eji.1830251214; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIGLEY K, 1995, J IMMUNOL, V154, P1136; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	28	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16077	16080		10.1074/jbc.272.26.16077	http://dx.doi.org/10.1074/jbc.272.26.16077			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195899	hybrid			2022-12-25	WOS:A1997XG01900003
J	Miyoshi, H; Inoue, M; Okamoto, S; Ohshima, M; Sakamoto, K; Iwamura, H				Miyoshi, H; Inoue, M; Okamoto, S; Ohshima, M; Sakamoto, K; Iwamura, H			Probing the ubiquinone reduction site of mitochondrial complex I using novel cationic inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE DINUCLEOTIDE DEHYDROGENASE; ENERGY-COUPLING SITE-1; 1-METHYL-4-PHENYLPYRIDINIUM MPP+; OXIDATIVE-PHOSPHORYLATION; ELECTRON-TRANSPORT; PIERICIDIN-A; NADH; OXIDOREDUCTASE; ANALOGS; ACCUMULATION	A wide variety of N-methylpyridinium and quinolinium cationic inhibitors of mitochondrial complex I was synthesized to develop potent and specific inhibitors acting selectively at one of the two proposed ubiquinone binding sites of this enzyme (Gluck, M. R., Krueger, M. J., Ramsay, R. R., Sablin, S. O., Singer, T. P., and Nicklas, W. J. (1994) J. Biol. Chem. 269, 3167-3174). N-Methyl-2-n-dodecyl-3-methylquinolinium (MQ18) inhibited electron transfer of complex I at under mu M order regardless of whether exogenous or endogenous ubiquinone was used as an electron acceptor, The presence of tetraphenylboron (TPB-) potentiated the inhibition by MQ18 in a different way depending upon the molar ratio of TPB- to MQ18, In the presence of a catalytic amount of TPB-, the inhibitory potency of MQ18 was remarkably enhanced, and the extent of inhibition was almost complete, The presence of equimolar TPB- partially reactivated the enzyme activity, and the inhibition was saturated at an incomplete level (similar to 50%), These results are explained by the proposed dual binding sites model for ubiquinone (cited above), The inhibition behavior of MQ18 for proton pumping activity was similar to that for electron transfer activity, The good correlation of the inhibition behavior for the two activities indicates that both ubiquinone binding sites contribute to redox-driven proton pumping, On the other hand, N-methyl-4-[2-methyl-3-(p-tert-butylphenyl)]propylpyridinium (MP6) without TPB- brought about approximately 50% inhibition at 5 mu M, but the inhibition reached a plateau at this level over a wide range of concentrations, Almost complete inhibition was readily obtained at low concentrations of MP6 in the presence of TPB-. Thus MP6 appears to be a selective inhibitor of one of the two ubiquinone binding sites, with a combined use of MP6 and 2,3-diethoxy-5-methyl-6-geranyl-1,4-benzoquinone, we also provided kinetic evidence for the existence of two ubiquinone binding sites.			Miyoshi, H (corresponding author), KYOTO UNIV, DEPT AGR CHEM, SAKYO KU, KYOTO 606, JAPAN.		Sakamoto, Kimitoshi/G-4539-2014					AKIBA K, 1984, B CHEM SOC JPN, V57, P1994, DOI 10.1246/bcsj.57.1994; DEJONG AMP, 1994, EUR J BIOCHEM, V222, P975; Esposti MD, 1996, BIOCHEM J, V313, P327, DOI 10.1042/bj3130327; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; GLUCK MR, 1994, J BIOL CHEM, V269, P3167; GUTMAN M, 1970, J BIOL CHEM, V245, P1992; GUTMAN M, 1970, BIOCHEMISTRY-US, V9, P2678, DOI 10.1021/bi00815a016; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HE DY, 1994, BIOCHEMISTRY-US, V33, P880, DOI 10.1021/bi00170a005; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; KAISER EM, 1975, SYNTHESIS-STUTTGART, P705; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; KEAN EA, 1971, J BIOL CHEM, V246, P2346; LANDINI D, 1975, SYNTHESIS-STUTTGART, P430; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MURPHY MP, 1995, BIOCHEM J, V306, P359, DOI 10.1042/bj3060359; RAMSAY RR, 1992, BIOCHEM BIOPH RES CO, V189, P47, DOI 10.1016/0006-291X(92)91523-S; RAMSAY RR, 1989, P NATL ACAD SCI USA, V86, P9168, DOI 10.1073/pnas.86.23.9168; RAMSAY RR, 1991, BIOCHEM J, V273, P481, DOI 10.1042/bj2730481; Sakamoto K, 1996, EUR J BIOCHEM, V237, P128, DOI 10.1111/j.1432-1033.1996.0128n.x; Sakamoto K, 1996, J BIOL CHEM, V271, P29897, DOI 10.1074/jbc.271.47.29897; Satoh T, 1996, BBA-BIOENERGETICS, V1273, P21, DOI 10.1016/0005-2728(95)00131-X; SAYRE LM, 1990, ARCH BIOCHEM BIOPHYS, V280, P274, DOI 10.1016/0003-9861(90)90330-2; UENO H, 1994, EUR J BIOCHEM, V225, P411, DOI 10.1111/j.1432-1033.1994.00411.x; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; VINOGRADOV AD, 1993, J BIOENERG BIOMEMBR, V25, P367, DOI 10.1007/BF00762462; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8; YAGI T, 1987, BIOCHEMISTRY-US, V26, P2822, DOI 10.1021/bi00384a025; YAGI T, 1988, J BIOL CHEM, V263, P16150	33	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16176	16183		10.1074/jbc.272.26.16176	http://dx.doi.org/10.1074/jbc.272.26.16176			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195916	hybrid			2022-12-25	WOS:A1997XG01900020
J	Ramjaun, AR; Micheva, KD; Bouchelet, I; McPherson, PS				Ramjaun, AR; Micheva, KD; Bouchelet, I; McPherson, PS			Identification and characterization of a nerve terminal-enriched amphiphysin isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; SYNAPTIC VESICLES; DYNAMIN; PROTEIN; GENE; ENDOCYTOSIS; DROSOPHILA; VIABILITY; SHIBIRE; CLONING	Amphiphysin is a nerve terminal-enriched protein thought to function in synaptic vesicle endocytosis, in part through Src homology 3 (SH3) domain-mediated interactions with dynamin and synaptojanin. Here, we report the characterization of a novel amphiphysin isoform (termed amphiphysin II) that was identified through a homology search of the data base of expressed sequence tags. Antibodies specific to amphiphysin II recognize a 90-kDa protein on Western blot that is brain-specific and highly enriched in nerve terminals. Like amphiphysin (now referred to as amphiphysin I), amphiphysin II binds to dynamin and synaptojanin through its SH3 domain. Further, both proteins bind directly to clathrin in an SH3 domain-independent manner. Taken together, these data suggest that amphiphysin II may participate with amphiphysin I in the regulation of synaptic vesicle endocytosis.	MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	McGill University			Micheva, Kristina/ABH-6913-2020	Micheva, Kristina/0000-0003-1138-3732				BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bouchelet I, 1996, MOL PHARMACOL, V50, P219; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Estes PS, 1996, J NEUROSCI, V16, P5443; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Haffner C, 1996, MOL BIOL CELL, V7, P455; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STONE J, 1987, MOL CELL BIOL, V7, P1679; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	38	149	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16700	16706		10.1074/jbc.272.26.16700	http://dx.doi.org/10.1074/jbc.272.26.16700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195986	hybrid			2022-12-25	WOS:A1997XG01900090
J	WildBode, C; Yamazaki, T; Capell, A; Leimer, U; Steiner, H; Ihara, Y; Haass, C				WildBode, C; Yamazaki, T; Capell, A; Leimer, U; Steiner, H; Ihara, Y; Haass, C			Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; METABOLISM; PATHWAY; CELLS	Amyloid beta-peptide (A beta) is known to accumulate in senile plaques of Alzheimer's disease (AD) patients and is now widely believed to play a major role in the disease. Two populations of peptides occur terminating either at amino acid 40 or at amino acid 42 (A beta 1-40 and A beta 1-42). Alternative N-terminal cleavages produce additional heterogeneity (A beta x-40 and A beta x-42), Peptides terminating at amino acid 42 are believed to be the major player in sporadic AD as well as familial AD (FAD). Whereas the cellular mechanism for the generation of AP terminating at amino acid 40 is well understood, very little is known about the cleavage of A beta after amino acid 42, By using two independent methods we demonstrate intracellular A beta 1-42 as well as A beta x-42 but less A beta x-40 and A beta 1-40 in kidney 293 cells stably transfected with wild type beta-amyloid precursor protein (beta APP) or the FAD-associated Val/Gly mutation, Moreover, retention of beta APP within the endoplasmic reticulum (ER) by treatment with brefeldin A does not block the cleavage at amino acid 42 but results in an increased production of all species of A beta terminating at amino acid 42. This indicates that the cleavage after amino acid 42 can occur within the ER. Treatment of cells with monensin, which blocks transport of (beta APP) within the Golgi causes a marked accumulation of intracellular A beta x-42 and A beta x-40. Therefore these experiments indicate that the gamma-secretase cleavage of A beta after amino acid 42 can occur within the ER and later within the secretory pathway within the Golgi. Moreover inhibition of reinternalization by cytoplasmic deletions of beta APP as well as inhibition of intracellular acidification by NH4Cl does not block intracellular A beta 1-42 or A beta x-42 production.	CENT INST MENTAL HLTH,DEPT MOL BIOL,D-68159 MANNHEIM,GERMANY; UNIV TOKYO,DEPT NEUROPATHOL,INST BRAIN RES,FAC MED,TOKYO 113,JAPAN	Central Institute of Mental Health; University of Tokyo								BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Capell A, 1996, AMYLOID, V3, P150, DOI 10.3109/13506129609045514; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cotman Carl W., 1994, P305; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; HAASS C, 1994, J BIOL CHEM, V269, P17741; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Leimer U, 1996, EXP CELL RES, V224, P88, DOI 10.1006/excr.1996.0114; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; Masliah E, 1996, J NEUROSCI, V16, P5795; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHINKAI Y, 1995, ANN NEUROL, V38, P421, DOI 10.1002/ana.410380312; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	33	281	291	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16085	16088		10.1074/jbc.272.26.16085	http://dx.doi.org/10.1074/jbc.272.26.16085			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195901	hybrid			2022-12-25	WOS:A1997XG01900005
J	Ryan, KM; Birnie, GD				Ryan, KM; Birnie, GD			Cell-cycle progression is not essential for c-Myc to block differentiation	ONCOGENE			English	Article						cell-cycle progression; DNA binding; Max; c-Myc; myeloid differentiation; ornithine decarboxylase	NERVE GROWTH-FACTOR; ORNITHINE DECARBOXYLASE; TRANSCRIPTIONAL ACTIVATION; HL-60 CELLS; DNA-BINDING; EXPRESSION; PROTEIN; MAX; PROLIFERATION; APOPTOSIS	The c-myc proto-oncogene has been shown to cause blockages to differentiation in many cell lineages, Although the mechanism by which c-Myc affects this process remains unknown, it is considered that it might result indirectly as an outcome of the continued cell-cycle progression invoked by c-Myc in cells which must growth arrest in order to differentiate, However, as there is little evidence to support this hypothesis, it is equally possible that a differentiation blockage occurs through a mechanism independent of c-Myc's involvement in cell-cycle progression, To explore this possibility me utilised a differentiation-defective variant of the U937 cell line, which still responds to the differentiation inducer by undergoing rapid growth Analysis of this line during growth arrest revealed that, although the expression of the Myc target gene, ornithine decarboxylase (ODC) was down-regulated, the cells differed from those of the parental line in that they continued to express high levels of c-Myc protein, did not but maintain levels of expression of the Myc antagonists, mad1 and mxi1. Moreover, antisense down-regulation of the c-Myc protein levels in these growth-arrested cells revealed that this continued c-Myc expression was essential for their differentiation blockage, These data therefore indicate that c-Myc can block differentiation by a mechanism dissociated from its ability to direct cell-cycle progression or the expression of ODC.	BEATSON INST CANC RES, CANC RES CAMPAIGN, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute				Ryan, Kevin M./0000-0002-1059-9681				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BACON TA, 1991, ONCOGENE RES, V6, P21; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CHAVANY C, 1995, MOL PHARMACOL, V48, P738; CROUCH DH, 1993, ONCOGENE, V8, P1849; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIELD JK, 1990, ANTICANCER RES, V10, P1; FINKLESTEIN R, 1988, ONCOGENE RES, V3, P287; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Ingvarsson S, 1990, Semin Cancer Biol, V1, P359; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LARSSON LG, 1994, ONCOGENE, V9, P1247; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUK GD, 1982, SCIENCE, V216, P75, DOI 10.1126/science.6950518; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARUYAMA K, 1987, ONCOGENE, V1, P361; MITCHELL LS, 1992, DIFFERENTIATION, V49, P119, DOI 10.1111/j.1432-0436.1992.tb00776.x; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; ROY AL, 1993, NATURE, V365, P356; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STACEY G, 1992, CYTOTECHNOLOGY, V9, P211, DOI 10.1007/BF02521748; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	49	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2835	2843		10.1038/sj.onc.1201124	http://dx.doi.org/10.1038/sj.onc.1201124			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190900				2022-12-25	WOS:A1997XD64300012
J	Martinez, JD; Craven, MT; Joseloff, E; Milczarek, G; Bowden, GT				Martinez, JD; Craven, MT; Joseloff, E; Milczarek, G; Bowden, GT			Regulation of DNA binding and transactivation in p53 by nuclear localization and phosphorylation	ONCOGENE			English	Article						p53; DNA binding; nuclear localization; phosphorylation; transactivation	TEMPERATURE-SENSITIVE MUTANT; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; DAMAGING AGENTS; INDUCED TUMORS; 3T3 CELLS; IN-VITRO; PROTEIN	Compelling evidence indicates that p53 acts as a transcription factor and that this activity is regulated by several factors including subcellular localization and phosphorylation status of the protein. To learn more about how these two processes determine whether p53 becomes activated, we studied the temperature sensitive murine p53, p53(val135). At nonpermissive temperatures, p53(val135) remains sequestered in the cytoplasm of cells ,which express it. Electrophoretic mobility shift assays demonstrated that, under these conditions, the protein lacked DNA binding activity. However, by shifting to the permissive temperature, p53(val135) became concentrated in the nucleus, hyperphosphorylated, and had acquired the ability to bind DNA in a sequence specific manner. This was accompanied by the induction of two p53 regulated genes, mdm2 and p21(waf1), which indicated that p53(val135) had become an active transcription factor. Two dimensional gel electrophoresis and tryptic peptide mapping showed that entry into the nucleus resulted in the appearance of new phosphorylated isoforms and that the protein had become extensively phosphorylation at the N-terminus. Notably, phosphorylation at the N-terminus occurred only in the nucleus, whereas phosphorylation at the C-terminus could occur in both the cytoplasm and the nucleus. Based on these observations, we suggest that phosphorylation of p53's N-terminus is compartmentally restricted.			Martinez, JD (corresponding author), UNIV ARIZONA,DEPT RADIAT ONCOL,TUCSON,AZ 85724, USA.				NCI NIH HHS [CA23074, CA40584, R29-CA64842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842, R01CA040584, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Boyle W J, 1991, Methods Enzymol, V201, P110; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARPER JW, 1993, CELL, V75, P805; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hecker D, 1996, ONCOGENE, V12, P953; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO L, 1991, CYANOGEN BROMIDE CLE, P149; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	52	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2511	2520		10.1038/sj.onc.1201095	http://dx.doi.org/10.1038/sj.onc.1201095			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191051				2022-12-25	WOS:A1997XA94900003
J	Malinda, KM; Goldstein, AL; Kleinman, HK				Malinda, KM; Goldstein, AL; Kleinman, HK			Thymosin beta(4) stimulates directional migration of human umbilical vein endothelial cells	FASEB JOURNAL			English	Article						migration; angiogenesis; human umbilical vein endothelial cells; T beta(4)	DEOXYNUCLEOTIDYL TRANSFERASE-ACTIVITY; DIFFERENTIAL EXPRESSION; BASEMENT-MEMBRANE; LIVING CELLS; BETA-4 GENE; IN-VITRO; ACTIN; ANGIOGENESIS; LAMININ; PEPTIDE	Thymosin beta(4) (T beta(4)) is a 4.9 kDa polypeptide that interacts with G-actin and is thought to be an important mediator in cell proliferation, migration, and differentiation. T beta(4) has been identified as a factor involved in the differentiation of human umbilical vein endothelial cells (HUVECs) cultured on Matrigel, Here we have used various in vitro and in vivo migration assays to demonstrate the role of T beta(4) in endothelial cell migration, Our results demonstrate that T beta(4) acts as a chemoattractant for endothelial cells, stimulating the migration of HUVECs in Boyden chambers four- to sixfold over that observed with media alone, Of the primary cell types tested, only human coronary artery cells responded to T beta(4) treatment, suggesting that the migration activity of T beta(4) was endothelial cell-specific, T beta(4) significantly accelerated the rate of migration into the scratch wounded area of a HUVEC monolayer, T beta(4) treatment also increased the production of matrix metalloproteinases that may degrade the basement membrane during angiogenesis, Additional experiments using subcutaneously implanted Matrigel showed that T beta(4) stimulated cell migration in vivo. These results provide the first direct evidence that T beta(4) has chemoattractive activity and promotes angiogenesis by stimulating the migration of endothelial cells.	NIDR,NIH,BETHESDA,MD 20892; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20037	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); George Washington University								CARPINTERO P, 1995, NEUROSCI LETT, V184, P63, DOI 10.1016/0304-3940(94)11169-J; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COCKERILL GW, 1995, INT REV CYTOL, V159, P113, DOI 10.1016/S0074-7696(08)62106-3; CODON MR, 1992, J MOL NEUROSCI, V3, P165; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; GOMEZMARQUEZ J, 1989, J IMMUNOL, V143, P2740; GONDO H, 1987, J IMMUNOL, V139, P3840; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; GRANT DS, 1995, J CELL SCI, V108, P3685; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU SK, 1981, MOL CELL BIOCHEM, V41, P49; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIBBEY MC, 1994, J CELL PHYSIOL, V160, P185, DOI 10.1002/jcp.1041600121; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lafrenie RM, 1996, J IMMUNOL, V157, P974; LIN SC, 1990, J MOL NEUROSCI, V2, P35, DOI 10.1007/BF02896924; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; LOW TLK, 1982, J BIOL CHEM, V257, P1000; MIHELIC M, 1994, AMINO ACIDS, V6, P1, DOI 10.1007/BF00808118; NAYLOR PH, 1984, IMMUNOPHARMACOLOGY, V7, P9, DOI 10.1016/0162-3109(84)90003-1; NAYLOR PH, 1986, INT J IMMUNOPHARMACO, V8, P667, DOI 10.1016/0192-0561(86)90001-9; OATES KK, 1995, BIOL THERAPY CANC, P841; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PASSANITI A, 1992, LAB INVEST, V67, P519; SAFER D, 1994, BIOESSAYS, V16, P473, DOI 10.1002/bies.950160706; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P307, DOI 10.1002/cm.970310407; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; SHAHABUDDIN N, 1994, AIDS RES HUM RETROV, V10, P1525; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; THURMAN GB, 1981, LYMPHOKINES THYMIC H, P145; WELLER FE, 1988, J BIOL RESP MODIF, V7, P91; YAMAMOTO M, 1992, BIOCHEM BIOPH RES CO, V184, P93, DOI 10.1016/0006-291X(92)91162-J; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1993, J BIOL CHEM, V268, P502	39	197	213	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					474	481		10.1096/fasebj.11.6.9194528	http://dx.doi.org/10.1096/fasebj.11.6.9194528			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194528				2022-12-25	WOS:A1997XE40400010
J	Schlesinger, PH; Blair, HC; Teitelbaum, SL; Edwards, JC				Schlesinger, PH; Blair, HC; Teitelbaum, SL; Edwards, JC			Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; INTRACELLULAR PH TRANSIENTS; PROTON PUMP; CARBONIC-ANHYDRASE; MEMBRANE-VESICLES; MARROW CULTURES; RECONSTITUTION; SUBUNIT; LOCALIZATION; PURIFICATION	Bone resorption by osteoclasts requires massive transcellular acid transport, which is accomplished by the parallel action of a V-type proton pump and a chloride channel in the osteoclast ruffled border. We have studied the molecular basis for the appearance of acid transport as avian bone marrow mononuclear cells acquire a bone resorptive phenotype in vitro. We demonstrate a critical role for regulated expression of a ruffled border chloride channel as the cells become competent to resorb bone. Molecular characterization of the chloride channel shows that it is related to the renal microsomal chloride channel, p64. In planar bilayers, the ruffled border channel is a stilbene sulfonate-inhibitable, outwardly rectifying chloride channel. A mechanism by which outward rectification of the single channel chloride current could allow efficient regulation of acidification by the channel is discussed.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; UNIV ALABAMA, DEPT PATHOL, BIRMINGHAM, AL 35294 USA; VET ADM MED CTR, LAB SERV, BIRMINGHAM, AL 35294 USA	Washington University (WUSTL); Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Schlesinger, PH (corresponding author), WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		Schlesinger, Paul H/C-6049-2012	Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046212] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42370] Funding Source: Medline; NIDDK NIH HHS [R29DK46212] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; ARKETT SA, 1992, ANN NY ACAD SCI, V671, P464, DOI 10.1111/j.1749-6632.1992.tb43831.x; BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BEKKER PJ, 1990, J BONE MINER RES, V5, P569, DOI 10.1002/jbmr.5650050606; Blair Harry C., 1992, P259; BLAIR HC, 1993, CLIN ORTHOP RELAT R, P7; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1990, BIOCHEM BIOPH RES CO, V171, P920, DOI 10.1016/0006-291X(90)90771-E; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; CHAMBERS TJ, 1984, J CELL SCI, V70, P61; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; DEWEER P, 1978, RESP PHYSIOL, V33, P41, DOI 10.1016/0034-5687(78)90082-8; DIFFENBACH LW, 1995, RESP PHYSL, V33, P41; GAY CV, 1974, SCIENCE, V183, P432, DOI 10.1126/science.183.4123.432; Harlow E., 1988, ANTIBODIES LAB MANUA; HATTERSLEY G, 1989, ENDOCRINOLOGY, V124, P1689, DOI 10.1210/endo-124-4-1689; Kahn A J, 1982, Prog Clin Biol Res, V110 Pt B, P239; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; MARUSHACK MM, 1992, AM J PHYSIOL, V263, pF171, DOI 10.1152/ajprenal.1992.263.1.F171; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; MATTSSON JP, 1993, BIOCHIM BIOPHYS ACTA, V1146, P106, DOI 10.1016/0005-2736(93)90344-Y; MATTSSON JP, 1992, ACTA PHYSIOL SCAND, V146, P253; NEUMAN WF, 1958, CHEM DYNAMICS BONE M, P23; PRALLET B, 1992, J BONE MINER RES, V7, P405; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAMBROOK J, 1989, MOL CLONING LAB MANU, P58; SCHLESINGER PH, 1994, MINER ELECTROL METAB, V20, P31; Sims Stephen M., 1992, P223; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; TETI A, 1989, J CLIN INVEST, V83, P227, DOI 10.1172/JCI113863; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VAES G, 1988, CLIN ORTHOP RELAT R, P239; ZAIDI M, 1993, BIOL REV, V68, P197, DOI 10.1111/j.1469-185X.1993.tb00996.x	40	144	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18636	18643		10.1074/jbc.272.30.18636	http://dx.doi.org/10.1074/jbc.272.30.18636			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228032	hybrid			2022-12-25	WOS:A1997XM34200023
J	Mecham, RP; Broekelmann, TJ; Fliszar, CJ; Shapiro, SD; Welgus, HG; Senior, RM				Mecham, RP; Broekelmann, TJ; Fliszar, CJ; Shapiro, SD; Welgus, HG; Senior, RM			Elastin degradation by matrix metalloproteinases - Cleavage site specificity and mechanisms of elastolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE SPECIFICITIES; MACROPHAGE ELASTASE; TISSUE INHIBITOR; IV COLLAGENASES; MATRILYSIN; GELATINASES; STROMELYSIN; PUMP; IDENTIFICATION; ACTIVATION	Insoluble elastin was used as a substrate to characterize the peptide bond specificities of human (HME) and mouse macrophage elastase (MME) and to compare these enzymes with other mammalian metalloproteinases and serine elastases, New amino termini detected by protein sequence analysis in insoluble elastin following proteolytic digestion reveal the P'(1) residues in the carboxyl-terminal direction from the scissile bond, The relative proportion of each amino acid in this position reflects the proteolytic preference of the elastolytic enzyme, The predominant amino acids detected by protein sequence analysis following cleavage of insoluble elastin with HME, MME, and 92-kDa gelatinase were Leu, Ile, Ala, Gly, and Val, HME and RIME were similar ill their substrate specificity and showed a stronger preference for Leu/Ile than did the 92-kDa enzyme, Fibroblast collagenase showed no activity toward elastin, The amino acid residues detected in insoluble elastin following hydrolysis with porcine pancreatic elastase and human neutrophil elastase were predominantly Gly and Ala, with lesser amounts of Val, Phe, Ile, and Leu, There were interesting specificity differences between the two enzymes, however, For both the serine and matrix metalloproteinases, catalysis of peptide bond cleavage in insoluble elastin was characterized by temperature effects and water requirements typical of common enzyme catalysed reactions, even those involving soluble substrates. In contrast to what has been observed for collagen, the energy requirements for elastolysis were not extraordinary, consistent with cleavage sites in elastin being readily accessible to enzymatic attack.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV PULM & CRIT CARE MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	Mecham, RP (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,BOX 8228,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053325, R01HL047328, R37HL053325, R01HL041926] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47328, HL41926, HL53325] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDA MJ, 1987, J CLIN INVEST, V79, P1314, DOI 10.1172/JCI112955; BANDA MJ, 1981, METHODS STUDYING MON, P603; Bieth JG, 1986, REGULATION MATRIX AC, P217; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; DAVIS EC, 1993, HISTOCHEMISTRY, V100, P17, DOI 10.1007/BF00268874; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; INDIK Z, 1990, GENES EXTRACELLULAR, P221; KETTNER C, 1981, BIOCHEM J, V195, P369, DOI 10.1042/bj1950369; LANSING AI, 1952, ANAT RECORD, V114, P555, DOI 10.1002/ar.1091140404; MEANS GE, 1971, CHEM MODIFICATION PR, P119; MORIHARA K, 1967, ARCH BIOCHEM BIOPHYS, V120, P68, DOI 10.1016/0003-9861(67)90599-1; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; RUCKER RB, 1984, ENV HLTH PERSPECT, V53, P179; SAULNIER J, 1992, EUR J CLIN CHEM CLIN, V30, P285; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, P160; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SHOTTON D M, 1970, Nature (London), V225, P811, DOI 10.1038/225811a0; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; SIRES UI, 1993, J BIOL CHEM, V268, P2069; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; WELGUS HG, 1981, J BIOL CHEM, V256, P9516; WELGUS HG, 1985, J BIOL CHEM, V260, P1052	31	175	184	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18071	18076		10.1074/jbc.272.29.18071	http://dx.doi.org/10.1074/jbc.272.29.18071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218437	hybrid			2022-12-25	WOS:A1997XL73500027
J	Sippel, CJ; Dawson, PA; Shen, TX; Perlmutter, DH				Sippel, CJ; Dawson, PA; Shen, TX; Perlmutter, DH			Reconstitution of bile acid transport in a heterologous cell by cotransfection of transporters for bile acid uptake and efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE CANALICULAR MEMBRANE; ECTO-ATPASE PROTEIN; INFLUENZA-VIRUS; RAT; EXPRESSION; TAUROCHOLATE; MECHANISMS; ADHESION; BICARBONATE; ISOFORMS	The rat liver canalicular bile acid transporter/ecto-ATPase/cell CAM 105 (CBATP) is a 110-kDa transmembrane phosphoglycoprotein that is thought to have bile acid efflux, ecto-ATPase, and cell adhesion properties, Its extracellular amino-terminal domain is highly homologous to carcinoembryonic antigen (CEA), a glycophosphatidyl inositol anchored membrane protein with cell adhesion properties and a marker for adenocarcinoma, In the current study, we examined the possibility of more clearly defining the role of CBATP in bile acid efflux by cotransfecting a heterologous cell, the COS cell, with cDNAs for a bile acid importer, the ileal bile acid transporter (IBAT), as well as for CBATP, The results show that when IBAT mediates uptake of [H-3]taurocholate to a level 20-fold higher than that achieved previously by nonspecific pinocytosis, CBATP mediates time-, temperature- and concentration-dependent efflux, Efflux of [H-3]taurocholate mediated by CBATP in the cotransfected COS cells is saturable and has curvilinear kinetic characteristics (V-max = 400 pmol/mg protein/min, K-m = 70 mu M). It is inhibited by 4,4'-diisothiocysanostilbene-2,2-disulfonic acid and dependent on ATP but not dependent; on membrane potential, Although CEA could not mediate bile acid efflux ill COS cells cotransfected with IBAT and CEA, efflux of [H-3]taurocholate was detected in COS cells cotransfected with HEAT and a chimeric molecule having the carboxyl-terminal tail and membrane spanning domain of CBATP and the amino-terminal extracellular tail of CEA. Taken together, these data provide further evidence that CBATP confers bile acid efflux properties on heterologous cells and that its cytoplasmic tail and membrane spanning segment are integral to this property. The data also establish a model system for more clearly defining the molecular determinants of bile acid transport mediated by this molecule.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DIV GASTROENTEROL & NUTR,ST LOUIS,MO 63110; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,WINSTON SALEM,NC 27157	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Wake Forest University; Wake Forest Baptist Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047084, R29DK047987] Funding Source: NIH RePORTER; NICHD NIH HHS [T32HDO7409] Funding Source: Medline; NIDDK NIH HHS [R29 DK047987, DK47084] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT T, 1988, Genomics, V3, P59, DOI 10.1016/0888-7543(88)90160-7; BECKER A, 1993, EUR J BIOCHEM, V214, P539, DOI 10.1111/j.1432-1033.1993.tb17952.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLITZER B, 1982, AM J PHYSIOL, V6, pG48; BLITZER BL, 1982, GASTROENTEROLOGY, V82, P346; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CULLEN BR, 1987, METHOD ENZYMOL, V152, P692; DUMONT M, 1980, GASTROENTEROLOGY, V79, P82; FORKER EL, 1977, ANNU REV PHYSIOL, V39, P323, DOI 10.1146/annurev.ph.39.030177.001543; GAITMAN ZC, 1995, PHYSIOL REV, V75, P261; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDISON WGM, 1978, AM J PHYSIOL, V235, pE158, DOI 10.1152/ajpendo.1978.235.2.E158; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KACZMAREK LK, 1991, NEW BIOL, V3, P315; KAST C, 1994, J BIOL CHEM, V269, P5179; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGILL JM, 1994, GASTROENTEROLOGY, V107, P236, DOI 10.1016/0016-5085(94)90082-5; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, HEPATOLOGY, V16, pA149; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; SCHARSCHMIDT BF, 1983, GASTROENTEROLOGY, V85, P1199; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; Sippel CJ, 1996, J BIOL CHEM, V271, P33095, DOI 10.1074/jbc.271.51.33095; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; SKEHEL JJ, 1992, NATURE, V358, P110, DOI 10.1038/358110b0; STEVE A, 1991, NEURON, V7, P403; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; WONG MH, 1994, J BIOL CHEM, V269, P1340; YIH LH, 1991, CELL BIOL INT REP, V15, P253, DOI 10.1016/0309-1651(91)90157-E	39	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18290	18297		10.1074/jbc.272.29.18290	http://dx.doi.org/10.1074/jbc.272.29.18290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218468	hybrid			2022-12-25	WOS:A1997XL73500058
J	Stevens, VL; Tang, JH				Stevens, VL; Tang, JH			Fumonisin B-1-induced sphingolipid depletion inhibits vitamin uptake via the glycosylphosphatidylinositol-anchored folate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-MONILIFORME; BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; INTRACELLULAR-TRANSPORT; EPITHELIAL-CELLS; MEMBRANE; CAVEOLAE; INTERNALIZATION; MICRODOMAINS; CANCER	The folate receptor, like many glycosylphosphatidylinositol-anchored proteins, is found associated with membrane domains that art? insoluble in Triton X-100 at low temperature and that are enriched in cholesterol and sphingolipids. Depletion of cellular cholesterol has been shown to inhibit vitamin uptake by this receptor (Chang, W.-J., Rothberg, K, G., Kamen, B. A,, and Anderson, BP. G. W. (1993) J, Cell Biol, IIS, 63-69), suggesting that these domains regulate this process. In this study, the importance of sphingolipids for folate receptor function was investigated in Caco-2 cells using fumonisin B-1, a mycotoxin that inhibits the biosynthesis of these lipids, The folate receptor-mediated transport of 5-methyltetrahydrofolate was almost completely blocked in cells in which sphingolipids had been reduced by similar to 40%. This inhibition was dependent on the concentration and duration of the treatment with the mycotoxin and was mediated by the sphingolipid decrease, Neither receptor-mediated nor facilitative transport was inhibited by fumonisin B-1 treatment, indicting that the effect of sphingolipid depletion was specific for folate receptor-mediated vitamin uptake, A concurrent loss in the total amount of folate binding capacity in the cells was seen as sphingolipids were depleted, suggesting a causal relationship between folate receptor number and vitamin uptake. These findings suggest that dietary exposure to fumonisin B-1 could adversely affect folate uptake and potentially compromise cellular processes dependent on this vitamin, Furthermore, because folate deficiency causes neural tube defects, some birth defects unexplained by other known risk factors may be caused by exposure to fumonisin B-1.	EMORY UNIV,SCH MED,DIV CANC BIOL,DEPT RADIAT ONCOL,ATLANTA,GA 30335; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30335	Emory University; Emory University								ALBRECHT LJ, 1994, TEX MED, V90, P16; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BEZUIDENHOUT SC, 1988, J CHEM SOC CHEM COMM, P743, DOI 10.1039/c39880000743; BIRN H, 1993, AM J PHYSIOL, V264, pC302, DOI 10.1152/ajpcell.1993.264.2.C302; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUTTERWORTH CE, 1993, J AM COLL NUTR, V12, P438, DOI 10.1080/07315724.1993.10718334; Canfield MA, 1996, AM J EPIDEMIOL, V143, P1; Canfield MA, 1996, AM J EPIDEMIOL, V143, P12; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; DANSKY LV, 1992, NEUROLOGY, V42, P32; DAVIES AA, 1984, BIOCHEM J, V219, P301, DOI 10.1042/bj2190301; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FLOSS JL, 1994, MYCOPATHOLOGIA, V128, P33, DOI 10.1007/BF01104276; FUTERMAN AH, 1995, TRENDS CELL BIOL, V5, P377, DOI 10.1016/S0962-8924(00)89078-9; GARCIA M, 1993, J CELL SCI, V104, P1281; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GROSS SM, 1994, MYCOPATHOLOGIA, V128, P111, DOI 10.1007/BF01103018; GROSS SM, 1994, MYCOPATHOLOGIA, V8, P2357; GROSS SM, 1994, FASEB J, V8, P2357; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIBBARD BM, 1993, BRIT J OBSTET GYNAEC, V100, P307, DOI 10.1111/j.1471-0528.1993.tb12970.x; HORVATH A, 1994, EMBO J, V13, P36877; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MARASAS WFO, 1984, INT J CANCER, V34, P383, DOI 10.1002/ijc.2910340315; MARASAS WFO, 1988, ONDERSTEPOORT J VET, V55, P197; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Rijnboutt S, 1996, J CELL BIOL, V132, P35, DOI 10.1083/jcb.132.1.35; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schroeder J. J., 1995, MOL APPROACHES FOOD, P429; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P285, DOI 10.1021/jf00091a064; *TEX DEP HLTH, 1992, INV CLUST NEUR TUB D, P4; WANG E, 1991, J BIOL CHEM, V266, P14486; YANG CS, 1980, CANCER RES, V40, P2633; YU J, 1973, J SUPRAMOL STRUCT, V3, P233	50	152	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18020	18025		10.1074/jbc.272.29.18020	http://dx.doi.org/10.1074/jbc.272.29.18020			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218430	hybrid			2022-12-25	WOS:A1997XL73500020
J	Zhou, QS; Zhao, J; Stout, JG; Luhm, RA; Wiedmer, T; Sims, PJ				Zhou, QS; Zhao, J; Stout, JG; Luhm, RA; Wiedmer, T; Sims, PJ			Molecular cloning of human plasma membrane phospholipid scramblase - A protein mediating transbilayer movement of plasma membrane phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOAGULANT ACTIVITY; HUMAN ERYTHROCYTES; PHOSPHATIDYLSERINE; EXPOSURE; CELL; REDISTRIBUTION; ASYMMETRY; PLATELETS; SURFACE	The rapid movement of phospholipids (PL) between plasma membrane leaflets in response to increased intracellular Ca2+ is thought to play a key role in expression of platelet procoagulant activity and in clearance of injured or apoptotic cells. We recently reported isolation of a similar to 37-kDa protein in erythrocyte membrane that mediates Ca2+-dependent movement of PL between membrane leaflets, similar to that observed upon elevation of Ca2+ in the cytosol (Basse, F., Stout, J. G., Sims, P. J., and Wiedmer, T. (1996) J. Biol. Chem. 271, 17205-17210). Based on internal peptide sequence obtained from this protein, a 1,445-base pair cDNA was cloned from a K-562 cDNA Library, The deduced ''PL scramblase'' protein is a proline-rich, type II plasma membrane protein with a single transmembrane segment near the C terminus. Antibody against the deduced C-terminal peptide was found to precipitate the similar to 37-kDa red blood cell protein and absorb PL scramblase activity, confirming the identity of the cloned cDNA to erythrocyte PL scramblase, Ca2+-dependent PL scramblase activity was also demonstrated in recombinant protein expressed from plasmid containing the cDNA. Quantitative immunoblotting revealed an approximately 10-fold higher abundance of PL scramblase in platelet (similar to 10(4) molecules/cell) than in erythrocyte (similar to 10(3) molecules/cell), consistent with apparent increased PL scramblase activity of the platelet plasma membrane, PL scramblase mRNA was found in a variety of hematologic and nonhematologic cells and tissues, suggesting that this protein functions in all cells.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53201	Versiti Blood Center of Wisconsin					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL36946] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSE F, 1996, J BIOL CHEM, V271, P17025; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BRATTON DL, 1994, J BIOL CHEM, V269, P22517; CHANG CP, 1993, J BIOL CHEM, V268, P7171; Comfurius P, 1996, BIOCHEMISTRY-US, V35, P7631, DOI 10.1021/bi9606859; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FADOK VA, 1992, J IMMUNOL, V148, P2207; MARTIN DW, 1995, J BIOL CHEM, V270, P10468, DOI 10.1074/jbc.270.18.10468; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; Sulpice JC, 1996, BIOCHEMISTRY-US, V35, P13345, DOI 10.1021/bi960624a; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; WANG RH, 1993, J CLIN INVEST, V92, P1326, DOI 10.1172/JCI116706; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	19	346	359	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18240	18244		10.1074/jbc.272.29.18240	http://dx.doi.org/10.1074/jbc.272.29.18240			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218461	hybrid			2022-12-25	WOS:A1997XL73500051
J	Cheng, J; Weber, JD; Baldassare, JJ; Raben, DM				Cheng, J; Weber, JD; Baldassare, JJ; Raben, DM			Ablation of G(o) alpha-subunit results in a transformed phenotype and constitutively active phosphatidylcholine-specific phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; BETA-GAMMA-SUBUNITS; MITOGENIC SIGNAL-TRANSDUCTION; CHOLINE KINASE-ACTIVITY; G-PROTEIN ONCOGENES; CULTURED FIBROBLASTS; ADENYLYL CYCLASE; PITUITARY-TUMORS; ENDOCRINE TUMORS; DNA-SYNTHESIS	Modulation of the components involved in mitogenic signaling cascades is critical to the regulation of cell growth. GTP-binding proteins and the stimulation of phosphatidylcholine (PC) hydrolysis have been shown to play major roles in these cascades, One of the enzymes involved in PC hydrolysis, a PC-specific phospholipase C (PC-PLC) has received relatively little attention, In this paper we examined the role of a particular heterotrimeric GTP-binding protein, G(o), in the regulation of cell growth and PC-PLC-mediated hydrolysis of PC in IIC9 fibroblasts. The G(o) alpha-subunit was ablated in IIC9 cells by stable expression of antisense RNA, These stably transfected cells acquired a transformed phenotype as indicated by: (a) the formation of multiple foci in monolayer cultures, (b) the acquisition of anchorage-independent growth in soft agar; and (c) an increased level of thymidine incorporation in the absence of added mitogens. These data implicate G(o) alpha as a novel tumor suppressor, Interestingly, PC-PLC activity was constitutively active in the G(o) alpha-ablated cells as evidenced by the chronically elevated levels of diacylglycerol and phosphorylcholine in the absence of growth factors, In contrast, basal activities of PG-phospholipase D, phospholipase A(2), or phosphoinositol-PLC were not affected, These data demonstrate, for the first time, a role for G(o) in regulating cell growth and provide definitive evidence for the existence of a PC-PLC in eukaryotic cells, The data further indicate that a subunit of G(o), is involved is regulating this enzyme.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; ST LOUIS UNIV, SCH MED, DEPT CELL SCI, ST LOUIS, MO 63104 USA; ST LOUIS UNIV, SCH MED, DEPT PHARMACOL SCI, ST LOUIS, MO 63104 USA; ST LOUIS UNIV, SCH MED, DEPT PHYSIOL SCI, ST LOUIS, MO 63104 USA	Johns Hopkins University; Saint Louis University; Saint Louis University; Saint Louis University				Weber, Jason/0000-0002-1069-6983	NHLBI NIH HHS [HL40901] Funding Source: Medline; NIGMS NIH HHS [GM51593] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM051593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1988, CANCER RES, V48, P2756; AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; AXELROD J, 1995, TRENDS NEUROSCI, V18, P64; BALDI E, 1994, AM J PHYSIOL, V266, pF957, DOI 10.1152/ajprenal.1994.266.6.F957; BARDI G, 1993, INT J CANCER, V55, P422, DOI 10.1002/ijc.2910550317; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BLANK JL, 1992, J BIOL CHEM, V267, P23069; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLLU R, 1988, ENDOCRINOLOGY, V122, P1176, DOI 10.1210/endo-122-3-1176; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOUGLASS EC, 1990, CYTOGENET CELL GENET, V53, P87, DOI 10.1159/000132901; EXTON JH, 1993, ADV SEC MESS PHOSPH, V28, P65; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FAURE M, 1994, J BIOL CHEM, V269, P7851; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HUFF V, 1992, CANCER RES, V52, P6117; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JOHANSEN T, 1994, MOL CELL BIOL, V14, P646, DOI 10.1128/MCB.14.1.646; KATO K, 1987, CANCER RES, V47, P5800; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LAVIADA ID, 1995, FEBS LETT, V364, P301, DOI 10.1016/0014-5793(95)00414-5; LEE SB, 1993, J BIOL CHEM, V268, P25952; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MANDAHL N, 1994, J CANCER RES CLIN, V120, P707, DOI 10.1007/BF01194267; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MURTHY KS, 1995, MOL PHARMACOL, V48, P293; NEWSHAM I, 1995, GENE CHROMOSOME CANC, V12, P1, DOI 10.1002/gcc.2870120102; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PESSIN MS, 1991, CELL REGUL, V2, P383, DOI 10.1091/mbc.2.5.383; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; Podo F, 1996, ANTICANCER RES, V16, P1399; PREISS J, 1986, J BIOL CHEM, V261, P8597; RABEN DM, 1990, J CELL BIOCHEM, V44, P117, DOI 10.1002/jcb.240440206; RABEN DM, 1987, J CELL PHYSIOL, V130, P466, DOI 10.1002/jcp.1041300322; RANDELL E, 1992, BIOCHIM BIOPHYS ACTA, V1124, P273, DOI 10.1016/0005-2760(92)90139-M; RANGAN LA, 1991, CELL REGUL, V2, P311, DOI 10.1091/mbc.2.4.311; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; SANDS WA, 1994, BIOCHEM BIOPH RES CO, V199, P461, DOI 10.1006/bbrc.1994.1251; SEUWEN K, 1992, ADV CANCER RES, V58, P75, DOI 10.1016/S0065-230X(08)60291-2; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TIAN WN, 1993, LIFE SCI, V52, P1899, DOI 10.1016/0024-3205(93)90630-L; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHARA H, 1995, J CUTAN PATHOL, V22, P146, DOI 10.1111/j.1600-0560.1995.tb01397.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAKELAM MJO, 1993, BIOCHEM SOC T, V21, P873; WATERFIELD MD, 1989, BRIT MED BULL, V45, P570, DOI 10.1093/oxfordjournals.bmb.a072343; WATKINS DC, 1994, BIOCHEM J, V299, P593, DOI 10.1042/bj2990593; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	66	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17312	17319		10.1074/jbc.272.28.17312	http://dx.doi.org/10.1074/jbc.272.28.17312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211868	hybrid			2022-12-25	WOS:A1997XK16500011
J	McNew, JA; Sogaard, M; Lampen, NM; Machida, S; Ye, RR; Lacomis, L; Tempst, P; Rothman, JE; Sollner, TH				McNew, JA; Sogaard, M; Lampen, NM; Machida, S; Ye, RR; Lacomis, L; Tempst, P; Rothman, JE; Sollner, TH			Ykt6p, a prenylated SNARE essential for endoplasmic reticulum golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SECRETORY PATHWAY; FUSION PROTEIN; TRITON X-114; IN-VITRO; YEAST; COMPLEX	Vesicular transport between secretory compartments requires specific recognition molecules called SNAREs, Here we report the identification of three putative SNAREs, p14 (Sft1p), p28 (Qos1p), and a detailed characterization of p26 (Ykt6p). All three were originally isolated as interacting partners of the cis Golgi target membrane-associated SNARE Sed5p, when Sec18p (yeast NSF) was inactivated, YKT6 is an essential gene that codes for a novel vesicle-associated SNARE functioning at the endoplasmic reticulum-Golgi transport step in the yeast secretory pathway, Depletion of Ykt6p results in the accumulation of the pi precursor (endoplasmic reticulum form) of the vacuolar enzyme carboxypeptidase Y and morphological abnormalities consistent with a defect in secretion, Membrane localization of Ykt6p is essential fur protein function and is normally mediated by isoprenylation, However, replacement of the isoprenylation motif with a bona fide transmembrane anchor results in a functional protein confirming that membrane localization, but not isoprenylation pel se, is required for function, Ykt6p and its homologues are highly conserved from yeast to human as demonstrated by the functional complementation of the lass of Ykt6p by its human counterpart, This is the first example of a human SNARE protein functionally replacing a yeast SNARE, This observation implies that the specific details of the vesicle targeting code, like the genetic code, are conserved in evolution.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			McNew, James/ABD-8081-2020; McNew, James/AAV-4911-2020	McNew, James/0000-0001-8459-3664	NCI NIH HHS [5 P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM17722] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017722] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P1095; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARDWICK KG, 1992, EMBO J, V11, P4187, DOI 10.1002/j.1460-2075.1992.tb05512.x; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MITCHELL DA, 1995, METHOD ENZYMOL, V250, P68; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567	58	174	185	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17776	17783		10.1074/jbc.272.28.17776	http://dx.doi.org/10.1074/jbc.272.28.17776			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211930	hybrid			2022-12-25	WOS:A1997XK16500073
J	Mould, AP; Askari, JA; Aota, S; Yamada, KM; Irie, A; Takada, Y; Mardon, HJ; Humphries, MJ				Mould, AP; Askari, JA; Aota, S; Yamada, KM; Irie, A; Takada, Y; Mardon, HJ; Humphries, MJ			Defining the topology of integrin alpha 5 beta 1-fibronectin interactions using inhibitory anti-alpha 5 and anti-beta 1 monoclonal antibodies - Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the alpha 5 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; ADHESIVE FUNCTION; LIGAND-BINDING; SITE; IDENTIFICATION; RECEPTOR; REGION; FRAGMENTS; MIGRATION	The high affinity interaction of integrin alpha 5 beta 1 with the central cell binding domain (CCBD) of fibronectin requires both the Arg-Gly-Asp (RGD) sequence (in the 10th type III repeat) and a second site (in the adjacent 9th type III repeat) which synergizes with RGD, We have attempted to map the fibronectin binding interface on alpha 5 beta 1 using monoclonal antibodies (mAbs) that inhibit ligand recognition, The binding of two anti-alpha 5 mAbs (P1D6 and JBS5) to alpha 5 beta 1 was strongly inhibited by a tryptic CCBD fragment of fibronectin (containing both synergy sequence and RGD) but not by GRGDS peptide. Using recombinant wild type and mutated fragments of the CCBD, we show that the synergy region of the 9th type III repeat is involved in blocking the binding of P1D6 and JBS5 to alpha 5 beta 1. In contrast, binding of the anti-beta 1 mAb P4C10 to alpha 5 beta 1 was inhibited to a similar extent by GRGDS peptide, the tryptic CCBD fragment, or recombinant proteins lacking the synergy region, indicating that the RGD sequence is involved in blocking P4C10 binding, P1D6 inhibited the interaction of a wild type CCBD fragment with alpha 5 beta 1 but had no effect on the binding of a mutant fragment that lacked the synergy region, The epitopes of P1D6 and JBS5 mapped to the NH2-terminal repeats of the alpha 5 subunit, Our results indicate that the synergy region is recognized primarily by the alpha 5 subunit (in particular by its NH2-terminal repeats) but that the beta 1 subunit plays the major role in binding of the RGD sequence. These findings provide new insights into the mechanisms, specificity, and topology of integrin-ligand interactions.	NIDR, CRANIOFACIAL DEV BIOL & REGENERAT BRANCH, NIH, BETHESDA, MD 20892 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; JOHN RADCLIFFE HOSP, NUFFIELD DEPT OBSTET & GYNAECOL, OXFORD OX3 9DU, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Scripps Research Institute; University of Oxford	Mould, AP (corresponding author), UNIV MANCHESTER, SCH BIOL SCI, WELLCOME TRUST CTR CELL MATRIX RES, 2-205 STOPFORD BLDG, OXFORD RD, MANCHESTER M13 9PT, LANCS, ENGLAND.			takada, yoshikazu/0000-0001-5481-9589; Yamada, Kenneth/0000-0003-1512-6805; Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MAHLER HR, 1966, BIOL CHEM, P250; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1996, J CELL SCI, V109, P2613; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; OBARA M, 1995, EXP CELL RES, V216, P273, DOI 10.1006/excr.1995.1033; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	37	139	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17283	17292		10.1074/jbc.272.28.17283	http://dx.doi.org/10.1074/jbc.272.28.17283			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211865	hybrid			2022-12-25	WOS:A1997XK16500008
J	Oh, CS; Toke, DA; Mandala, S; Martin, CE				Oh, CS; Toke, DA; Mandala, S; Martin, CE			ELO2 and ELO3, homologues of the Saccharomyces cerevisiae ELO1 gene, function in fatty acid elongation and are required for sphingolipid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; NEUROSPORA-CRASSA; PLASMA-MEMBRANE; ACYLTRANSFERASE; PHOSPHOLIPIDS; PHOSPHATE; INHIBITOR; CLONING	ELO2 and ELO3 were identified from the Saccharomyces cerevisiae genome data base as homologues of ELO1, a gene involved in the elongation of the fatty acid 14:0 to 16:0, Mutations in these genes have previously been shown to produce pleiotropic effects involving a number of membrane functions, The simultaneous disruption of ELO2 and ELO3 has also been shown to produce synthetic lethality, indicating that they have related and/or overlapping functions, Gas chromatography and gas chromatography/mass spectroscopy analyses reveal that mull mutations of ELO2 and ELO3 produce defects in the formation of very long chain fatty acids, Analysis of the null mutants indicates that these genes encode components of the membrane-bound fatty acid elongation systems that produce the 26-carbon very long chain fatty acids that are precursors for ceramide and sphingolipids, Elo2p appears to be involved in the elongation of fatty acids up to 24 carbons, it appears to have the highest affinity for substrates with chain lengths less than 22 carbons. Elo3p apparently has a broader substrate specificity and is essential for the conversion of 24-carbon acids to as carbon species. Disruption of either gene reduces cellular sphingolipid levels and results in the accumulation of the long chain base, phytosphingosine. Null mutations In ELO3 result in accumulation of labeled precursors into inositol phosphoceramide, with little labeling in the more complex mannosylated sphingolipids, whereas disruption of ELO2 results in reduced levels of all sphingolipids.	RUTGERS STATE UNIV,BUR BIOL RES,NELSON BIOL LABS,PISCATAWAY,NJ 08855; MERCK RES LABS,RAHWAY,NJ 07065	Rutgers State University New Brunswick; Merck & Company					NIGMS NIH HHS [GM45768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON LR, 1983, BIOCHIM BIOPHYS ACTA, V735, P252, DOI 10.1016/0005-2736(83)90300-0; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BESSOULE JJ, 1988, EUR J BIOCHEM, V177, P207, DOI 10.1111/j.1432-1033.1988.tb14363.x; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; GARCIAARRANZ M, 1994, J BIOL CHEM, V269, P18076; HANSON BA, 1980, J LIPID RES, V21, P309; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; LESTER RL, 1993, ADV LIPID RES, V26, P253; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; Sherman F., 1982, METHODS YEAST GENETI; Silve S, 1996, MOL CELL BIOL, V16, P2719; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	22	380	407	4	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17376	17384		10.1074/jbc.272.28.17376	http://dx.doi.org/10.1074/jbc.272.28.17376			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211877	hybrid			2022-12-25	WOS:A1997XK16500020
J	Hemmer, W; McGlone, M; Tsigelny, I; Taylor, SS				Hemmer, W; McGlone, M; Tsigelny, I; Taylor, SS			Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; REGULATORY SUBUNIT; PEPTIDE INHIBITOR; KINETIC MECHANISM; ESCHERICHIA-COLI; GAMMA-SUBUNIT; PHOSPHORYLATION; FAMILY; MUTAGENESIS	A glycine-rich loop in the ATP-binding site is one of the most highly conserved sequence motifs in protein kinases, Each conserved glycine (Gly-50, Gly-52, and Gly-SS) in the catalytic (C) subunit of cAMP-dependent protein kinase (cAPK) was replaced with Ser and/or Ala. Active mutant proteins were expressed in Escherichia coli, purified to apparent homogeneity, separated into phosphoisoforms, and characterized, Replacing Gly-55 had minimal effects on steady-state kinetic parameters, whereas replacement of either Gly-50 or Gly-52 had major effects on both K-m and k(cat) values consistent. with the prediction of the importance of the tip of the glycine-rich loop for catalysis, Substitution of Gly-50 caused a 5-8-fold reduction in K-m(ATP), an 8-12-fold increase in K-m(peptide), and a 3-5-fold drop in k(cat). The K-m(ATP) and K-m(peptide) values of C(G52S) were increased 8- and 18-fold, respectively, and the k(cat) was decreased 6-fold. In contrast to catalytic efficiency, the ATPase: rates of C(G50S) and C(G52S) were increased by more than an order of magnitude, The thermostability of each mutant was slightly increased, Unphosphorylated C(G52S) was characterized as well as several isoforms phosphorylated at a single site, Ser-338. All of these phosphorylation-defective mutants displayed a substantial decrease in bath enzymatic activity and thermal stability that correlated with the missing phosphate at Thr-197. These results are correlated with the crystal structure, models of the respective mutant proteins, and conservation of the Glys within the protein kinase family.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; SWISS FED OFF PUBL HLTH,DIV FOOD SCI,SECT MICROBIOL & HYG,CH-3003 BERN,SWITZERLAND	University of California System; University of California San Diego								ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; ADAMS JA, 1993, PROTEIN SCI, V2, P2177, DOI 10.1002/pro.5560021217; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BUBIS J, 1988, J BIOL CHEM, V263, P9668; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; COOKE M P, 1989, New Biologist, V1, P66; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEMMER W, 1996, ANAL BIOCHEM, V245, P115; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1992, BIOCHEMISTRY-US, V31, P10616, DOI 10.1021/bi00158a026; LEW J, 1997, IN PRESS BIOCHEMISTR; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	40	115	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16946	16954		10.1074/jbc.272.27.16946	http://dx.doi.org/10.1074/jbc.272.27.16946			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202006	hybrid			2022-12-25	WOS:A1997XH44600038
J	Tozser, J; Bagossi, P; Weber, IT; Louis, JM; Copeland, TD; Oroszlan, S				Tozser, J; Bagossi, P; Weber, IT; Louis, JM; Copeland, TD; Oroszlan, S			Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTRATE-BINDING-SITE; CLEAVAGE SITES; RETROVIRAL PROTEINASES; MOLECULAR-DYNAMICS; PROTEASE; TYPE-1; REQUIREMENTS; GAG	Two major types of cleavage sites with different sequence preferences have been proposed for the human immunodeficiency virus type 1 (HIV-1) proteinase, To understand the nature of these sequence preferences better, single and multiple amino acid substitutions were introduced into a type 1 cleavage site peptide, thus changing it to a naturally occurring type 2 cleavage site sequence, Our results indicated that the previous classification of the retroviral cleavage sites may not be generally valid and that the preference for a residue at a particular position in the substrate depends strongly on the neighboring residues, including both those at the same side and at the opposite side of the peptide backbone of the substrate, Based on these results, pseudosymmetric (palindromic) substrates were designed, The retroviral proteinases are symmetrical dimers of two identical subunits; however, the residues of naturally occurring cleavage sites do not show symmetrical arrangements, and no obvious symmetrical substrate preference has been observed for the specificity of HIV proteinase, To examine the role of the asymmetry created by the peptide bonds on the specificity of the respective primed and nonprimed halves of the binding site, amino acid substitutions were introduced into a palindromic sequence, In general, the results suggested that the asymmetry does not result in substantial differences in specificity of the S-3 and S-3' subsites, whereas its effect is more pronounced for the S-2 and S-2' subsites, Although it was possible to design several good palindromic substrates, asymmetrical arrangements may be preferred by the HIV proteinase.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; NIDDK, CELLULAR & DEV BIOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, MOL VIROL & CARCINOGENESIS LAB, ADV BIOSCI LABS, FREDERICK, MD 21702 USA	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Tozser, J (corresponding author), DEBRECEN UNIV MED, SCH MED, DEPT BIOCHEM, H-4012 DEBRECEN, HUNGARY.		Tozser, Jozsef/A-7840-2008	Tozser, Jozsef/0000-0003-0274-0056; Louis, John M/0000-0002-0052-1899; Tozser, Jozsef/0000-0001-5076-8729	NATIONAL CANCER INSTITUTE [R01CA058166] Funding Source: NIH RePORTER; NCI NIH HHS [CA58166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagossi P, 1996, PROTEIN ENG, V9, P997, DOI 10.1093/protein/9.11.997; BALDWIN ET, 1995, NAT STRUCT BIOL, V2, P244, DOI 10.1038/nsb0395-244; CAMERON CE, 1993, J BIOL CHEM, V268, P11711; Chou KC, 1996, PROTEINS, V24, P51, DOI 10.1002/(SICI)1097-0134(199601)24:1&lt;51::AID-PROT4&gt;3.0.CO;2-R; COLLINS JR, 1995, NAT STRUCT BIOL, V2, P334, DOI 10.1038/nsb0495-334; DREYER GB, 1993, BIOCHEMISTRY-US, V32, P937, DOI 10.1021/bi00054a027; DUNN BM, 1994, METHOD ENZYMOL, V241, P254; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FAN NS, 1995, J BIOL CHEM, V270, P13573; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; GAEDIGKNITSCHKO K, 1995, FEBS LETT, V357, P275, DOI 10.1016/0014-5793(94)01370-G; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; GROBELNY D, 1990, BIOCHEM BIOPH RES CO, V169, P1111, DOI 10.1016/0006-291X(90)92010-W; HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LOUIS JM, 1991, EUR J BIOCHEM, V199, P361, DOI 10.1111/j.1432-1033.1991.tb16132.x; Mellors JW, 1996, NAT MED, V2, P274, DOI 10.1038/nm0396-274; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PETTIT SC, 1991, J BIOL CHEM, V266, P14539; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; POZSGAY M, 1981, EUR J BIOCHEM, V115, P497; Ridky TW, 1996, J BIOL CHEM, V271, P4709, DOI 10.1074/jbc.271.9.4709; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STROP P, 1991, BIOCHEMISTRY-US, V30, P3437, DOI 10.1021/bi00228a013; TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279; TOMASSELLI AG, 1993, PROTEIN SCI, V2, P2167, DOI 10.1002/pro.5560021216; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; TOZSER J, 1992, BIOCHEMISTRY-US, V31, P4793, DOI 10.1021/bi00135a008; TOZSER J, 1991, FEBS LETT, V279, P356, DOI 10.1016/0014-5793(91)80186-7; TOZSER J, 1986, ACTA BIOCHIM BIOPHYS, V21, P335; Weber IT, 1996, PROTEIN ENG, V9, P679, DOI 10.1093/protein/9.8.679; Winslow D L, 1995, AIDS, V9 Suppl A, pS183; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	36	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16807	16814		10.1074/jbc.272.27.16807	http://dx.doi.org/10.1074/jbc.272.27.16807			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201986	hybrid			2022-12-25	WOS:A1997XH44600018
J	Finn, JP; Edwards, RH				Finn, JP; Edwards, RH			Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN GRANULES; RESERPINE BINDING; AMINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; DIHYDROTETRABENAZINE BINDING; LOCALIZATION; EXPRESSION; INHIBITORS; CLONING; CDNA	Molecular cloning has identified two vesicular monoamine transporters (VMATs), one expressed in non-neural cells of the periphery (VMAT1) and the other by multiple monoamine cell populations in the brain (VMAT2), Functional analysis has previously shown that VMAT2 has a higher affinity than VMAT1 for monoamine neurotransmitters as well as the inhibitor tetrabenazine, The analysis of chimeric transporters has also identified two major regions required for the high affinity interactions of VMAT2 with these ligands, We have now used site-directed mutagenesis to identify the individual residues responsible for these differences, Focusing on the region that spans transmembrane domains 9 through 12, we have replaced VMAT2 residues with the corresponding residues from VMAT1, Many residues in this region had no effect on the recognition of these ligands, but substitution of Tyr-434 with Phe and Asp-461 with Asn reduced the affinity for tetrabenazine, histamine, and serotonin, Although the ability to affect recognition of multiple ligands suggests a general structural role for these residues, the mutations did not affect dopamine recognition, indicating a more specific role, possibly in recognition of the ring nitrogen that occurs in tetrabenazine, histamine, and serotonin but not dopamine, The mutation K446Q reduced the affinity of VMATB for tetrabenazine and serotonin but not histamine, whereas F464Y reduced serotonin affinity and perhaps histamine recognition but not tetrabenazine sensitivity, providing more evidence for specificity, Interestingly, the V-max of both VMATs for dopamine exceeded that for serotonin by 3-5-fold, indicating a difference in the speed of packaging of these two neurotransmitters, We also found that VMAT1 has a higher affinity for tryptamine than VMAT2, This mutually exclusive interaction with serotonin and tryptamine also suggests a physiological rationale for the existence of two VMATs, Surprisingly, the residue responsible for this difference, Tyr-434, also accounts for the higher affinity interaction of VMAT2 with tetrabenazine, histamine, and serotonin, Interestingly, replacement of Tyr-434 with alanine increases the affinity of VMATB for both serotonin and dopamine and reduces the rate of dopamine transport.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; COHEN G, 1990, J NEUR TR S, P229; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1994, J EXP BIOL, V196, P237; KNOTH J, 1981, BIOCHEMISTRY-US, V20, P6625, DOI 10.1021/bi00526a016; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERICKEL A, 1995, NEUROPHARMACOLOGY, V34, P1543, DOI 10.1016/0028-3908(95)00148-Y; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1993, GENOMICS, V18, P720, DOI 10.1016/S0888-7543(05)80383-0; PETER D, 1994, J BIOL CHEM, V269, P7231; PETER D, 1995, J NEUROSCI, V15, P6179; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730	26	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16301	16307		10.1074/jbc.272.26.16301	http://dx.doi.org/10.1074/jbc.272.26.16301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195934	hybrid			2022-12-25	WOS:A1997XG01900038
J	Orita, S; Naito, A; Sakaguchi, G; Maeda, M; Igarashi, H; Sasaki, T; Takai, Y				Orita, S; Naito, A; Sakaguchi, G; Maeda, M; Igarashi, H; Sasaki, T; Takai, Y			Physical and functional interactions of Doc2 and Munc13 in Ca2+-dependent exocytotic machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN GROWTH-HORMONE; CAENORHABDITIS-ELEGANS; UNC-13 GENE; BINDING; EXPRESSION; COMPLEX; REGION	Doc2 has two C2 domains that interact with Ca2+ and phospholipid. Munc13 has two C2 domains and one C1 domain that interacts with phorbol ester or diacylglycerol (DAG) and phospholipid. Both Doca and Munc13 are implicated in Ca2+-dependent neurotransmitter release, but their modes of action still remain unclear. We show here that Doc2 interacts with Munc13 both in a cell-free system and in intact PC12 cells during the high K+-induced Ca2+-dependent exocytosis. The Doc2-Munc13 interactions are stimulated by phorbol ester through the C1 domain of Munc13. Overexpression of the Doc2-interacting domain of Munc13 reduces the Ca2+-dependent exocytosis from PC12 cells, and co expression with Doc2 suppresses this reduction. These results, together with the earlier findings that secretagogues produce DAG and elevate cytoplasmic Ca2+, suggest that the DAG-induced Doc2-Munc13 interactions play an important role in Ca2+-dependent exocytotic machinery.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; SHIONOGI INST MED SCI,SETTSU 566,JAPAN	Osaka University; Shionogi & Company Limited								Betz A, 1997, J BIOL CHEM, V272, P2520; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P10777, DOI 10.1074/jbc.270.18.10777; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Miller J.H., 1972, EXPT MOL GENETICS; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Naito A, 1997, MOL BRAIN RES, V44, P198, DOI 10.1016/S0169-328X(96)00198-2; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAKAGUCHI G, 1995, BIOCHEM BIOPH RES CO, V217, P1253; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKADE TD, 1991, J BIOL CHEM, V266, P6424; WICK PF, 1993, J BIOL CHEM, V268, P10983	27	115	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16081	16084		10.1074/jbc.272.26.16081	http://dx.doi.org/10.1074/jbc.272.26.16081			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195900	hybrid			2022-12-25	WOS:A1997XG01900004
J	Sethi, JK; Empson, RM; Bailey, VC; Potter, BVL; Galione, A				Sethi, JK; Empson, RM; Bailey, VC; Potter, BVL; Galione, A			7-deaza-8-bromo-cyclic ADP-ribose, the first membrane-permeant, hydrolysis-resistant cyclic ADP-ribose antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INDUCED CA2+ RELEASE; SEA-URCHIN EGGS; RYANODINE RECEPTOR; CALCIUM-RELEASE; FERTILIZATION; METABOLITE; TUBERCIDIN; TISSUES; CELLS	Cyclic ADP-ribose (cADPR) is a putative second messenger that has been demonstrated to mobilize Ca2+ in many cell types. Its postulated role as the endogenous regulator of ryanodine-sensitive Ca2+ release channels has been greatly supported by the advent and use of specific cADPR receptor antagonists such as 8-NH2-cADPR (Walseth, T. F., and Lee, H. C. (1993) Biochim. Biophys. Acta 1178, 235-242), However, investigations of the role of cADPR in physiological responses, such as fertilization, stimulus-secretion coupling, and excitation-contraction coupling, have been hindered by the susceptibility of cADPR receptor antagonists to hydrolysis and the need to introduce these molecules into cells by microinjection or patch clamp techniques. We have recently reported on the discovery of a poorly hydrolyzable analogue of cADPR, 7-deaza-cADPR (Bailey, V. C., Sethi, J. K., Fortt, S. M., Galione, A., and Potter, B. V. L. (1997) Chem. Biol. 4, 41-51) but this, like cADPR, is an agonist of ryanodine-sensitive Ca2+ release channels. We therefore explored the possibility of combining antagonistic activity with that of hydrolytic resistance and now report on the biological properties of the first hydrolysis-resistant cADPR receptor antagonist, 7-deaza-8-bromo-cADPR. In addition this compound has the advantage of being membrane-permeable. Together these properties make this hybrid molecule the most powerful tool to date for studying cADPR-mediated Ca2+ signaling in intact cells.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; UNIV BATH,SCH PHARM & PHARMACOL,DEPT MED CHEM,BATH BA2 7AY,AVON,ENGLAND	University of Oxford; University of Bath			Potter, Barry VL/A-1845-2012; Potter, Barry/AAX-4781-2020; Sethi, Jaswinder K./B-1413-2008	Sethi, Jaswinder K./0000-0003-4157-0475; Galione, Antony/0000-0002-4132-7646; Empson, Ruth/0000-0002-0415-6083	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1359, DOI 10.1039/c39950001359; BAILEY VC, 1997, J CHEM SOC CHEM COMM, V7, P695; BAILEY VC, 1997, CHEM BIOL, V4, P41; BERGSTROM DE, 1980, NUCLEIC ACIDS RES, V8, P6213, DOI 10.1093/nar/8.24.6213; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1996, RYANODINE RECEPTORS, P51; Galione A, 1996, BIOCH SMOOTH MUSCLE; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GUSE AH, 1995, J IMMUNOL, V155, P3353; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; JI LN, 1991, J CHEM SOC DALTON, P1367, DOI 10.1039/dt9910001367; KIM H, 1993, BIOCHEM BIOPH RES CO, V194, P1143, DOI 10.1006/bbrc.1993.1941; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; MAHANTY NK, 1995, SOC NEUR ABSTR, V21, P1806; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; PIKE JE, 1964, J HETEROCYCLIC CHEM, V1, P159; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SARDET C, 1987, CELL DIFFER DEV, V21, P1, DOI 10.1016/0045-6039(87)90443-X; SASAKI H, 1984, DEV BIOL, V101, P125, DOI 10.1016/0012-1606(84)90123-4; Sethi JK, 1996, BIOCHEM J, V319, P613, DOI 10.1042/bj3190613; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Willmott N, 1996, J BIOL CHEM, V271, P3699; WILLMOTT NJ, 1995, CELL CALCIUM, V18, P411, DOI 10.1016/0143-4160(95)90056-X; YOSHIKAWA M, 1969, B CHEM SOC JPN, V42, P3505, DOI 10.1246/bcsj.42.3505	36	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16358	16363		10.1074/jbc.272.26.16358	http://dx.doi.org/10.1074/jbc.272.26.16358			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195942	hybrid			2022-12-25	WOS:A1997XG01900046
J	Wei, MX; deTurenneTessier, M; Decaussin, G; Benet, G; Ooka, T				Wei, MX; deTurenneTessier, M; Decaussin, G; Benet, G; Ooka, T			Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus	ONCOGENE			English	Article						EBV; BARF1; immortalization; epithelial cells	LYMPHOCYTE GROWTH TRANSFORMATION; NASOPHARYNGEAL CARCINOMA; GENE-EXPRESSION; DNA; TRANSCRIPTION; PROTEINS	We previously reported that the BARF1 (BamH1-A right frame 1) gene product from Epstein-Barr Virus (EBV) may have oncogenic properties since injection into new-born rats of transfected cell lines resulted in the development of BARF1 expressing tumors, which were agressive in the case of murine fibroblasts and transient in that of human B lymphocytes. As EBV has been associated with nasopharyngeal carcinoma (NPC) and evidence of BARF1 transcription in this cancer was emerging from our biopsy analyses, we examined the effects of BARF1 transfection into primate primary epithelial cells. The expression of the BARF1 open reading frame in primary monkey kidney epithelial cells led us to the establishment of continuously dividing lines. The BARF1 transfectants showed the major characteristics of immortalized cells: morphological change, short cell doubling time, ability to divide at low cell density and continuous growth over 50 passages. Injection of BARF1 transfectants into nude mice did not induce any tumor. Established subclones were shown to be epithelial cells expressing known keratins as well as the BARF1 coded mRNA and protein. This is the first report indicating that expression of the BARF1 gene product in primary epithelial cells may contribute to the establishment of cell lines.	FAC MED R LAENNEC,UMR 5537 CNRS,MOL VIROL LAB,IVMC,F-69372 LYON 08,FRANCE; RHONE MERIEUX,F-69007 LYON,FRANCE									BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BOUZID M, 1994, INT J CANCER, V56, P468, DOI 10.1002/ijc.2910560403; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DECAUSSIN G, 1995, J VIROL, V69, P7309, DOI 10.1128/JVI.69.11.7309-7314.1995; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GRIFFIN BE, 1984, NATURE, V309, P78, DOI 10.1038/309078a0; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NIEDOBITEK G, 1992, VIRCHOWS ARCH B, V62, P55, DOI 10.1007/BF02899665; OOKA T, 1977, EXP CELL RES, V104, P319, DOI 10.1016/0014-4827(77)90097-0; SbihLammali F, 1996, J MED VIROL, V49, P7, DOI 10.1002/(SICI)1096-9071(199605)49:1&lt;7::AID-JMV2&gt;3.0.CO;2-A; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SUGDEN B, 1989, CELL, V57, P5, DOI 10.1016/0092-8674(89)90165-7; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TOOZE J, 1981, MOL BIOL TUMOUR VIRU; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; WEI MX, 1994, CANCER RES, V54, P1843; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988	32	64	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3073	3081		10.1038/sj.onc.1201128	http://dx.doi.org/10.1038/sj.onc.1201128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223671				2022-12-25	WOS:A1997XG10000010
J	Hiyama, H; Iavarone, A; LaBaer, J; Reeves, SA				Hiyama, H; Iavarone, A; LaBaer, J; Reeves, SA			Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression	ONCOGENE			English	Article						cyclin D1; p21; E2F; cell cycle; transcription; tetracycline	HUMAN BREAST-CARCINOMA; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; DEPENDENT KINASES; MAMMALIAN-CELLS; GROWTH ARREST; IN-VIVO; G(1); E2F	Cyclin D1 plays a key regulatory role during the G(1) phase of the cell cycle and its gene is amplified and overexpressed in many cancers. To address the relationship between cyclin D1 and other cell cycle regulatory proteins, we established human glioma and rodent fibroblast cell lines in which cyclin D1 expression could be regulated ectopically with tetracycline. In both of these cell lines, we found that ectopic expression of cyclin D1 in asynchronously growing cells was accompanied by increased levels of the p53 tumor suppressor protein and the cyclin/cdk inhibitor p21. Despite the induction of these cell cycle inhibitory proteins, cyclin D1-associated cdk kinase remained activated and the cells grew essentially like that of the parent cells. Although growth parameters were unchanged in these cells, morphological changes were clearly identifiable and anchorage independent growth was observed in NIH3T3 cells. In a first step toward elaborating the mechanism for cyclin D1-mediated induction of p21 gene expression we show that co-expression of E2F-1 and DP-1 can specifically transactivate the p21 promoter. In support of these findings and a direct effect of E2F on induction of p21 gene expression a putative E2F binding site was identified within the p21 promoter. In summary, our results demonstrate that ectopic expression of cyclin D1 can induce gene expression of the cdk inhibitor p21 through an E2F mechanism the consequences of which are not to growth arrest tells but possibly to stabilize cyclin D1/cdk function.	MASSACHUSETTS GEN HOSP,CTR NEUROSCI,NEUROSURG SERV,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center								ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Asano K, 1995, BIOCHEM BIOPH RES CO, V217, P1169, DOI 10.1006/bbrc.1995.2892; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bennett JD, 1996, ONCOGENE, V13, P1073; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fueyo J, 1996, ONCOGENE, V12, P103; GomezManzano C, 1996, CANCER RES, V56, P694; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HE J, 1994, CANCER RES, V54, P5804; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JUNG JM, 1995, ONCOGENE, V11, P2021; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAMMIE GA, 1991, ONCOGENE, V6, P439; Liu Y, 1996, CANCER RES, V56, P31; LOVEC H, 1994, ONCOGENE, V9, P323; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Marchetti A, 1996, ONCOGENE, V12, P1319; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Michieli P, 1996, ONCOGENE, V12, P775; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHUURING E, 1992, ONCOGENE, V7, P355; Sgambato A, 1996, CANCER RES, V56, P1389; SHAO ZH, 1995, ONCOGENE, V10, P221; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	69	88	89	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2533	2542		10.1038/sj.onc.1201080	http://dx.doi.org/10.1038/sj.onc.1201080			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191053				2022-12-25	WOS:A1997XA94900005
J	Shintani, T; Nomura, K; Ichishima, E				Shintani, T; Nomura, K; Ichishima, E			Engineering of porcine pepsin - Alteration of S-1 substrate specificity of pepsin to those of fungal aspartic proteinases by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY ANALYSES; HUMAN CATHEPSIN-D; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE; INHIBITOR COMPLEXES; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURES; PEPTIDE-INHIBITOR; 1.8-A RESOLUTION; RENIN INHIBITORS	The S-1 substrate specificity of porcine pepsin has been altered to resemble that of fungal aspartic proteinase with preference for a basic amino acid residue in P-1 by site directed mutagenesis. On the basis of primary and tertiary structures of aspartic proteinases, the active site-flap mutants of porcine pepsin were constructed, which involved the replacement of Thr-77 by Asp (T77D), the insertion of Ser between Gly-78 and Ser-79 (G78(S)S79), and the double mutation (T77D/G78(S)S79). The specificities of the mutants were determined using p-nitrophenylalanine-based substrates containing a Phe or Lys residue at the P-1 position. The double mutant cleaved the Lys-Phe(4-NO2) bonds, while wild-type enzyme digested other bonds. In addition, the pH dependence of hydrolysis of Lys-containing substrates by the double mutant indicates that the interactions between Asp-77 of the mutant and P-1 Lys contribute to the transition state stabilization. The double mutant was also able to activate bovine trypsinogen to trypsin by the selective cleavage of the Lys(6)-Ile(7) bond of trypsinogen. Results of this study suggest that the structure of the active site flap contributes to the S-1 substrate specificity for basic amino acid residues in aspartic proteinases.	TOHOKU UNIV,FAC AGR,DEPT APPL BIOL CHEM,LAB MOL ENZYMOL,AOBA KU,SENDAI,MIYAGI 981,JAPAN	Tohoku University			SHINTANI, Takahiro/ABE-1267-2020	Shintani, Takahiro/0000-0001-6630-5892				ABITA JP, 1969, EUR J BIOCHEM, V8, P314, DOI 10.1111/j.1432-1033.1969.tb00530.x; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; BLUNDELL TL, 1987, BIOCHEMISTRY-US, V26, P5585, DOI 10.1021/bi00392a001; COOPER J, 1992, BIOCHEMISTRY-US, V31, P8142, DOI 10.1021/bi00150a005; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; COOPER JB, 1989, BIOCHEMISTRY-US, V28, P8596, DOI 10.1021/bi00447a049; DEALWIS CG, 1994, J MOL BIOL, V236, P342, DOI 10.1006/jmbi.1994.1139; DHANARAJ V, 1992, NATURE, V357, P466, DOI 10.1038/357466a0; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P293; FRUTON JS, 1987, HYDROLYTIC ENZYMES, P1; FUJINAGA M, 1995, PROTEIN SCI, V4, P960; GABELOTEAU C, 1960, BIOCHIM BIOPHYS ACTA, V42, P230, DOI 10.1016/0006-3002(60)90786-1; Green BN, 1996, BIOCHEM J, V313, P241, DOI 10.1042/bj3130241; HOFMANN T, 1982, BIOCHEM J, V203, P603, DOI 10.1042/bj2030603; ICHISHIMA E., 1970, METHOD ENZYMOL, V19, P397; JAMES MNG, 1983, J MOL BIOL, V163, P299, DOI 10.1016/0022-2836(83)90008-6; JAMES MNG, 1985, ASPARTIC PROTEINASES, P163; KAGEYAMA T, 1983, J BIOCHEM, V93, P743, DOI 10.1093/jb/93.3.743; KAY J, 1985, BIOCHEM SOC T, V13, P1027, DOI 10.1042/bst0131027; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN XL, 1989, J BIOL CHEM, V264, P4482; LOWTHER WT, 1995, PROTEIN SCI, V4, P689; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILNERWHITE EJ, 1986, BIOCHEM J, V240, P289, DOI 10.1042/bj2400289; MORIHARA K, 1973, ARCH BIOCHEM BIOPHYS, V157, P561, DOI 10.1016/0003-9861(73)90675-9; NEWMAN M, 1991, J MOL BIOL, V221, P1295, DOI 10.1016/0022-2836(91)80127-G; POHL J, 1988, BIOCHEMISTRY-US, V27, P4827, DOI 10.1021/bi00413a037; RAO C, 1985, ASPARTIC PROTEINASES, P91; SCARBOROUGH PE, 1994, PROTEIN ENG, V7, P495, DOI 10.1093/protein/7.4.495; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shintani T, 1996, J BIOCHEM-TOKYO, V120, P974; SHINTANI T, 1994, BBA-PROTEIN STRUCT M, V1204, P257, DOI 10.1016/0167-4838(94)90016-7; SIEBERT PD, 1993, NUCLEIC ACIDS RES, V21, P2019, DOI 10.1093/nar/21.8.2019; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; SODEK J, 1970, METHOD ENZYMOL, V19, P372; STROP P, 1990, BIOCHEMISTRY-US, V29, P9863, DOI 10.1021/bi00494a016; SUGUNA K, 1987, P NATL ACAD SCI USA, V84, P7009, DOI 10.1073/pnas.84.20.7009; SUZUKI J, 1989, PROTEIN ENG, V2, P563, DOI 10.1093/protein/2.7.563; TANAKA N, 1977, BIOCHIM BIOPHYS ACTA, V485, P406, DOI 10.1016/0005-2744(77)90176-0; TANG J, 1973, P NATL ACAD SCI USA, V70, P3437, DOI 10.1073/pnas.70.12.3437; TSUKAGOSHI N, 1988, GENE, V65, P285; VALVERDE V, 1995, J BIOL CHEM, V270, P15821, DOI 10.1074/jbc.270.26.15821; VEERAPANDIAN B, 1990, J MOL BIOL, V216, P1017, DOI 10.1016/S0022-2836(99)80017-5; YANG JT, 1986, METHOD ENZYMOL, V130, P208; [No title captured]	47	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18855	18861		10.1074/jbc.272.30.18855	http://dx.doi.org/10.1074/jbc.272.30.18855			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228062	hybrid			2022-12-25	WOS:A1997XM34200053
J	Dhar, M; Mascareno, EM; Siddiqui, MAQ				Dhar, M; Mascareno, EM; Siddiqui, MAQ			Two distinct factor-binding DNA elements in cardiac myosin light chain 2 gene are essential for repression of its expression in skeletal muscle - Isolation of a cDNA clone for repressor protein Nished	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC TRANSCRIPTION; NEGATIVE REGULATORY ELEMENT; C-FOS PROMOTER; EVEN-SKIPPED PROTEIN; SILENCER ELEMENTS; OSTEOCALCIN GENE; VIMENTIN GENE; MESSENGER-RNA; ACTIN GENE; SEQUENCE	The expression of the cardiac myosin light chain 2 (MLCS) gene is repressed in skeletal muscle as a result of the negative regulation of its transcription. Two regulatory elements, the cardiac specific sequence (CSS) located upstream (-360 base pairs) and a downstream negative modulatory sequence (NMS), which function in concert with each other, are required for repression of the MLC2 promoter activity in skeletal muscle. Individually, CSS and NMS have no effect. Transient transfection analysis with recombinant plasmids indicated that CSS- and NMS-mediated repression of transcription is position- and orientation-dependent and is transferable to heterologous promoters. A minimal conserved motif, GAAG/CTTC, present in both CSS and NMS, is responsible for repression as the mutation in the core CTTC sequence alone was sufficient to abrogate its repressor activity. The DNA binding assay by gel mobility shift analysis revealed that one of the two complexes, CSSBP2, is significantly enriched in embryonic skeletal muscle relative to cardiac muscle. In extracts from adult skeletal muscle, where the cardiac MLC2 expression is suppressed, both complexes, CSSBP1 and CSSBP2, were present, whereas the cardiac muscle extracts contained CSSBP1 alone, suggesting that the protein(s) in the CSSBP2 complex accounts for the negative regulation of cardiac MLC2 in skeletal muscle. A partial cDNA clone (Nished) specific for the candidate repressor factor was isolated by expression screening of the skeletal muscle cDNA library by multimerized CSS-DNA as probe. The recombinant Nished protein binds to the CSS-DNA, but not to Delta CSS-DNA where the core CTTC sequence was mutated. The amino acid sequence of Nished showed a significant structural similarity to the sequence of transcription factor ''runt,'' a known repressor of gap and pair-rule gene expression in Drosophila.	SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, CTR CARDIOVASC & MUSCLE RES, BROOKLYN, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041923] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLD HH, 1988, EUR J BIOCHEM, V178, P53, DOI 10.1111/j.1432-1033.1988.tb14428.x; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; COVITZAN PA, 1993, GENE DEV, V7, P1398; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DYAN WS, 1989, CELL, V58, P1; EMERSON C, 1986, UCLA S MOL CELLULAR, V29; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRENKEL B, 1993, BIOCHEMISTRY-US, V32, P13636, DOI 10.1021/bi00212a031; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; GARZON RJ, 1994, MOL CELL BIOL, V14, P934, DOI 10.1128/MCB.14.2.934; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GOSWAMI S, 1994, MOL CELL BIOL, V14, P5130, DOI 10.1128/MCB.14.8.5130; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HERBST RS, 1990, MOL CELL BIOL, V10, P3896, DOI 10.1128/MCB.10.8.3896; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; IP YT, 1991, CELL, V64, P439; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KONDO S, 1992, MOL CELL BIOL, V12, P4496, DOI 10.1128/MCB.12.10.4496; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LENNY N, 1995, ONCOGENE, V11, P1761; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; MANOUKIAN AS, 1993, DEVELOPMENT, V118, P785; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MIN LW, 1992, J IMMUNOL, V148, P1913; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIZZEN K, 1992, GENE, V119, P293; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NISHIYAMA S, 1994, GENE, V141, P261, DOI 10.1016/0378-1119(94)90582-7; OGAWA E, 1993, P NATL ACAD SCI USA, V89, P11823; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; QASBA P, 1992, MOL CELL BIOL, V12, P1107, DOI 10.1128/MCB.12.3.1107; RINCONLIMAS DE, 1995, MOL CELL BIOL, V15, P6561; SAIDAPET C, 1984, ARCH BIOCHEM BIOPHYS, V233, P565, DOI 10.1016/0003-9861(84)90480-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TADA H, 1991, VIROLOGY, V180, P327, DOI 10.1016/0042-6822(91)90037-C; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; TROUCHE D, 1995, FEBS LETT, V361, P140, DOI 10.1016/0014-5793(95)00140-5; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; WERNER H, 1994, J BIOL CHEM, V269, P12577; ZARRAGA AM, 1986, J BIOL CHEM, V261, P3852; ZHOU MD, 1993, MOL CELL BIOL, V13, P1222, DOI 10.1128/MCB.13.2.1222; Zhou Ming-Dong, 1992, Gene Expression, V2, P127	63	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18490	18497		10.1074/jbc.272.29.18490	http://dx.doi.org/10.1074/jbc.272.29.18490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218494	hybrid			2022-12-25	WOS:A1997XL73500084
J	Leech, CA; Habener, JF				Leech, CA; Habener, JF			Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; MEDIATED CALCIUM ENTRY; PEPTIDE-I; SECRETING CELLS; INTRACELLULAR CALCIUM; ACINAR-CELLS; CA2+ INFLUX; G-PROTEIN; RECEPTOR; CHANNELS	Maitotoxin (MTX) activates a Ca2+-dependent non-selective cation current (ICa-NS) in insulinoma cells whose time course is identical to non selective cation currents activated by incretin hormones such as glucagon-like peptide-1 (GLP-1), which stimulate glucose-dependent insulin secretion by activating cAMP signaling pathways, We investigated the mechanism of activation of ICa-NS in insulinoma cells using specific pharmacological reagents, and these studies further support an identity between MTX- and GLP-1-activated currents, ICa-NS is inhibited by extracellular application of genistein, econazole, and SKF 96365. This inhibition by genistein suggests that tyrosine phophorylation may play a role in the activation of ICa-NS. ICa-NS is not inhibited by incubation of cells in glucose-free solution, by extracellular tetrodotoxin, nimodipine, or tetraethylammonium, or by intracellular dialysis with 4-aminopyridine, ATP, ryanodine, or heparin, ICa-NS is also not significantly inhibited by staurosporine, which does, however, partially inhibit the MTX-induced rise of intracellular Ca2+ concentration, These effects of staurosporine suggest that protein kinase C may not be involved in the activation of ICa-NS but that it may regulate intracellular Ca2+ release, Alternatively, ICa-NS may have a small component that is carried through separate divalent cation-selective channels that are inhibited by staurosporine. ICa-NS is neither activated nor inhibited by dialysis with KF, KF + AlF3 or GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)), suggesting that GTP-binding proteins do not play a major role in the activation of this current.			Leech, CA (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,LAB MOL ENDOCRINOL,BOSTON,MA 02114, USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BERTHOD A, 1995, CHROMATOGR SCI SERIE, V68, P1; BISCHOF G, 1995, AM J PHYSIOL-CELL PH, V268, pC154, DOI 10.1152/ajpcell.1995.268.1.C154; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; Estacion M, 1996, AM J PHYSIOL-CELL PH, V270, pC1145, DOI 10.1152/ajpcell.1996.270.4.C1145; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GEFEL D, 1990, ENDOCRINOLOGY, V126, P2164, DOI 10.1210/endo-126-4-2164; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; GROMADA J, 1995, DIABETES, V44, P767, DOI 10.2337/diabetes.44.7.767; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAHN HJ, 1988, BIOCHIM BIOPHYS ACTA, V630, P425; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; LEBRUN P, 1987, BIOCHEM BIOPH RES CO, V144, P172, DOI 10.1016/S0006-291X(87)80491-6; LEE KM, 1993, J BIOL CHEM, V268, P9945; Leech CA, 1996, ANN NY ACAD SCI, V805, P81; LEECH CA, 1995, ENDOCRINOLOGY, V136, P1530, DOI 10.1210/en.136.4.1530; LEECH CA, 1994, ENDOCRINOLOGY, V135, P365, DOI 10.1210/en.135.1.365; LEECH CA, 1994, METHOD CELL BIOL, V40, P135; MARUYAMA Y, 1984, J MEMBRANE BIOL, V81, P83, DOI 10.1007/BF01868812; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; Miura Y, 1996, BIOCHEM BIOPH RES CO, V224, P67, DOI 10.1006/bbrc.1996.0985; MURATA M, 1992, EUR J PHARM-MOLEC PH, V227, P43, DOI 10.1016/0922-4106(92)90140-Q; PFEIFFER F, 1995, PFLUG ARCH EUR J PHY, V430, P916, DOI 10.1007/BF01837405; Poyer JF, 1996, J MEMBRANE BIOL, V153, P13; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; RIBALET B, 1994, J MEMBRANE BIOL, V142, P395; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SATIN LS, 1995, ENDOCRINOLOGY, V136, P4589, DOI 10.1210/en.136.10.4589; SILVA AM, 1994, J BIOL CHEM, V269, P17095; SOERGEL DG, 1990, J PHARMACOL EXP THER, V255, P1360; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; STURGESS NC, 1986, FEBS LETT, V208, P397, DOI 10.1016/0014-5793(86)81056-0; STURGESS NC, 1987, PFLUG ARCH EUR J PHY, V409, P607, DOI 10.1007/BF00584661; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Vostal JG, 1996, J BIOL CHEM, V271, P19524, DOI 10.1074/jbc.271.32.19524; WOLTERS GHJ, 1984, DIABETES, V33, P409, DOI 10.2337/diabetes.33.5.409; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; WORLEY JF, 1994, J BIOL CHEM, V269, P32055; YADA T, 1994, J BIOL CHEM, V269, P1290	46	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17987	17993		10.1074/jbc.272.29.17987	http://dx.doi.org/10.1074/jbc.272.29.17987			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218425	hybrid			2022-12-25	WOS:A1997XL73500015
J	Popov, M; Tam, LY; Li, J; Reithmeier, RAF				Popov, M; Tam, LY; Li, J; Reithmeier, RAF			Mapping the ends of transmembrane segments in a polytopic membrane protein - Scanning N-glycosylation mutagenesis of extracytosolic loops in the anion exchanger, Band 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; STILBENE DISULFONATE BINDING; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; TRANSPORT PROTEIN; ENDOPLASMIC-RETICULUM; CYTOPLASMIC SIDE; SIGNAL SEQUENCE; P-GLYCOPROTEIN; CELL MEMBRANE	Band 3, the anion exchanger of human erythrocytes, contains up to 14 transmembrane (TM) segments and has a single endogenous site of N-glycosylation at Asn(642) in extracellular (EC) loop 4, The requirements for N-glycosylation of EC loops and the topology of this :polytopic membrane protein were determined by scanning N-glycosylation mutagenesis and cell-free translation in a reticulocyte lysate supplemented with microsomal membranes. The endogenous and novel acceptor sites located near the middle of the 35 residue EC loop 4 were efficiently N-glycosylated; however, no N-glycosylation occurred at sites located within sharply defined regions close to the adjacent TM segments, Acceptor sites located in the center of EC loop 3, which contains 25 residues, were poorly N-glycosylated, Expansion of this loop with a 4-residue insert containing an acceptor site increased N-glycosylation, Acceptor sites located in short (<10 residues) loops (putative EC loops 1, 2, 6, and 7) were not N-glycosylated; however, insertion of EC loop 4 into EC loops 1, 2, or 7, but not 6, resulted in efficient N-glycosylation, Acceptor sites in putative intracellular (IC) loop 5 exhibited a similar pattern of N-glycosylation as EC loop 4, indicating a lumenal disposition during biosynthesis, To be efficiently N-glycosylated, EC loops in polytopic membrane proteins must be larger than 25 residues in size, with acceptor sites located greater than 12 residues away from the preceding TM segment and greater than 14 residues away from the following TM segment, Application of this requirement allowed a significant refinement of the topology of Band 3 including a more accurate mapping of the ends of TM segments, The strict distance dependence for N-glycosylation of loops suggests that TM segments in polytopic membrane proteins are held quite precisely within the translocation machinery during the N-glycosylation process.	UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto								Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRUCE LJ, 1994, J BIOL CHEM, V269, P16155; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; COBB CE, 1990, BIOCHEMISTRY-US, V29, P8283, DOI 10.1021/bi00488a012; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; HUBNER S, 1992, BIOCHEM J, V285, P17; JENNINGS ML, 1984, BIOCHEMISTRY-US, V23, P6432, DOI 10.1021/bi00321a024; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1992, KIDNEY PHYSL PATHOPH, P503; Kalo MS, 1996, BIOCHEMISTRY-US, V35, P999, DOI 10.1021/bi951702h; KANG D, 1992, J BIOL CHEM, V267, P19211; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OKUBO K, 1994, J BIOL CHEM, V269, P1918; OKUBO K, 1991, J BIOL CHEM, V266, P16420; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PASSOW H, 1992, BIOPHYS J, V62, P98, DOI 10.1016/S0006-3495(92)81791-5; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; REITHMEIER RAF, 1996, TRANSPORT PROCESSES, V2, P281; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Simon S, 1993, CURR OPIN CELL BIOL, V5, P581, DOI 10.1016/0955-0674(93)90126-B; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P6903; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; Tam LY, 1996, BIOCHEM J, V318, P645, DOI 10.1042/bj3180645; TAM LY, 1994, J BIOL CHEM, V269, P32542; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; WAINWRIGHT SD, 1990, BIOCHEM J, V272, P265, DOI 10.1042/bj2720265; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; Wang L, 1997, J BIOL CHEM, V272, P10631; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	57	160	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18325	18332		10.1074/jbc.272.29.18325	http://dx.doi.org/10.1074/jbc.272.29.18325			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218473	hybrid			2022-12-25	WOS:A1997XL73500063
J	Avellar, MCW; Gregory, CW; Power, SGA; French, FS				Avellar, MCW; Gregory, CW; Power, SGA; French, FS			Androgen-dependent protein interactions within an intron 1 regulatory region of the 20-kDa protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; GLUCOCORTICOID RESPONSE ELEMENT; DNASEI HYPERSENSITIVE SITES; PROMOTER IN-VIVO; TRANSCRIPTION FACTORS; STEROID-HORMONES; BINDING PROTEINS; OVALBUMIN GENE; PROBASIN GENE; BENDS DNA	The 20-kDa protein gene is androgen regulated in rat ventral prostate, Intron 1 contains a 130-base pair complex response element (D2) that binds androgen (AR) and glucocorticoid receptor (GR) but transactivates only with AR in transient cotransfection assays in CV1 cells using the reporter vector D2-tkCAT. To better understand the function of this androgen-responsive unit, nuclear protein interactions with D2 were analyzed by DNase I footprinting in ventral prostate nuclei of intact or castrated rats and in vitro with ventral prostate nuclear protein extracts from intact, castrated, and testosterone-treated castrated rats, Multiple androgen-dependent protected regions and hypersensitive sites were identified in the D2 region with both methods, Mobility shift assays with P-32-labeled oligonucleotides spanning D2 revealed specific interactions with ventral prostate nuclear proteins. Four of the D2-protein complexes decreased in intensity within 24 h of castration, UV cross-linking of the androgen-dependent DNA binding proteins identified protein complexes of approximately 140 and 55 kDa. The results demonstrate androgen-dependent nuclear protein DNA interactions within the complex androgen response element D2.	UNIV N CAROLINA,LABS REPROD BIOL,SCH MED,DEPT PEDIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Avellar, Maria Christina W./E-2865-2013; Avellar, Maria Christina/E-2865-2013	Avellar, Maria Christina W./0000-0003-4392-7554; Avellar, Maria Christina/0000-0003-2810-3581	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018968, F32HD007992, R01HD004466, R37HD004466] Funding Source: NIH RePORTER; NICHD NIH HHS [HD04466, HD07992, P30-HD18968] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CELIS L, 1993, MOL CELL ENDOCRINOL, V94, P165, DOI 10.1016/0303-7207(93)90165-G; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; DAHLMANWRIGHT K, 1992, BIOCHEMISTRY-US, V31, P9040, DOI 10.1021/bi00152a047; Dean DM, 1996, MOL ENDOCRINOL, V10, P1489, DOI 10.1210/me.10.12.1489; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; DEVOS P, 1994, J STEROID BIOCHEM, V48, P317, DOI 10.1016/0960-0760(94)90071-X; FABER S, 1993, J BIOL CHEM, V268, P24976; FABRE S, 1994, J BIOL CHEM, V269, P5857; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRESSMANN ME, 1995, J BIOL CHEM, V270, P10968; HAECKER SAE, 1995, MOL ENDOCRINOL, V9, P1113, DOI 10.1210/me.9.9.1113; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Harris S E, 1988, Prog Clin Biol Res, V284, P53; HO KC, 1989, BIOCHEMISTRY-US, V28, P6367, DOI 10.1021/bi00441a032; HO KC, 1993, J BIOL CHEM, V268, P27226; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; KASPER S, 1994, J BIOL CHEM, V269, P31763; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MARSCHKE KB, 1995, ENDOCRINE, V3, P819, DOI 10.1007/BF02935687; Maxam A M, 1980, Methods Enzymol, V65, P499; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; NORDSTROM LA, 1993, J BIOL CHEM, V268, P13193; PRENDERGAST P, 1994, J STEROID BIOCHEM, V48, P1, DOI 10.1016/0960-0760(94)90245-3; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RHEE M, 1991, MOL ENDOCRINOL, V5, P564, DOI 10.1210/mend-5-4-564; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUPAKAR PC, 1993, J BIOL CHEM, V268, P26400; TAN JA, 1992, J BIOL CHEM, V267, P4456; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WINDERICKX J, 1994, J STEROID BIOCHEM, V48, P165, DOI 10.1016/0960-0760(94)90141-4; WINDERICKX J, 1990, MOL ENDOCRINOL, V4, P657, DOI 10.1210/mend-4-4-657; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; ZHANG YL, 1990, MOL ENDOCRINOL, V4, P1219, DOI 10.1210/mend-4-8-1219	61	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17623	17631		10.1074/jbc.272.28.17623	http://dx.doi.org/10.1074/jbc.272.28.17623			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211911	hybrid, Green Published			2022-12-25	WOS:A1997XK16500054
J	Beetham, JK; Myung, KS; McCoy, JJ; Wilson, ME; Donelson, JE				Beetham, JK; Myung, KS; McCoy, JJ; Wilson, ME; Donelson, JE			Glycoprotein 46 mRNA abundance is post-transcriptionally regulated during development of Leishmania chagasi promastigotes to an infectious form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; CUTANEOUS LEISHMANIASIS; DIFFERENTIAL EXPRESSION; EFFECTIVE IMMUNIZATION; MAJOR PROMASTIGOTES; NUCLEOTIDE-SEQUENCE; TRYPANOSOMA-BRUCEI; SURFACE PROTEASE; GP63 RNAS; DONOVANI	GP46 is an abundant glycoprotein of 46 kDa on the surface of the promastigote form of mast Leishmania species. We show that the steady stale level of GP46 mRNA increases >30-fold as Leishmania chagasi promastigotes develop in vitro from a less infections form during logarithmic growth to a highly infections form in the stationary phase of cultivation Nuclear run on experiments demonstrate that this increase in GP46 mRNA abundance is regulated post-transcriptionally. Plasmids containing the 3'-untranslated regions (UTRs) and downstream intergenic regions (IRs) of two differ ent GP46 genes fused immediately downstream of the beta-galactosidase coding region were transfected into L. chagasi, and beta-galactosidase activity and mRNA levels were examined. The presence of the 3'-UTR + IR of one GP46 gene (gp46A) resulted in a steady increase in p-galactosidase activity and mRNA level as the transfected promastigotes developed from logarithmic to stationary phase. This differential effect parallels that of the 3'-UTRs + IRs of a family of genes for an unrelated Leishmania surface glycoprotein, GP63. Thus, post-transcriptional regulation of the genes for two different surface glycoproteins of Leishmania occurs via a similar mechanism.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; VET AFFAIRS MED CTR,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System			Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032135, R01AI032135] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07121] Funding Source: Medline; NIAID NIH HHS [AI32135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; CHAMPSI J, 1988, INFECT IMMUN, V52, P3272; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473; Handman E, 1995, MOL BIOCHEM PARASIT, V74, P189, DOI 10.1016/0166-6851(95)02500-6; KAHL LP, 1987, J IMMUNOL, V138, P1587; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCMAHONPRATT D, 1993, INFECT IMMUN, V61, P3351, DOI 10.1128/IAI.61.8.3351-3359.1993; MCMAHONPRATT D, 1992, MOL BIOCHEM PARASIT, V50, P151, DOI 10.1016/0166-6851(92)90252-F; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; PEARSON RD, 1980, J IMMUNOL, V125, P2195; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SACKS DL, 1987, J IMMUNOL, V139, P3088; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEIN Y, 1993, PARASITOL TODAY, V9, P255, DOI 10.1016/0169-4758(93)90070-V; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SYMONS FM, 1994, MOL BIOCHEM PARASIT, V67, P103, DOI 10.1016/0166-6851(94)90100-7; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787; WILSON ME, 1993, J BIOL CHEM, V268, P15731; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	39	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17360	17366		10.1074/jbc.272.28.17360	http://dx.doi.org/10.1074/jbc.272.28.17360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211875	hybrid			2022-12-25	WOS:A1997XK16500018
J	Lander, HM; Tauras, JM; Ogiste, JS; Hori, O; Moss, RA; Schmidt, AM				Lander, HM; Tauras, JM; Ogiste, JS; Hori, O; Moss, RA; Schmidt, AM			Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; CELL-SURFACE; EXPRESSION; INDUCTION; MECHANISM; GLUCOSE; IDENTIFICATION; COMPLICATIONS	Advanced glycation end products (AGEs) exert their cellular effects on cells by interacting with specific cellular receptors, the best characterized of which is the receptor for AGE (RAGE), The transductional processes by which RAGE ligation transmits signals to the nuclei of cells is unknown and was investigated, AGE-albumin, a prototypic ligand, activated p21(ras) in rat pulmonary artery smooth muscle cells that express RAGE, whereas nonglycated albumin was without effect, MAP kinase activity was enhanced at concentrations of AGE-albumin, which activated p21(ras) and NF-kappa B, Depletion of intracellular glutathione rendered cells more sensitive to AGE-mediated activation of this signaling pathway, in contrast, signaling was blocked by preventing p21(ras) from associating with the plasma membrane or mutating Cys(118) on p21(ras) to Ser. Signaling was receptor-dependent, because it was prevented by blocking access to RAGE with either anti-RAGE IgG or by excess soluble RAGE, These data suggest that RAGE-mediated induction of cellular oxidant stress triggers a cascade of intracellular signals involving p21(ras) and MAP kinase, culminating in transcription factor activation, The molecular mechanism that triggers this pathway likely involves oxidant modification and activation of p21(ras).	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University	Lander, HM (corresponding author), CORNELL UNIV,COLL MED,DEPT BIOCHEM,1300 YORK AVE,NEW YORK,NY 10021, USA.			Moss, Rebecca/0000-0002-0139-5396	NIAID NIH HHS [AI37637] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NIGMS NIH HHS [GM55509] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055509] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DEFORGE LE, 1992, J CLIN INVEST, V90, P2123, DOI 10.1172/JCI116097; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DYER DG, 1991, J BIOL CHEM, V266, P11654; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FRIEDMAN J, 1994, CIRCULATION, V90, P1567; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NEEPER M, 1992, J BIOL CHEM, V267, P14998; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V92, P2155; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELL DR, 1989, J BIOL CHEM, V264, P21597; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; STEVENSON MA, 1994, CANCER RES, V54, P12; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1994, J BIOL CHEM, V269, P9889	36	637	671	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17810	17814		10.1074/jbc.272.28.17810	http://dx.doi.org/10.1074/jbc.272.28.17810			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211935	hybrid			2022-12-25	WOS:A1997XK16500078
J	Sandigursky, M; Yacoub, A; Kelley, MR; Deutsch, WA; Franklin, WA				Sandigursky, M; Yacoub, A; Kelley, MR; Deutsch, WA; Franklin, WA			The Drosophila ribosomal protein S3 contains a DNA deoxyribophosphodiesterase (dRpase) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; APURINIC APYRIMIDINIC SITES; ESCHERICHIA-COLI; DAMAGED DNA; FPG PROTEIN; EXCISION; REPAIR; ENDONUCLEASES; RESIDUES; GLYCOSYLASE	The Drosophila ribosomal protein S3 has been previously demonstrated to cleave DNA containing 8-oxoguanine residues and has also been found to contain an associated apurinic/apyrimidinic (AP) lyase activity that cleaves phosphodiester bonds via a beta, delta-elimination reaction. The activity of this protein on DNA substrates containing incised AP sites was examined. A glutathione S-transferase fusion protein of S3 was found to efficiently remove sugar-phosphate residues from DNA substrates containing 5'-incised AP sites as well as from DNA substrates containing 3'-incised sites. Removal of 2-deoxyribose-5-phosphate as 4-hydroxy-2-pentenal-5-phosphate from a substrate containing 5'-incised AP sites occurred via a beta-elimination reaction, as indicated by reaction of the released sugar-phosphate products with sodium thioglycolate. The reaction for the removal of 4-hydroxy-2-pentenal-5-phosphate from the substrate containing 3'-incised AP sites was dependent oil the presence of the Mg2+ cation. These findings suggest that the S3 ribosomal protein may function in several steps of the DNA base excision repair pathway in eukaryotes and may represent an important DNA repair function for the repair of oxidative and ionizing radiation-induced DNA damage.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT RADIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT RADIAT ONCOL,BRONX,NY 10461; LOUISIANA STATE UNIV,PENNINGTON BIOMED RES CTR,BATON ROUGE,LA 70808; INDIANA UNIV,SCH MED,DEPT PEDIAT,WELLS CTR PEDIAT RES,SECT PEDIAT ENDOCRINOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Kelley, Mark/0000-0002-6120-9532	NATIONAL CANCER INSTITUTE [R01CA052025, R29CA052025] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007815] Funding Source: NIH RePORTER; NCI NIH HHS [CA52025] Funding Source: Medline; NCRR NIH HHS [RR09884] Funding Source: Medline; NIEHS NIH HHS [ES07815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOITEUX S, 1990, J BIOL CHEM, V265, P3916; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FRANKLIN WA, 1988, EMBO J, V7, P3616; FRIEDBERG EC, 1995, DNA REPAIR; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LJUNGQUIST S, 1977, J BIOL CHEM, V252, P2808; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P1743; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; SANDIGURSKY M, 1992, NUCLEIC ACIDS RES, V20, P4699, DOI 10.1093/nar/20.18.4699; SANDIGURSKY M, 1992, RADIAT RES, V131, P332, DOI 10.2307/3578424; SANDIGURSKY M, 1996, RADIAT RES, V145, P629; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; WARNER HR, 1980, P NATL ACAD SCI-BIOL, V77, P4602, DOI 10.1073/pnas.77.8.4602; WILSON DM, 1994, J BIOL CHEM, V269, P25359; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; Yacoub A, 1996, NUCLEIC ACIDS RES, V24, P4298, DOI 10.1093/nar/24.21.4298	21	48	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17480	17484		10.1074/jbc.272.28.17480	http://dx.doi.org/10.1074/jbc.272.28.17480			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211893	hybrid			2022-12-25	WOS:A1997XK16500036
J	Choi, DJ; Koch, WJ; Hunter, JJ; Rockman, HA				Choi, DJ; Koch, WJ; Hunter, JJ; Rockman, HA			Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; FAILING HUMAN HEART; INOTROPIC RESPONSE; TRANSGENIC MICE; GAMMA-SUBUNITS; G-PROTEINS; EXPRESSION; TRANSDUCTION; ACTIVATION; INHIBITOR	Pressure overload cardiac hypertrophy in the mouse was achieved following 7 days of transverse aortic constriction, This was associated with marked beta-adrenergic receptor (beta-AR) desensitization in vivo, as determined by a blunted inotropic response to dobutamine. Extracts from hypertrophied hearts had approximate to 3-fold increase in cytosolic and membrane G protein-coupled receptor kinase (GRK) activity, Incubation with specific monoclonal antibodies to inhibit different GRK subtypes showed that the increase in activity could be attributed predominately to the beta-adrenergic receptor kinase (beta ARK), Although overexpression of a beta ARK inhibitor in hearts of transgenic mice did not alter the development of cardiac hypertrophy, the beta-AR desensitization associated with pressure overload hypertrophy was prevented, To determine whether the induction of beta ARK occurred because of a generalized response to cellular hypertrophy, beta ARK activity was measured in transgenic mice homozygous for oncogenic ras overexpression in the heart. Despite marked cardiac hypertrophy, no difference in beta ARK activity was found in these mice overexpressing oncogenic ras compared with controls, Taken together, these data suggest that beta ARK is a central molecule involved in alterations of beta-AR signaling in pressure overload hypertrophy, The mechanism for the increase in beta ARK activity appears not to be related to the induction of cellular hypertrophy but to possibly be related to neurohumoral activation.	UNIV CALIF SAN DIEGO, DEPT MED, SCH MED, LA JOLLA, CA 92093 USA; DUKE UNIV, DEPT SURG, DURHAM, NC 27710 USA	University of California System; University of California San Diego; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON EA, 1989, HYPERTENSION, V14, P177, DOI 10.1161/01.HYP.14.2.177; Benedict CR, 1996, CIRCULATION, V94, P690, DOI 10.1161/01.CIR.94.4.690; BOHM M, 1995, HYPERTENSION, V25, P962, DOI 10.1161/01.HYP.25.5.962; BOHM M, 1994, HYPERTENSION, V24, P653, DOI 10.1161/01.HYP.24.6.653; BOHM M, 1995, CIRCULATION, V92, P3006, DOI 10.1161/01.CIR.92.10.3006; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Eichhorn EJ, 1996, CIRCULATION, V94, P2285, DOI 10.1161/01.CIR.94.9.2285; FELDMAN AM, 1993, CIRCULATION, V87, P27; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; MERTENS MJF, 1992, J HYPERTENS, V10, P1361, DOI 10.1097/00004872-199211000-00008; MORAVEC CS, 1995, J MOL CELL CARDIOL, V27, P2101, DOI 10.1016/S0022-2828(95)91191-X; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; ROCKMAN HA, 1994, AM J PHYSIOL, V266, pH2468, DOI 10.1152/ajpheart.1994.266.6.H2468; ROCKMAN HA, 1993, CIRCULATION, V87, P14; Rockman HA, 1997, AM J PHYSIOL-HEART C, V272, pH1553, DOI 10.1152/ajpheart.1997.272.4.H1553; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Swertfeger DK, 1996, AM J PATHOL, V148, P1971; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; Ungerer M, 1996, CIRC RES, V79, P455, DOI 10.1161/01.RES.79.3.455; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; YURENEV AP, 1992, AM J HYPERTENS, V5, pS164, DOI 10.1093/ajh/5.6.266	44	219	222	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17223	17229		10.1074/jbc.272.27.17223	http://dx.doi.org/10.1074/jbc.272.27.17223			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202046	hybrid			2022-12-25	WOS:A1997XH44600078
J	Feng, L; Kim, E; Lee, WL; Miller, CJ; Kuang, B; Reisler, E; Rubenstein, PA				Feng, L; Kim, E; Lee, WL; Miller, CJ; Kuang, B; Reisler, E; Rubenstein, PA			Fluorescence probing of yeast actin subdomain 3/4 hydrophobic loop 262-274 - Actin-actin and actin-myosin interactions in actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRENE EXCIMER FLUORESCENCE; F-ACTIN; CONFORMATIONAL-CHANGES; STRUCTURAL DYNAMICS; POLYMERIZATION; TERMINUS; COMPLEX; MODEL; SUBFRAGMENT-1; TROPOMYOSIN	Residues 262-274 form a loop between subdomains 3 and 4 of actin, This loop may play an important role in actin filament formation and stabilization, To assess directly the behavior of this loop, we mutated Ser(265) Of yeast actin to cysteine (S265C) and created another mutant (S265C/C374A) by changing Cys(374) Of S265C actin to alanine, These changes allowed us to attach a pyrene maleimide stoichiometrically to either Cys(374) Or Cys(265), These mutations had no detectable effects on the protease susceptibility, intrinsic ATPase activity, and thermal stability of labeled or unlabeled G-actin. The presence of the loop cysteine, either labeled or unlabeled, did not affect the actin-activated S1 ATPase activity or the in vitro motility of the actin, Both mutant actins, either labeled or unlabeled, nucleated filament formation considerably faster than wild-type (WT) actin, although the critical concentration was not affected, Whereas the fluorescence of the C-terminal (WT) probe increased during polymerization, that of the loop (S265C/C374A) probe decreased, and the fluorescence of the doubly labeled actin (S265C) was similar to 50% less than the sum of the fluorescence of the individual fluorophores. Quenching was also observed in copolymers of labeled WT and S265C/C374A actins, An excimer peak was present in the emission spectrum of labeled S265C F-actin and in the labeled S265C/C374A-WT actin copolymers. These results show that in the filaments, the C-terminal pyrene of a substantial fraction of monomers directly interacts with the loop pyrene of neighboring monomers, bringing the two cysteine sulfurs to within 18 Angstrom of one another, Finally, when bound to labeled S265C/C374A F-actin, myosin S1, but not tropomyosin, caused an increase in fluorescence of the loop probe, Both proteins had no effect on excimer fluorescence, These results help establish the orientation of monomers in F-actin and show that the binding of S1 to actin subdomains 1 and 2 affects the environment of the loop between subdomains 3 and 4.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,DEPT CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of Iowa; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Rubenstein, Peter/0000-0003-1225-4414	NIAMS NIH HHS [R01 AR022031, AR-22031] Funding Source: Medline; NIGMS NIH HHS [GM-33689, GM-07185] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR022031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; COOK RK, 1991, J BIOL CHEM, V266, P16825; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CROSBIE RH, 1994, BIOCHEMISTRY-US, V33, P3210, DOI 10.1021/bi00177a010; FIEVEZ S, 1993, FEBS LETT, V316, P186, DOI 10.1016/0014-5793(93)81212-I; FRIEDEN C, 1980, J BIOL CHEM, V255, P8991; GEEVES MA, 1988, BIOCHEM J, V256, P41, DOI 10.1042/bj2560041; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; HEGRI G, 1992, PROTEIN SCI, V1, P132; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kim E, 1996, BIOPHYS J, V71, P1914, DOI 10.1016/S0006-3495(96)79390-6; Kim E, 1995, BIOPHYS J, V69, P2024, DOI 10.1016/S0006-3495(95)80072-X; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; Lehrer S S, 1995, Subcell Biochem, V24, P115; LEHRER SS, 1972, ARCH BIOCHEM BIOPHYS, V150, P164, DOI 10.1016/0003-9861(72)90023-9; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MEYER WH, 1987, BLOOD, V70, P363; MIHASHI K, 1981, EUR J BIOCHEM, V114, P33; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MONCMAN CL, 1993, CELL MOTIL CYTOSKEL, V25, P73, DOI 10.1002/cm.970250109; NG R, 1980, P NATL ACAD SCI USA, V77, P2546; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; ORLOVA A, 1994, BIOPHYS J, V66, P276, DOI 10.1016/S0006-3495(94)80791-X; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8	44	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16829	16837		10.1074/jbc.272.27.16829	http://dx.doi.org/10.1074/jbc.272.27.16829			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201989	hybrid			2022-12-25	WOS:A1997XH44600021
J	Li, H; Zhao, LL; Funder, JW; Liu, JP				Li, H; Zhao, LL; Funder, JW; Liu, JP			Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; TERMINAL TRANSFERASE; IMMORTAL CELLS; TUMOR-ANTIGEN; ENZYME; RIBONUCLEOPROTEIN; ASSOCIATION; TETRAHYMENA; YEAST; CYCLE	Most cancer cells have increased levels of telomerase activity implicated in cell immortalization. Activation of telomerase, a ribonucleoprotein complex, catalyzes the elongation of the ends of mammalian chromosomal DNA (telomeres), the length of which regulates cell proliferation. Currently, how telomerase is regulated in cancer is not yet established, The present study shows that telomerase activity is regulated by protein phosphorylation in human breast cancer cells, Incubation of cell nuclear telomerase extracts with protein phosphatase 2A (PP2A) abolished the telomerase activity; in contrast cytoplasmic telomerase activity was unaffected, and protein phosphatases 1 and 2B were ineffective, Inhibition of telomerase activity by PP2A was both concentration- and time-dependent and was prevented by the protein phosphatase inhibitor okadaic acid, In addition, nuclear telomerase inhibited by PP2A was reactivated by endogenous protein kinase(s) in the presence of ATP, but not in the presence of ATP gamma S, Furthermore, telomerase activity in cultured human breast cancer PMC42 cells was stimulated by okadaic acid, consistent with a role for PP2A in the regulation of telomerase activity in intact cells, These findings suggest that protein phosphorylation reversibly regulates the function of telomerase and that PP2A is a telomerase inhibitory factor in the nucleus of human breast cancer cells.	BAKER MED RES INST,PRAHRAN,VIC 3181,AUSTRALIA	Baker Heart and Diabetes Institute			Liu, Jun-Ping/AAA-5521-2020	Liu, Jun-Ping/0000-0001-7442-2116				ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; WHITEHEAD RH, 1984, JNCI-J NATL CANCER I, V73, P643; Xu D, 1996, LEUKEMIA, V10, P1354; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	40	170	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16729	16732		10.1074/jbc.272.27.16729	http://dx.doi.org/10.1074/jbc.272.27.16729			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201974	hybrid			2022-12-25	WOS:A1997XH44600006
J	Tamura, K; Umemura, S; Nyui, N; Yamaguchi, S; Ishigami, T; Hibi, K; Yabana, M; Kihara, M; Fukamizu, A; Murakami, K; Ishii, M				Tamura, K; Umemura, S; Nyui, N; Yamaguchi, S; Ishigami, T; Hibi, K; Yabana, M; Kihara, M; Fukamizu, A; Murakami, K; Ishii, M			A novel proximal element mediates the regulation of mouse Ren-1C promoter by retinoblastoma protein in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RENIN GENE; TRANSCRIPTION FACTOR PIT-1; SUSCEPTIBILITY GENE; SP1-MEDIATED TRANSCRIPTION; JUXTAGLOMERULAR CELLS; MOLECULAR MECHANISM; ANGIOTENSIN SYSTEM; TRANSGENIC MICE; BINDING-SITE; C-MYC	The protein product of the retinoblastoma susceptibility gene, RE, is a nuclear phosphoprotein that modulates transcription of genes involved in growth control via interactions with transcription factors. Renin is a rate-limiting enzyme of the renin-angiotensin system that regulates blood pressure and water-electrolyte balance. Renin gene expression is regulated in a tissue-specific and developmentally linked manner. Similarly, the expression of RE is controlled in a differentiation-linked manner, Thus, to investigate whether RE is involved in the regulation of renin gene expression, we examined the effects of RE on transcriptional activity of the mouse renin (Ren-1C) promoter. The Ren-1C promoter contains two transcriptionally important elements; the RU-1 (-224 to -138) and RP-2 (-75 to -47) elements. RE activated the Ren-IC promoter in human embryonic kidney cells. The promoter element responsible for RE-mediated transcriptional regulation was the RP-2 element, The results of DNA-protein binding experiments showed that RE increased nuclear binding activity to the RP-2 element, and site-directed mutation which disrupted binding of nuclear factors to the RP-2 element markedly reduced RE-mediated activation of Ren-IC promoter in human embryonic kidney cells. These results indicate that the RP-2 element plays an important role in RE-mediated transcriptional regulation of Ren-IC promoter activity in human embryonic kidney cells, thereby suggesting an interesting mechanism by which RE may modulate the renin-angiotensin system.	YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 2,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,SAKURA,IBARAKI 305,JAPAN	Yokohama City University; University of Tsukuba			fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; BURT DW, 1989, J BIOL CHEM, V264, P7357; CATANZARO DF, 1994, KIDNEY INT, V46, P1513, DOI 10.1038/ki.1994.433; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DZAU VJ, 1988, AM J PHYSIOL, V255, pF563, DOI 10.1152/ajprenal.1988.255.4.F563; FUKAMIZU A, 1991, BIOCHEM J, V278, P601, DOI 10.1042/bj2780601; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; Germain S, 1996, BIOCHEM J, V316, P107, DOI 10.1042/bj3160107; GILBERT MT, 1994, J BIOL CHEM, V269, P28049; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORIUCHI M, 1993, J CLIN INVEST, V92, P1805, DOI 10.1172/JCI116770; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Klemm DJ, 1996, J BIOL CHEM, V271, P8082, DOI 10.1074/jbc.271.14.8082; LEE WH, 1995, ANN NY ACAD SCI, V752, P432, DOI 10.1111/j.1749-6632.1995.tb17453.x; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATIN A, 1994, ONCOGENE, V9, P1333; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PAUL M, 1992, AM J PHYSIOL, V262, pE644, DOI 10.1152/ajpendo.1992.262.5.E644; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; SUN JD, 1993, J BIOL CHEM, V268, P1505; SUN JD, 1994, CIRC RES, V75, P624, DOI 10.1161/01.RES.75.4.624; TAMURA K, 1993, J BIOL CHEM, V268, P15024; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TAMURA K, 1994, J CLIN INVEST, V94, P1959, DOI 10.1172/JCI117547; Tamura K, 1995, Hypertens Res, V18, P7, DOI 10.1291/hypres.18.7; TAMURA K, 1994, J CLIN INVEST, V93, P1370, DOI 10.1172/JCI117113; TAMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1172, P306, DOI 10.1016/0167-4781(93)90218-3; TANIMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V302, P409, DOI 10.1006/abbi.1993.1232; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879	58	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16845	16851		10.1074/jbc.272.27.16845	http://dx.doi.org/10.1074/jbc.272.27.16845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201991	hybrid			2022-12-25	WOS:A1997XH44600023
J	Cong, YS; Yao, YL; Yang, WM; Kuzhandaivelu, N; Seto, E				Cong, YS; Yao, YL; Yang, WM; Kuzhandaivelu, N; Seto, E			The hepatitis B virus X-associated protein, XAP3, is a protein kinase C-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IMMEDIATE EARLY PROTEIN; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; REGULATORY PROTEIN; CELLULAR PROTEINS; TRANS-ACTIVATION; MAMMALIAN-CELLS; HBX PROTEIN; DNA	The hepatitis B virus X protein induces transcriptional activation of a wide variety of viral and cellular genes. In addition to its ability to interact directly with many nuclear transcription factors, several reports indicate that the X protein stimulates different cytoplasmic kinase signal cascades. Using the yeast two-hybrid screen, we have isolated a clone designated X-associated protein 3 (XAP3) that encodes a human homolog of the rat protein kinase C-binding protein. One of the activation domains of X (amino acids 90-122) is required for binding to XAP3, while the NH2-terminal part of XAP3 is necessary for binding to X. Both X and XAP3 bound specifically to the eta PKC isoenzyme synthesized in rabbit reticulocyte lysates. Overexpression of XAP3 enhanced X transactivation activity. These results support earlier findings that one of the mechanisms of transactivation by X is through involvement with the cellular protein kinase C pathway.	UNIV S FLORIDA, COLL MED, DEPT MED MICROBIOL & IMMUNOL, MOL ONCOL PROGRAM, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida				Yang, Wen-Ming/0000-0002-5871-5979	NCI NIH HHS [R01-CA61257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABMAYR SM, 1985, CELL, V43, P821, DOI 10.1016/0092-8674(85)90255-7; ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ARII M, 1992, ONCOGENE, V7, P397; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FABER SW, 1986, NUCLEIC ACIDS RES, V14, P6067, DOI 10.1093/nar/14.15.6067; FAKTOR O, 1990, ONCOGENE, V5, P867; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GLAZER RI, 1994, PROTEIN KINASE C, P171; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Harlow E., 1988, ANTIBODIES LAB MANUA; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Koike K, 1995, INTERVIROLOGY, V38, P134, DOI 10.1159/000150424; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; Lindholm PF, 1996, J VIROL, V70, P2525, DOI 10.1128/JVI.70.4.2525-2532.1996; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAHONEY CW, 1994, PROTEIN KINASE C, P16; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MICHAEL N, 1988, SCIENCE, V239, P1531, DOI 10.1126/science.2832940; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PARKER PJ, 1994, PROTEIN KINASE C, P3; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5468; Schaefer S, 1995, INTERVIROLOGY, V38, P143, DOI 10.1159/000150425; SCHEK N, 1991, ONCOGENE, V6, P1735; SETO E, 1989, VIROLOGY, V173, P764, DOI 10.1016/0042-6822(89)90594-1; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPALHOLZ BA, 1988, J VIROL, V62, P3143, DOI 10.1128/JVI.62.9.3143-3150.1988; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1994, ONCOGENE, V9, P341; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; WANG HD, 1995, MOL CELL BIOL, V15, P6720; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WOLF M, 1986, J BIOL CHEM, V261, P3327; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845	89	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16482	16489		10.1074/jbc.272.26.16482	http://dx.doi.org/10.1074/jbc.272.26.16482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195957	hybrid			2022-12-25	WOS:A1997XG01900061
J	Funato, K; Beron, W; Yang, CZ; Mukhopadhyay, A; Stahl, PD				Funato, K; Beron, W; Yang, CZ; Mukhopadhyay, A; Stahl, PD			Reconstitution of phagosome-lysosome fusion in streptolysin O-permeabilized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; GTP-BINDING-PROTEINS; VESICULAR TRANSPORT; MEMBRANE-FUSION; ENDOSOME FUSION; VESICLE FUSION; FREE SYSTEM; COMPARTMENTS; INVITRO; RAB5	We have reconstituted fusion between phagosomes and lysosomes in streptolysin O-permeabilized J774-E macrophages. Fusion was assessed by measuring the delivery of avidin-conjugated horseradish peroxidase pre-internalized into lysosomes to phagosomes containing biotinylated beta-glucuronidase-conjugated paramagnetic beads (1-2 mu m). Fusion was dependent on energy and exogenously supplied cytosol. Phagosome-lysosome fusion was greatly inhibited when microtubules were depolymerized by nocodazole treatment, suggesting that fusion occurs via microtubule-dependent transport. Furthermore, fusion was inhibited by GTP gamma S and Rab GDP dissociation inhibitor. These results suggest that rab proteins are involved in the regulation of fusion. Lastly, anti-NEM-sensitive factor (NSF) antibodies inhibited fusion, and addition of recombinant NSF wild type partially restored the fusogenic activity, indicating that NSF is required for fusion between phagosomes and lysosomes.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; RIKEN,INST PHYS & CHEM RES,ANIM & CELLULAR SYST LAB,WAKO,SAITAMA 35101,JAPAN; UNIV NACL CUYO,FAC CIENCIAS MED,INST HISTOL & EMBIOL,RA-5500 MENDOZA,ARGENTINA; NATL INST IMMUNOL,CELL BIOL LAB,NEW DELHI 110067,INDIA	Washington University (WUSTL); RIKEN; University Nacional Cuyo Mendoza; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)			Mukhopadhyay, Asok/C-4051-2009; Stahl, Philip/D-6315-2012					AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BERON W, 1995, TRENDS CELL BIOL, V5, P100, DOI 10.1016/S0962-8924(00)88958-8; BERON W, 1995, ARCH BIOCHEM BIOPHYS, V317, P337, DOI 10.1006/abbi.1995.1172; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Blocker A, 1996, J BIOL CHEM, V271, P3803; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; DESJARDINS M, 1995, TRENDS CELL BIOL, V5, P183, DOI 10.1016/S0962-8924(00)88989-8; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DIAZ R, 1991, EUR J CELL BIOL, V56, P223; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; GARCIADELPORTILLO F, 1995, TRENDS MICROBIOL, V3, P373, DOI 10.1016/S0966-842X(00)88982-9; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; Hackam DJ, 1996, J IMMUNOL, V156, P4377; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MELLMAN I, 1995, CELL, V82, P869, DOI 10.1016/0092-8674(95)90018-7; Mukhopadhyay A, 1997, J CELL BIOL, V136, P1227, DOI 10.1083/jcb.136.6.1227; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Tjelle TE, 1996, J CELL SCI, V109, P2905; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5	39	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16147	16151		10.1074/jbc.272.26.16147	http://dx.doi.org/10.1074/jbc.272.26.16147			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195911	hybrid			2022-12-25	WOS:A1997XG01900015
J	Ke, SH; Coombs, GS; Tachias, K; Navre, M; Corey, DR; Madison, EL				Ke, SH; Coombs, GS; Tachias, K; Navre, M; Corey, DR; Madison, EL			Distinguishing the specificities of closely related proteases - Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; HUMAN ALPHA-THROMBIN; DIRECTED MUTAGENESIS; SERINE PROTEINASES; CRYSTAL-STRUCTURE; TRYPSIN; IDENTIFICATION; SELECTION; PEPTIDES; RESIDUES	Elucidating subtle specificity differences between closely related enzymes is a fundamental challenge for both enzymology and drug design, We have addressed this issue for two intimately related serine proteases, tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), by modifying the technique of substrate phage display to create substrate subtraction libraries. Characterization of individual members of the substrate subtraction library accomplished the rapid, direct identification of small, highly selective substrates for t-PA. Comparison of the amino acid sequences of these selective substrates with the consensus sequence for optimal substrates for t-PA, derived using standard substrate phage display protocols, suggested that the P3 and P4 residues are the primary determinants of the ability of a substrate to discriminate between t-PA and u-PA. Mutagenesis of the P3 and P4 residues of plasminogen activator inhibitor type 1, the primary physiological inhibitor of both t-PA and u-PA, confirmed this prediction and indicated a predominant role for the P3 residue. Appropriate replacement of both the P3 and P4 residues enhanced the t-PA specificity of plasminogen activator inhibitor type 1 by a factor of 600, and mutation of the P3 residue alone increased this selectivity by a factor of 170. These results demonstrate that the combination of substrate phage display and substrate subtraction methods can be used to discover specificity differences between very closely related enzymes and that this information can be utilized to create highly selective inhibitors.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; AFFYMAX RES INST, SANTA CLARA, CA 95051 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute				Coombs, Gary/0000-0002-0711-185X	NHLBI NIH HHS [R01 HL52475, P01 HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERT AJ, 1990, J CHROMATOGR, V499, P177, DOI 10.1016/S0021-9673(00)96972-3; BAGGIO R, 1996, BIOCHEMISTRY-US, V35, P3551; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; BODE W, 1992, PROTEIN SCI, V1, P426; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; COLLEN D, 1991, BLOOD, V78, P3114; Coombs GS, 1996, J BIOL CHEM, V271, P4461; Crooke ST, 1996, NAT BIOTECHNOL, V14, P238, DOI 10.1038/nbt0396-238b; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GANU VS, 1982, INT J PEPT PROT RES, V20, P421; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBA B, 1996, J MOL BIOL, V258, P117; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Min HY, 1996, CANCER RES, V56, P2428; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Shapiro RL, 1996, CANCER RES, V56, P3597; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; Taylor J. R., 1982, INTRO ERROR ANAL STU; TEIXEIRA AV, 1994, BBA-GENE STRUCT EXPR, V1217, P23, DOI 10.1016/0167-4781(94)90120-1; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; URANO T, 1988, BIOCHEM BIOPH RES CO, V150, P45, DOI 10.1016/0006-291X(88)90484-6; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	39	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16603	16609		10.1074/jbc.272.26.16603	http://dx.doi.org/10.1074/jbc.272.26.16603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195973	hybrid			2022-12-25	WOS:A1997XG01900077
J	Lai, TS; Bielawska, A; Peoples, KA; Hannun, YA; Greenburg, CS				Lai, TS; Bielawska, A; Peoples, KA; Hannun, YA; Greenburg, CS			Sphingosylphosphocholine reduces the calcium ion requirement for activating tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; PROTEIN-KINASE; CERAMIDE; BINDING; GTP; IDENTIFICATION; SPHINGOMYELIN; MECHANISM; APOPTOSIS; CYCLE	Tissue transglutaminase (DTG) catalyzes a Ca2+-dependent transglutaminase reaction resulting in the formation of gamma-glutamyl-epsilon-lysine bonds and is activated during apoptosis to catalyze the formation of apoptotic body, We investigate whether lipids that are membrane components and involved in cell signaling could modify the Ca2+-dependent activation of tTG. We found that sphingosylphosphocholine (lyso-SM) was the only lipid to activate transglutaminase at low Ca2+ concentrations. In the presence of lyso-SM (125 mu M), transglutaminase was detectable at 10 mu M Ca2+, whereas in the absence of lyso-SM, similar activity was obtained at 160 mu M Ca2+. Furthermore, in the presence of lipid vesicles lyso-SM retained the ability to enhance the Ca2+-dependent activation of tTG. Lyso-SM did not significantly change the K-m for the glutamyl and primary amine substrates, However, the K-act, for Ca2+ was reduced from 300 mu M to 90 mu M. Structure-function studies of lyso-SM analogs indicate that phosphocholine group on C1, the free amino group at C2 and a C4-C5 double bond are critical for the activation of transglutaminase activity. This is the first demonstration that a specific sphingolipid could enhance the activity of tTG and could play a role in vivo in activation of the tTG at physiologic Ca2+ levels.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SPECIALIZED CTR BREAST CANC, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Duke University				, Thung-Shen/0000-0002-8791-9698	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38391, HL 38245] Funding Source: Medline; NIAMS NIH HHS [AR 39162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BELL RM, 1993, SPHINGOLIPIDS B; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BERGER A, 1995, P NATL ACAD SCI USA, V92, P5885, DOI 10.1073/pnas.92.13.5885; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; EISENTHAL R, 1993, ENZYME ASSAYS; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FESUS L, 1983, FEBS LETT, V155, P1, DOI 10.1016/0014-5793(83)80196-3; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1995, J CELL BIOCHEM, P151; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARSFALVI J, 1987, BIOCHIM BIOPHYS ACTA, V923, P42, DOI 10.1016/0304-4165(87)90123-1; HEROLD P, 1988, HELV CHIM ACTA, V71, P354, DOI 10.1002/hlca.19880710208; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KORNER G, 1989, BIOCHEM J, V262, P633, DOI 10.1042/bj2620633; LAI TS, 1994, J BIOL CHEM, V269, P24596; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nemes Z, 1996, EUR J CELL BIOL, V70, P125; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; SEIJO L, 1994, LIPIDS, V29, P359, DOI 10.1007/BF02537190; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611	42	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16295	16300		10.1074/jbc.272.26.16295	http://dx.doi.org/10.1074/jbc.272.26.16295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195933	hybrid			2022-12-25	WOS:A1997XG01900037
J	Enholm, B; Paavonen, K; Ristimaki, A; Kumar, V; Gunji, Y; Klefstrom, J; Kivinen, L; Laiho, M; Olofsson, B; Joukov, V; Eriksson, U; Alitalo, K				Enholm, B; Paavonen, K; Ristimaki, A; Kumar, V; Gunji, Y; Klefstrom, J; Kivinen, L; Laiho, M; Olofsson, B; Joukov, V; Eriksson, U; Alitalo, K			Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia	ONCOGENE			English	Article						VEGF; VEGF-B; VEGF-C; angiopoietin; angiogenesis	VASCULAR-PERMEABILITY FACTOR; FACTOR GENE-EXPRESSION; PROTEIN-KINASE-C; INDUCED TRANSCRIPTION; EPITHELIAL-CELLS; TYROSINE KINASE; MESSENGER-RNA; HA-RAS; P53; ANGIOGENESIS	The vascular endothelial growth factor (VEGF) family has recently been expanded by the isolation of two additional growth factors, VEGF-B and VEGF-C, Here we compare the regulation of steady-state levels of VEGF, VEGF-B and VEGF-C mRNAs in cultured cells by a variety of stimuli implicated in angiogenesis and endothelial cell physiology, Hypoxia, Ras oncoprotein and mutant p53 tumor suppressor, which are potent inducers of VEGF mRNA did not increase VEGF-B or VEGF-C mRNA levels. Serum and its component growth factors, platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) as well as transforming growth factor-beta (TGF-beta) and the tumor promoter phorbol myristate 12,13-acetate (PMA) stimulated VEGF-C, but not VEGF-B mRNA expression, Interestingly, these growth factors and hypoxia simultaneously downregulated the mRNA of another endothelial cell specific ligand, angiopoietin-1. Serum induction of VEGF-C mRNA occurred independently of protein synthesis; with an increase of the mRNA half-life from 3.5 h to 5.5-6 h, whereas VEGF-B mRNA was very stable (T-1/2>8h). Our results reveal that the three VEGF genes are regulated in a strikingly different manner, suggesting that they serve distinct, although perhaps overlapping functions in vivo.	UNIV HELSINKI,HAARTMAN INST,MOL CANC BIOL LAB,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,HAARTMAN INST,DEPT VIROL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT CLIN CHEM,HELSINKI 00290,FINLAND; UNIV HELSINKI,DEPT OBSTET & GYNECOL,HELSINKI 00290,FINLAND; LUDWIG INST CANC RES,S-17177 STOCKHOLM,SWEDEN	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Ludwig Institute for Cancer Research			Alitalo, Kari K/J-5013-2014; Joukov, Vladimir/K-3525-2019	Alitalo, Kari K/0000-0002-7331-0902; 				BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KIESER A, 1994, ONCOGENE, V9, P963; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lagercrantz J, 1996, BIOCHEM BIOPH RES CO, V220, P147, DOI 10.1006/bbrc.1996.0372; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LIU HS, 1992, CANCER RES, V52, P983; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; Mazure NM, 1996, CANCER RES, V56, P3436; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Paavonen K, 1996, CIRCULATION, V93, P1079, DOI 10.1161/01.CIR.93.6.1079; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493	50	377	399	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2475	2483		10.1038/sj.onc.1201090	http://dx.doi.org/10.1038/sj.onc.1201090			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188862				2022-12-25	WOS:A1997WZ68000011
J	Gotoh, T; Niino, Y; Tokuda, M; Hatase, O; Nakamura, S; Matsuda, M; Hattori, S				Gotoh, T; Niino, Y; Tokuda, M; Hatase, O; Nakamura, S; Matsuda, M; Hattori, S			Activation of R-Ras by Ras-guanine nucleotide-releasing factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR; FUNCTIONAL INTERACTION; GENE-PRODUCT; PROTEIN; GROWTH; IDENTIFICATION; P21; RESIDUES; BINDING; REGIONS	Ras-GRF/CDC25(Mm), mSos, and C3G have been identified as guanine nucleotide releasing factors for Ras family proteins. We investigated in this study the guanine nucleotide-releasing activities of Ras-GRF, mSos, and C3G toward R-Ras, which shows high sequence similarity to Ras. Ras-GRF markedly stimulated the dissociation of GDP from R-Ras, and C3G also promoted the release of R-Ras-bound GDP. Under the same conditions, mSos little affected the reaction. When Ras GRF and R-Ras were coexpressed in COS7 cells, the remarkable accumulation of the active GTP bound form of R-Ras was observed. C3G also increased active R-Ras in COS7 cells, while mSos did not give any effect. These results indicated that Ras-GRF and C3G could activate R-Ras. Furthermore, the activation of R-Ras by Ras-GRF was enhanced when cells were treated with ionomycin, which is known to increase the intracellular calcium concentration. The examination of tissue distribution of R-Ras, Ras-GRF, and mSos by the reverse transcription-polymerase chain reaction revealed that Ras GRF was expressed only in brain and testis, whereas R-Ras, C3G, and mSos were expressed rather ubiquitously. These findings raise the possibility that R-Ras is activated by Ras-GRF in brain and testis, and by C3G in other tissues, respectively.	NATL INST NEUROSCI,NATL CTR NEUROL & PSYCHIAT,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; KAGAWA MED UNIV,FAC MED,DEPT PHYSIOL,DIV 1,MIKI,KAGAWA 76107,JAPAN; INT MED CTR JAPAN,RES INST,DEPT PATHOL,SHINJUKU KU,TOKYO 162,JAPAN	National Center for Neurology & Psychiatry - Japan; Kagawa University; National Center for Global Health & Medicine - Japan				Matsuda, Michiyuki/0000-0002-5876-9969				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; COX AD, 1994, ONCOGENE, V9, P3281; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MUROYA K, 1992, ONCOGENE, V7, P277; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; REY I, 1994, ONCOGENE, V9, P685; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zippel R, 1996, ONCOGENE, V12, P2697	43	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18602	18607		10.1074/jbc.272.30.18602	http://dx.doi.org/10.1074/jbc.272.30.18602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228027	hybrid			2022-12-25	WOS:A1997XM34200018
J	Shields, JM; Yang, VW				Shields, JM; Yang, VW			Two potent nuclear localization signals in the gut-enriched Kruppel-like factor define a subfamily of closely related Kruppel proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; GROWTH-FACTORS; GENE; FAMILY; ENCODES; DOMAIN; NLS	The gut-enriched Kruppel-like factor (GKLF) is a newly identified transcription factor that contains three C2H2 Kruppel-type zinc fingers. Previous immunocytochemical studies indicate that GKLF is exclusively localized to the nucleus. To identify the nuclear localization signal (NLS) within GKLF, cDNA constructs with various deletions in the coding region of GKLF were generated and analyzed by indirect immunofluorescence in transfected COS-1 cells. In addition, constructs fusing regions representing putative NLSs of GKLF to green fluorescent protein (GFP) were generated and examined by fluorescence microscopy in similarly transfected cells. The results indicate that GKLF contains two potent, independent NLSs: one within the zinc fingers and the other in a cluster of basic amino acids (called 5' basic region) immediately preceding the first zinc finger. In comparison, putative NLSs within the zinc fingers and the 5' basic region of a related Kruppel protein, zif268/Egr-1, are relatively less efficient in their ability to translocate GFP into the nucleus. A search in the protein sequence data base revealed that despite the existence of numerous Kruppel proteins, only two, the lung Kruppel-like factor (LKLF) and the erythroid Kruppel-like factor (EKLF), exhibit similar NLSs to those of GKLF. These findings indicate that GKLF, LKLF, and EKLF are members of a subfamily of closely related Kruppel proteins.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,GI DIV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [DK52230, DK44484, R01 DK052230, R01 DK052230-03, P01 DK044484-100005] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, P01DK044484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MATHENY C, 1994, J BIOL CHEM, V269, P8176; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; PATWARDHAN S, 1991, ONCOGENE, V6, P917; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812	22	113	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18504	18507		10.1074/jbc.272.29.18504	http://dx.doi.org/10.1074/jbc.272.29.18504			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218496	hybrid, Green Accepted			2022-12-25	WOS:A1997XL73500086
J	Waring, P; Khan, T; Sjaarda, A				Waring, P; Khan, T; Sjaarda, A			Apoptosis induced by gliotoxin is preceded by phosphorylation of histone H3 and enhanced sensitivity of chromatin to nuclease digestion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CHROMOSOME CONDENSATION; INTRACELLULAR CALCIUM; DNA FRAGMENTATION; PROTEIN-SYNTHESIS; KINASE-ACTIVITY; INHIBITOR; CYCLE; CAMP; MACROPHAGES	The fungal toxin gliotoxin induces apoptotic I-ell death in a variety of cells. Apoptosis induced in thymocytes by gliotoxin is rapid, and DNA fragmentation is observable within 4 h treatment. Apoptosis induced by gliotoxin is calcium independent and unaffected by protein synthesis inhibitors. We have previously shown that gliotoxin results in phosphorylation of a 16.3-kDa protein within 10 min treatment of thymocytes. Here we show that this protein is histone HS and phosphorylation occurs on Ser-10. Cyclic AMP levels and activity of protein kinase A (PKA) are raised in cells treated with gliotoxin. Apoptosis is inhibited by genistein which also inhibits PKA and histone H3 phosphorylation. Apoptosis is also inhibited by a number of specific inhibitors of PKA suggesting apoptosis induced by gliotoxin is modulated by this kinase. The agents forskolin and cholera toxin do not induce rapid phosphorylation of H3 although some increase in phosphorylation of H3 does occur after 8 h with these agents. Forskolin and cholera toxin also induce apoptosis but over a longer time course than gliotoxin. In all cases levels of apoptosis correlate with degree of H3 phosphorylation. Cells: treated with gliotoxin show an early sensitivity to micrococcal nuclease and DNase I digestion indicating a functional relationship between DNA fragmentation and H3 phosphorylation.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV IMMUNOL & CELL BIOL, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BEAVER JP, 1994, IMMUNOL CELL BIOL, V72, P489, DOI 10.1038/icb.1994.73; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHOCHUNG YS, 1979, INFLUENCE HORMONES T, V1, P55; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COLOMBEL M, 1992, CANCER RES, V52, P4313; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; ELLIOTT ME, 1990, LIFE SCI, V46, P1479, DOI 10.1016/0024-3205(90)90465-4; FENG JL, 1991, BIOCHEMISTRY-US, V30, P4747, DOI 10.1021/bi00233a016; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Kerr J.F.R., 1987, P93; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LALLI E, 1994, J BIOL CHEM, V269, P17359; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; Lu ZX, 1996, BIOL CHEM H-S, V377, P373; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARTIN SJ, 1995, SCIENCE, V269, P106, DOI 10.1126/science.7604270; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MULLBACHER A, 1988, TRANSPLANTATION, V46, P120; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; Sutton P, 1995, BIOCHEM PHARMACOL, V50, P2009, DOI 10.1016/0006-2952(95)02101-9; SUTTON P, 1994, INFECT IMMUN, V62, P1192, DOI 10.1128/IAI.62.4.1192-1198.1994; THNG JPH, 1994, J BIOL CHEM, V269, P9568; THNG JPH, 1992, MOL CELLULAR APPROAC, P381; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; WARING P, 1990, INT J IMMUNOPHARMACO, V12, P445, DOI 10.1016/0192-0561(90)90028-L; Waring P, 1996, EXP CELL RES, V227, P264, DOI 10.1006/excr.1996.0276; WARING P, 1988, J BIOL CHEM, V263, P18493; Waring P, 1996, GEN PHARMACOL, V27, P1311, DOI 10.1016/S0306-3623(96)00083-3; WARING P, 1990, J BIOL CHEM, V265, P14476; WARING P, 1995, CELL DEATH DIFFER, V2, P201; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129	54	84	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17929	17936		10.1074/jbc.272.29.17929	http://dx.doi.org/10.1074/jbc.272.29.17929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218417	hybrid			2022-12-25	WOS:A1997XL73500007
J	Yip, JW; Ko, WH; Viberti, G; Huganir, RL; Donowitz, M; Tse, CM				Yip, JW; Ko, WH; Viberti, G; Huganir, RL; Donowitz, M; Tse, CM			Regulation of the epithelial brush border Na+/H+ exchanger isoform 3 stably expressed in fibroblasts by fibroblast growth factor and phorbol esters is not through changes in phosphorylation of the exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME REGULATION; MOLECULAR-CLONING; NHE1; ACTIVATION; PROTEINS; SITES; INHIBITION; MECHANISM; MUTATION; PH	The epithelial brush border Na+/H+ exchanger isoform 3 (NHE3) is regulated by growth factors and protein kinases. When stably expressed in PS120 fibro blasts, NHE3 is stimulated by serum and fibroblast growth factor (FGF) and inhibited by phorbol esters. To examine the role of phosphorylation of NHE3 in growth factor/protein kinase regulation, NHE3 was C-terminally tagged with an 11-amino acid epitope of the vesicular stomatitis virus glycoprotein (VSVG) and stably expressed in Na+/H+ exchanger null PS120 fibroblasts (PS120/NHE3V). NHE3V was regulated by serum, FGF, and phorbol ester in a manner identical to wild type non-VSVG-tagged NHE3. Phosphorylation of NHE3V was evaluated via immunoprecipitation with anti-VSVG antibody after in vivo labeling of PS120/NHE3V cells with [P-32]orthophosphate. NHE3V was phosphorylated under basal conditions. However, FGF and PMA, under conditions in which these agonists regulate NHE3V, altered neither the amount of phosphorylation of NHE3V as analyzed by one dimensional SDS-polyacrylamide gel electrophoresis and autoradiography nor two-dimensional phosphopeptide maps of tryptic digests of NHE3V. In contrast, while changes in NHE3V phosphorylation were not observed with serum exposure by one dimensional SDS-polyacrylamide gel electrophoresis, two-dimensional studies showed increases in two phosphopeptides. Under all these conditions, phosphoamino acid analysis showed that NHE3V was phosphorylated only on serine residues. By cell surface protein biotinylation studies under basal conditions, at least 27% of the NHE3V was expressed on the cell surface. To further analyze the phosphorylation status of the surface and intracellular forms of NHE3V under basal conditions and determine whether the amount of phosphorylation of the surface form changes upon serum, FGF, and PMA regulation, the surface form of NHE3V was separated from intracellular form by biotinylation/avidin-agarose precipitation. Under basal conditions, both intracellular and surface forms of NHE3V were phosphorylated. However, the amount of phosphorylation of the surface form of NHE3V did not change upon stimulation by serum and FGF and inhibition by PMA based on one-dimensional SDS-polyacrylamide gel electrophoresis and autoradiography. Thus, we conclude that when expressed in PS120 cells, while NHE3 is a phosphoprotein under basal conditions, its regulation by FGF and PMA is not by changes in the phosphorylation of NHE3, while regulation by serum may involve changes in its phosphorylation. Regulation of NHE3 probably involves intermediate associated regulatory proteins. The function of basal phosphorylation of NHE3 is not known.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,GI DIV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205; UNIV LONDON,UNITED MED & DENT SCH GUYS & ST THOMAS,DIV MED,LONDON SE1 9RT,ENGLAND	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of London; King's College London					NIDDK NIH HHS [R01DK26523, P01DK44484, R29DK43778] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, P01DK044484, R29DK043778] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAND B, 1994, J BIOL CHEM, V269, P13703; COTTARDI CJ, 1995, AM J PHYSIOL, V268, pF285; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Goss G, 1996, AM J PHYSIOL-CELL PH, V270, pC1493, DOI 10.1152/ajpcell.1996.270.5.C1493; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; JANECKI A, 1997, FASEB J, V11, pA376; JHOOGERWERF WA, 1996, AM J PHYSIOL, V270, pG29; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SARDET C, 1991, J BIOL CHEM, V266, P19166; SARDET C, 1990, SCIENCE, V218, P1219; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2134; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	29	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18473	18480		10.1074/jbc.272.29.18473	http://dx.doi.org/10.1074/jbc.272.29.18473			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218492	hybrid			2022-12-25	WOS:A1997XL73500082
J	Freedman, NJ; Ament, AS; Oppermann, M; Stoffel, RH; Exum, ST; Lefkowitz, RJ				Freedman, NJ; Ament, AS; Oppermann, M; Stoffel, RH; Exum, ST; Lefkowitz, RJ			Phosphorylation and desensitization of human endothelin A and B receptors - Evidence for G protein-coupled receptor kinase specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT-PHOSPHORYLATION; BETA-2-ADRENERGIC RECEPTOR; CARBOXYL-TERMINUS; RHODOPSIN; INVOLVEMENT; MECHANISMS; EXPRESSION; TERMINATION; INHIBITION; ACTIVATION	Although endothelin-l can elicit prolonged physiologic responses, accumulating evidence suggests that rapid desensitization affects the primary G protein-coupled receptors mediating these responses, the endothelin A and B receptors (ETA-R and ETB-R). The mechanisms by which this desensitization proceeds remain obscure, however. Because some intracellular domain sequences of the ETA-R and ETB-R. differ substantially, we tested the possibility that these receptor subtypes might. be differentially regulated by G protein-coupled receptor kinases (GRKs). Homologous, or receptor-specific, desensitization occurred within 4 min both in the ETA-R-expressing A10 cells and in 293 cells transfected with either the human ETA-R or ETB-R, In 293 cells, this desensitization corresponded temporally with agonist-induced phosphorylation of each receptor, assessed by receptor immunoprecipitation from P-32(i)-labeled cells. Agonist-induced receptor phosphorylation was not substantially affected by PKC inhibition but was reduced 40% (p < 0.03) by GRK inhibition, effected by a dominant negative GRK2 mutant, Inhibition of agonist-induced phosphorylation abrogated agonist-induced ETA-R desensitization. Overexpression of GRK2, -5, or -6 in 293 cells augmented agonist-induced ET-R phosphorylation similar to 2-fold (p < 0.02), but each kinase reduced receptor-promoted phosphoinositide hydrolysis differently. While GRK5 inhibited ET-R signaling by only similar to 25%, GRK2 inhibited ET-R signaling by 80% (p < 0.01), Congruent with its superior efficacy in suppressing ET-R signaling, GRK2, but not GRK5, co-immunoprecipitated with the ET-Rs in an agonist-dependent manner. ma conclude that both the ETA-R and ETB-R can be regulated indistinguishably by GRK-initiated desensitization, We propose that because of its affinity for ET-Rs demonstrated by co-immunoprecipitation, GRK2 is the most likely of the GRKs to initiate ET-R desensitization.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute	Freedman, NJ (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MED CARDIOL, BOX 3821, DURHAM, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL03008, HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CARDELL LO, 1992, BRIT J PHARMACOL, V105, P376, DOI 10.1111/j.1476-5381.1992.tb14261.x; CHUN MY, 1995, J BIOL CHEM, V270, P10855, DOI 10.1074/jbc.270.18.10855; Colton T., 1974, STAT MED, V1; CYR CR, 1993, J BIOL CHEM, V268, P26071; Diviani D, 1996, J BIOL CHEM, V271, P5049; DOKHAC L, 1994, MOL PHARMACOL, V46, P485; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GOLIGORSKY MS, 1994, J CELL PHYSIOL, V158, P485, DOI 10.1002/jcp.1041580313; GUAN XM, 1992, J BIOL CHEM, V267, P21995; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY PJ, 1993, BRIT J PHARMACOL, V110, P435, DOI 10.1111/j.1476-5381.1993.tb13829.x; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KITAZONO T, 1995, J PHARMACOL EXP THER, V273, P1; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; KOSHIMIZU T, 1995, BIOCHEM BIOPH RES CO, V217, P354, DOI 10.1006/bbrc.1995.2784; Krueger KM, 1997, J BIOL CHEM, V272, P5; LASSEGUE B, 1993, BIOCHEM J, V292, P509, DOI 10.1042/bj2920509; LEITE MF, 1994, AM J PHYSIOL-HEART C, V267, pH2193, DOI 10.1152/ajpheart.1994.267.6.H2193; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PARIS S, 1987, J BIOL CHEM, V262, P1970; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEI G, 1995, MOL PHARMACOL, V48, P173; POLLOCK DM, 1995, FASEB J, V9, P1196, DOI 10.1096/fasebj.9.12.7672512; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SEMLER DE, 1995, J PHARMACOL EXP THER, V272, P1052; Sokolovsky M, 1995, PHARMACOL THERAPEUT, V68, P435, DOI 10.1016/0163-7258(95)02015-2; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; Tiberi M, 1996, J BIOL CHEM, V271, P3771; VANHEUGTEN HAA, 1993, J MOL CELL CARDIOL, V25, P41, DOI 10.1006/jmcc.1993.1006; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174	52	174	177	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17734	17743		10.1074/jbc.272.28.17734	http://dx.doi.org/10.1074/jbc.272.28.17734			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211925	hybrid			2022-12-25	WOS:A1997XK16500068
J	Wang, WY; Hou, ZL; Honzatko, RB; Fromm, HJ				Wang, WY; Hou, ZL; Honzatko, RB; Fromm, HJ			Relationship of conserved residues in the IMP binding site to substrate recognition and catalysis in Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ISOTOPE EXCHANGE; SEQUENCE; PURIFICATION; PROTEINS; PURA; GENE	Gln(34), Gln(224), Leu(228), and Ser(240) are conserved residues in the vicinity of bound IMP in the crystal structure of Escherichia coli adenylosuccinate synthetase. Directed mutations were carried out, and wild-type and mutant enzymes were purified to homogeneity. Circular dichroism spectroscopy indicated no difference in secondary structure between the mutants and the wildtype enzyme in the absence of substrates. Mutants L228A and S240A exhibited modest changes in their initial rate kinetics relative to the wild-type enzyme, suggesting that neither Leu(228) nor Ser(240) play essential roles in substrate binding or catalysis. The mutants Q224M and Q224E exhibited no significant change in K-m(GTP) and K-m(ASP) and modest changes in K-m(IMP) relative to the wild-type enzyme. However, k(cat) decreased 13-fold for the Q224M mutant and 10(4)-fold for the Q224E mutant relative to the wild-type enzyme. Furthermore, the Q224E mutant showed an optimum pH at 6.2, which is 1.5 pH units lower than that of the wild-type enzyme. Tryptophan emission fluorescence spectra of Q224M, Q224E, and wild-type proteins under denaturing conditions indicate comparable stabilities. Mutant Q34E exhibits a 60-fold decrease in k(cat) compared with that of the wild-type enzyme, which is attributed to the disruption of the Gln(34) to Gln(224) hydrogen bond observed in crystal structures. Presented here is a mechanism for the synthetase, whereby Gln(224) works in concert with Asp(13) to stabilize the B-oxyanion of IMP.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NINDS NIH HHS [NS10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BASS MB, 1984, J BIOL CHEM, V259, P2330; Bouyoub A, 1996, J MOL BIOL, V261, P144, DOI 10.1006/jmbi.1996.0448; Braford M.M., 1976, ANAL BIOCHEM, V72, P248, DOI [10.1016/j.cj.2017.04.003, DOI 10.1016/J.CJ.2017.04.003]; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FonnePfister R, 1996, P NATL ACAD SCI USA, V93, P9431, DOI 10.1073/pnas.93.18.9431; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HEIM DR, 1995, PESTIC BIOCHEM PHYS, V53, P138, DOI 10.1006/pest.1995.1061; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; Kang CH, 1997, J BIOL CHEM, V272, P11881, DOI 10.1074/jbc.272.18.11881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; MANTSALA P, 1992, J BACTERIOL, V174, P1883; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; RUDOLPH FB, 1971, THESIS IOWA STATE U; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Siehl DL, 1996, PLANT PHYSIOL, V110, P753, DOI 10.1104/pp.110.3.753; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; Wang WY, 1997, J BIOL CHEM, V272, P7078, DOI 10.1074/jbc.272.11.7078; WANG WY, 1995, J BIOL CHEM, V270, P13160, DOI 10.1074/jbc.270.22.13160; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	35	11	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16911	16916		10.1074/jbc.272.27.16911	http://dx.doi.org/10.1074/jbc.272.27.16911			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202000	hybrid			2022-12-25	WOS:A1997XH44600032
J	Bromann, PA; Boetticher, EE; Lomasney, JW				Bromann, PA; Boetticher, EE; Lomasney, JW			A single amino acid substitution in the pleckstrin homology domain of phospholipase C delta 1 enhances the rate of substrate hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MONOLAYER SURFACE PRESSURE; INTERFACIAL CATALYSIS; HIGH-AFFINITY; INOSITOL TRISPHOSPHATE; KINETIC-ANALYSIS; BINDING; C-DELTA-1; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE	The pleckstrin homology (PH) domain has been postulated to serve as an anchor for enzymes that operate at a lipid/water interface. To understand further the relationship between the PH domain and enzyme activity, a phospholipase C (PLC) delta 1/PH domain enhancement-of-activity mutant was generated. A lysine residue was substituted for glutamic acid in the PH domain of PLC delta 1 at position 54 (E54K). Purified native and mutant enzymes were characterized using a phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2)/dodecyl maltoside mixed micelle assay and kinetics measured according to the dual phospholipid model of Dennis and co-workers (Hendrickson, H. S., and Dennis, E. A. (1984) J. Biol. Chem. 259, 5734-5739; Carmen, G. M., Deems, R. A., and Dennis, E. A. (1995) J. Biol; Chem. 270, 18711-18714). Our results show that both PLC delta 1 and E54K bind phosphatidylinositol bisphosphate cooperatively (Hill coefficients, n = 2.2 +/- 0.2 and 2.0 +/- 0.1, respectively). However, E54K shows a dramatically increased rate of (PI(4,5)P-2)-stimulated PI(4,5)P-2 hydrolysis (interfacial V-max for PLC delta 1 = 4.9 +/- 0.3 mu mol/min/mg and for E54K = 31 +/- 3 mu mol/min/mg) as well as PI hydrolysis (V-max for PLC delta 1 = 27 +/- 3.4 nmol/min/mg and for E54K = 95 +/- 12 nmol/min/mg). In the absence of PI(4,5)P-2 both native and mutant enzyme hydrolyze PI at similar rates. E54K also has a higher affinity for micellar substrate (equilibrium dissociation constant, K-s = 85 +/- 36 mu M for E54R and 210 +/- 48 mu M for PLC delta 1). Centrifugation binding assays using large unilamelar phospholipid vesicles confirm that E54K binds PI(4,5)P-2 with higher affinity than native enzyme. E54K is more active even though the interfacial Michaelis constant (K-m) for E54K (0.034 +/- 0.01 mol fraction PI(4,5)P-2) is higher than the K-m for native enzyme (0.012 +/- 0.002 mol fraction PI(4,5)P-2). D-Inositol trisphosphate is less potent at inhibiting E54K PI(4,5)P-2 hydrolysis compared with native enzyme. These results demonstrate that a single amino acid substitution in the PH domain of PLC delta 1 can dramatically enhance enzyme activity. Additionally, the marked increase in V-max for E54R argues for a direct role of PH domains in regulating catalysis by allosteric modulation of enzyme structure.	NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,DEPT PATHOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,DEPT PHARMACOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,INST NEUROSCI,CHICAGO,IL 60611	Northwestern University; Northwestern University; Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055591, R01HL055591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55591] Funding Source: Medline; NIMH NIH HHS [MH11219] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIANCO ID, 1995, BBA-PROTEIN STRUCT M, V1250, P197, DOI 10.1016/0167-4838(95)00051-U; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HENDRICKSON HS, 1992, BIOCHEMISTRY-US, V31, P12169, DOI 10.1021/bi00163a028; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JONES GA, 1993, J BIOL CHEM, V268, P20845; KATO H, 1992, J BIOL CHEM, V267, P6483; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; SHIMOHAMA S, 1995, BRAIN RES, V669, P217, DOI 10.1016/0006-8993(94)01239-E; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; WAHL MI, 1992, J BIOL CHEM, V267, P10447; YAGISAWA H, 1991, J HYPERTENS, V9, P997, DOI 10.1097/00004872-199111000-00004; YU FX, 1992, J BIOL CHEM, V267, P14616	39	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16240	16246		10.1074/jbc.272.26.16240	http://dx.doi.org/10.1074/jbc.272.26.16240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195925	hybrid			2022-12-25	WOS:A1997XG01900029
J	Mizukami, Y; Yoshioka, K; Morimoto, S; Yoshida, K				Mizukami, Y; Yoshioka, K; Morimoto, S; Yoshida, K			A novel mechanism of JNK1 activation - Nuclear translocation and activation of JNK1 during ischemia and reperfusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENES; NECROSIS-FACTOR-ALPHA; C-FOS EXPRESSION; PROTEIN-KINASE; CARDIAC MYOCYTES; AP-1 ACTIVITY; HA-RAS; HUMAN-PLATELETS; MAP KINASES; JUN	Cytokines and various cellular stresses are known to activate c-Jun NH2-terminal kinase (JNK), which plays a role in conveying signals from the cytosol to the nucleus. Here we investigate the translocation and activation of JNK1 during ischemia and reperfusion in perfused rat heart. Ischemia induces the translocation of JNK1 from the cytosol fraction to the nuclear fraction in a time-dependent manner. Immunohistochemical observation also shows that JNK1 staining in the nucleus is enhanced after ischemia. During reperfusion after ischemia, further nuclear translocation of JNK1 is apparently inhibited. In contrast, JNK1 activity in the nuclear fraction does not increased during ischemia but increases significantly during reperfusion with a peak at 10 min of reperfusion. The activation of JNK1 is confirmed by the phosphorylation of endogenous c-Jun (Ser-73) with similar kinetics. The level of c-jun mRNA also increases during reperfusion but not during ischemia. Based on fractionation and immunohistochemical analyses, an upstream kinase for JNK1, SAPK/ERK kinase 1 (SEK1), is constantly present in both the nucleus and cytoplasm throughout ischemia and reperfusion, whereas an upstream kinase for mitogen-activated protein kinase, MAPK/ERK kinase 1, remains in the cytosol. Furthermore, phosphorylation at Thr-223 of SEK1, necessary for its activation, rapidly increases in the nuclear fraction during postischemic reperfusion. These findings demonstrate that JNK1 translocates to the nucleus during ischemia without activation and is then activated during reperfusion, probably by SEK1 in the nucleus.	KANAZAWA UNIV,CANC RES INST,DEPT MOL PATHOL,KANAZAWA,ISHIKAWA 920,JAPAN; KYUSHU UNIV,SCH MED,DEPT CLIN PHARM,FUKUOKA 812,JAPAN	Kanazawa University; Kyushu University	Mizukami, Y (corresponding author), YAMAGUCHI UNIV,SCH MED,DEPT LEGAL MED,1144 KOGUSHI,UBE,YAMAGUCHI 755,JAPAN.			Morimoto, Sachio/0000-0001-9171-3636				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BAK MI, 1994, J CLIN INVEST, V93, P40, DOI 10.1172/JCI116974; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN B, 1992, J CLIN INVEST, V90, P1778, DOI 10.1172/JCI116052; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIM MY, 1991, J BIOL CHEM, V266, P484; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; MIZUKAMI Y, 1994, EUR J BIOCHEM, V224, P959, DOI 10.1111/j.1432-1033.1994.00959.x; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITELAW PF, 1992, BIOCHEM J, V281, P143, DOI 10.1042/bj2810143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIDA K, 1988, BIOCHEM J, V249, P487, DOI 10.1042/bj2490487; YOSHIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1182, P215, DOI 10.1016/0925-4439(93)90143-O; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X; YOSHIDA K, 1987, J BIOL CHEM, V262, P16048; YOSHIOKA K, 1990, EMBO J, V9, P535, DOI 10.1002/j.1460-2075.1990.tb08140.x; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	66	160	162	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16657	16662		10.1074/jbc.272.26.16657	http://dx.doi.org/10.1074/jbc.272.26.16657			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195981	hybrid			2022-12-25	WOS:A1997XG01900085
J	Toribara, NW; Ho, SB; Gum, JR; Lau, P; Kim, YS				Toribara, NW; Ho, SB; Gum, JR; Lau, P; Kim, YS			The carboxyl-terminal sequence of the human secretory mucin, MUC6 - Analysis of the primary amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; HUMAN GASTRIC MUCIN; GENE LOCUS PUM; MOLECULAR-CLONING; INTESTINAL MUCIN; VONWILLEBRAND-FACTOR; HELICOBACTER-PYLORI; EXPRESSION CLONING; EPITHELIAL MUCINS; CDNA SEQUENCES	The distribution of MUC6 suggests that its primary function is protection of vulnerable epithelial surfaces from damaging effects of constant exposure to a wide range of endogenous caustic or proteolytic agents. A combination of genomic, cDNA. and 3' rapid amplification of cDNA ends techniques was used to isolate the carboxyl-terminal end of MUC6. The 3' nontandem repeat region contained 1083 base pairs of coding sequence (361 amino acids) followed by 632 base pairs of 3'-untranslated region. The coding sequence consists of two distinct regions; region 1 contained the initial 270 amino acids (62% Ser-Thr-Pro with no Cys residues), and region 2 contained the COOH-terminal 91 amino acids (22% Ser-Thr-Pro with 12% Cys). Although region 1 had no homology to any sequences in GenBank, region 2 had approximately 25% amino acid homology to the COOH-terminal regions of human mucins MUC2, -5, and -5B and von Willebrand factor. The shortness of region 2 would leave little of the peptide backbone exposed to a potentially hostile environment. Antibody studies suggest that MUC6 in its native form exists as a disulfide-bonded multimer, The conservation of the 11 cysteine positions in region 2 suggests the importance of this short region to mucin polymerization.	UNIV CALIF SAN FRANCISCO, DIV GASTROENTEROL, SAN FRANCISCO, CA 94121 USA; UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55417 USA; DEPT VET AFFAIRS MED CTR, MINNEAPOLIS, MN 55417 USA	University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities	Toribara, NW (corresponding author), DEPT VET AFFAIRS MED CTR, GASTROINTESTINAL RES LAB 151M2, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.							AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BYRD JC, 1989, BIOCHEM J, V261, P617, DOI 10.1042/bj2610617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONG NV, 1990, HUM GENET, V86, P167; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; DEKKER J, 1990, J BIOL CHEM, V265, P18116; Forstner Janet F., 1994, P1255; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GERARD C, 1990, J CLIN INVEST, V86, P1921, DOI 10.1172/JCI114925; Gipson IK, 1997, BIOL REPROD, V56, P999, DOI 10.1095/biolreprod56.4.999; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; HO SB, 1995, CANCER RES, V55, P2681; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JANY BH, 1991, J CLIN INVEST, V87, P77, DOI 10.1172/JCI115004; Keates AC, 1997, BIOCHEM J, V324, P295, DOI 10.1042/bj3240295; Kitamura H, 1996, EUR J CANCER, V32A, P1788, DOI 10.1016/0959-8049(96)00168-2; KLOMP LWJ, 1994, BIOCHEM J, V304, P693, DOI 10.1042/bj3040693; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; Meier PB, 1996, GASTROENTEROLOGY, V110, pA417; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SLOMIANY BL, 1992, BIOCHEM BIOPH RES CO, V183, P506, DOI 10.1016/0006-291X(92)90511-I; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; YOUNAN F, 1982, GASTROENTEROLOGY, V82, P827	45	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16398	16403		10.1074/jbc.272.26.16398	http://dx.doi.org/10.1074/jbc.272.26.16398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195947	hybrid			2022-12-25	WOS:A1997XG01900051
J	Yamaguchi, I; Harmon, SK; Todd, RD; OMalley, KL				Yamaguchi, I; Harmon, SK; Todd, RD; OMalley, KL			The rat D-4 dopamine receptor couples to cone transducin (G alpha(t2)) to inhibit forskolin-stimulated cAMP accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; ALPHA-SUBUNIT; EXPRESSION; TRANSDUCIN; CELLS; GENE; SEQUENCE; PHOTORECEPTORS; AFFINITY	Based on its expression pattern and pharmacology, the D-4 dopamine receptor may play a role in schizophrenia. Thus it is of interest to know what signaling pathways are utilized by this receptor. Previously, we showed that activation of D-4 receptors in a mouse mesencephalic neuronal cell line (MN9D) inhibited forskolin-stimulated cAMP accumulation in a pertussis toxin-sensitive (Ptx-sensitive) fashion. Of the known Ptx-sensitive G-protein alpha subunits, MN9D expressed G alpha(i2), G alpha(oA), and G alpha(oB); however, none of these coupled td the D-4 receptor. Using a low stringency polymerase chain reaction cloning method, we found an additional Ptx-sensitive G-protein cone transducin (G alpha(t2)) expressed in the MN9D cells. We also found that G alpha(t2) mRNA is highly expressed in rat mesencephalic tissue. To test the hypothesis that the D-4 receptor couples to G alpha(t2) we cotransfected MNSD cells with the D-4 receptor and a mutagenized Ptx-resistant G alpha(t2) subunit (mG alpha(t2)). Application of the dopaminergic agonist quinpirole to cotransfected cells inhibited forskolin-stimulated cAMP accumulation in the presence or absence of Ptx. To our knowledge, this is the first report demonstrating that the D-4 dopamine receptor functionally couples to a specific G-protein and that a non-opsin-like receptor can couple with a transducin subunit.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Todd, Robert/GWM-4486-2022		NIDA NIH HHS [DA08818] Funding Source: Medline; NIMH NIH HHS [MH31302] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH031302, P50MH031302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008818] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHABERT C, 1994, J NEUROCHEM, V63, P62; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHIO CL, 1994, J BIOL CHEM, V269, P11813; CHOI HK, 1992, P NATL ACAD SCI USA, V89, P8943, DOI 10.1073/pnas.89.19.8943; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN AI, 1992, P NATL ACAD SCI USA, V89, P12093, DOI 10.1073/pnas.89.24.12093; COLOMA MJ, 1992, J IMMUNOL METHODS, V152, P89, DOI 10.1016/0022-1759(92)90092-8; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KUBO M, 1991, FEBS LETT, V291, P245, DOI 10.1016/0014-5793(91)81294-I; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; MCHALE M, 1994, FEBS LETT, V345, P147, DOI 10.1016/0014-5793(94)00423-4; MILLS A, 1993, FEBS LETT, V320, P130, DOI 10.1016/0014-5793(93)80077-8; Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0; OHara CM, 1996, J PHARMACOL EXP THER, V278, P354; OMALLEY KL, 1992, NEW BIOL, V4, P137; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SCHOOTS O, 1995, EUR J PHARM-MOLEC PH, V289, P67, DOI 10.1016/0922-4106(95)90169-8; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STRYER L, 1991, J BIOL CHEM, V266, P10711; Sun D, 1996, AM J PHYSIOL-RENAL, V271, pF391, DOI 10.1152/ajprenal.1996.271.2.F391; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TANG L, 1994, J PHARMACOL EXP THER, V268, P495; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31	36	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16599	16602		10.1074/jbc.272.26.16599	http://dx.doi.org/10.1074/jbc.272.26.16599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195972	hybrid			2022-12-25	WOS:A1997XG01900076
J	Yang, BX; Verkman, AS				Yang, BX; Verkman, AS			Water and glycerol permeabilities of aquaporins 1-5 and MIP determined quantitatively by expression of epitope-tagged constructs in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING TUBULE; MOLECULAR-CLONING; INTRINSIC PROTEIN; RAT-KIDNEY; CHANNEL; CHIP28; CELLS; MEMBRANE; DUCT; TISSUES	The goal of this study was to compare single channel water and glycerol permeabilities of mammalian aqua-porins (AQP) 1-5 and the major intrinsic protein of lens fiber (MIP). Each of the six cloned cDNAs from rat was left untagged or was epitope-tagged with c-Myc or FLAG at either the N or C terminus so that results would not depend on epitope identity or location. The constructs were expressed in Xenopus oocytes for measurement of osmotic water permeability (P-f), [H-3]glycerol uptake, and protein expression. Each of the 30 epitope-tagged constructs was expressed strongly at the oocyte plasma membrane. The 10-min uptake of [H-3]glycerol was increased significantly (range of 4.5-8-fold over control) in oocytes expressing untagged AQP3 (GLIP) and each of the four tagged AQP3 constructs; [H-3]glycerol uptake was not increased in oocytes expressing AQP1, AQP2, AQP4, AQP5, or MIP. In oocytes microinjected with 5 ng of cRNA, average P-f values (in cm/s x 10(-3)) were 0.67 +/- 0.06 (control), 19 +/- 2 (AQP1), 10 +/- 1 (AQP2), 8 +/- 2 (AQP3), 29 +/- 1 (AQP4), 10 +/- 1 (AQP5), and 1.3 +/- 0.2 (MIP), and they were relatively insensitive to the presence, identity, or location of the epitope tag. P-f values were not affected by protein kinase A or C activation. After normalization for plasma membrane expression by immunoprecipitation of microdissected plasma membranes, single channel water permeabilities (p(f), referenced to the AQP1 p(f) of 6 x 10(-14) cm(3)/s) were (in cm(3)/s x 10(-14)) 3.3 +/- 0.2 (AQP2), 2.1 +/- 0.3 (AQP3), 24 +/- 0.6 (AQP4), 5.0 +/- 0.4 (AQP5), and 0.25 +/- 0.05 (MIP); p(f) values were insensitive to epitope identity and location. These results indicate very different intrinsic water permeabilities for the mammalian aquaporin homologs, with the p(f) value for AQP4 remarkably higher than those for the others. The p(f) values establish limits on aquaporin tissue densities required for physiological function and suggest significant structural and functional differences among the aquaporins.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMI L, 1994, BBA-BIOMEMBRANES, V1192, P147, DOI 10.1016/0005-2736(94)90155-4; ABRAMI L, 1995, PFLUG ARCH EUR J PHY, V430, P447, DOI 10.1007/BF00373921; AGRE P, 1995, KIDNEY INT, V24, P1057; CHENG A, 1997, IN PRESS NATURE; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; Chubet RG, 1996, BIOTECHNIQUES, V20, P136; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Echevarria M, 1996, J BIOL CHEM, V271, P25079, DOI 10.1074/jbc.271.41.25079; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Fushimi Kiyohide, 1996, Journal of the American Society of Nephrology, V7, P1267; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; Katsura Toshiya, 1996, Journal of the American Society of Nephrology, V7, P1268; Kishore BK, 1996, AM J PHYSIOL-RENAL, V271, pF62, DOI 10.1152/ajprenal.1996.271.1.F62; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; MA T, 1997, IN PRESS J CLIN INVE; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MA TH, 1993, J BIOL CHEM, V268, P22756; MA TH, 1994, J BIOL CHEM, V269, P21845; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; Ma TH, 1996, AM J PHYSIOL-CELL PH, V271, pC1699, DOI 10.1152/ajpcell.1996.271.5.C1699; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1994, J BIOL CHEM, V269, P11869; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; SHI LB, 1994, J BIOL CHEM, V269, P10417; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; STRANGE K, 1987, J MEMBRANE BIOL, V96, P27, DOI 10.1007/BF01869332; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; Verkman AS, 1997, SCIENCE, V275, P1491; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; WALZ T, 1995, NAT STRUCT BIOL, V2, P730, DOI 10.1038/nsb0995-730; Yang BX, 1996, J BIOL CHEM, V271, P4577; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	55	322	330	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16140	16146		10.1074/jbc.272.26.16140	http://dx.doi.org/10.1074/jbc.272.26.16140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195910	hybrid			2022-12-25	WOS:A1997XG01900014
J	Simms, LA; Zou, TT; Young, J; Shi, YQ; Lei, JY; Appel, R; Rhyu, MG; Sugimura, H; ChenevixTrench, G; Souza, RF; Meltzer, SJ; Leggett, BA				Simms, LA; Zou, TT; Young, J; Shi, YQ; Lei, JY; Appel, R; Rhyu, MG; Sugimura, H; ChenevixTrench, G; Souza, RF; Meltzer, SJ; Leggett, BA			Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers	ONCOGENE			English	Article						microsatellite instability; repeats; colorectal cancer; gastric cancer	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; ESTROGEN-RECEPTOR; COLON-CANCER; RETINOIC ACID; MISMATCH REPAIR; II RECEPTOR; LUNG-CANCER	Genomic instability at simple repeated sequences has been observed in various types of human cancers and is considered an important mechanism in tumorigenesis. Alterations at microsatellite loci have been reported scattered throughout the genome. Recently, the transforming growth factor-beta receptor type II (TGF-beta RII) and the insulin-like growth factor II receptor (IGF-IIR) genes were shown to have inactivating mutations within coding microsatellite sequences. The demonstration of mutations in two growth regulatory genes supports the idea that other regulatory genes with repeat sequences may also be targets in tumours with defective mismatch repair. We examined genes involved in tumour suppression, cell adhesion and cell cycle regulation for mutations at small repeat sequences in replication error positive gastrointestinal cancers. Several polymorphisms were found which exhibited instability, but no other instability was present in the regions examined.	UNIV MARYLAND, SCH MED, DEPT MED, GI DIV, BALTIMORE, MD 21201 USA; BALTIMORE VA HOSP, BALTIMORE, MD 21201 USA; CATHOLIC UNIV, COLL MED, DEPT MICROBIOL, SEOUL 137701, SOUTH KOREA; HAMAMATSU UNIV SCH MED, DEPT PATHOL 1, HAMAMATSU, SHIZUOKA 43131, JAPAN; QUEENSLAND INST MED RES, BRISBANE, QLD 4029, AUSTRALIA	University System of Maryland; University of Maryland Baltimore; Catholic University of Korea; Hamamatsu University School of Medicine; QIMR Berghofer Medical Research Institute	Simms, LA (corresponding author), ROYAL BRISBANE HOSP FDN, CLIN RES CTR, GLAXO CONJOINT GASTROENTEROL LAB, BRISBANE, QLD 4029, AUSTRALIA.		Chenevix-Trench, Georgia/AAV-2014-2020; Leggett, Barbara A/D-3579-2011; Young, Joanne P/H-7774-2014; Young, Joanne P/B-9981-2011	Chenevix-Trench, Georgia/0000-0002-1878-2587; Leggett, Barbara/0000-0003-2062-7380; Simms, Lisa/0000-0002-5387-7397				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FIELD JK, 1995, BRIT J CANCER, V71, P1065, DOI 10.1038/bjc.1995.205; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONTANA JA, 1990, CANCER RES, V50, P1977; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; Greenblatt MS, 1996, CANCER RES, V56, P2130; HAN HJ, 1993, CANCER RES, V53, P5087; HEINEN CD, 1995, CANCER RES, V55, P4797; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUDDART RA, 1995, BRIT J CANCER, V72, P642, DOI 10.1038/bjc.1995.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JEGO N, 1993, ONCOGENE, V8, P209; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; KRAHE R, 1995, AM J HUM GENET, V56, P1067; KRUYER H, 1994, AM J HUM GENET, V54, P437; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOTAN R, 1993, J CELL BIOCHEM, P167; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MYEROFF LL, 1995, CANCER RES, V55, P5545; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; PATEL U, 1994, ONCOGENE, V9, P3695; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; UCHIDA T, 1995, ONCOGENE, V10, P1019; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; XU XM, 1994, MOL CELL ENDOCRINOL, V105, P197; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004	57	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2613	2618		10.1038/sj.onc.1201094	http://dx.doi.org/10.1038/sj.onc.1201094			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191061				2022-12-25	WOS:A1997XA94900013
J	Gugneja, S; Scarpulla, RC				Gugneja, S; Scarpulla, RC			Serine phosphorylation within a concise amino-terminal domain in nuclear respiratory factor 1 enhances DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; CASEIN KINASE-II; TRANSCRIPTION FACTOR; GENE; EXPRESSION; PROTEINS; SITES; NRF-1; ACTIVATION; INITIATION	Nuclear respiratory factor 1 (NRF-1) is a transcriptional activator that acts on a diverse set of nuclear genes required for mitochondrial respiratory function in mammalian cells, These genes encode respiratory proteins as well as components of the mitochondrial transcription, replication, and heme biosynthetic machinery, Here, we establish that NRF-1 is a phosphoprotein in vivo. Phosphorylation occurs on serine residues within a concise NH2-terminal domain with the major sites of phosphate incorporation at serines 39, 44, 46, 47, and 52. The in vivo phosphorylation pattern can be approximated in vitro by phosphorylating recombinant NRF-1 with purified casein kinase II, Phosphate incorporation at the sites utilized in vivo results in a marked stimulation of DNA binding activity which is not observed in mutated proteins lacking these sites, Pairwise expression of the wild-type protein with each of a series of truncated derivatives in transfected cells results in the formation of a dimer between wild-type and mutant forms demonstrating that a homodimer is the active binding species. Although NRF-1 can dimerize in the absence of DNA, phosphorylation does not enhance the formation of these dimers, These findings suggest that phosphorylation results in an intrinsic change in the NRF-1 dimer enhancing its ability to bind DNA.	NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOL BIOL, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32525-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; GOMEZCUADRADO A, 1995, MOL CELL BIOL, V15, P6670; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MANAK JR, 1993, ONCOGENE, V8, P703; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; Scarpulla RC, 1996, TRENDS CARDIOVAS MED, V6, P39, DOI 10.1016/1050-1738(95)00129-8; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x	36	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18732	18739		10.1074/jbc.272.30.18732	http://dx.doi.org/10.1074/jbc.272.30.18732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228045	hybrid			2022-12-25	WOS:A1997XM34200036
J	Noel, RJ; Antinozzi, PA; McGarry, JD; Newgard, CB				Noel, RJ; Antinozzi, PA; McGarry, JD; Newgard, CB			Engineering of glycerol-stimulated insulin secretion in islet beta cells - Differential metabolic fates of glucose and glycerol provide insight into mechanisms of stimulus-secretion coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; PANCREATIC-ISLETS; MALONYL-COA; GENE; DEHYDROGENASE; GLYCOLYSIS; INHIBITION; LANGERHANS; PHOSPHATE; CHANNELS	Insulin secretion from beta cells in the islets of Langerhans can be stimulated by a number of metabolic fuels, including glucose and glyceraldehyde, and is thought to be mediated by metabolism of the secretagogues and an attendant increase in the ATP:ADP ratio. Curiously, glycerol fails to stimulate insulin secretion, even though it has been reported that islets contain abundant glycerol kinase activity and oxidize glycerol efficiently, We have reinvestigated this point and find that rat islets and the well differentiated insulinoma cell line INS-1 contain negligible glycerol kinase activity. A recombinant adenovirus containing the bacterial glycerol kinase gene (AdCMV-GlpK) was constructed and used to express the enzyme in islets and INS-1 cells, resulting in insulin secretion in response to glycerol. In AdCMV-GlpK-treated INS-1 cells a greater proportion of glycerol is converted to lactate and a lesser proportion is oxidized compared with glucose. The two fuels are equally potent as insulin secretagogues, despite the fact that oxidation of glycerol at its maximally effective dose (2-5 mM) occurs at a rate that is similar to the rate of glucose oxidation at its basal, nonstimulatory concentration (3 mM). We also investigated the possibility that glycerol may signal via expansion of the glycerol phosphate pool to allow enhanced fatty acid esterification and formation of complex lipids. Addition of Triacsin-C, an inhibitor of long-chain acyl-CoA synthetase, to AdCMV-GlpK-treated INS-1 cells did not inhibit glycerol-stimulated insulin secretion despite the fact that it blocked glycerol incorporation into cellular lipids. We conclude from these studies that glycerol kinase expression is sufficient to activate glycerol signaling in beta cells, showing that the failure of normal islets to respond to this substrate is due to a lack of this enzyme activity. Further, our studies show that glycerol signaling is not Linked to esterification or oxidation of the substrate, but is likely mediated by its metabolism in the glycerol phosphate shuttle and/or the distal portion of the glycolytic pathway, either of which can lead to production of ATP and an increased ATP:ADP ratio.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK 46492-05] Funding Source: Medline; NIGMS NIH HHS [T32 GM08014] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046492, R37DK046492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008014] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BECKER TC, 1994, METHOD CELL BIOL, V43, P162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUKES ID, 1994, J BIOL CHEM, V269, P10979; FERBER S, 1994, J BIOL CHEM, V269, P11523; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, HORM METAB RES, V14, P678, DOI 10.1055/s-2007-1019117; McCrory W.J., 1988, VIROLOGY, V163, P614; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; MIYAURA C, 1991, MOL ENDOCRINOL, V5, P226, DOI 10.1210/mend-5-2-226; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PETTIGREW DW, 1988, J BIOL CHEM, V263, P135; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; SENER A, 1988, INT J BIOCHEM, V20, P595, DOI 10.1016/0020-711X(88)90098-5; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; YILMAZ MT, 1987, MOL CELL ENDOCRINOL, V52, P251, DOI 10.1016/0303-7207(87)90051-7	33	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18621	18627		10.1074/jbc.272.30.18621	http://dx.doi.org/10.1074/jbc.272.30.18621			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228030	hybrid			2022-12-25	WOS:A1997XM34200021
J	Perry, DK; Smyth, MJ; Stennicke, HR; Salvesen, GS; Duriez, P; Poirier, GG; Hannun, YA				Perry, DK; Smyth, MJ; Stennicke, HR; Salvesen, GS; Duriez, P; Poirier, GG; Hannun, YA			Zinc is a potent inhibitor of the apoptotic protease, caspase-3 - A novel target for zinc in the inhibition of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT ENDONUCLEASE; CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; INTRACELLULAR ZINC; IDENTIFICATION; CLEAVAGE; THYMOCYTES; ACTIVATION; LEUKEMIA	The prevention of apoptosis by Zn2+ has generally been attributed to its inhibition of an endonuclease acting in the late phase of apoptosis. In this study we investigated the effect of Zn2+ on an earlier event in the apoptotic process, the proteolysis of the ''death substrate'' poly(ADP-ribose) polymerase (PARP). Pretreatment of intact Molt4 leukemia cells with micromolar concentrations of Zn2+ caused an inhibition of PARP proteolysis induced by the chemotherapeutic agent etoposide, Using a cell-free system consisting of purified bovine PARP as a substrate and an apoptotic extract or recombinant caspase-3 as the PARP protease, Zn2+ inhibited PARP proteolysis in the low micromolar range. To rule out an effect of Zn2+ on PARP, a protein with two zinc finger domains, we used recombinant caspase-3 and a chromogenic tetrapeptide substrate containing the caspase-3 cleavage site. In this system, Zn2+ inhibited caspase-3 with an IC50 of 0.1 mu M. These results identify caspase-3 as a novel target of Zn2+ inhibition in apoptosis and suggest a regulatory role for Zn2+ in modulating the upstream apoptotic machinery.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,DURHAM,NC 27710; LA JOLLA CANC RES CTR,BURNHAM INST,LA JOLLA,CA 92037; UNIV LAVAL,CHU LAVAL,RES CTR,ST FOY,PQ G1V 4G2,CANADA	Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Sanford Burnham Prebys Medical Discovery Institute; Laval University				Duriez, Patrick/0000-0003-1814-2552; Poirier, Guy/0000-0002-4869-1424	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; COHEN JJ, 1984, J IMMUNOL, V132, P38; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; FADY C, 1995, J INTERF CYTOK RES, V15, P71, DOI 10.1089/jir.1995.15.71; FAILLA ML, 1978, BIOCHIM BIOPHYS ACTA, V538, P435, DOI 10.1016/0304-4165(78)90405-1; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; Jiang SN, 1997, CELL DEATH DIFFER, V4, P39, DOI 10.1038/sj.cdd.4400204; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LENTNER C, 1981, SCI TABLES, P79; MARTIN SJ, 1991, CLIN EXP IMMUNOL, V83, P338; Matsushita K, 1996, BRAIN RES, V743, P362, DOI 10.1016/S0006-8993(96)01112-2; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MCCABE MJ, 1993, LAB INVEST, V69, P101; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; PATTISON SE, 1986, FASEB J, V45, P2805; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; POWERS SG, 1981, J BIOL CHEM, V256, P1160; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SMITH GK, 1992, CANCER RES, V52, P4895; SUHY DA, 1995, MET IONS BIOL SYST, P557; SUNDERMAN FW, 1995, ANN CLIN LAB SCI, V25, P134; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P1; THOMAS DJ, 1991, TOXICOLOGY, V68, P327, DOI 10.1016/0300-483X(91)90078-F; TREVES S, 1994, EXP CELL RES, V211, P339, DOI 10.1006/excr.1994.1096; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251	33	407	419	4	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18530	18533		10.1074/jbc.272.30.18530	http://dx.doi.org/10.1074/jbc.272.30.18530			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228015	hybrid			2022-12-25	WOS:A1997XM34200006
J	Scheibel, T; Neuhofen, S; Weikl, T; Mayr, C; Reinstein, J; Vogel, PD; Buchner, J				Scheibel, T; Neuhofen, S; Weikl, T; Mayr, C; Reinstein, J; Vogel, PD; Buchner, J			ATP-binding properties of human Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR INACTIVATION; SPIN-RESONANCE SPECTROSCOPY; PROGESTERONE-RECEPTOR; MOLYBDATE IONS; KINASE; EPIMERIZATION; CHAPERONES; ACTIVATION; MECHANISM	Hsp90 is one of the most abundant proteins in the cytosol of eukaryotic cells, Under physiological conditions Hsp90 has been shown to play a major role in several specific signaling pathways, including maturation of various kinases and maintenance of steroid receptors in an activable state. It is well established that the level of Hsp90 increases severalfold under stress conditions, and it has been shown that the chaperone function of Hsp90 is ATP-independent. Although yeast Hsp90 does not bind ATP, as determined by a number of methods monitoring tight binding, ATP dependent functions of Hsp90 in the presence of co-factors and elevated temperatures are still under discussion. Here, we have reinvestigated ATP-binding properties and ATPase activity of human Hsp90 under various conditions, We show that human Hsp90 does not bind ATP tightly and does not exhibit detectable ATPase activity. However, using electron spin resonance spectroscopy, weak binding of spin-labeled ATP analogues with half-maximal binding at 400 mu M ATP was detected. The functional significance of this weak interaction remains enigmatic.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; UNIV KAISERSLAUTERN,FACHBEREICH CHEM BIOCHEM,D-67663 KAISERSLAUTERN,GERMANY; MAX PLANCK INST MOL PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	University of Regensburg; University of Kaiserslautern; Max Planck Society			Buchner, Johannes/A-2651-2010; Scheibel, Thomas/I-1170-2014	Scheibel, Thomas/0000-0002-0457-2423; Buchner, Johannes/0000-0003-1282-7737; Vogel, Pia/0000-0002-8135-4649				BAUER M, 1992, FEBS LETT, V313, P288, DOI 10.1016/0014-5793(92)81211-4; BILIK V, 1975, CHEM ZVESTI, V29, P690; BILIK V, 1978, CHEM ZVESTI, V32, P242; BILIK V, 1972, CHEM ZVESTI, V26, P182; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BODINE PVN, 1995, RECEPTOR, V5, P117; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOSE S, 1996, SCIENCE, V274, P171; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; BURGARD S, 1994, J BIOL CHEM, V269, P17815; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LEACH KL, 1979, J BIOL CHEM, V254, P1884; Losel RM, 1997, BIOCHEMISTRY-US, V36, P1188, DOI 10.1021/bi9614601; Losel RM, 1996, SPECTROCHIM ACTA A, V52, P73, DOI 10.1016/0584-8539(95)01549-3; MESHINCHI S, 1991, BIOCHEMISTRY-US, V30, P8617, DOI 10.1021/bi00099a018; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; Nardai G, 1996, J BIOSCIENCE, V21, P179, DOI 10.1007/BF02703107; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Neuhofen S, 1996, EUR J BIOCHEM, V240, P78, DOI 10.1111/j.1432-1033.1996.0078h.x; NIELSEN CJ, 1977, J BIOL CHEM, V252, P7568; PAIGEN K, 1958, J BIOL CHEM, V233, P388; PALLEROS DR, 1993, BIOCHEMISTRY-US, V32, P4314, DOI 10.1021/bi00067a021; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHUE GL, 1994, J BIOL CHEM, V269, P2707; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, STEROID HORMONE RECE, P247; STRECKENBACH B, 1980, BIOCHIM BIOPHYS ACTA, V601, P34, DOI 10.1016/0005-2736(80)90511-8; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; VOGELCLAUDE P, 1987, FEBS LETT, V227, P107; WALTER U, 1981, EXPERIENTIA, V37, P1263, DOI 10.1007/BF01948349; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	61	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18608	18613		10.1074/jbc.272.30.18608	http://dx.doi.org/10.1074/jbc.272.30.18608			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228028	Green Published, hybrid			2022-12-25	WOS:A1997XM34200019
J	Srinivasula, SM; Ahmad, M; Ottilie, S; Bullrich, F; Banks, S; Wang, Y; FernandesAlnemri, T; Croce, CM; Litwack, G; Tomaselli, KJ; Armstrong, RC; Alnemri, ES				Srinivasula, SM; Ahmad, M; Ottilie, S; Bullrich, F; Banks, S; Wang, Y; FernandesAlnemri, T; Croce, CM; Litwack, G; Tomaselli, KJ; Armstrong, RC; Alnemri, ES			FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN; PROTEIN; INTERACTS	We identified and cloned a novel human protein that contains FADD/Mortl death effector domain homology regions, designated FLAME-1, FLAME-1, although most similar in structure to Mch4 and Mch5, does not possess caspase activity but can interact specifically with FADD, Mch4, and Mch5. Interestingly, FLAME-1 is recruited to the Fas receptor complex and can abrogate Fas/TNFR-induced apoptosis upon expression in Fast/tumor necrosis factor-sensitive MCF-7 cells, possibly by acting as a dominant-negative inhibitor. These findings identify a novel endogenous control point that regulates Fas/TNFR1-mediated apoptosis.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107; IDUN PHARMACEUT,SAN DIEGO,CA 92121	Jefferson University; Jefferson University; Jefferson University			Young, Richard A/F-6495-2012; Alnemri, Emad S/B-4526-2010	Young, Richard A/0000-0001-8855-8647; 	NIA NIH HHS [AG 13487] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BULLRICH F, 1995, CANCER RES, V55, P1199; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HENKART PA, 1996, IMMUNITY, V4, P1955; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; SRINIVASULA SM, 1996, P NATL ACAD SCI USA, V93, P13706	16	292	307	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18542	18545		10.1074/jbc.272.30.18542	http://dx.doi.org/10.1074/jbc.272.30.18542			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228018	hybrid			2022-12-25	WOS:A1997XM34200009
J	Steel, DJ; Tieman, TL; Schwartz, JH; Feinmark, SJ				Steel, DJ; Tieman, TL; Schwartz, JH; Feinmark, SJ			Identification of an 8-lipoxygenase pathway in nervous tissue of Aplysia californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-CATALYZED TRANSFORMATION; ARACHIDONIC-ACID METABOLITES; LONG-TERM POTENTIATION; NORDIHYDROGUAIARETIC ACID; PRESYNAPTIC INHIBITION; PLEXAURA-HOMOMALLA; OOCYTE MATURATION; DENTATE GYRUS; K+-CHANNELS; 12-LIPOXYGENASE	Arachidonic acid is converted to (8R)-hydroperoxyeicosa-5,9,11,14-tetraenoic acid (8-HPETE) during incubations with homogenates of the central nervous system of the marine mollusc, Aplysia californica. 8-HPETE can be reduced to the corresponding hydroxy acid or be enzymatically converted to a newly identified metabolite, 8-ketoeicosa-5,9,11,14-tetraenoic acid (8-KETE). These metabolites were identified by high performance liquid chromatography, UV absorbance, and gas chromatography/mass spectrometry. Stereochemical analysis of the products demonstrate that the neuronal enzyme is an (8R)-lipoxygenase. Previously we have shown that the neurotransmitters, histamine and Phe-Met-Arg-Phe-amide, activate 12-lipoxygenase metabolism in isolated identified Aplysia neurons. We now show that acetylcholine activates the (8R)-lipoxygenase pathway within intact nerve cells. Thus, both (12S)- and (8R)-lipoxygenase co exist in intact Aplysia nervous tissue but are differentially activated by several neurotransmitters. The precise physiological role of the 8-lipoxygenase products is currently under investigation, but by analogy to the well-described 12-lipoxygenase pathway, we suggest that (8R)-HPETE and 8-KETE may serve as second messengers in Aplysia cholinoceptive neurons.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PHARMACOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University			Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029832] Funding Source: NIH RePORTER; NIMH NIH HHS [MH00921] Funding Source: Medline; NINDS NIH HHS [NS29832] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE M, 1995, BRAIN RES, V683, P200, DOI 10.1016/0006-8993(95)00375-Z; BABA A, 1989, J BIOL CHEM, V264, P15790; BELARDETTI F, 1989, NEURON, V3, P497, DOI 10.1016/0896-6273(89)90208-0; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BUNDY GL, 1986, J BIOL CHEM, V261, P747; BUTTNER N, 1989, NATURE, V342, P553, DOI 10.1038/342553a0; CARLEN PL, 1989, BRAIN RES, V497, P171, DOI 10.1016/0006-8993(89)90984-0; CHANG WC, 1992, J BIOL CHEM, V267, P3657; DELACLOS BF, 1987, PROSTAGLANDINS, V33, P315, DOI 10.1016/0090-6980(87)90016-5; EISENSTADT M, 1973, P NATL ACAD SCI USA, V70, P3371, DOI 10.1073/pnas.70.12.3371; FEINMARK SJ, 1992, ADV EXP MED BIOL, V318, P159; FEINMARK SJ, 1983, J CLIN INVEST, V72, P1839, DOI 10.1172/JCI111144; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; GLASGOW WC, 1986, J BIOL CHEM, V261, P200; HAMEDA H, 1994, AM J PHYSIOL, V266, pC243; HAMPSON AJ, 1992, BIOCHIM BIOPHYS ACTA, V1124, P143, DOI 10.1016/0005-2760(92)90090-I; HAWKINS DJ, 1987, J BIOL CHEM, V262, P7629; HERMAN RP, 1987, PROSTAGLANDINS, V34, P129; HILL EM, 1988, PROC R SOC SER B-BIO, V234, P455, DOI 10.1098/rspb.1988.0058; KEHOE J, 1972, J PHYSIOL-LONDON, V225, P115, DOI 10.1113/jphysiol.1972.sp009931; Liu B., 1996, Society for Neuroscience Abstracts, V22, P330; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MEIJER L, 1986, DEV BIOL, V114, P22, DOI 10.1016/0012-1606(86)90380-5; MEIJER L, 1986, J BIOL CHEM, V261, P7040; MEIJER L, 1986, PROSTAG LEUKOTR ESS, V23, P179, DOI 10.1016/0262-1746(86)90183-6; MURPHY RC, 1993, MASS SPECTROMETRY LI, P112; Nishiyama M., 1996, Society for Neuroscience Abstracts, V22, P1459; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PIOMELLI D, 1987, J NEUROSCI, V7, P3675; PIOMELLI D, 1988, J BIOL CHEM, V263, P16591; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P1721, DOI 10.1073/pnas.86.5.1721; POURPLANCHE C, 1994, J BIOL CHEM, V269, P31585; REYNAUD D, 1994, J BIOL CHEM, V269, P23976; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SCHWARTZ JH, 1987, METHOD ENZYMOL, V139, P277; SHAPIRO E, 1988, COLD SPRING HARB SYM, V53, P425, DOI 10.1101/SQB.1988.053.01.050; SONG WC, 1991, ARCH BIOCHEM BIOPHYS, V290, P427, DOI 10.1016/0003-9861(91)90562-W; TAUC L, 1967, PHYSIOL REV, V47, P521, DOI 10.1152/physrev.1967.47.3.521; Tieman T., 1996, Society for Neuroscience Abstracts, V22, P621; VOLTERRA A, 1988, P NATL ACAD SCI USA, V85, P7810, DOI 10.1073/pnas.85.20.7810; WATANABE T, 1993, EUR J BIOCHEM, V212, P605, DOI 10.1111/j.1432-1033.1993.tb17699.x; WILLIAMS JH, 1988, NEUROSCI LETT, V88, P81, DOI 10.1016/0304-3940(88)90319-9	45	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18673	18681		10.1074/jbc.272.30.18673	http://dx.doi.org/10.1074/jbc.272.30.18673			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228037	hybrid			2022-12-25	WOS:A1997XM34200028
J	Thompson, JF; Geoghegan, KF; Lloyd, DB; Lanzetti, AJ; Magyar, RA; Anderson, SM; Branchini, BR				Thompson, JF; Geoghegan, KF; Lloyd, DB; Lanzetti, AJ; Magyar, RA; Anderson, SM; Branchini, BR			Mutation of a protease-sensitive region in firefly luciferase alters light emission properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; ADENINE MOIETY; BIOLUMINESCENCE; SYNTHETASE; GENE	Luciferase (EC 1.13.12.7) from the North American firefly, Photinus pyralis, is widely used as a reporter enzyme in cell biology, One of its distinctive properties is a pronounced susceptibility to proteolytic degradation that causes luciferase to have a very short intracellular half-life, To define the structural basis for this behavior and possibly facilitate the design of more stable forms of luciferase, limited proteolysis studies were undertaken using trypsin and chymotrypsin to identify regions of the protein whose accessible and flexible character rendered them especially sensitive to cleavage. Regions of amino acid sequence 206-220 and 329-341 were found to be sensitive, and because the region around 206-220 had high homology with other luciferases, CoA ligases, and peptidyl synthetases, this region was selected for mutagenesis experiments intended to determine which of its amino acids were essential for activity, Surprisingly, many highly conserved residues including Ser(198), Ser(201), Thr(202), and Gly(203) could be mutated with little effect on the luminescent activity of P. pyralis luciferase, One mutation, however, S198T, caused several alterations in enzymatic properties including shifting the pH optimum from 8.1 to 8.7, lowering the K-m for Mg-ATP by a factor of 4 and increasing the half-time for light emission decay by a factor of up to 150. While the S198T luciferase was less active than wild type, activity could be restored by the introduction of the additional L194F and N197Y mutations. In addition to indicating the involvement of this region in ATP binding, these results provide a new form of the enzyme that affords a more versatile reporter system.	PFIZER INC,DIV CENT RES,DEPT MOL SCI,GROTON,CT 06340	Pfizer	Thompson, JF (corresponding author), CONNECTICUT COLL,DEPT CHEM,NEW LONDON,CT 06320, USA.			Thompson, John/0000-0001-8568-3311				AIRTH RL, 1958, BIOCHIM BIOPHYS ACTA, V27, P519, DOI 10.1016/0006-3002(58)90381-0; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Branchini BR, 1997, ARCH BIOCHEM BIOPHYS, V340, P52, DOI 10.1006/abbi.1997.9894; BRANCHINI BR, 1989, PHOTOCHEM PHOTOBIOL, V49, P689, DOI 10.1111/j.1751-1097.1989.tb08442.x; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; Dementieva EI, 1996, BIOCHEMISTRY-MOSCOW+, V61, P115; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORD SR, 1995, BBA-PROTEIN STRUCT M, V1252, P180, DOI 10.1016/0167-4838(95)00150-S; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; ORTIZ B, 1995, J PHOTOCH PHOTOBIO B, V29, P33; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; PAZZAGLI M, 1992, ANAL BIOCHEM, V204, P315, DOI 10.1016/0003-2697(92)90245-3; SELIGER HH, 1960, ARCH BIOCHEM BIOPHYS, V88, P136, DOI 10.1016/0003-9861(60)90208-3; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; VIVIANI VR, 1995, PHOTOCHEM PHOTOBIOL, V62, P490, DOI 10.1111/j.1751-1097.1995.tb02373.x; WOOD KV, 1995, PHOTOCHEM PHOTOBIOL, V62, P662, DOI 10.1111/j.1751-1097.1995.tb08714.x	18	55	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18766	18771		10.1074/jbc.272.30.18766	http://dx.doi.org/10.1074/jbc.272.30.18766			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228050	hybrid			2022-12-25	WOS:A1997XM34200041
J	Yan, SZ; Huang, ZH; Rao, VD; Hurley, JH; Tang, WJ				Yan, SZ; Huang, ZH; Rao, VD; Hurley, JH; Tang, WJ			Three discrete regions of mammalian adenylyl cyclase form a site for G(s alpha) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN; ALPHA; FORSKOLIN; MODELS	The interaction between the alpha subunit of G protein G(s) (G(s alpha)) and the two cytoplasmic domains of adenylyl cyclase (C-1 and C-2) is a key step in the stimulation of cAMP synthesis by hormones, Mutational analysis reveals that three discrete regions in the primary sequence of adenylyl cyclase affect the EC50 values for G(s alpha) activation and thus are the affinity determinants of G(s alpha). Based on the three-dimensional structure of C-2 forskolin dimer, these three regions (C-2, alpha 2, C-2 alpha 3/beta 4, and C-1 beta 1) are close together and form a negatively charged and hydrophobic groove the width of an alpha helix that can accommodate the positively charged adenylyl cyclase binding region of G(s alpha). Two mutations in the C-2 alpha 3/beta 4 region decrease the V-max values of G(s alpha) activation without an increase in the EC50 values, Since these three regions are distal to the catalytic site, the likely mechanism for G(s alpha) activation is to modulate the structure of the active site by controlling the orientation of the C-2 alpha 2 and alpha 3/beta 4 structures.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; NIDDK, MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Tang, Wei-Jen/0000-0002-8267-8995	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53459] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; HERN J, 1990, METHOD ENZYMOL, V183, P626; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1997, IN PRESS ADV 2 MESSE; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	28	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18849	18854		10.1074/jbc.272.30.18849	http://dx.doi.org/10.1074/jbc.272.30.18849			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228061	hybrid			2022-12-25	WOS:A1997XM34200052
J	Foresti, R; Clark, JE; Green, CJ; Motterlini, R				Foresti, R; Clark, JE; Green, CJ; Motterlini, R			Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells - Involvement of superoxide and peroxynitrite anions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; RELAXING FACTOR; HYDROGEN-PEROXIDE; UVA RADIATION; RAT-LIVER; GLUTATHIONE; ACCUMULATION; PROTEINS; NO; HYDROXOCOBALAMIN	Thiols are very important antioxidants that protect cells against oxidative insults. Recently, a different and new physiological role has been defined for these compounds because of their involvement in nitric oxide (NO) binding and transport in biological systems, in view of these characteristics, we examined the effect of thiols and NO on the expression of the inducible form of heme oxygenase (HO-1), a stress protein that degrades heme to carbon monoxide and biliverdin. Cultured bovine aortic endothelial cells exposed to the NO donors sodium nitroprusside (SNP) and S-nitroso-N-acetylpenicillamine (SNAP) resulted in increased heme oxygenase activity and HO-1 expression. Co-incubation with N-acetylcysteine, a precursor of glutathione synthesis, significantly attenuated heme oxygenase induction by SNP and SNAP, and a reduction in heme oxygenase activity was also observed when cells were preincubated with N-acetylcysteine for 16 h prior to exposure to NO donors. This effect appears to be associated with NO stabilization by thiols through the formation of S-nitroso-thiols. Hydroxocobalamin, a specific NO scavenger, significantly decreased endothelial heme oxygenase activity, indicating a direct involvement of NO released by NO donors to regulate the expression of this stress protein. Moreover, superoxide anion (0(-).(2)) and its reaction product with NO, peroxynitrite (ONOO-), were found to partially contribute to the observed NO-mediated activation of endothelial heme oxygenase. Thus, we suggest the existence of a dynamic equilibrium among free NO, 0(-).(2), and endogenous glutathione, which might constitute an interactive signaling mechanism modulating stress and adaptive responses in tissues.			Foresti, R (corresponding author), NORTHWICK PK INST MED RES,DEPT SURG RES,HARROW HA1 3UJ,MIDDX,ENGLAND.		Motterlini, Roberto/Q-1890-2019; Motterlini, Roberto/G-2489-2013	Motterlini, Roberto/0000-0003-2684-2612; Motterlini, Roberto/0000-0003-2684-2612; foresti, roberta/0000-0002-0836-7937				APPLEGATE LA, 1991, CANCER RES, V51, P974; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRUNE B, 1987, MOL PHARMACOL, V32, P497; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; FEELISCH M, 1996, METHODS NITRIC OXIDE, P521; Hara E, 1996, BIOCHEM BIOPH RES CO, V224, P153, DOI 10.1006/bbrc.1996.0999; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HENRY PJ, 1989, BRIT J PHARMACOL, V98, P757, DOI 10.1111/j.1476-5381.1989.tb14603.x; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KEYSE SM, 1990, CARCINOGENESIS, V11, P787, DOI 10.1093/carcin/11.5.787; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KHAN MT, 1987, FASEB J, V46, P385; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; Lilley E, 1996, BRIT J PHARMACOL, V119, P432, DOI 10.1111/j.1476-5381.1996.tb16004.x; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; MAINES MD, 1993, MOL CELL NEUROSCI, V4, P389, DOI 10.1006/mcne.1993.1049; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MALYSHEV IY, 1995, FEBS LETT, V370, P159, DOI 10.1016/0014-5793(95)00801-F; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Motterlini R, 1996, BIOCHEM BIOPH RES CO, V225, P167, DOI 10.1006/bbrc.1996.1148; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648, DOI 10.1152/ajpheart.1995.269.2.H648; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; Motterlini Roberto, 1996, P74; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RAJANAYAGAM MAS, 1993, BRIT J PHARMACOL, V108, P3, DOI 10.1111/j.1476-5381.1993.tb13429.x; RIZZARDINI M, 1994, BIOCHEM J, V304, P477, DOI 10.1042/bj3040477; ROCHELLE LG, 1995, J PHARMACOL EXP THER, V275, P48; ROCHELLE LG, 1994, TOXICOL APPL PHARM, V128, P123, DOI 10.1006/taap.1994.1189; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; UTZ J, 1991, BIOCHEM PHARMACOL, V41, P1195, DOI 10.1016/0006-2952(91)90658-R; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352	50	275	282	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18411	18417		10.1074/jbc.272.29.18411	http://dx.doi.org/10.1074/jbc.272.29.18411			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218484	hybrid			2022-12-25	WOS:A1997XL73500074
J	Mukhopadhyay, S; Shankar, S; Walden, W; Chakrabarty, AM				Mukhopadhyay, S; Shankar, S; Walden, W; Chakrabarty, AM			Complex formation of the elongation factor Tu from Pseudomonas aeruginosa with nucleoside diphosphate kinase modulates ribosomal GTP synthesis and peptide chain elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS	The elongation factor Tu (EF-Tu) from Pseudomonas aeruginosa was purified as a 45-kDa polypeptide that forms a complex with both the 12- and 16-kDa forms of nucleoside-diphosphate kinase (Ndk) and predominantly synthesizes GTP, 70 S ribosomes of P. aeruginosa predominantly synthesize GTP, which is inhibited in presence of anti-Ndk antibodies, Anti-EF-Tu antibodies change the specificity of ribosomal GTP synthesis to all nucleoside triphosphate synthesis, Ndk has been shown to be a part of 30 S ribosomes, whereas EF-Tu is found to be associated with the 50 S ribosomal subunit, These data indicate that GTP synthesis in the ribosome is modulated both by Ndk and by EF-Tu, Peptide chain elongation as measured by polymerization of Phe-tRNA on a poly(U) template in presence of GDP can be inhibited by anti Ndk antibodies and restored by the addition of GTP, Anti-EF-Tu antibodies similarly inhibit peptide chain elongation by P. aeruginosa ribosomes in the in vitro translation assay; however, this inhibition cannot be overcome by adding back GTP, Because the purified EF-Tu.16-kDa Ndk complex predominantly synthesizes GTP, it seems likely that this complex is a significant source of GTP for translational elongation in protein biosynthesis.	UNIV ILLINOIS, COLL MED, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031546, R01AI016790, R37AI016790] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31546-04, AI-16790-16] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER C, 1995, J BIOL CHEM, V270, P14541, DOI 10.1074/jbc.270.24.14541; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; Cashel M., 1994, METH MOL G, V3, P341; Chopade BA, 1997, J BACTERIOL, V179, P2181, DOI 10.1128/jb.179.7.2181-2188.1997; EHRENBERG M, 1990, RIBOSOME, P373; GARRILOVA LP, 1974, METHODS ENZUYMOL, V30, P452; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLINKER JF, 1995, BIOCHEM BIOPH RES CO, V209, P575, DOI 10.1006/bbrc.1995.1539; MARCH PE, 1992, MOL MICROBIOL, V6, P1253, DOI 10.1111/j.1365-2958.1992.tb00845.x; MOORE PB, 1995, SCIENCE, V270, P1453, DOI 10.1126/science.270.5241.1453; PILLUTLA RC, 1995, J BACTERIOL, V177, P2194, DOI 10.1128/jb.177.8.2194-2196.1995; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; Shankar S, 1996, J BACTERIOL, V178, P1777, DOI 10.1128/jb.178.7.1777-1781.1996; Shankar S, 1997, MOL MICROBIOL, V24, P477, DOI 10.1046/j.1365-2958.1997.3491724.x; SONNEMANN J, 1995, BIOCHEM BIOPH RES CO, V209, P490, DOI 10.1006/bbrc.1995.1528; SPIRIN AS, 1989, BIOL CELL, V66, P215, DOI 10.1016/0248-4900(89)90174-3; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; Sundin GW, 1996, MOL MICROBIOL, V20, P965, DOI 10.1111/j.1365-2958.1996.tb02538.x; ZHANG YX, 1994, J BACTERIOL, V176, P1184, DOI 10.1128/JB.176.4.1184-1187.1994	19	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17815	17820		10.1074/jbc.272.28.17815	http://dx.doi.org/10.1074/jbc.272.28.17815			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211936	hybrid			2022-12-25	WOS:A1997XK16500079
J	Shen, JR; Ikeuchi, M; Inoue, Y				Shen, JR; Ikeuchi, M; Inoue, Y			Analysis of the psbU gene encoding the 12-kDa extrinsic protein of photosystem II and studies on its role by deletion mutagenesis in Synechocystis sp. PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-STABILIZING PROTEIN; OXYGEN-EVOLUTION; PHORMIDIUM-LAMINOSUM; 33-KDA PROTEIN; SP PCC-6803; CYANOBACTERIAL MUTANTS; CYTOCHROME C-550; PARTICLES; POLYPEPTIDE; RECONSTITUTION	The gene encoding the 1a-kDa extrinsic protein of photosystem II from Synechocystis sp, PCC 6803 was cloned based on N-terminal sequence of the mature protein, This gene, named psbU, encodes a polypeptide of 131 residues, the first 36 residues of which were absent in the mature protein and thus served as a transit peptide required for its transport into the thylakoid lumen, A psbU gene deletion mutant grew photoautotrophically in normal BG11 medium at almost the same rate as that of the wild type strain, This mutant, however, grew apparently slower than the wild type did upon depletion of Ca2+ or Cl- from the growth medium, Photosystem II oxygen evolution decreased to 81% in the mutant as compared with that in the wild type, and the thermoluminescence B- and Q-bands shifted to higher temperatures accompanied by an increase in the Q-band intensity, These results indicate that the 12-kDa protein is not essential for oxygen evolution but may play a role in optimizing the ion (Ca2+ and Cl-) environment and maintaining a functional structure of the cyanobacterial oxygen-evolving complex, In addition, a double deletion mutant lacking cytochrome c-550 and the 1a-kDa protein grew photoautotrophically with a phenotype identical to that of the single deletion mutant of cytochrome c-550, This supports our previous biochemical results that the 1a-kDa protein cannot bind to photosystem II in the absence of cytochrome c-550 (Shen, J.-R., and Inoue, Y. (1993) Biochemistry 32, 1825-1832).	RIKEN, INST PHYS & CHEM RES, PHOTOSYNTHESIS RES LAB, WAKO, SAITAMA 35101, JAPAN; UNIV TOKYO, DEPT BIOL, TOKYO 153, JAPAN	RIKEN; University of Tokyo	Shen, JR (corresponding author), RIKEN, INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, WAKO, SAITAMA 35101, JAPAN.		Shen, Jian-Ren/B-2558-2011					BOCKHOLT R, 1991, FEBS LETT, V294, P59, DOI 10.1016/0014-5793(91)81343-7; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; Enami I, 1995, BBA-BIOENERGETICS, V1232, P208, DOI 10.1016/0005-2728(95)00122-0; ENGELS DH, 1994, PHOTOSYNTH RES, V42, P227, DOI 10.1007/BF00018265; HAN KC, 1994, FEBS LETT, V355, P121, DOI 10.1016/0014-5793(94)01182-6; Inoue Y, 1996, BIOPHYSICAL TECHNIQU, P93; Kaneko T, 1996, DNA Res, V3, P109; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; ONO T, 1986, BIOCHIM BIOPHYS ACTA, V850, P380, DOI 10.1016/0005-2728(86)90194-5; ONO T, 1984, FEBS LETT, V166, P381, DOI 10.1016/0014-5793(84)80117-9; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; ROLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V973, P220, DOI 10.1016/S0005-2728(89)80425-6; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SHEN JR, 1993, J BIOL CHEM, V268, P20408; SHEN JR, 1995, BIOCHEMISTRY-US, V34, P12661, DOI 10.1021/bi00039a023; SHEN JR, 1995, J BIOL CHEM, V270, P6901, DOI 10.1074/jbc.270.12.6901; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; STEWART AC, 1985, FEBS LETT, V193, P175, DOI 10.1016/0014-5793(85)80145-9; STEWART AC, 1985, BIOCHIM BIOPHYS ACTA, V808, P353, DOI 10.1016/0005-2728(85)90145-8; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALLACE TP, 1989, MOL GEN GENET, V216, P334, DOI 10.1007/BF00334373; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YU JJ, 1990, PLANT CELL, V2, P315	30	67	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17821	17826		10.1074/jbc.272.28.17821	http://dx.doi.org/10.1074/jbc.272.28.17821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211937	hybrid			2022-12-25	WOS:A1997XK16500080
J	Vaccaro, AM; Tatti, M; Ciaffoni, F; Salvioli, R; Barca, A; Scerch, C				Vaccaro, AM; Tatti, M; Ciaffoni, F; Salvioli, R; Barca, A; Scerch, C			Effect of saposins A and C on the enzymatic hydrolysis of liposomal glucosylceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BETA-GLUCOSIDASE; ACTIVATOR PROTEIN; GAUCHERS-DISEASE; PHOSPHATIDYLSERINE LIPOSOMES; BILAYER CURVATURE; BINDING; DEFICIENCY; GLUCOCEREBROSIDASE; FIBROBLASTS; VESICLES	The degradation of glucosylceramide in lysosomes is accomplished by glucosylceramidase with the assistance of, at least, another protein, saposin C (Sap C), which is generated from a large precursor together with three other similar proteins, saponins A, B, and D. In the present study, we have examined the effects of saposins on the enzymatic hydrolysis of glucosylceramide inserted in large and small phospholid liposomes. The glucosylceramide contained in large unilamellar vesicles (LUV) was degraded by glucosylceramidase at a rate 7-8-fold lower than glucosylceramide inserted in small unilamellar vesicles (SUV). The separate addition of either Sap A of Sap C to the LUV system partially stimulated the sphingolipid degradation while saposins B and D had no effect. In the presence of both Sap A and Sap C, the rate of sphingolipid degradation was higher than the sum of the rates with the two saposins individually, indicating synergism in their actions. The stimulatory effect of the two saposins depended on the incorporation of an acidic phospholipid such as phosphatidylserine (PS) into LUV. The characteristics of glucosylceramidase activation by Sap C were different from those of Sap A. Sap C increased the rate of hydrolysis of both the artificial water soluble substate, 4-methylumbelliferyl-beta-D-glucopyranoside, and the lipid substrate, glucosylceramide, while Sap A only stimulated degradation of the sphingolipid. Also the binding properties of Saps A and C were markedly different. At acidic pH values, Sap C bound to PS-containing LUV and promoted the association of glucosylceramidase with the membrane. In contrast, Sap A had poor affinity for the membrane even in the presence of glucosylceramide; moreover, Sap A did not potentiate the capacity of Sap C to mediate glucosylceramidase binding. In conclusion, our results show that both Sap A and Sap C are required for maximal hydrolysis of glucosylceramide inserted in PS-containing LUV, that their effects are synergistic, and that their mode of action is different. Sap C is responsible for the membrane binding of glucosylceramide, while Sap A stimulation is possibly related to its effect on the conformation of the enzyme. It can be envisaged that Sap A in conjunction with Sap C might have a physiological role in glucosylceramide degradation.			Vaccaro, AM (corresponding author), IST SUPER SANITA,DEPT METAB & PATHOL BIOCHEM,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		tatti, Massimo/N-1382-2017					BASU A, 1984, J BIOL CHEM, V259, P1714; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CURATOLO W, 1986, J BIOL CHEM, V261, P7177; FABBRO D, 1991, J BIOL CHEM, V266, P15021; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GLEW RH, 1988, LAB INVEST, V58, P5; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCMASTER MC, 1977, J LABELLED COMPD RAD, V13, P353, DOI 10.1002/jlcr.2580130309; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MURRAY GJ, 1985, ANAL BIOCHEM, V147, P301, DOI 10.1016/0003-2697(85)90276-3; NIR S, 1982, BIOCHIM BIOPHYS ACTA, V688, P275, DOI 10.1016/0005-2736(82)90604-6; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; OHKI S, 1984, J MEMBRANE BIOL, V77, P265, DOI 10.1007/BF01870574; PATON BC, 1989, EUR J CELL BIOL, V51, P157; QI XY, 1994, J BIOL CHEM, V269, P16746; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SANO A, 1988, J BIOL CHEM, V263, P19597; SARMIENTOS F, 1986, EUR J BIOCHEM, V160, P527, DOI 10.1111/j.1432-1033.1986.tb10071.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; VACCARO AM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P239, DOI 10.1016/0167-4838(92)90208-U; VACCARO AM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P55, DOI 10.1016/0005-2736(93)90024-T; VACCARO AM, 1993, FEBS LETT, V336, P159, DOI 10.1016/0014-5793(93)81631-9; VACCARO AM, 1990, BIOCHIM BIOPHYS ACTA, V1033, P73, DOI 10.1016/0304-4165(90)90196-4; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; VANDONGEN JM, 1985, EUR J CELL BIOL, V39, P179; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223	35	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16862	16867		10.1074/jbc.272.27.16862	http://dx.doi.org/10.1074/jbc.272.27.16862			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201993	hybrid			2022-12-25	WOS:A1997XH44600025
J	Gu, HH; Griffin, JD; Neel, BG				Gu, HH; Griffin, JD; Neel, BG			Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASE SYP; COLONY-STIMULATING FACTOR; TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; MAP KINASE; PHOSPHORYLATION; INSULIN; SH-PTP2; SHPTP2; IDENTIFICATION	Multiple studies have demonstrated an important role for the Src homology 2-containing tyrosine phosphatase 2 (SHP-2) in receptor tyrosine kinase-regulated cell proliferation and differentiation. Recent studies have identified potential SHP-2 substrates which mediate these effects. SHP-2 also is implicated in several cytokine receptor signaling pathways and in Bcr-Abl transformation. However, its precise role and targets in normal and abnormal hematopoietic cells remain to be determined. We identified two novel tyrosyl-phosphorylated proteins associated with SHP-2 in hematopoietic cells. The first, a 97-kDa cytosolic protein (p97), associates inducibly with SHP-2 upon cytokine stimulation and constitutively in Bcr-Abl-transformed cells. In contrast, p135, a 135-kDa transmembrane glycoprotein, forms a distinct complex with SHP-2, independent of cytokine stimulation or Bcr-Abl transformation. Far Western analysis reveals that SHP-2, via its Src homology 2 domains, can interact directly with either protein. In vitro dephosphorylation experiments, as well as transient transfection studies using wild type and mutant SHP-2 constructs, suggest that p97 and p135 also are SHP-2 substrates. Our results indicate that SHP-2 forms at least two separate complexes in hematopoietic cells and point to new potential SHP-2 targets.	HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Gu, HH (corresponding author), BETH ISRAEL HOSP, DEPT MED,DIV HEMATOL ONCOL,CANC BIOL PROGRAM, HIM 1043, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NCI NIH HHS [R01 CA 49152, CA 36167] Funding Source: Medline; NIDDK NIH HHS [P01-DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049152, R37CA036167, R01CA036167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 1996, CELL, V85, P15; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Allard JD, 1996, DEVELOPMENT, V122, P1137; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cleghon V, 1996, GENE DEV, V10, P566, DOI 10.1101/gad.10.5.566; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MIYAJIMA A, 1993, BLOOD, V82, P1960; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sattler M, 1996, ONCOGENE, V12, P839; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Van Etten R A, 1992, Cancer Treat Res, V63, P167; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16421	16430		10.1074/jbc.272.26.16421	http://dx.doi.org/10.1074/jbc.272.26.16421			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195950	hybrid			2022-12-25	WOS:A1997XG01900054
J	Li, M; DeBlas, AL				Li, M; DeBlas, AL			Coexistence of two beta subunit isoforms in the same gamma-aminobutyric acid type A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA(A) RECEPTOR; RAT-BRAIN; A RECEPTORS; MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; BENZODIAZEPINE RECEPTOR; FUNCTIONAL EXPRESSION; HETEROGENEITY; GABA(A)-RECEPTOR; SUBPOPULATIONS	Three novel subunit-specific antisera to the beta(1), beta(2), and beta(3) subunits of rat gamma-aminobutyric acid type A (GABA(A)) receptors have been used to study the native receptor in the rat brain. Affinity-purified anti-beta(1), anti-beta(2), and anti-beta(2) antibodies recognized in immunoblots protein bands of 57, 55, and 57 kDa, respectively. Quantitative immunoprecipitation of solubilized GABA(A) receptors from various rat brain regions showed that the beta(3), subunit was the most abundant isoform in cerebellum (in 96% of the GABA(A) receptors) and cerebral cortex (64%) but that it was the least abundant isoform in hippocampus (44%). The beta(3) subunit was found most abundant in hippocampus (64%) followed by cerebral cortex (48%) and cerebellum (33%). The beta(1) subunit was present in a very small proportion of the cerebellar GABA(A) receptors (3%), but it was present in a high proportion of the GABA(A) receptors from the hippocampus (49%) and cerebral cortex (32%). Quantitative receptor immunoprecipitation or immunopurification followed by immunoblotting experiments have revealed the existence of colocalization of two different beta subunit isoforms in a significant proportion of the brain GABA(A) receptors. Thus, in the rat cerebral cortex 33% of the GABA(A) receptors have both beta(2) and beta(3) subunits, and 19% of the receptors have both beta(2) and beta(3) subunits. The extent of colocalization of beta subunit isoforms varied among brain regions, being highest in hippocampus and lowest in cerebellum. These and other results taken together suggest that the number of alpha, beta, and gamma subunits (stoichiometry) in the brain GABA(A) receptor pentamers might not be unique. It might vary depending on receptor type.	UNIV MISSOURI,SCH BIOL SCI,DIV MOL BIOL & BIOCHEM,KANSAS CITY,MO 64110	University of Missouri System; University of Missouri Kansas City					NINDS NIH HHS [NS17708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; BENKE D, 1994, J BIOL CHEM, V269, P27100; BENKE D, 1991, J BIOL CHEM, V266, P4478; BUCHSTALLER A, 1991, FEBS LETT, V287, P27, DOI 10.1016/0014-5793(91)80008-Q; Chang YC, 1996, J NEUROSCI, V16, P5415; DEBLAS AL, 1984, BRAIN RES, V322, P277, DOI 10.1016/0006-8993(84)90118-5; DeBlas AL, 1996, MOL NEUROBIOL, V12, P55, DOI 10.1007/BF02740747; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; EBERT B, 1994, MOL PHARMACOL, V46, P957; FERNANDO LP, 1995, MOL BRAIN RES, V28, P94, DOI 10.1016/0169-328X(94)00188-K; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; HADINGHAM KL, 1993, MOL PHARMACOL, V44, P1211; HUH KH, 1995, MOL PHARMACOL, V48, P666; HUH KH, 1996, EUR J PHARMACOL, V301, P225; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; KHAN ZU, 1994, J NEUROCHEM, V63, P1466; KHAN ZU, 1994, J NEUROCHEM, V63, P371; Khan ZU, 1996, J NEUROCHEM, V66, P685; KHAN ZU, 1993, J NEUROCHEM, V60, P961, DOI 10.1111/j.1471-4159.1993.tb03243.x; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MACHU TK, 1993, J NEUROCHEM, V61, P2034, DOI 10.1111/j.1471-4159.1993.tb07439.x; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MORENO JI, 1994, J COMP NEUROL, V350, P260, DOI 10.1002/cne.903500209; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204; POLLARD S, 1993, J BIOL CHEM, V268, P3753; POLLARD S, 1991, FEBS LETT, V295, P81, DOI 10.1016/0014-5793(91)81390-T; PRICHETT DB, 1989, SCIENCE, V245, P1389; QUIRK K, 1994, MOL PHARMACOL, V45, P1061; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SMITH GB, 1990, MOL PHARMACOL, V37, P497; STEPHENSON FA, 1995, BIOCHEM J, V310, P1; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VITORICA J, 1988, J NEUROSCI, V8, P615; WAFFORD KA, 1994, NEURON, V12, P775, DOI 10.1016/0896-6273(94)90330-1; WISDEN W, 1992, J NEUROSCI, V12, P1040; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; ZHANG JH, 1991, J COMP NEUROL, V303, P637, DOI 10.1002/cne.903030409	45	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16564	16569		10.1074/jbc.272.26.16564	http://dx.doi.org/10.1074/jbc.272.26.16564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195967	hybrid			2022-12-25	WOS:A1997XG01900071
J	Hu, JS; Hastings, GA; Cherry, S; Gentz, R; Ruben, S; Coleman, TA				Hu, JS; Hastings, GA; Cherry, S; Gentz, R; Ruben, S; Coleman, TA			A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial and smooth muscle cells	FASEB JOURNAL			English	Article						COS-7 cells; vascular smooth muscle cells; PlGF; platelet-derived growth factor; VEGF-related protein	PLACENTA GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PERMEABILITY FACTOR; MITOGEN; IDENTIFICATION; VASCULOGENESIS; BIOACTIVITY; PROTEIN; BINDING; FLT-1	By high throughput sequencing, we have identified a cDNA encoding a polypeptide related to vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) in the VEGF/PDGF PDGF gene family, It is designated vascular endothelial growth factor 2 (VEGF-2), Similar to VEGF, expression of VEGF-2 mRNA is abundant in vascular smooth muscle cells and several highly vascularized tissues, VEGF-2 protein is expressed as a secreted 52 kDa precursor as well as the 30 kDa amino-terminal and 27 kDa carboxy-terminal cleavage products, The latter two cleavage products are linked via a disulfide bridge (or bridges) and can be copurified, Using copurified 30 and 27 kDa proteins, the effect of VEGF-2 on growth of several cell types, including vascular endothelial and smooth muscle cells, was determined, Our results demonstrate that VEGF-2 protein stimulates the growth of human vascular endothelial cells but inhibits growth of human aortic smooth muscle cells induced by platelet-derived growth factor, These studies establish VEGF-2 as a novel regulator for growth of vascular endothelial and smooth muscle cells.	HUMAN GENOME SCI INC,DEPT PROT EXPRESS,ROCKVILLE,MD 20850	GlaxoSmithKline; Human Genome Sciences Inc	Hu, JS (corresponding author), HUMAN GENOME SCI INC,DEPT PROT THERAPEUT,9410 KEY W AVE,ROCKVILLE,MD 20850, USA.							ADAMS MD, 1995, NATURE, V377, P3; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM SS, 1990, GENE, V88, P133, DOI 10.1016/0378-1119(90)90024-L; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Joukov V, 1996, EMBO J, V15, P290; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARK JE, 1994, J BIOL CHEM, V269, P25646; PAULSSON G, 1990, J MOL BIOL, V221, P331; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Sambrook J., 2002, MOL CLONING LAB MANU; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SHIFREN JL, 1994, J CLIN ENDOCR METAB, V79, P316, DOI 10.1210/jc.79.1.316; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	32	17	26	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					498	504		10.1096/fasebj.11.6.9194531	http://dx.doi.org/10.1096/fasebj.11.6.9194531			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194531				2022-12-25	WOS:A1997XE40400013
J	Baskaran, R; Chiang, GG; Mysliwiec, T; Kruh, GD; Wang, JYJ				Baskaran, R; Chiang, GG; Mysliwiec, T; Kruh, GD; Wang, JYJ			Tyrosine phosphorylation of RNA polymerase II carboxyl-terminal domain by the Abl-related gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ABL; CELL-CYCLE; ACTIVATING KINASE; BINDING; TRANSCRIPTION; ENCODES; MICE; DNA; CRK	The largest subunit of RNA polymerase II contains a C-terminal repeated domain (CTD) thai is the site of phosphorylation by serine (threonine) and tyrosine kinases. Phosphorylation of the CTD is correlated with transcription elongation. A number of different kinases have previously been shown to phosphorylate the CTD; among them is a nuclear tyrosine kinase encoded by the c-abl proto-oncogene. The processive and high stoichiometric phosphorylation of RNA polymerase II by c-Abl requires the tyrosine kinase, the SH2 domain, and a CTD-interacting domain (CTD-ID) in the Abl protein. The physiological tyrosine phosphorylation of RNA polymerase II by c-Abl in DNA damage response has previously been demonstrated. Basal tyrosine phosphorylation of RNA polymerase II, however, is observed in cells derived from abl-deficient mice, indicating the existence of other CTD tyrosine kinases. hi this report, we Show that the tyrosine kinase encoded by an Abl-related gene (Arg) also phosphorylates the CTD in vitro and in transfected cells. The SH2 and kinase domain of Arg are 95% identical to that of c-Abl. However, these two proteins Share only 29% identity in the large C-terminal region, Interestingly, a CTD-ID is also found in the C-terminal region of Arg. Mapping studies and sequence analysis have led to the identification of the CTD-that is highly conserved among the divergent C-terminal regions of Abl and Arg. These results indicate that tyrosine phosphorylation of RNA polymerase II CTD could be catalyzed by either c-Abl or Arg kinase.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111	University of California System; University of California San Diego; University of California System; University of California San Diego; Fox Chase Cancer Center				Chiang, Gary/0000-0003-3004-7400	NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, R37 CA043054, CA-43054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Baskaran R, 1996, MOL CELL BIOL, V16, P3361; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P838; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; Mysliwiec T, 1996, ONCOGENE, V12, P631; PEREGO R, 1991, ONCOGENE, V6, P1899; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang BL, 1996, ONCOGENE, V13, P193; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	32	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18905	18909		10.1074/jbc.272.30.18905	http://dx.doi.org/10.1074/jbc.272.30.18905			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228069	hybrid			2022-12-25	WOS:A1997XM34200060
J	Kapila, YL; Niu, JJ; Johnson, PW				Kapila, YL; Niu, JJ; Johnson, PW			The high affinity heparin-binding domain and the V region of fibronectin mediate invasion of human oral squamous cell carcinoma cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FN-C/H-V; SYNTHETIC PEPTIDE; SULFATE PROTEOGLYCAN; ADHESION; INTEGRIN; RECEPTOR; MOTILITY; ALPHA-4-BETA-1; IDENTIFICATION; METASTASIS	Fibronectin is an extracellular matrix molecule composed of repeating subunits that create functional domains. These domains contain multiple binding sites for heparin and for various cell-surface receptors that modulate cell function. To examine the role that the high affinity heparin-binding region and the alternatively spliced V region of fibronectin play in tumor invasion, we expressed and purified four complementary recombinant fibronectin proteins. These proteins either included or excluded the alternatively spliced V region and contained either a mutated, non-functional high affinity heparin-binding domain (Hep(-)) or an unmutated heparin-binding domain (Hep(+)), Cultured oral squamous cell carcinoma cells were assayed for invasion into a Matrigel/collagen matrix supplemented with these four purified recombinant proteins, and for spreading and motility on plastic, Increased invasion was observed in gels supplemented with the V(-)Hep(+) protein when compared with the V(-)Hep(-) protein. Inclusion of the V region in the proteins enhanced the invasion and migration associated with both Hep(+) and Hep(-) proteins, whereas cell spreading was enhanced with the Hep(+) recombinant proteins, These data demonstrate that both the high affinity heparin-binding domain and the V region of fibronectin play important roles in invasion, motility, and spreading of oral squamous cell carcinoma cells.	UNIV CALIF SAN FRANCISCO, SCH DENT, DEPT STOMATOL, DIV PERIODONTOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Kapila, Yvonne/AAG-5418-2021		NIDCR NIH HHS [D15-DE 00344-03] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; HAUGEN PK, 1992, J NEUROSCI, V12, P2034; HYNES RO, 1990, FIBRONECTINS, P115; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; JANIAK M, 1994, EXP HEMATOL, V22, P559; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; Mohri H, 1996, EXP CELL RES, V222, P326, DOI 10.1006/excr.1996.0042; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; PETERS JH, 1995, CELL ADHES COMMUN, V3, P67, DOI 10.3109/15419069509081278; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Regezi J, 1993, ORAL PATHOLOGY CLIN, P77; SAIKI I, 1993, JPN J CANCER RES, V84, P326, DOI 10.1111/j.1349-7006.1993.tb02874.x; SAIKI I, 1990, JPN J CANCER RES, V81, P1003, DOI 10.1111/j.1349-7006.1990.tb03338.x; SONCIN F, 1994, J BIOL CHEM, V269, P8999; VLODAVSKY I, 1992, ADV EXP MED BIOL, V313, P317; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAHL SM, 1994, J CLIN INVEST, V94, P655, DOI 10.1172/JCI117382; WILKE MS, 1993, J INVEST DERMATOL, V101, P43, DOI 10.1111/1523-1747.ep12358823; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YONEDA J, 1994, JPN J CANCER RES, V85, P723, DOI 10.1111/j.1349-7006.1994.tb02421.x; YONEDA J, 1995, EXP CELL RES, V217, P169, DOI 10.1006/excr.1995.1076; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	30	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18932	18938		10.1074/jbc.272.30.18932	http://dx.doi.org/10.1074/jbc.272.30.18932			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228073	hybrid			2022-12-25	WOS:A1997XM34200064
J	Rapaport, D; Neupert, W; Lill, R				Rapaport, D; Neupert, W; Lill, R			Mitochondrial protein import - Tom40 plays a major role in targeting and translocation of preproteins by forming a specific binding site for the presequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; OUTER-MEMBRANE; INTERMEMBRANE SPACE; RECEPTOR COMPLEX; INNER MEMBRANE; CELL VIABILITY; CROSS-LINKING; MACHINERY; INSERTION; MATRIX	During preprotein transport across the mitochondrial outer membrane, the N-terminal presequence initially binds to a surface-exposed site, termed cis site, of the protein translocation complex of this membrane (the TOM complex). The presequence then moves into the translocation pore and becomes exposed at the intermembrane space side. Membrane passage is driven by specific interaction of the presequence with the trans site, We have used chemical cross-linking to identify components in the vicinity of the translocating presequence. Preproteins bound to the surface-exposed cis site can be cross-linked via their N-terminal presequence to Tom20 and Tom22, demonstrating their direct association with this part of the preprotein, In addition, the presequence establishes an early contact to Tom40, a membrane-embedded protein of the TOM complex. Upon further entry of the preprotein into the translocation pore, the presequence loses its contact with Tom20/Tom22, but remains in firm association with Tom40, Our study suggests that Tom40 plays an important function in guiding the presequence of a preprotein across the mitochondrial outer membrane, We propose that Tom40 forms a major part of the traits presequence binding site.	UNIV MARBURG, INST ZYTOBIOL, D-35033 MARBURG, GERMANY; UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY	Philipps University Marburg; University of Munich				Lill, Roland/0000-0002-8345-6518				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brunner M, 1995, COLD SPRING HARB SYM, V60, P619, DOI 10.1101/SQB.1995.060.01.066; COURT DA, 1996, MOL CELL BIOL, V16, P4034; GAIKWAD AS, 1994, J BIOL CHEM, V269, P6437; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Komiya T, 1996, J BIOL CHEM, V271, P22105, DOI 10.1074/jbc.271.36.22105; Kouranov A, 1996, J BIOL CHEM, V271, P31009, DOI 10.1074/jbc.271.49.31009; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LILL R, 1996, ADV MOL CELL BIOL, P51; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; Nakai M, 1995, J BIOL CHEM, V270, P30571, DOI 10.1074/jbc.270.51.30571; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; TRANEL PJ, 1995, EMBO J, V14, P1436; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x	38	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18725	18731		10.1074/jbc.272.30.18725	http://dx.doi.org/10.1074/jbc.272.30.18725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228044	hybrid			2022-12-25	WOS:A1997XM34200035
J	Lim, HM; Lee, HJ; Jaxel, C; Nadal, M				Lim, HM; Lee, HJ; Jaxel, C; Nadal, M			Hin-mediated inversion on positively supercoiled DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; STRAND EXCHANGE; TN3 RESOLVASE; PHAGE-MU; REVERSE GYRASE; RES SITES; ENHANCER; INVITRO; GIN; PROTEIN	Hin recombinase requires negatively supercoiled DNA for an efficient inversion. We have generated positively supercoiled plasmid DNA using reverse gyrase from Sulfolobus shibatae and subjected it to he Hin-mediated inversion reaction. Both Hin and Fis showed the same DNA binding activity regardless of the superhelical handedness of the substrate plasmid. However, inversion activity on positively supercoiled DNA was less than 1% of negatively supercoiled DNA. Assays designed to probe steps in inversion, showed that on positively supercoiled DNA, Hin was able to cleave the recombination sites with the same efficiency shown on negatively supercoiled DNA but was not able to exchange the cleaved DNA. Based on the theoretical differences between positive and negative supercoiling, our data may suggest that unwinding of the double helix at recombination sites is needed after DNA cleavage for strand exchange to occur.	UNIV PARIS 11,INST GENET & MICROBIOL,LAB ENZYMOL ACIDES NUCL,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay	Lim, HM (corresponding author), CHUNGNAM NATL UNIV,COLL NAT RESOURCES,DEPT BIOL,TAEJON 305764,SOUTH KOREA.			NADAL, Marc/0000-0001-9637-7694; Lim, Heon/0000-0003-1711-2589				BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; DREW HR, 1985, EMBO J, V4, P1025, DOI 10.1002/j.1460-2075.1985.tb03734.x; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HWANG DS, 1992, J BIOL CHEM, V267, P23083; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; JOHNSON RC, 1984, COLD SPRING HARB SYM, V49, P751, DOI 10.1101/SQB.1984.049.01.085; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1988, P NATL ACAD SCI USA, V85, P752, DOI 10.1073/pnas.85.3.752; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KLIPPEL A, 1988, EMBO J, V7, P1229, DOI 10.1002/j.1460-2075.1988.tb02935.x; KLIPPEL A, 1993, EMBO J, V12, P1047, DOI 10.1002/j.1460-2075.1993.tb05746.x; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LIM HM, 1992, J BIOL CHEM, V267, P11183; LIM HM, 1992, J BIOL CHEM, V267, P11176; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MERTENS G, 1984, EMBO J, V3, P2415, DOI 10.1002/j.1460-2075.1984.tb02148.x; MIZUUCHI K, 1978, J MOL BIOL, V121, P375, DOI 10.1016/0022-2836(78)90370-4; NADAL M, 1994, J BIOL CHEM, V269, P5255; NADAL M, 1986, NATURE, V321, P256, DOI 10.1038/321256a0; PLASTERK RHA, 1984, P NATL ACAD SCI-BIOL, V81, P2689, DOI 10.1073/pnas.81.9.2689; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RICE PA, 1994, EMBO J, V13, P1514, DOI 10.1002/j.1460-2075.1994.tb06413.x; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1994, J MOL BIOL, V239, P25, DOI 10.1006/jmbi.1994.1348; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x	38	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18434	18439		10.1074/jbc.272.29.18434	http://dx.doi.org/10.1074/jbc.272.29.18434			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218487	hybrid			2022-12-25	WOS:A1997XL73500077
J	Nakahashi, Y; Nelson, E; Fagan, K; Gonzales, E; Guillou, JL; Cooper, DMF				Nakahashi, Y; Nelson, E; Fagan, K; Gonzales, E; Guillou, JL; Cooper, DMF			Construction of a full-length Ca2+-sensitive adenylyl cyclase aequorin chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RECOMBINANT AEQUORIN; CA2+ CONCENTRATION; INTACT-CELLS; NCB-20 CELLS; FREE CALCIUM; BIOLUMINESCENCE; PHOTOPROTEIN; ORGANELLES; MEMBRANES	Ca2+-sensitive adenylyl cyclases are key integrators of Ca2+ and cAMP signaling, To selectively probe dynamic changes in [Ca2+](i) at the plasma membrane where adenylyl cyclases reside, a full-length, Ca2+-inhibitable type VI adenylyl cyclase/aequorin chimera has been constructed by a two stage polymerase chain reaction method. The expressed adenylyl cyclase/aequorin chimera was appropriately localized to the plasma membrane, as judged by biochemical fractionation and functional analysis, The chimera retained full adenylyl cyclase activity and sensitivity to inhibition by physiological [Ca2+](i) elevation. The aequorin portion of the chimeric construct was also capable of measuring changes in [Ca2+] both in vitro and in vivo, When the plasma membrane-tagged aequorin and cytosolic aequorin were compared in their measurement of [Ca2+](i), they showed contrasting sensitivities depending on whether the [Ca2+](i) originated from internal stores or capacitative entry, This is the first full-length enzyme-aequorin chimera that retains the full biological properties of both aequorin and a Ca2+-sensitive adenylyl cyclase. This novel chimeric Ca2+ sensor provides the unique ability to directly report the dynamics of [Ca2+](i) that regulates this Ca2+-sensitive enzyme under a variety of physiological conditions, Since this chimera is localized to the plasma membrane, it can also be used to assess local changes in [Ca2+](i) at the plasma membrane as distinct from global changes in [Ca2+](i) within the cytosol.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM NEUROSCI, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Jean-Louis, Guillou/Y-2569-2019	Jean-Louis, Guillou/0000-0002-4497-9551	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028389] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 28389] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLIJANIAN MK, 1987, J PHARMACOL EXP THER, V241, P407; ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; CHARBONNEAU H, 1985, BIOCHEMISTRY-US, V24, P6762, DOI 10.1021/bi00345a006; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COOPER DMF, 1994, METHOD ENZYMOL, V238, P71; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; FAGAN KA, 1996, J BIOL CHEM, V271, P12433; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; NOMURA M, 1991, FEBS LETT, V295, P63, DOI 10.1016/0014-5793(91)81385-L; PHILLIPS DR, 1972, BIOCHEMISTRY-US, V11, P4582, DOI 10.1021/bi00774a025; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANLEY KK, 1980, BIOCHEM J, V186, P59, DOI 10.1042/bj1860059; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	28	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18093	18097		10.1074/jbc.272.29.18093	http://dx.doi.org/10.1074/jbc.272.29.18093			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218441	hybrid			2022-12-25	WOS:A1997XL73500031
J	Hall, JA; Ganesan, AK; Chen, J; Nikaido, H				Hall, JA; Ganesan, AK; Chen, J; Nikaido, H			Two modes of ligand binding in maltose-binding protein of Escherichia coli - Functional significance in active transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTODEXTRIN TRANSPORT; CYTOPLASMIC MEMBRANE; SYSTEM; COMPONENTS; SUBSTRATE; OVERPRODUCTION; SPECTROSCOPY; RECOGNITION; SPECIFICITY; DIFFUSION	In the preceding two papers (Hall, J. A., Gehring, K., and Nikaido, H. (1997) J. Biol. Chem. 272, 17605-17609; Hall, J. A., Thorgeirson, T. E., Liu, J., Shin, Y.-E., and Nikaido, H. (1997) J. Biol. Chem. 272, 17610-17614), we showed that ligands that bind to the Escherichia coli maltose-binding protein (MBP) without producing the closure of its two lobes are not transported into the cytoplasm. Here, we examine various combinations of ligands, MBPs, and membrane-associated transporters, by utilizing reconstituted proteoliposomes, right side out membrane vesicles, and intact cells. Closed forms of wild type MBP, complexed with maltose or maltodextrins, interacted with wild type transporter complex to stimulate the hydrolysis of ATP by MalK ATPase located on the other side of the membrane, as shown earlier for the maltose-MBP complex (Davidson, A. L., Shuman, H. A., and Nikaido, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2360-2364). In contrast, open forms of liganded MBPs, such as the complex containing wild type MBP and reduced, oxidized, or cyclic maltodextrins or the complex containing the mutant MBP MalE254 and unmodified maltodextrins, did not stimulate ATP hydrolysis, suggesting that the proper interaction between the ligand-MBP complex and the external surface of the transporter requires the former to be in the closed conformation. However, when a mutant transporter containing MalG511 was used, the already significant basal level of ATP hydrolysis was further stimulated not only by ligand MBPs in the closed form but also by those in the open form (except that containing beta-cyclodextrin), data suggesting that the mutant transporter does not always require the closed MBP complex presumably because of its exceptionally strong affinity to MBP, described earlier (Dean, D. A., Her, L.-I., Shuman, H. A., and Nikaido, H. (1992) Mel. Microbiol. 6, 2033-2040). Furthermore, this mutant transporter was able to transport reduced maltodextrin, and cells expressing the transporter were able to grow by using reduced maltodextrin, if the periplasmic concentrations of MBP were kept low so as not to inhibit the transport process.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DEAN DA, 1989, J BACTERIOL, V171, P503, DOI 10.1128/jb.171.1.503-510.1989; DEAN DA, 1992, MOL MICROBIOL, V6, P2033, DOI 10.1111/j.1365-2958.1992.tb01376.x; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1986, BIOCHIM BIOPHYS ACTA, V860, P44, DOI 10.1016/0005-2736(86)90496-7; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; GEHRING K, 1992, FEBS LETT, V300, P33, DOI 10.1016/0014-5793(92)80159-E; GEHRING K, 1991, BIOCHEMISTRY-US, V30, P5524, DOI 10.1021/bi00236a027; Gustedt W. V., 1996, Biophysical Journal, V70, pA203; Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610; Hall JA, 1997, J BIOL CHEM, V272, P17605, DOI 10.1074/jbc.272.28.17605; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; Kaback H R, 1974, Methods Enzymol, V31, P698; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MILLER JH, 1972, EXPT MOL GENETICS, P82; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; RASMUSSEN BA, 1985, J BACTERIOL, V164, P665, DOI 10.1128/JB.164.2.665-673.1985; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; REYES M, 1986, J BACTERIOL, V165, P918, DOI 10.1128/jb.165.3.918-922.1986; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; STOCK JB, 1977, J BIOL CHEM, V252, P7850; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; WANDERSMAN C, 1979, J BACTERIOL, V140, P1	33	48	48	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17615	17622		10.1074/jbc.272.28.17615	http://dx.doi.org/10.1074/jbc.272.28.17615			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211910	hybrid			2022-12-25	WOS:A1997XK16500053
J	Eitinger, T; Wolfram, L; Degen, O; Anthon, C				Eitinger, T; Wolfram, L; Degen, O; Anthon, C			A Ni2+ binding motif is the basis of high affinity transport of the Alcaligenes eutrophus nickel permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE; EXPRESSION; UREASE; MUTAGENESIS; CLONING; SYSTEM	Amino acid exchanges in the Alcaligenes eutrophus nickel permease (HoxN) were constructed by site-directed mutagenesis, and their effects on nickel ion uptake were investigated, Mutant hoxN alleles were expressed in Escherichia coli, and activity of the altered permeases was examined via a recently described physiological assay (Wolfram, L., Friedrich, B., and Eitinger, T. (1995) J. Bacteriol, 177, 1840-1843), Replacement of Cys-37, Cys-256, or Cys-318 by alanine did not severely affect nickel ion uptake, This activity of a C331A mutant was diminished by 60%, and a similar phenotype was obtained with a cysteine-less mutant harboring four Cys to Ala exchanges, Alterations in a histidine-containing sequence motif (His-62, Asp-67, His-68), which is conserved in microbial nickel transport proteins, strongly affected or completely abolished transport activity in the E. coli system, The analysis of HoxN alkaline phosphatase fusion proteins implied that His-62, Asp-67, and His-68 exchanges did not interfere with overall membrane topology or stability of the nickel permease, These mutations were reintroduced into the A, eutrophus wild-type strain, Analyses of the resulting HoxN mutants indicated that exchanges in the histidine motif led to a clearly decreased affinity of the permease for nickel ion.	FREE UNIV BERLIN,INST PFLANZENPHYSIOL & MIKROBIOL,D-14195 BERLIN,GERMANY	Free University of Berlin	Eitinger, T (corresponding author), HUMBOLDT UNIV BERLIN,INST BIOL MIKROBIOL,CHAUSSEESTR 117,D-10115 BERLIN,GERMANY.		Eitinger, Thomas/C-3926-2019	Eitinger, Thomas/0000-0003-1449-6433				Bernhard M, 1996, J BACTERIOL, V178, P4522, DOI 10.1128/jb.178.15.4522-4529.1996; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Eitinger T, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P235; EITINGER T, 1994, MOL MICROBIOL, V12, P1025, DOI 10.1111/j.1365-2958.1994.tb01090.x; EITINGER T, 1991, J BIOL CHEM, V266, P3222; FRIEDRICH B, 1993, ANNU REV MICROBIOL, V47, P351, DOI 10.1146/annurev.mi.47.100193.002031; FU CL, 1994, P NATL ACAD SCI USA, V91, P5099, DOI 10.1073/pnas.91.11.5099; HAUSINGER RP, 1993, BIOCH NICKEL, P181; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12272; Komeda H, 1997, P NATL ACAD SCI USA, V94, P36, DOI 10.1073/pnas.94.1.36; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZ O, 1994, J BACTERIOL, V176, P4385, DOI 10.1128/jb.176.14.4385-4393.1994; LOHMEYER M, 1987, ARCH MICROBIOL, V149, P130, DOI 10.1007/BF00425078; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA M, 1994, J BACTERIOL, V176, P432, DOI 10.1128/JB.176.2.432-442.1994; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MOBLEY HLT, 1995, MOL MICROBIOL, V16, P97, DOI 10.1111/j.1365-2958.1995.tb02395.x; MULROONEY SB, 1989, J GEN MICROBIOL, V135, P1769; NAVARRO C, 1993, MOL MICROBIOL, V9, P1181, DOI 10.1111/j.1365-2958.1993.tb01247.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P551; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; WOLFRAM L, 1995, J BACTERIOL, V177, P1840, DOI 10.1128/jb.177.7.1840-1843.1995; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	23	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17139	17144		10.1074/jbc.272.27.17139	http://dx.doi.org/10.1074/jbc.272.27.17139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202033	hybrid			2022-12-25	WOS:A1997XH44600065
J	MatsunoYagi, A; Hatefi, Y				MatsunoYagi, A; Hatefi, Y			Ubiquinol:cytochrome c oxidoreductase - The redox reactions of the bis-heme cytochrome b in unenergized and energized submitochondrial particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONMOTIVE Q-CYCLE; ELECTRON-TRANSFER; OXIDATIVE-PHOSPHORYLATION; BEEF-HEART; COMPLEX; MECHANISM; MITOCHONDRIA; INHIBITORS; ANTIMYCIN	The redox reactions of the bis-heme cytochrome b of the ubiquinol:cytochrome c oxidoreductase complex (complex III, bc(1) complex) were studied in bovine heart submitochondrial particles (SMP), It was shown that (i) when SMP were treated with the complex III inhibitor myxothiazol (or MOA-stilbene or stigmatellin) or with KCN and ascorbate rep reduce the high potential centers of complex III (iron-sulfur protein and cytochromes c + c(1)), NADH or succinate reduced heme b(L) slowly and incompletely, In contrast, heme b(H) was reduced by these substrates completely and much more rapidly, Only when the complex III inhibitor was antimycin, and the high potential centers were in the oxidized state, NADH or succinate was able to reduce both b(H) and b(L) rapidly and completely, (ii) When NADH or succinate was added to SMP inhibited at complex III by antimycin and energized by ATP, the bis-heme cytochrome b was reduced only partially, Prereduction of the high potential centers was not necessary for this partial b reduction, but slowed down the reduction rate, Deenergization of SMP by uncoupling (or addition of oligomycin to inhibit ATP hydrolysis) resulted in further b reduction. Addition of ATP after b was reduced by substrate resulted in partial b oxidation, and the heme remaining reduced appeared to be mainly b(L). Other experiments suggested that the redox changes of cytochrome ZI effected by energization and deenergization of SMP occurred via electronic communication with the ubiquinone pool, These results have been discussed in relation to current concepts regarding the mechanism of electron transfer by complex III.	Scripps Res Inst, DEPT MOL & EXPT MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK008126, R01DK008126] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWYER JR, 1981, FEBS LETT, V126, P93, DOI 10.1016/0014-5793(81)81041-1; BOWYER JR, 1980, FEBS LETT, V115, P171, DOI 10.1016/0014-5793(80)81160-4; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CHANCE B, 1970, P NATL ACAD SCI USA, V66, P1175, DOI 10.1073/pnas.66.4.1175; CHANCE B, 1974, DYNAMICS ENERGY TRAN, P553; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; HATEFI Y, 1982, BIOCHEMISTRY-US, V24, P6614; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MatsunoYagi A, 1996, J BIOL CHEM, V271, P6164, DOI 10.1074/jbc.271.11.6164; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1987, J BIOL CHEM, V262, P14158; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; RIESKE JS, 1971, ARCH BIOCHEM BIOPHYS, V145, P179, DOI 10.1016/0003-9861(71)90025-7; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P4608; TSAI AL, 1987, J BIOL CHEM, V262, P8677; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WILSON DF, 1970, BIOCHEM BIOPH RES CO, V39, P59, DOI 10.1016/0006-291X(70)90757-6; Xia D., 1996, Biophysical Journal, V70, pA253	24	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16928	16933		10.1074/jbc.272.27.16928	http://dx.doi.org/10.1074/jbc.272.27.16928			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202003	hybrid			2022-12-25	WOS:A1997XH44600035
J	Miaczynska, M; Lorenzetti, S; Bialek, U; BenitoMoreno, RM; Schweyen, RJ; Ragnini, A				Miaczynska, M; Lorenzetti, S; Bialek, U; BenitoMoreno, RM; Schweyen, RJ; Ragnini, A			The yeast Rab escort protein binds intracellular membranes in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; SACCHAROMYCES-CEREVISIAE; GERANYLGERANYL TRANSFERASE; COMPONENT-A; GENE ENCODES; CHOROIDEREMIA; HOMOLOG; ACYLATION; VESICLES; MRS6P	Tn both mammals and yeast, intracellular vesicular transport depends on the correct shuttling between membrane and cytosol of the Rab/Ypt small G proteins, Membrane association of these proteins requires prenylation by the Rab geranylgeranyl transferase that recognizes a complex formed by the Rab/Ypt protein and the Rab escort protein (REP), After prenylation the Rab/Ypt protein is delivered to the tar,aet membranes by REP, Little is known about the early steps of the Rab-REP complex formation and where this association occurs in the cell, Although prenylation is believed to take place in the cytosol, we show that the yeast Rab escort protein Mrs6 is present in both soluble and particulate fractions of cell extracts, Mrs6p is associated with the heavy microsomal fraction that contains endoplasmic reticulum-Golgi membranes but is absent iu the plasma membrane, vacuoles, mitochondria, and microsomal subfraction associated with mitochondria. The solubilization pattern of the particulate pool of Mrs6p implies that this protein is peripherally but tightly associated with membranes via hydrophobic interactions and metal ions. We also report that the C terminus of Mrs6p is important for maintaining the solubility of the protein because its deletion or replacement with the C terminus of RabGDI results in a protein that localizes only to membranes.	UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,A-1030 VIENNA,AUSTRIA	University of Vienna; Vienna Biocenter (VBC)			Białek-Wyrzykowska, Urszula/AAT-1041-2021; LORENZETTI, STEFANO/C-6063-2015; Ragnini, Antonella/A-8089-2014	LORENZETTI, STEFANO/0000-0001-5358-8002; Ragnini, Antonella/0000-0001-7963-7554; Miaczynska, Marta/0000-0003-0031-5267				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; Bauer BE, 1996, MOL BIOL CELL, V7, P1521, DOI 10.1091/mbc.7.10.1521; BENITOMORENO RM, 1994, CURR GENET, V27, P23, DOI 10.1007/BF00326574; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DAUM G, 1982, J BIOL CHEM, V257, P3028; FERRONOVICK S, 1995, GUIDEBOOK SMALL GTPA, P60; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; KOHRER K, 1993, J BIOL CHEM, V268, P559; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; Penefsky H. S., 1971, METHOD ENZYMOL, V22, P204; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; RAGNINI A, 1994, CURR GENET, V26, P308, DOI 10.1007/BF00310494; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEABRA MC, 1995, GUIDEBOOK SMALL GTPA, P45; Shen F, 1996, J BIOL CHEM, V271, P3692; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	40	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16972	16977		10.1074/jbc.272.27.16972	http://dx.doi.org/10.1074/jbc.272.27.16972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202009	hybrid			2022-12-25	WOS:A1997XH44600041
J	Berkhout, TA; Sarau, HM; Moores, K; White, JR; Elshourbagy, N; Appelbaum, E; Reape, TJ; Brawner, M; Makwana, J; Foley, JJ; Schmidt, DB; Imburgia, C; McNulty, D; Matthews, J; ODonnell, K; OShannessy, D; Scott, M; Groot, PHE; Macphee, C				Berkhout, TA; Sarau, HM; Moores, K; White, JR; Elshourbagy, N; Appelbaum, E; Reape, TJ; Brawner, M; Makwana, J; Foley, JJ; Schmidt, DB; Imburgia, C; McNulty, D; Matthews, J; ODonnell, K; OShannessy, D; Scott, M; Groot, PHE; Macphee, C			Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; CHEMOATTRACTANT PROTEIN-1; MOLECULAR-CLONING; ATHEROSCLEROTIC LESIONS; CYTOKINE FAMILY; TRANSDUCTION; CELLS; BIOLOGY; LIGAND; CDNA	Here we describe the characterization of a novel human CC chemokine, tentatively named monocyte chemotactic protein (MCP-4). This chemokine was detected by random sequencing of expressed sequence tags in cDNA libraries. The full-length cDNA revealed an open reading frame for a 98-amino acid residue protein, and a sequence alignment with known CC chemokines showed high levels of similarity (59-62%) with MCP-1, MCP-3, and eotaxin. MCP-4 cDNA was cloned into Drosophila S2 cells, and the mature protein (residues 24-98) was purified from the conditioned medium. Recombinant MCP-4 induced a potent chemotactic response (EC50 = 2.88 +/- 0.15 nM) and a transient rise in cytosolic calcium concentration in fresh human peripheral blood monocytes but not in neutrophils. Binding studies in monocytes showed that MCP-4 and MCP-3 were very potent in displacing high affinity binding of I-125-MCP-1 (IC50 for MCP-4, MCP-3, and unlabeled MCP-1 of 2.1 +/- 1.4, 0.85-1.6, and 0.7 +/- 0.2 nM respectively), suggesting that all three chemokines interact with the CC chemokine receptor-a (MCP-1 receptor). This was confirmed in binding studies with Chinese hamster ovary cells, stably transfected with the CC chemokine 2B receptor. Northern blot analysis in extracts of normal human tissues showed expression of mRNA for MCP-4 in small intestine, thymus, and colon, but the level of protein expression was too low to be detected in Western blot analysis. However, expression of MCP-4 protein was demonstrated by immunohistochemistry in human atherosclerotic lesion and found to be associated with endothelial cells and macrophages.	SMITHKLINE BEECHAM PHARMACEUT,DEPT VASC BIOL,WELWYN GARDEN CIT AL6 9AR,HERTS,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOPHARMACEUT SCI,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline				White, John R/0000-0003-2998-1626				ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Berliner Judith A., 1993, Current Opinion in Lipidology, V4, P373, DOI 10.1097/00041433-199310000-00005; BOYUM A, 1984, METHOD ENZYMOL, V108, P88; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DAUGHERRY DL, 1996, J EXP MED, V183, P2349; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; HORUK R, 1995, EXPERT OPIN THER PAT, V5, P1185; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KUMAMOTO M, 1995, HUM PATHOL, V26, P450, DOI 10.1016/0046-8177(95)90148-5; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NEWBY AC, 1993, CARDIOVASC RES, V27, P1173, DOI 10.1093/cvr/27.7.1173; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; RAMOS L, 1992, Patent No. 5247; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YAMAGAMI S, 1994, BIOCHEM BIOPH RES CO, V202, P1156, DOI 10.1006/bbrc.1994.2049; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953	40	87	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16404	16413		10.1074/jbc.272.26.16404	http://dx.doi.org/10.1074/jbc.272.26.16404			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195948	hybrid			2022-12-25	WOS:A1997XG01900052
J	DeAizpurua, HJ; Cram, DS; Naselli, G; Devereux, L; Dorow, DS				DeAizpurua, HJ; Cram, DS; Naselli, G; Devereux, L; Dorow, DS			Expression of mixed lineage kinase-1 in pancreatic beta-cell lines at different stages of maturation and during embryonic pancreas development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; BINDING PROTEINS; LEUCINE ZIPPER; SMALL GTPASES; GENE; RAT; INSULIN	Events controlling differentiation to insulin-secreting beta-cells in the pancreas are not well understood, although beta-cells are thought to arise from pluripotent ductal precursor cells, To search for signaling proteins that might be involved in beta-cell maturation, we analyzed protein kinase expression in two developmentally and functionally distinct pancreatic beta-cell lines, RIN-5AH and RIN-A12, by reverse transcriptase polymerase chain reaction, A number of tyrosine and serine/threonine kinases were identified in both lines, One protein kinase, mixed lineage kinase-1 (MLK-1), was expressed at both the RNA and protein levels in RIN-5AH cells, which display an immature beta-cell phenotype, but was not detected in the more mature RIN-A12 cells, Furthermore, levels of MLK-1 mRNA and protein were increased after brief stimulation of RIN-5AH cells with either the differentiation inducer, sodium butyrate, or with serum after serum starvation. These increases in expression were independent of phenotypic markers such as insulin secretion or surface expression of major histocompatibility class I- and A2B5-reactive ganglioside, In addition, increases in MLK-1 expression in the stimulated RIN-5AH cells were accompanied by phosphorylation of MLK-1 on serine but not tyrosine, Antisense oligonucleotides to two distinct regions of MLK-1 caused RIN-5AH cells, but not RIN-A12 cells, to adopt a highly undifferentiated morphology, with a reduction in DNA synthesis and MLR-1 protein levels and elevated glucagon mRNA levels, but with no effect on insulin mRNA, In an immunohistochemical survey of embryonic mouse tissues, we found that temporal expression of MLK-1 was regulated in a tissue-specific manner, In the embryonic pancreas, MLK-1 expression was evident in ductal cells from day 13 to 16 but was not detected in late stage gestation or neonatal pancreas, These data suggest that MLK-1 is regulated in immature pancreatic beta-cells and their ductal precursors at the level of functional maturity and may therefore play a role in beta-cell development.	PETER MACCALLUM CANC INST,TRESCOWTHICK RES LABS,MELBOURNE,VIC 3000,AUSTRALIA	Peter Maccallum Cancer Center	DeAizpurua, HJ (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,BURNET CLIN RES UNIT,PARKVILLE,VIC 3050,AUSTRALIA.			Devereux, Lisa/0000-0003-2435-5888				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ALTSHUL SF, 1990, J MOL BIOL, V215, P443; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTHOLOMEUSZ RK, 1990, CELL DIFFER DEV, V32, P39, DOI 10.1016/0922-3371(90)90097-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; HARRISON LC, 1990, ADV ENDOCRINOL METAB, V1, P35; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MADSON OD, 1986, J CELL BIOL, V102, P2025; Mares J, 1992, GROWTH FACTORS, V6, P93, DOI 10.3109/08977199209011013; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; NIELSEN JH, 1989, EXP CLIN ENDOCRINOL, V93, P277; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PHILIPPE J, 1987, MOL CELL BIOL, V7, P560, DOI 10.1128/MCB.7.1.560; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SWENNE I, 1983, DIABETES, V32, P14, DOI 10.2337/diabetes.32.1.14; SWENNE I, 1985, DIABETES, V34, P803, DOI 10.2337/diabetes.34.8.803; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TIETELMAN G, 1987, DEV BIOL, V121, P454; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	58	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16364	16373		10.1074/jbc.272.26.16364	http://dx.doi.org/10.1074/jbc.272.26.16364			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195943	hybrid			2022-12-25	WOS:A1997XG01900047
J	Engelman, JA; Wykoff, CC; Yasuhara, S; Song, KS; Okamoto, T; Lisanti, MP				Engelman, JA; Wykoff, CC; Yasuhara, S; Song, KS; Okamoto, T; Lisanti, MP			Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; RICH MEMBRANE DOMAINS; COLI LAC REPRESSOR; NIH 3T3 CELLS; TYROSINE KINASES; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; TRANSPORT VESICLES; PROTEIN-COMPONENT; RAS	Caveolae are plasma membrane-attached vesicular organelles. Caveolin-1, a 21-24-kDa integral membrane protein, is a principal component of caveolae membranes in vivo. Both caveolae and caveolin are most abundantly expressed in terminally differentiated cells: adipocytes, endothelial cells, and muscle cells. Conversely, caveolin-1 mRNA and protein expression are lost or reduced during cell transformation by activated oncogenes such as v-abl and H-ras (G12V); caveolae are absent from these cell lines. However, its remains unknown whether down-regulation of caveolin-1 protein and caveolae organelles contributes to their transformed phenotype. Here, we have expressed caveolin-1 in oncogenically transformed cells under the control of an inducible-expression system. Regulated induction of caveolin-1 expression was monitored by Western blot analysis and immunofluorescence microscopy. Our results indicate that caveolin-1 protein is expressed well using this system and correctly localizes to the plasma membrane. Induction of caveolin-1 expression in v-Abl-transformed and H-Ras (G12V)-transformed NIH 3T3 cells abrogated the anchorage-independent growth of these cells in soft agar and resulted in the de novo formation of caveolae as seen by transmission electron microscopy. Consistent with its antagonism of Ras-mediated cell transformation, caveolin-1 expression dramatically inhibited both Ras/MAPK-mediated and basal transcriptional activation of a mitogen-sensitive promoter. Using an established system to detect apoptotic cell death, it appears that the effects of caveolin-1 may, in part, be attributed to its ability to initiate apoptosis in rapidly dividing cells. In addition, we find that caveolin-1 expression levels are reversibly down-regulated by two distinct oncogenic stimuli. Taken together, our results indicate that down-regulation of caveolin-1 expression and caveolae organelles may be critical to maintaining the transformed phenotype in certain cell populations.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; CLEVELAND CLIN FDN, DEPT NEUROSCI, CLEVELAND, OH 44195 USA	Yeshiva University; Albert Einstein College of Medicine; Massachusetts Institute of Technology (MIT); Whitehead Institute; Cleveland Clinic Foundation			Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382	NIGMS NIH HHS [GM-50443, T32-GM07288] Funding Source: Medline; NIMH NIH HHS [MH-56036] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288, R29GM050443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056036] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; FAN JY, 1983, J CELL SCI, V61, P219; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FIGGE J, 1988, CELL, V52, P713, DOI 10.1016/0092-8674(88)90409-6; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; IKEZU T, 1994, J BIOL CHEM, V269, P31955; IZUMI T, 1988, ANAT REC, V220, P225, DOI 10.1002/ar.1092200302; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PRENDERGAST GC, 1994, BIOESSAYS, V16, P187, DOI 10.1002/bies.950160309; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WYBORSKI DL, 1991, NUCLEIC ACIDS RES, V19, P4647, DOI 10.1093/nar/19.17.4647; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x	80	338	348	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16374	16381		10.1074/jbc.272.26.16374	http://dx.doi.org/10.1074/jbc.272.26.16374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195944	hybrid			2022-12-25	WOS:A1997XG01900048
J	Koloteva, N; Muller, PP; McCarthy, JEG				Koloteva, N; Muller, PP; McCarthy, JEG			The position dependence of translational regulation via RNA-RNA and RNA-protein interactions in the 5'-untranslated region of eukaryotic mRNA is a function of the thermodynamic competence of 40 S ribosomes in translational initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; YEAST SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SECONDARY STRUCTURE; BINDING-PROTEIN; GENE-EXPRESSION; FERRITIN; INHIBITION; DETERMINANTS; EFFICIENCY	Cap proximity is a requirement to enable secondary structures and RNA-binding proteins to repress translational initiation via the 5'-untranslated region (5'-UTR) of mammalian mRNAs. We show that in Saccharomyces cerevisiae, unlike mammalian cells, the in vitro translational repressive effect of the mammalian iron regulatory protein 1 (IRP1) is independent of the site of its target in the 5'-UTR, the iron-responsive element (IRE). In vitro studies demonstrate that the binding affinity of IRP1 is also unaffected by the position of the IRE. Using IRE loop mutants, we observe an almost complete loss of IRP1-dependent repression in yeast concomitant with a 150-fold reduction in binding affinity for the IRE target. This mirrors the natural quantitative range of iron-induced adjustment of IRE/IRP1 affinity in mammalian cells. By enhancing the stability of the IRE stem-loop, we also show that its intrinsic folding energy acts together with the binding energy of IRP1 to give an additive capacity to restrict translational initiation. An IRE-IRP1 complex in a cap-distal position in yeast blocks scanning 40 S ribosomes on the 5'-UTR, It follows that the position effect of mammalian site-specific translational repression is dictated by the competence of the mammalian preinitiation complex to destabilize inhibitory structures at different steps of the initiation process.	UNIV MANCHESTER, INST SCI & TECHNOL, DEPT BIOMOL SCI, MANCHESTER M60 1QD, LANCS, ENGLAND; GESELL BIOTECHNOL FORSCH MBH, D-38124 BRAUNSCHWEIG, GERMANY	University of Manchester; Gesellschaft fur Biotechnologische Forschung mbH			Mueller, Peter P./H-8656-2019	Mueller, Peter P./0000-0002-1209-7546				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; CIGAN AM, 1987, GENE, V59, P1; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; Harford J, 1993, CONTROL MESSENGER ST, P239; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; JOBLING SA, 1988, NUCLEIC ACIDS RES, V16, P4483, DOI 10.1093/nar/16.10.4483; KIKINIS Z, 1995, NUCLEIC ACIDS RES, V23, P4190, DOI 10.1093/nar/23.20.4190; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LASO MRV, 1993, J BIOL CHEM, V268, P6453; Linz B, 1997, J BIOL CHEM, V272, P9131; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; NAGAI K, 1994, RNA PROTEIN INTERACT; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; STRIPECKE R, 1992, NUCLEIC ACIDS RES, V20, P5555, DOI 10.1093/nar/20.21.5555; Tuite M F, 1986, Yeast, V2, P35, DOI 10.1002/yea.320020103; VANZOELEN EJJ, 1992, ANAL BIOCHEM, V200, P393, DOI 10.1016/0003-2697(92)90485-P	39	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16531	16539		10.1074/jbc.272.26.16531	http://dx.doi.org/10.1074/jbc.272.26.16531			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195963	hybrid			2022-12-25	WOS:A1997XG01900067
J	Wang, P; Granados, RR				Wang, P; Granados, RR			Molecular cloning and sequencing of a novel invertebrate intestinal mucin cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; GENETIC-POLYMORPHISM; XENOPUS-LAEVIS; EXPRESSION; PROTEIN; RICH; DOMAINS; CELLS; GLYCOPROTEIN; SECRETION	The first invertebrate intestinal mucin, termed insect intestinal mucin (IIM), was recently identified from Trichoplusia ni larvae (Wang, P., and Granados, R. R. (1997) Proc. Natl. Acad. Sci. U. S. A., in press). We report the cDNA cloning and sequencing of IIM, which is only the second completely sequenced intestinal mucin after human intestinal mucin, MUC2. To clone and sequence the cDNA for IIM, a T. ni larval midgut cDNA expression library was constructed and screened with an anti-IIM antiserum. Two full-length cDNA clones for IIM were identified and sequenced, The deduced proteins from the two cDNA clones contained 807 and 788 amino acid residues, respectively. The structural organization of IIM is similar to that of MUC2, containing a 25-amino acid signal leading sequence and two threonine/proline/alanine-rich tandem repeat domains flanked by cysteine-rich sequences. One tandem repeat domain contained two repeating units, TTTQAP and AATTP, and the other contained one repeating unit, TAAP. The cysteine-rich regions showed potential chitin binding features. By immunolocalization in tissue sections, it was determined that IIM is expressed in midgut tissues. The IIM mRNA is abundant in the midgut tissue, and Northern blot analysis indicated that IIM transcripts were not polydispersed as is found in mammalian mucin transcription.	CORNELL UNIV, DEPT ENTOMOL, ITHACA, NY 14853 USA; CORNELL UNIV, BOYCE THOMPSON INST PLANT RES, ITHACA, NY 14853 USA	Cornell University; Cornell University; Boyce Thompson Institute for Plant Research								ALLEN A, 1993, PHYSIOL REV, V73, P823, DOI 10.1152/physrev.1993.73.4.823; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; [Anonymous], 1992, ZOOPHYSIOLOGY; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101; Forstner Janet F., 1994, P1255; GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hansen JE, 1996, NUCLEIC ACIDS RES, V24, P248, DOI 10.1093/nar/24.1.248; HAUSER F, 1992, J BIOL CHEM, V267, P24620; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; JARMAN AP, 1989, TRENDS GENET, V5, P367, DOI 10.1016/0168-9525(89)90171-6; KIMURA S, 1994, FISHERIES SCI, V60, P193, DOI 10.2331/fishsci.60.193; Kramerov AA, 1996, FEBS LETT, V378, P213, DOI 10.1016/0014-5793(95)01444-6; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; RINALDINI LM, 1954, J PHYSIOL-LONDON, V123, pP20; SHEEHAN JK, 1990, BIOCHEM J, V265, P169, DOI 10.1042/bj2650169; SMITH GR, 1987, ANNU REV GENET, V21, P179, DOI 10.1146/annurev.genet.21.1.179; SPECIAN RD, 1991, AM J PHYSIOL, V260, pC183, DOI 10.1152/ajpcell.1991.260.2.C183; Spence Kemet D., 1991, P77; SPICER AP, 1991, J BIOL CHEM, V266, P15099; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; Sugiura Y, 1995, FISHERIES SCI, V61, P1009, DOI 10.2331/fishsci.61.1009; Theopold U, 1996, J BIOL CHEM, V271, P12708, DOI 10.1074/jbc.271.22.12708; Troxler RF, 1995, BIOCHEM BIOPH RES CO, V217, P1112, DOI 10.1006/bbrc.1995.2884; VERMA M, 1993, P NATL ACAD SCI USA, V90, P7144, DOI 10.1073/pnas.90.15.7144; VERMA M, 1994, GLYCOCONJUGATE J, V11, P172, DOI 10.1007/BF00731215; WEBER K, 1969, J BIOL CHEM, V244, P4406; WU K, 1994, J BIOL CHEM, V269, P11950; YANAI K, 1992, J BACTERIOL, V174, P7398, DOI 10.1128/jb.174.22.7398-7406.1992	46	105	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16663	16669		10.1074/jbc.272.26.16663	http://dx.doi.org/10.1074/jbc.272.26.16663			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195982	hybrid			2022-12-25	WOS:A1997XG01900086
J	Zawada, RJX; Khosla, C				Zawada, RJX; Khosla, C			Domain analysis of the molecular recognition features of aromatic polyketide synthase subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERED BIOSYNTHESIS; STREPTOMYCES-GLAUCESCENS; ANTIBIOTIC BIOSYNTHESIS; CATALYTIC SPECIFICITY; NUCLEOTIDE-SEQUENCE; GENE; MANIPULATION; COELICOLOR; FRENOLICIN; CLUSTER	Bacterial aromatic polyketide synthases (PKSs) are a family of homologous multienzyme assemblies that catalyze the biosynthesis of numerous polyfunctional aromatic natural products, In the absence of direct insights into their structures, the use of gene fusions can be a powerful tool for understanding the structural basis for their properties. A series of truncated and hybrid proteins were constructed and analyzed within a family of PKS subunits, designated aromatases/cyclases (ARO/CYCs), When expressed alone, neither the N-terminal nor the C-terminal domain of the actinorhodin (act) or the griseusin (gris) ARO/CYC exhibited substantial aromatase activity. However, in the presence of each other, the half proteins were active. Furthermore, analysis of a set of hybrid proteins derived from the act and gris ARO/CYCs allowed us to localize the chain length dependence of this aromatase activity to their N-terminal domains. Unexpectedly, however, when the C-terminal domain of the gris ARO/CYC was expressed in a context where aromatase activity was absent, it could modulate the chain length specificity of the tetracenomycin (tcm) minimal PKS, leading to the formation of a novel 18-carbon product in addition to the expected 20-carbon one, It was-also found that monodomain ARO/CYCs such as tcmN cannot substitute for the the N-terminal domain of didomain ARO/CYCs, even though they exhibit high sequence similarity with the N-terminal domain, Together, these results illustrate the utility of protein engineering approaches for dissecting the structure-function relationships of PKS subunits and for the generation of mutant alleles with novel biosynthetic properties.	STANFORD UNIV, DEPT CHEM ENGN, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University; Stanford University; Stanford University				Khosla, Chaitan/0000-0001-6529-495X				BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; Carreras CW, 1996, J AM CHEM SOC, V118, P5158, DOI 10.1021/ja960479o; Fu H, 1994, Chem Biol, V1, P205, DOI 10.1016/1074-5521(94)90012-4; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; FU H, 1994, BIOCHEMISTRY-US, V33, P9321, DOI 10.1021/bi00197a036; FU H, 1994, J AM CHEM SOC, V116, P6443, DOI 10.1021/ja00093a058; HOPWOOD DA, 1992, CIBA F SYMP, V171, P88; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HOPWOOD DA, 1985, GENETIC MANIPULATION, P107; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; IWAI Y, 1978, J ANTIBIOT, V31, P959, DOI 10.7164/antibiotics.31.959; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Kramer PJ, 1997, J AM CHEM SOC, V119, P635, DOI 10.1021/ja962888q; MACNEIL DJ, 1988, J BACTERIOL, V170, P5607, DOI 10.1128/jb.170.12.5607-5612.1988; MANIATIS T, 1982, MOL CLONING LABORATO, P55; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1994, J AM CHEM SOC, V116, P10855, DOI 10.1021/ja00103a001; MCDANIEL R, 1995, J AM CHEM SOC, V117, P6805, DOI 10.1021/ja00131a001; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; OHagan D., 1991, POLYKETIDE METABOLIT; PIEPER R, 1995, NATURE, V378, P263, DOI 10.1038/378263a0; ROBINSON JA, 1991, PHILOS T ROY SOC B, V332, P107, DOI 10.1098/rstb.1991.0038; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; SHEN B, 1995, J AM CHEM SOC, V117, P6811, DOI 10.1021/ja00131a002; SHERMAN DH, 1991, TETRAHEDRON, V47, P6029, DOI 10.1016/S0040-4020(01)86494-2; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; TSUZUKI K, 1986, J ANTIBIOT, V39, P1343, DOI 10.7164/antibiotics.39.1343; YU TW, 1995, THESIS U E ANGLIA NO; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	32	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16184	16188		10.1074/jbc.272.26.16184	http://dx.doi.org/10.1074/jbc.272.26.16184			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195917	hybrid			2022-12-25	WOS:A1997XG01900021
J	Arai, K; Morishita, K; Shinmura, K; Kohno, T; Kim, SR; Nohmi, T; Taniwaki, M; Ohwada, S; Yokota, J				Arai, K; Morishita, K; Shinmura, K; Kohno, T; Kim, SR; Nohmi, T; Taniwaki, M; Ohwada, S; Yokota, J			Cloning of a human homolog of the yeast OGG1 gene that is involved in the repair of oxidative DNA damage	ONCOGENE			English	Article						oxidative DNA damage; 8-hydroxyguanine; DNA repair; mutagenesis; DNA glycosylase; endonuclease	ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; 8-HYDROXYGUANINE; MUTAGENESIS; 8-HYDROXYDEOXYGUANOSINE; 8-OXOGUANINE; GLYCOSYLASE; EXCISION; CANCER	We report the cloning of a human homolog of the yeast OGG1 gene, which encodes a DNA glycosylase that excises an oxidatively damaged form of guanine, 8-hydroxyguanine (also known as 7,8-dihydro-8-oxoguanine), Since the deduced amino acid sequence (68 amino acids) of a human expressed sequence tag, N55394, matched a short stretch of yeast OGG1 protein with greater than 40% amino acid identity, a full Length cDNA clone was isolated from a HeLa cell cDNA Library with the N55394 clone as a probe, The cDNA clone encodes a predicted protein of 345 amino acids which is homologous to yeast OGG1 protein throughout the entire polypeptide sequence and shares 38% amino acid identity with yeast OGG1 protein, Moreover, we found that both a human homolog and yeast OGG1 protein possess two distinct DNA binding motifs, a helix-hairpin-helix (HhH) motif and a C2H2 zinc finger like motif, and a domain homologous to human and E. coli MutY proteins. Expression of a human homolog suppressed spontaneous mutagenesis of an E. coli (mutM mutY) mutant as in the case of yeast OGG1 protein. The gene mas ubiquitously expressed in a variety of human organs and mapped to chromosome 3p26.2. These results strongly suggest that the gene isolated here is a human counterpart of the yeast OGG1 gene and is involved in the repair of oxidative DNA damage in human cells.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; GUNMA UNIV,SCH MED,DEPT SURG 2,MAEBASHI,GUMMA 371,JAPAN; NATL INST HLTH SCI,DIV GENET & MUTAGENESIS,SETAGAYA KU,TOKYO 158,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT INTERNAL MED 3,KAMIGYO KU,KYOTO 602,JAPAN	National Cancer Center - Japan; Gunma University; National Institute of Health Sciences - Japan; Kyoto Prefectural University of Medicine			Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AU KG, 1989, P NATL ACAD SCI USA, V86, P8771; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CHENG KC, 1992, J BIOL CHEM, V267, P166; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; GAZDAR AF, 1994, ANTICANCER RES, V13, P261; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HIBI K, 1992, ONCOGENE, V7, P445; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KASAI H, 1984, JPN J CANCER RES, V75, P565; KASAI H, 1984, JPN J CANCER RES, V75, P841; KOHNO T, 1995, HUM MOL GENET, V4, P667, DOI 10.1093/hmg/4.4.667; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NAGASHIMA M, 1995, CARCINOGENESIS, V16, P1441, DOI 10.1093/carcin/16.6.1441; Nagashima M, 1997, MUTAT RES-DNA REPAIR, V383, P49, DOI 10.1016/S0921-8777(96)00045-6; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIMODA R, 1994, CANCER RES, V54, P3171; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TOTTER JR, 1980, P NATL ACAD SCI-BIOL, V77, P1763, DOI 10.1073/pnas.77.4.1763; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	35	249	259	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2857	2861		10.1038/sj.onc.1201139	http://dx.doi.org/10.1038/sj.onc.1201139			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190902				2022-12-25	WOS:A1997XD64300014
J	Su, Y; Shi, YF; Shi, YB				Su, Y; Shi, YF; Shi, YB			Cyclosporin A but not FK506 inhibits thyroid hormone-induced apoptosis in tadpole intestinal epithelium	FASEB JOURNAL			English	Article						metamorphosis; immunosuppressant; cell death	PROGRAMMED CELL-DEATH; GENE-EXPRESSION; AMPHIBIAN METAMORPHOSIS; MOLECULAR-BIOLOGY; CONNECTIVE-TISSUE; XENOPUS-LAEVIS; LARVAL; THYMOCYTES; RECEPTOR; INVITRO	Amphibian metamorphosis and mammalian T cell development represent two of the best known systems where developmental programmed cell death through apoptosis takes place. Two immunosuppressants, cyclosporin A (CsA) and FK506, have been demonstrated to inhibit activation-induced cell death in immature T cells and T cell hybridomas. In this study, we have established an in vitro system in which isolated primary tadpole intestinal epithelial cells undergo typical apoptosis upon treatment with thyroid hormone (T-3), the causative agent of metamorphosis. It is surprising that this T-3-induced apoptosis was found to be inhibited only by CsA but not by FK506, whereas both immunosuppressants block activation-induced apoptosis in T cells. Since T-3 exerts its effect primarily by regulating gene transcription through direct binding to nuclear thyroid hormone receptors, our results strongly suggest that except for their similarity in the T cell receptor-mediated signal transduction process, CsA, but not FK506, also blocks another yet-unidentified step during the induction of apoptosis. The identification of this novel function of CsA may provide an important clue toward the understanding of the mechanism of apoptosis and helps in designing better clinical applications of the immunosuppressants.	NICHHD, MOL EMBRYOL LAB, NIH, BETHESDA, MD 20892 USA; AMER RED CROSS, HOLLAND LAB, DEPT IMMUNOL, ROCKVILLE, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); American Red Cross				Shi, Yun-Bo/0000-0002-6330-0639				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; Dauca M., 1985, METAMORPHOSIS, P36; Dodd M.H.I., 1976, P467; Gilbert L, 1981, METAMORPHOSIS PROBLE; Gilbert LI, 1996, METAMORPHOSIS POST E; HORNE SM, 1995, ARCH MICROBIOL, V163, P357, DOI 10.1007/s002030050215; ISHIZUYAOKA A, 1987, ANAT ANZEIGER, V164, P81; ISHIZUYAOKA A, 1992, J MORPHOL, V213, P185, DOI 10.1002/jmor.1052130205; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; ISHIZUYAOKA A, 1992, ROUX ARCH DEV BIOL, V201, P322, DOI 10.1007/BF00592113; Izutsu Y, 1996, DIFFERENTIATION, V60, P277, DOI 10.1046/j.1432-0436.1996.6050277.x; IZUTSU Y, 1993, J EXP ZOOL, V266, P163, DOI 10.1002/jez.1402660211; KERR JFR, 1974, J CELL SCI, V14, P571; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARSHALL JA, 1978, J ANAT, V126, P133; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PAHL A, 1992, J BACTERIOL, V174, P5888, DOI 10.1128/jb.174.18.5888-5894.1992; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; Shi YB, 1996, CURR TOP DEV BIOL, V32, P205, DOI 10.1016/S0070-2153(08)60429-9; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, TRENDS ENDOCRIN MET, V5, P14, DOI 10.1016/1043-2760(94)90116-3; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Shi Yun-Bo, 1996, Journal of Biomedical Science, V3, P307, DOI 10.1007/BF02257960; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; TATA JR, 1991, DEV BIOL, V146, P72, DOI 10.1016/0012-1606(91)90447-B; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WANG Z, 1993, J BIOL CHEM, V268, P16270; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; YOSHIZATO K, 1989, INT REV CYTOL, V119, P97	41	27	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					559	565		10.1096/fasebj.11.7.9212079	http://dx.doi.org/10.1096/fasebj.11.7.9212079			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212079				2022-12-25	WOS:A1997XH34200007
J	Chandel, NS; Budinger, GRS; Choe, SH; Schumacker, PT				Chandel, NS; Budinger, GRS; Choe, SH; Schumacker, PT			Cellular respiration during hypoxia - Role of cytochrome oxidase as the oxygen sensor in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CELLS; OXIDATIVE-PHOSPHORYLATION; ENERGY METABOLISM; MITOCHONDRIA; DEPENDENCE; GRADIENTS; ATP; O2	We previously reported that hepatocytes exhibit a reversible suppression of respiration during prolonged hypoxia (PO2 = 20 torr for 3-5 h), Also, isolated bovine heart cytochrome c oxidase undergoes a reversible decrease in apparent V-max when incubated under similar conditions, This study sought to link the hypoxia induced changes in cytochrome oxidase to the inhibition of respiration seen in intact cells, Hepatocytes incubated at PO2 = 20 torr exhibited decreases in respiration and increases in [NAD(P)H] after 2-3 h that were reversed upon reoxygenation (PO2 = 100 torr), Respiration during hypoxia was also inhibited when N,N,N',N'-tetramethyl-p-phenylenediamine (0.5 mM) and ascorbate (5 mM) were used to reduce cytochrome c, suggesting that cytochrome oxidase was partially inhibited. Similarly, liver submitochondrial particles revealed a 44% decrease in the apparent V-max of cytochrome oxidase after hypoxic incubation, In hepatocytes loaded with tetramethylrhodamine ethyl ester (10 nM) to quantify mitochondrial membrane potential, acute hypoxia (<30 min) produced no change in fluorescence, consistent with the absence of an acute change in respiration, However, fluorescence increased during acute reoxygenation after prolonged hypoxia, suggesting an increase in potential, The control exhibited by NADH over mitochondrial respiration was not altered during hypoxia, Thus, changes in the V-max of cytochrome oxidase during prolonged hypoxia correlate with the changes in respiration and mitochondrial potential, This suggests that the oxidase functions as an oxygen sensor in the intact hepatocyte.	UNIV CHICAGO,DEPT MED,SECT PULM & CRIT CARE,CHICAGO,IL 60637	University of Chicago				Schumacker, Paul T/0000-0001-9591-2034	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R55HL032646, R01HL032646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35440, HL32646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BROWN GC, 1990, EUR J BIOCHEM, V192, P355, DOI 10.1111/j.1432-1033.1990.tb19234.x; BUDINGER GRS, 1996, AM J PHYSIOL, V14, pL37; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x; JONES DP, 1978, J BIOL CHEM, V253, P4874; JONES DP, 1986, AM J PHYSIOL, V250, pC663, DOI 10.1152/ajpcell.1986.250.5.C663; JONES DP, 1992, ANNU REV NUTR, V12, P327, DOI 10.1146/annurev.nu.12.070192.001551; KADENBACH B, 1995, BBA-MOL BASIS DIS, V1271, P103, DOI 10.1016/0925-4439(95)00016-W; KENNEDY FG, 1986, AM J PHYSIOL, V250, pC374, DOI 10.1152/ajpcell.1986.250.3.C374; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; SEGLEN PO, 1972, EXP CELL RES, V74, P450, DOI 10.1016/0014-4827(72)90400-4; Warburg O, 1929, BIOCHEM Z, V214, P5; WILSON DF, 1988, J BIOL CHEM, V263, P2712	20	146	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18808	18816		10.1074/jbc.272.30.18808	http://dx.doi.org/10.1074/jbc.272.30.18808			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228055	hybrid			2022-12-25	WOS:A1997XM34200046
J	Hall, MC; Matson, SW				Hall, MC; Matson, SW			Mutation of a highly conserved arginine in motif IV of Escherichia coli DNA helicase II results in an ATP-binding defect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; INDUCED CONFORMATIONAL-CHANGES; SINGLE-STRANDED-DNA; UVRD GENE-PRODUCT; BOX RNA HELICASE; MISMATCH CORRECTION; EXCISION-REPAIR; POLYMERASE-I; PROTEIN; RECOMBINATION	A site-directed mutation in motif IV of Escherichia coli DNA helicase II (UvrD) was generated to examine the functional significance of this region. The highly conserved arginine at position 284 was replaced with alanine to construct UvrD-R284A. The ability of the mutant allele to function in methyl-directed mismatch repair and UvrABC-mediated nucleotide excision repair was examined by genetic complementation assays. The R284A substitution abolished function in both DNA repair pathways. To identify the biochemical defects responsible for the loss of biological function, UvrD-R284A was purified to apparent homogeneity, and its biochemical properties were compared with wild-type UvrD, UvrD-R284A failed to unwind a 92-base pair duplex region and was severely compromised in unwinding a 20-base pair duplex region. The K-m of UvrD-R284A for ATP was significantly greater than 3 mM compared with 80 mu M for UvrD. A large decrease in ATP binding was confirmed using a nitrocellulose filter binding assay. These data suggested that the R284A mutation severely reduced the affinity of helicase II for ATP. The reduced unwinding activity and loss of biological function of UvrD-R284A was probably the result of decreased affinity for ATP. These results implicate motif IV of superfamily I helicases in nucleotide binding and represent the first characterization of a helicase mutation outside motifs I and II that severely impacted the K-m for ATP.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Hall, Mark C./D-1698-2011	Hall, Mark/0000-0001-6429-2506	NIGMS NIH HHS [GM-33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTHUR HM, 1980, MOL GEN GENET, V180, P185, DOI 10.1007/BF00267368; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; Brosh RM, 1997, J BIOL CHEM, V272, P572; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CHAO KL, 1990, J BIOL CHEM, V265, P1067; FEINSTEIN SI, 1986, GENETICS, V113, P13; FERNANDEZ A, 1995, NUCLEIC ACIDS RES, V23, P1327, DOI 10.1093/nar/23.8.1327; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GravesWoodward KL, 1996, J BIOL CHEM, V271, P13629, DOI 10.1074/jbc.271.23.13629; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; Kornberg A., 1992, DNA REPLICATION; KUEMMERLE NB, 1980, J BACTERIOL, V142, P535, DOI 10.1128/JB.142.2.535-546.1980; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MENDONCA VM, 1993, J BACTERIOL, V175, P4641, DOI 10.1128/JB.175.15.4641-4651.1993; MENDONCA VM, 1995, J BACTERIOL, V177, P1326, DOI 10.1128/jb.177.5.1326-1335.1995; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; NEVERS P, 1975, MOL GEN GENET, V139, P233, DOI 10.1007/BF00268974; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; SCHELLHORN HE, 1991, J BACTERIOL, V173, P6192, DOI 10.1128/jb.173.19.6192-6198.1991; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TAUCHERSCHOLZ G, 1983, EUR J BIOCHEM, V137, P573, DOI 10.1111/j.1432-1033.1983.tb07864.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WASHBURN BK, 1993, J BACTERIOL, V175, P341, DOI 10.1128/JB.175.2.341-350.1993; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	60	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18614	18620		10.1074/jbc.272.30.18614	http://dx.doi.org/10.1074/jbc.272.30.18614			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228029	hybrid			2022-12-25	WOS:A1997XM34200020
J	Iyer, R; Delcour, AH				Iyer, R; Delcour, AH			Complex inhibition of OmpF and OmpC bacterial porins by polyamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PORINS; RECTIFIER K+ CHANNEL; CYTOPLASMIC POLYAMINES; INWARD RECTIFICATION; OUTER-MEMBRANE; ION CHANNELS; PATCH-CLAMP; BLOCK; DEPENDENCE; MECHANISM	The effects of four polyamines (putrescine, cadaverine, spermidine, and spermine) on the activity of bacterial porins OmpC and OmpF were investigated by electrophysiology. Membrane vesicles made from the outer membrane of Escherichia coli strains expressing only OmpC or OmpF were reconstituted into liposomes probed by patch clamp. The channel activity was recorded in control solutions and in the presence of increasing concentrations of a specific polyamine. In all cases, concentration- and voltage-dependent inhibitory effects were observed. They include both the suppression of channel openings and the enhancement of channel closures as well as the promotion of blocked or inactivated states, OmpF and OmpC, although highly homologous, have distinct sensitivities to modulation, especially by spermine. This compound inhibits OmpF in the nanomolar range, which is in agreement with its potency on eukaryotic channels. Putrescine was the least effective (upper millimolar range) and also had inhibitory effects qualitatively distinct from those exerted by the other polyamines. The compounds appear to bind to at least two distinct binding sites, one of which resides within the pore. The potencies to this site are lower when the polyamines are applied from the extracellular side than from the periplasmic side, suggesting an asymmetric binding site.	UNIV HOUSTON,DEPT BIOL,HOUSTON,TX 77204; UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204	University of Houston System; University of Houston; University of Houston System; University of Houston			Iyer, Ram/AAQ-1329-2020	Iyer, Ram/0000-0002-3638-2421	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034905, R01AI034905] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34905] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; BUECHNER M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P111, DOI 10.1016/0005-2736(90)90214-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; delaVega AL, 1996, J BACTERIOL, V178, P3715, DOI 10.1128/jb.178.13.3715-3721.1996; DELAVEGA AL, 1995, EMBO J, V14, P6058, DOI 10.1002/j.1460-2075.1995.tb00294.x; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Delcour AH, 1997, FEMS MICROBIOL LETT, V151, P115, DOI 10.1016/S0378-1097(97)00166-3; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GOMEZ M, 1995, PFLUG ARCH EUR J PHY, V430, P501, DOI 10.1007/BF00373886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; INGHAM C, 1990, J BACTERIOL, V172, P3577, DOI 10.1128/jb.172.7.3577-3583.1990; JAYARAMAN V, 1997, BIOPHYS J, V72, P334; Johnson TD, 1996, TRENDS PHARMACOL SCI, V17, P22, DOI 10.1016/0165-6147(96)81566-5; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KOSKI P, 1991, J BACTERIOL, V173, P3695, DOI 10.1128/JB.173.12.3695-3699.1991; LIU N, 1996, BIOPHYS J, V70, P352; LIU N, 1997, IN PRESS BIOPHYS BIO; LOPATIN AN, 1995, J GEN PHYSIOL, V106, P923, DOI 10.1085/jgp.106.5.923; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MANGAN PS, 1987, P NATL ACAD SCI USA, V84, P4896, DOI 10.1073/pnas.84.14.4896; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; MUNRO GF, 1972, J BIOL CHEM, V247, P1272; Neely MN, 1996, J BACTERIOL, V178, P5522, DOI 10.1128/jb.178.18.5522-5528.1996; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; Uehara A, 1996, BIOPHYS J, V71, P769, DOI 10.1016/S0006-3495(96)79276-7; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	35	86	88	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18595	18601		10.1074/jbc.272.30.18595	http://dx.doi.org/10.1074/jbc.272.30.18595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228026	hybrid			2022-12-25	WOS:A1997XM34200017
J	Pedersen, JI; Eggertsen, G; Hellman, U; Andersson, U; Bjorkhem, I				Pedersen, JI; Eggertsen, G; Hellman, U; Andersson, U; Bjorkhem, I			Molecular cloning and expression of cDNA encoding 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoyl-CoA oxidase from rabbit liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; RAT-LIVER; TRIHYDROXYCOPROSTANOYL-COA; CHOLIC-ACID; FATTY-ACIDS; PURIFICATION; PEROXISOMES; 3-ALPHA; PROTEIN; CHAIN	The steroid side chain cleavage in bile acid formation is catalyzed by liver peroxisomal enzymes (Pedersen, J. I. and Gustafsson, J. (1980) FEES Lett. 121, 345-348; Kase, F., Bjorkhem, I., and Pedersen, J. I. (1983) J. Lipid Res. 24, 1560-1567). We here describe the cloning and sequencing of a cDNA coding the first of these enzymes, a 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoyl-CoA oxidase (THCA-CoA oxidase) from rabbit liver peroxisomes. After tryptic digestion of purified protein in a polyacrylamide gel, five peptides were isolated and sequenced. Using two oligonucleotides deduced from the amino acid sequence data, two overlapping clones were isolated from a rabbit liver cDNA library, which together made up a unique cDNA sequence of 2139 base pairs. It contained an open reading frame of 2846 base pairs encoding a protein of 681 amino acids with a molecular mass of 76,209 daltons. All five peptides could be localized within the sequence. Transfection of COS cells with the coding part of the cDNA resulted in a significant expression of THCA-CoA oxidase activity. We were not able to demonstrate 3 alpha,7 alpha dihydroxy-5 beta-cholestanoyl-CoA oxidase activity under the same conditions. The obtained sequence showed 73.6% similarity with a proposed rat THCA-CoA oxidase and 81% similarity with a recently reported human branched chain acyl-CoA oxidase, indicating that these three proteins represent the same enzyme. The similarity with rat palmitoyl-CoA oxidase was 41.8%. The C-terminal tripeptide of the protein was SNL, a previously undescribed variant of the main class of peroxisomal targeting signals. Northern blot analysis revealed that the gene is transcribed in liver and kidney, and the major mRNA fraction had a size of approximately 2.6 kilobase pairs.	HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN CHEM,S-14186 HUDDINGE,SWEDEN; UNIV UPPSALA,LUDWIG INST CANC RES,BIOMEDICUM,S-75124 UPPSALA,SWEDEN	Karolinska Institutet; Ludwig Institute for Cancer Research; Uppsala University	Pedersen, JI (corresponding author), UNIV OSLO,INST NUTR RES,POB 1046,N-0316 OSLO,NORWAY.		Andersson, Ulf/ABD-5162-2021	Andersson, Ulf/0000-0003-0316-3860; Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				BATTA AK, 1979, J LIPID RES, V20, P935; BATTA AK, 1979, J BIOL CHEM, V254, P1907; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; Baumgart E, 1996, BIOCHEM J, V320, P115, DOI 10.1042/bj3200115; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; BJORKHEM I, 1985, NEW COMPREHENSIVE BI, V12, P231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CASTEELS M, 1990, J LIPID RES, V31, P1865; FARRANTS AKO, 1992, THESIS U OSLO; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUSTAFSSON J, 1975, J BIOL CHEM, V250, P3889; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HOFMANN AF, 1969, BIOCHIM BIOPHYS ACTA, V176, P204, DOI 10.1016/0005-2760(69)90092-7; KASE F, 1983, J LIPID RES, V24, P1560; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; PEDERSEN JI, 1988, BIOCHEM INT, V17, P163; PEDERSEN JI, 1993, BIOCHIMIE, V75, P159, DOI 10.1016/0300-9084(93)90073-2; Pedersen JI, 1996, BIOCHEM BIOPH RES CO, V224, P37, DOI 10.1006/bbrc.1996.0981; PEDERSEN JI, 1980, FEBS LETT, V121, P345, DOI 10.1016/0014-5793(80)80377-2; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; PRYDZ K, 1986, J LIPID RES, V27, P622; PRYDZ K, 1988, J LIPID RES, V29, P997; SCHEPERS L, 1989, BIOCHEM J, V257, P221, DOI 10.1042/bj2570221; SCHEPERS L, 1990, J BIOL CHEM, V265, P5242; SCHMITZ W, 1994, EUR J BIOCHEM, V222, P313, DOI 10.1111/j.1432-1033.1994.tb18870.x; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; SMALL GM, 1993, PEROXISOMES BIOL IMP, P1; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VANVELDHOVEN PP, 1994, BIOCHEM J, V304, P195, DOI 10.1042/bj3040195; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; WEBSTER LT, 1970, METHOD ENZYMOL, V77, P430; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	37	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18481	18489		10.1074/jbc.272.29.18481	http://dx.doi.org/10.1074/jbc.272.29.18481			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218493	hybrid			2022-12-25	WOS:A1997XL73500083
J	MacFarland, KJ; Shan, Q; Inman, RB; Cox, MM				MacFarland, KJ; Shan, Q; Inman, RB; Cox, MM			RecA as a motor protein - Testing models for the role of ATP hydrolysis in DNA strand exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DUPLEX DNA; NUCLEOSIDE TRIPHOSPHATE; NUCLEOPROTEIN FILAMENTS; GENETIC-RECOMBINATION; PARTIAL DENATURATION; HETEROLOGOUS INSERT; BINDING; COMPLEXES; MECHANISM	ATP hydrolysis (by RecA protein) fundamentally alters the properties of RecA protein-mediated DNA strand exchange reactions, ATP hydrolysis renders DNA strand exchange unidirectional, greatly increases the lengths of hybrid DNA created, permits the bypass of heterologous DNA insertions in one or both DNA substrates, and is absolutely required for exchange reactions involving four DNA strands, There are at least two viable models to explain how ATP hydrolysis is coupled to DNA strand exchange so as to bring about these effects, The first couples ATP hydrolysis to a redistribution of RecA monomers within a RecA filament, The second couples ATP hydrolysis to a facilitated rotation of the DNA substrates. The RecA monomer redistribution model makes the prediction that heterology bypass should not occur if the single-stranded DNA substrate is linear, The facilitated DNA rotation model predicts that RecA protein should promote the separation of paired DNA strands within a RecA filament if one of them is contiguous with a length of DNA being rotated about the filament exterior, Here, a facile bypass of heterologous insertions with linear DNA substrates is demonstrated, providing evidence against a role for RecA monomer redistribution in heterology bypass, In addition, we demonstrate that following a four-strand DNA exchange reaction, a distal segment of DNA hundreds of base pairs in length can be unwound in a nonreciprocal phase of the reaction, consistent with the direct coupling of an ATP hydrolytic motor to the proposed DNA rotation.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM 14711, GM 32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM032335, R01GM032335, R01GM014711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDALE WA, 1991, J BIOL CHEM, V266, P6499; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BIANCHI M, 1985, EMBO J, V4, P3025, DOI 10.1002/j.1460-2075.1985.tb04039.x; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; CHOW SA, 1992, J MOL BIOL, V223, P79, DOI 10.1016/0022-2836(92)90717-X; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; Cox M.M., 1989, P43; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; DUTREIX M, 1991, J MOL BIOL, V219, P645, DOI 10.1016/0022-2836(91)90661-O; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; Ishimori K, 1996, J MOL BIOL, V264, P696, DOI 10.1006/jmbi.1996.0670; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; JWANG BR, 1992, P NATL ACAD SCI USA, V89, P7596, DOI 10.1073/pnas.89.16.7596; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; Kubista M, 1996, BIOLOGICAL STRUCTURE AND DYNAMICS, VOL 1, P49; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOREL P, 1994, J BIOL CHEM, V269, P19830; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1987, J BIOL CHEM, V262, P1337; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; ULLSPERGER CJ, 1995, BIOCHEMISTRY-US, V34, P10859, DOI 10.1021/bi00034a019; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898	52	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17675	17685		10.1074/jbc.272.28.17675	http://dx.doi.org/10.1074/jbc.272.28.17675			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211918	hybrid			2022-12-25	WOS:A1997XK16500061
J	Zhang, H; Fan, SJ; Prochownik, EV				Zhang, H; Fan, SJ; Prochownik, EV			Distinct roles for MAX protein isoforms in proliferation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROTEIN; CELL-CYCLE PROGRESSION; DNA-BINDING; ORNITHINE DECARBOXYLASE; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION SITES; ONCOGENIC ACTIVITY; REPRESSOR SIN3; GROWTH-FACTOR	MAX is a basic helix-loop-helix-leucine zipper protein that plays a central role in the transcriptional control of Myc oncoproteins. MYC-MAX heterodimers stimulate transcription, whereas MAX homodimers, or heterodimers between MAX and members of the MAD family of basic helix-loop-helix-leuciue zipper proteins, repress transcription, Max exists in two major isomeric forms, MAX(L) and MAX(S), which differ from one another only by a 9-amino acid insertion/deletion. We show here that MAX(L) is much more effective at homodimeric DNA binding than MAX(S). In NIH3T3 cells, MAX(L) was able to repress a c-Myc-responsive reporter gene whereas MAX(S) either stimulated the reporter gene or had little effect on its expression. Hn comparison to control cell lines or those stably over-expressing MAX(S), MAX(L)-over-expressing cell lines showed reduced expression of transiently expressed or endogenous c-Myc responsive genes, grew more slowly, possessed a higher growth factor requirement, and showed accelerated apoptosis following growth factor deprivation, Differential effects on growth and apoptosis represent two previously unrecognized properties of MAX proteins. These can at least partly be explained by the differences in their DNA binding abilities and their effects on target gents expression.	CHILDRENS HOSP PITTSBURGH, HEMATOL ONCOL SECT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, MED CTR, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, INST CANC, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HL33741] Funding Source: Medline; PHS HHS [538572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COLLINS RJ, 1992, INT J RADIAT BIOL, V61, P451, DOI 10.1080/09553009214551201; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KULKARNI GV, 1994, J CELL SCI, V107, P1169; LEE LA, 1995, J CLIN INVEST, V95, P900, DOI 10.1172/JCI117741; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MIN SY, 1992, ONCOGENE, V7, P1531; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SOLLENBERGER KG, 1994, ONCOGENE, V9, P661; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	58	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17416	17424		10.1074/jbc.272.28.17416	http://dx.doi.org/10.1074/jbc.272.28.17416			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211884	hybrid			2022-12-25	WOS:A1997XK16500027
J	Zhang, L; Plow, EF				Zhang, L; Plow, EF			Identification and reconstruction of the binding site within alpha(M)beta(2) for a specific and high affinity ligand, NIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN CR3 CD11B/CD18; I-DOMAIN; LEUKOCYTE ADHESION; CRYSTAL-STRUCTURE; RECOGNITION SITE; INHIBITOR NIF; A-DOMAIN; MAC-1; CD18; GLYCOPROTEIN	Engagement of the alpha(M) beta(2) (CD11b/CD18, Mac-1) integrin on neutrophils supports adhesion and induces various cellular responses. These responses can be blocked by a specific ligand of alpha M beta(2), neutrophil inhibitory factor (MF). The molecular basis of alpha(M) beta(2)-NIF interactions was studied. The single chain alpha(M) subunit, expressed on the surface of human 293 cells, bound NIF with an affinity equivalent to that of alpha(M) beta(2) heterodimer. This observation, coupled with previous data showing that the alpha(M)I domain alone supported high affinity NIF binding, indicated that the binding site for NIF is restricted to the I domain. Guided by the crystal structure of the alpha(M)I domain, 16 segments corresponding to the entire enter hydrated surface of alpha(M)I domain were switched to their counterparts sequences in alpha(L), which does not bind NIF. Surface expression and heterodimer formation were achieved for all mutants, and correct folding was confirmed. Of the 16 switches, only 5 affected NIF binding substantially, reducing affinity by 8-300-fold. These data confined the NIF-binding site to a narrow region composed of Pro(147)-Arg(152), Pro(201)-Lys(217), and Asp(248) Arg(261) of alpha(M). Verifying this localization, when these segments were introduced inter the alpha(X)I-domain, the resulting chimeric receptor was converted into a high affinity NIF-binding protein.			Zhang, L (corresponding author), CLEVELAND CLIN FDN,DEPT MOL CARDIOL,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, BLOOD, V75, P1037; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BARNARD JW, 1995, J IMMUNOL, V155, P4876; BAUER C, 1995, SHOCK, V4, P187, DOI 10.1097/00024382-199509000-00006; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; HOGG N, 1989, EMBO J, V8, P3759; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26149; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; SCHMALSTIEG FC, 1988, PEDIATR INFECT DIS J, V867, P872; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	26	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17558	17564		10.1074/jbc.272.28.17558	http://dx.doi.org/10.1074/jbc.272.28.17558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211902	hybrid			2022-12-25	WOS:A1997XK16500045
J	Xie, LJ; Gross, SS				Xie, LJ; Gross, SS			Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	1996 ASBMB Meeting	JUN 02-06, 1996	NEW ORLEANS, LA	ASBMB			NITRIC-OXIDE SYNTHASE; L-ARGININE; RELAXING FACTOR; MESSENGER-RNA; ENDOTHELIAL-CELLS; L-CITRULLINE; UREA CYCLE; BIOSYNTHESIS; EXPRESSION; MEMBRANE	Immunostimulants trigger vascular smooth muscle cells (VSMC) to express both the inducible isoform of NO synthase (iNOS) and argininosuccinate synthetase (AS). With constitutively expressed argininosuccinate lyase (AL), AS confers cells with an Arg/Cit cycle that can sustain NO production via continuous regeneration of the NOS substrate, L-arginine (Arg), from the NOS coproduct, L-citrulline (Cit). To assess whether NO synthesis can be rate-limited by Arg recycling, we tested whether AS-overexpressing cells have an enhanced capacity for immununostimulant-induced NO synthesis. Rat VSMC were stably transfected with human AS cDNA in a eukaryotic cell expression vector, driven by a strong viral promoter. AS activity in transfected VSMC exceeded that induced in untransfected cells treated for 24 h with a combination of bacterial lipopolysaccharide and interferon-gamma (LPS/IFN). AS activity was predominantly associated with membranes but was also found in cytosol. Recombinant AS was purified from cytosol and possessed a specific activity exceeding that reported for native AS. Western blotting verified the basal expression of AS antigen in membranes from untreated AS-transfected VSMC and from untransfected VSMC after 24 h exposure to LPS/IFN. Epifluorescence histochemistry revealed a punctate distribution of AS antigen in transfected cells, consistent with a predominant membrane localization. Remarkably, on a per cell basis, LPS/IFN-induced NO production was 3-4-fold greater in AS-transfected cells than untransfected VSMC. In untransfected VSMC, maximal NO production during 48 h required millimolar Arg; notably, Cit was needed at approximate to 3-fold higher concentrations than Arg for a comparable NO synthesis rate. In contrast, AS-transfected VSMC utilized Arg and Cit equi-effectively and at much lower concentrations; 100 mu M of either precursor supported a maximal rate of NO synthesis for 48 h. The enhanced ability of AS-transfected cells to produce NO, compared with untransfected cells, could not be ascribed to differences in iNOS protein content or LPS/IFN potency for immunoactivation. We conclude that transfection with AS provides a continuous flux of Arg which drives NO synthesis in immunoactivated VSMC. Arg regeneration by AS is rate-limiting to NO synthesis and apparently provides iNOS with a preferred cellular source of Arg. In accord with the reported ''channeling'' of substrates by urea cycle enzymes, we hypothesize that the Arg/Cit cycle sequesters a discrete pool of recyclable substrate that sustains high-output NO synthesis.	CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, PROGRAM BIOCHEM & STRUCT BIOL, NEW YORK, NY 10021 USA	Cornell University; Cornell University					NHLBI NIH HHS [HL50656, HL 46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050656, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; DEMARQUOY J, 1994, MOL CELL BIOCHEM, V136, P145, DOI 10.1007/BF00926075; FAKLER CR, 1995, ACTA PAEDIATR, V84, P460, DOI 10.1111/j.1651-2227.1995.tb13673.x; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLODSTROM M, 1995, ENDOCRINOLOGY, V136, P3200, DOI 10.1210/en.136.8.3200; FREYTAG SO, 1984, MOL CELL BIOL, V4, P1978, DOI 10.1128/MCB.4.10.1978; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1995, BIOCHEM BIOPH RES CO, V215, P148, DOI 10.1006/bbrc.1995.2445; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HISHIKAWA K, 1992, JPN HEART J, V33, P41; KANNO K, 1992, CLIN EXP PHARMACOL P, V19, P619, DOI 10.1111/j.1440-1681.1992.tb00514.x; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; KIMBALL ME, 1980, BIOCHEMISTRY-US, V19, P705, DOI 10.1021/bi00545a015; MITCHELL JA, 1990, EUR J PHARMACOL, V176, P253, DOI 10.1016/0014-2999(90)90541-D; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NORTHRUP H, 1989, GENOMICS, V5, P442, DOI 10.1016/0888-7543(89)90007-4; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; OBRIEN WE, 1979, BIOCHEMISTRY-US, V18, P5353, DOI 10.1021/bi00591a015; Rengasamy A, 1996, J PHARMACOL EXP THER, V276, P30; RENGASAMY A, 1991, J PHARMACOL EXP THER, V259, P310; ROCHOVANSKY O, 1977, J BIOL CHEM, V252, P5287; SADRZADEH SM, 1994, CELL, V78, P915; SADRZADEH SMH, 1993, J PHARMACOL TOXICOL, V30, P103, DOI 10.1016/1056-8719(93)90013-5; SAHEKI T, 1977, J BIOCHEM, V81, P687, DOI 10.1093/oxfordjournals.jbchem.a131505; SHUTTLEWORTH CWR, 1995, NEUROSCIENCE, V68, P1295, DOI 10.1016/0306-4522(95)00193-M; SU TS, 1981, J BIOL CHEM, V256, P1826; SU YC, 1995, AM J PHYSIOL-LUNG C, V269, pL581, DOI 10.1152/ajplung.1995.269.5.L581; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; WATFORD M, 1991, ESSAYS BIOCHEM, V26, P49; YU YJ, 1995, J BIOCHEM-TOKYO, V117, P952, DOI 10.1093/oxfordjournals.jbchem.a124826	37	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16624	16630		10.1074/jbc.272.26.16624	http://dx.doi.org/10.1074/jbc.272.26.16624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	XG019	9195976	hybrid			2022-12-25	WOS:A1997XG01900080
J	Rahman, N; Arbour, L; Tonin, P; Baruchel, S; PritchardJones, K; Narod, SA; Stratton, MR				Rahman, N; Arbour, L; Tonin, P; Baruchel, S; PritchardJones, K; Narod, SA; Stratton, MR			The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene	ONCOGENE			English	Article						Wilms' tumour; loss of heterozygosity; dominant oncogene; tumour suppressor gene	MEDULLARY-THYROID CARCINOMA; ENDOCRINE NEOPLASIA TYPE-2A; RET PROTOONCOGENE; MUTATIONS; NEUROFIBROMATOSIS; PREDISPOSITION; ALLELES; CANCER; HETEROZYGOSITY; CHROMOSOME-11	A familial Wilms' tumour susceptibility gene, known as FWT1, has recently been localised to chromosome 17q12-q21 by genetic linkage analysis, Four Wilms' tumours from a family showing strong evidence of linkage to FWT1 were examined for allele loss using polymorphic microsatellite markers on chromosome 17q, In three tumours no loss of heterozygosity was observed, In the remaining case, loss of heterozygosity was detected at all markers analysed, However, the alleles lost in this Wilms' tumour were those segregating with the disease in the family, This is in contrast to the usual pattern observed in familial cancer syndromes, where the allele lost in tumours arising in gene carriers is the wild type inherited from the non mutation carrying parent, Taken together with previous data indicating that LOH on chromosome 17q is rare in sporadic Wilms' tumour, the results suggest that FWT1 is not a tumour suppressor gene, Moreover, loss of alleles linked to the disease and the implied absence of the mutated susceptibility gene in one tumour, suggests that a mutation in FWT1 may be necessary for the initiation of some familial Wilms' tumours but subsequently the maintenance of the neoplastic phenotype becomes independent of the FWT1 mutation.	INST CANC RES,PAEDIAT SECT,SUTTON SM2 5NG,SURREY,ENGLAND; MCGILL UNIV,DEPT MED,DIV MED GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT HUMAN GENET,DIV MED GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PEDIAT ONCOL,MONTREAL,PQ,CANADA; MONTREAL CHILDRENS HOSP,RES INST,MONTREAL,PQ H3H 1P3,CANADA; WOMENS COLL HOSP,TORONTO,ON M5S 1B2,CANADA	University of London; Institute of Cancer Research - UK; McGill University; McGill University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Womens College Hospital	Rahman, N (corresponding author), INST CANC RES,SECT MOL CARCINOGENESIS,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Narod, Steven A/AAA-6112-2022; Rahman, Nazneen/B-8890-2012; Pritchard-Jones, Kathy/F-4286-2014; Rahman, Nazneen/D-2802-2013	Pritchard-Jones, Kathy/0000-0002-2384-9475; Rahman, Nazneen/0000-0003-4376-0440; Arbour, Laura/0000-0002-9589-0880				BIGGS PJ, 1995, NAT GENET, V12, P441; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COLLINS N, 1995, ONCOGENE, V10, P1673; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; KELLER HD, 1993, HUM MOL GENET, V2, P851; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LANDSVATER RM, 1989, GENOMICS, V4, P246, DOI 10.1016/0888-7543(89)90327-3; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LEVY DB, 1994, CANCER RES, V54, P5953; MAW MA, 1992, CANCER RES, V52, P3094; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; NELKIN BD, 1989, CANCER RES, V49, P4114; PAL N, 1990, ONCOGENE, V5, P1665; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SHUIN T, 1994, CANCER RES, V54, P2852; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WADEY RB, 1990, ONCOGENE, V5, P901; Xing SH, 1996, ENDOCRINOLOGY, V137, P1512, DOI 10.1210/en.137.5.1512; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	31	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3099	3102		10.1038/sj.onc.1201107	http://dx.doi.org/10.1038/sj.onc.1201107			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223674				2022-12-25	WOS:A1997XG10000013
J	Smith, KS; Jacobs, Y; Chang, CP; Cleary, ML				Smith, KS; Jacobs, Y; Chang, CP; Cleary, ML			Chimeric oncoprotein E2a-Pbx1 induces apoptosis of hematopoietic cells by a p53-independent mechanism that is suppressed by Bcl-2	ONCOGENE			English	Article						apoptosis; inducible oncoprotein; translocation; homeodomain	LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PROTOONCOGENE PBX1; WILD-TYPE P53; DNA-BINDING; PRE-B; FUSION; E2A; TRANSCRIPTION; EXPRESSION	The chimeric oncoprotein E2a-Pbx1 results from fusion of the E2A and PBX1 genes following t(1;19) chromosomal translocations in B cell precursor acute leukemias. Experimentally B cell progenitors do not tolerate constitutive expression of E2a-Pbx1 which contrasts with transformation of several other cell types following its stable expression both in vitro and in vivo, To further investigate the effects of E2a-Pbx1 on the B cell progenitors, we conditionally expressed E2a-Pbx1 under control of a metal response element in hematopoietic precursor cell lines in vitro, Inducible expression of E2a-Pbx1 resulted in cell death with the morphologic and molecular features of apoptosis, A structure-function analysis demonstrated that induction of apoptosis was not a dominant-negative effect of the E2a moiety but, rather, required the DNA-binding homeodomain of Pbx1, E2a-Pbx1-induced apoptosis proceeded through a BCL2-responsive checkpoint eventuating in PARP inactivation but did require p53, Constitutive expression of E2a-Pbx1 did not induce apoptosis or continued cycling of Rat-1 fibroblasts in low serum conditions, These studies demonstrate that E2a-Pbx1 initiates programmed cell death of hematopoietic precursers by a mechanism that requires its chimeric transcriptional properties, but, unlike other nuclear oncoproteins, is independent of p53.			Smith, KS (corresponding author), STANFORD UNIV,MED CTR,DEPT PATHOL,EXPT ONCOL LAB,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42971, CA09151, CA66284] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042971, R01CA042971, F32CA066284] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHANG CP, 1997, IN RPESS MOL CELL BI; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMURA M, 1995, BLOOD, V85, P2546, DOI 10.1182/blood.V85.9.2546.bloodjournal8592546; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU QA, 1995, MOL CELL BIOL, V15, P3786; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZHOU H, 1996, SCIENCE, V272, P738	44	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2917	2926		10.1038/sj.onc.1201249	http://dx.doi.org/10.1038/sj.onc.1201249			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205098				2022-12-25	WOS:A1997XF55500005
J	Yanai, A; Arama, E; Kilfin, G; Motro, B				Yanai, A; Arama, E; Kilfin, G; Motro, B			ayk1, a novel mammalian gene related to Drosophila aurora centrosome separation kinase, is specifically expressed during meiosis	ONCOGENE			English	Article						serine/threonine protein kinase; centrosome separation; meiosis	KINESIN-LIKE PROTEIN; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; MESSENGER-RNAS; MUTATIONS; SEQUENCES; IDENTIFICATION; CLASSIFICATION; MITOSIS; MEMBERS	A novel murine gene, designated ayk1, which encodes a putative serine/threonine kinase has been cloned and characterized, The predicted catalytic domain of the protein is highly similar to that of Drosophila aurora (62.9% identity), and to that of Saccharomyces Ipl1 (49.4% identity), All three proteins also have very basic calculated isoelectric points (higher than 10), aurora has been recently shown to be crucial for centrosome separation and chromosome segregation, while Ipl1 is essential for yeast viability and accurate chromosome segregation, The results of Northern analysis and in situ RNA localization support a similar role for ayk1. The gene is specifically expressed in meiotically active cells, and during spermatogenesis, ayk1 transcripts accumulate just before the first meiotic division, Much lower levels are found in mitotically active cells, We propose that Ayk1, aurora and Ipl1 belong to a distinct new subfamily of kinases, These results suggest that the pathways controlling chromosome segregation are evolutionary conserved, and that similar control mechanisms operate in mitosis and meiosis.	BAR ILAN UNIV, DEPT LIFE SCI, IL-52900 RAMAT GAN, ISRAEL	Bar Ilan University			Arama, Eli/GYJ-0491-2022; /ABF-8487-2022					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASSOLD T, 1984, ANNU REV GENET, V6, P555; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; Kimura MA, 1985, NEUTRAL THEORY MOL E; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MOTRO B, 1991, DEVELOPMENT, V113, P1207; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAMBROOK J, 1988, MOL CLONIGN LAB MANU; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	34	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2943	2950		10.1038/sj.onc.1201144	http://dx.doi.org/10.1038/sj.onc.1201144			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205101				2022-12-25	WOS:A1997XF55500008
J	Merritt, AJ; Allen, TD; Potten, CS; Hickman, JA				Merritt, AJ; Allen, TD; Potten, CS; Hickman, JA			Apoptosis in small intestinal epithelia from p53-null mice: Evidence for a delayed, p53-indepdendent G2/M-associated cell death after gamma-irradiation	ONCOGENE			English	Article						p53; apoptosis; p53-independent apoptosis; radiation; small intestine; G2/M checkpoint	RADIATION-INDUCED APOPTOSIS; DNA-DAMAGE; GASTROINTESTINAL-TRACT; P53; CRYPTS; CYCLE; PROGRESSION; CHECKPOINT; TUMORS; CANCER	The death of small intestinal epithelial cells has been characterized and quantitated after irradiation of mice rendered homozygously null for the p53 gene, In wild-type animals homozygous for p53 a rapid (4.5 h) elevation of p53 protein was observed in the proliferative compartment of the crypts after 8 Gy of irradiation, Cells underwent cell death by apoptosis in this region, We had reported previously a total repression of apoptosis in small intestinal crypt epithelia 4.5 h after the gamma-irradiation (8 Gy) of p53 homozygously null animals, Thus, while 400 apoptotic cells mere observed in 200 half crypts taken from mild-type animals at 4.5 h, this fell to background levels (10-30) in the p53 null animals (Merritt et al., 1994) and did not increase by 12 h, However, we have nom found a delayed initiation of a p53-independent apoptosis after 8 Gy of gamma-radiation: at 24 h, approximately 100 apoptotic cells were observed in 200 half crypts, This late wave of apoptosis was not observed after 1 Gy of gamma-radiation. The morphological appearance of this p53-independent apoptosis suggested that death may have arisen as the result of aberrant mitosis, Analysis of the regeneration of crypts 3 days after irradiation of mice with between 11 and 17 Gy showed that there was no significant increase (P=0.135) in the potential of clonogenic cells from the p53 nub animals to repopulate the crypts, The data support the idea that a p53-independent apoptotic mechanism permits the engagement of apoptosis, probably by a mitotic catastrophe, after 8 Gy of gamma-irradiation in,live and that a loss of p53 does not make these epithelial cells radioresistant lit vivo to doses of 8 Gy and above, In contrast, irradiation with 1 GS failed to induce a p53-independent apoptosis in vivo, suggesting that the p53 'sensor' of damage was more sensitive than that engaging the p53-independent mechanism of cell death.	CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, DEPT EPITHELIAL BIOL, CANC RES CAMPAIGN, MANCHESTER M20 4BX, LANCS, ENGLAND; CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, DEPT ULTRASTRUCT, MANCHESTER M20 4BX, LANCS, ENGLAND; UNIV MANCHESTER, SCH BIOL SCI, MOL & CELLULAR PHARMACOL GRP, MANCHESTER M13 9PT, LANCS, ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fishel R, 1996, J NATL CANCER I, V88, P1608, DOI 10.1093/jnci/88.22.1608; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARMON BV, 1992, CELL PROLIFERAT, V25, P523, DOI 10.1111/j.1365-2184.1992.tb01457.x; HENDRY JH, 1979, RADIAT RES, V78, P404, DOI 10.2307/3574968; Kahlenberg MS, 1996, J NATL CANCER I, V88, P1665, DOI 10.1093/jnci/88.22.1665; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LESHER S, 1969, NATL CANCER I MONOGR, P185; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; Potten C. S., 1995, P45; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; POTTEN CS, 1981, INT J RADIAT BIOL, V40, P321, DOI 10.1080/09553008114551251; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; ROBERTS SA, 1990, INT J RADIAT BIOL, V57, P1243, DOI 10.1080/09553009014551321; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	183	192	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2759	2766		10.1038/sj.onc.1201126	http://dx.doi.org/10.1038/sj.onc.1201126			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190891				2022-12-25	WOS:A1997XD64300003
J	Shinagawa, T; Ishiguro, N; Horiuchi, M; Matsui, T; Okada, K; Shinagawa, M				Shinagawa, T; Ishiguro, N; Horiuchi, M; Matsui, T; Okada, K; Shinagawa, M			Deletion of c-myb exon 9 induced by insertion of repeats	ONCOGENE			English	Article						12-nucleotide repeat; c-myb; exon skipping; transcription; T lymphoma	DNA-BINDING DOMAIN; T-LYMPHOMA-CELLS; V-MYB; TRANSCRIPTIONAL ACTIVATION; PROVIRAL INTEGRATION; CELLULAR PROGENITOR; ONCOGENE PRODUCT; GENE-EXPRESSION; LEUKEMIA-VIRUS; PROTEIN	A simple repeat was found to be inserted into exon 9 of the c-myb gene in three out of 20 bovine T lymphomas. The repeat was composed of multiple copies of a 12-nucleotide motif and had no significant homology to the sequences reported so far. Tumor cells containing the repeat expressed two kinds of c-myb mRNA: (1) are that included the repetitive sequence in exon 9, and (2) are that lacked the whole sequence of exon 9. Transfection of an expression vector containing exon and intron sequences and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the mRNA demonstrated that the insertion of the repeat enhanced exon skipping of the transfected minigene. These observations imply that the insertion of the repeat may enhance exon skipping of the c-myb pre-mRNA. Although the transcription-activating activity by the c-Myb with the repeat was low, that by the c-Myb without exon 9 was three- to eightfold higher than the wild-type c-Myb. These data suggest that insertion of the 12-nucleotide repeat in codon 359 may result in c-Myb proteins having high- and low-transcription-activating activity.	OBIHIRO UNIV AGR & VET MED,DEPT VET PUBL HLTH,OBIHIRO,HOKKAIDO 080,JAPAN; OBIHIRO UNIV AGR & VET MED,DEPT VET PATHOL,OBIHIRO,HOKKAIDO 080,JAPAN; IWATE UNIV,DEPT VET PATHOL,MORIOKA,IWATE 020,JAPAN	Obihiro University of Agriculture & Veterinary Medicine; Obihiro University of Agriculture & Veterinary Medicine; Iwate University								BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; ESS KC, 1995, MOL CELL BIOL, V15, P5707; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FAVIER D, 1994, ONCOGENE, V9, P305; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; ISHIGURO N, 1994, J BIOL CHEM, V269, P26822; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1995, ONCOGENE, V11, P2113; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHINAGAWA T, 1994, J VET MED SCI, V56, P957, DOI 10.1292/jvms.56.957; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZOBEL A, 1991, ONCOGENE, V6, P1397	47	2	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2775	2783		10.1038/sj.onc.1201130	http://dx.doi.org/10.1038/sj.onc.1201130			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190893				2022-12-25	WOS:A1997XD64300005
J	Bellamy, COC; Clarke, AR; Wyllie, AH; Harrison, DJ				Bellamy, COC; Clarke, AR; Wyllie, AH; Harrison, DJ			p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage	FASEB JOURNAL			English	Article						cell cycle; carcinogenesis; hepatocyte; wild-type cell; liver carcinoma	HEPATOCELLULAR-CARCINOMA; P53-DEFICIENT MICE; GAMMA-IRRADIATION; IN-VIVO; GROWTH; GENE; RAT; HEPATOCYTES; PROTEIN; HEPATOCARCINOGENESIS	Despite good evidence for p53 dysfunction in human hepatocellular carcinomas, little is known of the significance of p53 to normal hepatocytes and whether p53 dysfunction is relevant to early hepatocarcinogenesis. We have therefore examined the consequences of targeted p53 deficiency in hepatocytes for regulation of apoptosis, proliferation, and ploidy. p53 deficiency was silent in normal liver and did not affect progression from diploidy to polyploidy in the aging liver. However, in primary culture the absence of p53 resulted in increased hepatocyte proliferation indices and decreased sensitivity to proliferation inhibition by TGF beta. Moreover, p53-deficient cells continued to survive and proliferate under conditions of minimal trophic support that led to growth arrest and apoptosis of wild-type cells. In vivo, p53-deficient mice had enhanced proliferative responses to both xenobiotic hepatomitogen and CCl4-induced liver necrosis, although lack of persistent proliferation showed that other control mechanisms are important. There was no simple relationship between p53 and apoptosis after DNA damage because UV irradiation led to p53-independent apoptosis, even though p53 was stabilized. However, p53 did couple DNA damage to growth arrest, and abnormal mitoses after gamma-irradiation of regenerating p53 null livers demonstrated circumstances where loss of G(1) and G(2) checkpoints may generate abnormal ploidy. Thus p53 becomes important when hepatocytes are released from G(0) and stressed, sensitizing them to mitogen and cytokine regulators of cell cycle progression and apoptosis. Hence p53 deficiency is likely to be significant in an environment of persistent regenerative stimuli and unfavorable trophic support or in the presence of other enabling genetic lesions. This model is relevant to human hepatocarcinogenesis, which almost always occurs against a background of chronic hepatocellular destruction in hepatitis and cirrhosis. In that context, by reducing the need for cytokine support and disabling DNA damage-induced growth arrest, p53 deficiency should facilitate the expansion of preneoplastic clones in chronic liver disease.			Bellamy, COC (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.			harrison, david/0000-0001-9041-9988; Clarke, Alan/0000-0002-4281-426X				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; BELLAMY COC, 1997, IN PRESS APOPTOSIS C; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; CATER DB, 1956, ACTA RADIOL, V46, P655, DOI 10.3109/00016925609171460; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto N, 1986, Symp Fundam Cancer Res, V39, P69; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; FUKS Z, 1994, CANCER RES, V54, P2582; GERACI JP, 1994, RADIAT RES, V140, P249, DOI 10.2307/3578909; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUIMARAES JP, 1966, EXPERIENTIA, V22, P661, DOI 10.1007/BF01902428; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hayashi H, 1995, HEPATOLOGY, V22, P1702; HUANG SN, 1995, HEPATOLOGY, V21, P620, DOI 10.1002/hep.1840210303; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KEMP CJ, 1995, MOL CARCINOGEN, V12, P132, DOI 10.1002/mc.2940120304; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LIANG TJ, 1995, HEPATOLOGY, V22, P1330, DOI 10.1002/hep.1840220445; LIVNI N, 1995, CANCER, V75, P2420, DOI 10.1002/1097-0142(19950515)75:10<2420::AID-CNCR2820751006>3.0.CO;2-6; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; ODA T, 1994, CANCER LETT, V83, P197, DOI 10.1016/0304-3835(94)90319-0; ODA T, 1992, CANCER RES, V52, P6358; POLAND A, 1980, MOL PHARMACOL, V18, P571; Rafferty JA, 1996, ONCOGENE, V12, P693; RENTON KW, 1978, MOL PHARMACOL, V14, P672; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; SELL C, 1995, CANCER RES, V55, P303; SHIMA A, 1985, INT J RADIAT BIOL, V47, P261, DOI 10.1080/09553008514550391; THOMPSON NL, 1986, CANCER RES, V46, P3111; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; ZHAO M, 1994, VIRCHOWS ARCH, V424, P613, DOI 10.1007/BF01069741	42	71	71	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					591	599		10.1096/fasebj.11.7.9212083	http://dx.doi.org/10.1096/fasebj.11.7.9212083			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212083				2022-12-25	WOS:A1997XH34200011
J	Murakami, M; Sonobe, MH; Ui, M; Kabuyama, Y; Watanabe, H; Wada, T; Handa, H; Iba, H				Murakami, M; Sonobe, MH; Ui, M; Kabuyama, Y; Watanabe, H; Wada, T; Handa, H; Iba, H			Phosphorylation and high level expression of Fra-2 in v-src transformed cells: A pathway of activation of endogenous AP-1	ONCOGENE			English	Article						AP-1; Fra-2; phosphorylation; transformation; v-src; ERK2	DNA-BINDING ACTIVITY; GROWTH-STIMULATING ACTIVITY; AFFINITY LATEX-PARTICLES; PROTEIN-KINASE; C-JUN; MAP KINASE; FOS GENE; SIGNAL-TRANSDUCTION; CELLULAR-TRANSFORMATION; TRANSCRIPTION FACTOR	Chicken embryo fibroblasts (CEF) transformed with v-src were previously reported to revert to normal phenotype after the introduction of dominant-negative mutants of Fos or Jun, indicating that endogenous AP-1 activity is essential for the cellular transformation, The major changes in the expression levels of fos and jun family genes induced by v-src were the elevation of fra-2 and c-jun transcripts. We show here that extensive phosphorylation of the AP-1 component Fra-2 is a major qualitative change in v-src transformed CEF and that several Ser and Thr residues in a C-terminal region of Fra-2 (amino acids 266-323) are phosphorylated specifically. The induced kinase activity was detected at the position of 42 kDa by in gel kinase assay using the Fra-2 C-terminal region as a substrate, and it was identified as chicken ERK2. JNK1 and JNK2, other members of the MAP kinase family, were not significantly activated in v-src transformed CEF and Fra-2 was not a good substrate for JNKs. fra-2 promoter analysis indicated that this promoter activity is elevated in v-src transformed CEP via two AP-1 binding sites and CRE-like sequence. We propose that phosphorylation of Fra-2 by ERK2 converts it from an inefficient transcriptional activator to an active one and further that fra-2 expression is autoregulated in response to the phosphorylation status of its gene product.	UNIV TOKYO,INST MED SCI,DEPT GENE REGULAT,MINATO KU,TOKYO 108,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	University of Tokyo; Tokyo Institute of Technology			Sonobe, Martha/I-2877-2015; Watanabe, Hirotaka/GZA-8002-2022					ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CATLING AD, 1993, ONCOGENE, V8, P1875; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Greulich H, 1996, ONCOGENE, V12, P1689; GRUDA MC, 1994, ONCOGENE, V9, P2537; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARTL M, 1991, ONCOGENE, V6, P1623; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; IBA H, 1988, ONCOGENE RES, V2, P121; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	56	53	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2435	2444		10.1038/sj.onc.1201077	http://dx.doi.org/10.1038/sj.onc.1201077			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188858				2022-12-25	WOS:A1997WZ68000007
J	Pozo, D; Delgado, M; FernandezSantos, JM; Calvo, JR; Gomariz, RP; MartinLacave, I; Ortiz, GG; Guerrero, JM				Pozo, D; Delgado, M; FernandezSantos, JM; Calvo, JR; Gomariz, RP; MartinLacave, I; Ortiz, GG; Guerrero, JM			Expression of the Mel(1a)-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen	FASEB JOURNAL			English	Article						pineal gland; gene expression; RNA extraction; DNA sequencing	VASOACTIVE-INTESTINAL-PEPTIDE; CYCLIC-AMP PRODUCTION; BINDING-SITES; PINEAL-GLAND; MELATONIN RECEPTOR; HORMONE MELATONIN; NUCLEAR RECEPTOR; BRAIN; GENE; 2-<I-125>MELATONIN	In the present work we analyze by reverse transcription, polymerase chain reaction, cDNA cloning, and sequence analysis the expression of membrane melatonin receptors in rat thymus and spleen. Results show, for the first time, that the melatonin receptor mRNA is expressed in both the thymus and spleen. Moreover, the melatonin receptor mRNA was expressed in all the lymphocyte subpopulations (CD4(+),CD8(+), double positive, double negative, and B cells) studied from the rat thymus. The Southern blot analysis with the melatonin receptor probe and sequence data also showed the identity of the DNA fragments in thymus, spleen, and the lymphocyte subpopulations studied. The melatonin receptor fragments amplified from rat brain, thymus, and spleen share identical nucleotide sequences with the rat MeI1a-melatonin receptor subtype. No signal was obtained with primers used to amplify the rat Mel(1b)-melatonin receptor subtype in both thymus and spleen. Finally, the melatonin receptor mRNA transcript distribution throughout the rat thymus was examined. Using digoxigenin-labeled cRNA probe to the specific melatonin receptor mRNA, examination of the whole thymus revealed a clear hybridization signal in both cortex and medulla. Melatonin receptor gene expression in the thymus and spleen supports the notion of the immunomodulatory role of melatonin.	UNIV SEVILLE, SCH MED, DEPT MED BIOCHEM & MOL BIOL, SEVILLE 41009, SPAIN; UNIV SEVILLE, SCH MED, DEPT NORMAL & PATHOL CYTOL & HISTOL, SEVILLE 41009, SPAIN; VIRGEN MACARENA HOSP, SEVILLE, SPAIN; UNIV COMPLUTENSE MADRID, SCH BIOL, MADRID, SPAIN; INST MEXICANO SEGURO SOCIAL, CTR INVEST BIOMED OCCIDENTE, GUADALAJARA, SPAIN	University of Sevilla; University of Sevilla; Hospital Universitario Virgen Macarena; Complutense University of Madrid			Guerrero, Josep M./D-5519-2014; Pozo, David/C-2149-2017; Guerrero, Josep M./Y-2929-2019; Calvo, Juan R./A-7338-2017; IBIS, NEUROINMUNO/O-9306-2015; Delgado, Mario/P-1524-2016	Guerrero, Josep M./0000-0001-5236-4592; Pozo, David/0000-0002-3732-4960; Calvo, Juan R./0000-0002-4854-2963; Delgado, Mario/0000-0003-1893-5982; Martin-Lacave, Ines/0000-0003-4645-0755; Fernandez-Santos, Jose Maria/0000-0003-4541-1033; Guerrero, Juan Miguel/0000-0001-7553-0119				ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; AKANO SF, 1985, AM J PHYSIOL, V219, pR527; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Berman L., 1921, GLANDS REGULATING PE; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; CALVO JR, 1995, J PINEAL RES, V18, P119, DOI 10.1111/j.1600-079X.1995.tb00149.x; CARDARELLI NF, 1990, J THEOR BIOL, V145, P397, DOI 10.1016/S0022-5193(05)80118-3; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CSABA G, 1966, EXPERIENTIA, V22, P168, DOI 10.1007/BF01897715; DELGOBBO V, 1986, INT J IMMUNOPHARMACO, V5, P567; DEVECERSKI V, 1963, ACTA ANAT, V54, P352; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; GUERRERO JM, 1992, ENDOCR RES, V18, P91, DOI 10.1080/07435809209035401; ISAACSON PG, 1987, LANCET, V2, P1488; JANKOVIC BD, 1970, IMMUNOLOGY, V18, P1; KENDALL MD, 1991, J ANAT, V177, P1; Lopez-Gonzalez Miguel A., 1993, Biotechnology Therapeutics, V4, P253; LOPEZGONZALEZ MA, 1992, J PINEAL RES, V12, P97, DOI 10.1111/j.1600-079X.1992.tb00034.x; LOPEZGONZALEZ MA, 1993, J NEUROIMMUNOL, V45, P121, DOI 10.1016/0165-5728(93)90171-T; LOPEZGONZALEZ MA, 1992, J PINEAL RES, V12, P174, DOI 10.1111/j.1600-079X.1992.tb00045.x; MAESTRONI GJM, 1995, J PINEAL RES, V18, P84, DOI 10.1111/j.1600-079X.1995.tb00144.x; MAESTRONI GJM, 1988, IMMUNOLOGY, V63, P465; MAESTRONI GJM, 1993, J PINEAL RES, V14, P1, DOI 10.1111/j.1600-079X.1993.tb00478.x; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; MARTINCACAO A, 1993, IMMUNOL LETT, V36, P59, DOI 10.1016/0165-2478(93)90069-E; MILCU SM, 1943, ACTA ENDOCRINOL-BUCH, V9, P13; MORREY KM, 1994, J IMMUNOL, V153, P2671; PANG CS, 1992, J PINEAL RES, V12, P167, DOI 10.1111/j.1600-079X.1992.tb00044.x; PERSENGIEV S, 1991, INT J BIOCHEM, V23, P1487, DOI 10.1016/0020-711X(91)90292-U; PERSENGIEV S, 1991, INT J BIOCHEM, V23, P1483, DOI 10.1016/0020-711X(91)90291-T; POON AMS, 1992, LIFE SCI, V50, P1719, DOI 10.1016/0024-3205(92)90427-Q; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; POZO D, 1996, IN PRESS J CELL BIOC; RAFIIELIDRISSI M, 1995, J NEUROIMMUNOL, V57, P171, DOI 10.1016/0165-5728(94)00182-N; REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SLAUGENHAUPT SA, 1995, GENOMICS, V27, P355, DOI 10.1006/geno.1995.1056; SPRENT J, 1989, LANCET, V2, P1488; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; YU ZH, 1991, NEUROSCI LETT, V125, P175, DOI 10.1016/0304-3940(91)90021-K	47	137	142	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1997	11	6					466	473		10.1096/fasebj.11.6.9194527	http://dx.doi.org/10.1096/fasebj.11.6.9194527			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194527				2022-12-25	WOS:A1997XE40400009
J	Puertollano, R; Li, SW; Lisanti, MP; Alonso, MA				Puertollano, R; Li, SW; Lisanti, MP; Alonso, MA			Recombinant expression of the MAL proteolipid, a component of glycolipid-enriched membrane microdomains, induces the formation of vesicular structures in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; EPITHELIAL-CELLS; PLASMA-MEMBRANE; MDCK CELLS; PROTEIN; CAVEOLAE; VESICLES; DOMAINS; DIFFERENTIATION; VIP21-CAVEOLIN	The MAL proteolipid has been identified as a component of glycolipid-enriched membrane microdomains resistant to detergent solubilization in epithelial Madin-Darby canine cells, as well as in T lymphocytes and in myelin-forming cells, To study the function of the MAL proteolipid we have ectopically expressed a tagged form of MAL in both mammalian and insect cellular backgrounds, Immunofluorescence analysis in transiently transfected COS-7 cells showed the presence of MAL in large vesicular structures, and biochemical analysis identified MAL in the fraction of membranes resistant to Triton X-100 solubilization, Electron microscopic analysis showed that the expression of MAL in Sf21 cells morphologically resulted in the intracellular accumulation of large vesicles with a diameter from 200 to greater than 700 nm that were absent in uninfected or control infected cultures, Thus, ectopic expression of MAL in this heterologous expression system was sufficient to drive the formation of vesicles with a size similar to that of the vesicles detected in mammalian cells, These vesicles were clearly different from the caveolae-like vesicles induced by caveolin expression, as evidenced by co-infection experiments using a recombinant caveolin baculovirus. Taken together, these results suggest that the MAL proteolipid might play a role as a component of the machinery of vesiculation of glycolipid-enriched membranes.	UNIV AUTONOMA MADRID,CTR BIOL MOL SEVERO OCHOA,CONSEJO SUPER INVEST CIENT,E-28049 MADRID,SPAIN; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael/B-6131-2018; Alonso, Miguel A/J-3945-2016; Lisanti, Michael P/C-6866-2013; Li, Shengwen Calvin/H-1725-2012; li, wj/HGD-7322-2022	Lisanti, Michael/0000-0003-2034-1382; Alonso, Miguel A/0000-0002-7001-8826; Li, Shengwen Calvin/0000-0002-9699-9204; 	NCI NIH HHS [F32 CA071326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; ALONSO MA, 1988, IMMUNOGENETICS, V27, P91, DOI 10.1007/BF00351081; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Millan J, 1997, BIOCHEM J, V321, P247, DOI 10.1042/bj3210247; Millan J, 1997, BIOCHEM BIOPH RES CO, V233, P707, DOI 10.1006/bbrc.1997.6530; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Possee RD., 1992, BACULOVIRUS EXPRESSI; RANCANO C, 1994, J BIOL CHEM, V269, P8159; RANCANO C, 1994, GENOMICS, V21, P447, DOI 10.1006/geno.1994.1294; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P6407; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2	33	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18311	18315		10.1074/jbc.272.29.18311	http://dx.doi.org/10.1074/jbc.272.29.18311			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218471	hybrid			2022-12-25	WOS:A1997XL73500061
J	Feron, O; Smith, TW; Michel, T; Kelly, RA				Feron, O; Smith, TW; Michel, T; Kelly, RA			Dynamic targeting of the agonist-stimulated m2 muscarinic acetylcholine receptor to caveolae in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; GUINEA-PIG; MEMBRANE; PROTEINS; CELLS; DESENSITIZATION; INTERNALIZATION; ENDOCYTOSIS; ANTIBODIES; MECHANISMS	In cardiac myocytes, as well as specialized conduction and pacemaker cells, agonist binding to muscarinic acetylcholine receptors (mAchRs) results in the activation of several sigma; transduction cascades including the endothelial isoform of nitric-oxide synthase (eNOS) expressed in these cells, Recent evidence indicates that, as in endothelial cells, eNOS in cardiac myocytes is localized to plasmalemma caveolae, specialized lipid microdomains that contain caveolin-3, a muscle-specific isoform of the scaffolding protein caveolin. In this report, using a detergent-free method for isolation of sarcolemmal caveolae from primary cultures of adult rat ventricular myocytes, we demonstrated that the muscarinic cholinergic agonist carbachol promotes the translocation of mAchR into low density gradient fractions containing most myocyte caveolin-3 and eNOS, Following isopycnic centrifugation, the different gradient fractions were exposed to the muscarinic radioligand [H-3]quinuclidinyl benzilate (QNB), and binding was determined after membrane filtration or immunoprecipitation, In a direct radioligand binding assay, we found that [H-3]QNB binding can be detected ill caveolin-enriched fractions only when cardiac myocytes have been previously exposed to carbachol, Furthermore, most of this [3H]QNB binding can be specifically immunoprecipitated by an antibody to the m2 mAchR, indicating that the translocation of this receptor subtype is responsible for the [H-3]QNB binding detected in the low density fractions, Moreover, the [H-3]QNB binding could be quantitatively immunoprecipitated from the light membrane fractions with a caveolin-3 antibody (but not a control IgG1 antibody), confirming that the m2 mAchR is targeted to caveolae after carbachol treatment, Importantly, atropine, a muscarinic cholinergic antagonist, did not induce translocation of m2 mAchR to caveolae and prevented receptor translocation in response to the agonist carbachol. Thus, dynamic targeting of sarcolemmal m2 mAchR to caveolae following agonist binding may be essential to initiate specific downstream signaling cascades in these cells.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School			FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286	NHLBI NIH HHS [HL-52320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Belhassen L, 1997, J BIOL CHEM, V272, P11198; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EGLEN RM, 1988, J PHARMACOL EXP THER, V247, P911; EVA C, 1990, J PHARMACOL EXP THER, V253, P257; FERON O, 1992, BRIT J PHARMACOL, V105, P480, DOI 10.1111/j.1476-5381.1992.tb14279.x; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GALLO MP, 1993, J PHYSIOL-LONDON, V471, P41, DOI 10.1113/jphysiol.1993.sp019890; Goldman PS, 1996, J BIOL CHEM, V271, P4215; HAN X, 1995, J GEN PHYSIOL, V106, P45, DOI 10.1085/jgp.106.1.45; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HO AKS, 1991, CELL SIGNAL, V3, P587, DOI 10.1016/0898-6568(91)90035-S; KORTH M, 1985, PFLUG ARCH EUR J PHY, V403, P266, DOI 10.1007/BF00583598; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LUTHIN GR, 1988, MOL PHARMACOL, V34, P327; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MUNTZ KH, 1994, TRENDS CELL BIOL, V6, P356; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Sharma VK, 1996, CIRC RES, V79, P86, DOI 10.1161/01.RES.79.1.86; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SVOBODA P, 1994, EUR J BIOCHEM, V224, P455, DOI 10.1111/j.1432-1033.1994.00455.x; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5; WOODWARD MP, 1978, P NATL ACAD SCI USA, V75, P4394, DOI 10.1073/pnas.75.9.4394	42	228	230	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17744	17748		10.1074/jbc.272.28.17744	http://dx.doi.org/10.1074/jbc.272.28.17744			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211926	hybrid			2022-12-25	WOS:A1997XK16500069
J	Liu, MY; Gui, GJ; Wei, BD; Preston, JF; Oakford, L; Yuksel, U; Giedroc, DP; Romeo, T				Liu, MY; Gui, GJ; Wei, BD; Preston, JF; Oakford, L; Yuksel, U; Giedroc, DP; Romeo, T			The RNA molecule CsrB binds to the global regulatory protein CsrA and antagonizes its activity in Escherichia coli.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTOVORA SUBSP CAROTOVORA; GLYCOGEN BIOSYNTHESIS; COMPUTER-SIMULATION; GENE-EXPRESSION; N-(3-OXOHEXANOYL)-L-HOMOSERINE LACTONE; ANTISENSE RNA; ERWINIA; IDENTIFICATION; BACTERIA; PRODUCT	The RNA-binding protein CsrA (carbon storage regulator) is a new kind of global regulator, which facilitates specific mRNA decay. A recombinant CsrA protein containing a metal-binding affinity tag (CsrA-H6) was purified to homogeneity and authenticated by N-terminal sequencing, matrix-assisted laser desorption/ionization time of flight mass spectrometry, and other studies. This protein was entirely contained within a globular complex of approximately 18 CsrA-H6 subunits and a single similar to 350-nucleotide RNA, CsrB. cDNA cloning and nucleotide sequencing revealed that the csrB gene is located downstream from syd in the 64-min region of the Escherichia coli K-12 genome and contains no open reading frames. The purified CsrA-CsrB ribonucleoprotein complex was active in regulating glg (glycogen biosynthesis) gene expression in vitro, as was the RNA-free form of the CsrA protein. Overexpression of csrB enhanced glycogen accumulation in E. coti, a stationary phase process that is repressed by CsrA. Thus, CsrB RNA is a second component of the Csr system, which binds to CsrA and antagonizes its effects on gene expression. A model for regulatory inter actions in Csr is presented, which also explains previous observations on the homologous system in Erwinia carotovora. A highly repeated nucleotide sequence located within predicted stem-loops and other single-stranded regions of CsrB, CAGGA(U/A/C)G, is a plausible CsrA-binding element.	UNIV N TEXAS, HLTH SCI CTR, DEPT IMMUNOL & MICROBIOL, FT WORTH, TX 76107 USA; UNIV N TEXAS, HLTH SCI CTR, DEPT ANAT & CELL BIOL, FT WORTH, TX 76107 USA; UNIV N TEXAS, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, FT WORTH, TX 76107 USA; UNIV FLORIDA, DEPT MICROBIOL & CELL SCI, GAINESVILLE, FL 32611 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; State University System of Florida; University of Florida; Texas A&M University System; Texas A&M University College Station			Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIAID NIH HHS [AI 40187] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040187] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1990, NUCLEIC ACIDS RES, V18, P3035, DOI 10.1093/nar/18.10.3035; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; CHATTERJEE A, 1995, APPL ENVIRON MICROB, V61, P1959, DOI 10.1128/AEM.61.5.1959-1967.1995; CUI Y, 1995, J BACTERIOL, V177, P5108, DOI 10.1128/jb.177.17.5108-5115.1995; DELIHAS N, 1995, MOL MICROBIOL, V15, P411, DOI 10.1111/j.1365-2958.1995.tb02254.x; FLEISCHMANN MD, 1995, SCIENCE, V269, P796; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GULTYAEV AP, 1991, NUCLEIC ACIDS RES, V19, P2489, DOI 10.1093/nar/19.9.2489; GULTYAEV AP, 1995, J MOL BIOL, V250, P37, DOI 10.1006/jmbi.1995.0356; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HEINS JN, 1966, P NUCL ACID RES; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU MY, 1995, J BACTERIOL, V177, P2663, DOI 10.1128/jb.177.10.2663-2672.1995; MCMASTER K, 1977, P NATL ACAD SCI USA, V11, P4835; Miller J.H., 1972, EXPT MOL GENETICS; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; MURATA H, 1994, APPL ENVIRON MICROB, V60, P3150, DOI 10.1128/AEM.60.9.3150-3159.1994; MURYAMA N, 1996, J MOL BIOL, V256, P483; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; ROMEO T, 1993, J BACTERIOL, V175, P5740, DOI 10.1128/JB.175.17.5740-5741.1993; ROMEO T, 1989, J BACTERIOL, V171, P2773, DOI 10.1128/jb.171.5.2773-2782.1989; ROMEO T, 1993, J BACTERIOL, V175, P4744, DOI 10.1128/JB.175.15.4744-4755.1993; Romeo T, 1996, RES MICROBIOL, V147, P505, DOI 10.1016/0923-2508(96)84004-6; SABNIS NA, 1995, J BIOL CHEM, V270, P29096, DOI 10.1074/jbc.270.49.29096; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT G, 1945, J BIOL CHEM, V161, P83; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOGO JM, 1987, ELECTRON MICROS, P61; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; White D, 1996, GENE, V182, P221, DOI 10.1016/S0378-1119(96)00547-1; Yang HH, 1996, J BACTERIOL, V178, P1012, DOI 10.1128/jb.178.4.1012-1017.1996; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	317	336	3	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17502	17510		10.1074/jbc.272.28.17502	http://dx.doi.org/10.1074/jbc.272.28.17502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211896	hybrid			2022-12-25	WOS:A1997XK16500039
J	Schleiff, E; Shore, GC; Goping, IS				Schleiff, E; Shore, GC; Goping, IS			Interactions of the human mitochondrial protein import receptor, hTom20, with precursor proteins in vitro reveal pleiotropic specificities and different receptor domain requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; SECONDARY STRUCTURE; YEAST MITOCHONDRIA; UNCOUPLING PROTEIN; INNER MEMBRANE; SIGNAL PEPTIDE; MOM19; POLYPEPTIDE; PREDICTION; INSERTION	Tom20 is part of a multiple component, dynamic complex that functions to import specific cytosolic proteins into or through the outer membrane of the mitochondrion, To analyze the contribution of Tom20 to precursor protein recognition, the cytosolic domain of the human mitochondrial import receptor, hTom20, has been expressed as a fusion protein with glutathione S-transferase and conditions established to measure specific interactions of the receptor component with precursor proteins in vitro, Reconstitution of receptor binding from purified components revealed that a prototypic matrix-destined precursor protein, pODHFR, interacts with Tom20 by a mechanism that is dependent on an active matrix targeting signal but does not require cytosolic components or ATP, Binding was influenced by both salt concentration and detergent, The effect of salt or detergent, however, varied for different precursor proteins, In particular, detergent selectively enhanced binding of pODHFR to receptor, possibly because of induced changes in the structure of the signal sequence, Finally, mutations were introduced into hTom20 which had a dramatic effect on binding of some precursor proteins but not on others, Taken together, the results suggest that; hTom20 recognizes and physically interacts with precursor proteins bearing a diverse array of topogenic sequences and that such pleiotropic specificity for these precursor proteins may involve different domains within the receptor molecule.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University			Schleiff, Enrico/C-5105-2017	Schleiff, Enrico/0000-0002-0518-3489				AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; ARGAN C, 1985, BIOCHEM BIOPH RES CO, V131, P289, DOI 10.1016/0006-291X(85)91801-7; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Bomer U, 1996, FEBS LETT, V382, P153, DOI 10.1016/0014-5793(96)00156-1; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; EPAND RM, 1986, J BIOL CHEM, V261, P17; GOPING IS, 1995, FEBS LETT, V373, P45; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; Heins L, 1996, PLANT J, V9, P829, DOI 10.1046/j.1365-313X.1996.9060829.x; HELENIUS A, 1972, J BIOL CHEM, V247, P3656; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LITHGOW T, 1995, J BIOL CHEM, V270, P14267, DOI 10.1074/jbc.270.24.14267; LIU XQ, 1988, J CELL BIOL, V107, P503, DOI 10.1083/jcb.107.2.503; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; McBride HM, 1996, J CELL BIOL, V134, P307, DOI 10.1083/jcb.134.2.307; MCBRIDE HM, 1995, BBA-BIOMEMBRANES, V1237, P162, DOI 10.1016/0005-2736(95)00088-K; Millar DG, 1996, J BIOL CHEM, V271, P25823, DOI 10.1074/jbc.271.42.25823; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALAMOV AA, 1995, J MOL BIOL, V247, P11, DOI 10.1006/jmbi.1994.0116; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SKERJANC IS, 1987, EMBO J, V6, P3117, DOI 10.1002/j.1460-2075.1987.tb02621.x; SKERJANC IS, 1990, J BIOL CHEM, V265, P9444; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLOVYEV VV, 1994, COMPUT APPL BIOSCI, V10, P661; STULTZ CM, 1993, PROTEIN SCI, V2, P305; WHITE JV, 1994, MATH BIOSCI, V119, P35, DOI 10.1016/0025-5564(94)90004-3; YI TM, 1993, J MOL BIOL, V232, P1117, DOI 10.1006/jmbi.1993.1464; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850	47	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17784	17789		10.1074/jbc.272.28.17784	http://dx.doi.org/10.1074/jbc.272.28.17784			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211931	hybrid			2022-12-25	WOS:A1997XK16500074
J	Shenoy, SK; Yu, L; Yu, CA				Shenoy, SK; Yu, L; Yu, CA			The smallest membrane anchoring subunit (QPs3) of bovine heart mitochondrial succinate-ubiquinone reductase - Cloning, sequencing, topology, and Q-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; ESCHERICHIA-COLI; BEEF-HEART; FLAVOPROTEIN SUBUNIT; FUMARATE REDUCTASE; DEHYDROGENASE; PROTEIN; COMPLEX; OXIDOREDUCTASE; IDENTIFICATION	The cDNA encoding the smallest membrane-anchoring subunit (QPs3) of bovine heart mitochondrial succinate-ubiquinone reductase was cloned and sequenced, This cDNA is 1330 base pairs long with an open reading frame of 474 base pairs that encodes the 103 amino acid residues of mature QPs3 and a 55-amino acid residue presequence. The cDNA insert has an 820-base pair long 3'-untranslated region, including a poly(A) tail. The molecular mass of QPs3, deduced from the nucleotide sequence, is 10,989 Pa. QPs3 is a very hydrophobic protein; the hydropathy plot of the amino acid sequence reveals three transmembrane helices, Previous photoaffinity labeling studies of succinate-ubiquinone reductase, using 3-azido-2-methyl-5-methoxy[H-3]-6-decyl-1,4- benzoquinone ([H-3]azido-Q), identified QPs3 as one of the putative Q-binding proteins in this reductase. An azido-Q-linked peptide with a retention time of 66 min is obtained by high performance liquid chromatography of the chymotrypsin digest of carboxymethylated and succinylated [H-3]azido Q-labeled QPs3 purified from labeled succinate-ubiquinone reductase by a procedure involving phenyl-Sepharose 4B column chromatography, preparative SDS-polyacrylamide gel electrophoresis, and acetone precipitation, The amino acid sequence of this peptide is NH2-L-N-P-C-S-A-M-D-Y-COOH, corresponding to residues 29-37, The structure of QPs3 in the inner mitochondrial membrane is proposed based on the hydropathy profile of the amino acid sequence, on the predicted tendencies to form alpha-helices and beta-sheets, and on immunobinding of Fab' fragment horseradish peroxidase conjugates prepared from antibodies against two synthetic peptides, corresponding to the NH, terminus region and the loop connecting helices 2 and 3 of QPs3, in mitoplasts and submitochondrial particles, The ubiquinone-binding domain in the proposed model of QPs3 is probably located at the end of transmembrane helix 1 toward the C-side of the mitochondrial inner membrane.	OKLAHOMA STATE UNIV, DEPT BIOCHEM & MOL BIOL, STILLWATER, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater			Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1980, J BIOL CHEM, V255, P2761; ALLEN JP, 1988, P NATL ACAD SCI USA, V85, P8487, DOI 10.1073/pnas.85.22.8487; BIRCHMACHIN MA, 1992, J BIOL CHEM, V267, P11553; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CHU TW, 1987, J BIOL CHEM, V262, P12806; *CLONTECH, 1995, CLONT, V10, P4; COCHRAN B, 1994, BBA-BIOENERGETICS, V1188, P162, DOI 10.1016/0005-2728(94)90035-3; COLE ST, 1982, EUR J BIOCHEM, V122, P479; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HARMON HJ, 1982, J BIOENERG BIOMEMBR, V14, P377, DOI 10.1007/BF00743065; HARMON HJ, 1976, BIOCHIM BIOPHYS ACTA, V440, P45, DOI 10.1016/0005-2728(76)90112-2; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HE DY, 1994, J BIOL CHEM, V269, P2292; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; JENNER ER, 1973, Patent No. 3737516; King T.E., 1967, METHOD ENZYMOL, V10, P322, DOI DOI 10.1016/0076-6879(67)10061-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; LI LB, 1991, BIOCHIM BIOPHYS ACTA, V1057, P215, DOI 10.1016/S0005-2728(05)80104-5; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Saruta F, 1996, BBA-BIOENERGETICS, V1276, P1, DOI 10.1016/0005-2728(96)00070-9; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; WEBER K, 1969, J BIOL CHEM, V244, P4406; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; YAO Y, 1986, IRON SULFUR PROTEIN, P240; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1992, J BIOL CHEM, V267, P24508; ZIEGLER DM, 1992, ARCH BIOC BIOPHYS, V97, P41	43	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17867	17872		10.1074/jbc.272.28.17867	http://dx.doi.org/10.1074/jbc.272.28.17867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211943	hybrid			2022-12-25	WOS:A1997XK16500086
J	Weber, JD; Cheng, J; Raben, DM; Gardner, A; Baldassare, JJ				Weber, JD; Cheng, J; Raben, DM; Gardner, A; Baldassare, JJ			Ablation of G(o) alpha overrides G(1) restriction point control through Ras/ERK/cyclin D1-CDK activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; ACTIVATED PROTEIN-KINASE; BETA-GAMMA-SUBUNITS; CELL-CYCLE; RETINOBLASTOMA PROTEIN; HUMAN CHROMOSOME-16; MAMMALIAN-CELLS; G1 PHASE; D1; RAS	We have generated stable IIC9 cell lines, Goa1 and Goa2, that overexpress full-length antisense G(o) alpha RNA, As shown previously, expression of antisense G(o) alpha RNA ablated the a subunit of the heterotrimeric G protein, G(o), resulting in growth in the absence of mitogen, To better understand this change in IIC9 phenotype, we have characterized the signaling pathway and cell cycle events previously shown to be important in control of IIC9 G(1)/S phase progression. In this paper we clearly demonstrate that ablation of G(o) alpha results in growth, constitutively active Ras/ERK, elevated expression of cyclin D1, and constitutively active cyclin D1-CDK complexes, all in the absence of mitogen, Furthermore, these characteristics were abolished by the transient overexpression of the transducin heterotrimeric G protein alpha subunit strongly suggesting the transformation of G(o) alpha-ablated cells involves G(o) beta gamma subunits. This is the first study to implicate a heterotrimeric G protein in tumor suppression.	ST LOUIS UNIV,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT CELL & MOL BIOL,ST LOUIS,MO 63104; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Saint Louis University; Saint Louis University; Johns Hopkins University				Weber, Jason/0000-0002-1069-6983	NHLBI NIH HHS [HL40901] Funding Source: Medline; NIGMS NIH HHS [GM51593] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM051593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AnamthawatJonsson K, 1996, CANCER GENET CYTOGEN, V88, P1, DOI 10.1016/0165-4608(95)00203-0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARDI G, 1993, INT J CANCER, V55, P422, DOI 10.1002/ijc.2910550317; BATES S, 1994, ONCOGENE, V9, P71; BIGGS PJ, 1995, NAT GENET, V11, P441, DOI 10.1038/ng1295-441; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; Cheng J, 1997, J BIOL CHEM, V272, P17312, DOI 10.1074/jbc.272.28.17312; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Doggett N A, 1996, Cytogenet Cell Genet, V72, P271; DORIONBONNET F, 1995, GENE CHROMOSOME CANC, V14, P171, DOI 10.1002/gcc.2870140304; DOUGLASS EC, 1990, CYTOGENET CELL GENET, V53, P87, DOI 10.1159/000132901; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAURE M, 1994, J BIOL CHEM, V269, P7851; FILMUS J, 1994, ONCOGENE, V9, P3627; GRANA X, 1995, ONCOGENE, V11, P211; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUFF V, 1992, CANCER RES, V52, P6117; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; KATO J, 1993, GENE DEV, V7, P331; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LI Y, 1989, ONCOGENE, V4, P795; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; MANDAHL N, 1994, J CANCER RES CLIN, V120, P707, DOI 10.1007/BF01194267; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McManus AP, 1996, CANCER GENET CYTOGEN, V87, P179, DOI 10.1016/0165-4608(95)00267-7; MURTAGH JJ, 1991, MOL CELL BIOL, V11, P1146, DOI 10.1128/MCB.11.2.1146; NEWSHAM I, 1995, GENE CHROMOSOME CANC, V12, P1, DOI 10.1002/gcc.2870120102; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TSUDA H, 1995, CANCER RES, V55, P3395; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Veronese ML, 1996, CANCER RES, V56, P728; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WEBER JD, 1997, IN PRESS BIOCH J; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Winston JT, 1996, ONCOGENE, V12, P127	48	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17320	17326		10.1074/jbc.272.28.17320	http://dx.doi.org/10.1074/jbc.272.28.17320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211869	hybrid			2022-12-25	WOS:A1997XK16500012
J	Bame, KJ; Danda, J; Hassall, A; Tumova, S				Bame, KJ; Danda, J; Hassall, A; Tumova, S			A beta(1-40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro - A role for heparan sulfate proteoglycan turnover in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CELL-SURFACE; A4 PEPTIDE; BINDING; ACCUMULATION; PROTEOLYSIS; AGGREGATION; INHIBITION; AFFINITY; RELEASE	Alzheimer's disease is characterized by senile plaques composed of polymeric fibrils of beta amyloid (A beta), a 39-42-amino acid peptide formed after proteolytic processing of the amyloid precursor protein (beta APP). Heparan sulfate proteoglycans have been shown to colocalize with A beta in Alzheimer's disease brain, and experimental evidence indicates that the interactions between the proteoglycan and the peptide are important for the promotion, deposition, and/or persistence of the senile plaques. Studies in rat brain indicated that both the core protein and the heparan sulfate glycosaminoglycan chains are required for amyloid fiber formation and deposition in vivo (Snow, A. D., Sekiguchi, R., Nochlin, D., Fraser, P., Kimata, K., Mizutani, A., Arai, Ra., Schreier, W. A., and Morgan, D. G. (1994) Neuron 12, 219-234), suggesting that one mechanism to prevent the formation of A beta-heparan sulfate proteoglycan complexes that lead to deposition of amyloid would be to degrade the proteoglycan. Normally, heparan sulfate proteoglycans are internalized and degraded to short glycosaminoglycans by intracellular heparanases. These reactions occur in the endosomal-lysosomal pathway, which is the same intracellular location where beta APP is processed to A beta. Using partially purified heparanase activities from Chinese hamster ovary cells we examined whether A beta(1-40) affects the catabolism of Chinese hamster ovary heparan sulfate glycosaminoglycans and proteoglycans in vitro. A beta(1-40) binds to both the long heparan sulfate glycosaminoglycans attached to core proteins and the short, heparanase-derived chains in a concentration-dependent and pH-dependent manner. When A beta(1-40) is added to heparanase assays, it prevents the partially purified activities from releasing heparan sulfate chains from core proteins and degrading them to short glycosaminoglycans; however, a large molar excess of the peptide to heparan sulfate is required to see the effect. Our results suggest that normally the levels of A beta in the endosomal pathway are not sufficient to interfere with heparanase activity in vivo. However, once the level of A beta-peptides are elevated, as they are in Alzheimer's disease, they could interact with heparan sulfate proteoglycans and prevent their catabolism. This could promote the formation and deposition of amyloid, since the binding of A beta to the proteoglycan species will predominate.			Bame, KJ (corresponding author), UNIV MISSOURI,SCH BIOL SCI,DIV MOL BIOL & BIOCHEM,KANSAS CITY,MO 64110, USA.		Tumova, Sarka/AAD-6353-2019	Tumova, Sarka/0000-0003-2044-4998				Bame KJ, 1997, J BIOL CHEM, V272, P2245; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1993, J BIOL CHEM, V268, P19956; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRAUKER JH, 1987, J BIOL CHEM, V262, P13093; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1991, ANAL BIOCHEM, V195, P238, DOI 10.1016/0003-2697(91)90323-L; BUEE L, 1993, BRAIN RES, V627, P199, DOI 10.1016/0006-8993(93)90321-D; BUEE L, 1993, BRAIN RES, V601, P154, DOI 10.1016/0006-8993(93)91706-X; BURDICK D, 1992, J BIOL CHEM, V267, P546; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOO EH, 1994, J BIOL CHEM, V269, P17386; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Tumova S, 1997, J BIOL CHEM, V272, P9078; YAMISHIRO DJ, 1987, J CELL BIOL, V105, P2723; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	30	42	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17005	17011		10.1074/jbc.272.27.17005	http://dx.doi.org/10.1074/jbc.272.27.17005			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202014	hybrid			2022-12-25	WOS:A1997XH44600046
J	Faux, MC; Scott, JD				Faux, MC; Scott, JD			Regulation of the AKAP79-protein kinase C interaction by Ca2+/calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; POSTSYNAPTIC DENSITIES; ANCHORING PROTEINS; CALCIUM CALMODULIN; BINDING-PROTEIN; MARCKS; PHOSPHATIDYLSERINE; PHOSPHORYLATION; LOCALIZATION; SUBSTRATE	The A kinase-anchoring protein AKAP79 coordinates the location of the cAMP-dependent protein kinase (protein kinase A), calcineurin, and protein kinase C (PKC) at the postsynaptic densities in neurons, Individual enzymes in the AKAP79 signaling complex are regulated by distinct second messenger signals; however, both PKC and calcineurin are inhibited when associated with the anchoring protein, suggesting that additional regulatory signals must be required to release active enzyme. This report focuses on the regulation of AKAP79-PKC interaction by calmodulin. AKAP79 binds calmodulin with high affinity (K-D of 28 +/- 4 nM (n = 3)) in a Ca2+-dependent. manner. Immunofluorescence staining shows that both proteins exhibit overlapping staining patterns in cultured hippocampal neurons. Calmodulin reversed the inhibition of PKC beta II by the AKAP79(31-52) peptide and reduced inhibition by the fun-length AKAP79 protein. The effect of calmodulin on inhibition of a constitutively active PKC fragment by the AKAP79(31-52) peptide was shown to be partially dependent on Ca2+, Ca2+/calmodulin reduced PKC coimmunoprecipitated with AKAP79 and resulted in a 2.6 +/- 0.5-fold (n = 6) increase in PKC activity in a preparation of postsynaptic densities. Collectively, these findings suggest that Ca2+/calmodulin competes with PKC for binding to AKAP79, releasing the inhibited kinase from its association with the anchoring protein.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NIGMS NIH HHS [GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CARR DW, 1992, J BIOL CHEM, V267, P16816; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DAVIES RD, 1994, TECH PROTEIN CHEM, V5, P2985; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FAUX MC, 1996, CELL, V70, P8; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P40; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1990, BIOCHEMISTRY-US, V29, P6656, DOI 10.1021/bi00480a015; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; SARKAR D, 1984, J BIOL CHEM, V259, P9840; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLF M, 1986, BIOCHEM BIOPH RES CO, V140, P691, DOI 10.1016/0006-291X(86)90787-4; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	38	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17038	17044		10.1074/jbc.272.27.17038	http://dx.doi.org/10.1074/jbc.272.27.17038			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202019	hybrid			2022-12-25	WOS:A1997XH44600051
J	Wang, MH; Julian, FM; Breathnach, R; Godowski, PJ; Takehara, T; Yoshikawa, W; Hagiya, M; Leonard, EJ				Wang, MH; Julian, FM; Breathnach, R; Godowski, PJ; Takehara, T; Yoshikawa, W; Hagiya, M; Leonard, EJ			Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; AMINO-ACID-SEQUENCE; TYROSINE KINASE; SCATTER FACTOR; EXTRACELLULAR DOMAIN; MOLECULAR EVOLUTION; GENE-PRODUCT; FAMILY; ACTIVATION; EXPRESSION	Macrophage stimulating protein (MSP) is a 78-kDa disulfide-linked heterodimer belonging to the plasminogen-related kringle protein family. MSP activates the RON receptor protein-tyrosine kinase, which results in cell migration, shape change, or proliferation. A structure-activity study of MSP was performed using pro-MSP, MSP, MSP alpha and beta chains, and a complex including the first two kringles and IgG Fc (MSP-NK2). Radioiodinated MSP and MSP beta chain both bound specifically to RON. The K-d of 1.4 nM for MSP beta chain is higher than the reported K-d range of 0.6-0.8 nM for MSP. Pro-MSP, MSP alpha chain, and MSP-NK2 did not bind. Only MSP stimulated RON autophosphorylation. Although the beta chain bound to RON and partially inhibited MSP-induced RON phosphorylation in kidney 293 cells, it did not induce RON phosphorylation. Pro-MSP, MSP alpha chain, or MSP-NK2 failed to activate RON, consistent with their inability to bind to the RON receptor. Functional studies showed that only MSP induced cell migration, and shape change in resident macrophages, and growth of murine keratinocytes. Our data indicate that the primary receptor binding domain is located in a region of the MSP beta chain, in contrast to structurally similar hepatocyte growth factor, in which the receptor binding site is in the alpha chain. However, full activation of RON requires binding of the complete MSP disulfide-linked alpha beta chain heterodimer.	NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21702; IMMUNOTECH SA,ANTIBODY DEPT,F-13276 MARSEILLE 09,FRANCE; INST BIOL,INSERM U211,F-44035 NANTES 01,FRANCE; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; TOYOBO CO LTD,OTSU,SHIGA 52002,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut National de la Sante et de la Recherche Medicale (Inserm); Roche Holding; Genentech; Toyobo Co., Ltd			Breathnach, Richard/K-7599-2015					Banu N, 1996, J IMMUNOL, V156, P2933; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Broxmeyer HE, 1996, ANN HEMATOL, V73, P1, DOI 10.1007/s002770050192; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PADMANABHAN K, 1994, PROTEIN SCI, V3, P898; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONSIN C, 1993, ONCOGENE, V8, P1195; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SOTTRUPJENSEN L, 1975, P NATL ACAD SCI USA, V72, P2577, DOI 10.1073/pnas.72.7.2577; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WANG MH, 1994, J BIOL CHEM, V269, P13806; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1994, J BIOL CHEM, V269, P3436; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	34	58	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16999	17004		10.1074/jbc.272.27.16999	http://dx.doi.org/10.1074/jbc.272.27.16999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202013	hybrid			2022-12-25	WOS:A1997XH44600045
J	Kester, HA; vanderLeede, BM; vanderSaag, PT; vanderBurg, B				Kester, HA; vanderLeede, BM; vanderSaag, PT; vanderBurg, B			Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; E-CADHERIN EXPRESSION; ANNEXIN-VI; ESTROGEN-RECEPTOR; TRANSCRIPTION ACTIVATION; DEVELOPMENTAL REGULATION; GLUCOCORTICOID RECEPTOR; ALPHA-CATENIN; 2ND LIGAND; LINES	Progesterone is an important regulator of normal and malignant breast epithelial cells. In addition to stimulating development of normal mammary epithelium, it can be used to treat hormone-dependent breast tumors. However, the mechanism of growth inhibition by progestins is poorly understood, and only a limited number of progesterone target genes are known so far. We therefore decided to clone such target genes by means of differential display polymerase chain reaction. In this paper, we describe an improved differential display strategy that eliminates false positives, along with the identification of nine positive (TSC-22, CD-9, Na+/K+ ATPase alpha 1, desmoplakin, CD-59, FKBP51, and three unknown genes) and one negative progesterone target genes (annexin-VI) from the mammary carcinoma cell line T47D, which is growth-inhibited by progestins. None of these genes have been reported before to be progesterone targets. Regulation of desmoplakin, CD-9, CD-59, Na+/K+-ATPase alpha 1, and annexin-VI by the progestin suggests that progesterone induces T47D cells to differentiate. Three of these genes were repressed by estradiol and up-regulated by the progestin. Estradiol treatment of T47D cells also leads to formation of lamellipodia and delocalization of two cell adhesion proteins, E-cadherin and alpha-catenin. All these effects were reversed by the progestin. These data suggest that estradiol dedifferentiates T47D cells, while progestins have the opposite effect. This may be linked to the capacity of progestins to inhibit tumor growth.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)								ALBINI A, 1986, P NATL ACAD SCI USA, V83, P8182, DOI 10.1073/pnas.83.21.8182; AMERONGEN HM, 1989, J CELL BIOL, V109, P2129, DOI 10.1083/jcb.109.5.2129; Balbin M, 1996, J BIOL CHEM, V271, P15175, DOI 10.1074/jbc.271.25.15175; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEHRENS J, 1994, INVAS METAST, V14, P1; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK DM, 1991, HISTOCHEMISTRY, V96, P405, DOI 10.1007/BF00315998; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; DILORENZO D, 1993, BIOCHEM BIOPH RES CO, V192, P1066, DOI 10.1006/bbrc.1993.1525; Fujimoto J, 1995, INVAS METAST, V15, P135; Fujimoto J, 1996, TUMOR BIOL, V17, P48, DOI 10.1159/000217966; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Jay P, 1996, BIOCHEM BIOPH RES CO, V222, P821, DOI 10.1006/bbrc.1996.0825; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KING RJB, 1993, BREAST CANCER RES TR, V27, P3, DOI 10.1007/BF00683189; KORETZ K, 1993, BRIT J CANCER, V68, P926, DOI 10.1038/bjc.1993.456; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LI FS, 1994, NUCLEIC ACIDS RES, V22, P1764, DOI 10.1093/nar/22.9.1764; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; LOZANO JJ, 1989, J CELL PHYSIOL, V138, P503, DOI 10.1002/jcp.1041380309; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MIYAKE M, 1995, CANCER RES, V55, P4127; Miyake M, 1996, CANCER RES, V56, P1244; Moore DD, 1995, GLOB MOB SURV; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; ONATE SA, 1995, SCIENCE, V270, P1354; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RIMM DL, 1995, LAB INVEST, V72, P506; ROCHA V, 1990, BIOCHEM SOC T, V18, P1110, DOI 10.1042/bst0181110; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sambrook J., 2002, MOL CLONING LAB MANU; SANTEN RJ, 1990, ENDOCR REV, V11, P1; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SHI YE, 1994, HUM REPROD, V9, P162, DOI 10.1093/humrep/9.suppl_1.162; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; SLATER EP, 1988, MOL ENDOCRINOL, V2, P485, DOI 10.1210/mend-2-6-485; SMITH DF, 1993, J BIOL CHEM, V268, P18365; Solomon KR, 1996, P NATL ACAD SCI USA, V93, P6053, DOI 10.1073/pnas.93.12.6053; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; THOMPSON EW, 1988, CANCER RES, V48, P6764; Van Roy F, 1992, Trends Cell Biol, V2, P163, DOI 10.1016/0962-8924(92)90035-L; VANDENBRULE FA, 1992, INT J CANCER, V52, P653, DOI 10.1002/ijc.2910520426; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERLEEDE BJM, 1993, MOL CARCINOGEN, V8, P112, DOI 10.1002/mc.2940080208; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VogeliLange R, 1996, NUCLEIC ACIDS RES, V24, P1385, DOI 10.1093/nar/24.7.1385; WANG ZM, 1994, AM J PHYSIOL, V267, P450; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; XU M, 1994, CELL GROWTH DIFFER, V5, P1225; YEATMAN TJ, 1995, NUCLEIC ACIDS RES, V23, P4007, DOI 10.1093/nar/23.19.4007; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11081, DOI 10.1073/pnas.92.24.11081	70	116	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16637	16643		10.1074/jbc.272.26.16637	http://dx.doi.org/10.1074/jbc.272.26.16637			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195978	hybrid			2022-12-25	WOS:A1997XG01900082
J	Marjamaki, A; Sato, M; BouetAlard, R; Yang, Q; LimonBoulez, I; Legrand, C; Lanier, SM				Marjamaki, A; Sato, M; BouetAlard, R; Yang, Q; LimonBoulez, I; Legrand, C; Lanier, SM			Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors - Integration of stimulatory and inhibitory input to the effector adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHORBOL ESTER TREATMENT; ALPHA-2-ADRENERGIC RECEPTOR; CELLS; CALMODULIN; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; EXPRESSION; SUBTYPES	To define the integration of multiple signals by different types of adenylyl cyclase (AC) within the cell, we altered the population of enzymes expressed in the cell and determined the subsequent processing of stimulatory and inhibitory input. DDT1-MF2 cells expressed AC VI-IX and were stably transfected with AC II, III, or IV. Enzyme expression was confirmed by RNA blot analysis and functional assays. Basal enzyme activity was only increased in AC II transfectants (6-fold). Maximum stimulation of enzyme activity was increased in each of the AC transfectants to varying extents. alpha(2)-AR activation elicited enzyme type-specific responses. alpha(2)-AR activation inhibited the effect of isoproterenol in control transfectants, and this action was magnified in AC III transfectants. In AC II and AC IV transfectants, alpha(2)-AR activation initiated both positive (G beta gamma) and negative signals (G(i) alpha) to the G(s) alpha-stimulated enzyme, and both types of signals were blocked by cell pretreatment with pertussis toxin. The negative input to AC II from the alpha(2)-AR was blocked by protein kinase C activation in AC II transfectants, but it was the positive input to AC IV that was compromised by protein kinase C activation. These data indicate that the integration of multiple signals by adenylyl cyclases is a dynamic process depending upon the enzyme type and phosphorylation status.	MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425; UNIV PARIS 06,REPROD PHYSIOL LAB,CNRS,URA 1449,F-75252 PARIS,FRANCE	Medical University of South Carolina; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite			Limon, Isabelle/P-2750-2017; Limon, Isabelle/AAJ-6169-2020	Limon, Isabelle/0000-0002-8773-6971; Limon, Isabelle/0000-0002-8773-6971; Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRINGS S, 1993, J GEN PHYSIOL, V101, P183, DOI 10.1085/jgp.101.2.183; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HAMAMDZIC D, 1995, AM J PHYSIOL-ENDOC M, V269, pE162, DOI 10.1152/ajpendo.1995.269.1.E162; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KATSUSHIKA S, 1993, J BIOL CHEM, V268, P2273; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KUBALAK SW, 1993, AM J PHYSIOL, V264, pH86, DOI 10.1152/ajpheart.1993.264.1.H86; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MHAOUTY S, 1995, J BIOL CHEM, V270, P11012, DOI 10.1074/jbc.270.18.11012; MHAOUTY S, 1995, THESIS U P M CURRIE; PIAN MS, 1995, J BIOL CHEM, V270, P7427, DOI 10.1074/jbc.270.13.7427; PORT JD, 1992, J BIOL CHEM, V267, P8468; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; XIA ZG, 1995, BEHAV BRAIN SCI, V18, P429, DOI 10.1017/S0140525X00039194; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	38	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16466	16473		10.1074/jbc.272.26.16466	http://dx.doi.org/10.1074/jbc.272.26.16466			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195955	hybrid			2022-12-25	WOS:A1997XG01900059
J	Rossi, G; Salminen, A; Rice, LM; Brunger, AT; Brennwald, P				Rossi, G; Salminen, A; Rice, LM; Brunger, AT; Brennwald, P			Analysis of a yeast SNARE complex reveals remarkable similarity to the neuronal SNARE complex and a novel function for the C terminus of the SNAP-25 homolog, Sec9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION COMPLEX; BOTULINUM NEUROTOXIN-A; SECRETORY PATHWAY; SYNAPTOBREVIN; SYNTAXIN; PROTEIN; SPECIFICITY; TRANSPORT; IDENTIFICATION; EXOCYTOSIS	SNARE proteins represent a family of related proteins that are thought to have a central role in vesicle targeting and fusion in all eukaryotic cells. The binding properties of the neuronal proteins synaptobrevin 1 (VAMP1), syntaxin 1, SNAP-25, and (s) under bar oluble (N) under bar-ethylmaleimide-(s) under bar ensitive (f) under bar actor (a) under bar ttachment (p) under bar rotein (alpha-SNAP), have been extensively studied. We report here the first biochemical characterization of a nonneuronal SNARE complex using recombinant forms of the yeast exocytic SNARE proteins Snc1, Sso1, and Sec9 and the yeast alpha-SNAP homolog, Sec17. Despite the low level of sequence identity, the association properties of the yeast and neuronal complexes are remarkably similar. The most striking difference we have found between the yeast and neuronal proteins is that individually neither of the target membrane SNAREs (t-SNAREs), Sso1 nor Sec9, show any detectable binding to the synaptobrevin homolog, Snc1. However, as a hetero-oligomeric complex, Sec9 and Sso1 show strong binding to Snc1. The clear dependence on the Sso1-Sec9 complex for t-SNARE function suggests that regulating the formation of this complex may be a key step in determining the site of vesicle fusion. In addition, we have used this in vitro assay to examine the biochemical effects of several mutations in Sec9 that result in pronounced growth defects in vivo. As expected, a temperature-sensitive mutation in the region most highly conserved between Sec9 and SNAP-25 is severely diminished in its ability to bind Sso1 and Snc1 in vitro. In contrast, a temperature-sensitive mutation near the C terminus of Sec9 shows no defect in SNARE binding in vitro. Similarly, a deletion of the C-terminal 17 residues, which is lethal in vivo, also binds Sso1 and Snc1 normally in vitro. Interestingly, we find that these same two C-terminal mutants, but not mutants that show SNARE assembly defects in vitro, act as potent dominant negative alleles when expressed behind a strong regulated promoter. Taken together these results suggest that the C-terminal domain of Sec9 is specifically required for a novel interaction that is required at a step following SNARE assembly.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Cornell University; Howard Hughes Medical Institute; Yale University; Yale University				Brunger, Axel/0000-0001-5121-2036; Rice, Luke/0000-0001-6551-3307				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OTTO H, 1995, BIOCHEM BIOPH RES CO, V212, P945, DOI 10.1006/bbrc.1995.2061; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0	22	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16610	16617		10.1074/jbc.272.26.16610	http://dx.doi.org/10.1074/jbc.272.26.16610			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195974	hybrid			2022-12-25	WOS:A1997XG01900078
J	Tsukamoto, T; Nigam, SK				Tsukamoto, T; Nigam, SK			Tight junction proteins form large complexes and associate with the cytoskeleton in an ATP depletion model for reversible junction assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-CELL POLARITY; CYTOSOLIC-FREE CALCIUM; INTRACELLULAR CALCIUM; E-CADHERIN; INJURY; ZO-1; KIDNEY; LOCALIZATION; MEMBRANE	A key feature of the ischemic epithelial cell phenotype is the disruption of tight junctions (TJ). In a Manin-Darby canine kidney cell model for ischemia-reperfusion/hypoxia-reoxygenation injury which employs inhibitors of glycolysis (2-deoxy-D-glucose) and oxidative phosphorylation (antimycin A), transepithelial electrical resistance, a measure of TJ integrity, dropped rapidly, correlating well with declining ATP levels, Although immunocytochemical studies revealed only subtle changes in the distribution of the TJ proteins, zonula occludens (ZO)-1, ZO-2, and cingulin, examination of the Triton X-100 solubilities of these proteins, an indicator of cytoskeletal association, revealed a striking shift of all three TJ proteins into the insoluble pool, consistent with increased cytoskeletal interaction during ATP depletion, In addition, rate-zonal centrifugation analysis of a detergent-soluble fraction showed an increase in the amount of ZO-1 and ZO-2 in high density fractions following ATP depletion, providing further evidence for association of TJ proteins into a large complex possibly involving the cytoskeleton. Analysis of immunoprecipitation data from [S-35]methionine-labeled cells revealed that ATP depletion led to the association of a 240-kDa protein with the ZO-1-containing complex. Western blots of this protein immunoprecipitated with anti-ZO-1 antibodies confirmed its identity as fodrin, a protein believed to link membrane and other proteins to the actin-based cytoskeleton. Together, our data suggest that in the absence of major immunocytochemical changes, ATP depletion leads TJ proteins to form large insoluble complexes and associate with the cytoskeleton. We propose a model in which a key, potentially regulated, step in the generation of the ischemic epithelial cell phenotype is the interaction between TJ proteins and fodrin and/or other cytoskeletal proteins.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								ALEJANDRO VSJ, 1995, KIDNEY INT, V48, P1308, DOI 10.1038/ki.1995.415; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; BACALLAO R, 1994, J CELL SCI, V107, P3301; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BUSH KT, 1994, J BIOL CHEM, V269, P23694; CANFIELD PE, 1991, AM J PHYSIOL, V261, pF1038, DOI 10.1152/ajprenal.1991.261.6.F1038; CARACENI P, 1994, AM J PHYSIOL, V266, pG799, DOI 10.1152/ajpgi.1994.266.5.G799; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DOCTOR RB, 1993, AM J PHYSIOL, V264, pC1003, DOI 10.1152/ajpcell.1993.264.4.C1003; DOCTOR RB, 1994, AM J PHYSIOL, V266, pC1803, DOI 10.1152/ajpcell.1994.266.6.C1803; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FISH EM, 1994, NEW ENGL J MED, V330, P1580; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GARZAQUINTERO R, 1993, AM J PHYSIOL, V265, pF605, DOI 10.1152/ajprenal.1993.265.5.F605; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; KRIBBEN A, 1994, J CLIN INVEST, V93, P1922, DOI 10.1172/JCI117183; KROSHIAN VM, 1994, AM J PHYSIOL, V266, pF21, DOI 10.1152/ajprenal.1994.266.1.F21; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; MADARA JL, 1987, AM J PHYSIOL, V253, pC171, DOI 10.1152/ajpcell.1987.253.1.C171; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; MANDEL LJ, 1994, J CELL SCI, V107, P3315; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MOLITORIS BA, 1990, J CLIN INVEST, V85, P3, DOI 10.1172/JCI114427; Molitoris BA, 1996, AM J PHYSIOL-RENAL, V271, pF790, DOI 10.1152/ajprenal.1996.271.4.F790; MOLITORIS BA, 1993, AM J PHYSIOL, V265, pF693, DOI 10.1152/ajprenal.1993.265.5.F693; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Nigam S K, 1992, Curr Opin Nephrol Hypertens, V1, P187, DOI 10.1097/00041552-199212000-00001; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; Nurko S, 1996, AM J PHYSIOL-RENAL, V270, pF39, DOI 10.1152/ajprenal.1996.270.1.F39; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; WEINBERG JM, 1991, J CLIN INVEST, V87, P581, DOI 10.1172/JCI115033; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	44	160	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16133	16139		10.1074/jbc.272.26.16133	http://dx.doi.org/10.1074/jbc.272.26.16133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195909	hybrid			2022-12-25	WOS:A1997XG01900013
J	Nakamura, T; WilliamsSimons, L; Westphal, H				Nakamura, T; WilliamsSimons, L; Westphal, H			A human papillomavirus type 18 E6/E7 transgene sensitizes mouse lens cells to human wild-type p53-mediated apoptosis	ONCOGENE			English	Article						lens; transgenic; HPV18; p53	RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR; CYCLE REGULATION; E6 PROTEIN; E7 GENES; MICE; P53	We have studied the concerted action of factors that influence the balance between cell proliferation and cell death in the developing lens of transgenic mice. We show that a human papillomavirus type 18 (HPV18) E6/E7 transgene that predominantly expresses the viral E7 gene product triggers apoptosis in a dose dependent manner, and causes retardation of lens growth or microphakia. E7 is known to inactivate pRB, the product of the retinoblastoma gene, and to enhance the action of p53. Our earlier work had demonstrated that over-expression of p53 itself can cause apoptosis of lens cells, and that a mutant p53 allele can interfere with this process. In the present study, we examined lenses that simultaneously express different constellations of the HPV18 E6/E7, wild-type and mutant human p53, and wild-type human PRE transgenes. We observed that lens cells expressing the HPV18 transgene are more sensitive to mild-type human p53 action than normal lens cells. As a result, there is severe microphakia in lenses that express both the HPV18 and the wild-type p53 transgenes. By contrast, apoptosis was reduced in lenses that coexpressed the HPV18 and either the PRE or the mutant p53 transgene. We conclude that levels of wild-type p53 are critical, and that any excess of p53 or suppression of PRE can cause cell death. Our results encourage attempts to counteract the deleterious action of human papillomaviruses in cervical cancer by a combination of measures that decrease cell proliferation and enhance apoptosis.			Nakamura, T (corresponding author), NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892, USA.							ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; COMERFORD SA, 1995, ONCOGENE, V10, P587; COULOMBRE AJ, 1964, J EXP ZOOL, V156, P39, DOI 10.1002/jez.1401560104; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; NAKAMURA T, 1989, New Biologist, V1, P193; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; SASAGAWA T, 1992, CANCER RES, V52, P4420; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; TSUNOKAWA Y, 1986, P NATL ACAD SCI USA, V83, P2200, DOI 10.1073/pnas.83.7.2200; VILLA LL, 1991, VIROLOGY, V181, P374; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; Yatsudo M, 1988, VIROLOGY, V166, P594; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	57	10	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					2991	2998		10.1038/sj.onc.1201155	http://dx.doi.org/10.1038/sj.onc.1201155			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223662				2022-12-25	WOS:A1997XG10000001
J	Micol, V; FernandezSilva, P; Attardi, G				Micol, V; FernandezSilva, P; Attardi, G			Functional analysis of in vivo and in organello footprinting of HeLa cell mitochondrial DNA in relationship to ATP and ethidium bromide effects on transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-STRAND TRANSCRIPTION; PROTEIN-BINDING; RIBOSOMAL-RNA; HEAVY-STRAND; INVITRO TRANSCRIPTION; IDENTIFICATION; PROMOTER; INITIATION; SITES; TERMINATION	In vivo and in organello footprinting techniques based on methylation interference have been utilized to investigate protein-DNA interactions in the transcription initiation and rDNA transcription termination regions of human mitochondrial DNA (mtDNA) in functionally active mitochondria, In particular, the changes in methylation reactivity of these regions in response to treatment of the organelles with ATP or ethidium bromide, which affects differentially the rates of mitochondrial rRNA and mRNA synthesis, have been analyzed, Two major sites of protein-DNA interactions have been identified in the main control region of mtDNA, both in vivo and in organello, which correspond to the regions of the light-strand promoter and heavy-strand rRNA-specific promoter, The in organello footprinting of the latter showed ATP- and ethidium bromide-dependent modifications that could be correlated with changes in the rate of rRNA but not of mRNA synthesis, By contrast, no ATP effects were observed on the in organello footprinting pattern of the termination region and on in vitro transcription termination, strongly suggesting that ATP control of rRNA synthesis occurs at the initiation level, Several methylation interference sites were found upstream of the whole H-strand transcription unit, pointing to possible protein-DNA interactions related to the activity of this unit, In vivo footprinting of the rDNA transcription termination region of human mtDNA has revealed a very strong protection pattern, indicating a high degree of occupancy of the termination site by mitochondrial transcription termination factor (similar to 80%).	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Silva, Patricio Fernandez/U-2256-2017; Micol, Vicente/K-6841-2014	Silva, Patricio Fernandez/0000-0001-8971-7355; Micol, Vicente/0000-0001-8089-0696	NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammini C V, 1996, Methods Enzymol, V264, P23, DOI 10.1016/S0076-6879(96)64005-1; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOGENHAGEN DF, 1984, CELL, V36, P1105, DOI 10.1016/0092-8674(84)90061-8; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2917, DOI 10.1128/MCB.8.7.2917; CANTATORE P, 1980, NUCLEIC ACIDS RES, V8, P2605, DOI 10.1093/nar/8.12.2605; CANTATORE P, 1987, FEBS LETT, V213, P144, DOI 10.1016/0014-5793(87)81480-1; CANTATORE P, 1995, J BIOL CHEM, V270, P25020, DOI 10.1074/jbc.270.42.25020; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHOMYN A, 1992, MOL MECHANISMS BIOEN, P483; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAGA A, 1993, J BIOL CHEM, V268, P8123; Enriquez JA, 1996, EUR J BIOCHEM, V237, P601, DOI 10.1111/j.1432-1033.1996.0601p.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FABER S, 1993, J BIOL CHEM, V268, P24976; Fernandez-Silva P, 1996, Methods Enzymol, V264, P129, DOI 10.1016/S0076-6879(96)64014-2; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1984, J MOL BIOL, V172, P451, DOI 10.1016/S0022-2836(84)80017-0; GAINES G, 1987, J BIOL CHEM, V262, P1907; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; GHIVIZZANI SC, 1993, J BIOL CHEM, V268, P8675; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; HIXSON JE, 1985, P NATL ACAD SCI USA, V82, P2660, DOI 10.1073/pnas.82.9.2660; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; Lawley P D, 1966, Prog Nucleic Acid Res Mol Biol, V5, P89, DOI 10.1016/S0079-6603(08)60232-9; MADSEN CS, 1993, MOL CELL BIOL, V13, P2162, DOI 10.1128/MCB.13.4.2162; Micol V, 1996, Methods Enzymol, V264, P3, DOI 10.1016/S0076-6879(96)64003-8; Micol V, 1996, Methods Enzymol, V264, P158, DOI 10.1016/S0076-6879(96)64017-8; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; NARASIMHAN N, 1987, P NATL ACAD SCI USA, V84, P4078, DOI 10.1073/pnas.84.12.4078; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OJALA D, 1980, CELL, V22, P393, DOI 10.1016/0092-8674(80)90350-5; YOZA BK, 1984, J BIOL CHEM, V259, P3909	43	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18896	18904		10.1074/jbc.272.30.18896	http://dx.doi.org/10.1074/jbc.272.30.18896			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228068	hybrid, Green Accepted			2022-12-25	WOS:A1997XM34200059
J	DeSmedt, F; Missiaen, L; Parys, JB; Vanweyenberg, V; DeSmedt, H; Erneux, C				DeSmedt, F; Missiaen, L; Parys, JB; Vanweyenberg, V; DeSmedt, H; Erneux, C			Isoprenylated human brain type I inositol 1,4,5-trisphosphate 5-phosphatase controls Ca2+ oscillations induced by ATP in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; SMOOTH-MUSCLE CELLS; RAT-BRAIN; POLYPHOSPHATE 5-PHOSPHATASE; BOVINE BRAIN; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; 3-KINASE ACTIVITY; ESCHERICHIA-COLI; KINASE-ACTIVITY	D-myo-Inositol 1,4,5-trisphosphate (InsP(3)) 5-phosphatase and 3-kinase are thought to be critical regulatory enzymes in the control of InsP(3) and Ca2+ signaling, In brain and many other cells, type I InsP(3) B-phosphatase is the major phosphatase that dephosphorylates InsP(3) and D-myo-inositol 1,3,4,5-tetrakisphosphate. The type I B-phosphatase appears to be associated with the particulate fraction of cell homogenates, Molecular cloning of the human brain enzyme identifies a C-terminal farnesylation site CVVQ. Post-translational modification of this enzyme promotes membrane interactions and changes in specific activity, We have now compared the cytosolic Ca2+ ([Ca2+](i)) responses induced by ATP, thapsigargin, and ionomycin in Chinese hamster ovary (CHO-K1) cells transfected with the intact InsP(3) B-phosphatase and with a mutant in which the C-terminal cysteine cannot be farnesylated, [Ca2+](i) was also measured in cells transfected with an InsP(3) 3-kinase construct encoding the A isoform, The Ca2+ oscillations detected in the presence of 1 mu M ATP in control cells were totally lost in 87.5% of intact (farnesylated) InsP(3) B-phosphatase-transfected cells, while such a loss occurred in only 1.1% of the mutant InsP(3) 5-phosphatase-transfected cells, All cells overexpressing the InsP(3) S-kinase also responded with an oscillatory pattern, However, in contrast to control cells, the [Ca2+](i) returned to base-line levels in between a couple of oscillations, The [Ca2+](i) responses to thapsigarin and ionomycin were identical for all cells, The four cell clones compared in this study also behaved similarly with respect to capacitative Ca2+ entry, In permeabilized cells, no differences in extent of InsP(3)-induced Ca2+ release nor in the threshold for InsP(3) action were observed among the four clones and no differences in the expression levels of the various InsP(3) receptor isoforms could be shown between the clones, Our data support the contention that the ATP-induced increase in InsP(3) concentration in transfected CHO-KI cells is essentially restricted to the site of its production near the plasma membrane, where it can be metabolized by the type I InsP(3) B-phosphatase. This enzyme directly controls the [Ca2+](i) response and the Ca2+ oscillations in intact cells.	FREE UNIV BRUSSELS, INST INTERDISCIPLINARY RES, B-1070 BRUSSELS, BELGIUM; CATHOLIC UNIV LEUVEN, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven				Parys, Jan/0000-0002-3591-4967				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BALLA T, 1991, J BIOL CHEM, V266, P24719; BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BIDEN TJ, 1987, J BIOL CHEM, V262, P9437; BIDEN TJ, 1988, BIOCHEM J, V256, P697, DOI 10.1042/bj2560697; Bird GSJ, 1996, J BIOL CHEM, V271, P6766, DOI 10.1074/jbc.271.12.6766; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1994, BIOCHEM J, V298, P669, DOI 10.1042/bj2980669; Communi D, 1997, EMBO J, V16, P1943, DOI 10.1093/emboj/16.8.1943; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; DeSmedt H, 1997, BIOCHEM J, V322, P575; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Drayer AL, 1996, BIOCHEM SOC T, V24, P1001, DOI 10.1042/bst0241001; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V134, P351, DOI 10.1016/0006-291X(86)90570-X; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; Gottesman M M, 1987, Methods Enzymol, V151, P3, DOI 10.1016/S0076-6879(87)51004-7; HARRISON RAP, 1990, CELL SIGNAL, V2, P277, DOI 10.1016/0898-6568(90)90055-F; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LEE SY, 1990, J BIOL CHEM, V265, P9434; Lobaugh LA, 1996, MOL PHARMACOL, V50, P493; MAILLEUX P, 1991, BRAIN RES, V539, P203, DOI 10.1016/0006-8993(91)91622-8; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1991, BIOCHEM J, V274, P622, DOI 10.1042/bj2740622; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NYE KE, 1992, CLIN EXP IMMUNOL, V89, P89; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Rowles SJ, 1996, BIOCHEM J, V319, P913, DOI 10.1042/bj3190913; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SWILLENS S, 1990, BIOCHEM J, V271, P835, DOI 10.1042/bj2710835; TAKAZAWA K, 1988, BIOCHEM BIOPH RES CO, V153, P632, DOI 10.1016/S0006-291X(88)81142-2; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM BIOPH RES CO, V174, P529, DOI 10.1016/0006-291X(91)91449-M; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; VanSande J, 1996, MOL CELL ENDOCRINOL, V119, P161, DOI 10.1016/0303-7207(96)03804-X; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x; VERJANS B, 1994, BIOCHEM J, V304, P679, DOI 10.1042/bj3040679; VERJANS B, 1990, CELL SIGNAL, V2, P595, DOI 10.1016/0898-6568(90)90082-L; WANG SSH, 1995, J GEN PHYSIOL, V105, P149, DOI 10.1085/jgp.105.1.149; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652	72	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17367	17375		10.1074/jbc.272.28.17367	http://dx.doi.org/10.1074/jbc.272.28.17367			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211876	hybrid			2022-12-25	WOS:A1997XK16500019
J	Morley, SJ; McKendrick, L				Morley, SJ; McKendrick, L			Involvement of stress-activated protein kinase and p38/RK mitogen-activated protein kinase signaling pathways in the enhanced phosphorylation of initiation factor 4E in NIH 3T9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTAMINE KINASE; FACTOR EIF-4E; COMPLEX-FORMATION; GROWTH-FACTOR; TRANSLATION; LYMPHOCYTES; ASSOCIATION; REGULATOR; DEFINE; P220	The initiation factor (eIF) 4E is regulated by modulating both the phosphorylation and the availability of the protein to participate in the initiation process. Here we show that either serum treatment or activation of the stress-activated protein kinase (JNK/SAPK) led to enhanced phosphorylation of eIF4E in quiescent NIH 3T3 cells, Although the immunosuppressant, rapamycin, was found to stabilize the association of eIF4E with its negative regulator, 4E-BP1, this drug did not prevent the early effects of serum stimulation on the overall rate of translation, polysome formation, the phosphorylation status of eIF4E, or the recruitment of eIF4E into the eIF4F complex. However, the rapid enhancement of eIF4E phosphorylation in response to serum was largely prevented by the inhibitor of mitogen-activated protein (MAP) kinase activation, PD98059. Activation of the JNK/SAPK signaling pathway with anisomycin resulted in enhanced phosphorylation of eIF4E, which was prevented by either rapamycin or the highly specific p38 MAP kinase inhibitor, SB203580. These data. illustrate that multiple signaling pathways, including those of distinct members of the MAP kinase family, mediate the phosphorylation of eIF4E and that the association of eIF4E with 4E-BP1 does not necessarily prevent phosphorylation of eIF4E in vivo.			Morley, SJ (corresponding author), UNIV SUSSEX,SCH BIOL SCI,BIOCHEM LAB,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMICK GD, 1992, BIOCHEM BIOPH RES CO, V183, P431, DOI 10.1016/0006-291X(92)90499-B; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BU X, 1993, J BIOL CHEM, V268, P4975; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Haas David W., 1992, Second Messengers and Phosphoproteins, V14, P163; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KLEIJN M, 1996, J CELL BIOCHEM, V59, P443; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MADER S, 1995, MOL CELL BIOL, V15, P4990; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; MORLEY SJ, 1996, PROTEIN PHOSPHORYLAT, P197; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; REDDY SAG, 1993, J BIOL CHEM, V268, P15298; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Shu JY, 1996, ONCOGENE, V13, P2421; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	47	110	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17887	17893		10.1074/jbc.272.28.17887	http://dx.doi.org/10.1074/jbc.272.28.17887			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211946	hybrid			2022-12-25	WOS:A1997XK16500089
J	Natochin, M; Granovsky, AE; Artemyev, NO				Natochin, M; Granovsky, AE; Artemyev, NO			Regulation of transducin GTPase activity by human retinal RGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENT MEMBRANES; CGMP PHOSPHODIESTERASE; G-PROTEIN; INHIBITORY SUBUNIT; MOLECULAR MECHANISM; VISUAL TRANSDUCTION; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; BINDING-SITE	The intrinsic GTPase activity of transducin controls inactivation of the effector enzyme, cGMP phosphodiesterase (PDE), during turnoff of the visual signal, The inhibitory gamma-subunit of PDE (P gamma), an unidentified membrane factor and a retinal specific member of ta-Le RGS family of proteins have been shown to accelerate GTP hydrolysis by transducin, ae have expressed a human homologue of murine retinal specific RGS (hRGSr) in Escherichia coli and investigated its role in the regulation of transducin GTPase activity, As other RGS proteins, hRGSr interacted preferentially with a transitional conformation of the transducin cu-subunit, G(t alpha)GDPAlF(4)(-), while its binding to G(t alpha)GTP gamma S or G(t alpha)GDP was weak, hRGSr and P gamma did not compete for the interaction with G(t alpha)GPAlF(4)(-) Affinity of the P gamma-G(t alpha)GDPAlF(4)(-) interaction was modestly enhanced by addition of hRGSr, as measured by a fluorescence assay of G(t alpha)DPAlF(4)(-) binding to P gamma labeled with 3-(bromoacetyl)-7-diethylaminocoumarin (P gamma BC), Binding of hRGSr to G(t alpha)GDPAlF(4)(-) complexed with P gamma BC resulted in a maximal similar to 40% reduction of BC fluorescence allowing estimation of the hRGSr affinity for G(t alpha)GDPAlF(4)(-) (K-d 35 nM). In a single turnover assay, hRGSr accelerated GTPase activity of transducin reconstituted with the urea-stripped rod outer segment (ROS) membranes by more than 10-fold to a rate of 0.23 s(-1), Addition of P gamma to the reconstituted system reduced the GTPase level accelerated by hRGSr (K-cat 0.085 s(-1)), The GTPase activity of transducin and the PDE inactivation rates in native ROS membranes in the presence of hRGSr were elevated 3-fold or more regardless of the membrane concentrations, In ROS suspensions containing 30 mu M rhodopsin these rates exceeded 0.7 s(-1), Our data suggest that effects of hRGSr on transducin's GTPase activity are attenuated by P gamma but. independent of a putative membrane GTPase activating protein factor, The rate of transducin GTPase activity in the presence of hRGSr is sufficient to correlate it with in vivo turnoff kinetics of the visual cascade.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa			Alex, Granovsky/EUV-7323-2022	Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAEHR W, 1982, J BIOL CHEM, V257, P6452; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; CLERC A, 1992, J BIOL CHEM, V267, P6620; CUNNICK J, 1994, BIOCHEM J, V297, P87, DOI 10.1042/bj2970087; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 1997, J BIOL CHEM, V272, P8853; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	49	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17444	17449		10.1074/jbc.272.28.17444	http://dx.doi.org/10.1074/jbc.272.28.17444			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211888	hybrid			2022-12-25	WOS:A1997XK16500031
J	Trzebiatowski, JR; EscalanteSemerena, JC				Trzebiatowski, JR; EscalanteSemerena, JC			Purification and characterization of CobT, the nicotinate-mononucleotide:5,6-dimethylbenzimidazole phosphoribosyltransferase enzyme from Salmonella typhimurium LT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC GENES; SPOROMUSA-OVATA; NUCLEOTIDE LOOP; COBALAMIN; VITAMIN-B12; CORRINOIDS; DIMETHYLBENZIMIDAZOLE; IDENTIFICATION; COBAMIDE; BACTERIA	We report the purification and biochemical characterization of the cobalamin biosynthetic enzyme nicotinate-mononucleotide:5,6-dimethylbenzimidazole phosphoribosyltransferase (CobT) from Salmonella typhimurium. cobT was overexpressed and the protein purified to approximately 97% homogeneity. NH2-terminal sequence analysis confirmed that the protein encoded by cobT was purified. Homogeneous CobT catalyzed the synthesis of N-1-(5-phospho-alpha-D-ribosyl)-5,6-dimethyl benzimidazole, The identity of high performance liquid chromatography-purified product was confirmed by fast atom bombardment mass spectrometry. CobT activity was optimal at 45 degrees C and pH 10.0. The apparent K-m for nicotinate mononucleotide was 680 mu M; the apparent K-m for 5,6-dimethylbenzimidazole was less than 10 mu M. CobT used nicotinamide mononucleotide as a ribose phosphate donor, CobT phosphoribosylated alternative base substrates including benzimidazole, 4,5-dimethyl-1,2-phenylenediamine, imidazole, histidine, adenine, and guanine in vitro. The resulting ribotides were incorporated into cobamides that were differentially utilized by methionine synthase (EC 2,1,1.13) ethanolamine ammonia-lyase (EC 4,3.1.7), and 1,2-propanediol dehydratase (EC 4.2,1.28) in vivo. The lack of base substrate specificity by CobT may explain the inability to isolate mutants blocked in the synthesis of 5,6-dimethylbenzimidazole in this bacterium.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM40313, R01 GM040313] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040313, R01GM040313] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLLAG DM, 1991, PROTEIN METHODS, P162; BRADBEER C, 1982, B12, V2, P31; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERON B, 1991, J BACTERIOL, V173, P6066, DOI 10.1128/jb.173.19.6066-6073.1991; CHANG GW, 1975, NATURE, V254, P150, DOI 10.1038/254150a0; CHEN P, 1995, J BACTERIOL, V177, P1461, DOI 10.1128/jb.177.6.1461-1469.1995; DAVIS RW, 1980, MANUAL GENETIC ENG A, P201; DRENNAN CL, 1994, SCIENCE, V266, P1660; EBERHARD G, 1988, BIOL CHEM H-S, V369, P1091, DOI 10.1515/bchm3.1988.369.2.1091; ESCALANTESEMERENA JC, 1992, J BACTERIOL, V174, P24, DOI 10.1128/jb.174.1.24-29.1992; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; FRIEDMAN.HC, 1965, J BIOL CHEM, V240, P413; FRIEDMANN HC, 1970, ANNU REV MICROBIOL, V24, P159, DOI 10.1146/annurev.mi.24.100170.001111; FYFE JA, 1969, J BIOL CHEM, V244, P1659; JETER RM, 1990, J GEN MICROBIOL, V136, P887, DOI 10.1099/00221287-136-5-887; JETER RM, 1984, J BACTERIOL, V159, P206, DOI 10.1128/JB.159.1.206-213.1984; JOHNSON MG, 1992, J BIOL CHEM, V267, P13302; KRAUTLER B, 1988, EUR J BIOCHEM, V176, P461, DOI 10.1111/j.1432-1033.1988.tb14303.x; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JG, 1995, J BACTERIOL, V177, P6371, DOI 10.1128/jb.177.22.6371-6380.1995; MERVYN L, 1964, PROG IND MICROBIOL, V5, P152; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; STUPPERICH E, 1987, J BACTERIOL, V169, P3076, DOI 10.1128/jb.169.7.3076-3081.1987; STUPPERICH E, 1989, EUR J BIOCHEM, V186, P657, DOI 10.1111/j.1432-1033.1989.tb15256.x; STUPPERICH E, 1988, EUR J BIOCHEM, V172, P459, DOI 10.1111/j.1432-1033.1988.tb13910.x; STUPPERICH E, 1988, ARCH MICROBIOL, V149, P213; TABOR S, 1990, CURRENT PROTOCOLS MO, V2; TAYLOR RT, 1973, ENZYMES, V9, P121; TRZEBIATOWSKI JR, 1994, J BACTERIOL, V176, P3568, DOI 10.1128/JB.176.12.3568-3575.1994; VOGEL HJ, 1956, J BIOL CHEM, V218, P97	35	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17662	17667		10.1074/jbc.272.28.17662	http://dx.doi.org/10.1074/jbc.272.28.17662			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211916	hybrid			2022-12-25	WOS:A1997XK16500059
J	Ginestra, A; Monea, S; Seghezzi, G; Dolo, V; Nagase, H; Mignatti, P; Vittorelli, ML				Ginestra, A; Monea, S; Seghezzi, G; Dolo, V; Nagase, H; Mignatti, P; Vittorelli, ML			Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; FIBROBLAST GROWTH-FACTOR; HUMAN AMNIOTIC MEMBRANE; MURINE MELANOMA-CELLS; HUMAN SARCOMA-CELLS; IV COLLAGENASE; MATRIX METALLOPROTEINASE; ENZYMATIC-PROPERTIES; ENDOTHELIAL-CELLS; TUMOR-CELLS	Membrane vesicles are shed by tumor cells both in vivo and in vitro, Although their functions are not well understood, it has been proposed that they may play multiple roles in tumor progression, We characterized membrane vesicles from human HT1080 fibrosarcoma cell cultures for the presence of proteinases involved in tumor invasion, By gelatin zymography and Western blotting, these Vesicles showed major bands corresponding to the zymogen and active forms of gelatinase B (MMP-9) and gelatinase A (MMP-2) and to the MMP-9.tissue inhibitor of metalloproteinase 1 complex, Both gelatinases appeared to be associated with the vesicle membrane, HT1080 cell vesicles also showed a strong, plasminogen-dependent fibrinolytic activity in I-125 fibrin assays; this activity was associated with urokinase plasminogen activator, as shown by casein zymography and Western blotting, Urokinase was bound to its high affinity receptor on the vesicle membrane, Addition of plasminogen resulted in activation of the progelatinases associated with the vesicles, indicating a role of the urokinase-plasmin system in MMP-2 and MMP-9 activation, We propose that vesicles shed by tumor cells may provide a large membrane surface for the activation of membrane-associated proteinases involved in extracellular matrix degradation and tissue invasion.	UNIV PALERMO, DEPT CELLULAR & DEV BIOL, I-90128 PALERMO, ITALY; UNIV AQUILA, DEPT EXPT MED, I-67010 LAQUILA, ITALY; UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOL BIOL, KANSAS CITY, KS 66160 USA; COBS, CTR ONCOBIOL SPERIMENTALE, I-90128 PALERMO, ITALY	University of Palermo; University of L'Aquila; University of Kansas; University of Kansas Medical Center			Dolo, Vincenza/AAB-2885-2021	Dolo, Vincenza/0000-0003-0424-6676; Mignatti, Paolo/0000-0002-8157-457X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALEXANDER P, 1974, CANCER RES, V34, P2077; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1990, CANCER RES, V50, P6184; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CHIBA I, 1989, CANCER RES, V49, P3972; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173; DOLO V, 1995, J SUBMICR CYTOL PATH, V27, P535; DOLO V, 1995, CLIN EXP METASTAS, V13, P277, DOI 10.1007/BF00133483; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; EMONARD HP, 1992, CANCER RES, V52, P5845; GARBISA S, 1980, CANCER LETT, V9, P359, DOI 10.1016/0304-3835(80)90030-0; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LERNER MP, 1983, CANCER LETT, V20, P125, DOI 10.1016/0304-3835(83)90040-X; Lim YT, 1996, J CELL PHYSIOL, V167, P333, DOI 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MILES LA, 1985, J BIOL CHEM, V260, P4303; MONSKY WL, 1993, CANCER RES, V53, P3159; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NAGASE H, 1996, MATRIX METALLOPROTEI, P153; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; POSTE G, 1980, P NATL ACAD SCI-BIOL, V77, P399, DOI 10.1073/pnas.77.1.399; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TARIN D, 1969, BRIT J CANCER, V23, P417, DOI 10.1038/bjc.1969.54; TARIN D, 1967, INT J CANCER, V2, P195, DOI 10.1002/ijc.2910020302; Taylor D D, 1986, Dev Biol (N Y 1985), V3, P33; TAYLOR DD, 1985, J NATL CANCER I, V74, P859; TAYLOR DD, 1988, INT J CANCER, V41, P629, DOI 10.1002/ijc.2910410425; TAYLOR DD, 1983, BIOCHEM BIOPH RES CO, V113, P470, DOI 10.1016/0006-291X(83)91749-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNKELESS JC, 1973, J EXP MED, V137, P85, DOI 10.1084/jem.137.1.85; VANBLITTERSWIJK WJ, 1982, BIOCHIM BIOPHYS ACTA, V688, P495, DOI 10.1016/0005-2736(82)90361-3; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	69	149	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17216	17222		10.1074/jbc.272.27.17216	http://dx.doi.org/10.1074/jbc.272.27.17216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202045	hybrid			2022-12-25	WOS:A1997XH44600077
J	Kondratyuk, T; Rossie, S				Kondratyuk, T; Rossie, S			Depolarization of rat brain synaptosomes increases phosphorylation of voltage-sensitive sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CAMP-DEPENDENT PHOSPHORYLATION; ALPHA-SUBUNIT; NA+ CHANNEL; CEREBROCORTICAL SYNAPTOSOMES; FUNCTIONAL MODULATION; CATALYTIC SUBUNIT; XENOPUS OOCYTES; CALCIUM ACTION; NEURONS	Depolarization of rat brain synaptosomes causes an increase in phosphorylation of serine residues 573, 610, 623, and 687 on voltage-sensitive sodium channels. Although these sites have bean shown to be phosphorylated by cAMP-dependent protein kinase in vitro and in situ, the depolarization-induced increase in their state of phosphorylation is not due to increased cAMP-dependent protein kinase activity, but requires calcium influx and protein kinase C, Since phosphorylation at this cluster of sites inhibits sodium current and would decrease neuronal excitability, this may be an important negative feedback mechanism whereby calcium influx during prolonged or repetitive depolarization can attenuate neuronal excitability and prevent further calcium accumulation. Phosphorylation of purified channels by protein kinase C decreases dephosphorylation of cAMP-dependent phosphorylation sites by purified calcineurin or protein phosphatase 2A, This suggests that one mechanism by which protein kinase C may increase phosphorylation of cAMP-dependent phosphorylation sites in sodium channels is to inhibit their dephosphorylation, This represents an important new mechanism for convergent regulation of an ion channel by two distinct signal transduction pathways.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT VET PATHOBIOL, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS031221, R01NS031221] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31221] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Cantrell AR, 1996, NEURON, V16, P1019, DOI 10.1016/S0896-6273(00)80125-7; CHANDLER LJ, 1989, J NEUROCHEM, V52, P1905, DOI 10.1111/j.1471-4159.1989.tb07275.x; CHEN TC, 1995, J BIOL CHEM, V270, P7750, DOI 10.1074/jbc.270.13.7750; COFFEY ET, 1993, J BIOL CHEM, V268, P21060; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; DASCAL N, 1991, NEURON, V6, P165, DOI 10.1016/0896-6273(91)90131-I; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DESDOUITS F, 1995, P NATL ACAD SCI USA, V92, P2682, DOI 10.1073/pnas.92.7.2682; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; FFRENCHMULLEN JMH, 1994, J NEUROSCI, V14, P1963; FORN J, 1978, P NATL ACAD SCI USA, V75, P5195, DOI 10.1073/pnas.75.10.5195; GERSHON E, 1992, J NEUROSCI, V12, P3743; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NICHOLLS DG, 1993, EUR J BIOCHEM, V212, P613, DOI 10.1111/j.1432-1033.1993.tb17700.x; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Quintaje SB, 1996, BIOCHEM BIOPH RES CO, V221, P539, DOI 10.1006/bbrc.1996.0632; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; ROTHERMEL JD, 1983, J BIOL CHEM, V258, P2125; SCHREIBMAYER W, 1991, FEBS LETT, V291, P341, DOI 10.1016/0014-5793(91)81316-Z; Smith RD, 1996, J NEUROSCI, V16, P1965; SUMMERS MD, 1987, TEXAS AGR EXPT STAT, V1555; SURMEIER DJ, 1993, PROG BRAIN RES, V99, P309; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WANG JKT, 1988, J NEUROSCI, V8, P281; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	48	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16978	16983		10.1074/jbc.272.27.16978	http://dx.doi.org/10.1074/jbc.272.27.16978			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202010	hybrid			2022-12-25	WOS:A1997XH44600042
J	LevakFrank, S; Weinstock, PH; Hayek, T; Verdery, R; Hofmann, W; Ramakrishnan, R; Sattler, W; Breslow, JL; Zechner, R				LevakFrank, S; Weinstock, PH; Hayek, T; Verdery, R; Hofmann, W; Ramakrishnan, R; Sattler, W; Breslow, JL; Zechner, R			Induced mutant mice expressing lipoprotein lipase exclusively in muscle have subnormal triglycerides yet reduced high density lipoprotein cholesterol levels in plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRACTIONAL CATABOLIC RATE; RECEPTOR-RELATED PROTEIN; TRANSGENIC MICE; MISSENSE MUTATION; ENZYME-ACTIVITY; DEFICIENCY; TISSUE; OVEREXPRESSION; METABOLISM; SEQUENCE	To determine the contribution of muscle lipoprotein lipase (LPL) to lipoprotein metabolism, induced mutant mice were generated that express human LPL exclusively in muscle, By cross-breeding heterozygous LPL knockout mice with transgenic mice expressing human LPL only in muscle, animals were obtained that express human LPL primarily in skeletal muscle on either the null (L0-MCK) or normal (L2-MCK) LPL backgrounds, and these were compared with control littermanes (L2), Fed and fasted post-heparin plasma (PHP) LPI; activities were increased 1.4- and 2.3-fold, respectively, in L2-MCK mice and were normal in L0-MCK mice compared with controls. The specific enzyme activities of human LPL in mouse plasma was comparable to human LPL in human PHP. Skeletal muscle LPL activity was increased in both LB-MCH and L0-MCK mice in the fed (6.6-fold) and fasted (4.2-fold ill L2-MCK; and 3.4-fold in L0-MCK) states, Adipose tissue LPL mRNA and activity were not detectable ill L0-MCK mice, Growth and body mass composition were similar among all groups, In the fasted and fed state, L2-MCK mice had 31% and 53% reductions, respectively, in plasma triglycerides (TG), compatible with increased PHP LPL activity. Unexpectedly, both ill the fasted and fed state the L0-MCK mice also had reduced TG (22%), despite normal PHP LPL activities. Very law density lipoprotein (VLDL) turnover studies revealed that She decreased TG were due Eo increased particle fractional catabolic rate in both L2-MCK and L0-MCK mice. Despite reduced TG, both L2-MCK and L0-MCK mice showed reduced high density lipoprotein (HDL) cholesterol levels (16% and 19%, respectively). HDL turnover studies indicated increased HDL cholesteryl ester fractional catabolic rate in the L2-MCK and L0-MCK compared with control mice. In summary, these Studies suggest that muscle LPL is particularly potent with regard to VLDL metabolism and is sufficient to compensate for the lack of LPL in other tissues with regard to lipolyzing VLDL particles. With regard to HDL, muscle LPL expression does not result in normal levels due to enhanced breakdown either by mediating accelerated HDL clearance or by failing to establish normal HDL particles that are then cleared more quickly than normal. These studies provide new insights on the tissue-specific effects of LPL on lipoprotein metabolism.	GRAZ UNIV,INST MED BIOCHEM,A-8010 GRAZ,AUSTRIA; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021; UNIV ARIZONA,ARIZONA CTR AGING,TUCSON,AZ 85721; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10021	University of Graz; Rockefeller University; University of Arizona; Columbia University			Weinstock, Peter H/AAD-2297-2021; Weinstock, Peter H/GQP-2426-2022; Breslow, Jan L/B-7544-2008	Zechner, Rudolf/0000-0001-5483-1182; Weinstock, Peter/0000-0002-4425-3232	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEBAUMBOWDEN D, 1985, ARTERIOSCLEROSIS, V5, P273, DOI 10.1161/01.ATV.5.3.273; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BORENSZTAJN J, 1970, J LIPID RES, V11, P102; BOSELLO O, 1984, INT J OBESITY, V8, P213; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; BRUN LD, 1989, METABOLISM, V38, P1005, DOI 10.1016/0026-0495(89)90013-9; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; CRYER A, 1985, REPROD NUTR DEV, V25, P255, DOI 10.1051/rnd:19850216; ECKEL RH, 1984, P NATL ACAD SCI-BIOL, V81, P7604, DOI 10.1073/pnas.81.23.7604; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; EISENBERG S, 1984, J LIPID RES, V25, P1017; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; GAVFELS ME, 1993, SOMAT CELL MOLEC GEN, V3, P557; Goldberg IJ, 1996, J LIPID RES, V37, P693; GREENWOOD MRC, 1985, INT J OBESITY, V9, P67; GREENWOOD MRC, 1984, INT J OBESITY, V8, P561; GRUEN R, 1979, METAB CLIN EXP, V27, P1955; HAYEK T, 1991, ARTERIOSCLER THROMB, V11, P1295, DOI 10.1161/01.ATV.11.5.1295; HUTTUNEN JK, 1976, CLIN SCI MOL MED, V50, P49; JENSEN GL, 1980, J BIOL CHEM, V255, P1141; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LITHELL H, 1977, ACTA U UPSAL, P272; LIU MS, 1994, J BIOL CHEM, V269, P11417; MAILLY F, 1995, ARTERIOSCL THROM VAS, V15, P468, DOI 10.1161/01.ATV.15.4.468; MATHEWS CME, 1957, PHYS MED BIOL, V2, P36; MIESENBOCK G, 1993, J CLIN INVEST, V91, P448, DOI 10.1172/JCI116222; MIKKILA EA, 1978, ATHEROSCLEROSIS, V29, P497; ODONKOR JM, 1984, BIOCHEM PHARMACOL, V33, P1337, DOI 10.1016/0006-2952(84)90189-8; OHRVALL M, 1995, METABOLISM, V44, P212, DOI 10.1016/0026-0495(95)90267-8; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; ROGERS MP, 1974, J LIPID RES, V15, P263; ROSSNER S, 1976, EUR J CLIN INVEST, V6, P299, DOI 10.1111/j.1365-2362.1976.tb00524.x; RUOTOLO G, 1992, J LIPID RES, V33, P1541; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCHOTZ MC, 1972, BIOCHIM BIOPHYS ACTA, V270, P472, DOI 10.1016/0005-2760(72)90112-9; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; STEIN O, 1983, BIOCHIM BIOPHYS ACTA, V750, P306, DOI 10.1016/0005-2760(83)90033-4; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TASKINEN MR, 1981, CLIN CHIM ACTA, V112, P325, DOI 10.1016/0009-8981(81)90455-1; TASKINEN MR, 1987, LIPOPROTEIN LIPASE, P247; TORNVALL P, 1995, ARTERIOSCL THROM VAS, V15, P1086, DOI 10.1161/01.ATV.15.8.1086; VERDERY RB, 1989, J LIPID RES, V30, P1085; VESSBY B, 1982, ATHEROSCLEROSIS, V44, P113, DOI 10.1016/0021-9150(82)90057-0; VILARO S, 1988, BIOCHEM J, V249, P549, DOI 10.1042/bj2490549; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; ZECHNER R, 1991, GENOMICS, V11, P62, DOI 10.1016/0888-7543(91)90102-K; ZSIGMOND E, 1994, J BIOL CHEM, V269, P18757	59	74	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17182	17190		10.1074/jbc.272.27.17182	http://dx.doi.org/10.1074/jbc.272.27.17182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202040	hybrid			2022-12-25	WOS:A1997XH44600072
J	Wu, T; Angus, CW; Yao, XL; Logan, C; Shelhamer, JH				Wu, T; Angus, CW; Yao, XL; Logan, C; Shelhamer, JH			p11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDa cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; CYTOPLASMIC PHOSPHOLIPASE-A(2); LIGHT-CHAIN; CALPACTIN-I; MAST-CELLS; ANNEXIN-II; KINASE-C; PHOSPHORYLATION; EXPRESSION; LIPOCORTIN	Using a two hybrid system screen of a human cDNA library, we have found that pll, a unique member of the S100 family of calcium-binding proteins, interacts with the carboxyl region of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)), p11 synthesized in a cell-free system interacts with cPLA(2) in vitro, The p11-cPLA(2) complex is detectable from a human bronchial epithelial cell line (BEAS 2B), Furthermore, pll inhibits cPLA(2) activity in vitro, Selective inhibition of pll expression in the BEAS 2B cells by antisense RNA results in an increased PLA(2) activity as well as an increased release of prelabeled arachidonic acid, This study demonstrates a novel mechanism for the regulation of cPLA(2) by an S100 protein.	NIH,CRIT CARE MED DEPT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								AARSMAN AJ, 1987, FEBS LETT, V219, P176, DOI 10.1016/0014-5793(87)81212-7; AHN NG, 1988, J BIOL CHEM, V263, P18657; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DURHAM ACH, 1983, CELL CALCIUM, V4, P33, DOI 10.1016/0143-4160(83)90047-7; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FONTEH AN, 1993, J IMMUNOL, V150, P563; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULDING NJ, 1992, IMMUNOL TODAY, V13, P295, DOI 10.1016/0167-5699(92)90040-E; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HARDER T, 1993, J CELL SCI, V104, P1109; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JOHNSSON N, 1990, PROG CLIN BIOL RES, V349, P123; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUBE E, 1991, GENE, V102, P255, DOI 10.1016/0378-1119(91)90086-Q; LABARCA C, 1980, ANAL BIOCHEM, V102, P334; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUSSOMARIE F, 1992, ANNEXINS, P35; Sambrook J., 2002, MOL CLONING LAB MANU; SARIS CJM, 1987, J BIOL CHEM, V262, P10663; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SMITH PD, 1994, TRENDS GENET, V10, P241, DOI 10.1016/0168-9525(94)90171-6; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; WINITZ S, 1994, J BIOL CHEM, V269, P1889; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; Wu T, 1996, BBA-MOL CELL RES, V1310, P175, DOI 10.1016/0167-4889(95)00143-3; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	63	99	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17145	17153		10.1074/jbc.272.27.17145	http://dx.doi.org/10.1074/jbc.272.27.17145			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202034	hybrid			2022-12-25	WOS:A1997XH44600066
J	Miranda, JD; Barnes, EM				Miranda, JD; Barnes, EM			Repression of gamma-aminobutyric acid type A receptor alpha 1-polypeptide biosynthesis requires chronic agonist exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A-RECEPTOR; CEREBRAL CORTICAL-NEURONS; SUBUNIT MESSENGER-RNAS; BENZODIAZEPINE RECEPTORS; DOWN-REGULATION; RAT-BRAIN; CHICK-EMBRYO; COMPLEX; IDENTIFICATION; EXPRESSION	Although it is well established that the number of gamma-aminobutyric acid type A (GABA(A)) receptors declines in cortical neurons exposed to GABA(A) receptor agonists, the mechanisms responsible for this use-dependent down-regulation remain unclear. Two hypotheses have been proposed: (i) agonist-evoked sequestration and degradation of surface GABA(A) receptors and (ii) repression of receptor subunit biosynthesis. We have addressed this problem using [S-35]Met/Cys pulse-chase labeling of chick cortical newtons in culture and immunoprecipitation and immunoblotting with an antibody (RP4) directed against a GABA(A) receptor alpha(1)-(331-381) fusion protein. Exposure of the cells to GABA or isoguvacine for 2 h to 4 days had no effect on the initial rate of S-35 incorporation into the GABA(A) receptor 51-kDa alpha 1 polypeptide, but this rate declined by 33% after a 7-day treatment, This is consistent with a previous report (Baumgartner, B. J., Harvey, R. J., Darlison, M. G., and Barnes, E. M. (1994) Mol. Brain Res. 26, 9-17) that a 7-day GABA treatment of this preparation produced a 45% reduction in the alpha 1 subunit mRNA level, while a 4-day exposure had no detectable effect. On the other hand, after a 4-day exposure to these agonists, a 30% reduction in the level of the alpha 1 polypeptide was observed on immunoblots, similar to that found previously for down-regulation of GABA(A) receptor ligand-binding sites, Thus, the de nova synthesis of GABA(A) receptor alpha 1 subunits is subject to a delayed use-dependent repression that was observed after, rather than before, the decline in neuronal levels of the polypeptide. Pulse-chase experiments showed a monophasic degradation of the GABA(A) receptor S-35-alpha 1 subunit With a t(1/2) = 7.7 h, a process that was unaffected by the addition of GABA to neurons during the chase period. These nascent S-35-labeled polypeptides are presumably diluted into the neuronal pool of unlabeled unassembled al subunits, which was found to exceed by a 4:1 molar ratio the amount assembled into [H-3]flunitrazepam binding sites. Thus, the data reveal an alternative scheme for degradation of GABA(A) receptor polypeptides: a pathway that may participate in the agonist-independent degradation of unassembled receptor subunits. This differs from another pathway for the agonist-dependent degradation of mature GABA(A) receptors derived from the neuronal surface (Calkin, P. A. and Barnes, E. M., Jr. (1994) J. Biol. Chem. 269, 1548-1553).	BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					NIGMS NIH HHS [GM14156] Funding Source: Medline; NINDS NIH HHS [NS11535, NS34253] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM014156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011535, R01NS034253, P01NS011535] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barnes EM, 1996, INT REV NEUROBIOL, V39, P53, DOI 10.1016/S0074-7742(08)60663-7; BATESON AN, 1991, MOL BRAIN RES, V9, P333, DOI 10.1016/0169-328X(91)90081-8; BAUMGARTNER BJ, 1994, MOL BRAIN RES, V26, P9, DOI 10.1016/0169-328X(94)90068-X; BENKE D, 1991, J RECEPTOR RES, V11, P407, DOI 10.3109/10799899109066418; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; Brown MJ, 1996, BRIT J PHARMACOL, V118, P1103, DOI 10.1111/j.1476-5381.1996.tb15512.x; BURT DR, 1994, CURR TOP MEMBR, V42, P215, DOI 10.1016/S0070-2161(08)60824-2; CALKIN PA, 1994, J BIOL CHEM, V269, P1548; CALKIN PA, 1994, MOL BRAIN RES, V26, P18, DOI 10.1016/0169-328X(94)90069-8; CELENTANO JJ, 1994, BIOPHYS J, V66, P1039, DOI 10.1016/S0006-3495(94)80885-9; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; CZAJKOWSKI C, 1989, MOL PHARMACOL, V35, P183; DARLISON MG, 1995, SEMIN NEUROSCI, V7, P115, DOI 10.1006/smns.1995.0013; DeBlas AL, 1996, MOL NEUROBIOL, V12, P55, DOI 10.1007/BF02740747; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; HABLITZ JJ, 1989, BRAIN RES, V501, P332, DOI 10.1016/0006-8993(89)90650-1; HIROUCHI M, 1992, MOL BRAIN RES, V15, P327, DOI 10.1016/0169-328X(92)90125-U; KANG I, 1991, BRIT J PHARMACOL, V103, P1285, DOI 10.1111/j.1476-5381.1991.tb09781.x; Katsura M, 1996, EUR J PHARMACOL, V298, P71, DOI 10.1016/0014-2999(95)00764-4; KENDRICK NC, 1994, ANAL BIOCHEM, V219, P297, DOI 10.1006/abio.1994.1269; KROLL DJ, 1993, DNA CELL BIOL, V12, P441, DOI 10.1089/dna.1993.12.441; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MAKSAY G, 1988, J NEUROCHEM, V50, P1865, DOI 10.1111/j.1471-4159.1988.tb02490.x; MALOTEAUX JM, 1987, EUR J PHARMACOL, V144, P173, DOI 10.1016/0014-2999(87)90517-6; MCKERNAN RM, 1991, FEBS LETT, V286, P44, DOI 10.1016/0014-5793(91)80936-W; MEHTA AK, 1992, MOL BRAIN RES, V16, P29, DOI 10.1016/0169-328X(92)90190-M; MHATRE MC, 1994, MOL BRAIN RES, V24, P159, DOI 10.1016/0169-328X(94)90128-7; Miranda J. D., 1995, Society for Neuroscience Abstracts, V21, P1839; Miranda JD, 1997, DEV BRAIN RES, V99, P176, DOI 10.1016/S0165-3806(97)00016-3; MONTPIED P, 1991, J BIOL CHEM, V266, P6011; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; ROCA DJ, 1990, MOL PHARMACOL, V37, P37; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; TEHRANI MHJ, 1986, DEV BRAIN RES, V25, P91; TEHRANI MHJ, 1988, NEUROSCI LETT, V87, P288, DOI 10.1016/0304-3940(88)90463-6; TEHRANI MHJ, 1993, J NEUROCHEM, V60, P1755; TEHRANI MHJ, 1991, J NEUROCHEM, V57, P1307, DOI 10.1111/j.1471-4159.1991.tb08295.x; TEHRANI MHJ, 1994, MOL BRAIN RES, V24, P55; THAMPY KG, 1983, DEV BRAIN RES, V8, P101, DOI 10.1016/0165-3806(83)90161-X	43	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16288	16294		10.1074/jbc.272.26.16288	http://dx.doi.org/10.1074/jbc.272.26.16288			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195932	hybrid			2022-12-25	WOS:A1997XG01900036
J	Kirischuk, S; Kettenmann, H; Verkhratsky, A				Kirischuk, S; Kettenmann, H; Verkhratsky, A			Na+/Ca2+ exchanger modulates kainate-triggered Ca2+ signaling in Bergmann glial cells in situ	FASEB JOURNAL			English	Article						cerebellum; [Na+](i); [Ca2+](i); glutamate receptors	SODIUM-CALCIUM EXCHANGE; GLUTAMATE; ASTROCYTES; RECEPTORS; ENTRY	The role of sodium-calcium exchanger in calcium homeostasis in Bergmann glial cells in situ was investigated by monitoring cytoplasmic calcium ([Ca2+](i)) and sodium ([Na+](i)) concentrations. The [Ca2+](i) and [Na+](i) transients were measured either separately by using fluorescent indicators fura-2 and SBFI, respectively, or simultaneously using the indicators fluo-3 and SBFI. Since the removal of extracellular Na+ induced a relatively small (similar to 50 nM) elevation of [Ca2+](i), the Na+/Ca2+ exchanger seems to play a minor role in regulation of resting [Ca2+](i). In contrast, kainate-triggered [Ca2+](i) increase was significantly suppressed by lowering of the extracellular Na+ concentration ([Na+](o)). In addition, manipulations with [N-a+](o) dramatically affected the recovery of the kainate-induced [Ca2+](i) transients. Simultaneous recordings of [Ca2+](i) and [Na+](i) revealed that kainate-evoked [Ca2+](i) transients were accompanied with an increase in [Na+](i). Moreover, kainate induced significantly larger [Ca2+](i) and smaller [Na+](i) transients under current-clamp conditions as compared to those recorded when the membrane voltage was clamped at -70 mV. The above results demonstrate that the Na+-Ca2+ exchanger is operative in Bergmann glial cells in situ and is able to modulate dynamically the amplitude and kinetics of [Ca2+](i) signals associated with an activation of ionotropic glutamate receptors.			Kirischuk, S (corresponding author), MAX DELBRUCK CTR MOL MED, ROBERT ROSSLE STR 10, D-13122 BERLIN, GERMANY.		Verkhratsky, Alexei/J-4527-2013; Kettenmann, Helmut/AAJ-5142-2021	Verkhratsky, Alexei/0000-0003-2592-9898; Kettenmann, Helmut/0000-0001-8208-0291				BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P254, DOI 10.1111/j.1749-6632.1991.tb17315.x; CARAFOLI E, 1988, ANN NY ACAD SCI, V551, P147, DOI 10.1111/j.1749-6632.1988.tb22333.x; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; DIPOLO R, 1983, ANNU REV PHYSIOL, V45, P313, DOI 10.1146/annurev.ph.45.030183.001525; Finkbeiner Steven M., 1995, P273; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; Golovina VA, 1996, GLIA, V16, P296; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLGADO A, 1995, GLIA, V14, P77, DOI 10.1002/glia.440140202; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kirischuk S, 1996, PFLUG ARCH EUR J PHY, V431, P977, DOI 10.1007/BF02332186; Kirischuk S, 1996, EUR J NEUROSCI, V8, P1198, DOI 10.1111/j.1460-9568.1996.tb01288.x; Kirischuk S, 1995, J NEUROSCI, V15, P7861; MULLER T, 1992, SCIENCE, V256, P1563, DOI 10.1126/science.1317969; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; Peters A., 1991, FINE STRUCTURE NERVO; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; TAKUMA K, 1994, GLIA, V12, P336, DOI 10.1002/glia.440120410; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5	23	106	106	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1997	11	7					566	572		10.1096/fasebj.11.7.9212080	http://dx.doi.org/10.1096/fasebj.11.7.9212080			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212080				2022-12-25	WOS:A1997XH34200008
J	Baldin, V; Cans, C; SupertiFurga, G; Ducommun, B				Baldin, V; Cans, C; SupertiFurga, G; Ducommun, B			Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control?	ONCOGENE			English	Article						cdc25B; cell cycle; protein phosphatase; splicing	FISSION YEAST CDC25; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; MITOTIC INDUCER; M-PHASE; PHOSPHORYLATION; ACTIVATION; MITOSIS; HOMOLOG	CDC25B2, a protein tyrosine phosphatase closely related to the putative CDC25B oncogene, was identified in a Burkitt lymphoma cDNA library, CDC25B2 differs from CDC25B by a 14 residue insertion and a 41 residue deletion, which are both located in the amino-terminal region of the protein, upstream of the catalytic domain. Examination of the genomic sequence revealed that CDC25B1 (formerly B) and CDC25B2 are splice variants of the same gene, A third variant, CDC25B3, that carries both the 14 and the 41 residue sequences was also identified in the same cDNA library. All three variants were detected in a panel of human primary culture and cell lines, although at different levels. In primary fibroblasts and in HeLa cells the CDC25B expression is cell cycle regulated, reaching a maximum in G(2)-phase. In vitro, CDC25B1 phosphatase is slightly more active than CDC25B2 and B3. However, episomal overexpression of the three CDC25B variants in fission yeast reveals that in vivo, CDC25B2 is largely more active than either B1 or B3 (B2>B3>B1) both to complement a thermosensitive S pombe CDC25 activity and to act as a mitotic inducer, Alternative splicing of CDC25B may therefore contribute to the control of cell proliferation.	UNIV TOULOUSE 2, INST PHARMACOL & BIOL STRUCT, CNRS, F-31077 TOULOUSE, FRANCE; EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY	Universite de Toulouse; Universite de Toulouse - Jean Jaures; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL)			DUCOMMUN, Bernard/B-3208-2008; BALDIN, Véronique/Y-8397-2019; Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019	BALDIN, Véronique/0000-0001-8523-0494; Superti-Furga, Giulio/0000-0002-0570-1768; DUCOMMUN, Bernard/0000-0002-7126-8368				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BETTICHER DC, 1995, ONCOGENE, V11, P1005; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DEMETRICK DJ, 1993, GENOMICS, V18, P144, DOI 10.1006/geno.1993.1440; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRANA X, 1994, ONCOGENE, V9, P2097; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LANE SA, 1993, GENOMICS, V15, P693, DOI 10.1006/geno.1993.1129; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGATA A, 1991, NEW BIOL, V3, P959; NARGI JL, 1994, IMMUNOGENETICS, V39, P99, DOI 10.1007/BF00188612; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SEWING A, 1994, J CELL SCI, V107, P581; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUPERTIFURGA G, 1996, IN PRESS NATURE BIOT; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Xu X, 1996, J BIOL CHEM, V271, P5118; YUSHERMAN M, 1992, EMBO J, V11, P71	48	92	95	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2485	2495		10.1038/sj.onc.1201063	http://dx.doi.org/10.1038/sj.onc.1201063			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188863				2022-12-25	WOS:A1997WZ68000012
J	Akasako, A; Haruki, M; Oobatake, M; Kanaya, S				Akasako, A; Haruki, M; Oobatake, M; Kanaya, S			Conformational stabilities of Escherichia coli RNase HI variants with a series of amino acid substitutions at a cavity within the hydrophobic core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RIBONUCLEASE HI; STRUCTURAL-ANALYSIS; PROTEIN CORE; T4 LYSOZYME; PACKING ARRANGEMENTS; CREATING MUTATIONS; FILLING MUTATIONS; INTERNAL CAVITIES; GLOBULAR-PROTEINS	Escherichia coli ribonuclease HI has a cavity within the hydrophobic core, Two core residues, Ala(52) and Val(74), resided at both ends of this cavity, We have constructed a series of single mutant proteins at Ala(52), and double mutant proteins, in which Ala(52) was replaced by Gly, Val, Ile, Leu, or Phe, and Val(74) was replaced by Ala or Leu, All of these mutant proteins, except for A52W, A52R, and A52G/V74A, were overproduced and purified, Measurement of the thermal denaturations of the proteins at pH 3.2 by CD suggests that the cavity is large enough to accommodate three methyl or methylene groups without creating serious strains, A correlation was observed between the protein stability and the hydrophobicity of the substituted residue, As a result, a number of the mutant proteins were more stable than the wild-type protein, The stabilities of the mutant proteins with charged or extremely bulky residues at the cavity were lower than those expected from the hydrophobicities of the substituted residues, suggesting that considerable strains are created at the mutation sites in these mutant proteins, However, examination of the far- and near-UV GD spectra and the enzymatic activities suggest that all of the mutant proteins have structures similar to that of the wild-type protein, These results suggest that the cavity in the hydrophobic core off. coli RNase HI is conformationally fairly stable, This may be the reason why the cavity-filling mutations effectively increase the thermal stability of this protein.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									AKASAKO A, 1995, BIOCHEMISTRY-US, V34, P8115, DOI 10.1021/bi00025a018; Axe DD, 1996, P NATL ACAD SCI USA, V93, P5590, DOI 10.1073/pnas.93.11.5590; Baldwin E, 1996, J MOL BIOL, V259, P542, DOI 10.1006/jmbi.1996.0338; BALDWIN EP, 1993, SCIENCE, V262, P1715, DOI 10.1126/science.8259514; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; CONNOLLY ML, 1986, INT J PEPT PROT RES, V28, P360; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; EIJSINK VGH, 1992, PROTEIN ENG, V5, P421, DOI 10.1093/protein/5.5.421; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; Gassner NC, 1996, P NATL ACAD SCI USA, V93, P12155, DOI 10.1073/pnas.93.22.12155; Gray TM, 1996, PROTEIN SCI, V5, P742; HARUKI M, 1994, J BIOL CHEM, V269, P26904; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P7136, DOI 10.1021/bi00079a010; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6171, DOI 10.1021/bi00075a009; ISHIKAWA K, 1993, PROTEIN ENG, V6, P85, DOI 10.1093/protein/6.1.85; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; KANAYA E, 1995, J BIOL CHEM, V270, P19853, DOI 10.1074/jbc.270.34.19853; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; KANAYA S, 1991, J BIOL CHEM, V266, P6038; Kanaya S, 1996, J BIOL CHEM, V271, P32729, DOI 10.1074/jbc.271.51.32729; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; KIMURA S, 1992, J BIOL CHEM, V267, P21535; KIMURA S, 1992, EUR J BIOCHEM, V206, P337, DOI 10.1111/j.1432-1033.1992.tb16932.x; KIMURA S, 1992, J BIOL CHEM, V267, P22014; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1991, NATURE, V352, P448, DOI 10.1038/352448a0; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; Miller J. H., 1972, EXPT MOL GENETICS, P433; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; PACE CN, 1992, J MOL BIOL, V226, P29, DOI 10.1016/0022-2836(92)90121-Y; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; SANDBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706, DOI 10.1073/pnas.88.5.1706; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER UH, 1992, J BIOL CHEM, V267, P2393; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SNEDDON SF, 1992, BIOCHEMISTRY-US, V31, P2842, DOI 10.1021/bi00125a028; Sun SJ, 1995, PROTEIN ENG, V8, P1205, DOI 10.1093/protein/8.12.1205; TAKANO K, 1995, J MOL BIOL, V254, P62, DOI 10.1006/jmbi.1995.0599; VANGUNSTEREN WF, 1992, J MOL BIOL, V227, P389, DOI 10.1016/0022-2836(92)90895-Q; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; WILSON KP, 1992, J BIOL CHEM, V267, P10842; Yamasaki K, 1995, BIOCHEMISTRY-US, V34, P16552, DOI 10.1021/bi00051a003; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441; Zhang H, 1996, J MOL BIOL, V259, P148, DOI 10.1006/jmbi.1996.0309; Zhang L, 1996, PROTEINS, V24, P433, DOI 10.1002/(SICI)1097-0134(199604)24:4<433::AID-PROT3>3.0.CO;2-F	60	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18686	18693		10.1074/jbc.272.30.18686	http://dx.doi.org/10.1074/jbc.272.30.18686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228039	hybrid			2022-12-25	WOS:A1997XM34200030
J	Imaizumi, K; Tsuda, M; Imai, Y; Wanaka, A; Takagi, T; Tohyama, M				Imaizumi, K; Tsuda, M; Imai, Y; Wanaka, A; Takagi, T; Tohyama, M			Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CULTURED SYMPATHETIC NEURONS; CELL-DEATH; FACTOR DEPRIVATION; PROTEIN-SYNTHESIS; FACTOR WITHDRAWAL; FACTOR DEPENDENCE; GENE-EXPRESSION; C-JUN; APOPTOSIS	To study the molecular mechanisms underlying neuronal programmed cell death (PCD), we performed differential display screening for genes, the expression of which was induced during PCD in the sympathetic neuron culture model deprived of NGF. We cloned a gene encoding a novel polypeptide (DP5) which consisted of 92 amino acids, DP5 polypeptide had no homology with any other known protein and contained no motif that would indicate its putative biochemical functions, DP5 mRNA levels peaked at 15 h after nerve growth factor withdrawal, concurrent with the time at which neurons were committed to die, The induction of DP5 gene expression was blocked when cell death was rescued by treatment with cycloheximide, KCl, or the cyclic AMP analogue CPTcAMP. Overexpression of the full-length DP5 in cultured sympathetic neurons was in itself sufficient to induce apoptosis, These results suggest that DP5 plays a role in programmed neuronal death.	OSAKA UNIV, SCH MED, DEPT ANAT & NEUROSCI, SUITA, OSAKA 565, JAPAN; TANABE SEIYAKU CO LTD, LEAD GENERAT RES LAB, OSAKA 532, JAPAN; FUKUSHIMA MED COLL, INST BIOMED SCI, DEPT CELL SCI, FUKUSHIMA 96012, JAPAN	Osaka University; Mitsubishi Tanabe Pharma Corporation; Fukushima Medical University	Imaizumi, K (corresponding author), OSAKA UNIV, SCH MED, TANABE, DEPT MOL NEUROBIOL, 2-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.		Wanaka, Akio/ABE-4671-2020; Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/GPW-8926-2022	Wanaka, Akio/0000-0001-9951-9862; 				ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; Shimizu S, 1996, ONCOGENE, V13, P21; STANISIC T, 1978, INVEST UROL, V16, P19; TANAKA S, 1992, BIOCHIM BIOPHYS ACTA, V1175, P114, DOI 10.1016/0167-4889(92)90017-6; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9	35	145	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18842	18848		10.1074/jbc.272.30.18842	http://dx.doi.org/10.1074/jbc.272.30.18842			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228060	hybrid			2022-12-25	WOS:A1997XM34200051
J	Xie, PG; Parsons, SH; Speckhard, DC; Bosron, WF; Hurley, TD				Xie, PG; Parsons, SH; Speckhard, DC; Bosron, WF; Hurley, TD			X-ray structure of human class IV sigma sigma alcohol dehydrogenase - Structural basis for substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RETINOIC ACID; RESOLUTION; METABOLISM; OXIDATION; ISOZYMES	The structural determinants of substrate recognition in the human class IV, or sigma sigma, alcohol dehydrogenase (ADH) isoenzyme were examined through x-ray crystallography and site-directed mutagenesis. The crystal structure of sigma sigma ADH complexed with NAD(+) and acetate was solved to 3-Angstrom resolution. The human beta(1) beta(1) and sigma sigma ADH isoenzymes share 69% sequence identity and exhibit dramatically different kinetic properties. Differences in the amino acids at positions 57, 116, 141, 309, and 317 create a different topology within the sigma sigma substrate-binding pocket, relative to the beta(1) beta(1) isoenzyme. The nicotinamide ring of the NAD(H) molecule, in the sigma sigma structure, appears to be twisted relative to its position in the beta(1) beta(1) isoenzyme. In conjunction with movements of Thr-48 and Phe-93, this twist widens the substrate pocket in the vicinity of the catalytic zinc and may contribute to this isoenzyme's high K-m for small substrates. The presence of Met-57, Met-141, and Phe-309 narrow the middle region of the sigma sigma substrate pocket and may explain the substantially decreased K-m values with increased chain length of substrates in sigma sigma ADH. The kinetic properties of a mutant sigma sigma enzyme (sigma 309L317A) suggest that widening the middle region of the substrate pocket increases K-m by weakening the interactions between the enzyme and smaller substrates while not affecting the binding of longer alcohols, such as hexanol and retinol.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202; LORAS COLL,DEPT CHEM,DUBUQUE,IA 52001	Indiana University System; Indiana University-Purdue University Indianapolis				HURLEY, THOMAS/0000-0002-5942-1163	NIAAA NIH HHS [K21-AA00150, R29-AA10399] Funding Source: Medline; PHS HHS [R37-07117] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA010399, K21AA000150] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Cleland W W, 1979, Methods Enzymol, V63, P103; Davis GJ, 1996, J BIOL CHEM, V271, P17057, DOI 10.1074/jbc.271.29.17057; EDENBERG HJ, 1989, ENZYMOLOGY MOL BIOL, V2, P181; EDENBERG HJ, 1997, COMPREHENSIVE TOXICO, V3, P119; EHRIG T, 1990, ALCOHOL ALCOHOLISM, V25, P105, DOI 10.1093/oxfordjournals.alcalc.a044985; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; HAGASHI T, 1990, RAXIS IIC DATA PROCE; HOOG JO, 1992, EUR J BIOCHEM, V205, P519, DOI 10.1111/j.1432-1033.1992.tb16808.x; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1992, BIOCHEM BIOPH RES CO, V183, P93, DOI 10.1016/0006-291X(92)91613-U; HURLEY TD, 1994, J MOL BIOL, V239, P415, DOI 10.1006/jmbi.1994.1382; HURLEY TD, 1995, ENZYMOLOGY MOL BIOL, V5, P321; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEBER CS, 1994, J TOXICOL-CLIN TOXIC, V32, P631, DOI 10.3109/15563659409017974; Moreno A, 1996, FEBS LETT, V395, P99, DOI 10.1016/0014-5793(96)01009-5; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1986, J BIOL CHEM, V261, P3592; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PAGE MI, 1973, CHEM SOC REV, V2, P295, DOI 10.1039/cs9730200295; PARES X, 1990, FEBS LETT, V277, P115, DOI 10.1016/0014-5793(90)80822-Z; PULLARKAT RK, 1991, ALCOHOL CLIN EXP RES, V15, P565, DOI 10.1111/j.1530-0277.1991.tb00561.x; Ramaswamy S, 1996, PROTEIN SCI, V5, P663; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; STONE CL, 1993, ALCOHOL CLIN EXP RES, V17, P911, DOI 10.1111/j.1530-0277.1993.tb00863.x; STONE CL, 1992, J BIOL CHEM, V268, P892; THEORELL H, 1969, ACTA CHEM SCAND, V23, P255, DOI 10.3891/acta.chem.scand.23-0255; VALLEE BL, 1983, ISOZYMES-CURR T BIOL, V8, P219; Yang ZN, 1997, J MOL BIOL, V265, P330, DOI 10.1006/jmbi.1996.0731; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x	38	72	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18558	18563		10.1074/jbc.272.30.18558	http://dx.doi.org/10.1074/jbc.272.30.18558			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228021	hybrid			2022-12-25	WOS:A1997XM34200012
J	Kresse, H; Liszio, C; Schonherr, E; Fisher, LW				Kresse, H; Liszio, C; Schonherr, E; Fisher, LW			Critical role of glutamate in a central leucine-rich repeat of decorin for interaction with type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; CORE PROTEIN; FIBRILLAR COLLAGEN; TENDON COLLAGEN; BINDING; EXPRESSION; FIBROBLASTS; CDNA; LOCALIZATION; FIBRONECTIN	The chondroitin/dermatan sulfate proteoglycan decorin is known to interact via its core protein with fibrillar collagens, thereby influencing the kinetics of fibril formation and the final diameter of the fibrils. To define the binding site(s) for type I collagen along the core protein, which is mainly composed of leucine-rich repeat structures, decorin cDNAs were constructed and expressed in human kidney 293 cells. The constructs encoded (i) C-terminally truncated molecules, (ii) core proteins with deletions of selected leucine-rich repeats, or (iii) various point mutations, The deletion of the sixth leucine-rich repeat Met(176)-Lys(201) and the mutation E180K drastically interfered with the binding to reconstituted type I collagen fibrils, In contrast, the deletion of the seventh repeat Leu(202)-Ser(222) led at the most to a marginally impaired binding, although the secretion of this proteoglycan was abnormally low. Decorin with two other point mutations in the sixth leucine-rich repeat, Lys(187) --> Gln and Lys(200) --> Gln, respectively, bound type I collagen either normally or even better than the normal recombinant proteoylycan. These data suggest that a major collagen-binding site of decorin is located within the sixth leucine-rich repeat and that glutamate-180 within this repeat is of special importance for ionic interactions between the two matrix components.	NIDR, CRANIOFACIAL & SKELETAL DIS BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Kresse, H (corresponding author), UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, WALDEYERSTR 15, D-48149 MUNSTER, GERMANY.							BEAVAN LA, 1993, J BIOL CHEM, V268, P9856; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Bittner K, 1996, BIOCHEM J, V314, P159, DOI 10.1042/bj3140159; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1986, NUCLEIC ACIDS RES, V14, P9861, DOI 10.1093/nar/14.24.9861; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HAUSSER H, 1992, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Hudson DL, 1996, MOL BIOL CELL, V7, P496; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KINGSTON RE, 1996, CURRENT PROTOCOLS MO, V1; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MANN DM, 1990, J BIOL CHEM, V265, P5317; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; ROSENBERG L, 1993, DERMATAN SULPHATE PR, P225; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SCOTT JE, 1993, DERMATAN SULPHATE PR, P165; SELDEN RF, 1996, CURRENT PROTOCOLS MO, V1; SPIRO RC, 1994, MOL BIOL CELL, V5, P303; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; ULDBJERG N, 1988, BIOCHEM J, V251, P643, DOI 10.1042/bj2510643; VANKUPPEVELT THMSM, 1987, HISTOCHEM J, V19, P520, DOI 10.1007/BF01675423; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WITSCHPREHM P, 1992, ARTHRITIS RHEUM-US, V35, P1042, DOI 10.1002/art.1780350909; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YU L, 1993, DERMATAN SULPHATE PR, P183	50	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18404	18410		10.1074/jbc.272.29.18404	http://dx.doi.org/10.1074/jbc.272.29.18404			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218483	hybrid			2022-12-25	WOS:A1997XL73500073
J	Falson, P; Menguy, T; Corre, F; Bouneau, L; deGracia, AG; Soulie, S; Centeno, F; Moller, JV; Champeil, P; leMaire, M				Falson, P; Menguy, T; Corre, F; Bouneau, L; deGracia, AG; Soulie, S; Centeno, F; Moller, JV; Champeil, P; leMaire, M			The cytoplasmic loop between putative transmembrane segments 6 and 7 in sarcoplasmic reticulum Ca2+-ATPase binds Ca2+ and is functionally important	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; GASTRIC H+/K+-ATPASE; CALCIUM-BINDING; 3-DIMENSIONAL STRUCTURE; TRANSPORT SITES; ADENOSINE-TRIPHOSPHATASE; CA-2+-BINDING PROTEINS; GEL-ELECTROPHORESIS; CATION OCCLUSION; NA/K-ATPASE	Limited proteolysis Toy proteinase K of rabbit SERCA1 Ca2+-ATPase generates 21 number of fragments which have been identified recently, Here, we have focused on two proteolytic C-terminal fragments, p20C and p19C, starting at Gly-808 and Asp-818, respectively. The longer peptide p20C binds Ca2+, as deduced from changes in migration rate by SDS-polyacrylamide gel electrophoresis performed in the presence of Ca2+ as well as from labeling with Ca-45(2+) in overlay experiments. In contrast, the shorter peptide p19C, a proteolysis fragment identical to p20C but for 10 amino acids missing at the N-terminal side, did not bind Ca2+ when submitted to the same experiments, Two cluster mutants of Ca2+-ATPase, D813A/D818A and D813A/D815A/D818A, expressed in the yeast Saccharomyces cerevisiae, were found to have a very low Ca2+-ATPase activity. Region 808-818 is thus essential for both Ca2+ binding and enzyme activity, in agreement with similar results recently reported for the homologous gastric H+, K+-ATPase (Swarts, H, G. P., Klaassen, C, H. W., de Boer, M., Fransen, J. A, M., and De Pont, J, J, H, Pi, M., (1996) J. Biol. Chem. 271, 29764-29772). However, the accessibility of proteinase K to the peptidyl huh between Leu-807 and Oly-808 clearly shows that the transmembrane segment M6 ends before region 808-818, It is remarkable that critical residues]far enzyme activity are located in a cytoplasmic loop starting at Gly-808.	CENS, CEA, DBCM, SBPM, F-91191 GIF SUR YVETTE, FRANCE; CENS, CNRS URA 2096, F-91191 GIF SUR YVETTE, FRANCE; AARHUS UNIV, DANISH BIOMEMBRANE RES CTR, DEPT BIOPHYS, DK-8000 AARHUS C, DENMARK	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Aarhus University			Centeno, Francisco/F-7287-2016	Centeno, Francisco/0000-0001-6154-5424; Falson, Pierre/0000-0002-9760-4577				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1992, FEBS LETT, V306, P101; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAMBERG E, 1994, SODIUM PUMP; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CAMPBELL KP, 1986, SARCOPLASMIC RETICUL, V1, P65; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COX JA, 1981, BIOCHEMISTRY-US, V20, P5430, DOI 10.1021/bi00522a012; COZENS B, 1984, J BIOL CHEM, V259, P6248; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; DUX L, 1985, J BIOL CHEM, V260, P1730; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; Groves JD, 1996, P NATL ACAD SCI USA, V93, P12245, DOI 10.1073/pnas.93.22.12245; HALL L, 1982, NUCLEIC ACIDS RES, V10, P3503, DOI 10.1093/nar/10.11.3503; HEBERT H, 1992, FEBS LETT, V299, P159, DOI 10.1016/0014-5793(92)80237-B; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1990, NATURE, V346, P617; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MOHRAZ M, 1987, J CELL BIOL, V105, P1, DOI 10.1083/jcb.105.1.1; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLLER JV, 1994, SODIUM PUMP, P131; OR E, 1993, J BIOL CHEM, V268, P16929; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; SKRIVER E, 1992, J STRUCT BIOL, V108, P176, DOI 10.1016/1047-8477(92)90017-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TANAKA Y, 1988, J BIOCHEM-TOKYO, V104, P489, DOI 10.1093/oxfordjournals.jbchem.a122495; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1	71	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17258	17262		10.1074/jbc.272.28.17258	http://dx.doi.org/10.1074/jbc.272.28.17258			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211861	hybrid			2022-12-25	WOS:A1997XK16500004
J	Sokurenko, EV; Chesnokova, V; Doyle, RJ; Hasty, DL				Sokurenko, EV; Chesnokova, V; Doyle, RJ; Hasty, DL			Diversity of the Escherichia coli type 1 fimbrial lectin - Differential binding to mannosides and uroepithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY-TRACT INFECTIONS; FUNCTIONAL-HETEROGENEITY; BACTERIAL ADHERENCE; FIMH GENES; PILI; ADHESION; RECEPTORS; COLONIZATION; STRAINS; MICE	Type I fimbriae are the most common adhesive organelles of Escherichia coli. Because of their virtual ubiquity, previous epidemiological studies have not found a correlation between the presence of type I fimbriae and urinary tract infections (UTIs). Recently it has become clear that type 1 fimbriae exhibit several different phenotypes, due to allelic variation of the gene for the lectin subunit, FimH, and that these phenotypes are differentially distributed among fecal and UTI isolates, In this study, me have analyzed in more detail the ability of isogenic, recombinant strains of E. coli expressing fimH genes of the predominant fecal and UTI phenotypes to adhere to glycoproteins and to uroepithelial cells. Evidence was obtained to indicate that type 1 fimbriae differ in their ability to recognize various mannosides, utilizing at least two different mechanisms. All FimH subunits studied to date are capable of mediating adhesion via trimannosyl residues, but only certain variants are capable of mediating high levels of adhesion via monomannosyl residues. The ability of the FimH lectins to interact with monomannosyl residues strongly correlates with their ability 60 mediate E. coli adhesion to uroepithelial cells. In this way, it: would be possible for certain phenotypic variants of type I fimbriae to contribute more than others to virulence off. coli in the urinary tract.	VET AFFAIRS MED CTR, RES SERV 151, MEMPHIS, TN 38104 USA; UNIV TENNESSEE, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA; UNIV LOUISVILLE, DEPT MICROBIOL & IMMUNOL, LOUISVILLE, KY 40292 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Louisville					NIDCR NIH HHS [DE-07218] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007218] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABRAHAM SN, 1985, INFECT IMMUN, V48, P625, DOI 10.1128/IAI.48.3.625-628.1985; ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; Ballou C, 1976, Adv Microb Physiol, V14, P93, DOI 10.1016/S0065-2911(08)60227-1; BLOCH CA, 1992, MOL MICROBIOL, V6, P697, DOI 10.1111/j.1365-2958.1992.tb01518.x; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; COHEN PS, 1994, FIMBRIAE ADHESION GE, P213; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; COURTNEY HS, 1991, INFECT IMMUN, V59, P1661, DOI 10.1128/IAI.59.5.1661-1666.1991; Donnenberg Michael S., 1996, P135; DOYLE RJ, 1985, MOL BASIS ORAL MICRO, P109; DUGUID JP, 1955, J PATHOL BACTERIOL, V70, P335, DOI 10.1002/path.1700700210; FIRON N, 1987, INFECT IMMUN, V55, P472, DOI 10.1128/IAI.55.2.472-476.1987; FU DT, 1994, CARBOHYD RES, V261, P173, DOI 10.1016/0008-6215(94)84015-6; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; HAGBERG L, 1981, INFECT IMMUN, V31, P564, DOI 10.1128/IAI.31.2.564-570.1981; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; HULTGREN SJ, 1986, INFECT IMMUN, V54, P613, DOI 10.1128/IAI.54.3.613-620.1986; IWAHI T, 1983, INFECT IMMUN, V39, P1307, DOI 10.1128/IAI.39.3.1307-1315.1983; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; KEITH BR, 1986, INFECT IMMUN, V53, P693, DOI 10.1128/IAI.53.3.693-696.1986; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KLEMM P, 1985, MOL GEN GENET, V199, P410, DOI 10.1007/BF00330751; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; MCCORMICK BA, 1989, INFECT IMMUN, V57, P3022, DOI 10.1128/IAI.57.10.3022-3029.1989; Moshier A, 1996, CURR MICROBIOL, V33, P200, DOI 10.1007/s002849900100; NEESER JR, 1986, INFECT IMMUN, V52, P428, DOI 10.1128/IAI.52.2.428-436.1986; OFEK I, 1988, INFECT IMMUN, V56, P539, DOI 10.1128/IAI.56.3.539-547.1988; OFEK I, 1977, NATURE, V265, P623, DOI 10.1038/265623a0; OFEK I, 1982, SCAND J INFECT DIS, P61; SCHAEFFER AJ, 1987, INFECT IMMUN, V55, P373, DOI 10.1128/IAI.55.2.373-380.1987; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; SHERMAN PM, 1985, INFECT IMMUN, V49, P797, DOI 10.1128/IAI.49.3.797-804.1985; SILVERBLATT FJ, 1979, J CLIN INVEST, V64, P333, DOI 10.1172/JCI109458; SOKURENKO EV, 1994, J BACTERIOL, V176, P748, DOI 10.1128/jb.176.3.748-755.1994; SOKURENKO EV, 1995, J BACTERIOL, V177, P3680, DOI 10.1128/jb.177.13.3680-3686.1995; SOKURENKO EV, 1992, INFECT IMMUN, V60, P4709, DOI 10.1128/IAI.60.11.4709-4719.1992; SOKURENKO EV, 1995, METHOD ENZYMOL, V253, P519; SVANBORG C, 1994, FIMBRIAE ADHESION GE, P239; Teraguchi S, 1996, INFECT IMMUN, V64, P1075, DOI 10.1128/IAI.64.3.1075-1077.1996; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630	42	143	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17880	17886		10.1074/jbc.272.28.17880	http://dx.doi.org/10.1074/jbc.272.28.17880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211945	hybrid			2022-12-25	WOS:A1997XK16500088
J	Bismuth, Y; Kavanaugh, MP; Kanner, BI				Bismuth, Y; Kavanaugh, MP; Kanner, BI			Tyrosine 140 of the gamma-aminobutyric acid transporter GAT-1 plays a critical role in neurotransmitter recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-NOREPINEPHRINE TRANSPORTERS; RAT-BRAIN; GABA TRANSPORTER; BINDING-SITE; GLUTAMATE TRANSPORTER; XENOPUS OOCYTES; SODIUM; DOMAINS; EXPRESSION; SUBSTRATE	The gamma-aminobutyric acid (GABA) transporter GAT-1 is located in nerve terminals and catalyzes the electrogenic reuptake of the neurotransmitter with two sodium ions and one chloride, We now identify a single tyrosine residue that is critical for GABA recognition and transport, It is completely conserved throughout the superfamily, and even substitution to the other aromatic amino acids, phenylalanine (Y140F) and tryptophan (Y140W), results in completely inactive transporters, Electrophysiological characterization reveals that both mutant transporters exhibit the sodium-dependent transient currents associated with sodium binding as well as the chloride-dependent lithium leak currents characteristic of GAT-1. On the other hand, in both mutants GABA is neither able to induce a steady-state transport current nor to block their transient currents. The nontransportable analog SKF 100330A potently inhibits the sodium-dependent transient in the wild type GAT-1 but not in the Y140W transporter. It partly blocks the transient of Y140F. Thus, although sodium and chloride binding are unimpaired in the tyrosine mutants, they have a specific defect in the binding of GABA. The total conservation of the residue throughout the family suggests that tyrosine 140 may be involved in the liganding of the amino group, the moiety common to all of the neurotransmitters.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91120 JERUSALEM,ISRAEL; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Hebrew University of Jerusalem; Oregon Health & Science University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48709] Funding Source: Medline; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALI FE, 1985, J MED CHEM, V28, P653, DOI 10.1021/jm50001a020; BARKER EL, 1994, MOL PHARMACOL, V46, P799; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; KANNER BI, 1994, FEBS LETT, V356, P191, DOI 10.1016/0014-5793(94)01255-5; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1985, J BIOL CHEM, V260, P1859; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	34	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16096	16102		10.1074/jbc.272.26.16096	http://dx.doi.org/10.1074/jbc.272.26.16096			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195904	Green Published, hybrid			2022-12-25	WOS:A1997XG01900008
J	Huntley, CC; De, BP; Banerjee, AK				Huntley, CC; De, BP; Banerjee, AK			Phosphorylation of Sendai virus phosphoprotein by cellular protein kinase C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; RESPIRATORY SYNCYTIAL VIRUS; P-PROTEIN; MEASLES-VIRUS; TRANSCRIPTIONAL ACTIVITY; MONOCLONAL-ANTIBODIES; NUCLEOCAPSID PROTEIN; GENE-EXPRESSION; RNA-SYNTHESIS; ACTIVATION	The phosphoproteins (P) of nonsegmented negative strand RNA viruses are viral RNA polymerase subunits involved in both transcription and replication during the virus life cycle. Phosphorylation of P proteins in several negative strand RNA viruses by specific cellular kinases was found to be required for P protein function. In the present study, using bacterially expressed unphosphorylated P protein of Sendai virus, a mouse parainfluenza virus, we have shown that the major cellular kinase that phosphorylates P protein in vitro is biochemically and immunologically indistinguishable from protein kinase C (PRC) zeta isoform. PKC zeta was packaged into the Sendai virion and remained associated with purified viral ribonucleoprotein, where it phosphorylated both the P and the nucleocapsid protein in vitro. When PHC zeta-specific inhibitory pseudosubstrate peptide was introduced into LLC-MK2 cells prior to Sendai virus infection, production of progeny virus was dramatically attenuated, and kinetic analysis revealed that primary transcription was repressed. These data indicate that phosphorylation of the Sendai virus P protein by PKC zeta plays a critical role in the virus life cycle.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIAID NIH HHS [AI32027] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE AK, 1991, PHARMACOL THERAPEUT, V51, P47, DOI 10.1016/0163-7258(91)90041-J; BARIK S, 1992, J VIROL, V66, P1109, DOI 10.1128/JVI.66.2.1109-1118.1992; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARIK S, 1995, VIROLOGY, V213, P405, DOI 10.1006/viro.1995.0013; BELL RM, 1991, J BIOL CHEM, V266, P4661; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BYRAPPA S, 1995, VIROLOGY, V208, P408, DOI 10.1006/viro.1995.1169; Byrappa S, 1996, VIROLOGY, V216, P228, DOI 10.1006/viro.1996.0052; Canter DM, 1996, VIROLOGY, V219, P376, DOI 10.1006/viro.1996.0263; CHATTOPADHYAY D, 1988, P NATL ACAD SCI USA, V85, P7977, DOI 10.1073/pnas.85.21.7977; CURRAN J, 1991, EMBO J, V10, P3079, DOI 10.1002/j.1460-2075.1991.tb07860.x; Curran J, 1996, VIROLOGY, V221, P130, DOI 10.1006/viro.1996.0359; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; DAS T, 1995, J BIOL CHEM, V270, P24100, DOI 10.1074/jbc.270.41.24100; DAS T, 1995, VIROLOGY, V211, P218, DOI 10.1006/viro.1995.1394; DE BP, 1995, P NATL ACAD SCI USA, V92, P5204, DOI 10.1073/pnas.92.11.5204; DESHPANDE KL, 1985, VIROLOGY, V140, P125, DOI 10.1016/0042-6822(85)90451-9; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DYER RM, 1994, J IMMUNOL, V153, P1171; EINBERGER H, 1990, J VIROL, V64, P4274, DOI 10.1128/JVI.64.9.4274-4280.1990; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; GALINSKI MS, 1986, VIROLOGY, V155, P46, DOI 10.1016/0042-6822(86)90167-4; GALINSKI MS, 1991, PARAMYXOVIRUSES; GAO Y, 1995, EMBO J, V14, P1240, DOI 10.1002/j.1460-2075.1995.tb07107.x; GOMBART AF, 1993, J VIROL, V67, P4133, DOI 10.1128/JVI.67.7.4133-4141.1993; GOMBART AF, 1995, VIRUS RES, V37, P63, DOI 10.1016/0168-1702(95)00020-Q; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTLEY CC, 1995, VIROLOGY, V211, P561, DOI 10.1006/viro.1995.1438; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; MAZUMDER B, 1994, VIROLOGY, V205, P104, DOI 10.1006/viro.1994.1624; MAZUMDER B, 1994, VIROLOGY, V205, P93, DOI 10.1006/viro.1994.1623; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RYAN KW, 1990, VIROLOGY, V174, P515, DOI 10.1016/0042-6822(90)90105-Z; RYAN KW, 1991, VIROLOGY, V180, P126, DOI 10.1016/0042-6822(91)90016-5; SANCHEZSECO MP, 1995, J GEN VIROL, V76, P425, DOI 10.1099/0022-1317-76-2-425; SAPDAFORA D, 1996, J VIROL, V70, P4538; SEGEV Y, 1995, J VIROL, V69, P2480, DOI 10.1128/JVI.69.4.2480-2485.1995; SHEN SS, 1990, DEV BIOL, V140, P272, DOI 10.1016/0012-1606(90)90077-V; SMALLWOOD S, 1994, VIROLOGY, V202, P154, DOI 10.1006/viro.1994.1331; TAKACS A, 1992, J VIROL, V30, P166; VIDAL S, 1988, J VIROL, V62, P2200, DOI 10.1128/JVI.62.6.2200-2203.1988; VILLANUEVA N, 1994, J GEN VIROL, V75, P555, DOI 10.1099/0022-1317-75-3-555	46	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16578	16584		10.1074/jbc.272.26.16578	http://dx.doi.org/10.1074/jbc.272.26.16578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195969	hybrid			2022-12-25	WOS:A1997XG01900073
J	Karas, M; Danilenko, M; Fishman, D; LeRoith, D; Levy, J; Sharoni, Y				Karas, M; Danilenko, M; Fishman, D; LeRoith, D; Levy, J; Sharoni, Y			Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; GENE-EXPRESSION; RAT; PROLIFERATION; POTENTIATION; FIBROBLASTS; MODULATION; HORMONE	The function of cell surface-associated insulin-like growth factor-binding proteins (IGFBPs) is controversial. Both inhibition and facilitation of IGF action as well as IGF-independent effects have been reported. We examined the influence of endogenous cell surface-associated IGFBPs on IGF-I receptor (IGF-IR) function in Ishikawa endometrial cancer cells by comparing the effects of IGF-I and its truncated analog des-(1-3)-IGF-I on several components of the IGF-IR signal transduction pathway in the absence of significant amounts of soluble IGFBPs. IGF-I and des-(1-3)-IGF-I are known to have similar affinities for IGF-IR, although the affinity of des(1-3)-IGF-I for IGFBPs is greatly reduced. Here we show that the two ligands were equipotent not only in IGF-IR binding but also in receptor activation in NIH 3T3 cells overexpressing IGF-IR and possessing a relatively small number of cell surface-associated IGFBPs. In contrast, des-(1-3)-IGF-I manifested a remarkably higher potency as compared with IGF-I in inducing short and middle term cellular responses in IGF-IR-transfected Ishikawa endometrial cancer cells possessing a high number of both the receptor and the cell membrane-bound IGFBP-3. Thus, this difference in the effects of IGF-I and des-(1-3)-IGF-I can be attributed to the attenuation of IGF-I-mediated IGF-IR signaling by membrane-bound IGFBP-3.	BEN GURION UNIV NEGEV, SOROKA MED CTR KUPAT HOLIM, FAC HLTH SCI, DEPT CLIN BIOCHEM, IL-84105 BEER SHEVA, ISRAEL; BEN GURION UNIV NEGEV, SOROKA MED CTR KUPAT HOLIM, FAC HLTH SCI, DEPT IMMUNOL & MICROBIOL, IL-84105 BEER SHEVA, ISRAEL; NIDDK, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA	Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			SHARONI, YOAV/F-1223-2012; Danilenko, Michael/F-2283-2012	Danilenko, Michael/0000-0001-9466-6169				BACH LA, 1992, DIABETES, V41, P499, DOI 10.2337/diabetes.41.4.499; BALLARD FJ, 1987, BIOCHEM BIOPH RES CO, V149, P398, DOI 10.1016/0006-291X(87)90380-9; BASERGA R, 1995, CANCER RES, V55, P249; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; Chevalier X, 1996, BRIT J RHEUMATOL, V35, P515; Conover CA, 1996, ENDOCRINOLOGY, V137, P2286, DOI 10.1210/en.137.6.2286; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CORTIZO AM, 1995, J ENDOCRINOL, V144, P119, DOI 10.1677/joe.0.1440119; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hatefi Y, 1974, Methods Enzymol, V31, P770; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Karas Michael, 1995, Progress in Growth Factor Research, V6, P513, DOI 10.1016/0955-2235(95)00033-X; KATO H, 1993, J BIOL CHEM, V268, P2655; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; Kleinman D, 1996, ENDOCRINOLOGY, V137, P1089, DOI 10.1210/en.137.3.1089; KLEINMAN D, 1995, ENDOCRINOLOGY, V136, P2531, DOI 10.1210/en.136.6.2531; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LORD APD, 1994, J ENDOCRINOL, V140, P475, DOI 10.1677/joe.0.1400475; LORENZO M, 1993, J CELL BIOL, V123, P1567, DOI 10.1083/jcb.123.6.1567; MCGRATH MF, 1991, ENDOCRINOLOGY, V129, P671, DOI 10.1210/endo-129-2-671; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; OKAJIMA T, 1992, ENDOCRINOLOGY, V130, P2201, DOI 10.1210/en.130.4.2201; PARK JHY, 1992, ENDOCRINOLOGY, V131, P1359, DOI 10.1210/en.131.3.1359; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; Rogers J, 1996, REGUL PEPTIDES, V61, P189, DOI 10.1016/0167-0115(95)00155-7; RUSSO VC, 1994, GROWTH FACTORS, V11, P301, DOI 10.3109/08977199409011003; SAMARAS SE, 1995, AM J PHYSIOL-ENDOC M, V268, pE1057, DOI 10.1152/ajpendo.1995.268.6.E1057; SILVERMAN LA, 1995, ENDOCRINOLOGY, V136, P720, DOI 10.1210/en.136.2.720; SUNIC D, 1995, BBA-GEN SUBJECTS, V1245, P43, DOI 10.1016/0304-4165(95)00076-N; TAMIR A, 1994, J IMMUNOL, V152, P3391; TOMINAGA T, 1994, ENDOCRINOLOGY, V135, P1212, DOI 10.1210/en.135.3.1212; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361	39	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16514	16520		10.1074/jbc.272.26.16514	http://dx.doi.org/10.1074/jbc.272.26.16514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195961	hybrid			2022-12-25	WOS:A1997XG01900065
J	Qie, LX; Nagiec, MM; Baltisberger, JA; Lester, RL; Dickson, RC				Qie, LX; Nagiec, MM; Baltisberger, JA; Lester, RL; Dickson, RC			Identification of a Saccharomyces gene, LCB3, necessary for incorporation of exogenous long chain bases into sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PALMITOYLTRANSFERASE; MUTANT STRAINS; CEREVISIAE; MEMBRANE; PROTEIN; BIOSYNTHESIS; YEAST; PHOSPHOLIPIDS; CERAMIDE	To identify genes necessary for sphingolipid synthesis in Saccharomyces cerevisiae we developed a procedure to enrich for mutants unable to incorporate exogenous long chain base into sphingolipids. We show here that a mutant strain, AG84-3, isolated by using the enrichment procedure, makes sphingolipids from endogenously synthesized but not from exogenously supplied long chain base. A gene termed LCB3 (YJL134W, GenBank designation X87371x21), which complements the long chain base utilization defect of strain AG84-3, was isolated from a genomic DNA library, The gene is predicted to encode a protein with multiple membrane-spanning domains and a COOH-terminal glycosylphosphatidylinositiol cleavage/attachment site, Deletion of the lcb3 gene in a wild type genetic background reduces the rate of exogenous long chain base incorporation into sphingolipids and makes the host strain more resistant to growth inhibition by long chain bases, Only one protein in current data bases, the S, cerevisiae open-reading frame YKR053C, whose function is unknown, shows homology to the Lcb3 protein, The two proteins are not, however, functional homologs because deletion of the YKR053C open reading frame does not impair long chain base utilization or enhance resistance of cells to growth inhibition by long chain bases, Based upon these data we hypothesize that the Lcb3 protein is a plasma membrane transporter capable of transporting sphingoid long chain bases into cells, It is the first candidate for such a transporter and the first member of what appears to be a new class of membrane-bound proteins.	UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GIETZ RD, 1992, NUCLEIC ACIDS RES, V8, P1425; HANSON BA, 1980, J LIPID RES, V21, P309; HANSON BA, 1980, J BACTERIOL, V142, P79, DOI 10.1128/JB.142.1.79-89.1980; JOHNSTON SA, 1982, P NATL ACAD SCI USA, V79, P6871; LESTER RL, 1993, ADV LIPID RES, V26, P253; LESTER RL, 1993, J BIOL CHEM, V268, P845; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; NAGIEC MM, 1997, J BIOL CHEM, V272, P9000; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	31	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16110	16117		10.1074/jbc.272.26.16110	http://dx.doi.org/10.1074/jbc.272.26.16110			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195906	hybrid			2022-12-25	WOS:A1997XG01900010
J	Tournamille, C; LeVanKim, C; Gane, P; Blanchard, D; Proudfoot, AE; Cartron, JP; Colin, Y				Tournamille, C; LeVanKim, C; Gane, P; Blanchard, D; Proudfoot, AE; Cartron, JP; Colin, Y			Close association of the first and fourth extracellular domains of the Duffy antigen/receptor for chemokines by a disulfide bond is required for ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-KNOWLESI MALARIA; NEGATIVE INDIVIDUALS; MOLECULAR-BASIS; A RECEPTOR; ANTIGEN; INTERLEUKIN-8; IDENTIFICATION; EXPRESSION; PARASITE; VIVAX	It has been demonstrated that the promiscuous chemokine binding profile of the Huffy antigen/reaeptor for chemokines (DARC) is given by its extracellular NH2-terminal region. However, the relationship among the Fy6, Fy(a)/(b), and Fy3 epitopes, localized in the first and fourth extracellular domains of DARC, respectively, and the chemokine binding sites remained a matter of controversy. Here, we performed cross-displacement and cross-inhibition experiments indicating that all anti-Fy6, anti-Fy(a), and anti-Fy3 monoclonal antibodies and interleukin 8 are antagonists for binding to red cells. Biopanning of phage peptide libraries with an anti-Fy6 monoclonal antibody led to the identification of the motif phe(22)-Glu(23), th, mutation of which altered the binding of both anti-Fy6 and chemokines (interleukin 8, MGSA, RANTES (regulated on activation normal T cell expressed)) to DARC transfectants. These results characterized the core of the Fy6 epitope and provided definitive proof of the tight relationship between Fy6 and the chemokine receptor site. Analysis of red cells treated by sulfhydryl group-modifying reagents suggested that the chemokine receptor function of DARC required the integrity of disulfide bond(s) but not that of free sulfhydryl group(s). Accordingly, mutation of cysteines 51 and 276 abolished chemokine binding to DARC transfectants. Altogether, our results suggested that the chemokine binding pocket of DARC included sequences located in the first and fourth extracellular domains which are brought into close vicinity by a disulfide bridge.	INST NATL TRANSFUS SANGUINE, INSERM, U76, F-75015 PARIS, FRANCE; ETAB TRANSFUS SANGUINE, F-44000 NANTES, FRANCE; GLAXO WELLCOME RES & DEV LTD, GENEVA BIOMED RES INST, CH-1228 GENEVA, SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); GlaxoSmithKline			colin, yves/O-1910-2017; le van kim, caroline/O-7030-2017	colin, yves/0000-0001-5196-4254; le van kim, caroline/0000-0002-3251-1310				ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; CHAUDHURI A, 1989, J BIOL CHEM, V264, P13770; CHAUDHURI A, 1995, BLOOD, V85, P615, DOI 10.1182/blood.V85.3.615.bloodjournal853615; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; Chitnis CE, 1996, J EXP MED, V184, P1531, DOI 10.1084/jem.184.4.1531; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HADLEY TJ, 1984, SCIENCE, V223, P597, DOI 10.1126/science.6695171; Hausman E, 1996, TRANSFUSION, V36, P421, DOI 10.1046/j.1537-2995.1996.36596282585.x; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HORUK R, 1994, J BIOL CHEM, V269, P17730; Horuk R, 1996, J LEUKOCYTE BIOL, V59, P29, DOI 10.1002/jlb.59.1.29; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Iwamoto S, 1996, BIOCHEM BIOPH RES CO, V222, P852, DOI 10.1006/bbrc.1996.0833; Iwamoto S, 1996, BLOOD, V87, P378; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LU ZH, 1995, J BIOL CHEM, V270, P26239; MALLINSON G, 1995, BRIT J HAEMATOL, V90, P823, DOI 10.1111/j.1365-2141.1995.tb05202.x; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEOTE K, 1994, BLOOD, V84, P44; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; RIWOM S, 1994, VOX SANG, V66, P61, DOI 10.1111/j.1423-0410.1994.tb00279.x; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RUSSO DCW, 1994, BLOOD, V84, P3518; SAMANTA AK, 1993, J BIOL CHEM, V268, P6147; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; TOURNAMILLE C, 1995, HUM GENET, V95, P407, DOI 10.1007/BF00208965; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Wasniowska K, 1996, MOL IMMUNOL, V33, P917; WASNIOWSKA K, 1994, TRANSFUS MED REV, V8, P281, DOI 10.1016/S0887-7963(94)70119-X	35	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16274	16280		10.1074/jbc.272.26.16274	http://dx.doi.org/10.1074/jbc.272.26.16274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195930	hybrid			2022-12-25	WOS:A1997XG01900034
J	Johnson, HJ; Rosenberg, L; Choi, HU; Garza, S; Hook, M; Neame, PJ				Johnson, HJ; Rosenberg, L; Choi, HU; Garza, S; Hook, M; Neame, PJ			Characterization of epiphycan, a small proteoglycan with a leucine-rich repeat core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; BOVINE ARTICULAR-CARTILAGE; GROWTH-FACTOR-BETA; OSTEOINDUCTIVE FACTOR; DECORIN; GLYCOSAMINOGLYCANS; FIBROMODULIN; BIGLYCAN; HOMOLOGY; BINDING	The epiphysis of developing bones is a cartilaginous structure that is eventually replaced by bone during skeletal maturation. We have separated a dermatan sulfate proteoglycan, epiphycan, from decorin and biglycan by using dissociative extraction of bovine fetal epiphyseal cartilage, followed by sequential ion-exchange, gel permeation, hydrophobic, and Zn2+ chelate chromatographic steps. Epiphycan is a member of the small leucine-rich proteoglycan family, contains seven leucine-rich repeats (LRRs), is related to osteoglycin (osteoinductive factor) (Bentz, H., Nathan, R. M., Rosen, D. M., Armstrong, R. M., Thompson, A. Y., Segarini, P. R., Mathews, M. C., Dasch, J., Piez, K. A., and Seyedin, S. M. (1989) J. Biol. Chem. 264, 20805-20810), and appears to be the bovine equivalent of the chick proteoglycan PG-Lb (Shinomura, T., and Kimata, K. (1992) J. Biol. Chem. 267, 1265-1270). The intact proteoglycan had a median size of similar to 133 kDa. The core protein was 46 kDa by electrophoretic analysis, had a calculated size of 34,271 Da, and had two approximately equimolar N termini (APTLES... and ETYDAT...) separated by 11 amino acids. There were at least three O-linked oligosaccharides in the N-terminal region of the protein, based on blank cycles in Edman degradation and corresponding serine or threonine residues in the translated cDNA sequence. The glycosaminoglycans ranged in size from 23 to 34 kDa were more heterogeneous than those in other dermatan sulfate small leucine-rich proteoglycans and were found in the acidic N-terminal region of the protein core, N-terminal to the LRRs. A four cysteine cluster was present at the N terminus of the LRRs, and a disulfide-bonded cysteine pair was present at the C terminus of the protein core. The seventh LRR and an N-linked oligosaccharide were between the two C-terminal cysteines. An additional potential N-glycosylation site near the C terminus did not appear to be substituted at a significant level.	SHRINERS HOSP CRIPPLED CHILDREN,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; MONTEFIORE MED CTR,ORTHOPED RES LABS,BRONX,NY 10467; TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030; TEXAS A&M UNIV,ALBERT B ALKEK INST BIOSCI & TECHNOL,CTR EXTRACELLULAR MATRIX BIOL,HOUSTON,TX 77030	State University System of Florida; University of South Florida; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Texas A&M University System; Texas A&M University System					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919, R01AR035322, R37AR021498] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35322, AR42919, AR21498] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Deere M, 1996, GENOMICS, V38, P399, DOI 10.1006/geno.1996.0643; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kurita K, 1996, BIOCHEM J, V318, P909, DOI 10.1042/bj3180909; MARCUM JA, 1991, BIOCHEM BIOPH RES CO, V175, P706, DOI 10.1016/0006-291X(91)91623-K; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SMALE G, 1992, ANAL BIOCHEM, V203, P352, DOI 10.1016/0003-2697(92)90324-Z; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	26	53	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18709	18717		10.1074/jbc.272.30.18709	http://dx.doi.org/10.1074/jbc.272.30.18709			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228042	hybrid			2022-12-25	WOS:A1997XM34200033
J	Ray, WJ; Bain, G; Yao, M; Gottlieb, DI				Ray, WJ; Bain, G; Yao, M; Gottlieb, DI			CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; IN-VITRO; METABOLISM; EXPRESSION; RECEPTORS; GENES; BRAIN; ENZYMES; SYSTEM	A novel member of the cytochrome P450 superfamily, CYP26, which represents a new family of cytochrome P450 enzymes, has been cloned. CYP26 mRNA is upregulated during the retinoic acid (RA)-induced neural differentiation of mouse embryonic stem cells in vitro and is transiently expressed by embryonic stem cells undergoing predominantly non-neural differentiation. CYP26 transcript is detectable as early as embryonic day 8.5 in mouse embryos, suggesting a function for the gene in early development. CYP26 is expressed in mouse and human liver, as expected for a cytochrome P450, and is also expressed in regions of the brain and the placenta. Acute administration of 100 mg/kg all-trans-RA increases steady-state levels of transcript in the adult liver, but not in the brain, CYP26 is highly homologous to a Zebrafish gene, CYPRA1, which has been proposed to participate in the degradation of RA, but is minimally homologous to other mammalian cytochrome P450 proteins. Thus, we report the cloning of a member of a novel cytochrome P450 family that is expressed in mammalian embryos and in brain and is induced by RA in the liver.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Ray, William J/E-9834-2016	Ray, William/0000-0002-4491-167X				Bain G, 1996, BIOCHEM BIOPH RES CO, V223, P691, DOI 10.1006/bbrc.1996.0957; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; BURKE MD, 1979, PHARMACOL THERAPEUT, V7, P549, DOI 10.1016/0163-7258(79)90042-1; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; GRAM TE, 1986, ANNU REV PHARMACOL, V26, P259; GUENGERICH FP, 1992, LIFE SCI, V50, P1471; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; LEO MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P305, DOI 10.1016/0003-9861(84)90353-9; LOHNES D, 1995, J STEROID BIOCHEM, V53, P475, DOI 10.1016/0960-0760(95)00094-G; LOPEZ SL, 1992, MECH DEVELOP, V36, P153, DOI 10.1016/0925-4773(92)90066-S; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NISITANI S, 1994, INT IMMUNOL, V6, P909, DOI 10.1093/intimm/6.6.909; NOJI S, 1992, J NUTR SCI VITAMINOL, V10, P481; PEMRICK SM, 1994, LEUKEMIA, V8, P1797; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SNODGRASS HR, 1992, J CELL BIOCHEM, V49, P225, DOI 10.1002/jcb.240490304; SOPRANO DR, 1995, ANNU REV NUTR, V10, P169; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Tallman MS, 1996, LEUKEMIA, V10, pS12; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WARNER M, 1994, METH NEUROSCI, V22, P51; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WINKLER RG, 1995, PLANT CELL, V7, P1307, DOI 10.1105/tpc.7.8.1307	40	259	266	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18702	18708		10.1074/jbc.272.30.18702	http://dx.doi.org/10.1074/jbc.272.30.18702			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228041	hybrid			2022-12-25	WOS:A1997XM34200032
J	Segnitz, B; Gehring, U				Segnitz, B; Gehring, U			The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TYROSINE KINASE INHIBITORS; GLUCOCORTICOID RECEPTOR; HERBIMYCIN-A; PROGESTERONE-RECEPTOR; WILD-TYPE; BINDING; EXPRESSION; CELLS; ASSOCIATION	The ansamycin antibiotic geldanamycin, which specifically interacts with the heat shock protein hsp90, was used to study the function of hsp90 in steroid hormone receptors, We observed inhibition of glucocorticoid-specific gene induction in several responsive cell systems, Hormone binding abilities of receptors for glucocorticoid, progestin, androgen, and estrogen were inhibited upon exposing intact cells to geldanamycin, Inhibition was only seen when geldanamycin was applied to cell cultures under growth conditions or was present during in vitro synthesis; presynthesized receptors in cell extracts were not affected, Upon withdrawal of geldanamycin, glucocorticoid binding ability was re gained; this was partially independent of de novo protein synthesis. Geldanamycin caused decreased levels of immunoreactive glucocorticoid receptors in wild-type cells with enhanced degradation occurring through the ubiquitin-proteasome pathway. Analysis of receptors from treated cells revealed a heteromeric structure of normal size in which the receptor polypeptide is complexed with normal amounts of hsp90 and the immunophilin p59, These data support the view that hsp90 actively participates in steroid-induced signal transduction, and they suggest that geldanamycin affects receptor action without disrupting hsp90-containing heterocomplexes per se. Nevertheless, complexes synthesized and assembled in vitro in the presence of geldanamycin differ from receptors of cellular origin.	UNIV HEIDELBERG,INST BIOL CHEM,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAAMANO CA, 1993, BIOCHEMISTRY-US, V32, P8589, DOI 10.1021/bi00084a028; Chavany C, 1996, J BIOL CHEM, V271, P4974; Clark JW, 1996, INT J CANCER, V65, P186; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GEHRING U, 1987, MOL CELL ENDOCRINOL, V53, P33, DOI 10.1016/0303-7207(87)90189-4; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HARRISON RW, 1987, RECENT ADV STEROID H, P467; HARTIG E, 1993, J VIROL, V67, P813; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYASHI SI, 1967, J BIOL CHEM, V242, P3998; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KULKA RG, 1988, J BIOL CHEM, V263, P15726; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIGITA K, 1994, J IMMUNOL, V153, P3457; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Moore DD, 1995, GLOB MOB SURV; MURAKAMI Y, 1994, BIOCHEM J, V301, P57, DOI 10.1042/bj3010057; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1992, J STEROID BIOCHEM, V42, P803, DOI 10.1016/0960-0760(92)90088-Z; OKABE M, 1994, LEUKEMIA RES, V18, P867, DOI 10.1016/0145-2126(94)90169-4; PRATT WB, 1996, STRESS INDUCIBLE CEL, P79; REXIN M, 1988, BIOCHEMISTRY-US, V27, P5593, DOI 10.1021/bi00415a030; REXIN M, 1991, J BIOL CHEM, V266, P24601; SCHMITT J, 1993, GENE, V132, P267, DOI 10.1016/0378-1119(93)90206-I; SEGNITZ B, 1990, J BIOL CHEM, V265, P2789; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SIMONS SS, 1994, VITAM HORM, V49, P49; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SPINDLERBARTH M, 1982, FEBS LETT, V138, P91, DOI 10.1016/0014-5793(82)80402-X; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; WESTPHAL HM, 1982, EMBO J, V1, P1467, DOI 10.1002/j.1460-2075.1982.tb01339.x; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705	50	145	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18694	18701		10.1074/jbc.272.30.18694	http://dx.doi.org/10.1074/jbc.272.30.18694			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228040	hybrid			2022-12-25	WOS:A1997XM34200031
J	Li, HL; Forman, MS; Kurosaki, T; Pure, E				Li, HL; Forman, MS; Kurosaki, T; Pure, E			Syk is required for BCR-mediated activation of p90Rsk, but not p70S6k, via a mitogen-activated protein kinase-independent pathway in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASE; GAP-ASSOCIATED PROTEIN; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CROSS-LINKING; S6 KINASE; PHOSPHORYLATION; P72(SYK); RAPAMYCIN	The tyrosine kinases Syk and Lyn are activated in B lymphocytes following antibody induced cross-linking of the B cell receptor for antigen (BCR). It has been suggested that activation of Syk is dependent on Lyn. We tested this hypothesis by comparing the phosphorylation and activation of several downstream effector molecules in parental DT40, DT40Syk(-) and DT40Lyn-B cells. The phosphorylation and activation of p90Rsk was ablated in Syk-deficient B cells but unaffected in Lyn-deficient B cells while the phosphorylation/activation of Ras GTPase activating protein (Ras GAP) and mitogen activated protein (MAP) kinase required both Syk and Lyn. Thus, these data indicate that Syk can be activated in the absence of Lyn after BCR cross-linking and results ire the activation of p90Rsk via a MAP kinase-independent pathway in DT40Lyn(-) cells. We also demonstrated that BCR mediates the activation of p70S6k. However, activation of p70S6k in DT40Syk(-) and DT40Lyn(-) cells was comparable with that observed in parental cells. Thus, either Syk or Lyn may be sufficient for activation of p70S6k, or activation of p70S6k occurs independently of both Syk and Lyn. The kinase activity of Syk was required for the phosphorylation/activation of each of these downstream effector molecules but only the phosphorylation of Ras GAP was affected in cells expressing a mutant of Syn in which tyrosines 525 and 526 were substituted to phenlyalanines.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; KANSAI MED UNIV,INST HEPAT RES,DEPT MOL GENET,MORIGUCHI,OSAKA 570,JAPAN	The Wistar Institute; Kansai Medical University			Kurosaki, Tomohiro/D-1306-2009; Li, Hsiu-Ling/C-3567-2011	Kurosaki, Tomohiro/0000-0002-6352-304X; 	NIAID NIH HHS [R01 AI25185] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025185] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAGAARDTILLERY KM, 1994, CELL IMMUNOL, V156, P493, DOI 10.1006/cimm.1994.1193; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; DARBY C, 1994, J IMMUNOL, V152, P5429; DUMONT FJ, 1994, J IMMUNOL, V152, P992; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; GOLD MR, 1993, J IMMUNOL, V150, P377; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kalab P, 1996, DEVELOPMENT, V122, P1957; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KINCH MS, 1994, J EXP MED, V180, P1729, DOI 10.1084/jem.180.5.1729; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANKESTER AC, 1994, J IMMUNOL, V152, P2157; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAW LC, 1996, MOL CELL BIOL, V16, P1305; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J CELL BIOL, V270, P16186; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; Pao LI, 1997, J IMMUNOL, V158, P2663; Pao LI, 1997, J IMMUNOL, V158, P1116; Patel HR, 1996, BIOCHEM BIOPH RES CO, V227, P507, DOI 10.1006/bbrc.1996.1537; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; STAHLS A, 1994, EUR J IMMUNOL, V24, P2491, DOI 10.1002/eji.1830241035; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TORDAI A, 1994, J BIOL CHEM, V269, P7538; TRAHEY MT, 1988, SCIENCE, V335, P1697; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VIVER E, 1993, EUR J IMMUNOL, V23, P1872; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Xiao J, 1996, J BIOL CHEM, V271, P7659, DOI 10.1074/jbc.271.13.7659; YAGURA H, 1993, BLOOD, V81, P1535; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	67	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18200	18208		10.1074/jbc.272.29.18200	http://dx.doi.org/10.1074/jbc.272.29.18200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218456	hybrid			2022-12-25	WOS:A1997XL73500046
J	Yu, B; Slepak, VZ; Simon, MI				Yu, B; Slepak, VZ; Simon, MI			Characterization of a Go alpha mutant that binds xanthine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; G-PROTEINS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ADP-RIBOSYLATION; PHOSPHOLIPASE-C; GTP HYDROLYSIS; RAS P21; SUBUNIT; RECEPTORS	Several GTP binding proteins, including EF-Tu, Ypt1, rab-5, and FtsY, and adenylosuccinate synthetase have been reported to bind xanthine nucleotides when the conserved aspartate residue in the NKXD motif was changed to asparagine, However, the corresponding single Go alpha mutant protein (D273N) did not bind either xanthine nucleotides or guanine nucleotides. Interestingly, the introduction of a second mutation to generate the Go alpha subunit D273N/Q205L switched nucleotide binding specificity to xanthine nucleotide. The double mutant protein Go alpha D273N/Q205L (Go alpha X) bound xanthine triphosphate, but not guanine triphosphate. Recombinant Go alpha X (Go alpha D273N/Q205L) formed heterotrimers with beta gamma complexes only in the presence of xanthine diphosphate (XDP),(1) and the binding to beta gamma was inhibited by xanthine triphosphate (XTP), Furthermore, as a result of binding to XTP, the Go alpha X protein underwent a conformational change similar to that of the activated wild-type Go alpha. In transfected COS-7 cells, we demonstrate that the interaction between Go alpha X and beta gamma occurred only when cell membranes were permeabilized to allow the uptake of xanthine diphosphate. This is the first example of a switch in nucleotide binding specificity from guanine to xanthine nucleotides in a heterotrimeric G protein alpha subunit.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology								AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOURNE HR, 1991, NATURE, V366, P654; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HENDERSON JF, 1973, NUCLEOTIDE METABOLIS, P97; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOFFENBERG S, 1995, BIOCHEM BIOPH RES CO, V215, P241, DOI 10.1006/bbrc.1995.2459; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KANG C, 1994, J BIOL CHEM, V269, P24046; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002	43	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18015	18019		10.1074/jbc.272.29.18015	http://dx.doi.org/10.1074/jbc.272.29.18015			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218429	hybrid, Green Accepted			2022-12-25	WOS:A1997XL73500019
J	Akeson, M; Sainz, E; Mantey, SA; Jensen, RT; Battey, JF				Akeson, M; Sainz, E; Mantey, SA; Jensen, RT; Battey, JF			Identification of four amino acids in the gastrin-releasing peptide receptor that are required for high affinity agonist binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LUNG-CARCINOMA CELLS; BOMBESIN RECEPTOR; NEUROMEDIN-B; MOLECULAR-CLONING; EXPRESSION; RHODOPSIN; SUBTYPES; DISTINCT	The bombesin family of G-protein-coupled receptors includes the gastrin-releasing peptide receptor (GRP-R), the neuromedin B receptor (NMB-R), bombesin receptor subtype 3 (BRS-3), and bombesin receptor subtype 4 (bb4). All species homologues of GRP-R, NMB-R, and bb4 bind bombesin with dissociation constants in the nanomolar range; by comparison, human BRS-3 binds bombesin at much lower affinity (K-d > 1 mu m). We used this difference to help identify candidate residues that were potentially critical for forming the bombesin binding pocket. We reasoned that amino acids essential for bombesin binding would be conserved among all homologues of bb4, NMB-R, and GRP-R; conversely, at least one of these amino acids would not be conserved among homologues of BRS-3. Amino acid sequence alignment revealed nine residues that fit this model. We replaced each of these amino acids in mouse GRP-R with the homologous amino acid in human BRS-3. Four substitutions resulted in a significant decrease in bombesin affinity (R288H, Q121R, P199S, and A308S). The analo gous mutations in BRS-3 (R127Q, H294R, S205P, and S315A) together resulted in a receptor with a 100-fold increase in bombesin and GRP affinities relative to wildtype BRS-3. From this, we propose a preliminary map of some of the amino acids comprising the agonist binding pocket.	NATL INST DEAFNESS & OTHER COMMUN DISORDERS,MOL BIOL LAB,NIH,ROCKVILLE,MD 20850; NIDDK,DIGEST DIS BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; DAVIS LG, 1994, BASIC METHODS MOL BI, P624; ERSPAMER GF, 1988, REGUL PEPTIDES, V21, P1; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FATHI Z, 1993, J BIOL CHEM, V268, P5979; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; HAN M, 1995, BIOCHEMISTRY-US, V34, P1425, DOI 10.1021/bi00004a037; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; KROOG GS, 1995, J BIOL CHEM, V270, P8217, DOI 10.1074/jbc.270.14.8217; MCDONALD TJ, 1979, BIOCHEM BIOPH RES CO, V90, P227, DOI 10.1016/0006-291X(79)91614-0; Meng F, 1996, J BIOL CHEM, V271, P32016, DOI 10.1074/jbc.271.50.32016; MINAMINO N, 1983, BIOCHEM BIOPH RES CO, V114, P541, DOI 10.1016/0006-291X(83)90814-8; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SPINDEL ER, 1990, MOL ENDOCRINOL, V43, P1950; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4	25	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17405	17409		10.1074/jbc.272.28.17405	http://dx.doi.org/10.1074/jbc.272.28.17405			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211882	hybrid			2022-12-25	WOS:A1997XK16500025
J	Annunen, P; Helaakoski, T; Myllyharju, J; Veijola, J; Pihlajaniemi, T; Kivirikko, KI				Annunen, P; Helaakoski, T; Myllyharju, J; Veijola, J; Pihlajaniemi, T; Kivirikko, KI			Cloning of the human prolyl 4-hydroxylase alpha subunit isoform alpha(II) and characterization of the type II enzyme tetramer - The alpha(I) and alpha(II) subunits do not form a mixed alpha(I)alpha(II)beta(2) tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EHLERS-DANLOS SYNDROME; LYSYL HYDROXYLASE GENE; SYNDROME TYPE-VI; BETA-SUBUNIT; BACULOVIRUS EXPRESSION; MOLECULAR-CLONING; 2 SIBLINGS; SEQUENCE; COLLAGEN	Prolyl 4-hydroxylase (proline hydroxylase, EC 1.14.11.2) catalyzes the formation of 4-hydroxyproline in collagens, The vertebrate enzyme is an alpha(2) beta(2) tetramer, the beta subunit of which is identical to protein disulfide-isomerase (PDI, EC 5.3.4.1), Pie report here on cloning of the recently discovered alpha(II) subunit from human sources, The mRNA for the alpha(II) subunit was found to be expressed in a variety of human tissues, and the presence of the corresponding polypeptide and the (alpha(II))(2) beta(2) tetramer was demonstrated in cultured human WI-38 and HT-1080 cells. The type II tetramer was found to represent about 30% of the total prolyl 4-hydroxylase in these cells and about 5-15% in various chick embryo tissues, The results of coexpression in insect cells argued strongly against the formation of a mixed alpha(I)alpha(II)beta(2) tetramer. PDI/beta polypeptide containing a histidine tag in its N terminus was found to form prolyl 4-hydroxylase tetramers as readily as the wild-type PDI/beta polypeptide, and histidine-tagged forms of prolyl 4-hydroxylase appear to offer an excellent source for a simple large scale purification of the recombinant enzyme. The properties of the purified human type II enzyme were very similar to Chose of the type I enzyme, beet the K-i of the former fbr poly(L-proline) was about 200-1000 times that of the latter. In agreement with this, a minor difference, about 3-6-fold, was found between the two enzymes in the K-m values for three peptide substrates. The existence of two forms of prolyl 4-hydroxylase in human cells raises the possibility that mutations in one enzyme form may not be lethal despite the central role of this enzyme in the synthesis of all collagens.	UNIV OULU, DEPT MED BIOCHEM, FIN-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, FIN-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				ATREYA PL, 1991, J BIOL CHEM, V266, P2852; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUJIMOTO D, 1969, J BIOL CHEM, V244, P205; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HA VT, 1994, J CLIN INVEST, V93, P1716, DOI 10.1172/JCI117155; HAUTALA T, 1993, GENOMICS, V15, P399, DOI 10.1006/geno.1993.1074; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; HYLAND J, 1992, NAT GENET, V2, P228, DOI 10.1038/ng1192-228; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1987, METHOD ENZYMOL, V144, P96; KOIVU J, 1987, J BIOL CHEM, V262, P6447; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PROCKOP DJ, 1969, J BIOL CHEM, V244, P4838; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUDERMAN L, 1975, EUR J BIOCHEM, V52, P9, DOI 10.1111/j.1432-1033.1975.tb03967.x; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467	32	102	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17342	17348		10.1074/jbc.272.28.17342	http://dx.doi.org/10.1074/jbc.272.28.17342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211872	hybrid			2022-12-25	WOS:A1997XK16500015
J	Gaits, F; Shiozaki, K; Russell, P				Gaits, F; Shiozaki, K; Russell, P			Protein phosphatase 2C acts independently of stress-activated kinase cascade to regulate the stress response in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; GENE PTC1; PATHWAYS; CELLS	Stress-activated signal transduction pathways, which are largely conserved among a broad spectrum of eukaryotic species, have a crucial role in the survival of many forms of stress. It is therefore important to discover how these pathways are both positively and negatively regulated. Recent genetic studies have implicated protein phosphatase 2C (PP2C) as a novel negative regulator of stress response pathways in both budding and fission yeasts, Moreover, it was hypothesized that PP2C dephosphorylates one or more components of protein kinase cascades that are at the core of stress-activated signal transduction pathways, Herein we present genetic and biochemical studies of the fission yeast Schizosaccharomyces pombe that disprove this hypothesis and indicate that PP2C instead negatively regulates a downstream element of the pathway. First, high expression of PPSC produces phenotypes that are inconsistent with negative regulation of the Wik1-Wis1-Spc1 stress-activated kinase cascade. Second, high expression of PPSC leads to sustained activating tyrosine phosphorylation of Spc1. Third, Spc1-dependent phosphorylation of Atf1, a transcription factor substrate of Spc1, is unaffected by high expression of PP2C, Fourth, high expression of PP2C suppresses Atf1-dependent transcription of a stress-response gene, These studies strongly suggest that PP2C acts down stream of Spc1 kinase in the stress-activated signal transduction pathway.	Scripps Res Inst, DEPT MOL BIOL MB3, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Shiozaki, Kazuhiro/K-3440-2019	Shiozaki, Kazuhiro/0000-0002-0395-5457; Gaits-Iacovoni, Frederique/0000-0002-9853-0442	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041281] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41281] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C., 1993, EXPT FISSION YEAST; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; ChinSang ID, 1996, GENE DEV, V10, P2314, DOI 10.1101/gad.10.18.2314; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Degols G, 1996, MOL CELL BIOL, V16, P2870; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUANG KN, 1995, GENETICS, V141, P1275; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIKAWA M, 1995, FEBS LETT, V375, P299, DOI 10.1016/0014-5793(95)01209-W; OTTILIE S, 1992, MOL CELL BIOL, V12, P5571, DOI 10.1128/MCB.12.12.5571; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; RUSSELL PR, 1983, J BIOL CHEM, V258, P143; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	30	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17873	17879		10.1074/jbc.272.28.17873	http://dx.doi.org/10.1074/jbc.272.28.17873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211944	hybrid			2022-12-25	WOS:A1997XK16500087
J	Lee, YM; Park, TY; Schulz, RA; Kim, YS				Lee, YM; Park, TY; Schulz, RA; Kim, YS			Twist-mediated activation of the NK-4 homeobox gene in the visceral mesoderm of Drosophila requires two distinct clusters of E-box regulatory elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL GRADIENT MORPHOGEN; HOMEODOMAIN PROTEINS; FUNCTIONAL-ANALYSIS; AUTO-REGULATION; MULTIPLE-MODES; CELL FATE; EXPRESSION; EMBRYO; HEART; DNA	NK-4, also called msh2 and tinman, encodes a homeodomain transcription factor that is required for the development of the dorsal mesoderm and its derivatives in the Drosophila embryo. Genetic analyses indicate that NK-4 resides downstream of the mesodermal determinant twist, which encodes a basic helix-loop-helix-type transcription factor. However, the regulation of NK-4 by twist remains poorly understood, Using expression assays in cultured cells and transgenic flies, we show that two distinct clusters of E-box regulatory sequences, present upstream of the NK-4 gene, mediate NK-4 expression in the visceral mesoderm. These elements are conserved between the Drosophila melanogaster and Drosophila virilis NK-4 genes and serve as binding sites for Twist (E1 cluster) and NK-4 (E2 cluster) proteins. In cultured cells, Twist and NK-4 binding results in activation of NK-4 gene expression. In transgenic animals, the E1 and E2 clusters are functionally connected, and both elements are required for NK-4 activation in cells of the visceral mesoderm and also for NK-4 repression in cells of the somatic musculature. These results demonstrate that NK-4 is a direct transcriptional target for Twist and its own gene product in visceral mesodermal cells, supporting the idea that twist and NK-4 function in the subdivision of the mesoderm during Drosophila embryogenesis.	NHLBI, LMC, NIH, BETHESDA, MD 20892 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; UTMD Anderson Cancer Center								AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Azpiazu N, 1996, GENE DEV, V10, P3183, DOI 10.1101/gad.10.24.3183; Bate Michael, 1993, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BODMER R, 1995, TRENDS CARDIOVAS MED, V5, P21, DOI 10.1016/1050-1738(94)00032-Q; Borkowski OMD, 1995, DEVELOPMENT, V121, P4183; Buchberger A, 1996, MECH DEVELOP, V56, P151, DOI 10.1016/0925-4773(96)00521-7; Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; Chung KW, 1996, MOL CELLS, V6, P197; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Dessain S., 1993, ADV DEV BIOCH, V2, P1, DOI [10.1016/s1064-2722(08)60035-3, DOI 10.1016/S1064-2722(08)60035-3]; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; EVANS SM, 1995, DEVELOPMENT, V121, P3889; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOEY T, 1988, MOL CELL BIOL, V8, P4598, DOI 10.1128/MCB.8.11.4598; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; IRVINE KD, 1993, DEVELOPMENT, V117, P387; JAGLA K, 1994, NUCLEIC ACIDS RES, V22, P1202, DOI 10.1093/nar/22.7.1202; JAGLA K, 1993, GENE, V127, P165, DOI 10.1016/0378-1119(93)90715-F; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee KH, 1996, DEV BIOL, V180, P722, DOI 10.1006/dbio.1996.0341; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAGGERT K, 1995, DEVELOPMENT, V121, P2107; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; NIRENBERG M, 1995, ANN NY ACAD SCI, V758, P224, DOI 10.1111/j.1749-6632.1995.tb24830.x; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; Park MY, 1996, DEV BIOL, V177, P104, DOI 10.1006/dbio.1996.0149; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; RAY RP, 1991, DEVELOPMENT, V113, P35; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; SIMPSON P, 1983, GENETICS, V105, P615; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STJOHNSTON D, 1992, CELL, V68, P201; SZYMANSKI P, 1995, EMBO J, V14, P2229, DOI 10.1002/j.1460-2075.1995.tb07217.x; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014	74	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17531	17541		10.1074/jbc.272.28.17531	http://dx.doi.org/10.1074/jbc.272.28.17531			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211899	hybrid			2022-12-25	WOS:A1997XK16500042
J	Kishore, R; Samuel, M; Khan, MY; Hand, J; Frenz, DA; Newman, SA				Kishore, R; Samuel, M; Khan, MY; Hand, J; Frenz, DA; Newman, SA			Interaction of the NH2-terminal domain of fibronectin with heparin - Role of the Omega-loops of the type I modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DRIVEN TRANSLOCATION; ULTRAVIOLET CIRCULAR-DICHROISM; NUCLEAR-MAGNETIC-RESONANCE; HUMAN-PLASMA FIBRONECTIN; AMINO-TERMINAL DOMAIN; FIBRIN-BINDING SITE; SECONDARY STRUCTURE; STAPHYLOCOCCUS-AUREUS; CELL-SURFACE; PROTEIN	Determinants of the interaction of the 29-kDa NH2-terminal domain of fibronectin with heparin were explored by analysis of normal and mutant recombinant NH2-terminal fibronectin fragments produced in an insect cell Baculovirus host vector system, A genomic/cDNA clone was constructed that specified a secretable human fibronectin NH2 fragment, With the use of site-directed mutagenesis a set of 29 kDa fragments was obtained that contained glycine or glutamic acid residues in place of basic residues at various candidate sites for heparin binding in the five type I modules that mako up the domain. The recombinant fragment containing the wild type sequence had a nearly normal circular dichroic spectra and a melting profile, as assayed by loss of ellipticity at 228 nm, that was indistinguishable from that of the native fragment obtained by trypsinization of plasma fibronectin, A substantial proportion of the wild type recombinant fragment bound to heparin-Sepharose, where it was eluted at the same NaCl concentration as the native fragment. The wild type fragment was capable of promoting matrix-driven translocation, a morphogenetic effect in artificial extracellular matrices that depends on the interaction of the fibronectin NH2 terminus with heparin-like molecules on the surfaces of particles. Mutant fragments in which arginines predicted to be most exposed in the folded fragment were converted to glycines retained the same affinity for heparin as the wild type fragment, In contrast, a mutant fragment in which the single basic residue (Arg(99)) in the minor loop (''Omega-loop'') Of the second type I module was converted to a glycine had an essentially normal melting profile but exhibited no binding to heparin and failed to promote matrix-driven translocation, A mutant fragment in which the single basic residue (Arg(52)) Of the first type I module was converted to a glycine also completely lacked heparin binding activity, but one in which the single basic residue (Arg(191)) the fourth type I module was converted to a glycine retained the ability to bind heparin. A mutant fragment in which the single basic residue (Lys(143)) in the Omega-loop of the third type I module was converted to a glutamic acid lacked heparin binding activity but had a CD spectrum similar to the heparin-liganded native protein and was capable of promoting matrix-driven translocation, The results indicate that multiple residues in the Omega-loops of the fibronectin NH2-terminal domain participate in its interactions with heparin, In addition, the conformation of one of the nonbinding mutants may mimic the heparin-induced structural alteration ill this fibronectin domain required for certain morphogenetic events.	NEW YORK MED COLL,DEPT BIOCHEM & MOL BIOL,VALHALLA,NY 10595; DR RAM MANOHAR LOHAI UNIV,DEPT BIOCHEM,FAIZABAD 224001,UTTAR PRADESH,INDIA; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OTOBIOL,BRONX,NY 10461	New York Medical College; Yeshiva University; Albert Einstein College of Medicine	Kishore, R (corresponding author), NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595, USA.		Newman, Stuart/W-1617-2019		NICHD NIH HHS [HD22564] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022564] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALON R, 1994, J IMMUNOL, V152, P1304; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BENECKY MJ, 1988, BIOCHEMISTRY-US, V27, P7565, DOI 10.1021/bi00419a058; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BOISSONVIDAL C, 1991, J BIOMED MATER RES, V25, P67, DOI 10.1002/jbm.820250106; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BRUMFELD V, 1993, ARCH BIOCHEM BIOPHYS, V302, P134, DOI 10.1006/abbi.1993.1191; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Downie SA, 1995, DEV BIOL, V172, P519, DOI 10.1006/dbio.1995.8068; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; DRAKE SL, 1993, J BIOL CHEM, V268, P15859; FORGACS G, 1989, J THEOR BIOL, V140, P417, DOI 10.1016/S0022-5193(89)80096-7; Forgacs G, 1994, COLLOID SURFACE B, V3, P139, DOI 10.1016/0927-7765(94)80061-8; FRENZ DA, 1989, DEV BIOL, V136, P87, DOI 10.1016/0012-1606(89)90132-2; FRENZ DA, 1989, DEV BIOL, V136, P97, DOI 10.1016/0012-1606(89)90133-4; GARCIAPARDO A, 1983, J BIOL CHEM, V258, P2670; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HALL BK, 1992, ANAT EMBRYOL, V186, P107; HAYASHI M, 1983, J BIOL CHEM, V258, P3332; HIDER RC, 1988, BIOPOLYMERS, V27, P113, DOI 10.1002/bip.360270109; HINES KL, 1994, P NATL ACAD SCI USA, V91, P5187, DOI 10.1073/pnas.91.11.5187; HOMANDBERG GA, 1987, THROMB RES, V48, P329, DOI 10.1016/0049-3848(87)90445-2; HUFF S, 1994, J BIOL CHEM, V269, P15563; Hynes RO, 1990, FIBRONECTINS; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; JAIKARIA NS, 1991, BIOCHEMISTRY-US, V30, P1538, DOI 10.1021/bi00220a014; JOZEFONVICZ J, 1990, Journal of Biomaterials Science Polymer Edition, V1, P147; Kahn P C, 1979, Methods Enzymol, V61, P339; KHAN MY, 1988, J BIOL CHEM, V263, P11314; KHAN MY, 1989, J BIOL CHEM, V264, P2139; KHAN MY, 1990, BIOCHEM J, V270, P33, DOI 10.1042/bj2700033; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; MATSUKA YV, 1994, J BIOL CHEM, V269, P9539; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; Mosher DF, 1989, FIBRONECTIN; Newman S, 1997, BIOPOLYMERS, V41, P337, DOI 10.1002/(SICI)1097-0282(199703)41:3<337::AID-BIP9>3.0.CO;2-T; NEWMAN SA, 1985, SCIENCE, V228, P885, DOI 10.1126/science.4001925; NEWMAN SA, 1987, P NATL ACAD SCI USA, V84, P4791, DOI 10.1073/pnas.84.14.4791; NEWMAN SA, 1996, STRUCTURE FUNCTION E, V2; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; ODERMATT E, 1982, J MOL BIOL, V159, P109, DOI 10.1016/0022-2836(82)90034-1; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROSTAGNO A, 1994, J BIOL CHEM, V269, P31938; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUEL M, 1994, THROMB RES, V75, P259, DOI 10.1016/0049-3848(94)90237-2; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; STEVENS ES, 1987, J MOL BIOL, V197, P743, DOI 10.1016/0022-2836(87)90481-5; WELSH EJ, 1983, BIOPOLYMERS, V22, P821, DOI 10.1002/bip.360220305; WILLIAMS MJ, 1993, BIOCHEMISTRY-US, V32, P7388, DOI 10.1021/bi00080a008; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; WOODY RW, 1972, BIOPOLYMERS, V11, P1149, DOI 10.1002/bip.1972.360110604; YANG JT, 1986, METHOD ENZYMOL, V130, P208	61	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17078	17085		10.1074/jbc.272.27.17078	http://dx.doi.org/10.1074/jbc.272.27.17078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202024	hybrid			2022-12-25	WOS:A1997XH44600056
J	Djie, MZ; Stone, SR; LeBonniec, BF				Djie, MZ; Stone, SR; LeBonniec, BF			Intrinsic specificity of the reactive site loop of alpha(1)-antitrypsin, alpha(1)-antichymotrypsin, antithrombin III, and protease nexin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NEURITE-PROMOTING FACTOR; HEPARIN COFACTOR-II; PROTEINASE-INHIBITORS; DIRECTED MUTAGENESIS; HUMAN ALPHA-1-ANTICHYMOTRYPSIN; CRYSTAL-STRUCTURE; ANTI-THROMBIN; EGLIN-C; ALPHA-1-ANTITRYPSIN	Members of the serpin (serine protease inhibitor) family share a similar backbone structure but expose a variable reactive-site loop, which binds to the catalytic groove of the target protease. Specificity originates in part from the sequence of this loop and also from secondary binding sites that contribute to the inhibitor function. To clarify the intrinsic contribution of the reactive-site loop, alpha(1)-antichymotrypsin has been utilized as a scaffold to construct chimeras carrying the loop of antithrombin III, protease nexin 1, or alpha(1)-antitrypsin. Reactive-site loops not only vary in sequence but also in length; therefore, the length of the reactive-site loop was also varied in the chimeras. The efficacy of the specificity transfer was evaluated by measuring the stoichiometry of the reaction, the ability to form an SDS-stable complex, and the association rate constant with a number of potential targets (chymotrypsin, neutrophil elastase, trypsin, thrombin, factor Xa, activated protein C, and urokinase). Overall, substitution of a reactive-site loop was not sufficient to transfer the specificity of a given serpin to alpha(1)-antichymotrypsin. Specificity of the chimera partly matched that of the loop donor and partly that of the acceptor, whereas the behavior as an inhibitor or a substrate depended upon the targeted protease. Results suggest that, aside from the contributions of the loop sequence and the framework-specific secondary binding sites, an intramolecular control may be essential for productive interaction.	UNIV CAMBRIDGE,MRC CTR,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge			Le Bonniec, Bernard/S-5756-2016; Le Bonniec, Bernard/ABA-1366-2020	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363				AVRON A, 1991, FEBS LETT, V280, P41, DOI 10.1016/0014-5793(91)80199-D; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BJORK I, 1992, J BIOL CHEM, V267, P1976; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CHEN ZG, 1983, J MOL BIOL, V164, P283, DOI 10.1016/0022-2836(83)90078-5; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ELDERING E, 1992, J BIOL CHEM, V267, P7013; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; FRIGERIO F, 1992, J MOL BIOL, V225, P107, DOI 10.1016/0022-2836(92)91029-O; GLOOR S, 1986, CELL, V47, P687; HEINZ DW, 1992, BIOCHEMISTRY-US, V31, P8755, DOI 10.1021/bi00152a011; HERMANS JM, 1993, BIOCHEM J, V295, P239, DOI 10.1042/bj2950239; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; KEIJER J, 1991, J BIOL CHEM, V266, P10700; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MADISON EL, 1990, J BIOL CHEM, V265, P21423; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; OLSON ST, 1995, J BIOL CHEM, V270, P9717, DOI 10.1074/jbc.270.17.9717; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; OWEN MC, 1991, FEBS LETT, V280, P216, DOI 10.1016/0014-5793(91)80296-F; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Sambrook J., 2002, MOL CLONING LAB MANU; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SHEFFIELD WP, 1994, FEBS LETT, V339, P147, DOI 10.1016/0014-5793(94)80403-6; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; Song HK, 1995, FEBS LETT, V377, P150; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TRAVIS J, 1981, METHOD ENZYMOL, V80, P765; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VIDAUD D, 1992, J CLIN INVEST, V89, P1537, DOI 10.1172/JCI115746; WALEY SG, 1985, BIOCHEM J, V227, P843, DOI 10.1042/bj2270843; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; YORK JD, 1991, J BIOL CHEM, V266, P8495	62	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16268	16273		10.1074/jbc.272.26.16268	http://dx.doi.org/10.1074/jbc.272.26.16268			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195929	hybrid			2022-12-25	WOS:A1997XG01900033
J	Jones, SA; Dewald, B; ClarkLewis, I; Baggiolini, M				Jones, SA; Dewald, B; ClarkLewis, I; Baggiolini, M			Chemokine antagonists that discriminate between interleukin-8 receptors - Selective blockers of CXCR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; HIGH-AFFINITY; GRO-ALPHA; CHEMOTACTIC CYTOKINES; SIGNAL-TRANSDUCTION; BINDING; RESIDUES; IL-8R1; NAP-2	Human neutrophils express two interleukin (IL)-8 receptors, CXC chemokine receptor (CXCR) 1 and CXCR2. IL-8 with changes to the NH2-terminal ELR motif can block IL-8-induced neutrophil functions (Moser, B., Dewald, B., Barella, L., Schumacher, C., Baggiolini, Ri., and Clark-Lewis, I. (1993) J. Biol. Chem. 268, 7125-7128). We have now examined the effect of NH2-terminally modified analogs of IL-8, GRO alpha, and PF4 on CXCR1 and CXCR2 independently. Using stable Jurkat transfectants expressing either CXCR1 or CXCR2, it was shown that analogs derived from IL-8 bound both IL-8 receptors with similar affinity and could block IL-8-induced Ca2+ mobilization. By contrast, analogs of GRO alpha and PF4, (R)GRO alpha and (R)PF4, bound only CXCR2 with high affinity and blocked Ca2+ mobilization induced only via CXCR2. The differential effect on CXCR1 and CXCR2 was also demonstrated in studies with isolated neutrophils. Thus (R)GRO alpha and (R)PF4 inhibited only the GRO alpha but not the IL-8-stimulated elastase release, and these two analogs had no effect on IL-8-elicited superoxide generation, a response that is mediated by CXCR1 but not by CXCR2. These results show that CXCR2 selective receptor antagonists can be generated based upon the secondary binding determinants of GRO alpha and PF4. They also highlight the primary importance of CXCR1 in chemokine-mediated release of granule enzymes and superoxide generation. The selective antagonists described may be used in future studies on IL-8 receptor signaling to define distinct steps leading to various functional responses induced in neutrophils via CXCR1 and CXCR2.	UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1W5,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER,BC V6T 1W5,CANADA	University of Bern; University of British Columbia; University of British Columbia			Jones, Simon Arnett/Q-7017-2018	Jones, Simon Arnett/0000-0001-7297-9711	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50969] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; GEISER T, 1993, J BIOL CHEM, V268, P15419; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JONES OTG, 1994, METHOD ENZYMOL, V233, P222; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; LEE J, 1992, J BIOL CHEM, V267, P16283; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, J BIOL CHEM, V268, P7125; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SCHUMACHER C, 1994, ANAL BIOCHEM, V222, P262, DOI 10.1006/abio.1994.1483; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745	26	108	115	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16166	16169		10.1074/jbc.272.26.16166	http://dx.doi.org/10.1074/jbc.272.26.16166			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195914	hybrid			2022-12-25	WOS:A1997XG01900018
J	Kobayashi, S; Okumura, N; Nakamoto, T; Okada, M; Hirai, H; Nagai, K				Kobayashi, S; Okumura, N; Nakamoto, T; Okada, M; Hirai, H; Nagai, K			Activation of pp60(c-src) depending on cell density in PC12h cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GROWTH-FACTOR; SH3 DOMAINS; PHOSPHORYLATED PROTEINS; EXTRACELLULAR-MATRIX; NEURITE OUTGROWTH; V-CRK; C-SRC; ADHESION; ASSOCIATION	The Src family tyrosine kinases and their substrates are involved in cell-cell and cell-matrix interactions. We found that in PC12h cells, an increase of cell density enhanced the tyrosine phosphorylation levels of several intracellular proteins including p130(cas). Because it is a possible substrate for Src family kinases, we measured pp60(c-src) activity and found that it was higher in high density cultures than in low density cultures. This phenomenon was also observed in PC12 (the parental cell line of the PC12h subclone), Balb/c 3T3, Swiss 3T3, and Hela cells, One of the possible mechanisms regulating the kinase activity of pp60(c-src) is the phosphorylation and dephosphorylation of its negative regulatory site located at its C terminus. However, the tyrosine phosphorylation level of the regulatory site did not change depending on cell density. Subcellular fractionation showed that in high density culture, pp60(c-src) was translocated from detergent-soluble to detergent-insoluble fractions, These results suggest that cell-cell interaction might induce the activation of pp60(c-src) without changing its tyrosine phosphorylation levels.	OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Osaka University; University of Tokyo								BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATANAKA H, 1981, BRAIN RES, V222, P225, DOI 10.1016/0006-8993(81)91029-5; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KHAN MA, 1995, FEBS LETT, V362, P201, DOI 10.1016/0014-5793(95)00250-D; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; OTTILIE S, 1992, ONCOGENE, V7, P1625; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264	39	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16262	16267		10.1074/jbc.272.26.16262	http://dx.doi.org/10.1074/jbc.272.26.16262			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195928	hybrid			2022-12-25	WOS:A1997XG01900032
J	Le, H; Tanguay, RL; Balasta, ML; Wei, CC; Browning, KS; Metz, AM; Goss, DJ; Gallie, DR				Le, H; Tanguay, RL; Balasta, ML; Wei, CC; Browning, KS; Metz, AM; Goss, DJ; Gallie, DR			Translation initiation factors eIF-iso4G and eIF-4B interact with the poly(A)-binding protein and increase its RNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; WHEAT-GERM; ISOZYME FORM; IN-VITRO; CAP; YEAST; IDENTIFICATION; TAX; DEADENYLATION; PURIFICATION	The 5'-cap and the poly(A) tail act synergistically to increase the translational efficiency of eukaryotic mRNAs, which suggests that these two mRNA elements communicate during translation, We report here that the cap-associated eukaryotic initiation factors (eLFs), i.e, the two isoforms of the cap-binding complex (eIF-4F and eLF-iso4F) and eIF-4B, bind to the poly(A)-binding protein (PABP) both in the presence and absence of poly(A) RNA, The interactions between PABP and eIF-4F, eIF-iso4F, and eIF-4B were measured in the absence of poly(A) RNA using far Western analysis and confirmed by direct fluorescence titration studies, The functional consequence of the interaction between these initiation factors and PABP was examined using RNA binding assays and RNA mobility shift analysis, eIF-4F, eIF-iso4F, and eIF-4B promoted PARR activity through a shift in its equilibrium affinity for poly(A), eIF-iso4G, the large subunit of eIF-iso4F, was the subunit responsible for the interaction between eLF-iso4F and PABP and was the subunit that promoted PABP RNA binding activity, Truncation analysis of eIF-iso4G indicated that a domain close to its N-terminal end appeared to be involved in binding PARR, These results suggest that the interaction between PABP and eIF-4B and eIF-iso4G may be involved in mediating the functional co-dependence observed between the cap and the poly(A) tail during translation.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; CUNY HUNTER COLL, DEPT CHEM, NEW YORK, NY 10021 USA; UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA	University of California System; University of California Riverside; City University of New York (CUNY) System; Hunter College (CUNY); University of Texas System; University of Texas Austin				Wei, Chin-Chuan/0000-0001-6453-9409				ALLEN ML, 1992, J BIOL CHEM, V267, P23232; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BALASTA ML, 1993, J BIOL CHEM, V268, P18599; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1987, J BIOL CHEM, V262, P538; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; BROWNING KS, 1985, FED PROC, V44, P1224; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Firpo MA, 1996, J BIOL CHEM, V271, P4693; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAX SR, 1986, METHOD ENZYMOL, V118, P109; Le H, 1997, EUR J BIOCHEM, V243, P350, DOI 10.1111/j.1432-1033.1997.0350a.x; Methot N, 1996, RNA, V2, P38; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	35	225	229	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16247	16255		10.1074/jbc.272.26.16247	http://dx.doi.org/10.1074/jbc.272.26.16247			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195926	hybrid			2022-12-25	WOS:A1997XG01900030
J	Li, JF; Schmidt, AM				Li, JF; Schmidt, AM			Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OCTAMER-BINDING-PROTEINS; TUMOR-NECROSIS-FACTOR; CIS-ACTING ELEMENTS; ALZHEIMER-DISEASE; OXIDANT STRESS; DNA-BINDING; DIABETIC COMPLICATIONS; NEURITE OUTGROWTH; VASCULAR-DISEASE	The receptor for advanced glycation end products, RAGE, is a member of the immunoglobulin superfamily of cell surface molecules differentially expressed on a range of cell types. Ligation of RAGE perturbs homeostatic mechanisms and, potentially, provides a basis for cellular dysfunction in pathologic situations in which its ligands accumulate. To understand factors underlying RAGE expression, we cloned the 5'-flanking region of the RAGE gene and characterized putative regulatory motifs. Analysis of the putative promoter region revealed the presence of three potential NF-kappa B-like and two SP1 binding sites. Transient transfection of vascular endothelial and smooth muscle cells using chimeric 5'-deletion constructs linked to luciferase reporter revealed that the region -1543/-587 contributed importantly to both basal and stimulated expression of the RAGE gene. This region of the RAGE gene contained three putative NF-kappa B-like binding sites and was responsible for increased luciferase activity observed when endothelial or smooth muscle cells were stimulated with lipopolysaccharide. DNase I footprinting assays and electrophoretic mobility shift assay revealed that two of the three NF-kappa B-like binding sites (1 and 2) were likely functional and responsive to stimuli. Upon simultaneous mutation of NF-kappa B-like sites 1 and 2, both basal promoter expression and response to stimulation with LPS, as measured by relative luciferase activity, were significantly diminished. These results point to NF-kappa B-dependent mechanisms regulating cellular expression of RAGE and suggest a means of linking RAGE to the inflammatory response.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NIA NIH HHS [AG00602] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUONO P, 1993, FEBS LETT, V328, P243, DOI 10.1016/0014-5793(93)80936-O; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREDMAN J, 1994, CIRCULATION, V90, P1567; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; Maxam A M, 1980, Methods Enzymol, V65, P499; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MIYATA T, 1994, J CLIN INVEST, V93, P521, DOI 10.1172/JCI117002; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Park L, 1996, CIRCULATION, V94, P200; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RITTHALER U, 1995, AM J PATHOL, V146, P688; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1994, CIRCULATION, V90, P1251; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; SMITH MA, 1994, AM J PATHOL, V145, P42; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yan Shi Du, 1996, Neurology, V46, pA276	45	418	450	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16498	16506		10.1074/jbc.272.26.16498	http://dx.doi.org/10.1074/jbc.272.26.16498			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195959	hybrid			2022-12-25	WOS:A1997XG01900063
J	Nehyba, J; Hrdlickova, R; Bose, HR				Nehyba, J; Hrdlickova, R; Bose, HR			Differences in kappa B DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein	ONCOGENE			English	Article						v-Rel; c-Rel; DNA binding; oncogene; NF-kappa B	CHICKEN SPLEEN-CELLS; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTIONAL ACTIVATION; CYTOPLASMIC RETENTION; EMBRYO FIBROBLASTS; AMINO-ACIDS; RECOGNITION SEQUENCE; GENE-EXPRESSION; HOMOLOGY DOMAIN	The oncogene v-rel of Reticuloendotheliosis virus, strain T, is derived from an avian c-rel proto-oncogene, c-rel encodes a member of the Rel/NF-kappa B family of transcription factors, The highly oncogenic v-Rel differs from c-Rel which has low transforming potential by the acquisition of numerous mutations, In this manuscript, we demonstrate that the oncogenic mutations in v-Rel directly alter the ability of this protein to bind to DNA, Electrophoretic mobility shift analysis with Rel proteins synthesized in vitro as well as isolated from nuclei of Rel expressing cells showed that three mutation clusters, present in the N-terminus, the center and the C-terminus of v-Rel, altered three different aspects of DNA binding, In contrast, the oncogenic C-terminal deletion of 118 amino acids present in v-Rel had almost no influence on its DNA binding. The N-terminal mutation cluster altered the kappa B DNA-binding specificity of the v-Rel oncoprotein relative to c-Rel. The mutation Met-20-->Thr was found to be principally responsible for this alteration, The second mutation cluster was responsible for increased binding of v-Rel to all the KB sites examined presumably because it stabilized v-Rel homodimers, This alteration in DNA binding was mapped to the group of two mutations within the cluster, In contrast, the third mutation cluster in the C-terminus of v-Rel destabilized the binding of v-Rel to all of the kappa B sites examined, This is the first indication that regions outside the Rel Homology Region can participate in the control of binding of the c-Rel protein to DNA, The three mutation clusters examined contributed to the tumorigenic potential of v-Rel with the relative strength decreasing with their position from the N-terminus to the C-terminus, These results suggest that the oncogenic mutations in v-Rel cooperate and enable v-Rel to form nuclear complexes with aberrant DNA-binding properties that may directly alter gene expression and DNA replication resulting in the transformation of the cell.	UNIV TEXAS, DEPT MICROBIOL, AUSTIN, TX 78712 USA; UNIV TEXAS, CELL RES INST, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER; NCI NIH HHS [CA33192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALTIMORE D, 1995, NATURE, V373, P287, DOI 10.1038/373287a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BREITMAN ML, 1980, VIROLOGY, V100, P450, DOI 10.1016/0042-6822(80)90535-8; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN ISY, 1982, CELL, V31, P111, DOI 10.1016/0092-8674(82)90410-X; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; COLEMAN TA, 1993, MOL CELL BIOL, V13, P3850, DOI 10.1128/MCB.13.7.3850; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FILARDO EJ, 1994, VIROLOGY, V202, P116, DOI 10.1006/viro.1994.1328; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1995, FRONTIERS MOL BIOL E, P1204; GILMORE TD, 1995, DNA PROVIRUS H TEMIN, P105; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1992, ONCOGENE, V7, P567; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KROEMER G, 1990, IMMUNOGENETICS, V31, P405, DOI 10.1007/BF02115020; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LU D, 1991, ONCOGENE, V6, P1235; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STOKER AW, 1987, J GEN VIROL, V68, P2481, DOI 10.1099/0022-1317-68-9-2481; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TONY Y, 1995, CURR BIOL, V5, P1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; WHITE DW, 1995, ONCOGENE, V10, P857; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	93	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2881	2897		10.1038/sj.onc.1201150	http://dx.doi.org/10.1038/sj.onc.1201150			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205096				2022-12-25	WOS:A1997XF55500003
J	Thatikunta, P; Raj, GV; Kundu, M; Khalili, K; Amini, S				Thatikunta, P; Raj, GV; Kundu, M; Khalili, K; Amini, S			The transcription factor E2F-1 modulates TGF-beta 1 RNA expression in glial cells	ONCOGENE			English	Article						E2F1; TGF-beta 1; gene expression; oncoproteins; central nervous system	RETINOBLASTOMA GENE-PRODUCT; GROWTH FACTOR-BETA-1 GENE; TGF-BETA; TUMOR-ANTIGEN; S-PHASE; PROTEIN; CYCLE; PROMOTER; BINDING; INHIBITION	The cell type specificity of the regulation of expression of the potent growth inhibitory cytokine transforming growth factor-beta (TGF-beta), prompted our analyses of the regulation of TGF-beta 1 gene expression in glial cells by viral and cellular oncoproteins. We have shown that SV40 T-antigen diminished TGF-beta 1 expression in glial cells and this repression was dependent on the ability of T-antigen to interact with the tumor suppressor protein, pRb, and two structurally related proteins, p107 and p130. The cellular transcription factor E2F-1, which is a downstream effector of T-antigen, was unable to influence expression from the TGF-beta 1 promoter by itself. Interestingly, E2F-1 could overcome viral T-antigen-mediated repression of the TGF-beta 1 promoter, suggesting potential feedback loop between TGF-beta and E2F in virally transformed glial cells. Using deletion analyses, we have mapped two E2F-1-responsive regions on the TGF-beta 1 promoter: a T-antigen-dependent negative regulatory sequence (TdNRS) between - 323 and - 175, and a T-antigen-independent positive regulatory sequence (TiPRS) between - 34 and + 10 on the TGF-beta 1 promoter, Further examination of TiPRS revealed the presence of a functional E2F binding site. Interestingly, the amino terminus of E2F-1 was required for its activation of TGF-beta 1 expression, as mutations in that domain abolished the ability of E2F-1 to increase TGF-beta 1 expression. These data suggest that yet-uncharacterized interaction between the amino terminus of E2F-1 and cellular proteins regulates TGF-beta 1 expression, The mechanism for E2F-1-mediated Tantigen-dependent regulation of TGF-beta 1 expression from TdNRS awaits further characterization.	ALLEGHENY UNIV HLTH SCI,CTR NEUROVIROL,PHILADELPHIA,PA 19107; ALLEGHENY UNIV HLTH SCI,DEPT NEUROL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT MICROBIOL & IMMUNOL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Drexel University; Drexel University; Jefferson University			Kundu, Mondira/N-8139-2018	Kundu, Mondira/0000-0001-9946-2472				BENZAKOUR O, 1994, B CANCER, V81, P1014; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DATTA PK, 1994, J BIOL CHEM, V269, P25392; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIM SJ, 1989, J BIOL CHEM, V264, P402; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAJ GV, 1994, MOL CELL BIOL, V14, P7770, DOI 10.1128/MCB.14.12.7770; Raj GV, 1996, ONCOGENE, V12, P1279; ROBERTS AB, 1991, CANCER CELL-MON REV, V3, P19; ROBERTS AB, 1990, ANN NY ACAD SCI, V593, P43, DOI 10.1111/j.1749-6632.1990.tb16098.x; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SALA A, 1994, CANCER RES, V54, P1402; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; VERITY AN, 1993, J NEUROCHEM, V60, P577, DOI 10.1111/j.1471-4159.1993.tb03188.x; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	42	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2959	2969		10.1038/sj.onc.1201129	http://dx.doi.org/10.1038/sj.onc.1201129			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205103				2022-12-25	WOS:A1997XF55500010
J	Thomas, RS; Tymms, MJ; McKinlay, LH; Shannon, MF; Seth, A; Kola, I				Thomas, RS; Tymms, MJ; McKinlay, LH; Shannon, MF; Seth, A; Kola, I			ETS1, NF kappa B and AP1 synergistically transactivate the human GM-CSF promoter	ONCOGENE			English	Article						GM-CSF; transcription; ETS1; NF kappa B; API	COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; AP-1 TRANSCRIPTION FACTORS; DNA-BINDING ACTIVITY; T-CELLS; MESSENGER-RNA; MICE LACKING; INFLAMMATORY RESPONSES; COSTIMULATORY SIGNALS; COOPERATIVE BINDING	Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system, Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription, Cis-acting elements with NF kappa B, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation, ETS1 is a transcription factor of the ETS family that is expressed in T cells, We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation, Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors, Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NF kappa B or AP1 transcription factors are supplied by co-transfection, We confirm that binding of endogenous NF kappa B and AP1 is induced following PMA/ionomycin treatment of T cells, Transactivation by ETS1, NF kappa B and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent, Our results suggest that constitutive ETS1, and inducible NF kappa B and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.	MONASH UNIV, MOL GENET & DEV GRP, INST REPROD & DEV, MELBOURNE, VIC 3168, AUSTRALIA; INST MED & VET SCI, DIV HUMAN IMMUNOL, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA; UNIV TORONTO, WOMENS COLL HOSP, DEPT PATHOL, TORONTO, ON, CANADA	Monash University; Institute Medical & Veterinary Science Australia; University of Toronto; Womens College Hospital			Kola, Ismail/C-5254-2013; Thomas, Ross/C-6434-2008					ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRORSON KA, 1991, J IMMUNOL, V147, P3601; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FISHER CL, 1991, J IMMUNOL, V146, P1743; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; IWAI Y, 1993, J IMMUNOL, V150, P4386; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOIZUMI S, 1990, ONCOGENE, V5, P675; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LI CCH, 1994, J BIOL CHEM, V269, P30089; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MAKOVER D, 1991, ONCOGENE, V6, P455; MASUDA ES, 1994, BIOCHEM BIOPH RES CO, V205, P1518, DOI 10.1006/bbrc.1994.2839; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; OSBORNE CS, 1995, J IMMUNOL, V155, P226; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHANNON MF, 1995, J LEUKOCYTE BIOL, V57, P767, DOI 10.1002/jlb.57.5.767; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; THOMAS RS, 1995, ONCOGENE, V11, P2135; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yang BS, 1996, MOL CELL BIOL, V16, P538; Ye JP, 1996, MOL CELL BIOL, V16, P157; YE JP, 1994, NUCLEIC ACIDS RES, V22, P5672, DOI 10.1093/nar/22.25.5672	77	134	136	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2845	2855		10.1038/sj.onc.1201125	http://dx.doi.org/10.1038/sj.onc.1201125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190901				2022-12-25	WOS:A1997XD64300013
J	Whitesell, L; Sutphin, P; An, WG; Schulte, T; Blagosklonny, MV; Neckers, L				Whitesell, L; Sutphin, P; An, WG; Schulte, T; Blagosklonny, MV; Neckers, L			Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo	ONCOGENE			English	Article						ubiquitin; lactacystin; benzoquinone ansamycins; proteasome	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE; MULTICATALYTIC PROTEINASE; ACTIVATING MUTATIONS; PROTEOLYTIC SYSTEM; TRANSFORMED-CELLS; E6 ONCOPROTEIN; MUTANT P53; DEGRADATION; COMPLEX	Mutation of the tumor suppressor gene p53 is the most common genetic abnormality detected in human cancers, Wild type p53 is a short-lived protein with very low basal intracellular levels, Most mutated forms of the protein, however, display markedly increased intracellular levels as an essential feature of their positive transforming activity, In this report, we have used selective inhibitors of the 20S proteasome to demonstrate that processing of p53 by ubiquitination and proteasome-mediated degradation is impaired by commonly occurring mutations of the protein, We found that this impairment of p53 turnover can be reversed by treatment of tumor cells with the benzoquinone ansamycin, geldanamycin, leading to a marked reduction in intracellular p53 levels. Finally, using cells which over-express a mutant p53 protein, we were able to demonstrate that restoration of proteasome-mediated degradation by geldanamycin is accompanied by p53 polyubiquitination, Although much remains to be learned about the mechanisms involved, our data demonstrate that selective de-stabilization of mutant transforming proteins such as p53 can be achieved pharmacologically with agents such as geldanamycin which modify the function of molecular chaperone proteins within tumor cells.	UNIV ARIZONA,DEPT PEDIAT,STEELE MEM CHILDRENS RES CTR,TUCSON,AZ 85724; NCI,CLIN PHARMACOL BRANCH,NIH,BETHESDA,MD 20892	University of Arizona; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [R29 CA-69537-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HADARI T, 1992, J BIOL CHEM, V267, P719; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Maki CG, 1996, CANCER RES, V56, P2649; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125	36	115	117	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2809	2816		10.1038/sj.onc.1201120	http://dx.doi.org/10.1038/sj.onc.1201120			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190897				2022-12-25	WOS:A1997XD64300009
J	Kiyokawa, N; Lee, EK; Karunagaran, D; Lin, SY; Hung, MC				Kiyokawa, N; Lee, EK; Karunagaran, D; Lin, SY; Hung, MC			Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; KINASE-C PHOSPHORYLATION; CELL-CYCLE; EGF-RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; NEU GENE; IN-VIVO; ACTIVATION; INDUCTION	The function of epidermal growth factor receptor (EGFR) was found to be negatively regulated in M phase in which it showed less phosphotyrosine content and reduced intrinsic kinase activity accompanied by retarded electrophoretic mobility owing to total hyperphosphorylation, Ligand induced autophosphorylation and downstream signaling of EGFR were tightly suppressed in M phase due to a decrease in ligand binding affinity and the inability of epidermal growth factor (EGF) to induce receptor dimerization. There was no change in the number of surface-exposed EGF receptors between G(0)/G(1) and M phases of the cell cycle. Hyperphosphorylation (due to serine and/or threonine phosphorylation) correlates with the unresponsiveness of cells to EGF-mediated stimulation of tyrosine phosphorylation in cells that express the normal or basal level of EGFR. This M phase-specific negative regulation was overcome by overexpression of EGFR, which was responsive to ligand throughout the cell cycle and revealed ligand-induced signaling in the M phase. These findings indicate that EGFR does not respond to ligand stimulation in M phase and suggest that a negative regulation of ligand-receptor interactions in M phase may control the normal function of receptor tyrosine kinase and that receptor overexpression will disrupt this cell cycle-dependent regulation of receptor tyrosine kinases.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021; Karunagaran, Devarajan/A-8148-2010	Hung, Mien-Chie/0000-0003-4317-4740; Karunagaran, Devarajan/0000-0001-9331-8947	NATIONAL CANCER INSTITUTE [R01CA058880, P30CA016672, R01CA060856] Funding Source: NIH RePORTER; NCI NIH HHS [CA58880, CA60856, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DERYNCK R, 1987, CANCER RES, V47, P707; DIFORE PP, 1987, CELL, V51, P1063; DIMARCO E, 1989, ONCOGENE, V4, P831; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; GULLICK WJ, 1986, CANCER RES, V46, P285; HARPER JW, 1993, CELL, V75, P805; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; KUPPUSWAMY D, 1991, CELL SIGNAL, V3, P107, DOI 10.1016/0898-6568(91)90017-O; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MASSOGLIA S, 1990, MOL CELL BIOL, V10, P3048, DOI 10.1128/MCB.10.6.3048; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; NEWBERRY EP, 1995, BIOCHEM BIOPH RES CO, V208, P253, DOI 10.1006/bbrc.1995.1331; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PILLAY I, 1995, CELL GROWTH DIFFER, V6, P39; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SAINSBURY JRC, 1985, LANCET, V1, P364; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNEIDER CA, 1986, P NATL ACAD SCI USA, V83, P333, DOI 10.1073/pnas.83.2.333; Sizeland A, 1991, GROWTH FACTORS, V4, P129, DOI 10.3109/08977199109000264; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	56	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18656	18665		10.1074/jbc.272.30.18656	http://dx.doi.org/10.1074/jbc.272.30.18656			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228035	hybrid			2022-12-25	WOS:A1997XM34200026
J	Slack, JP; Grupp, IL; Ferguson, DG; Rosenthal, N; Kranias, EG				Slack, JP; Grupp, IL; Ferguson, DG; Rosenthal, N; Kranias, EG			Ectopic expression of phospholamban in fast-twitch skeletal muscle alters sarcoplasmic reticulum Ca2+ transport and muscle relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; DEPENDENT PROTEIN-KINASE; CALCIUM-RELEASE CHANNEL; GENE-EXPRESSION; FUNCTIONAL RECONSTITUTION; PHOSPHOLIPID-VESICLES; CA-2+ ATPASE; PHOSPHORYLATION; CA-2+-ATPASE; SLOW	There are three isoforms of the sarcoplasmic reticulum Ca2+-ATPase; they are known as SERCA1, SERCA2, and SERCA3. Phospholamban is present in tissues that express the SERCA2 isoform and is an inhibitor of the affinity of SERCA2 for calcium, In vitro reconstitution and cell culture expression studies have shown that phospholamban can also regulate SERCA1, the fast-twitch skeletal muscle isoform, To determine whether regulation of SERCA1 by phospholamban can be of physiological relevance, we generated transgenic mice that ectopically express phospholamban in fast-twitch skeletal muscle, a tissue normally devoid of phospholamban, Ectopic expression of phospholamban was associated with a decrease in the affinity of SERCA1 for calcium, Assessment of isometric twitch contractions of intact fast-twitch skeletal muscles revealed depressed rates of relaxation in transgenic mice compared with wild-type cohorts, Furthermore, the prolongation of muscle relaxation appeared to correlate with the levels of phospholamban expressed in two transgenic mouse lines, These findings indicate that ectopic expression of phospholamban in fast-twitch skeletal muscle is associated with inhibition of SERCA1 activity and decreased relaxation rates of this muscle.	UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA; CASE WESTERN RESERVE UNIV, DEPT ANAT, CLEVELAND, OH 44106 USA; MASSACHUSETTS GEN HOSP E, CARDIOVASC RES CTR, CHARLESTOWN, MA 02129 USA	University System of Ohio; University of Cincinnati; Case Western Reserve University				Rosenthal, Nadia/0000-0002-7599-7365	NHLBI NIH HHS [HL52318, HL26057, HL22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, P50HL052318, R01HL026057, R37HL026057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BOWMAN WC, 1980, HDB EXPT PHARMACOLOG, V54, P47; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; DRAGO GA, 1995, BIOCHEM SOC T, V2345, pS15; FEHER JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P171, DOI 10.1016/0003-9861(88)90382-7; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HARRER JM, 1995, BIOTECHNIQUES, V18, P995; HARRER JM, 1995, MOL CELL BIOCHEM, V146, P13, DOI 10.1007/BF00926876; HAWKINS C, 1995, MOL CELL BIOCHEM, V142, P131, DOI 10.1007/BF00928934; HOFFMAN B B, 1990, P187; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KIM HW, 1990, J BIOL CHEM, V265, P1702; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; KRANIAS EG, 1983, BIOCHIM BIOPHYS ACTA, V749, P62, DOI 10.1016/0167-4838(83)90151-6; KRANIAS EG, 1985, BIOCHEM J, V226, P113, DOI 10.1042/bj2260113; LEWISCARL SA, 1995, MUSCLE NERVE, V18, P1232; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MIYAKODA G, 1987, J BIOCHEM-TOKYO, V102, P211, DOI 10.1093/oxfordjournals.jbchem.a122034; PAGANI ED, 1984, AM J PHYSIOL, V247, pH909, DOI 10.1152/ajpheart.1984.247.6.H909; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; ROTMAN EI, 1995, J BIOL CHEM, V270, P16371, DOI 10.1074/jbc.270.27.16371; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SLACK JP, 1997, IN PRESS AM J PHYSL; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; SZYMANSKA G, 1992, MOL CELL BIOCHEM, V114, P65; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; XIAO RP, 1994, J BIOL CHEM, V269, P19151	42	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18862	18868		10.1074/jbc.272.30.18862	http://dx.doi.org/10.1074/jbc.272.30.18862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228063	hybrid			2022-12-25	WOS:A1997XM34200054
J	Keidel, S; Lamour, FPY; Apfel, CM				Keidel, S; Lamour, FPY; Apfel, CM			Mutational analysis reveals that all-trans-retinoic acid, 9-cis-retinoic acid, and antagonist interact with distinct binding determinants of RAR alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; RECEPTOR-ALPHA; X-RECEPTOR; NUCLEAR RECEPTORS; RXR-ALPHA; BETA; LIGAND; PROTEIN; GAMMA; DOMAIN	Retinoids exert their pleiotropic effects on cell differentiation and proliferation through specific nuclear receptors, the retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Two biologically highly active natural retinoids have been identified, all-trans-retinoic acid (t-RA) and 9-cis-retinoic acid (9-cis-RA). The RXRs exclusively bind 9-cis-RA, whereas the RARs bind both isomers of RA with comparable affinity. Recently published results suggest that RARs have the same binding site for t-RA and 9-cis-RA but with different determinants (1-3). Antagonist binding on RAR alpha has been suggested to induce distinct conformational changes in comparison with agonist binding, To elucidate the region minimally required for efficient binding of agonist (t-RA and 9-cis-RA) and antagonist Ro 41-5253 to the RAR alpha, we generated N- and C-terminally truncated mutants of the receptor. Characterization of these deletion mutant proteins using protease mapping and ligand binding experiments revealed that different parts of the ligand-binding domain are necessary for t-RA, 9-cis-RA, and antagonist binding. Three distinct regions of the ligand-binding domain of the human retinoic acid receptor-alpha are required for binding of t-RA (RAR alpha 187-402), 9-cis-RA (RAR alpha 188-409), and the antagonist Ro 41-5253 (RAR alpha 226-414).	F HOFFMANN LA ROCHE & CO LTD,PRPI,DEPT INFECT DIS,PRECLIN RES,CH-4070 BASEL,SWITZERLAND	Roche Holding								ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHYTIL F, 1984, PHARMACOL REV, V36, P93; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; Ekena K, 1997, J BIOL CHEM, V272, P5069, DOI 10.1074/jbc.272.8.5069; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KEIDEL S, 1992, EUR J BIOCHEM, V204, P1141, DOI 10.1111/j.1432-1033.1992.tb16739.x; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; Lamour FPY, 1996, MOL CELL BIOL, V16, P5386; LAUDET V, 1992, Current Biology, V2, P293; LEFEBVRE B, 1995, BIOCHEMISTRY-US, V34, P5477, DOI 10.1021/bi00016a019; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; ORFANOS CE, 1987, DRUGS, V34, P459, DOI 10.2165/00003495-198734040-00003; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Roberts A.B., 1984, RETINOIDS, V2, P210; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAIRIS N, 1995, J BIOL CHEM, V270, P18380, DOI 10.1074/jbc.270.31.18380; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	49	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18267	18272		10.1074/jbc.272.29.18267	http://dx.doi.org/10.1074/jbc.272.29.18267			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218465	hybrid			2022-12-25	WOS:A1997XL73500055
J	Hu, SM; Vincenz, C; Ni, J; Gentz, R; Dixit, VM				Hu, SM; Vincenz, C; Ni, J; Gentz, R; Dixit, VM			I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME	The pivotal discovery that the death proteases caspase 8 (FLICE) and caspase 10 (Mch4/FLICE2) are recruited to the CD-95 and tumor necrosis factor receptor-1 signaling complexes suggested a mechanism used by these cytotoxic receptors to initiate apoptosis, In this report, we describe the cloning and characterization of I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis, The overall architecture of I-FLICE is strikingly similar to that of FLICE and Mch4/FLICE2, However, I-FLICE lacks both a catalytic active site and residues that form the substrate binding pocket, in keeping with its dominant negative inhibitory function, I-FLICE is the first example of a catalytically inert caspase that can inhibit apoptosis.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			dixit, vishva m/A-4496-2012; Hu, Shimin/H-3427-2019	dixit, vishva m/0000-0001-6983-0326; Hu, Shimin/0000-0001-7110-3814	NATIONAL INSTITUTE ON AGING [R01AG013671] Funding Source: NIH RePORTER; NIA NIH HHS [AG13671] Funding Source: Medline; NIEHS NIH HHS [ES08111] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	23	357	375	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17255	17257		10.1074/jbc.272.28.17255	http://dx.doi.org/10.1074/jbc.272.28.17255			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211860	hybrid			2022-12-25	WOS:A1997XK16500003
J	Wu, GY; Krupnick, JG; Benovic, JL; Lanier, SM				Wu, GY; Krupnick, JG; Benovic, JL; Lanier, SM			Interaction of arrestins with intracellular domains of muscarinic and alpha(2)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; RHODOPSIN INTERACTION; WILD-TYPE; BINDING; INACTIVATION; EXPRESSION; FAMILY	The intracellular domains of G-protein-coupled receptors provide sites for interaction with key proteins involved in signal inititaion and termination. As an initial approach to identify proteins interacting with these receptors and the receptor motifs required for such interactions, we used intracellular subdomains of G-protein-coupled receptors as probes to screen brain cytosol proteins. Peptides from the third intracellular loop (i3) of the M-2-muscarinic receptor (MR) (His(208)-Arg(387)), M-3-MR (Gly(308)-Leu(497)), or alpha(2A/D)-adrenergic receptor (AR) (Lys(224)-Phe(374)) were generated in bacteria as glutathione S-transferase (GST) fusion proteins, bound to glutathione-Sepharose and used as affinity matrices to detect interacting proteins in fractionated bovine brain cytosol. Bound proteins were identified by immunoblotting following SDS-polyacrylamide gel electrophoresis. Brain arrestins bound to the GST-M-3 fusion protein, but from the alpha(2A/D)-AR and M-2-MR. However, each of the receptor subdomains bound purified beta-arrestin and arrestin-3. The interaction of the M-3-MR and M-2-Mr i3 peptides with arrestins was further investigated. the tin and [H-3]arrestin-3, but did not interact with in vitro translated or purified visual arrestin. The properties and specificity of the interaction of in vitro translated [H-3]beta-arrestin, [H-3]visual arrestin, and [H-3]beta-arrestin/ visual arrestin chimeras with the M-2-MR, i3 peptide were similar to those observed with the intact purified M-2-MR that was phosphorylated and/or activated by agonist, Subsequent binding site localization studies indicated that the interaction of p-arrestin with the M-3-MR peptide required both the amino (Gly(308)-Leu(368)) and carbonyl portions (Lys(425)-Leu(497)) of the receptor subdomain, in contrast, the carboxyl region of the M-3-MR i3 peptide was sufficient for its interaction with arrestin-3.	MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Medical University of South Carolina; Jefferson University				Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47419] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PLANGGER A, 1994, J BIOL CHEM, V269, P26969; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH WC, 1994, J BIOL CHEM, V269, P15407; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; ZUAHG J, 1996, J BIOL CHEM, V271, P18302	26	127	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17836	17842		10.1074/jbc.272.28.17836	http://dx.doi.org/10.1074/jbc.272.28.17836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211939	hybrid			2022-12-25	WOS:A1997XK16500082
J	Chen, HI; Einbond, A; Kwak, SJ; Linn, H; Koepf, E; Peterson, S; Kelly, JW; Sudol, M				Chen, HI; Einbond, A; Kwak, SJ; Linn, H; Koepf, E; Peterson, S; Kelly, JW; Sudol, M			Characterization of the WW domain of human yes-associated protein and its polyproline-containing ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PEPTIDES; ROUS-SARCOMA VIRUS; SH3 DOMAINS; INSITU HYBRIDIZATION; CHANNEL ACTIVITY; SOLID SUPPORTS; BINDING; GENE; HOMOLOGY; MUTATION	We had previously identified the WW domain as a novel globular domain that is composed of 38-40 semi-conserved amino acids and is involved in mediating protein-protein interaction, The WW domain is shared by proteins of diverse functions including structural, regulatory, and signaling proteins in yeast, nematode, and mammals, Functionally it is similar to the Src homology 3 domain in that it binds polyproline ligands. By screening a 16-day mouse embryo expression library, we identified two putative ligands of the WW domain of Yes kinase-associated protein which we named WW domain-binding proteins 1 and 2, These proteins interacted with the WW domain via a short proline-rich motif with She consensus sequence of four consecutive prolines followed by a tyrosine, Herein, we report the cDNA cloning and characterization of the human orthologs of WW domain-binding proteins I and 2, The products encoded by these cDNA clones represent novel proteins with no known function, Furthermore, these proteins show no homology to each other except for a proline-rich motif, By fluorescence in situ hybridization oil human metaphase chromosomes, we mapped the human genes for WW domain-binding proteins 1 and 2 to chromosomes 2p12 and 17q25, respectively. In addition, using site-directed mutagenesis, we determined which residues in the WW domain of Yes kinase-associated protein are critical for binding. Finally, by synthesizing peptides in which the various positions of the four consecutive proline-tyrosine motif and the five surrounding residues were replaced by all possible amino acid residues, we further elucidated the binding requirements of this motif.	CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; ROCKEFELLER UNIV, MOL ONCOL LAB, NEW YORK, NY 10021 USA; TEXAS A&M UNIV, DEPT CHEM, COLLEGE STN, TX 77843 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; Texas A&M University System; Texas A&M University College Station					NCI NIH HHS [CAO1605, CA45757] Funding Source: Medline; NIGMS NIH HHS [TT32GM07739-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BASTARD C, 1992, BLOOD, V79, P2527; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN HI, 1996, TECH PROTEIN CHEM, V7, P3; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; HANG HHQ, 1994, MOL BIOL IN SITU HYB, P35; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HILDEBRANDT F, 1993, AM J HUM GENET, V53, P1256; HURET JL, 1986, HUM GENET, V74, P447, DOI 10.1007/BF00280504; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SCIOT R, 1993, HISTOPATHOLOGY, V23, P439, DOI 10.1111/j.1365-2559.1993.tb00492.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	162	175	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17070	17077		10.1074/jbc.272.27.17070	http://dx.doi.org/10.1074/jbc.272.27.17070			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202023	hybrid			2022-12-25	WOS:A1997XH44600055
J	Gellibolian, R; Bacolla, A; Wells, RD				Gellibolian, R; Bacolla, A; Wells, RD			Triplet repeat instability and DNA topology: An expansion model based on statistical mechanics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-CLOSURE PROBABILITIES; MONTE-CARLO; TORSIONAL RIGIDITY; WORMLIKE CHAINS; CIRCULAR DNA; FLEXIBILITY; TRANSCRIPTION; REPLICATION; ENERGETICS; DEPENDENCE	The variance of writhe, the contribution of writhe to supercoiling, and the free energies of supercoiling were calculated for (CTG.CAG)(n) and (CGG.CCG)(n) triplet repeat sequences (TRS) by statistical mechanics from the bending and torsional moduli previously determined, Expansions of these sequences are inherited by non-mendelian transmission and are linked with several hereditary neuromuscular diseases, The variance of writhe was greater for the TRS than for random B-DNA, For random B-DNA, (CGG)(n), and (CTG)(n), the contribution of writhe to supercoiling was 70, 78, and 79%, whereas the free energy of supercoiling at a length of 10 kilobase pairs was 1040.RT, 760.RT, and 685.RT, respectively, These data indicate that the TRS are preferential sites for the partitioning of supercoiling, Calculations of the differences in free energy of supercoiling between the TRS and random B-DNA revealed a local minimum at similar to 520 base pairs, Human medical genetic studies have shown that individuals carrying up to 180-200 copies of TRS (540-600 base pairs, premutations) in the fragile X or myotonic dystrophy gene loci are usually asymptomatic, whereas large expansions (>200 repeats, full mutations), which lead to disease, are observed in their offspring, Therefore, the length corresponding to the local minimum in free energy of supercoiling correlates with the genetic breakpoint between premutation and full mutation, We propose that (a) TRS instability is mediated by DNA mispairing caused by the accumulation of supercoiling within the repeats, and (b) the expansions that take place at the premutation to full mutation threshold are associated with increased mispairing caused by the optimal partitioning of writhe within the TRS at this length.	TEXAS A&M UNIV,TEXAS MED CTR,CTR GENOME RES,INST BIOSCI & TECHNOL,HOUSTON,TX 77030; TEXAS A&M UNIV,TEXAS MED CTR,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Texas A&M University System; Baylor College of Medicine; Texas A&M University System			Bacolla, Albino/AAP-1727-2020; Bacolla, Albino/N-3877-2013	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NIGMS NIH HHS [GM 52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BEDNAR J, 1995, J MOL BIOL, V254, P579, DOI 10.1006/jmbi.1995.0640; BURD JF, 1970, J MOL BIOL, V53, P435, DOI 10.1016/0022-2836(70)90076-8; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DIEKMANN S, 1982, BIOPHYS CHEM, V15, P263, DOI 10.1016/0301-4622(82)80009-4; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; HAGERMAN PJ, 1985, BIOPOLYMERS, V24, P1881, DOI 10.1002/bip.360241004; HODGESGARCIA Y, 1995, J BIOL CHEM, V270, P197, DOI 10.1074/jbc.270.1.197; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LEBRET M, 1980, BIOPOLYMERS, V19, P619, DOI 10.1002/bip.1980.360190312; LEVENE SD, 1986, J MOL BIOL, V189, P73, DOI 10.1016/0022-2836(86)90382-7; LEVENE SD, 1986, J MOL BIOL, V189, P61, DOI 10.1016/0022-2836(86)90381-5; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; SHIMADA J, 1984, MACROMOLECULES, V17, P689, DOI 10.1021/ma00134a028; SHIMADA J, 1985, J MOL BIOL, V184, P319, DOI 10.1016/0022-2836(85)90383-3; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77	36	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16793	16797		10.1074/jbc.272.27.16793	http://dx.doi.org/10.1074/jbc.272.27.16793			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201984	hybrid			2022-12-25	WOS:A1997XH44600016
J	Richieri, GV; Low, PJ; Ogata, RT; Kleinfeld, AM				Richieri, GV; Low, PJ; Ogata, RT; Kleinfeld, AM			Mutants of rat intestinal fatty acid-binding protein illustrate the critical role played by enthalpy-entropy compensation in ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT-PROBE ADIFAB; TRANSPORT PROTEINS; RETINOL-BINDING; REFINEMENT; RESOLUTION; PALMITATE; ADIPOCYTE; FAMILY	Site-specific variants of rat intestinal fatty acid-binding protein were constructed to identify the molecular interactions that are important for binding to fatty acids (FAs). Several variants displayed affinities that appeared incompatible with the crystal structure of the protein-FA complex. Thermodynamic measurements provided an explanation for these apparent inconsistencies and revealed that binding affinities often inaccurately reported changes in protein-FA interactions because changes in the binding entropy and enthalpy were usually compensatory. These results demonstrate that understanding the effects of amino acid replacements on ligand binding requires measurements of enthalpy and entropy, in addition to affinity.	MED BIOL INST,LA JOLLA,CA 92037						NIGMS NIH HHS [GM46931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; Cistola DP, 1996, BIOCHEMISTRY-US, V35, P7559, DOI 10.1021/bi952912x; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COOK HW, 1991, BIOCH LIPIDS LIPOPRO, V20, P141; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; Dill KA, 1997, J BIOL CHEM, V272, P701, DOI 10.1074/jbc.272.2.701; EADS J, 1993, J BIOL CHEM, V268, P26375; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; RICH MR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P87, DOI 10.1016/0167-4889(93)90113-4; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SANDBERG WS, 1993, P NATL ACAD SCI USA, V90, P8367, DOI 10.1073/pnas.90.18.8367; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6	23	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16737	16740		10.1074/jbc.272.27.16737	http://dx.doi.org/10.1074/jbc.272.27.16737			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201976	hybrid			2022-12-25	WOS:A1997XH44600008
J	Goyal, J; Wang, KW; Liu, M; Subbaiah, PV				Goyal, J; Wang, KW; Liu, M; Subbaiah, PV			Novel function of lecithin-cholesterol acyltransferase - Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; HUMAN-PLASMA; FACTOR-ACETYLHYDROLASE; ENDOTHELIAL-CELLS; LIPID-PEROXIDATION; LYSOLECITHIN ACYLTRANSFERASE; PAF-ACETYLHYDROLASE; SMOOTH-MUSCLE; LDL	Although the major function of lecithin-cholesterol acyltransferase (LCAT) is cholesterol esterification, our previous studies showed that it can also hydrolyze platelet-activating factor (PAF), Because of the structural similarities between PAF and the truncated phosphatidylcholines (polar PCs) generated during lipoprotein oxidation, we investigated the possibility that LCAT may also hydrolyze polar PCs to lyso-PC during the oxidation of plasma. PAF acetylhydrolase (PAF=AH), which is known to hydrolyze polar PCs in human plasma, was completely inhibited by 0.2 mM p-amino-ethyl benzenesulfonyl fluoride (Pefabloc), a new serine esterase inhibitor, which had no effect on LCAT at this concentration. On the other hand, 1 mM diisopropylfluorophosphate (DFP) completely inhibited LCAT but had no effect on PAF-AH, Polar PC accumulation during the oxidation of plasma increased by 44% in the presence of 0.2 mM Pefabloc and by 30% in the presence of 1 mM DFP, The formation of lyso-PC was concomitantly inhibited by both of the inhibitors. The combination of the two inhibitors resulted in the maximum accumulation of polar PCs, suggesting that both PAF-AH and LCAT are involved in their breakdown, Oxidation of chicken plasma, which has no PAF-AH activity, also resulted in the formation of lyse-PC from the hydrolysis of polar PC, which was inhibited by DFP, Polar PCs, either isolated from oxidized plasma or by oxidation of labeled synthetic PCs, were hydrolyzed by purified LCAT, which had no detectable PAF-AH activity. These results demonstrate a novel function for LCAT in the detoxification of polar PCs generated during lipoprotein oxidation, especially when the PAF-AH is absent or inactivated.	RUSH MED COLL,SECT ENDOCRINOL & METAB,DEPT MED,CHICAGO,IL 60612; RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612	Rush University; Rush University			Subbaiah, Papasani/U-1104-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052597] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52597] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; ARON L, 1978, J BIOL CHEM, V253, P7220; BIELICKI JK, 1995, BBA-LIPID LIPID MET, V1258, P35, DOI 10.1016/0005-2760(95)00092-Q; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; CABOT MC, 1984, COMP BIOCHEM PHYS B, V78, P37, DOI 10.1016/0305-0491(84)90141-X; CHEN CH, 1982, J LIPID RES, V23, P680; DENTAN C, 1994, ARTERIOSCLER THROMB, V14, P353, DOI 10.1161/01.ATV.14.3.353; Dentan C, 1996, BBA-LIPID LIPID MET, V1299, P353, DOI 10.1016/0005-2760(95)00226-X; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; Glomset J A, 1979, Prog Biochem Pharmacol, V15, P41; GLOMSET JA, 1968, J LIPID RES, V9, P155; HABERLAND ME, 1992, MONOGR HUM GENET, V14, P35; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HENGSTSCHLAGEROTTNAD E, 1995, J BIOL CHEM, V270, P26139, DOI 10.1074/jbc.270.44.26139; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; ITABE H, 1994, J BIOL CHEM, V269, P15274; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; KAMIDO H, 1995, J LIPID RES, V36, P1876; KAPLANHARRIS L, 1980, J LIPID RES, V21, P617; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; KLIMOV A N, 1989, Biokhimiya, V54, P118; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LEHR HA, 1993, ARTERIOSCLER THROMB, V13, P1013, DOI 10.1161/01.ATV.13.7.1013; LIAPIKOS TA, 1994, BBA-LIPID LIPID MET, V1212, P353, DOI 10.1016/0005-2760(94)90210-0; LIU M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P144, DOI 10.1016/0005-2760(93)90118-S; LIU M, 1994, P NATL ACAD SCI USA, V91, P6035, DOI 10.1073/pnas.91.13.6035; LODGE JK, 1995, BBA-LIPID LIPID MET, V1256, P130, DOI 10.1016/0005-2760(94)00253-U; MACKNESS MI, 1989, BIOCHEM PHARMACOL, V38, P385, DOI 10.1016/0006-2952(89)90376-6; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; MARINETTI GV, 1962, J LIPID RES, V3, P1; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MIWA M, 1984, J BIOCHEM-TOKYO, V96, P761, DOI 10.1093/oxfordjournals.jbchem.a134894; MUROHARA T, 1994, AM J PHYSIOL-HEART C, V267, pH2441, DOI 10.1152/ajpheart.1994.267.6.H2441; NEVILLE TA, 1996, CIRCULATION, V94, P222; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; PIRAN U, 1976, J BIOCHEM-TOKYO, V80, P887, DOI 10.1093/oxfordjournals.jbchem.a131352; Puettmann Michael, 1993, Clinical Chemistry, V39, P782; QU SJ, 1993, BIOCHEMISTRY-US, V32, P3089, DOI 10.1021/bi00063a021; QUINN MT, 1991, BIOCHIM BIOPHYS ACTA, V1082, P293, DOI 10.1016/0005-2760(91)90205-V; Schlame M, 1996, J LIPID RES, V37, P2608; SCHMITT A, 1995, BBA-LIPID LIPID MET, V1256, P284, DOI 10.1016/0005-2760(95)00032-8; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUBBAIAH PV, 1980, J BIOL CHEM, V255, P9275; SUBBAIAH PV, 1992, BIOCHIM BIOPHYS ACTA, V1128, P83, DOI 10.1016/0005-2760(92)90261-S; Subbaiah PV, 1996, BBA-LIPID LIPID MET, V1301, P115, DOI 10.1016/0005-2760(96)00028-8; SUGIYAMA S, 1994, CIRC RES, V74, P565, DOI 10.1161/01.RES.74.4.565; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; Tokumura A, 1996, LIPIDS, V31, P1251, DOI 10.1007/BF02587909; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; YAMADA Y, 1994, P NATL ACAD SCI USA, V91, P10320, DOI 10.1073/pnas.91.22.10320	64	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16231	16239		10.1074/jbc.272.26.16231	http://dx.doi.org/10.1074/jbc.272.26.16231			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195924	hybrid			2022-12-25	WOS:A1997XG01900028
J	Tomashek, JJ; Garrison, BS; Klionsky, DJ				Tomashek, JJ; Garrison, BS; Klionsky, DJ			Reconstitution in vitro of the V-1 complex from the yeast vacuolar proton-translocating ATPase - Assembly recapitulates mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; 14-KDA SUBUNIT; ENCODES; PUMP; MEMBRANE; BINDING; ENZYME	Oligomeric assembly is a fundamental aspect of many complex enzymes, Using our native gel technique for examining subcomplexes of the V-ATPase V-1 sector, we have developed an in vitro reconstitution assay for assembly of this complex. Assembly of complex II, the soluble V-1 complex observed in native gels, is dependent upon the presence of divalent cations and physiological temperatures. Assembly of soluble V-1 can occur in a stepwise fashion from smaller subcomplexes found in some strains deleted for V-ATPase subunits. Specifically, V-1 can be assembled directly from complex III (subunits E and G) with complex IV (subunits A, B, D, and F) without prior disassembly of complex IV. The formation of complex III in vivo is also shown to be essential and could not be achieved in vitro. Assembly from simpler precursors is possible and is enhanced by added ATP. Assembly can be blocked by N-ethylmaleimide in a Vma1p (subunit A)-specific manner. From these data, we extend our previous model to consider an assembly pathway whose steps reflect the catalytic mechanism of the Boyer binding-change model.	UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NIGMS NIH HHS [GM53396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; FENG Y, 1992, J BIOL CHEM, V267, P5817; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HARVEY WR, 1992, J EXP BIOL, V172, P1; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KANE PM, 1995, J BIOL CHEM, V270, P17025; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; MORANO KA, 1994, J CELL SCI, V107, P2813; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1994, J BIOL CHEM, V269, P24150; Okamoto M, 1996, J BIOCHEM-TOKYO, V120, P608; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; TOGNOLI L, 1985, EUR J BIOCHEM, V146, P581, DOI 10.1111/j.1432-1033.1985.tb08691.x; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; Ward JM, 1995, METHOD CELL BIOL, V50, P149, DOI 10.1016/S0091-679X(08)61028-6; Xie XS, 1996, J BIOL CHEM, V271, P30980	23	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16618	16623		10.1074/jbc.272.26.16618	http://dx.doi.org/10.1074/jbc.272.26.16618			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195975	hybrid			2022-12-25	WOS:A1997XG01900079
J	Nelson, DA; Ludlow, JW				Nelson, DA; Ludlow, JW			Characterization of the mitotic phase pRb-directed protein phosphatase activity	ONCOGENE			English	Article						serine/threonine phosphatase; PP1; cell cycle; retinoblastoma protein; dephosphorylation	SERINE THREONINE PHOSPHATASES; CELL-CYCLE REGULATION; SV40 LARGE-T; RETINOBLASTOMA PROTEIN; CATALYTIC SUBUNIT; SKELETAL-MUSCLE; GENE-PRODUCT; PHOSPHOPROTEIN PHOSPHATASE; TYPE-1; PHOSPHORYLATION	We have previously reported on the M-phase specific dephosphorylation of pRb and identified a type 1 serine/ threonine protein phosphatase (PPI) as the enzyme mediating pRb dephosphorylation. In this report, we have characterized the pRb-directed phosphatase activity found in mitotic cells with respect to dose dependence and demonstrate that the pRb isoform conversion detected in vitro mirrors the pRb isoform conversion which occurs during mitosis of intact cells. Cell fractionation and PP1 catalytic subunit isolation studies support the notion that the pRb-directed phosphatase activity involves subpopulations of PP1 catalytic subunits. Coprecipitation studies revealed that PPI can form a complex with hypophosphorylated pRb which was converted from the hyperphosphorylated form in mitotic cell extracts. Taken together with data from previous reports in the literature, a model for the regulation of PP1 activity towards pRb during mitotic exit is proposed.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, CTR CANC, DIV DEV THERAPEUT, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				Nelson, Deirdre/0000-0001-5527-2570	NATIONAL CANCER INSTITUTE [R29CA056940, P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198, CA56940] Funding Source: Medline; NIDCR NIH HHS [DE07202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRAUTIGAN DL, 1982, BIOCHEMISTRY-US, V21, P1977, DOI 10.1021/bi00538a001; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHATRA BS, 1986, J BIOL CHEM, V261, P8944; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; RADULESCU RT, 1995, MED HYPOTHESES, V44, P28, DOI 10.1016/0306-9877(95)90297-X; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLAMORUZZI E, 1992, FEBS LETT, V304, P211, DOI 10.1016/0014-5793(92)80621-M; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WOODFORD TA, 1986, J BIOL CHEM, V261, P4669; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x	37	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2407	2415		10.1038/sj.onc.1201081	http://dx.doi.org/10.1038/sj.onc.1201081			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188855				2022-12-25	WOS:A1997WZ68000004
J	Ju, H; Zou, R; Venema, VJ; Venema, RC				Ju, H; Zou, R; Venema, VJ; Venema, RC			Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; MEMBRANE DOMAINS; SEQUENCE; PROTEIN; COMPONENT; MECHANISMS; VESICLES; DISEASE; REVEALS; VIP21	Endothelial nitric-oxide synthase (eNOS) and caveolin-1 are associated within endothelial plasmalemmal caveolae. It is not known, however, whether eNOS and caveolin-1 interact directly or indirectly or whether the interaction affects eNOS activity. To answer these questions, we have cloned the bovine caveolin-1 cDNA and have investigated the eNOS-caveolin-1 interaction in an in vitro binding assay system using glutathione S-transferase (GST)-caveolin-1 fusion proteins and baculovirus-expressed bovine eNOS. We have also mapped the domains involved in the interaction using an in vivo yeast two-hybrid system. Results obtained using both in vitro and in vivo protein interaction assays show that both Nand C-terminal cytosolic domains of caveolin-1 interact directly with the eNOS oxygenase domain. Interaction of eNOS with GST-caveolin-1 fusion proteins significantly inhibits enzyme catalytic activity. A synthetic peptide corresponding to caveolin-1 residues 82-101 also potently and reversibly inhibits eNOS activity by interfering with the interaction of the enzyme with Ca2+/calmodulin (CaM). Regulation of eNOS in endothelial cells, therefore, may involve not only positive allosteric regulation by Ca2+/CaM, but also negative allosteric regulation by caveolin-1.	MED COLL GEORGIA, VASC BIOL CTR, DEPT PEDIAT, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057201, R01HL057201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VENEMA RC, 1996, J BIOL CHEM, V226, P703	27	507	528	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18522	18525		10.1074/jbc.272.30.18522	http://dx.doi.org/10.1074/jbc.272.30.18522			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228013	hybrid			2022-12-25	WOS:A1997XM34200004
J	Mynarcik, DC; Williams, PF; Schaffer, L; Yu, GQ; Whittaker, J				Mynarcik, DC; Williams, PF; Schaffer, L; Yu, GQ; Whittaker, J			Identification of common ligand binding determinants of the insulin and insulin-like growth factor 1 receptors - Insights into mechanisms of ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; HIGH-AFFINITY BINDING; MONOCLONAL-ANTIBODIES; CROSS-LINKING; ALPHA-SUBUNIT; SIDE-CHAIN; SITE; DOMAIN; REGION; MUTAGENESIS	Insulin and insulin-like growth factor 1 (IGF-1) are peptides that share nearly 50% sequence homology. However, although their cognate receptors also exhibit significant overall sequence homology, the affinity of each peptide for the non-cognate receptor is 2-3 orders of magnitude lower than for the cognate receptor. The molecular basis for this discrimination is unclear, as are the molecular mechanisms underlying ligand binding. We have recently identified a major ligand binding site of the insulin receptor by alanine scanning mutagenesis. These studies revealed that a number of amino acids critical for insulin binding are conserved in the IGF-1 receptor, suggesting that they may play a role in ligand binding. We therefore performed alanine mutagenesis of these amino acids to determine whether this is the case. cDNAs encoding alanine-substituted secreted recombinant IGF-1 receptors were expressed in 293 EBNA cells, and the ligand binding properties of the expressed proteins were evaluated. Mutation of Phe(701) resulted in a receptor with undetectable IGF-1 binding; alanine substitution of the corresponding amino acid of the insulin receptor, Phe(714), produces a 140-fold reduction in affinity for insulin, Mutation of Asp(8), Asn(11), Phe(58), Phe(692), Glu(693), His(697), and Asn(698) produces a 3.5-6-fold reduction in affinity for IGF-1. In contrast, alanine mutation of the corresponding amino acids of the insulin receptor with the exception of Asp(12) produces reductions in affinity that are 50-fold or greater. The affinity of insulin for these mutants relative to wild type receptor was similar to that of their relative affinity for IGF-1 with two exceptions; the IC50 values for insulin binding to the mutants of Arg(10), which has normal affinity for IGF-1, and His(697), which has a 6-fold reduction in affinity for IGF-1, were both at least 2 orders of magnitude greater than for wild type receptor. The K-d values for insulin of the corresponding alanine mutants of the insulin receptor, Arg(14) and His(710), are 2-3 orders of magnitude greater than for wild type receptor. However, in contrast, the relative affinity of des(25-30)[Phe(B25) alpha-carboxamide]insulin for these IGF-1 receptor mutants is reduced only 4- and 50-fold, respectively.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; NOVO NORDISK AS, INSULIN RES, DK-2880 BAGSVAERD, DENMARK	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Novo Nordisk	Mynarcik, DC (corresponding author), SUNY STONY BROOK, HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL,HSC T15, RM 060, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1990, J BIOL CHEM, V265, P15648; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; DREYER, 1991, DIABETES, V40, P1488; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; Harlow E., 1988, ANTIBODIES LAB MANUA; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Leroith Derek, 1992, Biological Signals, V1, P173; McPherson M. J., 1991, PCR PRACTICAL APPROA; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; MYRNARCIK DC, 1997, J BIOL CHEM, V272, P2077; NAKAGAWA SH, 1987, J BIOL CHEM, V262, P12054; NAKAGAWA SH, 1986, J BIOL CHEM, V261, P7332; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; NAKAGAWA SH, 1989, J BIOL CHEM, V264, P272; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	39	72	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18650	18655		10.1074/jbc.272.30.18650	http://dx.doi.org/10.1074/jbc.272.30.18650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228034	hybrid			2022-12-25	WOS:A1997XM34200025
J	Sheikh, S; Ni, L; Hurley, TD; Weiner, H				Sheikh, S; Ni, L; Hurley, TD; Weiner, H			The potential roles of the conserved amino acids in human liver mitochondrial aldehyde dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; ESTERASE-ACTIVITY; CYSTEINE RESIDUE; EXPRESSION; RAT; PURIFICATION; INVOLVEMENT; SERINE-74	The sequence alignment of all known aldehyde dehydrogenases showed that only 23 residues were completely conserved (Hempel, J., Nicholas, R., and Lindahl, R. (1993) Protein Sci, 2, 1890-1900). Of these 14 were glycines and prolines, Site-directed mutagenesis showed that Cys(302) was the essential nucleophile and that Glu(268) was the general base necessary to activate Cys(302) for both the dehydrogenase and esterase reaction, Here we report the mutational analysis of other conserved residues possessing reactive side chains Arg(84), Lys(192), Thr(384), Glu(399), and Ser(471), along with partially conserved Glu(398) and Lys(489), to determine their involvement in the catalytic process and correlate these finding with the known structure of mitochondrial ALDH (Steinnetz, C. G., Xie, P.-G., Weiner, H., and Hurley, T. D. (1997) Structure 5, 701-711), No residue was found to be absolutely essential, but all the mutations caused a decrease in the specific activity of the enzyme, None of the mutations affected the K-m for aldehyde significantly, although k(3), the rate constant calculated for aldehyde binding was decreased, The K-m and dissociation constant (R-ia) for NAD(+) increased significantly for R192Q and S471A compared with the native enzyme, Mutations of only Lys(192) and Glu(399), both NAD(+)-ribose binding residues, led to a change in the rate-limiting step such that hydride transfer became rate-limiting, not deacylation. Esterase activity of all mutants decreased even though mutations affected different catalytic steps in the dehydrogenase reaction.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis				HURLEY, THOMAS/0000-0002-5942-1163	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA05812] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABELES RH, 1992, BIOCHEMISTRY-US, P126; ABROILA DP, 1987, BIOCHEMISTRY-US, V26, P5679; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; FARRES J, 1994, J BIOL CHEM, V269, P13854; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; FELDMAN RI, 1972, J BIOL CHEM, V247, P260; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HEMPEL JD, 1981, J BIOL CHEM, V256, P889; KITSON TM, 1985, ENZYMOLOGY CARBONYL, V2, P43; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; LOOMES KM, 1990, BIOCHEMISTRY-US, V29, P2070, DOI 10.1021/bi00460a015; LOOMES KM, 1986, BIOCHEM J, V238, P617, DOI 10.1042/bj2380617; Ni L, 1997, J BIOL CHEM, V272, P18823, DOI 10.1074/jbc.272.30.18823; NUKHERJEE N, 1992, ARCH BIOCHEM BIOPHYS, V299, P23; ROUT UK, 1994, BIOCHEMISTRY-US, V33, P8955, DOI 10.1021/bi00196a013; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDHU RS, 1975, J BIOL CHEM, V250, P7894; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKAHASHI K, 1980, ARCH BIOCHEM BIOPHYS, V205, P571, DOI 10.1016/0003-9861(80)90140-X; TU GC, 1988, J BIOL CHEM, V263, P1212; VASILIOU V, 1995, EUR J DRUG METAB PH, V20, P53; VEDADI M, 1997, ENZYMOLOGY CARBONYL, V6, P269; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; WEINER H, 1976, J BIOL CHEM, V251, P3853; WEINER H, 1985, ENZYMOLOGY CARBONYL, V2, P57; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	30	68	69	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18817	18822		10.1074/jbc.272.30.18817	http://dx.doi.org/10.1074/jbc.272.30.18817			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228056	hybrid			2022-12-25	WOS:A1997XM34200047
J	Banan, M; Rojas, IC; Lee, WH; King, HL; Harriss, JV; Kobayashi, R; Webb, CF; Gottlieb, PD				Banan, M; Rojas, IC; Lee, WH; King, HL; Harriss, JV; Kobayashi, R; Webb, CF; Gottlieb, PD			Interaction of the nuclear matrix-associated region (MAR)-binding proteins, SATB1 and CDP/Cux, with a MAR element (L2a) in an upstream regulatory region of the mouse CD8a gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; MUTUALLY EXCLUSIVE INTERACTION; HEAVY-CHAIN ENHANCER; DNA-BINDING PROTEIN; GAMMA-GLOBIN GENE; TOPOISOMERASE-II; CELL-TYPE; DROSOPHILA-MELANOGASTER; HOMEODOMAIN PROTEIN; NEGATIVE REGULATION	Matrix-associated regions (MARs), AT-rich DNA segments that have an affinity for the nuclear matrix, have been shown to play a role in transcriptional regulation of eukaryotic genes. The present study demonstrates that a DNA element, called L2a, which has been implicated in the transcriptional regulation of the mouse CD8a gene encoding an important T cell coreceptor, is a MAR. Moreover, thee identities of two nuclear proteins, L2a-P1 and L2a-P2, previously shown to bind to the L2a element, have been determined. The L2a-P1 protein found to be present in all CD8-positive T cell lines tested is SATB1, a known MAR-binding protein. The widely expressed L2a-P2 protein is CDP/Cux, a MAR-binding protein that has been associated with repression of gene transcription, interaction of both proteins with the L2a element was studied using the missing nucleoside approach. DNase i footprinting, and electrophoretic mobility shift assays with wild type and mutant L2a elements. The data suggest that CDP/Cux bound to the L2a element is displaced by binding of SATB1 and the accompanying conformational change in the DNA lying between the primary binding sites of SATB1 and CDP/Cux. We suggest that displacement of CDP/Cux by SATB1 favors transcription of the CD8a gene, possibly by enhancing or altering its association with the nuclear matrix.	UNIV TEXAS, DEPT MICROBIOL, AUSTIN, TX 78712 USA; UNIV TEXAS, INST MOL & CELLULAR BIOL, AUSTIN, TX 78712 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; OKLAHOMA MED RES FDN, DEPT IMMUNOL, OKLAHOMA CITY, OK 73104 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Cold Spring Harbor Laboratory; Oklahoma Medical Research Foundation			Banan, Mehdi/L-9762-2017		NCI NIH HHS [CA45508] Funding Source: Medline; NIGMS NIH HHS [GM46462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM046462, R29GM046462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBONE AM, 1988, J IMMUNOL, V141, P1369; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURDA PJ, 1976, J EXP MED, V144, P476, DOI 10.1084/jem.144.2.476; DURDA PJ, 1978, J IMMUNOL, V121, P983; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GARRARD WT, 1990, NUCLEIC ACIDS MOL BI, V4, P163; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GETZENBERG RH, 1994, J CELL BIOCHEM, V55, P22, DOI 10.1002/jcb.240550105; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GU JJ, 1992, IMMUNOGENETICS, V36, P283; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HWANG I, 1993, IMMUNOGENETICS, V37, P129; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LANDRY DB, 1993, J EXP MED, V178, P941, DOI 10.1084/jem.178.3.941; LEE WH, 1994, INT IMMUNOL, V6, P1307, DOI 10.1093/intimm/6.9.1307; LEFRANCOIS L, 1995, IMMUNOL TODAY, V16, P16, DOI 10.1016/0167-5699(95)80065-4; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MANIATIS T, 1983, MOL CLONING; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RALPH P, 1973, J IMMUNOL, V110, P1470; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; WHITE J, 1989, J IMMUNOL, V143, P1822; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2; ZONG RT, 1995, J BIOL CHEM, V270, P24010, DOI 10.1074/jbc.270.41.24010	60	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18440	18452		10.1074/jbc.272.29.18440	http://dx.doi.org/10.1074/jbc.272.29.18440			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218488	hybrid			2022-12-25	WOS:A1997XL73500078
J	Vilalta, A; Trivedi, A; Wang, ZX; Roeder, RC; Johnson, DL				Vilalta, A; Trivedi, A; Wang, ZX; Roeder, RC; Johnson, DL			An RNA polymerase III-defective mutation in TATA-binding protein disrupts its interaction with a transcription factor IIIB subunit in Drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL SEQUENCE ELEMENT; MAMMALIAN U6 GENES; FACTOR-TFIIIB; CONTAINING COMPLEX; 2 COMPONENTS; IN-VITRO; TBP; SPECIFICITY; EXPRESSION; LESS	A subunit of the Drosophila RNA polymerase III transcription factor IIIB (TFIIIB) complex has been identified using antibodies directed against the analogous human protein, hIIIB90. This protein has an apparent molecular mass of 105 kDa and has been designated dTAF(III)105. Drosophila S-2 cell extracts that were immunodepleted of dTAF(III)105 were substantially reduced in their capacity to support tRNA gene transcription, A protein (far Western) blot analysis revealed chat dTAF(III)105, present in a TFIIIB fraction, directly interacts with TATA-binding protein (TBP). Coimmunoprecipitation assays demonstrated that this protein associates with TBP in S-2 cell extracts, Our previous studies have identified a mutation at position 332 within Drosophila TBP that changes a highly conserved arginine residue to a histidine residue, which renders it specifically defective in its ability to support RNA polymerase III transcription in S-2 cells (Trivedi, A., Vilalta, A., Gopalan, S., and Johnson, D. L. (1996) Mot. Cell, Biol. 16, 6909-6916), We further demonstrate that extracts prepared from a stable cell line expressing epitope tagged wild-type TBP exhibit an increase in tRNA gene transcription, whereas extracts derived from cells expressing the mutant TBP protein do not. Coimmunoprecipitation assays and far Western blot analysis demonstrate that this mutation in TBP abolishes its ability to stably interact with dTAF(III)105. Thus, we have identified both a Drosophila protein that is directly associated with TBP in the TFIIIB complex, dTAF(III)105, and an amino acid residue within the highly conserved carboxyl-terminal region of TBP that is critical for dTAF(III)105-TBP interactions.	UNIV SO CALIF, SCH PHARM, DEPT MOL PHARMACOL & BIOCHEM, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT MOL PHARMACOL & BIOCHEM, LOS ANGELES, CA 90033 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	University of Southern California; University of Southern California; Rockefeller University								BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; DINGERMANN T, 1982, J BIOL CHEM, V257, P4738; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; GARBER ME, 1994, MOL CELL BIOL, V14, P339, DOI 10.1128/MCB.14.1.339; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3432, DOI 10.1093/nar/22.16.3432; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; JOHNSON DL, 1991, J BIOL CHEM, V266, P16037; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM K, 1994, J BIOL CHEM, V269, P4891; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; McBryant SJ, 1996, MOL CELL BIOL, V16, P4639; MEISSNER W, 1995, MOL CELL BIOL, V15, P5888; Mital R, 1996, MOL CELL BIOL, V16, P7031; MUT V, 1997, SCIENCE, V275, P1136; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; Trivedi A, 1996, MOL CELL BIOL, V16, P6909; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG HD, 1995, MOL CELL BIOL, V15, P6720; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; Yoon JB, 1996, MOL CELL BIOL, V16, P1; YOON JB, 1995, MOL CELL BIOL, V15, P2019; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	54	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18087	18092		10.1074/jbc.272.29.18087	http://dx.doi.org/10.1074/jbc.272.29.18087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218440	hybrid			2022-12-25	WOS:A1997XL73500030
J	Yan, C; Whitsett, JA				Yan, C; Whitsett, JA			Protein kinase A activation of the surfactant protein B gene is mediated by phosphorylation of thyroid transcription factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY EPITHELIUM; CATALYTIC SUBUNIT; MESSENGER-RNA; CYCLIC-AMP; FACTOR-I; SP-A; LUNG; EXPRESSION; CAMP; MECHANISMS	Thyroid transcription factor 1 (TTF-1) is a homeodomain-containing nuclear transcription factor expressed in epithelial cells of the lung and thyroid. TTF-1 binds to and activates the transcription of genes expressed selectively in the respiratory epithelium including pulmonary surfactant A, B, C and Clara cell secretory protein. Transfection with a plasmid encoding the cyclic AMP-dependent protein kinase (protein kinase A; PKA) catalytic subunit, Cat-beta, stimulated the phosphorylation of a TTF-l-flag fusion protein 6-7-fold in H441 pulmonary adenocarcinoma cells. Recombinant TTF-1 was phosphorylated by purified PKA catalytic subunit in the presence of [gamma-P-32]ATP. PKA catalytic subunit family members, Cat-alpha and Cat-beta markedly enhanced the transcriptional activation of surfactant B gene promoters by TTF-1 in vitro. Peptide mapping was used to identify a PKA phosphorylation site at the NH2 terminus of TTF-1. A 17-amino acid synthetic peptide comprising this site completely inhibited the PKA-dependent phosphorylation of TTF-1 in vitro. A substitution mutation of TTF-1 (Thr(9) --> Ala) abolished phosphorylation by PKA and reduced transactivation of the surfactant B gene promoter. Transfection with a plasmid encoding the cAMP regulatory element binding factor inhibited transcriptional activity of the surfactant protein B gene promoter. Phosphorylation of TTF-1 mediates PKA-dependent activation of surfactant protein B gene transcription.	CHILDRENS HOSP,MED CTR,DIV NEONATOL,TCHRF,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,DIV PULM BIOL,TCHRF,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038859, P01HL051832, R37HL038859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38859, HL51832] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; FARRELL PM, 1990, BIOCHIM BIOPHYS ACTA, V1044, P84, DOI 10.1016/0005-2760(90)90222-J; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; Holzinger A, 1996, HYBRIDOMA, V15, P49, DOI 10.1089/hyb.1996.15.49; HOWARD P, 1991, J BIOL CHEM, V266, P10189; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311, DOI 10.1177/41.9.8354874; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WHITE G, 1995, RECEPTOR CHANNEL, V3, P1; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; WHITSETT JA, 1996, LUNG SCI FDN, P2167; WHITSETT JA, 1991, PULMONARY SURFACTANT, P77; WHITSETT JA, 1991, BASIC MECH PEDIAT RE, P303; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; YAN C, 1992, P NATL ACAD SCI USA, V89, P8859, DOI 10.1073/pnas.89.19.8859; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	35	66	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17327	17332		10.1074/jbc.272.28.17327	http://dx.doi.org/10.1074/jbc.272.28.17327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211870	hybrid			2022-12-25	WOS:A1997XK16500013
J	Pedram, A; Razandi, M; Hu, RM; Levin, ER				Pedram, A; Razandi, M; Hu, RM; Levin, ER			Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NATRIURETIC-PEPTIDE; GENE-EXPRESSION; C-RECEPTOR; IN-VIVO; HYPOXIA; ATRIAL; ANGIOGENESIS; INDUCTION; SECRETION	The proliferation of vascular endothelial cells (EC) is an important event in angiogenesis, The synthesis of the EC growth factor, vascular endothelial cell growth factor (VEGF), is stimulated by a variety of activators; but the effects of important vasoactive peptides are not well understood, and there are no known natural inhibitors of VEGF production, We found that the vasoactive peptides endothelin (ET)-1 and ET-3 stimulated the synthesis of VEGF protein 3-4-fold in cultured human vascular smooth muscle cells, comparable in magnitude to hypoxia. ET-1 and ET-3 acted through the ETA and ETB receptors, respectively, and signaling through protein kinase C was important. Atrial natriuretic peptide (ANP), C-type natriuretic peptide, and C-ANP-(4-23), a ligand for the natriuretic peptide clearance receptor, equipotently inhibited production of VEGF by as much as 88% and inhibited ET- or hypoxia-stimulated VEGF transcription, EC proliferation and invasion of matrix were stimulated by VEGF secreted into the medium by ET-incubated vascular smooth muscle cells, This was inhibited by ANP. Our results identify the natriuretic peptides as the first peptide inhibitors of VEGF synthesis and indicate a novel mechanism by which vasoactive peptides could modulate angiogenesis.	UNIV CALIF IRVINE, DEPT MED, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT PHARMACOL, IRVINE, CA 92717 USA; DEPT VET AFFAIRS MED CTR, LONG BEACH, CA 90822 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System			Levin, Ellis/J-5402-2013		NHLBI NIH HHS [HL-50161] Funding Source: Medline; NINDS NIH HHS [NS-30521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; Doi K, 1996, HYPERTENSION, V27, P811, DOI 10.1161/01.HYP.27.3.811; FARRE AL, 1993, CIRCULATION, V88, P1166, DOI 10.1161/01.CIR.88.3.1166; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FRANK HJL, 1993, ENDOCRINOLOGY, V133, P1092, DOI 10.1210/en.133.3.1092; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FURUYA M, 1993, BIOCHEM BIOPH RES CO, V193, P248, DOI 10.1006/bbrc.1993.1616; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HU RM, 1993, DIABETES, V42, P351, DOI 10.2337/diabetes.42.2.351; HU RM, 1992, J BIOL CHEM, V267, P17384; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; Joukov V, 1996, EMBO J, V15, P290; KAGAMU H, 1994, BIOCHEM BIOPH RES CO, V202, P1612, DOI 10.1006/bbrc.1994.2117; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MCCARRON RM, 1993, NEUROSCI LETT, V156, P31, DOI 10.1016/0304-3940(93)90432-K; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORBIDELLI L, 1995, AM J PHYSIOL-HEART C, V269, pH686, DOI 10.1152/ajpheart.1995.269.2.H686; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NAZARIO B, 1995, J CLIN INVEST, V95, P1151, DOI 10.1172/JCI117763; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PORTER JG, 1992, AM J PHYSIOL, V263, pC1001, DOI 10.1152/ajpcell.1992.263.5.C1001; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; REZANDI M, 1996, AM J PHYSIOL, V270, pH1342; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SCHREY MP, 1992, CANCER RES, V52, P1786; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SVETLOV S, 1993, BIOCHIM BIOPHYS ACTA, V1177, P75, DOI 10.1016/0167-4889(93)90160-Q; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG YZ, 1994, AM J PHYSIOL-CELL PH, V267, pC1130, DOI 10.1152/ajpcell.1994.267.4.C1130; YOSHIMOTO S, 1991, STROKE, V22, P378, DOI 10.1161/01.STR.22.3.378	62	175	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17097	17103		10.1074/jbc.272.27.17097	http://dx.doi.org/10.1074/jbc.272.27.17097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202027	hybrid			2022-12-25	WOS:A1997XH44600059
J	Gamard, CJ; Dbaibo, GS; Liu, B; Obeid, LM; Hannun, YA				Gamard, CJ; Dbaibo, GS; Liu, B; Obeid, LM; Hannun, YA			Selective involvement of ceramide in cytokine-induced apoptosis - Ceramide inhibits phorbol ester activation of nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HL-60 CELL-DIFFERENTIATION; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; SPHINGOMYELIN TURNOVER; ACID SPHINGOMYELINASE; CYCLE ARREST; FREE SYSTEM; TNF-ALPHA; PATHWAY	Among its diverse biologic effects, the cytokine tumor necrosis factor cu causes the rapid nuclear translocation of the transcription factor, nuclear factor kappa B (NF-kappa B). The p55 tumor necrosis factor (TNF) receptor shares with the related APO-1/Fas antigen the ability to initiate apoptosis. We investigated the role of the sphingolipid mediator ceramide in the cytokine-induced signaling mechanisms leading to NF-kappa B activation and cell death. Several lines of evidence presented here suggest that ceramide generated in response to TNF alpha or Fas activation is not involved in NF-kappa B activation. (i) Cell-permeable ceramides and exogenous sphingomyelinase failed to induce either nuclear translocation of NF-kappa B or degradation of its cytosolic inhibitor, I-kappa B, in Jurkat T cells. (ii) Ceramide treatment of cells inhibited phorbol ester-induced activation of NF-kappa B. (iii) TNF alpha potently activated NF-kappa B in a cell. line deficient in acid sphingomyelinase. (iv) TNF alpha activated NF-kappa B within minutes without altering ceramide levels. (v) Treatment of Jurkat cells with cross-linking antibodies to APO-1/Fas induced large scale increases in ceramide and apoptosis without affecting NF-kappa B. (vi) Ceramide generation in response to pas activation was inhibited by N-acetyltyrosinylvalinylalanylaspartyl chloromethyl ketone, a peptide inhibitor of interleukin-lp-converting enzymelike proteases, whereas TNF alpha-induced NF-kappa B activation was unaffected by the inhibitor. These results show that ceramide accumulation belongs selectively to the apoptotic pathway(s) induced by cytokines, and, if anything, ceramide may participate in negative feedback regulation of NF-kappa B.	DUKE UNIV,MED CTR,DEPT MED & CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710	Duke University; Duke University			Dbaibo, Ghassan S./X-2978-2019	obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG012467, R55AG012467] Funding Source: NIH RePORTER; NIA NIH HHS [AG12467] Funding Source: Medline; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Higuchi M, 1996, J IMMUNOL, V157, P297; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KIM MY, 1991, J BIOL CHEM, V266, P484; KRONKE M, 1990, CELL SIGNAL, V2, P1, DOI 10.1016/0898-6568(90)90027-8; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; PREISS J, 1986, J BIOL CHEM, V261, P8597; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RENSINGEHL A, 1995, J INFLAMM, V45, P161; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Totpal K, 1996, J INTERF CYTOK RES, V16, P259, DOI 10.1089/jir.1996.16.259; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YANG ZH, 1993, J BIOL CHEM, V268, P20520	55	94	96	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16474	16481		10.1074/jbc.272.26.16474	http://dx.doi.org/10.1074/jbc.272.26.16474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195956	hybrid			2022-12-25	WOS:A1997XG01900060
J	Kumar, CS; James, IE; Wong, A; Mwangi, V; Feild, JA; Nuthulaganti, P; Connor, JR; Eichman, C; Ali, F; Hwang, SM; Rieman, DJ; Drake, FH; Gowen, M				Kumar, CS; James, IE; Wong, A; Mwangi, V; Feild, JA; Nuthulaganti, P; Connor, JR; Eichman, C; Ali, F; Hwang, SM; Rieman, DJ; Drake, FH; Gowen, M			Cloning and characterization of a novel integrin beta(3) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIIA; VITRONECTIN RECEPTOR; BONE-RESORPTION; CELL-ADHESION; CYTOPLASMIC DOMAIN; EXTRACELLULAR-MATRIX; OSTEOCLASTS; EXPRESSION; INHIBITION; APOPTOSIS	We have identified a novel integrin beta(3) subunit, termed beta(3C), from a human osteoclast cDNA library. The COOH-terminal sequence and 5'-untranslated region of the beta(3C) subunit differs from the previously reported beta(3A) (platelet) and beta(3B) (placenta) sequences, while the regions coding for the transmembrane and extracellular domains are identical. The beta(3C) cytoplasmic domain contains 37 amino acids, the last 17 of which are encoded by a novel exon located about 6 kilobase pairs downstream of exon 14 of the beta(3A) gene. HEK 293 cells were stably co-transfected with alpha(V) and either beta(3C) (HEK beta(3C)) or beta(3A) (HEK beta(3A). The viability of HER beta(3C) cells was lower than that of HER beta(3A) cells, and HEH beta(3C) cells in culture grew as clusters rather than as a monolayer. The novel cytoplasmic domain did not affect receptor binding affinity; both alpha(V) beta(3A) and alpha(V) beta(3C) isoforms exhibited high affinity binding to I-125-echistatin and cyclic and linear RGD peptides. However, in contrast to HEK beta(3A) HEK beta(3C) cells failed to adhere to osteopontin, an alpha(V) beta(3) matrix protein. The data provide further support for the key role of the cytoplasmic domain of the beta(3) integrin in cell adhesion and suggest a potential role for the beta(3C) integrin subunit in modulating cell-matrix interactions.	SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Kumar, CS (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,DEPT MOL GENET,709 SWEDELAND RD,POB 1539,KING OF PRUSSIA,PA 19406, USA.		Kumar, Dr Suresh/HHZ-2615-2022; chitta, suresh kumar/N-1569-2016; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604				AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; Belkin A. M., 1995, Molecular Biology of the Cell, V6, p284A; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; FILDARO EJ, 1995, J CELL BIOL, V130, P441; FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HENSLEY P, 1994, J BIOL CHEM, V269, P23949; HORTON M, 1990, INT J EXP PATHOL, V71, P741; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; HUGHES DE, 1995, J BONE MINER RES, V10, pS326; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAMES IE, 1991, J HISTOCHEM CYTOCHEM, V39, P905, DOI 10.1177/39.7.1865107; JOHNSON GD, 1981, TECHNIQUES CLIN IMMU, P106; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOUTIT JF, 1982, IMMUNOBIOLOGY, V161, P193, DOI 10.1016/S0171-2985(82)80074-0; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; Parfitt AM, 1996, J BONE MINER RES, V11, P150; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; ROSA JP, 1988, BLOOD, V72, P593; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAMBROOK J, 1989, CLONING LAB MANUAL, V2; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SATO M, 1994, J BONE MINER RES, V9, P1441; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TOIN HM, 1989, P NATL ACAD SCI USA, V86, P5415; Wong A, 1996, MOL PHARMACOL, V50, P529; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	47	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16390	16397		10.1074/jbc.272.26.16390	http://dx.doi.org/10.1074/jbc.272.26.16390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195946	hybrid			2022-12-25	WOS:A1997XG01900050
J	Ossina, NK; Cannas, A; Powers, VC; Fitzpatrick, PA; Knight, JD; Gilbert, JR; Shekhtman, EM; Tomei, LD; Umansky, SR; Kiefer, MC				Ossina, NK; Cannas, A; Powers, VC; Fitzpatrick, PA; Knight, JD; Gilbert, JR; Shekhtman, EM; Tomei, LD; Umansky, SR; Kiefer, MC			Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; IN-VIVO; MOLECULAR-CLONING; BCL-2 HOMOLOG; DNA-DAMAGE; PROTEIN; FAMILY; FAS; REGULATORS	Interferon (IFN)-gamma increases the sensitivity of tumor cell lines, many of which are p53 mutants, to tumor necrosis factor-alpha-mediated and anti Fas antibody-mediated cell death. To better understand the mechanism of IFN-gamma action in modulating the cell death response independently of p53 function, we analyzed the death of the human colon adenocarcinoma cell line, HT-29, following treatment with IFN-gamma and various cytotoxic agents. Here we show that IFN-gamma modulates cell death by sensitizing the cells to killing by numerous pro-apoptotic stimuli but not pro-necrotic stimuli. Furthermore, we show that select genes from several important apoptosis-related gene families are induced by IFN-gamma, including the apoptosis-signaling receptors CD95 (Fas/APO-1) and TNFR 1 and interleukin-1 beta-converting enzyme (Ice) family members Ice, CPP32 (Yama, apopain), ICErel-II (TX, Ich-2), Mch-3 (ICE-LAP3, CMH-1), Mch-4, and Mch-5 (MACH, FLICE). Of the bcl-2 family members, IFN-gamma directly induced bah but notably not bar, which is activated by p53. The IFN-responsive transcriptional activator interferon regulatory factor-1 was also strongly induced and translocated into the nucleus following IFN-gamma treatment. We propose that IFN-gamma modulates a p53-independent apoptotic pathway by both directly and indirectly inducing select apoptosis-related genes.	LXR BIOTECHNOL INC,RICHMOND,CA 94804					Ossina, Natalya/0000-0002-0444-8174				BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALABRESI P, 1990, PHARMACOL BASIS THER, P1202; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, CANCER RES, V56, P2422; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lomo J, 1996, CANCER RES, V56, P40; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOMEI LD, 1991, APOPTOSIS MOL BASIS, P1; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; UMANSKY SR, 1982, J THEOR BIOL, V97, P591, DOI 10.1016/0022-5193(82)90360-5; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	58	249	257	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16351	16357		10.1074/jbc.272.26.16351	http://dx.doi.org/10.1074/jbc.272.26.16351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195941	hybrid			2022-12-25	WOS:A1997XG01900045
J	Chen, LC; Fitzpatrick, VD; Vandlen, RL; Tashjian, AH				Chen, LC; Fitzpatrick, VD; Vandlen, RL; Tashjian, AH			Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; AMP-INDEPENDENT ACTIONS; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; BRAIN; RAT; HORMONE; KIDNEY	To elucidate the signaling events mediated by specific somatostatin receptor (SSTR) subtypes, we expressed SSTR1 and SSTR2 individually in rat pituitary GH(1)2C(1) and F4C1 cells, which lack endogenous somatostatin receptors. In transfected GH(1)2C(1) cells, both SSTR1 and SSTR2 coupled to inhibition of Ca2+ influx and hyperpolarization of membrane potential via a pertussis toxin (PTx)-sensitive mechanism. These effects reflected modulation of ion channel activities which are important for regulation of hormone secretion. Somatostatin analogs MK678 and CH275 acted as subtype selective agonists as expected. In transfected F4C1 cells, both SSTR1 and SSTR2 mediated somatostatin-induced inhibition of adenylyl cyclase via a PTx-sensitive pathway. In addition, activation of SSTR2 in F4C1 cells, but not SSTR1, stimulated phospholipase C (PLC) activity and an increase in [Ca2+](i) due to release of Ca2+ from intracellular stores. Unlike adenylyl cyclase inhibition, the PLC-mediated response was only partially sensitive to PTx. To determine the structural determinants in SSTR2 necessary for activation of PLC, we constructed chimeric receptors in which domains of SSTR2 were introduced into SSTR1. Chimeric receptors containing only the third intracellular loop, or all three intracellular loops from SSTR2, mediated inhibition of adenylyl cyclase, but failed to stimulate PLC activity as did wild-type SSTR2. Furthermore, the C terminal tail of SSTR2 was not required for coupling to PLC. Thus, by expressing individual somatostatin receptor subtypes in pituitary cells, we have identified both overlapping and distinct signaling pathways for SSTR1 and SSTR2, and have shown that sequences other than simply the intracellular domains are required for SSTR2 to couple to the PLC signaling pathway.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Roche Holding; Genentech					NIDDK NIH HHS [DK11011] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHEN L, 1994, 76 ANN M END SOC, P589; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; FITZPATRICK VD, 1994, J BIOL CHEM, V269, P24621; FUJII Y, 1994, FEBS LETT, V355, P117, DOI 10.1016/0014-5793(94)01159-1; GARCIA PD, 1994, MOL PHARMACOL, V45, P402; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; KAUPMANN K, 1993, FEBS LETT, V331, P53, DOI 10.1016/0014-5793(93)80296-7; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOCH BD, 1988, J BIOL CHEM, V263, P216; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOSHIYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P551, DOI 10.1016/0006-291X(91)92019-G; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LI XJ, 1992, J BIOL CHEM, V267, P21307; Liapakis G, 1996, J PHARMACOL EXP THER, V276, P1089; LIU YF, 1994, J BIOL CHEM, V269, P13880; MARIN P, 1991, P NATL ACAD SCI USA, V88, P9016, DOI 10.1073/pnas.88.20.9016; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6473; STRADER CD, 1987, J BIOL CHEM, V262, P16439; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422	39	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18666	18672		10.1074/jbc.272.30.18666	http://dx.doi.org/10.1074/jbc.272.30.18666			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228036	hybrid			2022-12-25	WOS:A1997XM34200027
J	Gangarosa, LM; Sizemore, N; GravesDeal, R; Oldham, SM; Der, CJ; Coffey, RJ				Gangarosa, LM; Sizemore, N; GravesDeal, R; Oldham, SM; Der, CJ; Coffey, RJ			A Raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA TGF-ALPHA; ACTIVATION; PROTEIN; KINASE; RNA; HYBRIDIZATION; EXPRESSION	We recently have shown that activated Ras, but not Raf, causes transformation of intestinal (RIE-1, IEC-6) epithelial cells, whereas both activated Ras and Raf transform NIH 3T3 fibroblasts (Oldham, S. M., Clark, G. J., Gangarosa, L. M., Coffey, R. J., and Her, C. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6924-6928). The observations that conditioned medium from Ras-, but not Raf-, transfected RIE-1 cells, as well as exogenous transforming growth factor alpha (TGF alpha), promoted morphological transformation of parental RIE-1 cells prompted us to identify epidermal growth factor (EGF) receptor (EGFR) ligands produced by Ras-transformed RIE-1 cells responsible for this autocrine effect. Since studies in fibroblasts have shown that v-Src is transforming, we also determined if v-Src could transform RIE-1 cells. H- or K-Ras-transformed cells secreted significant amounts of TGF alpha protein, and mRNA transcripts for TGF alpha, amphiregulin (AR), and heparin-binding EGF-like growth factor (HB-EGF) were induced. Like Ras, v-Src caused morphological and growth transformation of parental RIE-1 cells. However, TGF alpha protein was not secreted by RIE-1 cells stably expressing v-Src or activated Raf, and only minor increases in EGFR ligand mRNA expression were detected in these cells. A selective EGFR tyrosine kinase inhibitor PD153035 attenuated the Ras-, but not Src-, transformed phenotype. Taken together, these observations provide a mechanistic and biochemical basis for the ability of activated Ras, but not activated Raf, to cause transformation of RIE-1 cells. Finally, we suggest that an EGFR dependent mechanism is necessary for Ras, but not Src, transformation of these intestinal epithelial cells.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37232; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA46413, CA55008, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413, R01CA042978, R01CA055008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BLAY J, 1985, BIOCHEM J, V225, P85, DOI 10.1042/bj2250085; BOS JL, 1989, CANCER RES, V49, P4682; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COFFEY RJ, 1988, CANCER RES, V48, P1596; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; DOBNER PR, 1981, P NATL ACAD SCI-BIOL, V78, P2230, DOI 10.1073/pnas.78.4.2230; FILMUS J, 1993, ONCOGENE, V8, P1017; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	29	99	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18926	18931		10.1074/jbc.272.30.18926	http://dx.doi.org/10.1074/jbc.272.30.18926			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228072	hybrid			2022-12-25	WOS:A1997XM34200063
J	Hayashi, Y; Kiyono, T; Fujita, M; Ishibashi, M				Hayashi, Y; Kiyono, T; Fujita, M; Ishibashi, M			cca1 is required for formation of growth-arrested confluent monolayer of rat 3Y1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL DISPLAY; MESSENGER-RNAS; VIRUS; RETROVIRUS; PROTEIN	A novel cDNA fragment, named cca1 (confluent 3Y1 cell-associated 1), was previously isolated on the basis of preferential accumulation of the corresponding mRNA in growth-arrested confluent but not in growing subconfluent rat 3Y1 cells, The cca1 cDNA was found to consist of 5022 nucleotides with an open reading frame of 1905 nucleotides, encoding a protein of 635 amino acids. Unlike the 3Y1 cell case, cca1 mRNA was not detected in confluent 3Y1 BU, 3Y1 BU/pTK, 3Y1-16E6, or F2408 cells, whose growth patterns monitored by phalloidin staining and bromodeoxyuridine incorporation were different from those of the confluent 3Y1. cells. A restoration of the confluent 3Y1-type growth pattern was observed in the cca1 cDNA-introduced 3Y1 BU and 3Y1 BU/pTK cells after reaching confluence but not in the cDNA-introduced 3Y1-16E6 or F2408 cells, The results allow us to conclude that cca1 is required but not sufficient for formation of growth-arrested confluent monolayer of 3Y1 cells.	AICHI CANC CTR,RES INST,LAB VIRAL ONCOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center			Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; FUJITA M, 1994, BLOOD, V84, P2591, DOI 10.1182/blood.V84.8.2591.bloodjournal8482591; Hayashi Y, 1997, BBA-GENE STRUCT EXPR, V1352, P145, DOI 10.1016/S0167-4781(97)00051-1; HEDBERG KM, 1995, EXP CELL RES, V219, P266, DOI 10.1006/excr.1995.1227; HIRAIWA A, 1993, VIROLOGY, V192, P102, DOI 10.1006/viro.1993.1012; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7	16	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18082	18086		10.1074/jbc.272.29.18082	http://dx.doi.org/10.1074/jbc.272.29.18082			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218439	hybrid			2022-12-25	WOS:A1997XL73500029
J	Hall, JA; Thorgeirsson, TE; Liu, J; Shin, YK; Nikaido, H				Hall, JA; Thorgeirsson, TE; Liu, J; Shin, YK; Nikaido, H			Two modes of ligand binding in maltose-binding protein of Escherichia coli - Electron paramagnetic resonance study of ligand-induced global conformational changes by site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-TRANSPORT; MEMBRANE; OVERPRODUCTION; SPECTROSCOPY; CHEMOTAXIS; RECEPTOR; MUTANTS; SYSTEM	Binding of ligands to the maltose-binding protein (MBP) of Escherichia coli often causes a global conformational change involving the closure of its two lobes. We have introduced a cysteine residue onto each of these lobes by site-directed mutagenesis and modified these residues with spin labels. Using EPR spectroscopy, we examined the changes, caused by the Ligand binding, in distance between the two spin labels, hence between the two lobes. The binding of both maltose and maltotetraose induced a considerable closure of the N- and C-terminal lobes of MBP, Little closure occurred upon the binding of maltotetraitol or beta-cyclodextrin. Previous study by fluorescence and UV differential absorbance spectroscopy (Ball, J. A., Gehring, K., and Nikaido, H. (1997) J. Biol. Chem. 272, 17605-17609) showed that maltose and a large portion of maltotetraose bound to MBP via one mode (R mode or ''end-on'' mode), which is physiologically active and leads to the subsequent transport of the ligands across the cytoplasmic membrane, in contrast, maltotetraitol and beta-cyclodextrin bound to MBP via a different mode (B mode or ''middle'' mode), which is physiologically inactive. The present work suggests that the B mode is nonproductive because ligands binding in this manner prevent the closure of the two domains of MBP, and, as a result, the resulting ligand-MBP complex is incapable of interacting properly with the inner membrane-associated transporter complex.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733; Thorgeirsson, Thorgeir/0000-0002-5149-7040	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009644, R01AI009644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051290, R01GM051290] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline; NIGMS NIH HHS [GM-51290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BETH AH, 1984, J BIOL CHEM, V259, P9717; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DUPLAY P, 1984, J BIOL CHEM, V259, P606; GEHRING K, 1992, FEBS LETT, V300, P33, DOI 10.1016/0014-5793(92)80159-E; GEHRING K, 1991, BIOCHEMISTRY-US, V30, P5524, DOI 10.1021/bi00236a027; Hall JA, 1997, J BIOL CHEM, V272, P17615, DOI 10.1074/jbc.272.28.17615; Hall JA, 1997, J BIOL CHEM, V272, P17605, DOI 10.1074/jbc.272.28.17605; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; MILLHAUSER GL, 1995, METHOD ENZYMOL, V246, P589; MILLHAUSER GL, 1992, TRENDS BIOCHEM SCI, V17, P448, DOI 10.1016/0968-0004(92)90486-S; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHARFF AJ, 1995, J MOL BIOL, V246, P8, DOI 10.1006/jmbi.1994.0059; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; ZUKIN RS, 1979, BIOCHEMISTRY-US, V18, P2139, DOI 10.1021/bi00578a001	24	58	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17610	17614		10.1074/jbc.272.28.17610	http://dx.doi.org/10.1074/jbc.272.28.17610			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211909	hybrid			2022-12-25	WOS:A1997XK16500052
J	Requena, JR; Ahmed, MU; Fountain, CW; Degenhardt, TP; Reddy, S; Perez, C; Lyons, TJ; Jenkins, AJ; Baynes, JW; Thorpe, SR				Requena, JR; Ahmed, MU; Fountain, CW; Degenhardt, TP; Reddy, S; Perez, C; Lyons, TJ; Jenkins, AJ; Baynes, JW; Thorpe, SR			Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; ADVANCED GLYCOSYLATION; LIPID-PEROXIDATION; COMPLICATIONS; INVIVO; PHOSPHATIDYLSERINE; ERYTHROCYTES; PROTEINS; STRESS	N-epsilon-(Carboxymethyl)lysine (CML) is a stable chemical modification of proteins formed from both carbohydrates and lipids during autoxidation reactions, We hypothesized that carboxymethyl lipids such as (carboxymethyl)phosphatidylethanolamine (carboxymethyl-PE) would also be formed in these reactions, and we therefore developed a gas chromatography-mass spectrometry assay for quantification of carboxymethylethanolamine (CME) following hydrolysis of phospholipids. In vitro, CME was formed during glycation of dioleoyl-PE under air and from linoleoylpalmitoyl-PE, but not from dioleoyl-PE, in the absence of glucose, In vivo, CME was detected in lipid extracts of red blood cell membranes, similar to 0.14 mmol of CME/mol of ethanolamine, from control and diabetic subjects, (n = 22, p > 0.5), Levels of CML in erythrocyte membrane proteins were similar to 0.2 mmol/mol of lysine for both control and diabetic subjects (p > 0.5), For this group of diabetic subjects there was no indication of increased oxidative modification of either lipid or protein components of red cell membranes, CME was also detected in fasting urine at 2-3 nmol/mg of creatinine in control and diabetic subjects (p = 0.085), CME inhibited detection of advanced glycation end product (AGE)-modified protein in a competitive enzyme-linked immunosorbent assay using an anti-AGE antibody previously shown to recognize CML, suggesting that carboxymethyl-PE may be a component of AGE lipids detected in AGE low density lipoprotein, Measurement of levels of CME in blood, tissues, and urine should be useful for assessing oxidative damage to membrane lipids during aging and in disease.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208; MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29245	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina				Lyons, Timothy/0000-0003-2106-1622; Jenkins, Alicia/0000-0003-0583-3717	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011472] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL55782] Funding Source: Medline; NIA NIH HHS [AG11472] Funding Source: Medline; NIDDK NIH HHS [DK19971] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BEISSWENGER PJ, 1993, J CLIN INVEST, V92, P2212; Beutler E., 1995, WILLIAMS HEMATOLOGY, P364; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; DYER DG, 1991, Z ERNAHRUNGSWISS, V30, P29, DOI 10.1007/BF01910730; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; JAIN SK, 1988, BIOCHIM BIOPHYS ACTA, V937, P205, DOI 10.1016/0005-2736(88)90242-8; JAIN SK, 1985, J CLIN INVEST, V76, P281, DOI 10.1172/JCI111958; JAIN SK, 1989, DIABETES, V38, P1539, DOI 10.2337/diabetes.38.12.1539; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; KUME S, 1995, AM J PATHOL, V147, P654; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; LYONS TJ, 1995, DIABETES CLIN SCI PR, P288; LYONS TJ, 1997, IN PRESS DIABETES RE; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MLAKAR A, 1994, BBA-LIPID LIPID MET, V1214, P209; MONNIER VM, 1989, MAILLARD REACTION AG, P1; PAMPLONA R, 1995, LIFE SCI, V57, P873, DOI 10.1016/0024-3205(95)02020-J; Ravandi A, 1996, FEBS LETT, V381, P77, DOI 10.1016/0014-5793(96)00064-6; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; VLASSARA H, 1994, J LAB CLIN MED, V124, P19; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027	32	80	83	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17473	17479		10.1074/jbc.272.28.17473	http://dx.doi.org/10.1074/jbc.272.28.17473			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211892	Green Published, hybrid			2022-12-25	WOS:A1997XK16500035
J	Flores, MVC; Atkins, D; Wade, D; OSullivan, WJ; Stewart, TS				Flores, MVC; Atkins, D; Wade, D; OSullivan, WJ; Stewart, TS			Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMMERHEAD RIBOZYMES; MESSENGER-RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES; CATALYTIC ACTIVITY; MALARIA PARASITES; CELLULAR UPTAKE; GENE-TRANSFER; IN-VITRO; SEQUENCE; STABILITY	Catalytic RNA (ribozymes) suppressed the growth of the human malarial parasite Plasmodium falciparum in vitro. The phosphorothioated hammerhead ribozymes targeted unique regions of the P. falciparum carbamoylphosphate synthetase II gene. The P. falciparum carbamoyl-phosphate synthetase II gene encodes the first and limiting enzyme in the pathway, and its mRNA transcript contains two large insert regions absent in other carbamoyl-phosphate synthetases, including that from humans, These inserts are ideal targets for nucleic acid therapy, Exogenous delivery of ribozymes to cultures reduced malarial viability up to 55% at 0.5 mu M ribozyme concentrations, which is significantly greater than control levels (5-15% reduction), suggesting a sequence-specific inhibition, This inhibition was shown to be stage-specific, with optimal inhibitions being detected after 24 h, coincident with maximal production of the carbamoyl-phosphate synthetase enzyme in the course of the life cycle of the parasite, A decrease in total carbamoyl-phosphate synthetase activity was observed only in cultures treated with the ribozymes. The task of developing alternative therapeutic agents against malaria is urgent due to the evolution of drug-resistant strains of P. falciparum, the most virulent of all human malarial parasites, Another critical issue to be addressed is the possibility of eliminating or reducing any systemic toxicity to the host, which can potentially be provided by nucleic acid therapy, This work is the first reported assessment of the ability of ribozymes as antimalarials. Ribozyme inhibition assays can also aid in identifying important antimalarial loci for chemotherapy The malarial parasite can, in turn, be a useful in vivo host to study the catalysis and function of new ribozyme designs.	JOHNSON & JOHNSON RES PROPRIETARY LTD,ST LEONARDS,NSW 2065,AUSTRALIA	Johnson & Johnson	Flores, MVC (corresponding author), UNIV NEW S WALES,SCH BIOCHEM & MOL GENET,SYDNEY,NSW 2052,AUSTRALIA.							Barker RH, 1996, P NATL ACAD SCI USA, V93, P514, DOI 10.1073/pnas.93.1.514; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; CLARK DL, 1994, MOL BIOCHEM PARASIT, V63, P129, DOI 10.1016/0166-6851(94)90015-9; COLLINS FH, 1995, ANNU REV ENTOMOL, V40, P195, DOI 10.1146/annurev.en.40.010195.001211; DAWSON PA, 1993, MOL BIOCHEM PARASIT, V60, P153, DOI 10.1016/0166-6851(93)90039-Z; Desjardins JP, 1996, J PHARMACOL EXP THER, V278, P1419; FLORES MV, 1991, INT J PARASITOL, V21, P605, DOI 10.1016/0020-7519(91)90067-H; FLORES MVC, 1994, MOL BIOCHEM PARASIT, V68, P315, DOI 10.1016/0166-6851(94)90176-7; FLORES MVC, 1997, IN PRESS PARASITOL R; Flory CM, 1996, P NATL ACAD SCI USA, V93, P754, DOI 10.1073/pnas.93.2.754; GERO AM, 1990, BLOOD CELLS, V16, P467; GERO AM, 1984, J PARASITOL, V70, P536, DOI 10.2307/3281402; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1994, J BIOL CHEM, V269, P2131; HENDRIKS EF, 1996, THESIS U NEW S WALES; HENDRY P, 1995, NUCLEIC ACIDS RES, V23, P3928, DOI 10.1093/nar/23.19.3928; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; KIEHNTOPF M, 1995, J MOL MED, V73, P65, DOI 10.1007/BF00270579; KOZARSKY PE, 1994, CURR OPIN INFECT DIS, V7, P701, DOI 10.1097/00001432-199412000-00014; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LEVIS JT, 1995, ANTISENSE RES DEV, V5, P251, DOI 10.1089/ard.1995.5.251; LI WB, 1991, MOL BIOCHEM PARASIT, V46, P229, DOI 10.1016/0166-6851(91)90047-A; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MAHIEU M, 1994, BLOOD, V84, P3758, DOI 10.1182/blood.V84.11.3758.bloodjournal84113758; MAKLER MT, 1993, AM J TROP MED HYG, V48, P205, DOI 10.4269/ajtmh.1993.48.205; MILLER N, 1994, PARASITOL TODAY, V10, P92, DOI 10.1016/0169-4758(94)90006-X; Perriman R, 1993, Antisense Res Dev, V3, P253; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; RAPAPORT E, 1992, P NATL ACAD SCI USA, V89, P8577, DOI 10.1073/pnas.89.18.8577; SARTORIUS C, 1991, PARASITOL TODAY, V7, P90, DOI 10.1016/0169-4758(91)90204-2; SARTORIUS C, 1991, NUCLEIC ACIDS RES, V19, P1613, DOI 10.1093/nar/19.7.1613; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; Stein CA, 1996, TRENDS BIOTECHNOL, V14, P147, DOI 10.1016/0167-7799(96)20006-X; SULLIVAN SM, 1994, J INVEST DERMATOL, V103, pS85, DOI 10.1038/jid.1994.15; TAO LF, 1995, ANTISENSE RES DEV, V5, P123, DOI 10.1089/ard.1995.5.123; TEMSAMANI J, 1994, ANTISENSE RES DEV, V4, P35, DOI 10.1089/ard.1994.4.35; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997	40	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16940	16945		10.1074/jbc.272.27.16940	http://dx.doi.org/10.1074/jbc.272.27.16940			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202005	hybrid			2022-12-25	WOS:A1997XH44600037
J	Hazen, SL; Gaut, JP; Hsu, FF; Crowley, JR; dAvignon, A; Heinecke, JW				Hazen, SL; Gaut, JP; Hsu, FF; Crowley, JR; dAvignon, A; Heinecke, JW			p-hydroxyphenylacetaldehyde, the major product of L-tyrosine oxidation by the myeloperoxidase-H2O2-chloride system of phagocytes, covalently modifies epsilon-amino groups of protein lysine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; HYPOCHLOROUS ACID; LIPID-PEROXIDATION; HUMAN-NEUTROPHILS; 6-AMINOQUINOLYL-N-HYDROXYSUCCINIMIDYL CARBAMATE; ATHEROSCLEROTIC LESIONS; APOLIPOPROTEIN-B; MACROPHAGES; DERIVATIZATION	Activated human phagocytes employ the myeloperoxidase-H2O2-Cl- system to convert L-tyrosine to p-hydroxyphenylacetaldehyde (pHA). We have explored the possibility that pHA covalently reacts with proteins to form Schiff base adducts, which may play a role in modifying targets at sites of inflammation, Because Schiff bases are labile to acid hydrolysis, prior to analysis the adducts were rendered stable by reduction with NaC-NBH3. Purified pHA reacted with N-alpha-acetyllysine, an analog of protein lysine residues. The reduced reaction product was identified as N-alpha-acetyl-N-epsilon-(2-(p-hydroxyphenyl)ethyl)lysine by H-1 NMR spectroscopy and mass spectrometry. The compound N-epsilon-(2-(p-hydroxyphenyl)ethyl)lysine (pHA-lysine) was likewise identified in acid hydrolysates of bovine serum albumin (BSA) that were first exposed to myeloperoxidase, H2O2, L-tyrosine, and Cl- and then reduced with NaCNBH3. Other halides (F-, Br-, I-) and the pseudohalide SCN- could not replace Cl- as a substrate in the myeloperoxidase-H2O2-L-tyrosine system. In the absence of the enzymatic system, pHA-lysine was detected in reduced reaction mixtures of BSA, L-tyrosine, and reagent HOCl. In contrast, pHA-lysine was undetectable when BSA was incubated with L-tyrosine and HOBr-, peroxynitrite, hydroxyl radical, or a variety of other peroxidases, indicating that the aldehyde-protein adduct was selectively produced by HOCl. Human neutrophils activated in the presence of tyrosine also modified BSA lysine residues, pHA-lysine formation required L-tyrosine and cell activation; it tvas inhibited by peroxidase inhibitors and catalase, implicating myeloperoxidase and H2O2 in the reaction pathway, pHA-lysine was detected in inflamed human tissues that were reduced, hydrolyzed, and then analyzed by mass spectrometry, indicating that the reaction of pHA with proteins may be of physiological importance. These observations raise the possibility that the identification of pHA-lysine in tissues will pinpoint targets where phagocytes inflict oxidative damage in vivo.	WASHINGTON UNIV, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT CHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Gaut, Joseph/ABD-4600-2021; Gaut, Joseph/ABB-3387-2020; Hazen, Stanley L/ABD-5845-2021	Hsu, Fong-Fu/0000-0001-5368-0183	NCRR NIH HHS [RR-05018, RR-00954] Funding Source: Medline; NIA NIH HHS [R01 AG12298] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agner K., 1972, STRUCTURE FUNCTION O, P329; AHMED MU, 1986, J BIOL CHEM, V261, P4889; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWNLEE M, 1991, ANNU REV MED, V42, P159, DOI 10.1146/annurev.me.42.020191.001111; Bucala R, 1992, Adv Pharmacol, V23, P1; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; DABBAGH AJ, 1995, J CLIN INVEST, V96, P1958, DOI 10.1172/JCI118242; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HORI H, 1994, J BIOL CHEM, V269, P8388; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LIEBER CS, 1994, ANN MED, V26, P325, DOI 10.3109/07853899409148346; LINDER M, 1992, NUTR BIOCH METABOLIS, P98; LIU HJ, 1994, J CHROMATOGR A, V670, P59; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RHODES J, 1995, NATURE, V377, P71, DOI 10.1038/377071a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SELL DR, 1989, J BIOL CHEM, V264, P21597; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; WEIL I, 1949, J AM CHEM SOC, V71, P1664, DOI 10.1021/ja01173a033; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	57	72	72	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16990	16998		10.1074/jbc.272.27.16990	http://dx.doi.org/10.1074/jbc.272.27.16990			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202012	hybrid			2022-12-25	WOS:A1997XH44600044
J	HerreraVelit, P; Knutson, KL; Reiner, NE				HerreraVelit, P; Knutson, KL; Reiner, NE			Phosphatidylinositol 3-kinase-dependent activation of protein kinase C-zeta in bacterial lipopolysaccharide-treated human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; CELLS; ISOFORM; 3-KINASE; ENDOTOXIN; RESPONSES; INHIBITOR; RECEPTOR; ISOZYME; ALPHA	The isoform identity of activated protein kinase C (PRC) and its regulation were investigated in bacterial lipopolysaccharide (LPS)-treated human monocytes. Resolution of detergent-soluble lysates prepared from LPS-treated, peripheral blood monocytes using Mono Q anion-exchange chromatography revealed two principal peaks of myelin basic protein kinase activity. Immunoblotting and immunoprecipitation with isoform-specific anti-PKC antibodies showed that the major and latest eluting peak is accounted for by PKC-zeta. In addition to primary monocytes, activation of PKC-zeta in response to LPS was also observed in the human promonocytic cell lines, U937 and THP-1. Consistent with its identity as PKC-zeta, the kinase did not depend upon the presence of lipids, Ca2+, or diacylglycerol for activity. In addition, the kinase phosphorylates peptide a and myelin basic protein with equal efficiency but phosphorylates Kemptide and protamine sulfate poorly. Translocation of PKC-zeta from the cytosolic to the particulate membrane fraction upon exposure of monocytes to LPS provided further evidence for activation of the kinase. Preincubation of monocytes with the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitors, wortmannin or LY294002, abrogated LPS-induced activation of PKC-zeta. Furthermore, activation of PKC-zeta failed to occur in U937 cells transfected with a dominant negative mutant Of the p85 subunit of PI 3-kinase, PKC-zeta activity was also observed to be enhanced in vitro by the addition of phosphatidylinositol 3,4,5P(3). These findings are consistent with a model in which PKC-zeta is activated downstream of PI 3-kinase in monocytes in response to LPS.	UNIV BRITISH COLUMBIA,FAC MED,DEPT MED,DIV INFECT DIS,VANCOUVER,BC V5Z 3J5,CANADA; UNIV BRITISH COLUMBIA,FAC MED,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V5Z 3J5,CANADA; UNIV BRITISH COLUMBIA,FAC SCI,VANCOUVER,BC V5Z 3J5,CANADA; VANCOUVER HOSP & HLTH SCI CTR,RES INST,VANCOUVER,BC V5Z 3J5,CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia				Herrera, Patricia/0000-0001-8754-9335				BAIER G, 1993, J BIOL CHEM, V268, P4997; BATLLE E, 1994, FEBS LETT, V344, P161, DOI 10.1016/0014-5793(94)00379-3; Boutin JA, 1996, J CHROMATOGR B, V684, P179, DOI 10.1016/0378-4347(95)00563-3; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Gomez J, 1997, J IMMUNOL, V158, P1516; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; KILEY SC, 1995, J CELL SCI, V108, P1003; KNUTSON KL, 1994, ENDOCRINOLOGY, V135, P881, DOI 10.1210/en.135.3.881; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; LIU MK, 1994, J IMMUNOL, V153, P2642; LOZANO J, 1994, J BIOL CHEM, V269, P19200; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHAPIRA L, 1994, J IMMUNOL, V153, P1818; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TOKER A, 1994, J BIOL CHEM, V269, P32358; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WATSON RWG, 1994, J LEUKOCYTE BIOL, V56, P95, DOI 10.1002/jlb.56.1.95; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZHOU GS, 1994, EXP CELL RES, V214, P1, DOI 10.1006/excr.1994.1227	32	120	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16445	16452		10.1074/jbc.272.26.16445	http://dx.doi.org/10.1074/jbc.272.26.16445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195953	hybrid			2022-12-25	WOS:A1997XG01900057
J	Wang, YP; Kuropatwinski, KK; White, DW; Hawley, TS; Hawley, RG; Tartaglia, LA; Baumann, H				Wang, YP; Kuropatwinski, KK; White, DW; Hawley, TS; Hawley, RG; Tartaglia, LA; Baumann, H			Leptin receptor action in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PLASMA-PROTEINS; RESPONSE ELEMENTS; INSULIN-RECEPTOR; CYTOKINE-RESPONSE; GROWTH-HORMONE; GENES; VIRUS; PHOSPHORYLATION; INTERLEUKIN-6; SUBSTRATE-1	Leptin, an adipocyte-secreted hormone, is one of the central regulators of body weight homeostasis. In humans and rodents, two major forms of leptin receptors (OB-R) are expressed. The short form (OB-R-S), considered to lack signaling capability, is detected in many organs. In contrast, OB-R long form (OB-R-L) predominates in the hypothalamus, but is also present at low levels in peripheral tissues. Transient transfection experiments have demonstrated that OB-R-L transduces an intracellular signaling similar to interleukin (IL)-6 type-cytokine receptors. To define the specificity by which OB-R induces genes and cooperates with signal transduction pathways utilized by other hormones and cytokines, rat and human hepatoma cell lines were generated which stably express human OB-R-L. Hepatoma cell lines selected for appreciable levels of OB-R-L mRNA display enhanced leptin binding and responded to leptin with an IL-6 receptor-like signaling that includes the activation of STAT proteins, induction of acute-phase plasma proteins, and synergism with IL-1 and tumor necrosis factor-alpha. A leptin-mediated recruitment of phosphatidylinositol 3-kinase to insulin receptor substrate-2 was also detected. However, no significant tyrosine phosphorylation of insulin receptor substrate-2 and modulation of the immediate cell response to insulin were observed. The data suggest that OB-R-L action in hepatic cells is equivalent to that of IL-6 receptor. However, leptin does not play a specific role in muting insulin action on hepatoma cells and therefore may not contribute to the diabetic symptoms associated with obesity.	ROSWELL PK CANC INST, DEPT MOL & CELLULAR BIOL, BUFFALO, NY 14263 USA; MILLENNIUM PHARMACEUT INC, CAMBRIDGE, MA 02139 USA; TORONTO HOSP, ONCOL GEN THERAPY PROGRAM, TORONTO, ON M5G 2M1, CANADA	Roswell Park Cancer Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University of Toronto; University Toronto Affiliates; University Health Network Toronto				Hawley, Robert/0000-0003-3512-5818	NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAUMANN H, 1993, J IMMUNOL, V151, P4248; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; BRECHNER T, 1991, MOL BIOL MED, V8, P267; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; HAWLEY RG, 1994, GENE THER, V1, P136; Hawley RG, 1996, P NATL ACAD SCI USA, V93, P10297, DOI 10.1073/pnas.93.19.10297; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Klein S, 1996, DIABETES, V45, P984, DOI 10.2337/diabetes.45.7.984; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; WHITE MF, 1994, J BIOL CHEM, V269, P1; Won K., 1993, ACUTE PHASE PROTEINS, P255; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	48	183	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16216	16223		10.1074/jbc.272.26.16216	http://dx.doi.org/10.1074/jbc.272.26.16216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195922	hybrid			2022-12-25	WOS:A1997XG01900026
J	White, KA; Kaltashov, IA; Cotter, RJ; Raetz, CRH				White, KA; Kaltashov, IA; Cotter, RJ; Raetz, CRH			A mono-functional 3-deoxy-D-manno-octulosonic acid (Kdo) transferase and a Kdo kinase in extracts of Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A MUTANTS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; LIPOPOLYSACCHARIDE BIOSYNTHESIS; BORDETELLA-PERTUSSIS; IDENTIFICATION; ENDOTOXINS; STRAIN; OLIGOSACCHARIDE	Lipopolysaccharide of Haemophilus influenzae contains a single 3-deoxy-D-manno-octulosonic acid (Kdo) residue, linked to the 6' position of lipid A. In Escherichia coli and related organisms, a Kdo disaccharide is attached to lipid A. In previous studies, we cloned the gene (kdtA) encoding the E. coli Kdo transferase and demonstrated that homogeneous preparations of KdtA polypeptide catalyzed the attachment of both Kdo groups to the precursor, lipid IVA. E. coli KdtA produced only traces of mono-glycosylated product. We now show that a single Kdo is transferred to lipid IVA in extracts of H. influenzae. The mono-functional Kdo transferase of H. influenzae is membrane-bound, and the reaction is dependent upon a CMP-Kdo-generating system, as in E. coli. The specific activity of Kdo transfer to lipid IVA is 0.5-1 nmol/min/mg in H. influenzae membranes. Utilizing solubilized H. influenzae membranes, milligram quantities of Kdo-lipid IVA were prepared for analysis. Matrix-assisted laser desorption/ionization mass spectrometry revealed a parent ion (M - H)(-) at m/z 1626.0, consistent with the addition of a single Kdo moiety. Like lipid IVA, Kdo-lipid IVA was an excellent substrate for the bi-functional Kdo transferase of E. coli. In membranes of H. influenzae, but not E. coli, Kdo-lipid IVA was further phosphorylated in the presence of ATP, yielding a mono-phosphorylated Kdo-lipid IVA with a parent ion (M - H)(-) at m/z 1703.9. The identification of the monofunctional H. influenzae Kdo transferase, which is encoded by a KdtA homologue that displays 50% identity to its E. coli counterpart, should facilitate the mechanistic dissection of more complex multi-functional Kdo transferases, like those of E. coli and Chlamydia trachomatis.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; JOHNS HOPKINS UNIV, DEPT PHARMACOL, MIDDLE ATLANTIC MASS SPECTROMETRY LAB, BALTIMORE, MD 21205 USA	Duke University; Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033967, R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33967, GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P18702; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BOCK K, 1994, EUR J BIOCHEM, V225, P1029, DOI 10.1111/j.1432-1033.1994.1029b.x; BRADE H, 1985, J BACTERIOL, V161, P795, DOI 10.1128/JB.161.2.795-798.1985; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAROFF M, 1987, CARBOHYD RES, V161, P4; CHABY R, 1975, EUR J BIOCHEM, V59, P277, DOI 10.1111/j.1432-1033.1975.tb02452.x; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; KUMADA H, 1995, J BACTERIOL, V177, P2098, DOI 10.1128/jb.177.8.2098-2106.1995; KUMADA H, 1993, CURR MICROBIOL, V26, P239, DOI 10.1007/BF01577383; LEDUR A, 1978, EUR J BIOCHEM, V84, P579, DOI 10.1111/j.1432-1033.1978.tb12201.x; LEE NG, 1995, J BIOL CHEM, V270, P27151, DOI 10.1074/jbc.270.45.27151; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Miller J.H., 1972, EXPT MOL GENETICS; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; RUAN M, 1990, J IMMUNOL, V145, P3379; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; ZAMZE SE, 1987, BIOCHEM J, V245, P583, DOI 10.1042/bj2450583; [No title captured]	40	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16555	16563		10.1074/jbc.272.26.16555	http://dx.doi.org/10.1074/jbc.272.26.16555			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195966	hybrid			2022-12-25	WOS:A1997XG01900070
J	Cheng, JQ; Altomare, DA; Klein, MA; Lee, WC; Kruh, GD; Lissy, NA; Testa, JR				Cheng, JQ; Altomare, DA; Klein, MA; Lee, WC; Kruh, GD; Lissy, NA; Testa, JR			Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis	ONCOGENE			English	Article						AKT2; transformation; cell cycle; serine/threonine kinase	PROTEIN-KINASE-B; SIGNAL-TRANSDUCTION; C-AKT; MOLECULAR-CLONING; V-AKT; PRODUCT; LOCALIZATION; CARCINOMAS; SUBFAMILY; DOMAINS	The AKT2 oncogene encodes a protein-serine/threonine kinase containing a pleckstrin homology domain characteristic of many signaling proteins. Recently, it was shown that AKT2 kinase activity can be induced by platelet-derived growth factor through phosphatidylinositol-3-OH kinase, suggesting that AKT2 may be an important signal mediator that contributes to the control of cell proliferation, We previously reported amplification and overexpression of AKT2 in human cancers, To investigate the transforming activity of AKT2, we used a retrovirus-based construct to express AKT2 in NIH3T3 cells. Overexpression of AKT2 was found to transform NIH3T3 cells, as determined by growth in soft agar and tumor formation in nude mice, The oncogenic activity of AKT2 was diminished by truncation of a 70-amino acid proline-rich region at the carboxyl-terminus. To facilitate the characterization of AKT2, we generated monoclonal and polyclonal antibodies against this protein. AKT2 was localized to the cytoplasm by cell fractionation experiments, immunocytochemistry, and immunofluorescence, Protein levels were more abundant in mitotic cells than in interphase cells. Western blot analysis of synchronized pancreatic cancer cells demonstrated that the expression level of AKT2 protein in mitotic cells is three to fivefold higher than in their interphase counterparts, A time-course study of phytohemagglutinin-stimulated lymphocytes revealed that AKT2 mRNA and AKT2 protein levels are highest 48-72h after addition of mitogen, when cells are actively dividing. These data suggest that AKT2 could play a significant role in cell cycle progression and that the oncogenic activity of overexpressed AKT2 may be mediated by aberrant regulation of cellular proliferation.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [R01 CA077429, P30 CA006927, CA-06927, CA 09035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arranz E, 1996, CANCER GENET CYTOGEN, V87, P1, DOI 10.1016/0165-4608(95)00230-8; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; RICHMAN DP, 1980, J CELL BIOL, V85, P459, DOI 10.1083/jcb.85.2.459; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SMITH DB, 1994, CURRENT PROTOCOLS MO; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; WILLINGHAM MC, 1990, FOCUS, V12, P62	32	129	142	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2793	2801		10.1038/sj.onc.1201121	http://dx.doi.org/10.1038/sj.onc.1201121			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190895				2022-12-25	WOS:A1997XD64300007
J	Fan, JG; Bertino, JR				Fan, JG; Bertino, JR			K-ras modulates the cell cycle via both positive and negative regulatory pathways	ONCOGENE			English	Article						ras; cell cycle; gene regulation	BREAST-CANCER CELLS; DNA-BINDING ACTIVITY; GENE-EXPRESSION; E2F FAMILY; IN-VIVO; S-PHASE; P53-REGULATED PROTEIN; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; TUMOR-SUPPRESSOR	The effect of activated human K-ras on cell cycle proteins was studied by use of a stable MCF-7 transfectant expressing inducible activated K-ras under the control of a tetracycline (Tet)-responsive promoter. Induction of activated K-ras by Tet withdrawal accelerated cell growth and entry into S-phase, To understand the mechanism(s) by which activated K-ras exerts its effect on the cell cycle, expression of both cell cycle stimulatory proteins as well as cell cycle inhibitors was examined. Upon induction of activated K-ras, several cell cycle stimulators were up-regulated, including cyclins A, D3, and E, and the E2F family of transcription factors, which was accompanied by increased cyclin A-associated kinase activity and E2F transcriptional activity, respectively. Up-regulation of cyclin A occurred at the transcriptional level and in a serum-dependent manner, Furthermore, induction of activated K-ras down-regulated p27(Kip1) and up-regulated p53. Up-regulation of p53 was correlated with enhanced p53 transactivation and accompanied by up-regulation of p21(Waf1) and Gadd 45, two p53 effecters and negative cell cycle regulators. In addition, activated K-ras upregulates bcl-2 but has no effect on bax or bcl-x expression. Taken together, these data indicate that activated K-ras affects the cell cycle by modulating both positive and negative cell cycle regulatory pathways.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA062948, P01CA047179] Funding Source: NIH RePORTER; NCI NIH HHS [CA62948-02, P01-CA-47179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrams SI, 1996, SEMIN ONCOL, V23, P118; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAE IS, 1995, CANCER RES, V55, P2387; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLUME E, 1993, J NATL CANCER I, V85, P1542, DOI 10.1093/jnci/85.19.1542; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCK V, 1995, ONCOGENE, V11, P31; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CASEY G, 1991, ONCOGENE, V6, P1791; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN J, 1997, IN PRESS BIOCH PHARM; Fan JG, 1997, ONCOGENE, V14, P1191, DOI 10.1038/sj.onc.1200940; FILMUS J, 1994, ONCOGENE, V9, P3627; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTARDIS MM, 1995, ENDOCRINOLOGY, V136, P5659, DOI 10.1210/en.136.12.5659; Gotz C, 1996, REV PHYSIOL BIOCH P, V127, P65, DOI 10.1007/BFb0048265; GRAHAM KA, 1986, BREAST CANCER RES TR, V8, P29, DOI 10.1007/BF01805922; HALDAR S, 1994, CANCER RES, V54, P2095; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON LF, 1994, J CELL BIOCHEM, V54, P387, DOI 10.1002/jcb.240540405; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY E, 1994, CARCINOGENESIS, V15, P845, DOI 10.1093/carcin/15.5.845; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mangues R, 1992, Semin Cancer Biol, V3, P229; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NEGRINI M, 1994, CANCER RES, V54, P1818; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAN BT, 1994, J BIOL CHEM, V269, P5968; PINES J, 1992, CIBA F SYMP, V170, P187; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINBERG RA, 1996, CELL, V85, P242; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Winston JT, 1996, ONCOGENE, V12, P127; WU CL, 1995, MOL CELL BIOL, V15, P2536; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; WU H, 1993, GENE DEV, V7, P1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YAMATO K, 1995, ONCOGENE, V11, P1; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	84	58	63	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2595	2607		10.1038/sj.onc.1201105	http://dx.doi.org/10.1038/sj.onc.1201105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191059				2022-12-25	WOS:A1997XA94900011
J	Ivan, M; Bond, JA; Prat, M; Comoglio, PM; WynfordThomas, D				Ivan, M; Bond, JA; Prat, M; Comoglio, PM; WynfordThomas, D			Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells	ONCOGENE			English	Article						met; ras; ret; thyroid; epithelium; paracrine	TYROSINE KINASE; HGF RECEPTOR; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; SCATTER FACTOR; DNA-SYNTHESIS; CANCER; OVEREXPRESSION; GENE; PROTOONCOGENE	Hepatocyte Growth Factor (HGF) receptor, encoded by the protooncogene c-met, is overexpressed in many human tumours, including those of thyroid epithelium. The absence in most cases of any primary structural abnormality of the met gene suggests that overexpression is secondary to mutation of other gene(s). To test this hypothesis we investigated the effect on met expression of two activated oncogenes known to play a major role in thyroid oncogenesis, ras and ret. To minimize the possibility of unknown co-operating events, we introduced these genes directly into normal human thyrocytes in primary culture using amphotropic retroviral vectors and assessed met expression as early as possible in the resulting epithelial colonies. Double immunofluorescence revealed expression of met protein, strictly localized to cells expressing the mutant ras and ret vectors, expression in background normal cells being barely detectable. In contrast, colonies induced to proliferate at a comparable rate by a vector expressing SV40 T showed no increase in met expression. To permit quantitation by Western blotting we also extended these findings to a thyroid cell line (R18) containing a zinc-inducible mutant ras gene. Induction of the oncogene led to a fourfold increase in met protein expression. We conclude that overexpression of met is induced by activation of the ras or ret signalling pathway and not simply by deregulation of the cell cycle per se. The data suggest that the proliferative advantage conferred by these oncogenes may be in part due to the resulting sensitization of tumour epithelium to paracrine HGF secreted by stromal cells.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES; UNIV TURIN,DEPT BIOMED SCI & ONCOL,SCH MED,TURIN,ITALY	Cardiff University; University of Turin			Ivan, Mircea/A-8109-2012	Ivan, Mircea/0000-0003-3424-6642; Comoglio, Paolo/0000-0002-7056-5328				BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; BOND JA, IN PRESS INT J CANC; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; DAWSON TP, 1995, CANCER RES, V55, P915; DAWSON TP, 1991, BRIT J CANCER, V63, P897, DOI 10.1038/bjc.1991.197; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Eccles N, 1996, MOL CELL ENDOCRINOL, V117, P247, DOI 10.1016/0303-7207(95)03757-8; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LIU C, 1992, ONCOGENE, V7, P181; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; NALDINI L, 1991, ONCOGENE, V6, P501; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCARPELLI DG, 1994, PATHOLOGY, P794; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; SUAREZ HG, 1990, ONCOGENE, V5, P565; Thomas G. A., 1995, Journal of Endocrinology, V144, pRC3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WILLIAMS DW, 1988, THYROID TUMOURS, P57; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115	44	136	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2417	2423		10.1038/sj.onc.1201083	http://dx.doi.org/10.1038/sj.onc.1201083			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188856				2022-12-25	WOS:A1997WZ68000005
J	Collins, RN; Brennwald, P; Garrett, M; Lauring, A; Novick, P				Collins, RN; Brennwald, P; Garrett, M; Lauring, A; Novick, P			Interactions of nucleotide release factor Dss4p with Sec4p in the post-Golgi secretory pathway of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; SITE-SPECIFIC MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; GDP/GTP EXCHANGE; ENDOPLASMIC-RETICULUM; PHENOTYPIC SELECTION; VESICULAR TRANSPORT; ACTIVATING PROTEIN; ESCHERICHIA-COLI	SEC4 is an essential gene encoding a small GTPase that is involved in Golgi to cell surface transport in Saccharomyces cerevisiae and is a paradigm for studies on the mode of action of Rab proteins. We describe]here the features of interaction of Sec4p with the accessory protein Dss4p, Dss4p is found both on membranes and in the cytosol; however, it is the membrane fraction that is complexed to Sec4p. Dss4p, like its mammalian counterpart, Mss4, binds zinc, and disruption of the zinc-binding site disrupts the ability of the protein to interact with Sec4p, DSS4 overexpression can rescue the lethal phenotype of two alleles of SEC4, corresponding to dominant mutations of Ras, We demonstrate that this suppression is due to the ability of Dss4p to form a tight complex with the mutant forms of Sec4p and hence sequester the mutant protein from its inhibitory effect. These results imply an in vivo role for Dss4p as a guanine nucleotide dissociation stimulator. In vitro the protein has the ability to stimulate the dissociation rate of both GDP and GTP from Sec4p. We examined the relationship of GDI1 and DSS4 with SEC4 both genetically and biochemically. These results exclude a role for DSS4 in the recruitment of Sec4p/GDI onto membranes.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA	Yale University					NCI NIH HHS [CA46128] Funding Source: Medline; NIGMS NIH HHS [GM35370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035370, R37GM035370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BoyMarcotte E, 1996, MOL BIOL CELL, V7, P529, DOI 10.1091/mbc.7.4.529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HWANG YW, 1989, ARCH BIOCHEM BIOPHYS, V274, P394, DOI 10.1016/0003-9861(89)90452-9; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JOHN J, 1993, J BIOL CHEM, V268, P923; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MIYAZAKI A, 1994, FEBS LETT, V350, P333, DOI 10.1016/0014-5793(94)00804-3; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NOVICK P, 1992, METHOD ENZYMOL, V219, P352; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROBERTS DM, 1995, METHOD ENZYMOL, V257, P84; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J, 1989, J SAMBROOK MOL CLONI; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANBOKHOVEN H, 1994, HUM MOL GENET, V3, P1047, DOI 10.1093/hmg/3.7.1047; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	55	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18281	18289		10.1074/jbc.272.29.18281	http://dx.doi.org/10.1074/jbc.272.29.18281			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218467	hybrid			2022-12-25	WOS:A1997XL73500057
J	Elwess, NL; Filoteo, AG; Enyedi, A; Penniston, JT				Elwess, NL; Filoteo, AG; Enyedi, A; Penniston, JT			Plasma membrane Ca2+ pump isoforms 2a and 2b are unusually responsive to calmodulin and Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; BINDING DOMAINS; CALCIUM-ATPASE; CA-2+ PUMP; CA2+-ATPASE; EXPRESSION; PRODUCTS; MUSCLE; ENZYME	The full-length a and b variants of the rat plasma membrane calcium pump, isoform 2 (rPMCA2a and rPMCA2b), were constructed and expressed in COS-7 cells, To characterize these isoforms, calcium transport was determined in a microsomal fraction, Both rPMCA2a and rPMCA2b had a much higher affinity for calmodulin than the corresponding forms of hPMCA4, and rPMCA2b had the highest affinity among the isoforms that have been tested so far, When analyzed at a relatively high calmodulin concentration, rPMCA2b and, to a lesser extent, rPRMCA2a showed higher apparent calcium affinity; i.e. they were more active at lower Ca2+ concentrations than hPMCA4b. This indicates that these two variants of rat isoform 2 will tend to maintain a lower free cytosolic Ca2+ level in cells where they are expressed, Both variants also showed a higher level of basal activity (in the complete absence of calmodulin) than hPMCA4b, a property which would reinforce their ability to maintain a low free cytosolic Ca2+ concentration, Experiments designed to determine the source of the higher apparent Ca2+ affinity of rPMCA2b showed that it came from the properties of the carboxyl terminus, rather than from any difference in the catalytic core.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; NATL INST HAEMATOL & IMMUNOL,H-1113 BUDAPEST,HUNGARY	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KHAN I, 1991, BIOCHEM J, V277, P345, DOI 10.1042/bj2770345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PENNISTON JT, 1994, CELL PHYSIOL BIOCHEM, V4, P148, DOI 10.1159/000154718; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; Verma AK, 1996, J BIOL CHEM, V271, P3714; VERMA AK, 1994, J BIOL CHEM, V269, P1687	22	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17981	17986		10.1074/jbc.272.29.17981	http://dx.doi.org/10.1074/jbc.272.29.17981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218424	hybrid			2022-12-25	WOS:A1997XL73500014
J	Pohl, M; Silvente-Poirot, S; Pisegna, JR; Tarasova, NI; Wank, SA				Pohl, M; Silvente-Poirot, S; Pisegna, JR; Tarasova, NI; Wank, SA			Ligand-induced internalization of cholecystokinin receptors - Demonstration of the importance of the carboxyl terminus for ligand-induced internalization of the rat cholecystokinin type B receptor but not the type a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; AGONIST-INDUCED INTERNALIZATION; SWISS 3T3 CELLS; G-PROTEIN; SIGNAL-TRANSDUCTION; INDUCED DESENSITIZATION; PHEROMONE RECEPTOR; SEQUESTRATION; ENDOCYTOSIS	Internalization of a variety of different heptahelical G protein-coupled receptors has been shown to be influenced by a number of different structural determinants of the receptors, including the carboxyl terminus. To investigate the role of the carboxyl terminus of cholecystokinin (CCK) receptors in receptor internalization, the rat wild type (WT) CCK-A receptor (WT CCKAR) and the rat WT CCK-B receptor (WT CCKBR) were truncated after amino acid residue 399 (CCKAR Tr399) and 408 (CCKBR Tr408), thereby deleting the carboxyl-terminal 45 and 44 residues, respectively. All WT and mutant CCK receptors were stably expressed in NIH/3T3 cells. Internalization of the CCKAR Tr399 was not significantly different from the WT CCKAR. In contrast, internalization of the CCKBR Tr408 was decreased to 26% compared with the WT CCKBR internalization of 92%. The mutation of all 10 serine and threonine residues (as potential phosphorylation sites) in the carboxyl terminus of the CCKBR to alanines (mutant CCKBR Delta SP/T) could account for the majority of this effect (39% internalization). All mutant receptors displayed similar ligand binding characteristics, G protein coupling, and signal transduction as their respective WT receptors, indicating that the carboxyl termini are not necessary for these processes. Thus, internalization of the CCKBR, unlike that of the CCKAR, depends on the carboxyl terminus of the receptor. These results suggest that, despite the high degree of homology between CCKAR and CCKBR, the structural determinants that mediate the interaction with the endocytic pathway reside in different regions of the receptors.	NIDDK, DIGEST DIS BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MOL ASPECTS DRUG DESIGN SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Poirot, Sandrine/D-5448-2017	Tarasova, Nadya/0000-0002-4949-0069; Silvente-Poirot, Sandrine/0000-0003-2245-9069	NIDDK NIH HHS [P30 DK041301] Funding Source: Medline; BLRD VA [I01 BX004560] Funding Source: Medline; RRD VA [I01 RX000194] Funding Source: Medline; VA [5I01RX000194-03] Funding Source: Federal RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA; RRD VA; VA(US Department of Veterans Affairs)		ABDELMOUMENE S, 1980, AM J PHYSIOL, V239, pG272, DOI 10.1152/ajpgi.1980.239.4.G272; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BODEN PR, 1988, NEUROPEPTIDES, V12, P95, DOI 10.1016/0143-4179(88)90037-6; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHERNER JA, 1989, AM J PHYSIOL, V256, pG837, DOI 10.1152/ajpgi.1989.256.5.G837; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CIVAN MM, 1993, AM J PHYSIOL, V265, pC1658, DOI 10.1152/ajpcell.1993.265.6.C1658; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GATES LK, 1993, AM J PHYSIOL, V264, pG840, DOI 10.1152/ajpgi.1993.264.5.G840; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Hermans E, 1996, MOL PHARMACOL, V49, P365; HERTEL C, 1990, J BIOL CHEM, V265, P17988; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MARC S, 1988, BIOCHEM J, V255, P705; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OZCELEBI F, 1995, J BIOL CHEM, V270, P3435, DOI 10.1074/jbc.270.7.3435; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tarasova NI, 1997, CELL TISSUE RES, V287, P325, DOI 10.1007/s004410050757; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; YANG J, 1995, MOL PHARMACOL, V48, P477; YU SS, 1993, J BIOL CHEM, V268, P337; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	44	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18179	18184		10.1074/jbc.272.29.18179	http://dx.doi.org/10.1074/jbc.272.29.18179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218453	Green Accepted, hybrid			2022-12-25	WOS:A1997XL73500043
J	Scholten, JD; Zimmerman, KK; Oxender, MG; Leonard, D; SeboltLeopold, J; Gowan, R; Hupe, DJ				Scholten, JD; Zimmerman, KK; Oxender, MG; Leonard, D; SeboltLeopold, J; Gowan, R; Hupe, DJ			Synergy between anions and farnesyldiphosphate competitive inhibitors of farnesyl:protein transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; FARNESYLTRANSFERASE; MECHANISM; BINDING; BRAIN	Investigation of the comparative activities of various inhibitors of farnesyl:protein transferase (FPTase) has led to the observation that the presence of phosphate or pyrophosphate ions in the assay buffer increases the potency of farnesyl diphosphate (FPP) competitive inhibitors, In addition to exploring the phenomenon of phosphate synergy, we report here the effects of various other ions including sulfate, bicarbonate, and chloride on the inhibitory ability of three FPP competitive compounds: Cbz-His-Tyr-Ser(OBn)TrpNH(2) (2), Cbz-His-Tyr(OPO42-)-Ser(OBn)TrpNH(2) (3), and alpha-hydroxyfarnesyl phosphonic acid (4), Detailed kinetic analysis of FPTase inhibition revealed a high degree of synergy for compound 2 and each of these ions, Phosphorylation of 2 to give 3 completely eliminated any ionic synergistic effect, Moreover, these ions have an antagonistic effect on the inhibitory potency of compound 4, The anions in the absence of inhibitor exhibit non-competitive: inhibition with respect to FPP, These results suggest that phosphate, pyrophosphate, bicarbonate, sulfate, and chloride ions may be binding at the active site of both free enzyme and product-bound enzyme with normal substrates, These bound complexes increase the potency of FPP competitive inhibitors and mimic an enzyme:product form of the enzyme, None of the anions studied here proved to be synergistic with respect to inhibition of geranylgeranyl transferase I, These findings provide insight into the mechanism of action of FPP competitive inhibitors for FPTase and point to enzymatic differences between FPTase and geranylgeranyl transferase I that may facilitate the design of more potent and specific inhibitors for these therapeutically relevant target enzymes.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT CHEM,ANN ARBOR,MI 48105	Pfizer	Scholten, JD (corresponding author), WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT BIOCHEM,ANN ARBOR,MI 48105, USA.							AMATRUDA TT, 1960, J CLIN ENDOCR METAB, V20, P339, DOI 10.1210/jcem-20-3-339; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BODANSKY M, 1984, PRACTICE PEPTIDE SYN; BUCHLI R, 1994, PEDIATR RES, V35, P431, DOI 10.1203/00006450-199404000-00009; DOLENCE JM, 1995, P NATL ACAD SCI USA, V92, P5008, DOI 10.1073/pnas.92.11.5008; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; JAMES WJ, 1992, BIOCHEMISTRY-US, V31, P6421; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LEFTHERIS K, 1994, BIOORG MED CHEM LETT, V4, P887, DOI 10.1016/S0960-894X(01)80257-2; LEONARD D, 1994, 107 ACS NAT M SAN DI; Leonard DM, 1997, J MED CHEM, V40, P192, DOI 10.1021/jm960602m; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; Scholten JD, 1996, BIOORGAN MED CHEM, V4, P1537, DOI 10.1016/0968-0896(96)00146-0; SEBOLTLEOPOLD J, 1994, 85 ANN M AACR TOR CA; SEGAL IH, 1975, ENZYME KINETICS BEHA, P493; SEIDEL HM, 1994, BIOCHEMISTRY-US, V33, P5641, DOI 10.1021/bi00184a037; SIESS EA, 1984, EUR J BIOCHEM, V141, P543, DOI 10.1111/j.1432-1033.1984.tb08227.x; SINGH SB, 1993, TETRAHEDRON, V49, P5917, DOI 10.1016/S0040-4020(01)87178-7; Stewart JM, 1984, SOLID PHASE PEPTIDE; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Wai J S, 1994, Bioorg Med Chem, V2, P939, DOI 10.1016/S0968-0896(00)82043-X	30	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18077	18081		10.1074/jbc.272.29.18077	http://dx.doi.org/10.1074/jbc.272.29.18077			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218438	hybrid			2022-12-25	WOS:A1997XL73500028
J	Yao, RJ; Yoshihara, M; Osada, H				Yao, RJ; Yoshihara, M; Osada, H			Specific activation of a c-Jun NH2-terminal kinase isoform and induction of neurite outgrowth in PC-12 cells by staurosporine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; PC12 CELLS; MAP KINASE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; HA-RAS; DIFFERENTIATION; RAF-1; RECEPTOR	Staurosporine, a protein kinase inhibitor, is known to mimic the effect of nerve growth factor (NGF) in promoting neurite outgrowth, To elucidate the mechanism by which staurosporine induces neurite outgrowth in PC-12 cells, we performed an in-gel kinase assay using myelin basic protein as a substrate, and found that staurosporine induced the activation of a kinase with an apparent molecular mass of 57 kDa, The dose of staurosporine required to activate this kinase was consistent with that required to induce neurite outgrowth, Interestingly, the staurosporine-activated kinase was immunoprecipitated by anti-c-Jun NH2-terminal kinase (JNK) isoforms antibody, but not by anti-JNK1-specific antibody or anti-ERK1 antibody, raising the possibility that this kinase is a novel JNK isoform, The substrate specificity of the kinase was distinct from those of osmotic shock-activated JNKs and NGF-activated ERK1, The kinase phosphorylates transcription factors including c-Jun, Elk-l, and ATF2, as well as myelin basic protein, suggesting that it plays a role in gene induction. Furthermore, staurosporine induced immediate-early genes including Nur77 and fos, but not jun. The activation of the staurosporine-activated kinase, as well as the induction of neurite outgrowth, did not require Res function, while Pas was required for the activation of ERKs and neurite outgrowth induced by NGF. Taken together, these results indicate staurosporine specifically activates a JNK isoform, which may contribute to biological activities including neurite outgrowth.	INST PHYS & CHEM RES,ANTIBIOT LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN			Osada, Hiroyuki/AAY-6254-2020					AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; FUKUDA M, 1995, ONCOGENE, V11, P239; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HASHIMOTO S, 1989, EXP CELL RES, V184, P351, DOI 10.1016/0014-4827(89)90334-0; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HIO M, 1993, GENE DEV, V7, P2135; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Sambrook J., 2002, MOL CLONING LAB MANU; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TISCHLER AS, 1990, J NEUROCHEM, V55, P1159, DOI 10.1111/j.1471-4159.1990.tb03120.x; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	45	84	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18261	18266		10.1074/jbc.272.29.18261	http://dx.doi.org/10.1074/jbc.272.29.18261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218464	hybrid			2022-12-25	WOS:A1997XL73500054
J	Feschenko, MS; Sweadner, KJ				Feschenko, MS; Sweadner, KJ			Phosphorylation of Na,K-ATPase by protein kinase C at Ser(18) occurs in intact cells but does not result in direct inhibition of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULE CELLS; NA+-K+-ATPASE; NA+,K+-ATPASE ACTIVITY; CATALYTIC SUBUNIT; ALPHA-SUBUNIT; STIMULATION; INSULIN; KIDNEY; SITE; IDENTIFICATION	Na,K-ATPase activity has been demonstrated to be regulated by a variety of hormones in different tissues. It is known to be directly phosphorylated on its alpha-subunit, but the functional effects of protein kinases remain controversial, We have developed a sensitive, antibody-based assay for detection of the level of phosphorylation of the alpha 1-isoform of rat Na,K-ATPase at the serine residue that is most readily phosphorylated by protein kinase C (PKC) in vitro, Ser(18), By stimulation of endogenous PKC and inhibition of phosphatase activity, it was possible to consistently obtain a very high stoichiometry of phosphorylation (close to 0.9) in several types of intact cells, This demonstrates the accessibility and competency of the site for endogenous phosphorylation. The cells used were derived from rat (NRK 52E, C6, L6, and primary cultures of cerebellar granule cells, representing epithelial cells, glia, muscle cells, and neurons). In the presence of the phosphatase inhibitor calyculin A, full phosphorylation was preserved during subsequent assays of enzyme activity in vitro. Assay of the hydrolysis of ATP in NRK and C6 cells, however, indicated that there was no significant effect of phosphorylation on the V-max of the Na,K-ATPase or on the apparent affinity for Na+, Any regulatory effect of PHC on sodium pump activity thus must be lost upon disruption or permeabilization of the cells and is not a direct consequence of enzyme alteration by covalent phosphorylation of Ser(18).	MASSACHUSETTS GEN HOSP, CTR NEUROSCI, LAB MEMBRANE BIOL, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27653] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; Beguin P, 1996, AM J PHYSIOL-CELL PH, V270, pC131, DOI 10.1152/ajpcell.1996.270.1.C131; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BERTORELLO AM, 1992, J CELL SCI, V101, P343; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BORGHINI I, 1994, P NATL ACAD SCI USA, V91, P6211, DOI 10.1073/pnas.91.13.6211; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FERAILLE E, 1994, AM J PHYSIOL, V267, pF55, DOI 10.1152/ajprenal.1994.267.1.F55; FERAILLE E, 1995, AM J PHYSIOL-CELL PH, V268, pC1277, DOI 10.1152/ajpcell.1995.268.5.C1277; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; Jorgensen P L, 1974, Methods Enzymol, V32, P277; LAVER W G, 1990, Methods (Orlando), V1, P70, DOI 10.1016/S1046-2023(05)80148-3; LI DL, 1995, AM J PHYSIOL-RENAL, V269, pF673, DOI 10.1152/ajprenal.1995.269.5.F673; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; Lopina O. D., 1995, Biophysical Journal, V68, pA308; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; Marcaida G, 1996, J NEUROCHEM, V66, P99; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MCKEE M, 1994, P NATL ACAD SCI USA, V91, P12056, DOI 10.1073/pnas.91.25.12056; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; Ominato M, 1996, J MEMBRANE BIOL, V152, P235, DOI 10.1007/s002329900101; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PENG LA, 1991, DEV BRAIN RES, V63, P1, DOI 10.1016/0165-3806(91)90061-M; SATOH T, 1993, AM J PHYSIOL, V265, pF399, DOI 10.1152/ajprenal.1993.265.3.F399; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3	41	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17726	17733		10.1074/jbc.272.28.17726	http://dx.doi.org/10.1074/jbc.272.28.17726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211924	hybrid			2022-12-25	WOS:A1997XK16500067
J	Glickman, JF; Pavlovich, JG; Reich, NO				Glickman, JF; Pavlovich, JG; Reich, NO			Peptide mapping of the murine DNA methyltransferase reveals a major phosphorylation site and the start of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA-CELLS; GENE PROMOTER; EXPRESSION; BINDING; PROTEIN; METHYLATION; SPECIFICITY; ACTIVATION; CDNA; (CYTOSINE-5-)-METHYLTRANSFERASE	The murine DNA methyltransferase catalyzes the transfer of methyl groups from S-adenosylmethionine to cytosines within d(CpG) dinucleotides. The enzyme is necessary for normal embryonic development and is implicated in a number of important processes, including the control of gene expression and cancer, Metabolic labeling and high pressure liquid chromatography-electrospray ionization-mass spectrometry (HPLC-ESI-MS) were performed on DNA methyltransferase purified from murine erythroleukemia cells, Serine 514 was identified as a major phosphorylation site that lies in a domain required for targeting of the enzyme to the replication foci, These results present a potential mechanism for the regulation of DNA methylation. HPLC-ESI-MS peptide mapping data demonstrated that the purified murine DNA methyltransferase protein contains the N-terminal regions predicted by the recently revised 5' gene sequences (Yoder, J. A., Yen, R.-W. C., Vertino, P. M., Bestor, T. H., and Baylin, S. B. (1996) J. Biol, Chem, 271, 31092-31097), The evidence suggests a start of translation at the first predicted methionine, with no alternate translational start sites, Our peptide mapping results provide a more detailed structural characterization of the DNA methyltransferase that will facilitate future structure/function studies.	UNIV CALIF SANTA BARBARA, PROGRAM BIOCHEM & MOL BIOL, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT CHEM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara			Glickman, Joseph/H-3021-2013	Glickman, Joseph/0000-0002-6706-4039				Aniello F, 1996, GENE, V178, P57, DOI 10.1016/0378-1119(96)00334-4; BENOIT G, 1994, BIOL REPROD, V50, P1312, DOI 10.1095/biolreprod50.6.1312; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; CAIAFA P, 1991, BIOCHIM BIOPHYS ACTA, V1090, P38, DOI 10.1016/0167-4781(91)90034-J; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; Glickman JF, 1997, BIOCHEM BIOPH RES CO, V230, P280, DOI 10.1006/bbrc.1996.5943; GLICKMAN JF, 1994, BIOCHEM BIOPH RES CO, V204, P1003, DOI 10.1006/bbrc.1994.2562; GREEN GR, 1993, J BIOL CHEM, V268, P11247; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; Kimura H, 1996, J BIOCHEM, V120, P1182; KREBS EG, 1975, BIOCH CARBOHYDRATES, P337; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI CCH, 1994, J BIOL CHEM, V269, P30089; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Nan XS, 1996, MOL CELL BIOL, V16, P414; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SUZUKI M, 1990, J BIOCHEM-TOKYO, V108, P356, DOI 10.1093/oxfordjournals.jbchem.a123206; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; TEUBNER B, 1995, J CELL PHYSIOL, V165, P284, DOI 10.1002/jcp.1041650209; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRASLER JM, 1992, NUCLEIC ACIDS RES, V20, P2541, DOI 10.1093/nar/20.10.2541; WILLIAMS KR, 1993, PRACTICAL GUIDE PROT, P45; XU GR, 1995, BIOCHEM BIOPH RES CO, V207, P544, DOI 10.1006/bbrc.1995.1222; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Zhang XY, 1996, FEBS LETT, V392, P179, DOI 10.1016/0014-5793(96)00810-1; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZUCKER KE, 1985, J CELL BIOCHEM, V29, P337, DOI 10.1002/jcb.240290407	41	53	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17851	17857		10.1074/jbc.272.28.17851	http://dx.doi.org/10.1074/jbc.272.28.17851			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211941	hybrid			2022-12-25	WOS:A1997XK16500084
J	Pepitoni, S; Wood, IC; Buckley, NJ				Pepitoni, S; Wood, IC; Buckley, NJ			Structure of the m1 muscarinic acetylcholine receptor gene and its promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; CHO-K1 CELLS; RAT; EXPRESSION; SUBTYPES; REGION; TRANSCRIPTION; SEQUENCE; CLONING; NEURONS	The mi receptor is one of five muscarinic receptors that mediate the metabotropic actions of acetylcholine in the nervous system where it is expressed predominantly in the telencephalon and autonomic ganglia, RNase protection, primer extension, and 5'-rapid amplification of cDNA ends analysis of a rat cosmid clone containing the entire mi gene demonstrated that the rat mi. gene consists of a single 657-base pairs (bp) noncoding exon separated by a 13.5-kilobase (kb) intron from a 2.54-kb coding exon that contains the entire open reading frame. The splice acceptor for the coding exon starting at -71 bp relative to the adenine of the initiating methionine. This genomic structure is similar to that of the m4 gene (Wood, I. C., Roopra, A., Harrington, C. A., and Buckley, N. J. (1995) J. Biol, Chem. 270, 30933-30940 and Wood, I, C., Roopra, A., and Buckley, N. J. (1996) J. Biol. Chem. 271, 14221-14225). Like the m4 gene, the mi promoter lacks TATA and CAAT consensus motifs, and the first exon and 5'-flanking region are not gc-rich, The 5'-flanking region also contains the consensus regulatory elements Sp-1, NZF-1, AP-I, AP-2, E-box, NF kappa B, and Oct-1, Unike the m4 promoter, there is no evidence of a RE1/NRSE silencer element in the mi promoter. Deletional analysis and transient transfection assays demonstrates that reporter constructs containing 0.9 kb of 5'-flanking sequence and the first exon are sufficient to drive cell-specific expression of reporter gene in IMR32 neuroblastoma cells while remaining silent in 3T3 fibrobasts.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,WELLCOME LAB MOL PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London			Wood, Ian/AAK-9423-2021; Buckley, Noel J/B-9675-2012	Wood, Ian/0000-0003-1886-2533; Buckley, Noel J/0000-0003-1152-0653	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOEM LJ, 1993, MOL BRAIN RES, V17, P194, DOI 10.1016/0169-328X(93)90002-7; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANN MR, 1987, MOL PHARMACOL, V32, P450; Brown D. A., 1995, MOL B INT U, P165; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; HASSALL CJS, 1993, NEUROSCIENCE, V56, P1041, DOI 10.1016/0306-4522(93)90149-A; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOYLE GW, 1994, J NEUROSCI, V14, P2455; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAMOUROUX A, 1993, J NEUROCHEM, V60, P364, DOI 10.1111/j.1471-4159.1993.tb05861.x; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; MARRION NV, 1989, BRIT J PHARMACOL, V98, P557, DOI 10.1111/j.1476-5381.1989.tb12630.x; Mieda M, 1996, J BIOL CHEM, V271, P5177; Mieda M, 1997, J BIOL CHEM, V272, P5854, DOI 10.1074/jbc.272.9.5854; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MURASAWA S, 1993, J BIOL CHEM, V268, P26996; MURASAWA S, 1995, J BIOL CHEM, V270, P20042, DOI 10.1074/jbc.270.34.20042; Parks CL, 1996, J BIOL CHEM, V271, P4417; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; ROSOFF ML, 1997, P NATL ACAD SCI USA, V93, P14889; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; Wood IC, 1995, J BIOL CHEM, V270, P30933, DOI 10.1074/jbc.270.52.30933; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221; Xu G, 1996, J BIOL CHEM, V271, P16008, DOI 10.1074/jbc.271.27.16008; ZHOU QY, 1992, J NEUROCHEM, V59, P1875, DOI 10.1111/j.1471-4159.1992.tb11023.x; ZHU QS, 1995, J NEUROSCI, V15, P4885	47	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17112	17117		10.1074/jbc.272.27.17112	http://dx.doi.org/10.1074/jbc.272.27.17112			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202029	hybrid			2022-12-25	WOS:A1997XH44600061
J	Suzuki, A; Shibata, N; Suzuki, M; Saitoh, F; Oyamada, H; Kobayashi, H; Suzuki, S; Okawa, Y				Suzuki, A; Shibata, N; Suzuki, M; Saitoh, F; Oyamada, H; Kobayashi, H; Suzuki, S; Okawa, Y			Characterization of beta-1,2-mannosyltransferase in Candida guilliermondii and its utilization in the synthesis of novel oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL MANNAN; YEAST GLYCOPROTEIN-BIOSYNTHESIS; ALBICANS NIH A-207; SACCHAROMYCES-CEREVISIAE; PATHOGENIC YEAST; OUTER CHAIN; SEROTYPE-A; OLIGOMANNOSYL RESIDUES; LINKED OLIGOSACCHARIDES; B-792 STRAIN	A particulate insoluble enzyme fraction containing mannosyltransferases from Candida guilliermondii IFO 10279 strain cells was obtained as the residue after extracting a 105,000 x g pellet of cell homogenate with 1% Triton X-100. Incubation of this fraction with a mannopentaose, Man alpha 1-->3(Man alpha 1-->6)Man alpha 1-->2Man alpha 1-->2Man, in the presence of GDP-mannose and Mn2+ ion at pH 6.0 save a third type of beta-1,2 linkage-containing mannohexaose, Man beta 1-->2Man alpha 1-->3(Man alpha 1-->6)Man alpha 1-->2Man alpha 1-->2Man, the structure of which was identified by means of a sequential NMR assignment. The results of a substrate specificity study indicated that the beta-1,2-mannosyltransferase requires a mannobiosyl unit, Man alpha 1-->3Man alpha 1-->, at the nonreducing terminal site. We synthesized novel oligosaccharides using substrates possessing a nonreducing terminal alpha-1,3-linked mannose unit prepared from various yeast mannans. Further incubation of the enzymatically synthesized oligosaccaride with the enzyme fraction gave the following structure, Man beta 1-->2Man beta 1-->2Man alpha 1-->3(Man alpha 1-->6)Man alpha 1-->2Man alpha 1-->2Man, which has been found to correspond to antigenic factor 9. Incubation of Candida albicans serotype B mannan with the enzyme fraction gave significantly transformed mannan, which contains the third type of beta-1,2-linked mannose units.			Suzuki, A (corresponding author), TOHOKU COLL PHARMACEUT SCI, DEPT HYG CHEM 2, AOBA KU, 4-4-1 KOMATSUSHIMA, SENDAI, MIYAGI 981, JAPAN.							BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; FAILLE C, 1990, INFECT IMMUN, V58, P3537, DOI 10.1128/IAI.58.11.3537-3544.1990; GAIKWAD SM, 1995, BBA-PROTEIN STRUCT M, V1250, P144, DOI 10.1016/0167-4838(95)00082-6; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HEARN VM, 1993, STRUCTURE ANTIGENS, P211; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HILL K, 1992, GENETICS, V130, P273; KARSON EM, 1978, J BIOL CHEM, V253, P6484; KOBAYASHI H, 1992, INFECT IMMUN, V60, P2106, DOI 10.1128/IAI.60.5.2106-2109.1992; Kobayashi H, 1996, FEBS LETT, V395, P109, DOI 10.1016/0014-5793(96)01013-7; KOBAYASHI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P662, DOI 10.1016/0003-9861(92)90739-J; KOBAYASHI H, 1994, INFECT IMMUN, V62, P615, DOI 10.1128/IAI.62.2.615-622.1994; KOBAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V272, P364, DOI 10.1016/0003-9861(89)90230-0; KOBAYASHI H, 1990, ARCH BIOCHEM BIOPHYS, V278, P195, DOI 10.1016/0003-9861(90)90248-W; LEHLE L, 1974, BIOCHIM BIOPHYS ACTA, V350, P225, DOI 10.1016/0005-2744(74)90220-4; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; LI RK, 1993, J BIOL CHEM, V268, P18293; Lussier M, 1996, J BIOL CHEM, V271, P11001, DOI 10.1074/jbc.271.18.11001; MALLET L, 1994, YEAST, V10, P819, DOI 10.1002/yea.320100612; MIYAKAWA Y, 1992, INFECT IMMUN, V60, P2493, DOI 10.1128/IAI.60.6.2493-2499.1992; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NISHIKAWA A, 1990, MICROBIOL IMMUNOL, V34, P825, DOI 10.1111/j.1348-0421.1990.tb01061.x; ROMERO PA, 1994, GLYCOBIOLOGY, V4, P135, DOI 10.1093/glycob/4.2.135; ROMERO PA, 1989, J BIOL CHEM, V264, P1946; SAITO K, 1993, EUR J BIOCHEM, V217, P677, DOI 10.1111/j.1432-1033.1993.tb18293.x; SANBLAS G, 1994, J MED VET MYCOL, V32, P321; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; Shibata N, 1996, ARCH BIOCHEM BIOPHYS, V336, P49, DOI 10.1006/abbi.1996.0531; SHIBATA N, 1993, ARCH BIOCHEM BIOPHYS, V302, P113, DOI 10.1006/abbi.1993.1188; SHIBATA N, 1992, BIOCHEMISTRY-US, V31, P5680, DOI 10.1021/bi00139a036; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; Shibata N, 1996, J BIOL CHEM, V271, P9259, DOI 10.1074/jbc.271.16.9259; SHIBATA N, 1993, EUR J BIOCHEM, V217, P1, DOI 10.1111/j.1432-1033.1993.tb18211.x; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; SHIBATA N, 1997, IN PRESS EUR J BIOCH; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUZUKI A, 1995, FEBS LETT, V373, P275, DOI 10.1016/0014-5793(95)01061-I; Suzuki A, 1996, EUR J BIOCHEM, V240, P37, DOI 10.1111/j.1432-1033.1996.0023h.x; SUZUKI S, 1991, FUNGAL CELL WALL IMM, P111; VEROSTEK MF, 1995, GLYCOBIOLOGY, V5, P671, DOI 10.1093/glycob/5.7.671; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; ZHANG W, 1981, J BIOL CHEM, V256, P73	48	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16822	16828		10.1074/jbc.272.27.16822	http://dx.doi.org/10.1074/jbc.272.27.16822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201988	hybrid			2022-12-25	WOS:A1997XH44600020
J	Wang, K; Peterson, PA; Karlsson, L				Wang, K; Peterson, PA; Karlsson, L			Decreased endosomal delivery of major histocompatibility complex class II-invariant chain complexes in dynamin-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; B-LYMPHOBLASTOID-CELLS; ENDOCYTIC PATHWAY; HLA-DR; ANTIGEN PRESENTATION; SURFACE EXPRESSION; PRESENTING CELLS; PLASMA-MEMBRANE; MOLECULES; COMPARTMENT	Major histocompatibility complex class II molecules are heterodimeric cell surface molecules which acquire antigenic peptides in the endosomal/lysosomal system. Invariant chain (Ii), a third chain which is associated with class II molecules intracellularly mediates the endosomal targeting, but it is debated whether class II molecules reach the endosomal system mainly from the trans-Golgi network or via the cell surface. Dynamin is a cytosolic GTPase which is necessary for the formation of clathrin-coated vesicles from the plasma membrane, but which is not required for vesicle formation from the trans-Golgi network. Here we have used HeLa cells expressing a dominant negative form of dynamin to show that inhibition of clathrin-mediated uptake from the plasma membrane leads to accumulation of transfected Ii-class II complexes at the cell surface, while delivery of such complexes to endosomes/lysosomes is decreased. Our data therefore suggest that in this experimental system the majority of Ii-class II complexes traverse the cell surface before they reach the endosomal system.	RW JOHNSON PHARMACEUT RES INST,SAN DIEGO,CA 92121	Johnson & Johnson; Johnson & Johnson USA								AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BARNES KA, 1995, J EXP MED, V181, P1715, DOI 10.1084/jem.181.5.1715; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LINDSTEDT R, 1995, IMMUNITY, V3, P561, DOI 10.1016/1074-7613(95)90127-2; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; Takaesu NT, 1997, J IMMUNOL, V158, P187; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warmerdam PAM, 1996, J CELL BIOL, V133, P281, DOI 10.1083/jcb.133.2.281; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	43	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17055	17060		10.1074/jbc.272.27.17055	http://dx.doi.org/10.1074/jbc.272.27.17055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202021	hybrid			2022-12-25	WOS:A1997XH44600053
J	Bailly, S; Brand, C; Chambaz, EM; Feige, JJ				Bailly, S; Brand, C; Chambaz, EM; Feige, JJ			Analysis of small latent transforming growth factor-beta complex formation and dissociation by surface plasmon resonance - Absence of direct interaction with thrombospondins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE; CONDITIONED MEDIUM; ENDOTHELIAL-CELLS; FACTOR-BETA-1; ACTIVATION; BINDING; IDENTIFICATION; REQUIREMENT; MECHANISM; RECEPTOR	Transforming growth factor-beta (TGF beta) is a pluripotent regulator of cell growth and differentiation. The growth factor is expressed as a latent complex that must be converted to an active form before interacting with its ubiquitous high affinity receptors. This conversion involves the release of the mature TGF beta through disruption of the noncovalent interactions with its propeptide or latency associated protein (LAP). Complex formation or dissociation between LAP and TGF beta plays a very important role in TGF beta biological activity at different steps. To further characterize the kinetic parameters of this interaction, we have employed surface plasmon resonance biosensor methodology. Using this technique, we observed real time association of LAP with mature TGF beta 1. The complex formation showed an equilibrium K-d around 3-7 nM. Furthermore, we observed dissociation of the complex in the presence of extreme pH, chaotropic agents, or plasmin, confirming their effects on TGF beta activation, The same approach was used to examine whether latent TGF beta 1 could interact with thrombospondins, previously described as activators of latent TGF beta. Using this method, we could not detect any direct interaction of thrombospondins with either LAP alone, TGF beta 1 alone, or the small latent TGF beta 1 complex. This suggests that activation of latent TGF beta 1 complex by thrombospondins is through an indirect mechanism.			Bailly, S (corresponding author), CEA GRENOBLE,DBMS,BRCE,INSERM,U244,17 RUE MARTYRS,F-38054 GRENOBLE 9,FRANCE.		bailly, sabine/G-3540-2013; Feige, Jean-Jacques/M-8905-2017	bailly, sabine/0000-0003-1043-7030; Feige, Jean-Jacques/0000-0002-1354-7692				ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; LAWLER J, 1982, J BIOL CHEM, V257, P2257; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; PELLERIN S, 1993, J BIOL CHEM, V268, P18810; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; SOUCHELNITSKIY S, 1995, ENDOCRINOLOGY, V136, P5118, DOI 10.1210/en.136.11.5118; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932	27	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16329	16334		10.1074/jbc.272.26.16329	http://dx.doi.org/10.1074/jbc.272.26.16329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195938	hybrid			2022-12-25	WOS:A1997XG01900042
J	Nakagawa, H; Inomoto, T; Rustgi, AK				Nakagawa, H; Inomoto, T; Rustgi, AK			A CACCC box-like cis-regulatory element of the Epstein-Barr virus ED-LS promoter interacts with a novel transcriptional factor in tissue-specific squamous epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATINOCYTE-SPECIFIC TRANSCRIPTION; BETA-GLOBIN PROMOTER; BINDING-PROTEINS; NUCLEAR PROTEINS; TRANSGENIC MICE; GENE-EXPRESSION; SV40 ENHANCER; CELLS; DIFFERENTIATION; DNA	The Epstein-Barr (EBV) virus induces a lytic state after infecting epithelial cells. Subsequently, there is infection of B lymphocytes with two types of cycles, latent and lytic. Apart from linkage of the EBV latent membrane protein-1 (LMP-1) with benign and malignant conditions of squamous epithelial cells, little is known about other EBV gene products that may be important in these processes as well as cellular transcriptional factors that regulate EBV gene expression in these epithelial cells. The EBV ED-L2 promoter, an early lytic cycle promoter, is located upstream of a transcription start site for a short open reading frame designated BNLF2 and just downstream of the BNLF1 (LMP-1) open reading frame. We have previously used the EBV ED-L2 promoter to target oncogenes in transgenic mice, resulting in tissue-specific expression in the tongue, esophagus, forestomach, and skin, all sharing stratifying squamous epithelia, alternatively called keratinocytes. In the present study, we have functionally dissected the ED-L2 promoter by making deletion constructs fused to the luciferase reporter gene with transient transfections into squamous and nonsquamous epithelial cell lines as well as B lymphocytes. A CACCC box-like cis-regulatory element has been identified that is located between -218 and -187 base pairs of the ED-L2 promoter that confers significant promoter activity only in squamous epithelial cells. This cis-regulatory element is active in a heterologous minimal herpes simplex virus thymidine kinase promoter reporter gene construct when transfected into squamous epithelial cells but not in nonsquamous epithelial cells. DNA gel mobility shift assays have led to the identification of DNA-protein complexes that bind the CACCC box-like element. One of these proteins is a novel transcriptional factor that is uniquely active in stratified squamous epithelial cells, designated as keratinocyte specific factor (KSF). KSF may be related to Sp1 but appears to be distinct from Sp1. In addition, KSF may interact with related or identical cis-regulatory elements found in human papillomavirus-11 E6 and cytokeratin K3 promoters that are active in keratinocytes. In aggregate, KSF may be important in the transcriptional regulation of viral and eukaryotic genes in keratinocytes.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NIDDK NIH HHS [DK40561, DK43351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK040561] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHUNG DC, 1995, J BIOL CHEM, V270, P8829, DOI 10.1074/jbc.270.15.8829; COHEN JI, 1993, ANN INTERN MED, V118, P45; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; Jenkins TD, 1996, ONCOGENE, V13, P1809; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kieff E, 1996, VIROLOGY, P2343; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RAABTRAUB N, 1983, J VIROL, V48, P580, DOI 10.1128/JVI.48.3.580-590.1983; RHEINWALD JG, 1981, CANCER RES, V41, P1657; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TSENG H, 1992, P NATL ACAD SCI USA, V89, P10311, DOI 10.1073/pnas.89.21.10311; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WU RL, 1994, J BIOL CHEM, V269, P28450; WU RL, 1993, J CELL SCI, V105, P303; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794	40	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16688	16699		10.1074/jbc.272.26.16688	http://dx.doi.org/10.1074/jbc.272.26.16688			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195985	hybrid			2022-12-25	WOS:A1997XG01900089
J	Szaszi, K; Buday, L; Kapus, A				Szaszi, K; Buday, L; Kapus, A			Shrinkage-induced protein tyrosine phosphorylation in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; C-JUN; TRANSPORT PATHWAYS; VOLUME REGULATION; ACTIVATION; EXCHANGE; STRESS; YEAST; GRB2	To investigate the signal transduction of osmotic stress, we examined hypertonicity-induced tyrosine phosphorylations in Chinese hamster ovary cells. Hyperosmosis elicited characteristic phosphotyrosine accumulation in at least 3 proteins (approximate to 42, approximate to 85, and approximate to 120 kDa). The most prominent response occurred in the 85-kDa band (p85) whose phosphorylation was rapid, sustained, apparent already at mild hypertonicity (350 mosM), proportional to the extracellular osmotic concentration, and reversible. Hyperosmotic environment could not induce tyrosine phosphorylation if cell shrinkage was prevented by nystatin and appropriately composed media. Conversely, isotonic shrinkage caused strong tyrosine phosphorylation. Thus, the initial signal is a decrease in cell volume and not an increase in the intra- or extracellular osmotic concentration, or a rise in cytosolic K+ and Cl- levels. Tyrosine phosphorylation of p85 was not due to the hypertonicity-induced protein kinase C-dependent stimulation of the extracellular signal-regulated protein kinase, nor to the activation of stress-activated protein kinases. Tonicity-responsive proteins interacted with Grb2-glutathione S-transferase fusion proteins: the 120-kDa protein complexed with the SH2 and both SH3 domains, whereas p85 associated with the SH2 and the N-terminal SH3 domains of the adapter. Tyrosine phosphorylation of p85 is a sensitive indicator of reduced intracellular hydration and might signify a hitherto unrecognized, early volume-dependent signaling event.	SEMMELWEIS UNIV MED,DEPT PHYSIOL,H-1444 BUDAPEST 8,HUNGARY; SEMMELWEIS UNIV MED,LAB CELLULAR & MOL PHYSIOL,H-1444 BUDAPEST 8,HUNGARY; SEMMELWEIS UNIV MED,DEPT MED CHEM MOL BIOL & PATHOBIOCHEM,H-1444 BUDAPEST 8,HUNGARY	Semmelweis University; Semmelweis University; Semmelweis University			Szaszi, Katalin/J-7522-2012	Szaszi, Katalin/0000-0002-2490-8422				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; ALLESSI DR, 1995, J BIOL CHEM, V270, P27489; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; BREITWIESER GE, 1990, AM J PHYSIOL, V258, pC749, DOI 10.1152/ajpcell.1990.258.4.C749; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GARGOVA GZ, 1994, SCIENCE, V265, P806; GARNER MM, 1994, AM J PHYSIOL, V266, pC877, DOI 10.1152/ajpcell.1994.266.4.C877; GOOD DW, 1995, J BIOL CHEM, V270, P9883, DOI 10.1074/jbc.270.17.9883; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; HAAS M, 1995, J BIOL CHEM, V270, P28955, DOI 10.1074/jbc.270.48.28955; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; Haussinger D, 1996, BIOCHEM J, V313, P697; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; IKEHARA T, 1986, J MEMBRANE BIOL, V90, P231; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANIUS RA, 1993, MOL BRAIN RES, V20, P192, DOI 10.1016/0169-328X(93)90041-M; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; OCONNELL ME, 1995, AM J PHYSIOL, V269, pC1513; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAJENDRAN VM, 1995, J BIOL CHEM, V270, P11051, DOI 10.1074/jbc.270.19.11051; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Rottenberg H, 1979, Methods Enzymol, V55, P547; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TREHARNE KJ, 1994, AM J PHYSIOL-LUNG C, V267, pL592, DOI 10.1152/ajplung.1994.267.5.L592; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	57	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16670	16678		10.1074/jbc.272.26.16670	http://dx.doi.org/10.1074/jbc.272.26.16670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195983	hybrid			2022-12-25	WOS:A1997XG01900087
J	Jackson, JH; Vollenweider, M; Hill, J; Rodriguez, H; Schwabacher, AW; Mitra, G; Kuo, CY				Jackson, JH; Vollenweider, M; Hill, J; Rodriguez, H; Schwabacher, AW; Mitra, G; Kuo, CY			Stimulated human leukocytes cause activating mutations in the K-ras protooncogene	ONCOGENE			English	Article						inflammation; carcinogenesis; oxidants; DNA damage; K-ras	POLYMERASE CHAIN-REACTION; SITE-SPECIFIC MUTAGENESIS; C-HA-RAS; MAMMALIAN-CELLS; TUMOR PROMOTER; DNA TEMPLATES; POLYMORPHONUCLEAR LEUKOCYTES; IONIZING-RADIATION; ULCERATIVE-COLITIS; OXIDATIVE DAMAGE	Human tissues which are chronically infiltrated with inflammatory leukocytes are more likely to develop malignancies than non-inflamed tissues, however the mechanism(s) by which leukocytes contribute to carcinogenesis is unknown. Stimulated human leukocytes release superoxide anion and hydrogen peroxide which, in the presence of iron, can be converted into the potent oxidant, hgdroxyl radical (. OH). Previous studies have shown that leukocyte-derived . OH (or a . OH-Like species) can cause DIVA damage, however a relationship between leukocyte-induced DNA damage and carcinogenesis has not been established. The present report demonstrates that leukocyte-derived . OH-induced DNA damage can cause K-ras oncogene activation, and suggests that there may be a characteristic pattern of . OH-induced k-ras oncogene activation. Since activation of the k-ras oncogene is believed to play a crucial role in the pathogenesis of many human malignancies . OH induced K-ras oncogene activation could be an important mechanism by which human leukocytes contribute to carcinogenesis.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PROMEGA CORP, MADISON, WI 53711 USA	Princeton University; Promega Corporation	Jackson, JH (corresponding author), Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, BOX 1MM 12, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA-54298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BERKOW RL, 1983, J LAB CLIN MED, V102, P732; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; BOS JL, 1989, CANCER RES, V49, P4682; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHENG KC, 1992, J BIOL CHEM, V267, P166; DEVROEDE GJ, 1971, NEW ENGL J MED, V285, P17, DOI 10.1056/NEJM197107012850103; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FRENKEL K, 1986, CANCER RES, V46, P5533; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREENSTEIN AJ, 1979, GASTROENTEROLOGY, V77, P290; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1989, J CLIN INVEST, V84, P1644, DOI 10.1172/JCI114342; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAMIYA H, 1992, CANCER RES, V52, P3483; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LEWIS JG, 1985, CANCER RES, V45, P1270; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NASSICALO L, 1989, CARCINOGENESIS, V10, P1055, DOI 10.1093/carcin/10.6.1055; ORITA S, 1991, VIRUS GENES, V5, P75, DOI 10.1007/BF00571733; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; WEITZMAN SA, 1990, BLOOD, V76, P655; WEITZMAN SA, 1982, J IMMUNOL, V128, P2770; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; ZIMMERMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P2085, DOI 10.1073/pnas.81.7.2085	47	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2803	2808		10.1038/sj.onc.1201118	http://dx.doi.org/10.1038/sj.onc.1201118			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190896				2022-12-25	WOS:A1997XD64300008
J	Reddy, TR; Tang, HL; Li, XQ; WongStaal, F				Reddy, TR; Tang, HL; Li, XQ; WongStaal, F			Functional interaction of the HTLV-1 transactivator Tax with activating transcription factor-4 (ATF4)	ONCOGENE			English	Article						human T-cell leukemia virus-1; Tax; ATF-4; transactivation	VIRUS TYPE-I; LONG TERMINAL REPEAT; NF-KAPPA-B; DNA-BINDING PROTEINS; RESPONSIVE ELEMENT; GENE; ENHANCER; IDENTIFICATION; TRANSFORMATION; LYMPHOCYTES	The Tax protein of the Human T-cell Leukemia Virus (HTLV) activates the expression of viral mRNA through a three 21 bp repeat enhancer located within the HTLV-1 LTR, Since Tax does not bind to the 21bp DNA repeats directly, it has been speculated that Tax interacts with cellular protein(s) which mediate binding to the enhancer, We employed the yeast two hybrid system to identify host proteins that are potentially relevant to Tax transactivation. We identified a Tax binding protein encoded from a cDNA expression library derived from peripheral blood lymphocytes. The corresponding cDNA has sequence identity with a known transcription factor, activating factor-4 (ATF-4). ATF-4 also binds to GST-Tax fusion protein in vitro. Tax mutants that did not transactivate the HTLV-1 LTR also failed to bind ATF-4. The critical domain for Tax binding resides in a 85 amino acid stretch in the C-terminus of ATF-4, which contains the basic domain and leucine zipper, We further demonstrated that both full length and N-terminal truncated ATF-4 were able to enhance Tax transactivation, Thus, ATF-4 may act as an adapter between Tax and the TRE (Tax responsive element), and play an important role in Tax-mediated transactivation.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Tang, Hengli/F-2085-2014		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R01AI031378] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [P30-AI36214-03, R01 AI31378] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P, 1991, NEW BIOL, V2, P1034; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REDDY TR, 1995, AIDS RES HUM RETROV, V11, P663, DOI 10.1089/aid.1995.11.663; SEEMES OJ, 1992, J VIROL, V66, P7183; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V226, P177; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, ONCOGENE, V8, P2391; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	37	60	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2785	2792		10.1038/sj.onc.1201119	http://dx.doi.org/10.1038/sj.onc.1201119			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190894				2022-12-25	WOS:A1997XD64300006
J	Briggs, SD; Sharkey, M; Stevenson, M; Smithgall, TE				Briggs, SD; Sharkey, M; Stevenson, M; Smithgall, TE			SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC ACTIVITY; FC-GAMMA-RI; SH3 DOMAIN; FUNCTIONAL ASSOCIATION; HIGH-AFFINITY; GENE HCK; RECEPTOR; BINDING; CELLS; MACROPHAGES	Tyrosine kinases of the Src family are regulated via their Src homology 2 (SH2) and SH3 domains. The Nef protein of human immunodeficiency virus-1 (HIV-1) has previously been shown to bind with high affinity and specificity in vitro to the SH3 domain of Hck, a Src family member expressed primarily in myeloid cells. However, the effect of Nef on Hck activity in living cells is unknown. Here we show that Rat-2 fibroblasts coexpressing Hck and Nef rapidly developed transformed foci, whereas control cells expressing either protein alone did not. Nef formed a stable complex with Hck and stimulated its tyrosine kinase activity in vivo. Mutagenesis of the Nef proline-rich motif essential for SH3 binding completely blocked complex formation, kinase activation, and transformation, indicating that the Nef SH3-binding function is required for its effects on Hck, These results provide direct evidence that SH3 engagement is sufficient to activate a Src family kinase in vivo and suggest that Hck may be activated by Nef in HIV-infected macrophages.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68198 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, WORCESTER, MA 01605 USA	University of Nebraska System; University of Nebraska Medical Center; University of Massachusetts System; University of Massachusetts Worcester				Briggs, Scott D/0000-0003-2852-3594	NCI NIH HHS [CA58667] Funding Source: Medline; NIAID NIH HHS [AI 32890, AI 39812] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; Balter M, 1996, SCIENCE, V274, P1464, DOI 10.1126/science.274.5292.1464; BOULET I, 1992, ONCOGENE, V7, P703; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FULTZ PN, 1991, J VIROL, V65, P4902, DOI 10.1128/JVI.65.9.4902-4909.1991; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; Myers G, 1994, HUMAN RETROVIRUSES A; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1993, J BIOL CHEM, V268, P18070; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stevenson M, 1996, NAT STRUCT BIOL, V3, P303, DOI 10.1038/nsb0496-303; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	43	177	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17899	17902		10.1074/jbc.272.29.17899	http://dx.doi.org/10.1074/jbc.272.29.17899			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218412	hybrid			2022-12-25	WOS:A1997XL73500002
J	Jordan, SW; Cronan, JE				Jordan, SW; Cronan, JE			A new metabolic link - The acyl carrier protein of lipid synthesis donates lipoic acid to the pyruvate dehydrogenase complex in Escherichia coli and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; NEUROSPORA-CRASSA; BIOSYNTHESIS; PURIFICATION; DOMAIN; PHOSPHORYLATION; EXPRESSION; LIGASE; GENES; LPLA	Lipoic acid is an essential enzyme cofactor that requires covalent attachment to its cognate proteins to confer biological activity. The major lipoylated proteins are highly conserved enzymes of central metabolism the pyruvate and alpha-ketoglutarate dehydrogenase complexes. The classical lipoate ligase uses ATP to activate the lipoate carboxyl group followed by attachment of the cofactor to a specific subunit of each dehydrogenase complex, and it was assumed that all lipoate attachment proceeded by this mechanism. However, our previous work indicated that Escherichia coli could form lipoylated proteins in the absence of detectable ATP-dependent ligase activity raising the possibility of a Glass of enzyme that attaches lipoate to the dehydrogenase complexes by a different mechanism. We now report that E. coli and mitochondria contain lipoate transferases that use lipoyl-acyl carrier protein as the lipoate donor. This finding demonstrates a direct link between fatty acid synthesis and lipoate attachment and also provides the first direct demonstration of a role for the enigmatic acyl carrier proteins of mitochondria.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	Jordan, SW (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,CHEM & LIFE SCI LAB B103,601 S GOODWIN AVE,URBANA,IL 61801, USA.		Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI ST, 1990, MOL MICROBIOL, V4, P943, DOI 10.1111/j.1365-2958.1990.tb00667.x; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CHUMAN L, 1989, EUR J BIOCHEM, V184, P643, DOI 10.1111/j.1432-1033.1989.tb15061.x; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; Macherel D, 1996, EUR J BIOCHEM, V236, P27, DOI 10.1111/j.1432-1033.1996.00027.x; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; Mattevi A., 1992, CURR OPIN STRUC BIOL, V2, P877, DOI [10.1016/0959-440X(92)90114-M, DOI 10.1016/0959-440X(92)90114-M]; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; PARRY RJ, 1977, J AM CHEM SOC, V99, P6464, DOI 10.1021/ja00461a061; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RANDALL DD, 1977, BIOCHIM BIOPHYS ACTA, V485, P336, DOI 10.1016/0005-2744(77)90169-3; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; Reed L.J., 1966, METHOD ENZYMOL, V9, P247; REED LJ, 1958, J BIOL CHEM, V232, P123; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; Schaefer AL, 1996, P NATL ACAD SCI USA, V93, P9505, DOI 10.1073/pnas.93.18.9505; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; SHINTANI DK, 1994, PLANT PHYSIOL, V104, P1221, DOI 10.1104/pp.104.4.1221; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; WADA H, 1998, P NATL ACAD SCI USA, V94, P1591; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WIELAND OH, 1972, FEBS LETT, V27, P240, DOI 10.1016/0014-5793(72)80630-6; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F	35	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17903	17906		10.1074/jbc.272.29.17903	http://dx.doi.org/10.1074/jbc.272.29.17903			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218413	hybrid			2022-12-25	WOS:A1997XL73500003
J	Boylan, MO; Jepeal, LI; Jarboe, LA; Wolfe, MM				Boylan, MO; Jepeal, LI; Jarboe, LA; Wolfe, MM			Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene in a mouse neuroendocrine tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; DIABETES-MELLITUS; PEPTIDE GIP; TRANSCRIPTION FACTORS; ACID-SECRETION; RELEASE; RAT; CHOLECYSTOKININ; HORMONES; PREPROGLUCAGON	Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid gastrointestinal regulatory peptide that, in the presence of glucose, stimulates insulin secretion. GIP is expressed in K cells of the small intestine and in cells of the submandibular salivary gland. Using a rat GIP cDNA as a specific probe, we screened a number of established cell lines for the expression of GIP mRNA. STC-1 cells, a cell line derived from a mouse neuroendocrine tumor, were found to express high levels of GIP mRNA. GIP-specific transcripts were not detected in other cell lines tested, which included cells of intestinal, salivary, and endocrine origin. Analysis of GIP-luciferase fusions identified two promoters, a distal and a proximal promoter, upstream of the translation initiation codon for GIP. The distal promoter, located upstream of position +1, corresponds to the principal promoter of the GIP gene and can promote cell-specific transcription. Sequential deletion and site-directed mutational analysis of the distal promoter demonstrated that the sequence between -193 and -182 determines cell-specific expression of GIP. Contained in this region is a consensus GATA motif, suggesting that a member of the GATA family of DNA-binding proteins is involved in the cell-specific regulation of the GIP gene.	BOSTON MED CTR, GASTROENTEROL SECT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, GASTROENTEROL SECT, BOSTON, MA 02118 USA	Boston Medical Center; Boston University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048042] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK48042] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGERBERTH B, 1993, EUR J BIOCHEM, V216, P623, DOI 10.1111/j.1432-1033.1993.tb18182.x; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BROWN JC, 1978, DIABETES, V27, P782, DOI 10.2337/diab.27.7.782; BROWN JC, 1970, SCAND J GASTROENTERO, V5, P537; BROWN JC, 1971, CAN J BIOCHEM CELL B, V49, P867, DOI 10.1139/o71-122; BUCHAN AMJ, 1978, HISTOCHEMISTRY, V56, P37, DOI 10.1007/BF00492251; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEATOR IGM, 1975, AM J SURG, V130, P128, DOI 10.1016/0002-9610(75)90360-8; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; DUPRE J, 1973, J CLIN ENDOCR METAB, V37, P826, DOI 10.1210/jcem-37-5-826; EBERT R, 1979, GASTROENTEROLOGY, V76, P515; ELAHI D, 1984, DIABETES, V33, P950, DOI 10.2337/diabetes.33.10.950; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GAJIC D, 1993, ENDOCRINOLOGY, V132, P1055, DOI 10.1210/en.132.3.1055; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HIGASHIMOTO Y, 1993, BIOCHEM BIOPH RES CO, V193, P182, DOI 10.1006/bbrc.1993.1607; HIGASHIMOTO Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P72, DOI 10.1016/0167-4781(92)90054-4; HIGASHIMOTO Y, 1995, COMP BIOCHEM PHYS C, V110, P207, DOI 10.1016/0742-8413(94)00087-Q; INAGAKI N, 1989, MOL ENDOCRINOL, V3, P1014, DOI 10.1210/mend-3-6-1014; JONES IR, 1989, DIABETOLOGIA, V32, P668; KIEFFER TJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE316, DOI 10.1152/ajpendo.1995.269.2.E316; KIEFFER TJ, 1994, AM J PHYSIOL-ENDOC M, V267, pE489, DOI 10.1152/ajpendo.1994.267.4.E489; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lawson MA, 1996, MOL CELL BIOL, V16, P3596; LEE ME, 1990, J BIOL CHEM, V265, P10446; MADSEN OD, 1986, J CELL BIOL, V103, P2025, DOI 10.1083/jcb.103.5.2025; MANGEL AW, 1993, AM J PHYSIOL, V264, pG1031, DOI 10.1152/ajpgi.1993.264.6.G1031; MAXWELL V, 1980, DIGEST DIS SCI, V25, P113, DOI 10.1007/BF01308308; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; PEDERSON RA, 1975, DIABETES, V24, P1050, DOI 10.2337/diabetes.24.12.1050; PEDERSON RA, 1976, ENDOCRINOLOGY, V99, P780, DOI 10.1210/endo-99-3-780; RINDI G, 1990, AM J PATHOL, V136, P1349; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SOMEYA Y, 1993, FEBS LETT, V317, P67, DOI 10.1016/0014-5793(93)81493-J; TAKEDA J, 1987, P NATL ACAD SCI USA, V84, P7005, DOI 10.1073/pnas.84.20.7005; THOMAS FB, 1977, GASTROENTEROLOGY, V72, P49; TISCHLER AS, 1983, SCAND J GASTROENTERO, V18, P33; TSENG CC, 1994, AM J PHYSIOL, V266, pG887, DOI 10.1152/ajpgi.1994.266.5.G887; TSENG CC, 1995, MOL CELL ENDOCRINOL, V115, P13, DOI 10.1016/0303-7207(95)03665-T; TSENG CC, 1993, P NATL ACAD SCI USA, V90, P1992, DOI 10.1073/pnas.90.5.1992; VILLAR HV, 1976, ANN SURG, V184, P97, DOI 10.1097/00000658-197607000-00016; WOLFE MM, 1983, GASTROENTEROLOGY, V84, P941; YAMAGISHI T, 1980, GASTROENTEROLOGY, V78, P931	47	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17438	17443		10.1074/jbc.272.28.17438	http://dx.doi.org/10.1074/jbc.272.28.17438			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211887				2022-12-25	WOS:A1997XK16500030
J	Orii, Y; Miki, T				Orii, Y; Miki, T			Oxidation process of bovine heart ubiquinol cytochrome c reductase as studied by stopped-flow rapid-scan spectrophotometry and simulations based on the mechanistic Q cycle model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; PROTONMOTIVE Q-CYCLE; YEAST COMPLEX-III; ELECTRON-TRANSFER; BEEF-HEART; SUCCINATE-UBIQUINONE; BC(1) COMPLEX; BC1 COMPLEX; OXIDOREDUCTASE; UBISEMIQUINONE	Stopped-flow rapid-scan spectrophotometry was employed to study complicated oxidation processes of ubiquinol-cytochrome c reductase (QCR) that was purified from bovine heart mitochondria and maximally contained 0.36 mol of ubiquinone-10/mol of heme c(1). When fully reduced QCR was allowed to react with dioxygen in the presence of cytochrome c plus cytochrome c oxidase, the oxidation of b-type hemes accompanied an initial lag, apparently low potential heme b(L) was oxidized first, followed by high potential heme b(H). Antimycin A inhibited the oxidation of both b-type hemes, The oxidation of heme c(1) was triphasic and became biphasic in the presence of antimycin A, On the other hand, starting from partially reduced QCR that was poised at a higher redox potential with succinate and succinate-cytochrome c reductase, the b-type hemes were oxidized immediately without a lag, When the ubiquinone content in QCR was as low as 0.1 mol/mol heme c(1) the oxidation of the b-type hemes was almost suppressed. As the Q-deficient QCR was supplemented with ubiquinol-2, the rapid oxidation of b-type hemes was restored to some extent, These results indicate that a limited amount of ubiquinone-10 found in purified preparations of QCR is obligatory for electron transfer from the b-type hemes to iron-sulfur protein (ISP) and heme c(1), The characteristic oxidation profiles of heme b(L), heme b(H), and heme c(1) were simulated successfully based on a mechanistic Q cycle model, According to She simulations the two-electron oxidation of ubiquinol-10 via the ISP and heme c(1) pathway, which is more favorable thermodynamically than the bifurcation of electron flow into both ISP and heme b(L), does really occur as long as heme b(L) is in the reduced state and provides ubiquinone-10 at center i. Mechanistically this process takes time, thus explaining the initial lag in the oxidation of the b-type hemes. With the partially reduced QCR, inherent ubisemiquinone at center i immediately oxidizes reduced heme b(H) thus eliminating the lag. The mechanistic Q cycle model consists of 56 reaction species, which are interconnected by the reaction paths specified with microscopic rate constants, The simulations further indicate that the rate constants for electron transfer between the redox centers can be from 10(5) to 10(3) s(-1) and are rarely rate-limiting. On the other hand, a shuttle of ubiquinone or ubiquinol between center o and center i and the oxidation of heme c(1) can be rate-limiting, The interplay of the microscopic rate constants determines the actual reaction pathway that is shown schematically by the ''reaction map,'' Most significantly, the simulations support the consecutive oxidation of ubiquinol in center o as long as both heme b(L) and heme b(H) are in the reduced state, Only when heme b(L) is oxidized and ISP is reduced can SQ(o) donate an electron to heme b(L). Thus, we propose that a kinetic control mechanism, or ''a kinetic switch,'' is significant for the bifurcation of electron flow.			Orii, Y (corresponding author), KYOTO UNIV, GRAD SCH MED, DEPT PUBL HLTH, SAKYO KU, KYOTO 606, JAPAN.							Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BRAUDT U, 1996, BIOCHIM BIOPHYS ACTA, V1275, P41; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; DEVRIES S, 1988, BIOCHIM BIOPHYS ACTA, V935, P208, DOI 10.1016/0005-2728(88)90217-4; DEVRIES S, 1980, FEBS LETT, V122, P143; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; HATEFI Y, 1982, BIOCHEMISTRY-US, V21, P6614, DOI 10.1021/bi00268a045; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; KAWAMOTO M, 1994, J MOL BIOL, V244, P238, DOI 10.1006/jmbi.1994.1722; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; KUNZ WS, 1984, FEBS LETT, V172, P261, DOI 10.1016/0014-5793(84)81137-0; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MatsunoYagi A, 1996, J BIOL CHEM, V271, P6164, DOI 10.1074/jbc.271.11.6164; MIKI T, 1994, J BIOL CHEM, V269, P1827; MIKI T, 1991, BIOCHEMISTRY-US, V30, P230, DOI 10.1021/bi00215a033; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P10561, DOI 10.1021/bi00201a001; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; ORII Y, 1990, FEBS LETT, V267, P117, DOI 10.1016/0014-5793(90)80303-Z; ORII Y, 1991, J BIOL CHEM, V266, P14310; ORII Y, 1984, J BIOL CHEM, V259, P7187; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; RICH PR, 1983, BIOCHIM BIOPHYS ACTA, V722, P271, DOI 10.1016/0005-2728(83)90073-7; RICH PR, 1986, FEBS LETT, V194, P176, DOI 10.1016/0014-5793(86)80072-2; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; Saribas AS, 1995, BIOCHEMISTRY-US, V34, P16004, DOI 10.1021/bi00049a014; Tolkatchev D, 1996, J BIOL CHEM, V271, P12356, DOI 10.1074/jbc.271.21.12356; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TSAI AL, 1987, J BIOL CHEM, V262, P8677; TSAI AL, 1983, J BIOL CHEM, V258, P2122; VANHOEK AN, 1987, BIOCHIM BIOPHYS ACTA, V892, P152, DOI 10.1016/0005-2728(87)90257-X; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; WIKSTROM M, 1986, J BIOENERG BIOMEMBR, V18, P181, DOI 10.1007/BF00743463; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1974, J BIOL CHEM, V249, P4905; YU CA, 1972, J BIOL CHEM, V247, P1012; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU L, 1982, J BIOL CHEM, V257, P2016	50	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17594	17604		10.1074/jbc.272.28.17594	http://dx.doi.org/10.1074/jbc.272.28.17594			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211907	hybrid			2022-12-25	WOS:A1997XK16500050
J	Wohrl, BM; Krebs, R; Thrall, SH; LeGrice, SFJ; Scheidig, AJ; Goody, RS				Wohrl, BM; Krebs, R; Thrall, SH; LeGrice, SFJ; Scheidig, AJ; Goody, RS			Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated in the primer grip region of p66 - Implications for DNA synthesis and dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS; SUBUNIT; P51; RESISTANCE; MECHANISM; TEMPLATE	The highly conserved primer grip region in the p66 subunit of HIV-1 reverse transcriptase (RT) is formed by the beta 12-beta 13 hairpin (residues 227-235), It has been proposed to play a role in aligning the 3'-OH end of the primer in a position for nucleophilic attack on an incoming dNTP, To analyze the importance of the primer grip for RT function, mutant RTs were used that contain single alanine substitutions of residues Trp(229), Met(230), Gly(231), and Tyr(232) in the p66 subunit of the heterodimeric p66/51 enzyme, Steady-state and pre-steady-state kinetic analyses of the enzymes were performed, All mutant enzymes revealed reduced polymerase activity, Mutation of Y232A showed the smallest effect on polymerase function, Equilibrium fluorescence titrations demonstrated that the affinity of the mutants for tRNA was only slightly affected. However, the affinity for primer-template DNA was reduced 27-fold for mutant p66(W229A)/51 and 23-fold for mutant p66(G231A)/51, and the maximal pre-steady-state rate of nucleotide incorporation, k(pol), was reduced 27-fold for p66(W229A)/51 and 70-fold for p66(G231A)/51, respectively, Mutant p66(M230A)/51 revealed no reduced affinity for primer-template but showed a 71-fold reduced affinity for dTTP. Additionally, the mutations Trp(229) and Gly(231) affected the stability of the RT heterodimer.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Case Western Reserve University	Wohrl, BM (corresponding author), MAX PLANCK INST MOL PHYSIOL, PHYS BIOCHEM ABT, RHEINLANDDAMM 201, D-44139 DORTMUND, GERMANY.		Goody, Roger S/J-8845-2014; Scheidig, Axel/C-9141-2011	Goody, Roger S/0000-0002-0772-0444; 	NIGMS NIH HHS [GM52263] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052263] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PL, 1994, ANTIMICROB AGENTS CH, V38, P1909, DOI 10.1128/AAC.38.9.1909; DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; JONCKHEERE H, 1994, J BIOL CHEM, V269, P25255; KATI WM, 1992, J BIOL CHEM, V267, P25988; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	26	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17581	17587		10.1074/jbc.272.28.17581	http://dx.doi.org/10.1074/jbc.272.28.17581			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211905	hybrid			2022-12-25	WOS:A1997XK16500048
J	Jayadev, S; Hayter, HL; Andrieu, N; Gamard, CJ; Liu, B; Balu, R; Hayakawa, M; Ito, F; Hannun, YA				Jayadev, S; Hayter, HL; Andrieu, N; Gamard, CJ; Liu, B; Balu, R; Hayakawa, M; Ito, F; Hannun, YA			Phospholipase A(2) is necessary for tumor necrosis factor alpha-induced ceramide generation in L929 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; SPHINGOMYELIN TURNOVER; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; CYTOTOXIC ACTION; APOPTOSIS; DIFFERENTIATION; ACTIVATION; RECEPTOR; MEDIATOR	The role of cytosolic phospholipase A(2) (cPLA(2)) in the regulation of ceramide formation was examined in a cell line (L929) responsive to the cytotoxic action of tumor necrosis factor alpha (TNF alpha). In L929 cells, the addition of TNF alpha resulted in the release of arachidonate, which was followed by a prolonged accumulation of ceramide occurring over 5-12 h and reaching 250% over base line. The formation of ceramide was accompanied by the hydrolysis of sphingomyelin and the activation of three distinct sphingomyelinases (neutral Mg2+-dependent, neutral Mg2+-independent, and acidic enzymes). The variant cell line C12, which lacks cPLA(2), is resistant to the cytotoxic action of TNF alpha. TNF alpha was able to activate nuclear factor kappa B in both the wild-type L929 cells and the C12 cells. However, TNF alpha was unable to cause the release of arachidonate or the accumulation of ceramide in C12 cells. C-6-ceramide overcame the resistance to TNF alpha and caused cell death in C12 cells to a level similar to that in L929 cells, The introduction of the cPLA(2) gene into C12 cells resulted in partial restoration of TNF alpha-induced arachidonate release, ceramide accumulation, and cytotoxicity. This study suggests that cPLA(2) is a necessary component in the pathways leading to ceramide accumulation and cell death.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; INST LOUIS BUGNARD,LAB BIOCHIM MALAD METAB,F-31054 TOULOUSE,FRANCE; SETSUNAN UNIV,DEPT BIOCHEM,HIRAKATA,OSAKA 57301,JAPAN	Duke University; Duke University; Setsunan University			Andrieu-Abadie, Nathalie/N-6793-2013	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Ito, Fumiaki/0000-0002-4129-4899	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Enari M, 1996, EUR J BIOCHEM, V236, P533, DOI 10.1111/j.1432-1033.1996.t01-1-00533.x; GOTTSCHALK AR, 1995, IMMUNOL CELL BIOL, V73, P8, DOI 10.1038/icb.1995.2; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAYAKAWA M, 1991, CELL STRUCT FUNCT, V16, P333, DOI 10.1247/csf.16.333; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMYTH MJ, 1992, J CELL BIOCHEM, V50, P210, DOI 10.1002/jcb.240500211; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	27	143	145	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17196	17203		10.1074/jbc.272.27.17196	http://dx.doi.org/10.1074/jbc.272.27.17196			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202042	hybrid			2022-12-25	WOS:A1997XH44600074
J	Larson, EM; OBrien, CM; Zhu, GH; Spreitzer, RJ; Portis, AR				Larson, EM; OBrien, CM; Zhu, GH; Spreitzer, RJ; Portis, AR			Specificity for activase is changed by a Pro-89 to Arg substitution in the large subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; CHLAMYDOMONAS CHLOROPLAST GENE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RUBISCO ACTIVASE; XYLULOSE 1,5-BISPHOSPHATE; DIRECTED MUTAGENESIS; CO2/O-2 SPECIFICITY; OXYGENASE ACTIVASE; CRYSTAL-STRUCTURE; REINHARDTII	Tobacco activase does not markedly facilitate the activation of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco, EC 4.1.1.39) from non-Solanaceae species, including the green alga Chlamydomonas reinhardtii, To examine the basis of this specificity, we focused on two exposed residues in the large subunit of Rubisco that are unique to the Solanaceae proteins, By employing in vitro mutagenesis and chloroplast transformation, P89R and K356Q substitutions were separately made in the Chlamydomonas enzyme to change these residues to those present in tobacco. Both mutants were indistinguishable from the wild type when grown with minimal medium in the light and contained wild-type levels of holoenzyme. Purified Rubisco was assessed for facilitated activation by spinach and tobacco activase, Both wild-type and K356Q Rubisco were similar in that spinach activase was much more effective than tobacco activase, In contrast, P89R Rubisco was not activated by spinach activase but was well activated by tobacco activase, Thus, the relative specificities of the spinach and tobacco activases for Chlamydomonas Rubisco were switched by changing a single residue at position 89, This result provides evidence for a site on the Rubisco holoenzyme that interacts directly with Rubisco activase.	AGR RES SERV,PHOTOSYNTH RES UNIT,USDA,URBANA,IL 61801; UNIV ILLINOIS,DEPT CROP SCI,URBANA,IL 61801; UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588	United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Nebraska System; University of Nebraska Lincoln								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS A, 1988, PLANT PHYSIOL, V87, P244, DOI 10.1104/pp.87.1.244; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; DWLWICHE CF, 1996, MOL BIOL EVOL, V13, P873; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1390, DOI 10.1104/pp.93.4.1390; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; JORDAN DB, 1983, J BIOL CHEM, V258, P3752; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN Y, 1991, PLANT PHYSIOL, V95, P604, DOI 10.1104/pp.95.2.604; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; Mate CJ, 1996, PLANTA, V198, P604, DOI 10.1007/BF00262648; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; NEWMAN SM, 1991, MOL GEN GENET, V230, P65, DOI 10.1007/BF00290652; PORTIS AR, 1995, J EXP BOT, V46, P1285, DOI 10.1093/jxb/46.special_issue.1285; PORTIS AR, 1992, ANNU REV PLANT PHYS, V43, P415, DOI 10.1146/annurev.pp.43.060192.002215; PORTIS AR, 1995, PLANT PHYSIOL, V109, P1441, DOI 10.1104/pp.109.4.1441; ROBINSON SP, 1989, PLANT PHYSIOL, V90, P968, DOI 10.1104/pp.90.3.968; ROESLER KR, 1990, PLANT PHYSIOL, V94, P1837, DOI 10.1104/pp.94.4.1837; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; SOMERVILLE CR, 1982, PLANT PHYSIOL, V70, P381, DOI 10.1104/pp.70.2.381; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1983, P NATL ACAD SCI-BIOL, V80, P6293, DOI 10.1073/pnas.80.20.6293; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG ZY, 1992, PLANT PHYSIOL, V100, P1858, DOI 10.1104/pp.100.4.1858; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952; ZHU GH, 1991, PLANT PHYSIOL, V97, P1348, DOI 10.1104/pp.97.4.1348	41	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17033	17037		10.1074/jbc.272.27.17033	http://dx.doi.org/10.1074/jbc.272.27.17033			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202018	hybrid			2022-12-25	WOS:A1997XH44600050
J	Park, J; Kim, I; Oh, YJ; Lee, KW; Han, PL; Choi, EJ				Park, J; Kim, I; Oh, YJ; Lee, KW; Han, PL; Choi, EJ			Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEIN-KINASE; OXYGEN	Bcl-2 is an intracellular membrane-associated protein that prevents cell death induced by a variety of apoptotic stimuli. A mechanism by which Bcl-2 exerts an anti-cell death effect is, however, not fully understood, In the present study, Bcl-2 suppressed cell death of N18TG neuroglioma cells caused by various apoptotic stresses, including etoposide, staurosporine, anisomycin, and ultraviolet irradiation. Concomitantly, Bcl-2 disrupted a signaling cascade to the c-Jun N-terminal kinase activation induced by the apoptotic stresses. Bcl-2 also prevented the etoposide-induced stimulation of MEKK1. Furthermore, overexpression of c-Jun N-terminal kinase antagonized the death-protective function of Bcl-2. These data suggest that suppression of the c-Jun N-terminal kinase signaling pathway may be critical for Bcl-2 action.	HANHYO INST TECHNOL,CELL BIOL LAB,YUSEONG KU,TAEJON 305390,SOUTH KOREA; HANHYO INST TECHNOL,GENET MOL LAB,YUSEONG KU,TAEJON 305390,SOUTH KOREA; KOREA UNIV,GRAD SCH BIOTECHNOL,SEOUL 136701,SOUTH KOREA; YONSEI UNIV,COLL SCI,DEPT BIOL,SEOUL 120749,SOUTH KOREA	Korea University; Yonsei University				Han, Pyung-Lim/0000-0002-1735-6746				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAMPLIN R, 1987, BLOOD, V69, P1551; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMESAKI S, 1993, CANCER RES, V53, P4251; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Park JR, 1996, J CELL BIOCHEM, V60, P12, DOI 10.1002/(SICI)1097-4644(19960101)60:1<12::AID-JCB3>3.0.CO;2-6; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	26	118	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16725	16728		10.1074/jbc.272.27.16725	http://dx.doi.org/10.1074/jbc.272.27.16725			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201973	hybrid			2022-12-25	WOS:A1997XH44600005
J	Plancon, L; Chami, M; Letellier, L				Plancon, L; Chami, M; Letellier, L			Reconstitution of FhuA, an Escherichia coli outer membrane protein, into liposomes - Binding of phage T5 to FhuA triggers the transfer of DNA into the proteoliposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR LIPOSOMES; REVERSE-PHASE EVAPORATION; ION CHANNELS; TRITON X-100; RECEPTOR; K-12; TRANSPORT; INVOLVEMENT; INSERTION; INJECTION	The Escherichia coli outer membrane protein FhuA catalyzes the transport of ferrichrome and is the receptor of bacteriophage T5. Purified FhuA was reconstituted into liposomes. The size of the proteoliposomes and the distribution of the proteins in the vesicles were determined by freeze fracture electron microscopy. Unilamellar vesicles with a diameter larger than 200 nm were observed frequently. FhuA was symetrically oriented in the proteoliposomes. Reconstituted FhuA was functional as binding of phage T5 induced the release of phage DNA and its transfer inside the vesicles.	UNIV PARIS 11, LAB BIOMEMBRANES, URA CNRS 1116, F-91405 ORSAY, FRANCE	UDICE-French Research Universities; Universite Paris Saclay								AGGERBECK LP, 1986, METHOD ENZYMOL, V128, P457; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; BOULANGER P, 1992, J BIOL CHEM, V267, P3168; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; CARMEL G, 1991, J BACTERIOL, V173, P4394, DOI 10.1128/JB.173.14.4394-4403.1991; CHATTORAJ DK, 1978, J MOL BIOL, V121, P327, DOI 10.1016/0022-2836(78)90367-4; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; HOFFMANN H, 1986, J BACTERIOL, V166, P404, DOI 10.1128/jb.166.2.404-411.1986; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; KILLMANN H, 1992, J BACTERIOL, V174, P3479, DOI 10.1128/JB.174.11.3479-3486.1992; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; LABEDAN B, 1974, J VIROL, V13, P1093, DOI 10.1128/JVI.13.5.1093-1100.1974; LETELLIER L, 1989, BIOCHIMIE, V71, P167, DOI 10.1016/0300-9084(89)90147-8; Letellier L, 1997, J BIOL CHEM, V272, P8836; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; Locher KP, 1997, J BIOL CHEM, V272, P1448, DOI 10.1074/jbc.272.3.1448; MOECK GS, 1995, J BACTERIOL, V177, P6118, DOI 10.1128/jb.177.21.6118-6125.1995; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; PLANCON L, 1996, THESIS U PARIS SUD O; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; ROESSNER CA, 1983, J BIOL CHEM, V258, P643; TOSI F, 1984, J VIROL, V50, P213, DOI 10.1128/JVI.50.1.213-219.1984; ZWEIG M, 1973, VIROLOGY, V51, P443, DOI 10.1016/0042-6822(73)90443-1	27	48	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16868	16872		10.1074/jbc.272.27.16868	http://dx.doi.org/10.1074/jbc.272.27.16868			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201994	hybrid			2022-12-25	WOS:A1997XH44600026
J	Wang, Z; Yang, ZQ; Chacko, S				Wang, Z; Yang, ZQ; Chacko, S			Functional and structural relationship between the calmodulin-binding, actin-binding, and actomyosin-ATPase inhibitory domains on the C terminus of smooth muscle caldesmon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-MEROMYOSIN; CHICKEN GIZZARD; F-ACTIN; KINASE PHOSPHORYLATION; MYOSIN SUBFRAGMENTS; REGULATORY PROTEIN; TROPOMYOSIN; PURIFICATION; EXPRESSION; SITES	Multiple functional domains responsible for calmodulin (CaM) binding and actin-binding/actomyosin ATPase inhibition are present in the region between residues 598-756 of the chicken gizzard smooth muscle caldesmon (CaD) molecule, To precisely localize these functional domains and to further elucidate the structural basis of these domains, we analyzed a series of purified mutants of chicken gizzard smooth muscle CaD generated by internal deletions of amino acid sequences and expression in a baculovirus expression system. Our results demonstrate that, in addition to a strong actin-binding site sequence between residues 718-723 (Wang, Z., and Chacko, S, (1996) J, Biol. Chem, 271, 25707-25714), two weak actin-binding motifs are present in the regions between residues 690-699 and 650-666. These weak actin-binding regions function independently and are associated with weak actomyosin inhibitory activity, Analysis of the CaM-binding sites A (residues 658-666) slid B (residues 690-695), the major CaM-binding sites in the C-terminal region of CaD, provided direct evidence for the involvement of both CaM-binding sites in the CaM-mediated reversal of the inhibition of actomyosin ATPase activity by CaD and for the functional independence of the two CaM-binding sites, Furthermore, the sequences between residues 598-649, upstream of CaM-binding site ih, and 700-717, downstream of CaM-binding site B, appear to have no effect on either actin-binding or CaM-binding. The data also suggest that both CaM-binding sites A and B structurally overlap or Pie in close proximity to the adjacent weak actin-binding sites and weak actomyosin ATPase inhibitory determinants.	UNIV PENN, SCH VET MED, DEPT PATHOBIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DIV UROL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039740, R01DK047514] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47514, DK 39740] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; Borovikov YS, 1996, BIOCHEMISTRY-US, V35, P13849, DOI 10.1021/bi960996j; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHACKO S, 1981, BIOCHEMISTRY-US, V20, P702, DOI 10.1021/bi00507a005; CHACKO S, 1990, J BIOL CHEM, V265, P2105; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DOBROWOLSKI Z, 1988, BIOCHIM BIOPHYS ACTA, V956, P140, DOI 10.1016/0167-4838(88)90260-9; FRASER IDC, 1995, J BIOL CHEM, V270, P19688, DOI 10.1074/jbc.270.34.19688; HEASLIP RJ, 1985, BIOCHEMISTRY-US, V24, P2731, DOI 10.1021/bi00332a020; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1995, J MUSCLE RES CELL M, V16, P11, DOI 10.1007/BF00125306; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; LASH JA, 1986, J BIOL CHEM, V261, P6155; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANI RS, 1995, J BIOL CHEM, V270, P6658, DOI 10.1074/jbc.270.12.6658; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1991, BIOCHEM J, V279, P1; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; Wang Z, 1996, J BIOL CHEM, V271, P25707, DOI 10.1074/jbc.271.41.25707; Wang Z, 1996, J BIOL CHEM, V271, P2234, DOI 10.1074/jbc.271.4.2234; WANG Z, 1994, J MUSCLE RES CELL M, V15, P646, DOI 10.1007/BF00121072; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	48	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16896	16903		10.1074/jbc.272.27.16896	http://dx.doi.org/10.1074/jbc.272.27.16896			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201998	hybrid			2022-12-25	WOS:A1997XH44600030
J	AsanteAppiah, E; Skalka, AM				AsanteAppiah, E; Skalka, AM			A metal-induced conformational change and activation of HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; DNA-BINDING DOMAIN; MONOCLONAL-ANTIBODIES; CATALYTIC DOMAIN; RETROVIRAL INTEGRATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; VIRAL-DNA; C-TERMINUS; IN-VITRO	Retroviral integrases are composed of three independently folding domains whose organization relevant to one another is largely unknown. As an approach to understanding its structure, we have investigated the effect of the required metal cofactor(s), Mn2+ or Mg2+, on the conformation of human immunodeficiency virus type 1 (HIV-1) integrase (IN) using monoclonal antibodies (mAbs) that are specific for each of these three domains, Upon the addition of increasing concentrations of the divalent cations to immobilized HIV-1 IN in ELISA assays, binding of mAbs specific for either the C-terminal domain or for an epitope in the catalytic core domain was lost, whereas binding of an N terminus-specific mAb was unaffected. Size exclusion chromatography of a nonaggregating derivative of HIV-1 IN showed that the oligomeric state of the protein did not change under conditions in which recognition of the core and C terminus-specific mAbs was lost. Preincubation with Mn2+ increased the resistance of HIV-1 IN to proteolytic digestion and produced a digestion pattern that was significantly different from that observed with the apoprotein. A derivative that lacked the N-terminal domain, IN(50-288), exhibited the same metal-dependent changes observed with the full-length protein, whereas the isolated catalytic core domain IN(50-212) did not. From this we conclude that the metal-induced conformational change comprises a reorganization of the core and C-terminal domains. Preincubation with Mn2+ increased the specific activity of HIV-1 IN 5-fold. Enzymatic activity was inhibited by the conformation-sensitive C terminus-specific mAb, but this inhibition was reduced greatly if the enzyme was first preincubated with metal ions. Thus, it appears that apo-HIV-1 IN exists predominantly in an inactive conformation that is converted into a catalytically competent form upon the addition of metal ions.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927, R35CA047486] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47486, CA-06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRAKE MD, 1995, J BIOL CHEM, V270, P29299, DOI 10.1074/jbc.270.49.29299; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; HOLLER TP, 1993, GENE AMST, V126, P323; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P1358, DOI 10.1093/nar/19.6.1358; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10215, DOI 10.1021/bi00032a015; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; MURRYBRELIER A, 1990, J BIOL CHEM, V265, P7987; PETERSON CB, 1987, J BIOL CHEM, V262, P7552; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; RAMPRASAD S, 1993, CANCER RES, V53, P5361; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SOLOMON B, 1989, BIOCHEMISTRY-US, V28, P1235, DOI 10.1021/bi00429a042; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; Wolfe AL, 1996, J VIROL, V70, P1424, DOI 10.1128/JVI.70.3.1424-1432.1996; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	55	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16196	16205		10.1074/jbc.272.26.16196	http://dx.doi.org/10.1074/jbc.272.26.16196			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195919	hybrid			2022-12-25	WOS:A1997XG01900023
J	Han, P; Zhu, XY; Michaeli, T				Han, P; Zhu, XY; Michaeli, T			Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CALMODULIN-DEPENDENT PHOSPHODIESTERASE; PROTEIN-KINASE-A; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; ANCHORING PROTEINS; EXPRESSION; PHOSPHORYLATION; LOCALIZATION; MYOBLASTS	To further our understanding of the structure and function of phosphodiesterases of the newly identified family of high affinity cAMP-specific phosphodiesterases (PDE7), we identified and characterized the isozyme expressed in human skeletal muscle and the protein product of the previously isolated isozyme HCP1 (designated HSPDE7A1). We report the isolation of a cDNA encoding the full-length skeletal muscle isoform of human PDE7A (HSPDE7A2). The DNA sequence of this skeletal muscle cDNA indicates that PDE7A2 is a novel 5' splice variant of PDE7A encoding an isoform with a novel, hydrophobic N terminus. The 456-amino acid PDE7A2 protein is detected on Western blots as a band with an apparent mobility of 50 kDa. PDE7A2 is a high affinity cAMP-specific PDE (K-m = 0.1 mu M), which is localized to particulate cellular fractions. The PDE7A1 (HCP1) isozyme is detected on Western blots as a band with an apparent mobility of 57 kDa, demonstrating that the previously isolated HCP1 cDNA encodes the full-length PDE7A1 protein. The even distribution of PDE7A mRNA among fetal tissues and the relative abundance of its two mRNAs strongly suggest that the expression of PDE7A is regulated throughout development.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV & MOL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine								[Anonymous], MOL CLONING LAB MANU; BALL EH, 1980, J BIOL CHEM, V255, P2962; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BELTMAN J, 1993, MOL CELL BIOCHEM, V128, P239, DOI 10.1007/BF01076775; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HIDAKA H, 1977, BIOCHIM BIOPHYS ACTA, V484, P398, DOI 10.1016/0005-2744(77)90095-X; ICHIMURA M, 1993, BIOCHEM BIOPH RES CO, V193, P985, DOI 10.1006/bbrc.1993.1722; KEMP RG, 1996, METHOD ENZYMOL, V38, P240; KOVALA T, 1994, J BIOL CHEM, V269, P8680; Loughney K, 1996, J BIOL CHEM, V271, P796, DOI 10.1074/jbc.271.2.796; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NARINDRASORASAK S, 1982, J BIOL CHEM, V257, P4618; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SETH PK, 1983, J CELL PHYSIOL, V116, P336, DOI 10.1002/jcp.1041160311; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; TAIRA M, 1993, J BIOL CHEM, V268, P18573	35	91	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16152	16157		10.1074/jbc.272.26.16152	http://dx.doi.org/10.1074/jbc.272.26.16152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195912	hybrid			2022-12-25	WOS:A1997XG01900016
J	Hashimoto, H; Sakakibara, A; Yamasaki, M; Yoda, K				Hashimoto, H; Sakakibara, A; Yamasaki, M; Yoda, K			Saccharomyces cerevisiae VIG9 encodes GDP-mannose pyrophosphorylase, which is essential for protein glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MUTANTS DEFICIENT; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; GENE-CLUSTER; SEQUENCE; BIOSYNTHESIS; DEFECTS; PATHWAY; FAMILY; DNA	A genomic DNA fragment that complements a newly identified protein glycosylation-defective mutation, vig9, of Saccharomyces cerevisiae was cloned. Chromosomal integration of this fragment by homologous recombination indicated that it contains the wild type VIG9 gene. The nucleotide sequence was determined. A predicted gene product showed significant amino acid sequence homology with several bacterial enzymes that catalyze the synthesis of (deoxy)ribonucleotide diphosphate sugars from sugar phosphates and (deoxy)ribonucleotide triphosphate. We examined the enzyme activity to synthesize GDP-mannose in the cell extracts of the wild type, vig9-1 mutant, and VIG9 transformant yeasts. Reduction of the activity in the mutant cell and its restoration by VIG9 suggested that the VIG9 gene is the structural gene for GDP-mannose pyrophosphorylase of S. cerevisiae which catalyzes the production of GDP-mannose. We demonstrated the enzyme activity of Vig9 protein using a recombinant fusion protein produced in Escherichia coli.	UNIV TOKYO,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; Benton BK, 1996, CURR GENET, V29, P106, DOI 10.1007/BF02221573; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; DISTLER J, 1987, NUCLEIC ACIDS RES, V15, P8041, DOI 10.1093/nar/15.19.8041; FERRONOVICK S, 1984, J CELL BIOL, V98, P35, DOI 10.1083/jcb.98.1.35; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; Guthrie C, 1991, GUIDE YEAST GENETICS; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL K, 1992, GENETICS, V130, P273; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; KANIKENNULAT C, 1995, GENETICS, V140, P933; KEPES F, 1988, J BIOL CHEM, V263, P9155; KESSLER AC, 1993, J BACTERIOL, V175, P1412, DOI 10.1128/JB.175.5.1412-1422.1993; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHLE L, 1995, GLYCOPROTEINS, P475; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Poster JB, 1996, J BIOL CHEM, V271, P3837; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; Tajima M, 1985, Yeast, V1, P67, DOI 10.1002/yea.320010108; TSAI PK, 1984, J BIOL CHEM, V259, P3805; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	42	74	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16308	16314		10.1074/jbc.272.26.16308	http://dx.doi.org/10.1074/jbc.272.26.16308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195935	hybrid			2022-12-25	WOS:A1997XG01900039
J	Schiemann, WP; Bartoe, JL; Nathanson, NM				Schiemann, WP; Bartoe, JL; Nathanson, NM			Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase - Evidence for participation of multiple signaling pathways which converge at Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ONCOSTATIN-M; HEMATOPOIETIN RECEPTORS; SERINE PHOSPHORYLATION; INTERLEUKIN-6 FAMILY; GENE-EXPRESSION; NEURONAL CELLS; GROWTH-HORMONE; STAT PROTEINS; LIF RECEPTOR	Chimeric receptors containing the entire or various cytoplasmic domains of either gp130 or leukemia inhibitory factor receptor alpha (LIFR) were used to identify signaling molecules and regions of these polypeptides required for the stimulation of mitogen-activated protein kinase (MAPK). Coexpression of dominant-negative Jak2 inhibited chimeric receptor-stimulated MAPK activity by similar to 70%, while expression of dominant-negative Ras completely blocked MAPK activation by either receptor polypeptide. Deletion analysis identified a 24-amino acid region of gp130 that was necessary for maximal stimulation of MAPK, and contained box 3 (positions 120-129) and a consensus tyrosine binding motif (Tyr-118) for the protein-tyrosine phosphatase, SHP2. Expression of receptors lacking: this region or of chimeric gp130(Y118F) point mutants inhibited MAPK activity by similar to 55%, suggesting that Tyr-118, but not box 3, was required during activation of MAPK by gp130. Similarly, expression of chimeric LIFR constructs lacking box 3 maximally stimulated MAPK activity, while those lacking Tyr-115, a putative SHP2 binding site, inhibited stimulation of MAPK by this polypeptide. Our results demonstrate that gp130 and LIFR stimulate MAPK activity through box 3-independent mechanisms involving: (i) effects at Tyr-118 and Tyr-115, respectively, for maximal stimulation of MAPK activity and (ii) a Jak/Tyk-dependent pathway that, together with Tyr-118- or Tyr-115-generated signals, converges at the level of Ras during activation of MAPK by cytokine.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM07018, GM07750] Funding Source: Medline; NINDS NIH HHS [NS30410] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTOE JL, 1996, SOC NEUR ABSTR, V22; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Taga T, 1996, J NEUROCHEM, V67, P1; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMA B, 1994, J BIOL CHEM, V269, P6215; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WANG XY, 1995, J BIOL CHEM, V270, P27999; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YIN TG, 1994, J BIOL CHEM, V269, P3731; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	40	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16631	16636		10.1074/jbc.272.26.16631	http://dx.doi.org/10.1074/jbc.272.26.16631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195977	hybrid			2022-12-25	WOS:A1997XG01900081
J	Thoenges, D; Schoner, W				Thoenges, D; Schoner, W			2'-O-dansyl analogs of ATP bind with high affinity to the low affinity ATP site of Na+/K+-ATPase and reveal the interaction of two ATP sites during catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; (NA+ + K+)-ATPASE; PHOSPHORYLATION; NA,K-ATPASE; NA+,K+-ATPASE; COMPLEX; SODIUM; PHOSPHATE; TURNOVER; ENZYME	Na+/H+-transport through mammalian cell membranes by Na+/R+-ATPase (EC 3.6.1.37) needs the interaction of ATP sites with different binding affinities during catalysis: one with catalytic (high affinity site) and one with regulatory properties (low affinity site). To find affinity labels for the latter one, the effects of 2'-O-dansylated ATP analogs on Na+/K+-ATPase and its partial activities were analyzed. DANS-ATP (2'-O-(6-dimethylaminonaphthalenesulfonyl)adenosine 5'-triphosphate) inhibited noncompetitively at low ATP concentrations and competitively at high ATP concentrations the Na+/K+-activated hydrolysis of ATP under turnover conditions. It interacted preferentially with the low affinity ATP site as shown by its protective effect against the inactivation of Na+/K+-ATPase by Co(NH3)(4)ATP and Cr(H2O)(4)ATP. DANS-N-3-ATP, however, inactivated Na+/K+-ATPase, The initial velocity of inactivation shows a sigmoid concentration dependence that was converted to a hyperbola in the presence of ATP, DANS-N-3-ATP inhibited competitively the K+-activated hydrolysis of p-nitrophenyl phosphate in a fluorescein isothiocyanate-blocked enzyme but did not effect Na+-dependent phosphoenzyme formation from [gamma-P-32]ATP in a Co(NH3)(4)PO4-blocked enzyme, These effects could be described by a Koshland-Nemethy-Filmer model assuming two nucleotide binding sites in strong cooperation, Fitting all data to this model revealed that ATP was bound in a negative cooperative way with a K-d = 0.3-1 mu M to the first site and a K-d = 100-120 mu M to the second site of the enzyme containing already one ATP bound, The hydrolysis of ATP through a pathway with two ATP bound was 30 times faster than hydrolysis with one ATP bound. DANS-N-3-ATP bound in a positive cooperative way with a K-d = 500 +/- 100 mu M to the first site and a K-d = 2.5 +/- 0.5 mu M to the second site containing already one DANS-N-3-ATP bound, Therefore, DANS-N-3-ATP may be an useful affinity marker of the low affinity, regulatory ATP site.	UNIV GIESSEN,FACHBEREICH VET MED,INST BIOCHEM & ENDOKRINOL,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen								BOLDYREV AA, 1994, INT J BIOCHEM, V26, P1323, DOI 10.1016/0020-711X(94)90174-0; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CAMPOS M, 1994, J BIOL CHEM, V269, P18028; CHUAN H, 1989, J BIOL CHEM, V264, P7981; CORNELIUS RD, 1977, INORG CHEM, V16, P2799, DOI 10.1021/ic50177a025; DUMAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HAMER E, 1993, EUR J BIOCHEM, V213, P743, DOI 10.1111/j.1432-1033.1993.tb17815.x; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LINNERTZ H, 1995, EUR J BIOCHEM, V232, P420, DOI 10.1111/j.1432-1033.1995.tb20827.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; PAULS H, 1980, EUR J BIOCHEM, V109, P523, DOI 10.1111/j.1432-1033.1980.tb04824.x; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; PELUFFO RD, 1994, J BIOL CHEM, V269, P1051; PISZKIEWICZ D, 1971, BIOCHEMISTRY-US, V10, P4544, DOI 10.1021/bi00800a031; PLESNER IW, 1987, BIOPHYS J, V51, P69, DOI 10.1016/S0006-3495(87)83312-X; POST RL, 1972, J BIOL CHEM, V247, P6530; REPKE KRH, 1973, ACTA BIOL MED GER, V31, pK19; ROBERTS G, 1995, PLANT PHYSIOL, V108, P813, DOI 10.1104/pp.108.2.813; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHEINERBOBIS G, 1987, EUR J BIOCHEM, V168, P123, DOI 10.1111/j.1432-1033.1987.tb13396.x; SCHONER W, 1967, EUR J BIOCHEM, V1, P334, DOI 10.1111/j.1432-1033.1967.tb00078.x; SCHONER W, 1994, SODIUM PUMP, P332; SCHWARZBAUM PJ, 1995, BBA-BIOMEMBRANES, V1233, P33, DOI 10.1016/0005-2736(94)00229-I; Segel I.H., 1975, ENZYME KINETICS; SERPERSU EH, 1990, EUR J BIOCHEM, V191, P397, DOI 10.1111/j.1432-1033.1990.tb19135.x; SIEBERT H, 1958, Z ANORG ALLG CHEM, V296, P280, DOI 10.1002/zaac.19582960129; THOENGES D, 1994, SODIUM PUMP STRUCTUR, P421; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989	34	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16315	16321		10.1074/jbc.272.26.16315	http://dx.doi.org/10.1074/jbc.272.26.16315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195936	hybrid			2022-12-25	WOS:A1997XG01900040
J	Howl, J; Langel, U; Hawtin, SR; Valkna, A; Yarwood, NJ; Saar, K; Wheatley, M				Howl, J; Langel, U; Hawtin, SR; Valkna, A; Yarwood, NJ; Saar, K; Wheatley, M			Chimeric strategies for the rational design of bioactive analogs of small peptide hormones	FASEB JOURNAL			English	Article						bradykinin; vasopressin; galanin; antagonist; mastoparan	BRADYKININ RECEPTOR ANTAGONISTS; V1A VASOPRESSIN RECEPTOR; ARGININE-VASOPRESSIN; AGONIST; PHARMACOLOGY; GALANIN; LIGANDS; KININS; CELLS; NEUROPEPTIDES	The aim of this study was to evaluate a variety of synthetic strategies pertinent to the development of chimeric analogs of the structurally divergent nonapeptide hormones arginine vasopressin (AW) and bradykinin (BK). Single-chain peptides combining AW and BK directly, AVP(1-9)-BK(1-9) or via a flexible aminohexanoic acid (epsilon Ahx) linker, AVP(1-9)-epsilon Ahx-BK(1-9), bind with relatively high affinity to the bovine kidney medulla B-2a bradykinin receptor (B-2a BKR). Significantly, amino-terminal extended chimeric analogs of BK including AVP(1-9)BK(1-9) and galanin(1-13)-BK(1-9), are functional B-2 BKR agonists. These findings illustrate that chimeric peptides can activate G-protein-coupled receptors (GPCRs) in a manner analogous to that of endogenous monomeric agonists. Further development, combining the sequences of receptor subtype-selective antagonist, produced high-affinity chimeric antagonists of the V-1a vasopressin receptor (V-1a VPR) and the B-2a BKR. We also determined the pharmacological characteristics of high-affinity chimeric hormone analogs derivatized with the membrane targeting function of mastoparan. Homodimers of an amino-terminal extended BK analog and a V-1a-selective antagonist represent the first examples of new classes of B-2 BKR and V-1a VPR antagonists, respectively. These findings are discussed in relation to the GPCR binding site for small peptides and the development of novel biological probes and therapeutic agents.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT NEUROCHEM & NEUROTOXICOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	Howl, J (corresponding author), UNIV BIRMINGHAM,SCH BIOCHEM,POB 363,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Langel, Ulo/0000-0001-6107-0844; Howl, John/0000-0001-9341-3717; Wheatley, Mark/0000-0001-6261-5682				ACHER R, 1993, REGUL PEPTIDES, V45, P1, DOI 10.1016/0167-0115(93)90174-7; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; CALLAHAN JF, 1989, J MED CHEM, V32, P391, DOI 10.1021/jm00122a017; CANN JR, 1994, BIOPOLYMERS, V34, P869, DOI 10.1002/bip.360340706; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHERONIS JC, 1994, J MED CHEM, V37, P348, DOI 10.1021/jm00029a006; CHERONIS JC, 1992, J MED CHEM, V35, P1563, DOI 10.1021/jm00087a010; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; CONN PM, 1982, NATURE, V296, P653, DOI 10.1038/296653a0; GITELMAN HJ, 1980, SCIENCE, V207, P893, DOI 10.1126/science.7355269; HOWL J, 1993, EUR J BIOCHEM, V213, P711, DOI 10.1111/j.1432-1033.1993.tb17811.x; HOWL J, 1995, GEN PHARMACOL-VASC S, V26, P1143, DOI 10.1016/0306-3623(95)00016-T; HOWL J, 1991, BIOCHEM J, V276, P189, DOI 10.1042/bj2760189; Howl J, 1996, KIDNEY INT, V50, P586, DOI 10.1038/ki.1996.353; Howl J, 1996, NEUROPEPTIDES, V30, P73, DOI 10.1016/S0143-4179(96)90058-X; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; HOWL J, 1991, MOL CELL ENDOCRINOL, V77, P123, DOI 10.1016/0303-7207(91)90066-2; HOWL J, 1993, METHODS NEUROSCI, V13, P281; JACKSON TR, 1987, EMBO J, V6, P49, DOI 10.1002/j.1460-2075.1987.tb04717.x; Jard S, 1987, PROG BRAIN RES <D>, V72, P173; JONES PM, 1993, MOL CELL ENDOCRINOL, V94, P97, DOI 10.1016/0303-7207(93)90056-P; Jureus A., 1996, ACTA CHIM SLOV, V43, P51, DOI DOI 10.1007/S008940100045; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; Langel U, 1996, REGUL PEPTIDES, V62, P47, DOI 10.1016/0167-0115(96)00002-X; LASZLO FA, 1991, PHARMACOL REV, V43, P73; LONG DLW, 1996, PEPTIDES CHEM STRUCT, P595; MANNING M, 1984, TRENDS NEUROSCI, V7, P6, DOI 10.1016/S0166-2236(84)80179-4; MANNING M, 1992, J MED CHEM, V35, P382, DOI 10.1021/jm00080a027; MANNING M, 1991, PEPTIDES 1990, P665; MANNING M, 1987, NATURE, V329, P839, DOI 10.1038/329839a0; MANNING M, 1987, VASOPRESSIN PRINCIPL, P335; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; Mezna Mokdad, 1997, Biochemical Society Transactions, V25, p450S; MOUILLAC B, 1995, J BIOL CHEM, V270, P25711; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; OSTENSSON CG, 1997, IN PRESS ENDOCRINOLO; OTTER A, 1993, BIOPOLYMERS, V33, P769, DOI 10.1002/bip.360330506; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; REGOLI D, 1993, CAN J PHYSIOL PHARM, V71, P556, DOI 10.1139/y93-079; REGOLI D, 1994, LIFE SCI, V55, P735, DOI 10.1016/0024-3205(94)00557-5; REGOLI D, 1980, PHARMACOL REV, V32, P1; REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P156, DOI 10.1016/0165-6147(90)90067-I; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; SCHMIDT JM, 1991, EUR J BIOCHEM, V201, P355, DOI 10.1111/j.1432-1033.1991.tb16293.x; Sejbal J, 1996, J MED CHEM, V39, P1281, DOI 10.1021/jm950485f; Sermasi E, 1995, NEUROENDOCRINOLOGY, V62, P634, DOI 10.1159/000127060; SHARMA JN, 1993, GEN PHARMACOL, V24, P267, DOI 10.1016/0306-3623(93)90302-E; STEWART JM, 1995, BIOPOLYMERS, V37, P143, DOI 10.1002/bip.360370208; UFER E, 1995, FEBS LETT, V362, P19, DOI 10.1016/0014-5793(95)00150-8; VALKNA A, 1995, PROTEIN PEPTIDE LETT, V2, P267; WEI CM, 1993, J CLIN INVEST, V92, P2048, DOI 10.1172/JCI116800	54	29	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					582	590		10.1096/fasebj.11.7.9212082	http://dx.doi.org/10.1096/fasebj.11.7.9212082			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212082				2022-12-25	WOS:A1997XH34200010
J	Liu, MY; Yu, B; Nabanishi, O; Wieland, T; Simon, M				Liu, MY; Yu, B; Nabanishi, O; Wieland, T; Simon, M			The Ca2+-dependent binding of calmodulin to an N-terminal motif of the heterotrimeric G protein beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-DERIVED CELLS; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; POTASSIUM CHANNEL; PEPTIDE COMPLEX; ALPHA-SUBUNITS; KINASE-II; ACTIVATION; BRAIN	Ca2+ ion concentration changes are critical events in signal transduction, The Ca2+-dependent interactions of calmodulin (CaM) with its target proteins play an essential role in a variety of cellular functions, In this study, we investigated the interactions of G protein beta gamma sub units with CaM, We found that CaM binds to known beta gamma subunits and these interactions are Ca2+-dependent, The CaM-binding domain in G beta gamma subunits is identified as G beta residues 40-63. Peptides derived hom the G beta protein not only produce a Ca2+-dependent gel mobility shifting of CaM but also inhibit the CaM-mediated activation of CaM kinase II, Specific amino acid residues critical for the binding of G beta gamma to CaM were also identified, We then investigated the potential function of these interactions and showed that binding of CaM to G beta gamma inhibits the pertussis toxin-catalyzed ADP-ribosylation of G alpha o subunits, presumably by inhibiting heterotrimer formation, Furthermore, we demonstrated that interaction with CaM has Little effect on the activation of phospholipase C-beta 2 by G beta gamma subunits, supporting the notion that different domains of G beta gamma are responsible for the interactions of different effecters, These findings shed light on the molecular basis for the interactions of G beta gamma with Ca2+-CaM and point to the potential physiological significance of these interactions in cellular functions.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				ASANO T, 1986, FEBS LETT, V205, P135; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM D, ANN REV NEUROSCI, V17, P441; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEGRADO WF, 1987, PROTEINS, V2, P20, DOI 10.1002/prot.340020104; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MA JY, 1994, P NATL ACAD SCI USA, V91, P12351, DOI 10.1073/pnas.91.25.12351; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WIELAND T, 1991, EUR J BIOCHEM, V196, P707, DOI 10.1111/j.1432-1033.1991.tb15869.x; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	54	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18801	18807		10.1074/jbc.272.30.18801	http://dx.doi.org/10.1074/jbc.272.30.18801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228054	hybrid			2022-12-25	WOS:A1997XM34200045
J	Park, JS; Choi, E; Lee, SH; Lee, C; Seo, YS				Park, JS; Choi, E; Lee, SH; Lee, C; Seo, YS			A DNA helicase from Schizosaccharomyces pombe stimulated by single-stranded DNA-binding protein at low ATP concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; REPLICATION PROTEIN; SACCHAROMYCES-CEREVISIAE; DEPENDENT ATPASE; CALF THYMUS; CELLS; YEAST; REPAIR; PURIFICATION; PRIMASE	A DNA helicase named DNA helicase I was isolated from cell-free extracts of the fission yeast Schizosaccharomyces pombe. Both DNA helicase and single-stranded DNA-dependent ATPase activities copurified with a polypeptide of 95 kDa on an SDS-polyacrylamide gel. The helicase possessed a sedimentation coefficient of 6.0 S and a Stokes radius of 44.8 Angstrom determined by glycerol gradient centrifugation and gel filtration analysis, respectively. From these data the native molecular mass was calculated to be 110 kDa, indicating that the active enzyme is a monomer. The DNA-unwinding and ATP hydrolysis activities associated with DNA helicase I have been examined. One notable property of the enzyme was its relatively high rate of ATP turnover (35-50 molecules of ATP hydrolyzed/s/enzyme molecule) that may contribute to its inefficient unwinding activity at low concentrations of ATP (<0.2 mM). Addition of an ATP-regenerating system to the reaction mixture re stored the DNA-unwinding activity of the enzyme. S. pombe single-stranded DNA-binding protein (SpSSB, also called SpRPA) stimulated the DNA helicase activity significantly at low levels of ATP (0.025-0.2 mM) even in the absence of an ATP-regenerating system. In contrast, SpRPA had no effect on ATP hydrolysis at any ATP concentration examined. These observations suggest that the stimulation of DNA unwinding by SpRPA is not simply a result of suppression of nonproductive ATP hydrolysis. Rather, the role of SpRPA is to lower the K-m for ATP in the unwinding reaction, allowing the helicase to function efficiently at low ATP concentrations.	SAMSUNG BIOMED RES INST, BASIC RES CTR, SEOUL 135230, SOUTH KOREA	Sungkyunkwan University (SKKU); Samsung Medical Center			Seo, Yeonsoo/C-1605-2011					ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; BISWAS EE, 1995, BIOCHEM BIOPH RES CO, V206, P850, DOI 10.1006/bbrc.1995.1121; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUZDER SN, 1994, NATURE, V369, P568; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; LI XY, 1992, CHROMOSOMA, V102, pS93, DOI 10.1007/BF02451791; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MELENDY T, 1993, J BIOL CHEM, V268, P3389; PARK MS, 1996, J BIOL CHEM, V271, P1896; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKI M, 1987, BIOCHEMISTRY-US, V26, P2924, DOI 10.1021/bi00384a038; SEKI M, 1994, J BIOCHEM-TOKYO, V115, P523, DOI 10.1093/oxfordjournals.jbchem.a124369; SEO YS, 1991, J BIOL CHEM, V266, P13161; SEO YS, 1993, J BIOL CHEM, V268, P10282; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SHIMIZU K, 1993, J BIOL CHEM, V268, P9578; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; SUGINO A, 1986, J BIOL CHEM, V261, P1744; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; Tuteja N, 1996, NAT GENET, V13, P11, DOI 10.1038/ng0596-11; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	56	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18910	18919		10.1074/jbc.272.30.18910	http://dx.doi.org/10.1074/jbc.272.30.18910			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228070	hybrid			2022-12-25	WOS:A1997XM34200061
J	Whistler, JL; Rine, J				Whistler, JL; Rine, J			Ras2 and Ras1 protein phosphorylation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-ANALYSIS; LUNG CARCINOMAS; TYROSINE KINASE; YEAST; CYCLASE; CELLS; DNA; TRANSFORMATION; ACTIVATION; MUTATIONS	This work describes the phosphorylation of Saccharomyces cerevisiae Ras proteins and explores the physiological role of the phosphorylation of Ras2 protein, Proteins expressed from activated alleles of RAS were less stable and less phosphorylated than proteins from cells expressing wild-type alleles of RAS. This difference in phosphorylation level did not result from increased signaling through the Ras-cAMP pathway or reflect the primarily GTP-bound nature of activated forms of Ras protein per se. In addition, phosphorylation of Ras protein was not dependent on proper localization of the Ras2 protein to the plasma membrane nor on the interaction of Ras2p with its exchange factor, Cdc25p. The preferred phosphorylation site on Ras2 protein was identified as serine 214, This site, when mutated to alanine, led to promiscuous phosphorylation of Ras2 protein on nearby serine residues, A decrease in phosphorylation may lead 60 a decrease in signaling through the Ras-cAMP pathway.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035827, T32GM007232] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ESO 1896] Funding Source: Medline; NIGMS NIH HHS [GM35827, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1994, GENETICS, V136, P87; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ASBBY MN, 1995, METHOD ENZYMOL, V250, P235; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; COBITZ AR, 1989, P NATL ACAD SCI USA, V86, P858, DOI 10.1073/pnas.86.3.858; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; Freeman NL, 1996, MOL CELL BIOL, V16, P548; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Harlow E, 1988, ANTIBODIES LABORATOR, P521; HAYASHI K, 1983, JPN J CANCER RES, V74, P798; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCCORMICK F, 1991, COLD SH Q B, V56, P237; MINTZER KA, 1994, CELL SIGNAL, V6, P681, DOI 10.1016/0898-6568(94)90050-7; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MORISHITA T, 1995, SCIENCE, V270, P1213, DOI 10.1126/science.270.5239.1213; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NAKANO H, 1984, P NATL ACAD SCI-BIOL, V81, P71, DOI 10.1073/pnas.81.1.71; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260	39	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18790	18800		10.1074/jbc.272.30.18790	http://dx.doi.org/10.1074/jbc.272.30.18790			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228053	hybrid			2022-12-25	WOS:A1997XM34200044
J	Maiti, T; Maitra, U				Maiti, T; Maitra, U			Characterization of translation initiation factor 5 (eIF5) from Saccharomyces cerevisiae - Functional homology with mammalian eIF5 and the effect of depletion of eIF5 on protein synthesis in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTES; IMMUNOCHEMICAL CHARACTERIZATION; PURIFICATION; COMPLEX; YEAST; EXPRESSION; RELEASE; MECHANISM; BINDING; CLONING	Eukaryotic translation initiation factor 5 (eIF5) interacts in vitro with the 40 S initiation complex (40 S.AUG.Met-tRNA(f).eIF2.GTP) to mediate the hydrolysis of ribosome-bound GTP, In Saccharomyces cerevisiae, eIF5 is encoded by a single copy essential gene, TIF5, that encodes a protein of 45,346 daltons, To understand the function of eIF5 in vivo, we constructed a conditional mutant yeast strain in which a functional but a rapidly degradable form of eIF5 fusion protein was synthesized from the repressible GAL promoter, Depletion of eIF5 from this mutant yeast strain resulted in inhibition of both cell growth and the rate of in, vivo protein synthesis, Analysis of the polysome profiles of eIF5-depleted cells showed greatly diminished polysomes with simultaneous increase in free ribosomes. Furthermore, lysates of cells depleted of eIF5 were dependent on exogenously added yeast eIF5 for efficient translation of mRNAs in vitro, This is the first demonstration that the TIF5 gene encodes a protein involved in initiation of translation in eukaryotic cells, Additionally, we show that rat eIF5 can functionally substitute yeast eIF5 in translation of mRNAs in vitro as well as in complementing in vivo a genetic disruption in the chromosomal copy of TIF5.			Maiti, T (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,JACK & PEARL RESNICK CAMPUS,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA1330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BENNE R, 1978, J BIOL CHEM, V253, P3078; BENNE R, 1978, J BIOL CHEM, V253, P3070; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GORDON ED, 1987, J BIOL CHEM, V262, P16585; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUSSAIN I, 1986, GENE, V46, P13, DOI 10.1016/0378-1119(86)90162-9; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KANG HA, 1994, J BIOL CHEM, V269, P3934; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MEHTA KD, 1990, J BIOL CHEM, V265, P8802; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MERRICK WC, 1995, TRANSLATIONAL CONTRO, P31; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL PJ, 1991, NUCLEIC ACIDS RES, V19, P4949, DOI 10.1093/nar/19.18.4949; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; Si KS, 1996, J BIOL CHEM, V271, P16934, DOI 10.1074/jbc.271.28.16934; SIROSKI RS, 1989, GENETICS, V122, P19; THOMAS A, 1979, EUR J BIOCHEM, V98, P329, DOI 10.1111/j.1432-1033.1979.tb13192.x; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; [No title captured]	44	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18333	18340		10.1074/jbc.272.29.18333	http://dx.doi.org/10.1074/jbc.272.29.18333			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218474	hybrid			2022-12-25	WOS:A1997XL73500064
J	Sem, DS; Casimiro, DR; Kliewer, SA; Provencal, J; Evans, RM; Wright, PE				Sem, DS; Casimiro, DR; Kliewer, SA; Provencal, J; Evans, RM; Wright, PE			NMR spectroscopic studies of the DNA-binding domain of the monomer-binding nuclear orphan receptor, human estrogen related receptor-2 - The carboxyl-terminal extension to the zinc-finger region is unstructured in the free form of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; SECONDARY STRUCTURE ELEMENTS; MULTIPLE QUANTUM NMR; GLUCOCORTICOID RECEPTOR; RETINOIC ACID; SEQUENTIAL ASSIGNMENTS; RESPONSE ELEMENTS; HETERONUCLEAR NMR; CRYSTAL-STRUCTURE; HYDROPHOBIC CORE	Unlike steroid and retinoid receptors, which associate with DNA as dimers, human estrogen related receptor-2 (hERR2) belongs to a growing subclass of nuclear hormone receptors that bind DNA with high affinity as monomers. A carboxyl-terminal extension (CTE) to the zinc-finger domain has bean implicated to be responsible for determining the stoichiometry of binding by a nuclear receptor to its response element. To better understand the mechanism by which DNA specificity is achieved, the solution structure of the DNA-binding domain of hERR2 (residues 96-194) consisting of the two putative zinc fingers and the requisite 26-amino acid CTE was analyzed by multidimensional heteronuclear magnetic resonance spectroscopy. The highly conserved zinc-finger region (residues 103-168) has a fold similar to those reported for steroid and retinoid receptors, with two helices that originate from the carboxyl-terminal ends of the two zinc fingers and that pack together orthogonally, forming a hydrophobic core. The CTE element of hERR2 is unstructured and highly flexible, exhibiting nearly random coil chemical shifts, extreme sensitivity of the backbone amide protons to solvent presaturation, and reduced heteronuclear {H-1-N-15} nuclear Overhauser effect values. This is in contrast to the dimer-binding retinoid X and thyroid hormone receptors, where, in each case, a helix has been observed within the CTE. The implications of this property of the hERR2 CTE are discussed.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Sem, Daniel/0000-0002-2108-6646; Wright, Peter/0000-0002-1368-0223				BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BAX A, 1987, J AM CHEM SOC, V109, P6511, DOI 10.1021/ja00255a047; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; Blake P R, 1994, Adv Inorg Biochem, V10, P201; BRAUNSCHWEILER L, 1983, MOL PHYS, V48, P535, DOI 10.1080/00268978300100381; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; DAVIS DG, 1989, J MAGN RESON, V81, P603, DOI 10.1016/0022-2364(89)90100-5; DELSUC MA, 1986, J MAGN RESON, V69, P504, DOI 10.1016/0022-2364(86)90164-2; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JASANOFF A, 1993, BIOCHEMISTRY-US, V32, P1423, DOI 10.1021/bi00057a005; KATAHIRA M, 1992, BIOCHEMISTRY-US, V31, P6474, DOI 10.1021/bi00143a017; KNEGTEL RMA, 1993, J BIOMOL NMR, V3, P1, DOI 10.1007/BF00242472; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PARKER KL, 1993, TRENDS ENDOCRIN MET, V4, P46, DOI 10.1016/S1043-2760(05)80014-1; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN XQ, 1992, BIOCHEMISTRY-US, V31, P7463, DOI 10.1021/bi00148a006; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; RANCE M, 1986, CHEM PHYS LETT, V124, P572, DOI 10.1016/0009-2614(86)85078-3; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795	58	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18038	18043		10.1074/jbc.272.29.18038	http://dx.doi.org/10.1074/jbc.272.29.18038			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218433	hybrid			2022-12-25	WOS:A1997XL73500023
J	Grujic, D; Susulic, VS; Harper, ME; HimmsHagen, J; Cunningham, BA; Corkey, BE; Lowell, BB				Grujic, D; Susulic, VS; Harper, ME; HimmsHagen, J; Cunningham, BA; Corkey, BE; Lowell, BB			beta 3-adrenergic receptors on white and brown adipocytes mediate beta 3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake - A study using transgenic and gene knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; MESSENGER-RNA; OBESE GENE; MOLECULAR CHARACTERIZATION; ADRENERGIC-RECEPTOR; EXPRESSION; ADIPOSE; CLONING; TISSUES; RATS	beta 3-Adrenergic receptors (beta,7-ARs) are expressed predominantly on white and brown adipocytes, and acute treatment of mice with CL 316,243, a potent and highly selective beta 3-AR agonist, produces a a-fold increase in energy expenditure, a 50-100-fold increase in insulin levels, and a 40-50% reduction in food intake, Recently, we generated gene knockout mice lacking functional beta 3-ARs and demonstrated that each of these responses were mediated exclusively by beta 3-ARs. However, the tissue site responsible for producing these actions is unknown. In the present study, genetically engineered mice were created in which beta 3-ARs are expressed exclusively ill white and brown adipocytes (WAT+BAT-mice), or in brown adipocytes only (BAT-mice). This was accomplished by injecting tissue-specific beta 3-AR transgenic constructs into mouse zygotes homozygous for the beta 3-AR knockout allele. Control, knockout, WAT+BAT, and BAT-mice were then treated acutely with CL, and the effects on various parameters were assessed, As previously observed, all effects of CL were completely absent in gene knockout mice lacking beta 3-ARs. The effects on O-2 consumption, insulin secretion, and food intake were completely rescued with transgenic re-expression of beta 3-ARs in white and brown adipocytes (WAT+BAT-mice), demonstrating that each of these responses is mediated exclusively by beta 3-Ars in white and/or brown adipocytes, and that beta 3-ARs in other tissue sites were not required. Importantly, transgenic re-expression of beta 3-Ars in brown adipocytes only (BAT-mice) failed to rescue, in any way, CL-mediated effects on insulin levels and food intake and only minimally restored effects on oxygen consumption, indicating that any effect on insulin secretion and food intake, and a full stimulation of oxygen consumption required the presence of beta 3-ARs in white adipocytes. The mechanisms by which beta 3-AR. agonist stimulation of white adipocytes produces these responses are unknown but may involve novel mediators not previously known to effect: these processes.	BETH ISRAEL DEACONESS MED CTR, DEPT MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1H 8M5, CANADA; BOSTON UNIV, MED CTR,DEPT BIOCHEM,EVANS DEPT MED, DIABET & METAB UNIT, BOSTON, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Ottawa; Boston University			Corkey, Barbara/E-7712-2015	Corkey, Barbara/0000-0002-5467-1630; Harper, Mary-Ellen/0000-0003-3864-5886	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049569, P30DK046200, K08DK002119] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49569, DK46200, DK02119] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BERKOWITZ DE, 1995, EUR J PHARM-MOLEC PH, V289, P223, DOI 10.1016/0922-4106(95)90098-5; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; BROBECK JR, 1960, RECENT PROG HORM RES, V16, P439; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; Cunningham BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE702, DOI 10.1152/ajpendo.1996.271.4.E702; Deng CJ, 1996, BRIT J PHARMACOL, V118, P929, DOI 10.1111/j.1476-5381.1996.tb15488.x; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; GRANNEMAN JG, 1994, ENDOCRINOLOGY, V135, P1025, DOI 10.1210/en.135.3.1025; GRANNEMAN JG, 1992, MOL PHARMACOL, V42, P964; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GRANNEMAN JG, 1995, CELL SIGNAL, V7, P9, DOI 10.1016/0898-6568(94)00066-K; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; Hogan B, 1994, MANIPULATING MOUSE E; HOLLOWAY BR, 1992, AM J CLIN NUTR, V55, P262; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; RODRIGUEZ M, 1995, MOL BRAIN RES, V29, P369, DOI 10.1016/0169-328X(94)00274-I; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; STROMINGER JL, 1953, YALE J BIOL MED, V25, P383; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; THOMAS RF, 1993, MOL PHARMACOL, V43, P343; TSUJII S, 1992, BRAIN RES, V587, P226, DOI 10.1016/0006-8993(92)91001-U; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; WOODS SC, 1990, INT J OBESITY, V14, P69; WOODS SC, 1989, ANN NY ACAD SCI, V575, P236; YOSHIDA T, 1992, AM J CLIN NUTR, V55, P237; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	40	195	195	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17686	17693		10.1074/jbc.272.28.17686	http://dx.doi.org/10.1074/jbc.272.28.17686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211919	hybrid			2022-12-25	WOS:A1997XK16500062
J	Liao, J; Ku, NO; Omary, MB				Liao, J; Ku, NO; Omary, MB			Stress, apoptosis, and mitosis induce phosphorylation of human keratin 8 at Ser-73 in tissues and cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC SKIN DISEASES; INTERMEDIATE FILAMENTS; EPITHELIAL-CELLS; TRANSGENIC MICE; MITOTIC ARREST; PROTEIN-KINASE; SEQUENCE; EXPRESSION; CDNA; CYTOKERATIN-8	Simple epithelia express keratins 8 (K8) and 18 (K18) as their major intermediate filament proteins, We previously showed that several types of cell stress such as heat and virus infection result in a distinct hyperphosphorylated form of K8 (termed HK8). To better characterize K8/18 phosphorylation, we generated monoclonal antibodies by immunizing mice with hyperphosphorylated keratins that were purified from colonic cultured human HT29 cells pretreated with okadaic acid. One antibody specifically recognized HK8, and the epitope was identified as (71)LLpSPL which corresponds to K8 phosphorylation at Ser-73, Generation of HK8 occurs in mitotic HT29 cells, basal crypt mitotic cells in normal mouse intestine, and in regenerating mouse hepatocytes after partial hepatectomy, Prominent levels of HK8 were also generated in HT29 cells that were induced to undergo apoptosis using anisomycin or etoposide. In addition, mouse hepatotoxicity that is induced by chronic feeding with griseofulvin resulted in HK8 formation in the liver. Our results demonstrate that a ''reverse immunological'' approach, coupled with enhancing in vivo phosphorylation using phosphatase inhibitors, can result in the identification of physiologic phosphorylation states, As such, K8 Ser-73 phosphorylation generates a distinct HK8 species under a variety of in vivo conditions including mitosis, apoptosis, and cell stress. The low steady state levels of HK8 during mitosis, in contrast to stress and apoptosis, suggest that accumulation of HK8 may represent a physiologic stress marker for simple epithelia.	VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,CTR DIGEST DIS,STANFORD,CA 94305	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University				Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK47918, DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047918, P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; Ando S, 1996, BIOCHEM BIOPH RES CO, V221, P67, DOI 10.1006/bbrc.1996.0546; CHAN YM, 1993, P NATL ACAD SCI USA, V90, P7414, DOI 10.1073/pnas.90.15.7414; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1994, J CELL SCI, V107, P1833; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; COLLIN C, 1992, DIFFERENTIATION, V51, P137, DOI 10.1111/j.1432-0436.1992.tb00690.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GLASS C, 1988, J CELL BIOL, V107, P1337, DOI 10.1083/jcb.107.4.1337; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HUTTER H, 1993, LAB INVEST, V69, P576; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KLINGE EM, 1987, J MOL EVOL, V24, P319, DOI 10.1007/BF02134130; KNAPP B, 1986, NUCLEIC ACIDS RES, V14, P751, DOI 10.1093/nar/14.2.751; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRAUSS S, 1990, GENE, V86, P241, DOI 10.1016/0378-1119(90)90285-Y; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1997, J BIOL CHEM, V272, P7556, DOI 10.1074/jbc.272.11.7556; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; Ku NO, 1997, J CLIN INVEST, V99, P19, DOI 10.1172/JCI119127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LIAO J, 1995, EXP CELL RES, V219, P348, DOI 10.1006/excr.1995.1238; Liao J, 1996, ELECTROPHORESIS, V17, P1671, DOI 10.1002/elps.1150171104; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIAO J, 1995, J CELL BIOL, V131, P1291, DOI 10.1083/jcb.131.5.1291; LOCK RB, 1994, CANCER RES, V54, P4933; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORITA T, 1988, GENE, V68, P109; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; SAKAGUCHI Y, 1995, CANCER RES, V55, P5459; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; YAMAMOTO R, 1990, MOL ENDOCRINOL, V4, P370, DOI 10.1210/mend-4-3-370; Yang JM, 1996, J INVEST DERMATOL, V107, P439, DOI 10.1111/1523-1747.ep12365483	50	110	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17565	17573		10.1074/jbc.272.28.17565	http://dx.doi.org/10.1074/jbc.272.28.17565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211903	hybrid			2022-12-25	WOS:A1997XK16500046
J	Sundaramoorthy, M; Kishi, K; Gold, MH; Poulos, TL				Sundaramoorthy, M; Kishi, K; Gold, MH; Poulos, TL			Crystal structures of substrate binding site mutants of manganese peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; LIGNIN-DEGRADING BASIDIOMYCETE; EXTRACELLULAR HEME ENZYME; SPECTRAL CHARACTERIZATION; NONPHENOLIC LIGNIN; OXIDIZED STATES; MODEL COMPOUNDS; DEGRADATION; OXIDATION; MECHANISM	Manganese peroxidase (MnP), an extracellular heme enzyme from the lignin-degrading basidiomycetous fungus, Phanerochaete chrysosporium, catalyzes the oxidation of Mn-II to Mn-III. The latter, acting as a diffusible redox mediator, is capable of oxidizing a variety of lignin model compounds. The proposed Mn-II binding site of MnP consists of a heme propionate, three acidic Ligands (Glu-35, Glu-39, and Asp-179), and two water molecules. Using crystallographic methods, this binding site was probed by altering the amount of Mn-II bound to the protein. Crystals grown in the absence of Mn-II, or in the presence of EDTA, exhibited diminished electron density at this site, Crystals prawn in excess Mn-II exhibited increased electron density at the proposed binding site but nowhere else in the protein. This suggests that there is only one major Mn-II binding site in MnP. Crystal structures of a single mutant (D179N) and a double mutant (E35Q,D179N) at this site were determined, The mutant structures lack a cation at the Mn-II binding site. The structure of the Mn-II binding site is altered significantly in both mutants, resulting in increased access to the solvent and substrate.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92697; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOL BIOL,PORTLAND,OR 97291	University of California System; University of California Irvine; University of California System; University of California Irvine								Alic M, 1997, BBA-PROTEIN STRUCT M, V1338, P1, DOI 10.1016/S0167-4838(96)00235-X; ALIC M, 1990, CURR GENET, V17, P305, DOI 10.1007/BF00314877; BANCI L, 1993, BIOCHEMISTRY-US, V32, P5825, DOI 10.1021/bi00073a015; BAO WL, 1994, FEBS LETT, V354, P297, DOI 10.1016/0014-5793(94)01146-X; BRUNGER AT, 1992, XPLOP MANUAL; BUMPUS JA, 1987, BIOESSAYS, V6, P166, DOI 10.1002/bies.950060405; BUSWELL JA, 1987, CRC CR REV BIOTECHN, V6, P1, DOI 10.3109/07388558709086984; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; EDWARDS SL, 1987, BIOCHEMISTRY-US, V26, P1503, DOI 10.1021/bi00380a002; ENGH R, 1991, ACTA CRYSTALLOGR A, V47, P110; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GODFREY BJ, 1990, GENE, V93, P119, DOI 10.1016/0378-1119(90)90144-G; GOLD MH, 1989, ACS SYM SER, V389, P127; GOLD MH, 1993, MICROBIOL REV, V57, P605, DOI 10.1128/MMBR.57.3.605-622.1993; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HAMMEL KE, 1989, ENZYME MICROB TECH, V11, P776, DOI 10.1016/0141-0229(89)90129-4; HARRIS RZ, 1991, J BIOL CHEM, V266, P8751; HATAKKA A, 1994, FEMS MICROBIOL REV, V13, P125, DOI 10.1016/0168-6445(94)90076-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P824; JOHNSON F, 1993, PLANT PEROXIDASES BI, P31; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JOSHI DK, 1993, APPL ENVIRON MICROB, V59, P1779, DOI 10.1128/AEM.59.6.1779-1785.1993; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; Kishi K, 1996, BIOCHEMISTRY-US, V35, P8986, DOI 10.1021/bi960679c; KISHI K, 1994, BIOCHEMISTRY-US, V33, P8694, DOI 10.1021/bi00195a010; KUAN IC, 1993, J BIOL CHEM, V268, P20064; KUSTERSVANSOMEREN M, 1995, BIOCHEMISTRY-US, V34, P10620, DOI 10.1021/bi00033a037; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; MAYFIELD MB, 1994, GENE, V142, P231, DOI 10.1016/0378-1119(94)90266-6; MINO Y, 1988, J BIOL CHEM, V263, P7029; ORTH AB, 1994, GENE, V148, P161, DOI 10.1016/0378-1119(94)90251-8; ORTH AB, 1993, APPL ENVIRON MICROB, V59, P4017, DOI 10.1128/AEM.59.12.4017-4023.1993; PEASE EA, 1989, J BIOL CHEM, V264, P13531; PERIE FH, 1991, APPL ENVIRON MICROB, V57, P2240; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; SUNDARAMOORTHY M, 1994, J MOL BIOL, V238, P845, DOI 10.1006/jmbi.1994.1338; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; VALLI K, 1992, APPL ENVIRON MICROB, V58, P221, DOI 10.1128/AEM.58.1.221-228.1992; VALLI K, 1992, J BACTERIOL, V174, P2131, DOI 10.1128/JB.174.7.2131-2137.1992; WARIISHI H, 1989, J BIOL CHEM, V264, P14185; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X; WARIISHI H, 1992, J BIOL CHEM, V267, P23688	53	78	81	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17574	17580		10.1074/jbc.272.28.17574	http://dx.doi.org/10.1074/jbc.272.28.17574			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211904	hybrid			2022-12-25	WOS:A1997XK16500047
J	Bacolla, A; Gellibolian, R; Shimizu, M; Amirhaeri, S; Kang, S; Ohshima, K; Larson, JE; Harvey, SC; Stollar, BD; Wells, RD				Bacolla, A; Gellibolian, R; Shimizu, M; Amirhaeri, S; Kang, S; Ohshima, K; Larson, JE; Harvey, SC; Stollar, BD; Wells, RD			Flexible DNA: Genetically unstable CTG center dot CAG and CGG center dot CCG from human hereditary neuromuscular disease genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; HELICAL REPEAT; ESCHERICHIA-COLI; DYNAMIC CONTRIBUTIONS; PERSISTENCE LENGTH; TORSIONAL RIGIDITY; TRIPLET REPEATS; RING-CLOSURE; FLEXIBILITY; DEPENDENCE	The properties of duplex CTG.CAG and CGG.CCG, which are involved in the etiology of several hereditary neurodegenerative diseases, were investigated by a variety of methods, including circularization kinetics, apparent helical repeat determination, and polyacrylamide gel electrophoresis, The bending moduli were 1.13 x 10(-19) erg.cm for CTG and 1.27 x 10(-19) erg cm for CGG, similar to 40% less than for random B-DNA. Also, the persistence lengths of the triplet repeat sequences were similar to 60% the value for random B-DNA. However, the torsional moduli and the helical repeats were 2.3 x 10(-19) erg.cm and 10.4 base pairs (bp)/turn for CTG and 2.4 x 10(-19) erg.cm and 10.3 bp/turn for CGG, respectively, all within the range for random B-DNA, Determination of the apparent helical repeat by the band shift assay indicated that the writhe of the repeats was different from that of random B-DNA, In addition, molecules of 224-245 bp in length (64-71 triplet repeats) were able to form topological isomers upon cyclization. The low bending moduli are consistent with predictions from crystallographic variations in slide, roll, and tilt. No unpaired bases or non-B-DNA structures could be detected by chemical and enzymatic probe analyses, two-dimensional agarose gel electrophoresis, and immunological studies. Hence, CTG and CGG are more flexible and highly writhed than random B-DNA and thus would be expected to act as sinks for the accumulation of superhelical density.	TEXAS A&M UNIV, CTR GENOME RES, INST BIOSCI & TECHNOL, TEXAS MED CTR, HOUSTON, TX 77030 USA; TEXAS A&M UNIV, CTR GENOME RES, DEPT BIOCHEM & BIOPHYS, TEXAS MED CTR, HOUSTON, TX 77030 USA; UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Baylor College of Medicine; Texas A&M University System; Baylor College of Medicine; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston; University of Alabama System; University of Alabama Birmingham; Tufts University			Shimizu, Miho/O-9903-2019; Shimizu, Miho/Q-8522-2017; Bacolla, Albino/AAP-1727-2020; Bacolla, Albino/N-3877-2013	Shimizu, Miho/0000-0003-4070-8209; Shimizu, Miho/0000-0003-4070-8209; Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032375, P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32375, GM 52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BEDNAR J, 1995, J MOL BIOL, V254, P579, DOI 10.1006/jmbi.1995.0640; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; DAVIES KE, 1993, GENOME ANAL GENOME R, V7; Deissler H, 1996, J BIOL CHEM, V271, P4327; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DIEKMANN S, 1982, BIOPHYS CHEM, V15, P263, DOI 10.1016/0301-4622(82)80009-4; ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HARRINGTON RE, 1994, PROG NUCLEIC ACID RE, V47, P195, DOI 10.1016/S0079-6603(08)60253-6; Herbert JM, 1996, J BIOL CHEM, V271, P25928; HODGESGARCIA Y, 1995, J BIOL CHEM, V270, P197, DOI 10.1074/jbc.270.1.197; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KRAHE R, 1995, HYPERVARIABLE GENETI, P29; LEVENE SD, 1986, J MOL BIOL, V189, P73, DOI 10.1016/0022-2836(86)90382-7; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; NELSON DL, 1993, GENOME ANAL, V7, P1; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PANZER S, 1995, STEM CELLS, V13, P146, DOI 10.1002/stem.5530130206; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; SCHELLMAN JA, 1995, BIOPHYS CHEM, V55, P95, DOI 10.1016/0301-4622(94)00144-9; SHIMADA J, 1984, MACROMOLECULES, V17, P689, DOI 10.1021/ma00134a028; SHIMADA J, 1985, J MOL BIOL, V184, P319, DOI 10.1016/0022-2836(85)90383-3; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; Sinden R. R., 1995, DNA STRUCTURE FUNCTI; STOLLAR BD, 1992, PROG NUCLEIC ACID RE, V42, P39, DOI 10.1016/S0079-6603(08)60573-5; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; Trifonov E.N., 1987, STRUCTURE EXPRESSION, P243; ULANOVSKY L, 1986, P NATL ACAD SCI USA, V83, P862, DOI 10.1073/pnas.83.4.862; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WANG JC, 1966, J MOL BIOL, V19, P469, DOI 10.1016/S0022-2836(66)80017-7; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; YOUNG MA, 1995, BIOPHYS J, V68, P2454, DOI 10.1016/S0006-3495(95)80427-3	60	91	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16783	16792		10.1074/jbc.272.27.16783	http://dx.doi.org/10.1074/jbc.272.27.16783			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201983	hybrid			2022-12-25	WOS:A1997XH44600015
J	Collins, BE; Kiso, M; Hasegawa, A; Tropak, MB; Roder, JC; Crocker, PR; Schnaar, RL				Collins, BE; Kiso, M; Hasegawa, A; Tropak, MB; Roder, JC; Crocker, PR; Schnaar, RL			Binding specificities of the sialoadhesin family of I-type lectins - Sialic acid linkage and substructure requirements for binding of myelin-associated glycoprotein, Schwann cell myelin protein, and sialoadhesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE CD22-BETA; NEURON-SPECIFIC GANGLIOSIDE; LINKED CARBOHYDRATE UNITS; IMMUNOGLOBULIN SUPERFAMILY; FUNCTIONAL TOPOGRAPHY; ERYTHROCYTE RECEPTOR; TISSUE MACROPHAGES; NATURAL LIGANDS; L-SELECTIN; CD22	The carbohydrate binding specificities of three sialoadhesins, a subgroup of I-type lectins (immunoglobulin superfamily lectins), were compared by measuring lectin-transfected COS cell adhesion to natural and synthetic gangliosides. The neural sialoadhesins, myelin-associated glycoprotein (MAG) and Schwann cell myelin protein (SMP), had similar and stringent binding specificities, Each required an alpha 2,3-linked sialic acid on the terminal galactose of a neutral saccharide core, and they shared the following rank-order potency of binding: G(Q1b alpha) much greater than G(D1a) = G(T1b) much greater than G(M3) = G(M4) much greater than G(M1), G(D1b), G(D3), G(Q1b) (nonbinders). In contrast, sialoadhesin had less exacting specificity, binding to gangliosides that bear either terminal alpha 2,3- or alpha 2,8-linked sialic acids with the following rank-order potency of binding: G(Q1b alpha) > G(D1a) = G(D1b) = G(T1b) = G(M3) = G(M4) > G(D3) = G(Q1b) much greater than G(M1) (nonbinder), CD22 did not bind to any ganglioside tested. Binding of MAG, SMP, and sialoadhesin was abrogated by chemical modification of either the sialic acid carboxylic acid group or glycerol side chain on a target ganglioside. Synthetic ganglioside G(M3) derivatives further distinguished lectin binding specificities, Deoxy and/or methoxy derivatives of the 4-, 7-, 8-, or g-position of sialic acid attenuated or eliminated binding of MAG, as did replacement of the sialic acid acetamido group with a hydroxyl. In contrast, the 4- and 7-deoxysialic acid derivatives supported sialoadhesin binding at near control levels (the other derivatives did not support binding). These data are consistent with sialoadhesin binding to one face of the sialic acid moiety, whereas MAG (and SMP) may have more complex binding sites or may bind sialic acids only in the context of more restricted oligosaccharide conformations.	JOHNS HOPKINS UNIV,DEPT PHARMACOL,SCH MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT NEUROSCI,SCH MED,BALTIMORE,MD 21205; GIFU UNIV,DEPT APPL BIOORGAN CHEM,GIFU 50111,JAPAN; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND	Johns Hopkins University; Johns Hopkins University; Gifu University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Cancer Research UK; University of Oxford			Roder, John/G-6468-2013; Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Crocker, Paul/0000-0001-6230-0293	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07626] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTIA J, 1993, J NEUROCHEM, V61, P718; BLACKBURN CC, 1986, J BIOL CHEM, V61, P2873; BLACKBURN CC, 1983, J BIOL CHEM, V258, P11800; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; CROCKER PR, 1989, J EXP MED, V169, P1333, DOI 10.1084/jem.169.4.1333; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; CROCKER PR, 1986, J EXP MED, V164, P1862, DOI 10.1084/jem.164.6.1862; DELL A, 1994, METHOD ENZYMOL, V230, P108; DERRINGTON EA, 1989, J NEUROCHEM, V53, P1686, DOI 10.1111/j.1471-4159.1989.tb09231.x; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; FAHRIG T, 1993, EUR J NEUROSCI, V5, P1118, DOI 10.1111/j.1460-9568.1993.tb00966.x; FERRETTI P, 1986, J NEUROCHEM, V46, P1888; FINNE J, 1975, BIOCHIM BIOPHYS ACTA, V412, P317, DOI 10.1016/0005-2795(75)90046-X; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HOTTA K, 1995, J CARBOHYD CHEM, V14, P491, DOI 10.1080/07328309508005353; HOTTA K, 1994, J CARBOHYD CHEM, V13, P665, DOI 10.1080/07328309408011673; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KISO M, 1994, METHOD ENZYMOL, V242, P173; Kogan TP, 1995, J MED CHEM, V38, P4976, DOI 10.1021/jm00026a004; LEDEEN RW, 1979, COMPLEX CARBOHYDRATE, P1; MEYERFRANKE A, 1995, J NEUROSCI RES, V41, P311, DOI 10.1002/jnr.490410304; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RAO BNN, 1994, J BIOL CHEM, V269, P19663; SADOUL R, 1990, J NEUROSCI RES, V25, P1, DOI 10.1002/jnr.490250102; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SGROI D, 1993, J BIOL CHEM, V268, P7011; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR6; TRAPP BD, 1990, ANN NY ACAD SCI, V605, P29, DOI 10.1111/j.1749-6632.1990.tb42378.x; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; Yang LJS, 1996, ANAL BIOCHEM, V236, P161, DOI 10.1006/abio.1996.0145	53	121	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16889	16895		10.1074/jbc.272.27.16889	http://dx.doi.org/10.1074/jbc.272.27.16889			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201997	hybrid			2022-12-25	WOS:A1997XH44600029
J	Hubner, S; Xiao, CY; Jans, DA				Hubner, S; Xiao, CY; Jans, DA			The protein kinase CK2 site (Ser(111/112)) enhances recognition of the Simian virus 40 large T-antigen nuclear localization sequence by importin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; TRANSPORT; IDENTIFICATION; SIGNAL; PHOSPHORYLATION; SUBSTRATE; CELLS; NUCLEOPORINS; LOCATION; BINDING	The mechanism by which phosphorylation regulates nuclear localization sequence (NLS)-dependent nuclear protein import is largely unclear. Whereas nuclear accumulation of SV40 large tumor antigen (T-ag) fusion proteins is completely dependent on the T-ag NLS (amino acids 126-132), the rate of nuclear import is increased 50-fold by amino acid residues 111-125 and in particular a site for the protein kinase CK2 (CK2) at serine 111/112. Because the first step of nuclear protein import involves the binding of the NLS by an NLS-receptor complex such as the importin 58/97 heterodimer, we established a novel enzyme-linked immunosorbent assay to test whether NLS recognition is influenced by amino acids amino-terminal to the NLS and the CK2 site. We found that recognition of the T-ag NLS by importin 58/97 was enhanced 10-fold in the presence of amino acid residues 111-125 and strongly dependent on importin 97. A T-ag fusion protein in which the spacer between the CK2 site and the NLS was decreased showed 30% reduced binding by importin 58/97. Maximal nuclear accumulation of this protein was reduced by more than 50%, indicating the physiological importance of the correctly positioned CK2 site. Phosphorylation by CR2 increased the T-ag NLS binding affinity for importin 58/97 by a further 40%. We conclude that flanking sequences and in particular phosphorylation at the CK2 site are mechanistically important in NLS recognition and represent the basis of their enhancement of T-ag nuclear import. This study thus represents the first elucidation of the mechanistic basis of the regulation of nuclear protein import through phosphorylation within a phosphorylation-regulated NLS.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOL BIOL, NUCL SIGNAL LAB, CANBERRA, ACT 2601, AUSTRALIA	Australian National University; John Curtin School of Medical Research								ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451	38	217	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17191	17195		10.1074/jbc.272.27.17191	http://dx.doi.org/10.1074/jbc.272.27.17191			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202041	hybrid			2022-12-25	WOS:A1997XH44600073
J	Kahsai, TZ; Enders, GC; Gunwar, S; Brunmark, C; Wieslander, J; Kalluri, R; Zhou, J; Noelken, ME; Hudson, BG				Kahsai, TZ; Enders, GC; Gunwar, S; Brunmark, C; Wieslander, J; Kalluri, R; Zhou, J; Noelken, ME; Hudson, BG			Seminiferous tubule basement membrane - Composition and organization of type IV collagen chains, and the linkage of alpha 3(IV) and alpha 5(IV) chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCOLLAGENOUS DOMAIN HEXAMER; RECESSIVE ALPORT SYNDROME; AMINO-ACID-SEQUENCE; GOODPASTURE ANTIGEN; POLYACRYLAMIDE GELS; ALPHA-4(IV) CHAIN; CDNA ISOLATION; COL4A3 GENE; IDENTIFICATION; LOCALIZATION	Seminiferous tubule basement membrane (STEM) plays an important role in spermatogenesis, In the present study, the composition and structural organization of type IV collagen of bovine STEM was investigated, STEM was found to be composed of all six a-chains of type IV collagen based upon immunocytochemical and biochemical analysis, The content of alpha 3(IV) chain (40%) and the alpha 4(IV) chain (18%) was substantially higher than in any other basement membrane collagen, The supramolecular structure of the six alpha(IV) chains was investigated using pseudolysin (EC 3.4.24.26) digestion to excise triple-helical molecules, subsequent collagenase digestion to produce NC1 hexamers and antibody affinity chromatography to resolve populations of NC1 hex amers, The hexamers, which reflect specific arrangements of alpha(IV) chains, were characterized for their alpha(IV) chain composition using high performance liquid chromatography, two-dimensional electrophoresis, and immunoblotting with alpha(IV) chain-specific antibodies, Three major hexamer populations were found that represent the classical network of the alpha 1(IV) and alpha 2(IV) chains and two novel networks, one composed of the alpha 1(IV)-alpha 6(IV) chains and the other composed of the alpha 3(IV)-alpha 6(IV) chains, The results establish a structural linkage between the alpha 3(IV) and alpha 5(IV) chains, suggesting a molecular basis for the conundrum in which mutations in the gene encoding the alpha 5(IV) chain cause defective assembly of the alpha 3(IV) chain in the glomerular basement membrane of patients with Alport syndrome.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT ANAT & CELL BIOL,KANSAS CITY,KS 66160; UNIV LUND HOSP,DEPT NEPHROL,S-22185 LUND,SWEDEN; UNIV PENN,SCH MED,PENN CTR MOL STUDIES KIDNEY DIS RENAL ELECTROLYTE,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Lund University; Skane University Hospital; University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Harvard Medical School			; Kalluri, Raghu/E-2677-2015	Hudson, Billy/0000-0002-5420-4100; Kalluri, Raghu/0000-0002-2190-547X	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381] Funding Source: NIH RePORTER; NCRR NIH HHS [BRSG S07 RR05373] Funding Source: Medline; NIDDK NIH HHS [DK 18381] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; DAVIDOFF MS, 1990, CELL TISSUE RES, V262, P253, DOI 10.1007/BF00309880; DEKRETSER DM, 1975, BIOL REPROD, V12, P317, DOI 10.1095/biolreprod12.3.317; ENDERS GC, 1986, J CELL BIOL, V103, P1109, DOI 10.1083/jcb.103.3.1109; ENDERS GC, 1995, BIOL REPROD, V53, P1489, DOI 10.1095/biolreprod53.6.1489; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUNWAR S, 1991, AM J RESP CELL MOL, V5, P107, DOI 10.1165/ajrcmb/5.2.107; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KALLURI R, 1995, KIDNEY INT, V47, P1199, DOI 10.1038/ki.1995.170; KALLURI R, 1994, KIDNEY INT, V45, P721, DOI 10.1038/ki.1994.96; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269; LIAN G, 1992, BIOL REPROD, V47, P316, DOI 10.1095/biolreprod47.3.316; LONG CG, 1995, BIOPOLYMERS, V35, P621, DOI 10.1002/bip.360350608; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Miner JH, 1996, J CELL BIOL, V135, P1403, DOI 10.1083/jcb.135.5.1403; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; MORIHARA K, 1995, METHOD ENZYMOL, V248, P242; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OOHASHI T, 1994, J BIOL CHEM, V269, P7520; PARANKO J, 1992, CELL TISSUE RES, V268, P521, DOI 10.1007/BF00319159; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; QUINONES S, 1992, J BIOL CHEM, V267, P19780; SALOMON F, 1982, LAB INVEST, V47, P543; SAUS J, 1989, J BIOL CHEM, V264, P6318; SAUS J, 1988, J BIOL CHEM, V263, P13374; SCHLATT S, 1993, J ANDROL, V14, P340; SOININEN R, 1987, FEBS LETT, V225, P188; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; TUNG K, 1988, HOSP PRACT, V23, P191; TUNG K, 1988, HOSP PRACT OFF ED, V23, P205; TUNG K, 1988, HOSP PRACT OFF ED, V23, P201; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; VERGOUWEN RPFA, 1991, J REPROD FERTIL, V93, P233, DOI 10.1530/jrf.0.0930233; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WISDOM BJ, 1992, CONNECT TISSUE RES, V27, P225, DOI 10.3109/03008209209006998; YURCHENCO PD, 1994, METHOD ENZYMOL, V245, P489; ZHOU J, 1994, J BIOL CHEM, V269, P13193; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1992, J BIOL CHEM, V267, P12475; [No title captured]	66	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17023	17032		10.1074/jbc.272.27.17023	http://dx.doi.org/10.1074/jbc.272.27.17023			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202017	hybrid			2022-12-25	WOS:A1997XH44600049
J	Matsumoto, A; Mitchell, A; Kurata, H; Pyle, L; Kondo, K; Itakura, H; Fidge, N				Matsumoto, A; Mitchell, A; Kurata, H; Pyle, L; Kondo, K; Itakura, H; Fidge, N			Cloning and characterization of HB2, a candidate high density lipoprotein receptor - Sequence homology with members of the immunoglobulin superfamily of membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; RAT; PURIFICATION; LIVER; EXPRESSION; CELLS; ACID	The protection against coronary artery disease attributed to high density lipoprotein (HDL) may be associated with several functions, including its central role in reverse cholesterol transport, possible antioxidant and antithrombotic properties and others not yet identified which may depend on specific interactions between HDL and cell receptors. Several HDL-binding proteins have been identified including two candidate liver HDL receptors, HB1 and HB2 recently purified in this laboratory, We now report the cloning, sequencing and some properties of HB2, the most abundant of the pair, it shows significant homology with the adhesion molecules ALCAM and BEN of the immunoglobulin superfamily and the cDNA, when transfected into HepG2 or eos cells, caused specific HDL3 binding to increase by 80-100%. Further, ligand blotting of glycoproteins isolated from phorbol 12-myristate 13-acetate-treated THP-1 cells or from transfected HepG2 and Chinese hamster ovary cells also provided evidence of increased binding of HDL3 to HB2, Differentiation of THP-1 cells into macrophages resulted in a striking increase in HB2 mRNA which was attenuated if cells were cholesterol-loaded by incubation with attenuated law density lipoprotein. If the interaction between HDL and NE, reduces the adhesion-induced inflammatory cellular events that characterize arterial wall injury, thereby achieving the protect-ion associated with higher plasma levels of HDL, these findings may provide a clue to one mitigating effect of HDL in heart disease.	BAKER MED RES INST,MELBOURNE,VIC 3181,AUSTRALIA; NATL INST HLTH & NUTR,TOKYO 162,JAPAN	Baker Heart and Diabetes Institute; National Institute of Health & Nutrition - Japan								Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AILHAUD G, 1992, CURR OPIN LIPIDOL, V3, P222; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOND HM, 1991, BIOCHEM J, V279, P633, DOI 10.1042/bj2790633; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; DECROM RPG, 1994, ARTERIOSCLER THROMB, V14, P305, DOI 10.1161/01.ATV.14.2.305; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HABENER JF, 1988, P NATL ACAD SCI USA, V85, P1735, DOI 10.1073/pnas.85.6.1735; HIDAKA H, 1992, BIOCHEM J, V284, P161, DOI 10.1042/bj2840161; KAGAMI A, 1985, J LIPID RES, V26, P705; LUTTON C, 1994, CR ACAD SCI III-VIE, V317, P731; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; MATHAI D, 1990, ARTERIOSCLEROSIS, V10, P1045, DOI 10.1161/01.ATV.10.6.1045; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; PIETERS MN, 1991, BIOCHEM J, V280, P359, DOI 10.1042/bj2800359; POURQUIE O, 1992, P NATL ACAD SCI USA, V89, P5261, DOI 10.1073/pnas.89.12.5261; REICHL D, 1989, ARTERIOSCLEROSIS, V9, P785, DOI 10.1161/01.ATV.9.6.785; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; Tribble DL, 1995, J LIPID RES, V36, P2580; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; ZEIHER AM, 1994, CIRCULATION, V89, P2525, DOI 10.1161/01.CIR.89.6.2525	24	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16778	16782		10.1074/jbc.272.27.16778	http://dx.doi.org/10.1074/jbc.272.27.16778			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201982	hybrid			2022-12-25	WOS:A1997XH44600014
J	Schwarz, O; Schurmann, P; Strotmann, H				Schwarz, O; Schurmann, P; Strotmann, H			Kinetics and thioredoxin specificity of thiol modulation of the chloroplast H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; ENERGY-DEPENDENT CHANGES; GAMMA-SUBUNIT; SPINACH-CHLOROPLASTS; CDNA SEQUENCE; SYNTHASE; ACTIVATION; PHOTOPHOSPHORYLATION; CONFORMATION; HYDROLYSIS	The kinetics of thiol modulation of the chloroplast H+-ATPase (CF0CF1) in membrana were analyzed by employing thioredoxins that were kept reduced by 0.1 mM dithiothreitol. The kinetics of thiol modulation depend on the extent of the proton gradient. The process is an exponential function of the thioredoxin concentration and reaction time and can be described by an irreversible second order reaction. The results indicate that the formation of the complex between thioredoxin and CF0CF1 is slow compared with the subsequent reduction step. Furthermore we have compared the efficiencies of the Escherichia coli thioredoxin Trx and the two chloroplast thioredoxins Tr-m and Tr-f. The second order rate constants are 0.057 (Tr-f), 0.024 (Trx), and 0.010 s(-1) mu M-1 (Tr-m) suggesting that Tr-f rather than Tr-m is the physiological reductant for the chloroplast ATPase. The often employed artificial reductant dithiothreitol exhibits a second order rate constant in thiol modulation of 1.02.10(-6) s(-1) mu M-1.	UNIV DUSSELDORF,INST BIOCHEM PFLANZEN,D-40225 DUSSELDORF,GERMANY; UNIV NEUCHATEL,LAB BIOCHIM VEGETALE,CH-2007 NEUCHATEL,SWITZERLAND	Heinrich Heine University Dusseldorf; University of Neuchatel								AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BAKKERGRUNWALD T, 1974, BIOCHIM BIOPHYS ACTA, V347, P290, DOI 10.1016/0005-2728(74)90052-8; BARZVI D, 1980, FEBS LETT, V119, P68, DOI 10.1016/0014-5793(80)80999-9; BUCHANAN BB, 1979, TRENDS BIOCHEM SCI, V4, P93, DOI 10.1016/0968-0004(79)90191-9; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DANN MS, 1992, PLANT PHYSIOL, V99, P153, DOI 10.1104/pp.99.1.153; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GALMICHE JM, 1990, BIOCHIMIE, V72, P25, DOI 10.1016/0300-9084(90)90169-H; GRABER P, 1977, BIOCHIM BIOPHYS ACTA, V461, P426, DOI 10.1016/0005-2728(77)90231-6; GROTH G, 1995, FEBS LETT, V358, P142, DOI 10.1016/0014-5793(94)01414-V; JACQUOT JP, 1978, FEBS LETT, V96, P243, DOI 10.1016/0014-5793(78)80410-4; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; KOMATSUTAKAKI M, 1992, J BIOL CHEM, V267, P2360; KOTHEN G, 1995, BBA-BIOENERGETICS, V1229, P208, DOI 10.1016/0005-2728(95)00005-4; LOHSE D, 1989, BIOCHIM BIOPHYS ACTA, V976, P94, DOI 10.1016/S0005-2728(89)80193-8; LOHSE D, 1989, BIOCHIM BIOPHYS ACTA, V976, P85, DOI 10.1016/S0005-2728(89)80192-6; MCCARN DF, 1988, J BACTERIOL, V170, P3448, DOI 10.1128/jb.170.8.3448-3458.1988; MCCARTY RE, 1968, J BIOL CHEM, V243, P129; MCKINNEY DW, 1977, PHYTOCHEMISTRY, V17, P794; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MILLS JD, 1980, FEBS LETT, V112, P173, DOI 10.1016/0014-5793(80)80173-6; MORONEY JV, 1982, J BIOL CHEM, V257, P5915; MORONEY JV, 1984, J BIOL CHEM, V269, P7281; PANCIC PG, 1993, FEBS LETT, V320, P61, DOI 10.1016/0014-5793(93)81658-M; PETRACK B, 1965, J BIOL CHEM, V240, P906; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; SCHULDINER S, 1972, EUR J BIOCHEM, V25, P64, DOI 10.1111/j.1432-1033.1972.tb01667.x; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SCHUMANN J, 1981, PHOTOSYNTHESIS, V2, P881; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; SHOSHAN V, 1979, J BIOL CHEM, V254, P8801; STRELOW F, 1993, FEBS LETT, V323, P19, DOI 10.1016/0014-5793(93)81439-7; STROTMANN H, 1990, EUR J BIOCHEM, V193, P879, DOI 10.1111/j.1432-1033.1990.tb19412.x; STROTMANN H, 1987, FEBS LETT, V221, P265, DOI 10.1016/0014-5793(87)80938-9; STROTMANN H, 1984, ANNU REV PLANT PHYS, V35, P97; STROTMANN H, 1973, BIOCHIM BIOPHYS ACTA, V314, P202, DOI 10.1016/0005-2728(73)90135-7; STROTMANN H, 1977, BIOCHIM BIOPHYS ACTA, V460, P126, DOI 10.1016/0005-2728(77)90158-X; VanWalraven HS, 1996, FEBS LETT, V379, P309, DOI 10.1016/0014-5793(95)01536-1; WEISS MA, 1977, J BIOL CHEM, V252, P8007; WERNER S, 1990, FEBS LETT, V261, P204, DOI 10.1016/0014-5793(90)80671-5; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; WOLOSIUK RA, 1977, NATURE, V266, P565, DOI 10.1038/266565a0; YU LM, 1988, J BIOL CHEM, V263, P19342	44	82	84	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16924	16927		10.1074/jbc.272.27.16924	http://dx.doi.org/10.1074/jbc.272.27.16924			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202002	Green Submitted, hybrid			2022-12-25	WOS:A1997XH44600034
J	Zhang, N; Zhong, R; Wang, ZY; Deuel, TF				Zhang, N; Zhong, R; Wang, ZY; Deuel, TF			Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFIN REGULATORY PEPTIDE; HEPARIN-BINDING-PROTEIN; DEVELOPING BRAIN; CELLS; EXPRESSION; CLONING; ACID; PURIFICATION; MOUSE; TUMOR	Pleiotrophin (PTN) is a recently described 18- kDa heparin binding growth/differentiation factor. It also is a proto-oncogene; cells transformed by the Ptn gene form highly angiogenic tumors when implanted into the nude mouse. PTN may be an important regulator of transformation in other tumors, because constitutively high levels of expression of the pleiotrophin (Ptn) gene are found in human breast cancer and other malignant cell lines, and its levels of expression are high in many human tumor specimens. To determine whether PTN is an important regulator of the malignant phenotype of human breast cancer cells, we constructed a mutant cDNA to encode a truncated PTN designed to heterodimerize with the product of the endogenous Ptn gene during processing, The mutant gene product blocked transformation of NIH 3T3 cells by the wild type (wt) Ptn gene product, The mutant Ptn cDNA was then introduced into human breast cancer MDA-MB-231 cells, and clonal lines that stably express the mutant Ptn cDNA were selected. The truncated PTN was shown to form heterodimers with the endogenous Ptn gene product in these cells. Furthermore, the MDA-MB-231 cells that express the mutant Ptn gene were no longer transformed; they failed to form plaques or colonies in soft agar and were unable to form tumors in the athymic nude mouse, The results establish an important role of PTN in the dysregulated growth of human breast cancer cells and suggest that constitutive expression of PTN may be essential to the malignant phenotype of human breast cancers in vivo.	HARVARD UNIV, SCH MED,DIV GROWTH REGULAT, BETH ISRAEL DEACONESS MED CTR,DEPT MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NCI NIH HHS [CA66029, CA49712-06] Funding Source: Medline; NHLBI NIH HHS [HL14147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712, R01CA066029] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen Y, 1996, MOL CARCINOGEN, V17, P112, DOI 10.1002/(SICI)1098-2744(199611)17:3<112::AID-MC2>3.0.CO;2-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DELBE J, 1995, J CELL PHYSIOL, V164, P47, DOI 10.1002/jcp.1041640107; FABRI L, 1992, BIOCHEM INT, V28, P1; FANG WJ, 1992, J BIOL CHEM, V267, P25889; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; RAULAIS D, 1991, BIOCHEM BIOPH RES CO, V174, P708, DOI 10.1016/0006-291X(91)91475-R; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAMATSU H, 1992, BIOCHEM BIOPH RES CO, V185, P224, DOI 10.1016/S0006-291X(05)80979-9; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; TSUTSUI J, 1993, CANCER RES, V53, P1281; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; YEH HJ, 1993, 23 ANN M SOC NEUR; ZHOU HY, 1992, BIOCHEM BIOPH RES CO, V186, P1288, DOI 10.1016/S0006-291X(05)81545-1	26	75	81	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16733	16736		10.1074/jbc.272.27.16733	http://dx.doi.org/10.1074/jbc.272.27.16733			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201975	hybrid			2022-12-25	WOS:A1997XH44600007
J	Liu, B; Hannun, YA				Liu, B; Hannun, YA			Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACID SPHINGOMYELINASE; CELL-DIFFERENTIATION; HL-60 CELLS; CERAMIDE; APOPTOSIS; PURIFICATION; METABOLISM; DEPLETION; CYCLE	Sphingomyelin hydrolysis through the activation of sphingomyelinases has become a potentially important signaling pathway with the product ceramide implicated in the regulation of cell growth, differentiation, apoptosis, and inflammatory responses. However, little is known about the regulation of sphingomyelinases, In this study, we show that the magnesium-dependent, neutral pH-optimum and membrane-associated sphingomyelinase (N-SMase) is inhibited, in a dose-dependent manner, by glutathione (GSH) at physiological concentrations with a greater than 95% inhibition observed at 5 mn GSH. The inhibitory effect of GSH was reproduced by gamma-glutamyl-cysteine, but not the cysteinyl-glycine fragment of GSH, The S-modified GSH analogs were as effective as GSH in inhibiting the N-SMase. On the other hand, neither dithiothreitol nor beta-mercaptoethanol had any effect on the N-SMase, suggesting that the sulfhydryl in GSH is not required for inhibition of N-SMase, GSH had no effect on the acid pH-optimum SMase, whereas dithiothreitol inhibited the acid SMase. These results suggest that in cells the N-SMase is inactive in the presence of physiological concentrations of GSH (1-20 mM). Finally, treatment of cultured Molt-4 cells with the GSH synthesis inhibitor, L-buthionine-(SR)-sulfoximine, resulted in a time-dependent depletion of GSH, accompanied by an increased hydrolysis of sphingomyelin and production of ceramide. Since GSH depletion is observed in a variety of cells in the process of cellular injury and apoptosis, these studies suggest that depletion of GSH may be an important mechanism in activation of N-SMase. This mechanism may therefore bring together the fields of oxidative stress and signaling through products of sphingomyelin hydrolysis.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825, F32GM017426] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM017426, F32 GM017426-01A1, GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; CHRISTIE NA, 1994, ARCH BIOCHEM BIOPHYS, V313, P131, DOI 10.1006/abbi.1994.1369; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; GERARDMONNIER D, 1992, BIOCHEM PHARMACOL, V43, P451, DOI 10.1016/0006-2952(92)90563-X; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KIM MY, 1991, J BIOL CHEM, V266, P484; KITAGAWA T, 1987, JPN J HUM GENET, V32, P55, DOI 10.1007/BF01893159; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LEVINE ES, 1993, CARDIOVASC RES, V27, P1248, DOI 10.1093/cvr/27.7.1248; LU SC, 1992, J CLIN INVEST, V90, P524, DOI 10.1172/JCI115890; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MUTOH H, 1991, AM J PHYSIOL, V261, pG65, DOI 10.1152/ajpgi.1991.261.1.G65; Nyberg L, 1996, BBA-LIPID LIPID MET, V1300, P42, DOI 10.1016/0005-2760(95)00245-6; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PIERSON HF, 1985, CANCER RES, V45, P4727; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; STRUM JC, 1994, J BIOL CHEM, V269, P15493; TATE SS, 1974, J BIOL CHEM, V249, P7593; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TIEFZE F, 1969, ANAL BIOCHEM, V27, P502; Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAMANAKA T, 1982, J NEUROCHEM, V38, P1753, DOI 10.1111/j.1471-4159.1982.tb06659.x; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	52	257	274	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16281	16287		10.1074/jbc.272.26.16281	http://dx.doi.org/10.1074/jbc.272.26.16281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195931	hybrid			2022-12-25	WOS:A1997XG01900035
J	Cairns, LA; Crotta, S; Minuzzo, M; RicciardiCastagnoli, P; Pozzi, L; Ottolenghi, S				Cairns, LA; Crotta, S; Minuzzo, M; RicciardiCastagnoli, P; Pozzi, L; Ottolenghi, S			Immortalization of neuro-endocrine cells from adrenal tumors arising in SV40 T-transgenic mice	ONCOGENE			English	Article						pheochromocytoma; transgenic mice; adrenal medullary tumor; ret	INTENSELY FLUORESCENT CELLS; NERVE GROWTH-FACTOR; RET PROTOONCOGENE; CHROMAFFIN CELLS; CREST DERIVATIVES; EXPRESSION; GENE; DIFFERENTIATION; RAT; GLUCOCORTICOIDS	Pheochromocytomas are adrenal medullary tumors which arise from the transformation of neural crest-derived cells. In the course of studies of mice transgenic for an SV40 T-gene ectopically expressed in the adrenal medulla, we observed the occurrence of large, mainly bilateral tumors in a high proportion of transgenic animals. From these tumors we established immortalized cell lines which grow in vitro at 32 degrees C (the permissive temperature for the tsA58 T-protein encoded by the transgene), but not at 38 degrees C. These cells demonstrate characteristics of both neuronal (160 kd neurofilament) and endocrine (chromogranins) cells. The expression of Mash-1 and ret supports their initial characterization as early bipotential neuro-endocrine progenitors.	CNR,CTR STUDIO FARMACOL CELLULARE & MOL,I-20133 MILAN,ITALY; UNIV ROME,SEZ BIOL CELLULARE,DIP BIOPATHOL UMANA,ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Cairns, LA (corresponding author), UNIV MILAN,DIP GENET & BIOL MICROORGANISMI,MILAN,ITALY.			Crotta, Stefania/0000-0003-4676-8616				Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; ANDERSON DJ, 1989, TRENDS GENET, V5, P74; BABINET C, 1989, GENOME, V31, P938, DOI 10.1139/g89-165; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; CAIRNS LA, 1994, EMBO J, V13, P4577, DOI 10.1002/j.1460-2075.1994.tb06779.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAUDE P, 1988, NEURON, V1, P783, DOI 10.1016/0896-6273(88)90126-2; DOUPE AJ, 1985, J NEUROSCI, V5, P2143; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; EIDEN LE, 1987, NEUROSCIENCE, V21, P1019, DOI 10.1016/0306-4522(87)90056-X; ERANKO O, 1972, HISTOCHEM J, V4, P49, DOI 10.1007/BF01005268; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; IKEDA I, 1990, ONCOGENE, V5, P1291; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; LANDIS SC, 1981, TRENDS NEUROSCI, V4, P172, DOI 10.1016/0166-2236(81)90056-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POSSENTI R, 1989, EMBO J, V8, P2217, DOI 10.1002/j.1460-2075.1989.tb08345.x; ROBINSON MO, 1994, P NATL ACAD SCI USA, V91, P12798, DOI 10.1073/pnas.91.26.12798; SANTORO M, 1990, ONCOGENE, V5, P1595; SHALNIK DG, 1991, MOL CELL BIOL, V11, P4518; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; UNSICKER K, 1989, INT J DEV NEUROSCI, V7, P413, DOI 10.1016/0736-5748(89)90002-6; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WHITE LA, 1994, J NEUROSCI, V14, P6744; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3093	3098		10.1038/sj.onc.1201137	http://dx.doi.org/10.1038/sj.onc.1201137			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223673				2022-12-25	WOS:A1997XG10000012
J	Edelson, MI; Scherer, SW; Tsui, LC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Edelson, MI; Scherer, SW; Tsui, LC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas	ONCOGENE			English	Article						ovary; cancer; borderline; LOH; chromosome 7	TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; HUMAN BORDERLINE; SQUAMOUS-CELL; ALLELIC LOSS; CANCER; HETEROZYGOSITY; HUMAN-CHROMOSOME-7; MALIGNANCIES; ALLELOTYPE	We have used polymerase chain reaction (PCR) amplification of tandem repeats to study the pattern of allelic loss on chromosome 7q31 in invasive epithelial ovarian carcinomas and borderline ovarian tumors. Using 13 primer sets spanning loci from 7q31 to 7q32, 16 borderline and 54 invasive ovarian tumor tissue, together with their corresponding normal tissue, were analysed. Invasive epithelial ovarian tumors demonstrated loss of heterozygosity (LOH) at one or more loci on 7q in 32 of 54 cases (59%). The invasive epithelial ovarian tumors demonstrated the highest percentage of LOH at the loci D7S643 (20 of 40 informative cases, 50%) and GATA44F09 (18 of 42 informative cases, 43%). In contrary, only one borderline ovarian tumor showed LOH at one locus (GATA44F09, one of 14 informative cases, 7%). Our results display a sharp contrast in the pattern of LOH between invasive and borderline ovarian tumors suggesting that allelic loss at chromosome 7q31.3 may be involved in the development and progression of invasive epithelial ovarian tumors but not borderline ovarian tumors. Further analysis of the deletion map for the invasive epithelial ovarian tumors showed two regions Likely to harbor ovarian tumor suppressor genes including a novel 1300 kilobase common loss region flanked by GATA44F09 and D7S643.	BRIGHAM & WOMENS HOSP,LAB GYNECOL ONCOL,DIV GYNECOL ONCOL,DEPT OBSTET GYNECOL & REPROD BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999	NATIONAL CANCER INSTITUTE [R01CA063381, R01CA069291, R01CA069453] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69291, R01CA69453, R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON GM, 1993, AM J HEMATOL, V42, P171, DOI 10.1002/ajh.2830420206; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; Bryan EJ, 1996, CANCER RES, V56, P719; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CLIBY W, 1993, CANCER RES, V53, P2393; Davis M, 1996, CANCER RES, V56, P741; DODSON MK, 1993, CANCER RES, V53, P4456; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1992, DIS MARKERS, V10, P95; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1990, GYNECOL ONCOL, V38, P473, DOI 10.1016/0090-8258(90)90094-2; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; Kerr J, 1996, ONCOGENE, V13, P1815; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; LEE JH, 1990, CANCER RES, V50, P2724; Lin JC, 1996, ONCOGENE, V13, P2001; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SATO T, 1991, CANCER RES, V51, P5118; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TANAKA K, 1989, CANCER GENET CYTOGEN, V43, P1, DOI 10.1016/0165-4608(89)90122-2; Tangir J, 1996, ONCOGENE, V12, P735; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	37	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2979	2984		10.1038/sj.onc.1201271	http://dx.doi.org/10.1038/sj.onc.1201271			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205105				2022-12-25	WOS:A1997XF55500012
J	Knoepfler, PS; Kamps, MP				Knoepfler, PS; Kamps, MP			The highest affinity DNA element bound by Pbx complexes in t(1;19) leukemic cells fails to mediate cooperative DNA-binding or cooperative transactivation by E2a-Pbx1 and class I Hox proteins - Evidence for selective targetting of E2a-Pbx1 to a subset of Pbx-recognition elements	ONCOGENE			English	Article						Pbx; E2a-Pbx1; Hox; t(1;19) pre-B ALL	EMBRYONAL CARCINOMA-CELLS; HUMAN PROTOONCOGENE PBX1; HOMEOBOX GENES; RETINOIC ACID; PRE-B; TRANSLOCATION PROTEIN; TRANSCRIPTION FACTOR; HOMEODOMAIN; MOTIF; EXTRADENTICLE	Oncoprotein E2a-Pbx1 contains the N-terminal transactivation domains of E2a and the majority of the homeodomain protein, Pbx1, Using recombinant proteins, both Pbx1 and E2a-Pbx1 heterodimerize with Hox proteins on bipartite elements, Pbx1 binding a 5' TGAT core and Class I Hox proteins binding adjacent 3' TAAT, TTAT, or TGAT cores. In contrast to these in vitro results, nuclear extracts from E2a-Pbx1-transformed cells assemble an abundant Pbx-containing complex on TGATTGAT that excludes E2a-Pbx1, suggesting that an uncharacterized in vivo partner discriminates between E2a-Pbx1 and Pbx proteins, distinguishing it from Hox proteins. Here, we describe the DNA-binding properties of this complex, and identify TGATTGAC (PCE; Pbx Consensus Element) as its optimal recognition motif. In vitro, the PCE fails to bind heterodimers of Class I Hox proteins plus either Pbx1 or E2a-Pbx1. Likewise, in vivo, the PCE fails to mediate cooperative transactivation by E2a-Pbx1 plus Class I Hox proteins. Thus, the PCE binds a Pbx dimer partner that behaves unlike Class I Hox proteins, Competition analysis indicates that the Pbx-containing complex that binds the PCE also binds the TGATTGAT Pbx-Hox element and binds promoter elements required for tissue-specific expression of a number of cellular genes. Thus, different Pbx partners dictate targetting of Pbx heterodimers to related DNA motifs that differ in the sequence of their 3' half-sites, and E2a-Pbx1 heterodimerizes with only a subset of Pbx partners, restricting its potential DNA targets.			Knoepfler, PS (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.			Knoepfler, Paul/0000-0001-5444-334X	NATIONAL CANCER INSTITUTE [P01CA050528, R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876, 2 PO1 CA50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1991, GENE DEV, V5, P353; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KNOEPFLER PS, 1997, IN PRESS MECH DEV; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SPOEREL NA, 1993, J MOL BIOL, V230, P151, DOI 10.1006/jmbi.1993.1132; TANG SQ, 1995, NUCLEIC ACIDS RES, V23, P1928, DOI 10.1093/nar/23.11.1928; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; ZWARTKRUIS F, 1993, EXP CELL RES, V205, P422, DOI 10.1006/excr.1993.1108	44	38	39	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2521	2531		10.1038/sj.onc.1201097	http://dx.doi.org/10.1038/sj.onc.1201097			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191052				2022-12-25	WOS:A1997XA94900004
J	Lane, S; Farlie, P; Watson, R				Lane, S; Farlie, P; Watson, R			B-Myb function can be markedly enhanced by cyclin A-dependent kinase and protein truncation	ONCOGENE			English	Article						B-Myb; cyclin A; transactivation; cell cycle	DNA-BINDING ACTIVITY; C-MYB; TRANSCRIPTIONAL ACTIVATION; CELL-CYCLE; GENE-PRODUCT; ONCOGENE; TRANSACTIVATION; EXPRESSION; DOMAINS; TRANSFORMATION	Transcription of the B-Myb gene is cell cycle regulated by an E2F-dependent mechanism and its product, B-Myb, is itself a transcription factor required for S-phase entry. Previously, rye have shown that B-Myb is specifically phosphorylated during S-phase and that similar modification to a less electrophoretically mobile form could be induced by baculovirus-expressed cyclin A/Cdk2 kinase. We report here that cyclin A-mediated phosphorylation of B-Myb is associated with a marked increase in transactivation function in U-2 OS cells. In contrast to previous studies, transactivation of the luciferase reporter was dependent upon Myb binding sites located upstream of the promoter. Enhancement of B-Myb activation function was also obtained by truncation of the C-terminus just downstream of a domain conserved in evolution. Potentiation of B-Myb activity by phosphorylation was not simply a consequence of overcoming the negative effect of the C-terminus, however, as the truncated protein was to a lesser extent also activated by cyclin A/Cdk2. Whereas wild-type B-Myb transactivation activity could not be potentiated by cyclin A/Cdk2 in NIH3T3 cells, the truncated protein was hyperactive. Finally, we showed that B-Myb synergises with cyclin A to promote U-2 OS cells into S-phase.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,ST MARYS HOSP,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,ST MARYS HOSP,DEPT MED MICROBIOL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London								ARSURA M, 1992, BLOOD, V79, P2708; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLAY J, 1994, ONCOGENE, V9, P2469; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MA XP, 1994, CANCER RES, V54, P6512; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Robinson C, 1996, ONCOGENE, V12, P1855; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, ONCOGENE, V10, P1699; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	70	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2445	2453		10.1038/sj.onc.1201086	http://dx.doi.org/10.1038/sj.onc.1201086			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188859				2022-12-25	WOS:A1997WZ68000008
J	Thiriet, C; Hayes, JJ				Thiriet, C; Hayes, JJ			Antisera directed against anti-histone H4 antibodies recognize linker histones - Novel immunological probes to detect histone interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CHROMATIN SUBUNITS; NUCLEOSOMAL DNA; ACETYLATION; ORGANIZATION; RESOLUTION; PROTEINS; OCTAMER; SURFACE; TAILS	We introduce a novel immunological approach to detect structural interactions between chromosomal proteins, Antigenically pure core histone H4 was prepared from chicken erythrocytes and used to produce antihistone H4 antisera, IgG fractions were isolated from purified anti-H4 antibodies and used as antigens to produce ''second generation'' antisera. Epitopes cross-reacting with the second generation antisera were then identified within chromosomal proteins, These epitopes were presumed to mimic the complementary molecular surface of the original anti-H4 antibodies, and thus proteins containing these epitopes were putatively identified as specific ligands of H4 in chromatin, Surprisingly, we found this immunoreactivity was predominantly directed against H1 compared with H5 from chicken erythrocytes. Further, the immunoreactive epitopes were located within the C-terminal tail domain of the linker histones, These results suggest similar complementary interactions occur between H4 and the C-terminal tail domain of H1s in native chromatin, This could occur either within a single nucleosome as suggested by a previous report (Baneres, J.-L., Essalouh, L., Jariel-Encontre, I., Mesnier, D., Garrod, S., and Parello, J. (1994) J. Mol. Biol., 243, 48-59) or between neighboring nucleosomes within the condensed chromatin fiber, The implications of these results with regard to the structure of the chromatin fiber and the future utility of this technique are discussed.	UNIV ROCHESTER, MED CTR, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester					NIGMS NIH HHS [R01GM52426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BANERES JL, 1994, J MOL BIOL, V243, P48, DOI 10.1006/jmbi.1994.1629; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Bustin M, 1979, Curr Top Microbiol Immunol, V88, P105; DOUSSON S, 1989, EUR J IMMUNOL, V19, P1123, DOI 10.1002/eji.1830190624; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; HACQUES MF, 1990, BIOCHEM BIOPH RES CO, V168, P637, DOI 10.1016/0006-291X(90)92368-A; HARLOW E, 1988, ANTIBODIES; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; Hayes JJ, 1996, BIOCHEMISTRY-US, V35, P11931, DOI 10.1021/bi961590+; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HELLIGER W, 1988, BIOCHEM J, V255, P23, DOI 10.1042/bj2550023; Karantza V, 1996, BIOCHEMISTRY-US, V35, P2037, DOI 10.1021/bi9518858; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOIDL P, 1987, J BIOL CHEM, V262, P10195; MENDELSON E, 1984, BIOCHEMISTRY-US, V23, P3459, DOI 10.1021/bi00310a012; MULLER S, 1982, EMBO J, V1, P421, DOI 10.1002/j.1460-2075.1982.tb01185.x; MULLER S, 1985, FEBS LETT, V182, P459, DOI 10.1016/0014-5793(85)80354-9; MULLER S, 1982, EMBO J, V1, P939, DOI 10.1002/j.1460-2075.1982.tb01275.x; MULLER S, 1991, MOL IMMUNOL, V28, P763, DOI 10.1016/0161-5890(91)90119-5; MULLER S, 1989, METHOD ENZYMOL, V170, P431; NOTHACKER KD, 1986, EUR J CELL BIOL, V39, P278; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; STOLLAR BD, 1970, J BIOL CHEM, V245, P1261; STROSBERG AD, 1983, SPRINGER SEMIN IMMUN, V6, P67, DOI 10.1007/BF01857367; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THIRIET C, 1995, ELECTROPHORESIS, V16, P357, DOI 10.1002/elps.1150160161; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; TURNER BM, 1981, EUR J CELL BIOL, V24, P266; TURNER BM, 1991, J CELL SCI, V99, P13; van Holde KE., 1989, SPRINGER SERIES MOL; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wolffe A., 1995, CHROMATIN STRUCTURE	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18740	18745		10.1074/jbc.272.30.18740	http://dx.doi.org/10.1074/jbc.272.30.18740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228046	hybrid			2022-12-25	WOS:A1997XM34200037
J	Balla, T; Downing, GJ; Jaffe, H; Kim, S; Zolyomi, A; Catt, KJ				Balla, T; Downing, GJ; Jaffe, H; Kim, S; Zolyomi, A; Catt, KJ			Isolation and molecular cloning of wortmannin-sensitive bovine type III phosphatidylinositol 4-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL TRANSDUCTION; BINDING PROTEIN; PURIFICATION; GENE; CELLS; PHOSPHORYLATION; TRANSFORMATION	Agonist-sensitive phosphoinositide pools are maintained by recently-identified wortmannin (WT)-sensitive phosphatidylinositol (PI) 4-kinase(s) (Nakanishi, S., Catt, K. J., and Balla, T. (1995) Proc, Natl. Acad. Sci, U.S.A. 92, 5317-5321). Two loosely membrane-associated WT-sensitive type III: PI 4-kinases were isolated from bovine adrenal cortex as [H-3]WT-labeled 110- and 210-kDa proteins, Based on peptide sequences from the smaller enzyme, a 3.9-kilobase pair (kb) cDNA with an open reading frame encoding a 90-kDa protein was isolated from a bovine brain cDNA library, Expression of this cDNA in COS-7 cells yielded a 110-kDa protein with WT-sensitive PI 4-kinase activity. Northern blot analysis of a human mRNA panel showed a single similar to 3.8-kb transcript. Peptide sequences obtained from the 210-kDa enzyme corresponded to those of a recently described rat 230-kDa PI 4-kinase, A 6.5-kb cDNA containing an open reading frame of 6129 nucleotides that encoded a 230-kDa protein, was isolated from brain cDNA, Northern blot analysis of human mRNA revealed a major 7.5-kb transcript, The molecular cloning of these novel WT-sensitive type III PI 4-kinases will allow detailed analysis of their signaling and other regulatory functions in mammalian cells.	NINCDS,LNC,PROT PEPTIDE SEQUENCING FACIL,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Balla, T (corresponding author), NICHHD,ENDOCRINOL & REPROD RES BRANCH,NIH,BLDG 49,RM 6A36,49 CONVENT DR,BETHESDA,MD 20892, USA.			Balla, Tamas/0000-0002-9077-3335				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chen CD, 1996, J BIOL CHEM, V271, P28607, DOI 10.1074/jbc.271.45.28607; COCHET C, 1991, J BIOL CHEM, V266, P637; COCKCROFT S, 1985, FEBS LETT, V11, P259; DOUGHERTY RW, 1984, BIOCHEM J, V222, P307, DOI 10.1042/bj2220307; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gehrmann T, 1996, BBA-MOL CELL RES, V1311, P53, DOI 10.1016/0167-4889(95)00180-8; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; HARWOOD JL, 1969, BIOCHIM BIOPHYS ACTA, V171, P75, DOI 10.1016/0005-2744(69)90107-7; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIU JP, 1994, J BIOL CHEM, V269, P21043; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MICHELL RH, 1967, BIOCHIM BIOPHYS ACTA, V144, P649, DOI 10.1016/0005-2760(67)90053-7; MORITZ RL, 1995, TECH PROT CHEM, V6, P311, DOI 10.1016/S1080-8914(06)80039-6; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; OKADA T, 1994, J BIOL CHEM, V269, P3568; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PORTER FD, 1988, J BIOL CHEM, V263, P8989; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WETZKER R, 1991, EUR J BIOCHEM, V200, P179, DOI 10.1111/j.1432-1033.1991.tb21065.x; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG K, 1994, J BIOL CHEM, V269, P28878; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YANO H, 1993, J BIOL CHEM, V268, P25846; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	52	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18358	18366		10.1074/jbc.272.29.18358	http://dx.doi.org/10.1074/jbc.272.29.18358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218477	hybrid			2022-12-25	WOS:A1997XL73500067
J	Bujacz, G; Alexandratos, J; Wlodawer, A				Bujacz, G; Alexandratos, J; Wlodawer, A			Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; RESOLUTION; PROTEIN; REGION	Retroviral integrases (INs) contain two known metal binding domains, The N-terminal domain includes a zinc finger motif and has been shown to bind Zn2+, whereas the central catalytic core domain includes a triad of acidic amino acids that bind Mn2+ or Mg2+, the metal cofactors required for enzymatic activity, The integration reaction occurs in two distinct steps; the first is a specific endonucleolytic cleavage step called ''processing,'' and the second is a polynucleotide transfer or ''joining'' step, Our previous results showed that the metal preference for in vitro activity of avian sarcoma virus IN is Mn2+ > Mg2+ and that a single cation of either metal is coordinated by two of the three critical active site residues (Asp-64 and Asp-121) in crystals of the isolated catalytic domain, Here, we report that Ca2+, Zn2+, and Cd2+ can also bind in the active site of the catalytic domain, Furthermore, two zinc and cadmium cations are bound at the active site, with all three residues of the active site triad (Asp-64, Asp-121, and Glu-157) contributing to their coordination, These results are consistent with a two-metal mechanism for catalysis by retroviral integrases, We also show that Zn2+ can serve as a cofactor for the endonucleolytic reactions catalyzed by either the full-length protein, a derivative lacking the N-terminal domain, or the isolated catalytic domain of avian sarcoma virus IN, However, polynucleotidyl transferase activities are severely impaired or undetectable in the presence of Zn2+. Thus, although the processing and joining steps of integrase employ a similar mechanism and the same active site triad, they can be clearly distinguished by their metal preferences.	NCI,FREDERICK CANC RES & DEV CTR,MACROMOL STRUCT LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; TECH UNIV LODZ,FAC FOOD CHEM & BIOTECHNOL,PL-90924 LODZ,POLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Lodz University of Technology			Bujacz, Grzegorz/M-4446-2018	Bujacz, Grzegorz/0000-0002-3787-7522	NCI NIH HHS [CA-06927, CA-47486] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047486, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BOCK CW, 1995, J AM CHEM SOC, V117, P3754, DOI 10.1021/ja00118a012; Bujacz G, 1996, FEBS LETT, V398, P175, DOI 10.1016/S0014-5793(96)01236-7; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; OTWINOWSKI Z, 1992, OSCILLATION DATA PRO; RICE P, 1996, CURR OPIN STRUC BIOL, V6, P78; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZHENG R, 1996, P NATL ACAD SCI USA, V93, P13639	28	126	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18161	18168		10.1074/jbc.272.29.18161	http://dx.doi.org/10.1074/jbc.272.29.18161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218451	hybrid			2022-12-25	WOS:A1997XL73500041
J	Kataoka, M; Yoshiyama, K; Matsuura, K; Hijiya, N; Higuchi, Y; Yamamoto, S				Kataoka, M; Yoshiyama, K; Matsuura, K; Hijiya, N; Higuchi, Y; Yamamoto, S			Structure of the murine CD156 gene, characterization of its promoter, and chromosomal location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-EGG FUSION; TRANSCRIPTION FACTOR; METALLOPROTEASE DOMAIN; INSITU HYBRIDIZATION; MEMBRANE-PROTEINS; INTERFERON-GAMMA; REGULATED GENE; DNA-BINDING; FACTOR-I; EXPRESSION	The murine cell surface antigen mCD156 is a glycoprotein that is expressed in monocytic cell limes and consists of a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, and an epidermal growth factor-like domain in the extracellular region, The mCD156 gene is composed of 24 exons and 23 introns and spans approximately 14 kilobases, The first exon encodes most of the signal peptide sequence, and the transmembrane region is encoded by a single exon (19), In contrast, the other regions are composed of multiple exons, Of these, exons 7-12 and 12-15 encode a metalloprotease domain and a disintegrin domain, respectively, Sequence analysis of the 5'-flanking DNA revealed many potential regulatory motifs, Chloramphenicol acetyltransferase analysis demonstrated that nucleotides at positions -183, -334, and -623 contained cis-acting enhancing elements in a mouse monocytic cell line, aHINS-B3, Nucleotides at positions -183 and -390 contained elements responsible for lipopolysaccharide (LPS) inducibility, although several other 5'-flanking regions were also involved in LPS responsiveness, Regions -202, -507, and -659 play a role in interferon-gamma inducibility. Some of the potential regulatory motifs and other unknown cis elements may be involved in the constitutive expression, and LPS and interferon-gamma inducibilities, The mCD156 gene was mapped to chromosome 7, region F3-F4.	OITA MED UNIV,DEPT PATHOL,OITA 87955,JAPAN	Oita University								ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERG AJ, 1978, CELL, V12, P721; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENATHNACH R, 1981, ANN REV BIOCH, V50, P349; Cho CH, 1996, GENOMICS, V34, P413, DOI 10.1006/geno.1996.0305; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CUNIFF NFA, 1991, MOL CELL BIOL, V11, P4; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FENG GS, 1994, ONCOGENE, V9, P1745; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; HEINLEIN UAO, 1994, DEV GROWTH DIFFER, V36, P49; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, FISH DETECTION DAPI; HIGUCHI Y, 1997, TISSUE ANTIGENS, V48, P423; HOWARD DL, 1996, BIOCHEM J, V317, P45; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; KATAGIRI T, 1995, CYTOGENET CELL GENET, V68, P39, DOI 10.1159/000133884; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Maniatis T., 1982, MOL CLONING; MATSUURA K, 1992, J BIOL CHEM, V267, P2787; MAYERS RM, 1986, SCIENCE, V232, P613; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PERRY ACF, 1992, BIOCHEM J, V286, P671, DOI 10.1042/bj2860671; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; RYALS J, 1985, CELL, V41, P497, DOI 10.1016/S0092-8674(85)80023-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAKOV AN, 1990, J EXP MED, V171, P35; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SHIN HS, 1994, MOL CELL BIOL, V14, P2914, DOI 10.1128/MCB.14.5.2914; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; TANAKA T, 1995, CELL, V78, P931; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585; Yoshiyama K, 1997, GENOMICS, V41, P56, DOI 10.1006/geno.1997.4607; ZAHNG DE, 1994, MOL CELL BIOL, V14, P373	64	37	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18209	18215		10.1074/jbc.272.29.18209	http://dx.doi.org/10.1074/jbc.272.29.18209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218457	hybrid			2022-12-25	WOS:A1997XL73500047
J	Assaraf, YG; Goldman, ID				Assaraf, YG; Goldman, ID			Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L1210 LEUKEMIA-CELLS; DIHYDROFOLATE-REDUCTASE; BINDING-PROTEINS; TRANSPORT; METHOTREXATE; EFFLUX; PYRIMETHAMINE; MITOCHONDRIA; TRIMETREXATE; EXPRESSION	We previously described a 1,000-fold pyrimethamine-resistant Chinese hamster ovary cell line (Pyr(R100)) which retains parental dihydrofolate reductase activity and methotrexate (MTX) sensitivity, This study characterizes the basis for the 14-fold decrease in folic acid and leucovorin concentrations required for clonogenic growth of pyr(R100) cells relative to parental AA8 cells. Under conditions in which folic acid reduction was blocked by trimetrexate, Pyr(R100) cells displayed relative to parental AAS cells a: 1) 17- and 5-fold increase in the net transport of folic acid and MTX, respectively; 2) 23- and 5-fold decrease in the efflux rate constant for folic acid and MTX, respectively; and 3) a-fold increase in folic acid influx with no significant change in MTX influx. The markedly increased net folic acid transport in Pyr(R100) cells could not be explained by cellular folic acid binding, mitochondrial sequestration, polyglutamylation, nor by a decreased membrane potential. The effect of energy deprivation all folic acid and MTX transport in both cell. lines was quite different. Glucose and pyruvate deprivation nearly abolished the increase in net folic acid transport in Pyr(R100) cells. In contrast, energy deprivation increased net MTX transport in AAS cells, whereas no change was seen with Pyr(R100) cells, Furthermore, while folic acid influx in Pyr(R100) and AA8 cells was markedly reduced with energy deprivation, MTX influx was slot affected, Provision of glucose and pyruvate to energy-deprived cells resulted in a rapid onset of MTX efflux hom parental AAS cells but not from Pyr(R100) cells, Taken together these results indicate that the markedly enhanced net transport of folic acid and MTX in Pyr(R100) cells is largely due to the complete loss of exit pump activity, Furthermore, the energy source that sustains the augmented levels of folic acid appears linked to the influx process and is distinct from the energy source that sustains MTX gradients under these conditions, We conclude that the loss of folic acid efflux is an efficient means of augmenting cellular uptake of folate cofactors and subsequent survival on picomolar folate concentrations, This constitutes the first demonstration of the loss of folic acid exporter activity in mammalian cells as a response to lipophilic antifolate selective pressure.	TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL; YESHIVA UNIV ALBERT EINSTEIN COLL MED, CTR CANC, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, CTR CANC, DEPT MOL PHARMACOL, BRONX, NY 10461 USA	Technion Israel Institute of Technology; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Assaraf, Yehuda G./0000-0001-6692-8221	NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; ASSARAF YG, 1993, J BIOL CHEM, V268, P4556; BLAKELY RD, 1985, FOLATES PTERINS CHEM, V2; BLAKELY RL, 1986, FOLATES PTERINS NUTR, V3; BOBZIEN WF, 1972, J CLIN INVEST, V51, P1688, DOI 10.1172/JCI106970; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; HENDERSON GB, 1981, BIOCHEM BIOPH RES CO, V99, P163, DOI 10.1016/0006-291X(81)91727-7; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; Kumar CK, 1997, J BIOL CHEM, V272, P6226, DOI 10.1074/jbc.272.10.6226; LICHTSTEIN D, 1979, P NATL ACAD SCI USA, V76, P2580, DOI 10.1073/pnas.76.6.2580; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; ROSENBLATT DS, 1978, MOL PHARMACOL, V14, P1143; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Saxena M, 1996, BIOCHEM PHARMACOL, V51, P975, DOI 10.1016/0006-2952(96)00051-2; SAXENA M, 1995, J BIOL CHEM, V270, P5312, DOI 10.1074/jbc.270.10.5312; Saxena M, 1996, BIOCHEM J, V320, P273, DOI 10.1042/bj3200273; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; SPRECHER H, 1995, J BIOL CHEM, V270, P20668, DOI 10.1074/jbc.270.35.20668; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898	33	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17460	17466		10.1074/jbc.272.28.17460	http://dx.doi.org/10.1074/jbc.272.28.17460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211890	hybrid			2022-12-25	WOS:A1997XK16500033
J	Sato, N; Sadar, MD; Bruchovsky, N; Saatcioglu, F; Rennie, PS; Sato, S; Lange, PH; Gleave, ME				Sato, N; Sadar, MD; Bruchovsky, N; Saatcioglu, F; Rennie, PS; Sato, S; Lange, PH; Gleave, ME			Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-jun in the human prostate cancer cell line LNCaP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; OSTEOCALCIN GENE; RETINOIC ACID; AP-1 SITE; FOS-JUN; C-JUN	In exploring the possible mechanisms of androgen independence of prostate-specific antigen (PSA) gene expression, we investigated the effect of elevating AP-1 by both 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment and transfection of the c-Jun expression vector in LNCaP cells, Transcription of PSA is initiated when ligand-activated androgen receptor (AR) binds to a region in the PSA promoter that contains an androgen-responsive element (ARE), It was found that TPA inhibited androgen-induced PSA gene expression by a mechanism that did not alter nuclear levels of AR protein, Overexpression of AP-1 (jun and fos proteins) also inhibited androgen-induced PSA promoter activity, These observations were apparently related to the disruption of AR ARE complexes as demonstrated by the results of electrophoretic mobility shift assays, Specifically, c-Jun inhibited the formation of AR ARE complexes and conversely that AR-glutathione S-transferase proteins inhibited the formation of c-Jun TPA-responsive element (TRE) complexes, Consistent with the inhibitory effect of both proteins, anti-c-Jun antibody blocked the inhibition of AR.ARE complex formation by c-Jun, A similar, but less marked, effect was obtained when anti-AR antibody was used to prevent AR inhibition of c-Jun TRE complex formation, These findings together with results obtained from co-immunoprecipitation experiments strongly suggest that mutual repression of DNA binding activity is due to direct interaction between the two proteins and that the degree of repression may be determined by the ratio of AR to c-Jun, The mechanism of repression studied in mutant analysis experiments yielded evidence of an interaction between the DNA- and ligand-binding domains of AR and the leucine zipper region of c-Jun, Thus, the AR is similar to other nuclear receptors in its ability to interact with AP-1, This association provides a link between AP-1 and AR signal transduction pathways and may play a role in the regulation of the androgen-responsive PSA gene.	BRITISH COLUMBIA CANC AGCY,DEPT CANC ENDOCRINOL,VANCOUVER,BC V5Z 4E6,CANADA; UNIV CALIF SAN DIEGO,SCH MED,CTR MOL GENET,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV WASHINGTON,DEPT UROL,SEATTLE,WA 98195	British Columbia Cancer Agency; University of California System; University of California San Diego; University of Washington; University of Washington Seattle			Sadar, Marianne/E-9136-2012	Sadar, Marianne/0000-0003-0599-9215	NIDDK NIH HHS [P50 DK47656] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047656] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAIGHN ME, 1979, INVEST UROL, V17, P16; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN KH, 1991, BIOTECHNIQUES, V11, P752; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PRINS GS, 1991, ENDOCRINOLOGY, V129, P3187, DOI 10.1210/endo-129-6-3187; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sato N, 1996, J STEROID BIOCHEM, V58, P139, DOI 10.1016/0960-0760(96)00018-0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VERMA IM, 1989, CURR OPIN CELL BIOL, V1, P536; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; VOGT PK, 1990, CANCER BIOL, V1, P27; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOUNG CYF, 1994, ONCOL RES, V6, P203; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	54	184	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17485	17494		10.1074/jbc.272.28.17485	http://dx.doi.org/10.1074/jbc.272.28.17485			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211894	hybrid			2022-12-25	WOS:A1997XK16500037
J	Yao, J; Mackman, N; Edgington, TS; Fan, ST				Yao, J; Mackman, N; Edgington, TS; Fan, ST			Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells - Regulation by Egr-1, c-Jun, and NF-kappa B transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR GENE; ACTIVATOR PROTEIN-1; MESSENGER-RNA; E-SELECTIN; REGION; MACROPHAGES; ELEMENT; VIRUS	Biosynthesis of tumor necrosis factor-alpha (TNF-alpha) is predominantly by cells of the monocytic lineage. This study examined the role of various cis-acting regulatory elements in the lipopolysaccharide (LPS) induction of the human TNF-alpha promoter in cells of monocytic lineage, Functional analysis of monocytic THP-1 cells transfected with plasmids containing various lengths of TNF-alpha promoter localized enhancer elements in a region (-182 to -37 base pairs (bp)) that were required for optimal transcription of the TNF-alpha gene in response to LPS, Two regions were identified: region I (-182 to -162 bp) contained an overlapping Sp1/Egr-1 site, and region II (-119 to -88) contained CRE and NF-kappa B (designated kappa B3) sites, In unstimulated THP-1, CRE-binding protein and, to a lesser extent, c-Jun complexes were found to bind to the CRE site, LPS stimulation increased the binding of c-Jun-containing complexes, In addition, LPS stimulation induced the binding of cognate nuclear factors to the Egr-1 and kappa B3 sites, which were identified as Egr-1 and p50/p65, respectively, The CRE and kappa B3 sites in region II together conferred strong LPS responsiveness to a heterologous promoter, whereas individually they failed to provide transcriptional activation, Furthermore, increasing the spacing between the CRE and the kappa B3 sites completely abolished LPS induction, suggesting a cooperative interaction between c-Jun complexes and p50/p65, These studies indicate that maximal LPS induction of the TNF-alpha promoter is mediated by concerted participation of at least two separate cis-acting regulatory elements.	SCRIPPS RES INST, DEPT IMMUNOL, IMM 17, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, R01HL048872] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16411, HL-48872] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLEMAN DL, 1992, J IMMUNOL, V149, P3045; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DOKTER WHA, 1993, BLOOD, V81, P337; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; FAN ST, 1995, J IMMUNOL, V154, P3266; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; KARIN M, 1995, J BIOL CHEM, V270, P16488; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; RHOADES KL, 1995, CELL IMMUNOL, V161, P125, DOI 10.1006/cimm.1995.1016; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TREDE NS, 1995, J IMMUNOL, V155, P902; Tsai EY, 1996, MOL CELL BIOL, V16, P459; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	31	410	422	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17795	17801		10.1074/jbc.272.28.17795	http://dx.doi.org/10.1074/jbc.272.28.17795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211933	hybrid			2022-12-25	WOS:A1997XK16500076
J	Sacher, M; Stone, S; FerroNovick, S				Sacher, M; Stone, S; FerroNovick, S			The synaptobrevin-related domains of Bos1p and Sec22p bind to the syntaxin-like region of Sed5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; GOLGI TRANSPORT; FUSION COMPLEX; YEAST; VESICLES; ER; IDENTIFICATION; ENCODES; YPT1	SNAREs (soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptors) ape cytoplasmically oriented membrane proteins that reside on vesicular carriers (V-SNARE) and target organelles (t-SNARE). The pairing of a stage-specific v-SNARE with its cognate t-SNARE may mediate the specificity of membrane traffic. In the yeast Saccharomyces cerevisiae transport between the endoplasmic reticulum and Golgi complex employs two v-SNAREs, Bos1p and Sec22p, each containing a domain that is related to the neuronal v-SNARE synaptobrevin, Sed5p, which is homologous to syntaxin, is the t-SNARE that functions at this stage of the secretory pathway. Here we report that, regions of Bos1p and Sec22p, which are homologous to synaptobrevin, bind to the syntaxin-like domain of Sed5p, Furthermore, we demonstrate that efficient v-SNARE/t-SNARE interactions require the participation of both v-SNAREs, indicating that, unlike post-Golgi membrane traffic, the active form of the endoplasmic reticulum to Golgi V-SNARE is a heteromeric complex.	HOWARD HUGHES MED INST,BOYER CTR MOL MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University								DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P182; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Jiang Y, 1995, COLD SPRING HARB SYM, V60, P119, DOI 10.1101/SQB.1995.060.01.015; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STONE S, 1997, IN PRESS MOL BIOL CE	18	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17134	17138		10.1074/jbc.272.27.17134	http://dx.doi.org/10.1074/jbc.272.27.17134			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202032	hybrid			2022-12-25	WOS:A1997XH44600064
J	Wayman, GA; Tokumitsu, H; Soderling, TR				Wayman, GA; Tokumitsu, H; Soderling, TR			Inhibitory cross-talk by cAMP kinase on the calmodulin-dependent protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BRAIN CALMODULIN; IV KINASE; PHOSPHORYLATION; REQUIREMENT; ACTIVATION; EXPRESSION	The calmodulin-dependent kinase (CaM-K) cascade, a Ca2+-triggered system involving phosphorylation and activation of CaM-KI and CaM-KIV by CaM kinase kinase (CaM-KK), regulates transcription through direct phosphorylation of transcription factors such as cAMP response element-binding protein, We have shown previously that activated CaM-KIV can activate the mitogen-activated protein kinases (Enslen, H., Tokumitsu, H., Stork, P. J. S., Davis, R. J., and Soderling, T. R. (1996) Proc. Natl., Acad. Sci. U. S. A. 93, 10803-10808), and the present paper describes a novel regulatory cross-talk between cAMP kinase (PKA) and CaM-KK. PKA gave rapid phosphorylation in vitro and in cells of recombinant CaM-KK, resulting in 50-75% inhibition of CaM-KK activity, part of which was due to suppression of CaM-binding by phosphorylation of Ser(458) in the CaM-binding domain, However, the Ser(458) --> Ala mutant, or a truncation mutant in which the CaM-binding and autoinhibitory domains were deleted, was still partially suppressed by PKA-mediated phosphorylation, The second inhibitory site was identified as Thr(108) by site-specific mutagenesis, Treatments of COS-7, PC12, hippocampal, or Jurkat cells with the PKA activators forskolin or isoproterenol gave 30-90% inhibition of either endogenous or transfected CaM-KK and/or CaM-KIV activities. These results demonstrate that the CaM kinase cascade is negatively regulated in cells by the cAMP/PKA pathway.	OREGON HLTH SCI UNIV,VOLLUM INST L 474,PORTLAND,OR 97201	Oregon Health & Science University			Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794	NIDDK NIH HHS [DK07674] Funding Source: Medline; NIGMS NIH HHS [GM41292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; CHENG HC, 1986, J BIOL CHEM, V261, P989; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CONTI MA, 1981, J BIOL CHEM, V256, P3178; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; KAMESHITA I, 1991, BIOCHEM BIOPH RES CO, V180, P191, DOI 10.1016/S0006-291X(05)81275-6; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; LEE JSC, 1994, J BIOL CHEM, V269, P2158; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wayman GA, 1996, MOL CELL BIOL, V16, P6075	28	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16073	16076		10.1074/jbc.272.26.16073	http://dx.doi.org/10.1074/jbc.272.26.16073			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195898	hybrid			2022-12-25	WOS:A1997XG01900002
J	Dupressoir, A; Heidmann, T				Dupressoir, A; Heidmann, T			Expression of intracisternal A-particle retrotransposons in primary tumors of oncogene-expressing transgenic mice	ONCOGENE			English	Article						oncogenes; IAP; tumors; transgenic mice	LONG TERMINAL REPEAT; CAMP RESPONSE ELEMENT; HEMATOPOIETIC-CELLS; HA-RAS; C-MYC; GENES; METHYLATION; SEQUENCE; ACTIVATION; PROMOTER	Intracisternal A-Particle (IAP) sequences are endogenous retrovirus-like mobile elements, present at 1000 copies in the mouse genome, These elements transpose in a replicative manner via an RNA intermediate and its reverse transcription, and their transposition should therefore be tightly controlled by their transcription level, The in vi,to pattern of expression of these potentially mutagenic elements had previously been analysed in normal mice, and we have now investigated their expression in transgenic mice carrying different oncogenes (e.g. c-myc, v-Ha-ras, SV40 T-antigen) under tissue-specific promoters and disclosing tumors within the brain, the mammary or salivary glands, or the lymphoid organs, Northern blot analysis of IAP expression within the resulting tumors demonstrates a lack of significant and/or systematic effect of v-Ha-ras and SV40 T-antigen expression, but a systematic IAP induction in the myc-induced tumors, In this case, however, analysis of double transgenic mice obtained by crossing the tumor-prone mice with previously described transgenic mice carrying IAP reporter genes did not provide any evidence for induction of the IAP transgenes, therefore strongly suggesting that c-myc expression had an effect on only a limited number of IAP sequences - most probably depending on their position and/or methylation state, These results strengthen the importance of in vivo studies for a correct appraisal of complex biological processes, and moderate previous conclusions derived from in vitro analyses on the general activation of IAPs by oncogenes and on the role of these transposable elements in tumorigenesis.	INST GUSTAVE ROUSSY,UNITE PHYSICOCHIM & PHARMACOL MACROMOL BIOL,CNRS URA147,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy			Dupressoir, Anne/M-5280-2018	Dupressoir, Anne/0000-0002-3464-8513				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASCH BB, 1990, CANCER RES, V50, P2404; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; AUGENLICHT LH, 1984, J BIOL CHEM, V259, P1842; BEGEMANN M, 1988, MOL CARCINOGEN, V1, P196, DOI 10.1002/mc.2940010308; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; DEOCA FHM, 1984, BIOL CELL, V52, P199; DRAGANI TA, 1987, J CANCER RES CLIN, V113, P223, DOI 10.1007/BF00396377; DRAGANI TA, 1986, CANCER RES, V46, P1915; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; Dupressoir A, 1995, BBA-GENE STRUCT EXPR, V1264, P397, DOI 10.1016/0167-4781(95)00181-6; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; FEENSTRA A, 1986, NUCLEIC ACIDS RES, V14, P4343, DOI 10.1093/nar/14.10.4343; GALIEN R, 1994, ONCOGENE, V9, P1101; GALIEN R, 1991, ONCOGENE, V6, P849; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HEBERLEIN C, 1990, ONCOGENE, V5, P1799; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HSIAO WLW, 1986, J VIROL, V57, P1119, DOI 10.1128/JVI.57.3.1119-1126.1986; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; Lamb Bruce T., 1991, Gene Expression, V1, P185; Lueders K K, 1995, Curr Top Microbiol Immunol, V194, P405; LUEDERS KK, 1986, NUCLEIC ACIDS RES, V14, P1495, DOI 10.1093/nar/14.3.1495; LUEDERS KK, 1993, MOL CELL BIOL, V13, P7439, DOI 10.1128/MCB.13.12.7439; LURIA S, 1986, J VIROL, V57, P998, DOI 10.1128/JVI.57.3.998-1003.1986; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MOWAT M, 1990, ONCOGENE, V5, P241; Puech A, 1997, J BIOL CHEM, V272, P5995, DOI 10.1074/jbc.272.9.5995; ROLAND J, 1993, CELL GROWTH DIFFER, V4, P891; RONAI Z, 1992, MOL CARCINOGEN, V5, P81, DOI 10.1002/mc.2940050113; SHENONG GLC, 1984, J VIROL, V49, P171, DOI 10.1128/JVI.49.1.171-177.1984; SHENONG GLC, 1982, J VIROL, V42, P411, DOI 10.1128/JVI.42.2.411-421.1982; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901	43	20	22	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2951	2958		10.1038/sj.onc.1201148	http://dx.doi.org/10.1038/sj.onc.1201148			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205102				2022-12-25	WOS:A1997XF55500009
J	Chiba, N; Watanabe, T; Nomura, S; Tanaka, Y; Minowa, M; Niki, M; Kanamaru, R; Satake, M				Chiba, N; Watanabe, T; Nomura, S; Tanaka, Y; Minowa, M; Niki, M; Kanamaru, R; Satake, M			Differentiation dependent expression and distinct subcellular localization of the protooncogene product, PEBP2 beta/CBF beta, in muscle development	ONCOGENE			English	Article						PEBP2 beta/CBF beta; transcription factor; acute myeloid leukemia; muscle development; immunohistochemistry	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; SKELETAL-MUSCLE; E-CADHERIN; AML1 GENE; FUSION TRANSCRIPT; DNA-BINDING; PROTEIN; RUNT; DOMAIN	The Pebpb2/Cbfb gene encodes the non-DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF. To examine the expression of the PEBP2 beta/CBF beta protein in vivo, we carried out immunohistochemistry using the tissues from adult mice as well as embryos, Although PEBP2 beta/CBF beta was detected in various tissues to various degrees, interesting features of expression were observed in the skeletal myogenic cells. Here PEBP2 beta/CBF beta was found mainly to occur as cytoplasmic staining and the intensity of this staining increased depending on the differentiation stage of the cells, In the undifferentiated myoblasts PEBP2 beta/CBF beta was undetectable, whereas moderate levels of PEBP2 beta/CBF beta were detected in the elongated and aligned myocytes. PEBP2 beta/CBF beta appeared to accumulate further when the cells fused to each other to become multinucleated myotubes, Once the muscle fibers were established, PEBP2 beta/CBF beta was relocated onto or around the Z-lines. PEBP2 beta/CBF beta was also detected in the cytoplasm of cardiac myocytes and in the smooth muscle cells of the digestive tract. In all the above, the skeletal myotubes were the only case that showed both nuclear and cytoplasmic staining of PEBP2 beta/CBF beta. Thus, we could show differentiation dependent pattern of PEBP2 beta/CBF beta expression in muscle development and establish PEBP2 beta/CBF beta to be a cytoplasmic as well as nuclear protein in vivo.	TOHOKU UNIV,DEPT MOL IMMUNOL,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOHOKU UNIV,DEPT CLIN ONCOL,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN	Tohoku University; Tohoku University; Osaka University								ABERLE H, 1994, J CELL SCI, V107, P3655; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOBER E, 1994, DEVELOPMENT, V120, P603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVLIN RB, 1978, CELL, V13, P599, DOI 10.1016/0092-8674(78)90211-8; ERICKSON P, 1992, BLOOD, V80, P1825; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MASAKI T, 1967, J BIOCHEM-TOKYO, V62, P630, DOI 10.1093/oxfordjournals.jbchem.a128717; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORRIS EJ, 1994, J CELL SCI, V107, P377; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	42	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2543	2552		10.1038/sj.onc.1201109	http://dx.doi.org/10.1038/sj.onc.1201109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191054				2022-12-25	WOS:A1997XA94900006
J	Ko, YH; Bianchet, M; Amzel, LM; Pedersen, PL				Ko, YH; Bianchet, M; Amzel, LM; Pedersen, PL			Novel insights into the chemical mechanism of ATP synthase - Evidence that in the transition state the gamma-phosphate of ATP is near the conserved alanine within the P-loop of the beta-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; RAT-LIVER; ESCHERICHIA-COLI; ADENYLATE KINASE; F1 MOIETY; BINDING; MYOSIN; VANADATE; PHOTOCLEAVAGE; MITOCHONDRIA	The chemical mechanism by which the F-1 moiety of ATP synthase hydrolyzes and synthesizes ATP remains unknown, For this reason, we have carried out studies with orthovanadate (V-i), a phosphate analog which has the potential of ''locking'' all ATPase, in its transition state by forming a MgADP.V-i complex, and also the potential, in a photochemical reaction resulting in peptide bond cleavage, of identifying an amino, acid very near the gamma-phosphate of ATP. Upon incubating purified rat liver F-1 with MgADP and V-i for 2 h to promote formation of a MgADP.V-i-F-1 complex, the ATPase activity of the enzyme was markedly inhibited in a reversible manner, When the resultant complex was formed in the presence of ultraviolet light inhibition could not be reversed, and SDS-polyacrylamide gel electrophoresis revealed, in addition to the five known subunit bands characteristic of F-1 (i.e. alpha, beta, gamma, delta, and epsilon), two new electrophoretic species of 17 and 34 kDa, Western blot and N-terminal sequencing analyses identified both bands as arising from the beta subunit with the site of peptide bond cleavage occurring at alanine 158, a conserved residue within F-1-ATPases and the third residue within the nucleotide binding consensus GX(4)GK(T/S) (P-loop). Quantification of the amount of ADP bound within the MgADP.V-i-F-1 complex revealed about 1.0 mol/mol F-1, while quantification of the peptide cleavage products revealed that no more than one beta subunit had been cleaved, Consistent with the cleavage reaction involving oxidation of the methyl group of alanine was the finding that [H-3] from NaB[H-3](4) incorporates into MgADP.V-i-F-1 complex following treatment with ultraviolet light, These novel findings provide information about the transition state involved in the hydrolysis of ATP by a single beta subunit within F-1-ATPases and implicate alanine 158 as residing very near the gamma-phosphate of ATP during catalysis, When considered with earlier studies on myosin and adenylate kinase, these studies also implicate a special role for the third residue within the GX(4)GK(T/S) sequence of many other nucleotide-binding proteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University			Bianchet, Mario a/K-2131-2015	Bianchet, Mario a/0000-0001-9032-7549; Amzel, L. Mario/0000-0002-0129-9572	NCI NIH HHS [CA10951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V12, P186; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Coulston GW, 1997, SCIENCE, V275, P191, DOI 10.1126/science.275.5297.191; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CREMO CR, 1992, BIOCHEMISTRY-US, V31, P491, DOI 10.1021/bi00117a027; CROSS RL, 1982, J BIOL CHEM, V257, P2101; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Grammer JC, 1996, BIOCHEMISTRY-US, V35, P15582, DOI 10.1021/bi961901g; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PEDERSEN PL, 1981, J BIOL CHEM, V256, P1362; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; TAGAYA M, 1989, J BIOL CHEM, V264, P990; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILLIAMS N, 1987, BIOCHEMISTRY-US, V26, P162, DOI 10.1021/bi00375a023; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202	28	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18875	18881		10.1074/jbc.272.30.18875	http://dx.doi.org/10.1074/jbc.272.30.18875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228065	hybrid			2022-12-25	WOS:A1997XM34200056
J	Lochhead, A; Nekrasova, E; Arshavsky, VY; Pyne, NJ				Lochhead, A; Nekrasova, E; Arshavsky, VY; Pyne, NJ			The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to gamma subunit of the photoreceptor cGMP phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CATESBIANA ROD PHOTORECEPTORS; INHIBITORY SUBUNIT; NUCLEOTIDE PHOSPHODIESTERASE; VISUAL TRANSDUCTION; CATALYTIC SUBUNITS; PHOSPHORYLATION; LUNG; SITES; KINASE	The cGMP phosphodiesterase from retinal rods (PDE-6) is an alpha beta gamma(2) heterotetramer, The alpha and beta subunits contain catalytic sites for cGMP hydrolysis, whereas the gamma subunits serve as a protein inhibitor of the enzyme, Visual excitation of photoreceptors enables the activated GTP-bound form of the G-protein transducin to remove the inhibitory action of the gamma subunit, thereby triggering PDE-B activation, The type 5 phosphodiesterase (PDE-B) isoform shares a number of similar characteristics with PDE-6, including binding of cGMP to non catalytic sites, the cyclic nucleotide specificity, and inhibitor sensitivities, Although the functional role of PDE 5 remains unclear, it has been shown to be activated by protein kinase A (PKA) (Burns, F., Rodger, I. W. & Pyne, N. J. (1992) Biochem, J. 283, 487-491), Here we report that both the recombinant gamma subunit and a peptide corresponding to amino acids 24-46 in this protein inhibited the activation of PDE-5 by PKA, Furthermore, immunoblotting airway smooth muscle membranes with a specific antibody against amino acids 24-46 of the PDE-6 gamma subunit identified two major immunoreactive small molecular mass proteins of 14 and 18 kDa (p14 and p18), These appear to form a complex with PDE-5, because PDE activity was immunoprecipitated using antibody against the PDE-6 gamma subunit, p14 and p18 were also substrates for phosphorylation by a unidentified kinase that was stimulated by a pertussis toxin-sensitive G-protein, Phosphorylation of p14/p18 in membranes treated with guanine nucleotides correlated with a concurrent reduction in the activation of PDE-B by PKA, We suggest that p14 and p18 share an epitope common to PDE-B gamma and that this region may interact with PDE-6 to prevent its activation by PKA.	UNIV STRATHCLYDE,DEPT PHYSIOL & PHARMACOL,GLASGOW G1 1XW,LANARK,SCOTLAND; HARVARD UNIV,SCH MED,HOWE LAB OPHTHALMOL,BOSTON,MA 02114	University of Strathclyde; Harvard University; Harvard Medical School				Pyne, Nigel/0000-0002-5657-4578	NATIONAL EYE INSTITUTE [R01EY010336] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10336] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BURNS F, 1992, BIOCHEM BIOPH RES CO, V189, P1389, DOI 10.1016/0006-291X(92)90228-D; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; FRANCIS SH, 1988, METHOD ENZYMOL, V159, P722; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GRADY M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P313, DOI 10.1016/0167-4889(93)90060-3; HARRISON SA, 1986, MOL PHARMACOL, V29, P506; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; MUMBY MC, 1982, J BIOL CHEM, V257, P13283; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; PYNE NJ, 1986, BIOCHEM J, V234, P325, DOI 10.1042/bj2340325; PYNE S, 1993, BIOCHEM PHARMACOL, V45, P593, DOI 10.1016/0006-2952(93)90132-G; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; WU Z, 1992, BIOL CYCLIC NUCLEOTI, P29; WYATT TM, 1994, FASEB J, V8, P372; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702	36	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18397	18403		10.1074/jbc.272.29.18397	http://dx.doi.org/10.1074/jbc.272.29.18397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218482	hybrid			2022-12-25	WOS:A1997XL73500072
J	Murao, K; Terpstra, V; Green, SR; Kondratenko, N; Steinberg, D; Quehenberger, O				Murao, K; Terpstra, V; Green, SR; Kondratenko, N; Steinberg, D; Quehenberger, O			Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE CHOLESTEROL TRANSPORT; GENE FAMILY; MEDIATED ENDOCYTOSIS; SIGNAL TRANSDUCTION; SELECTIVE UPTAKE; SR-BI; A-I; CD36; MACROPHAGES; ESTERS	Recently, a murine scavenger receptor type B class I (SR-BI) was identified that binds high density lipoprotein (HDL) and mediates the selective uptake of cholesterol esters, The human (C) under bar D36 and (L) under bar IMPII (a) under bar nalogous-1 (CLA-1) receptor shows high sequence homology with SR-BI, but their functional relationship has not been determined, Transfected cells expressing CLA-1 bound HDL with a K-d of about 35 mu g/ml, similar to the K-d for HDL binding to rodent SR-BI. This binding resulted in an intracellular accumulation of HDL-derived [H-3]cholesterol esters without internalization or degradation of I-125-apolipoprotein. CLA-1 was strongly expressed in the adrenal gland and was also abundant in liver and testis, suggesting that CLA-I, like SR-BI, could play a role in the metabolism of HDL, However, CLA-1 was also expressed in monocytes and, like SR-BI, recognized modified forms of low density lipoproteins as well as native LDL and anionic phospholipids. These findings suggest that CLA-1 might have additional physiological functions, We found that CLA-1 recognizes apoptotic thymocytes. Our results demonstrate that CLA-1, a close structural homologue of SR-BI, is also functionally related to SR-BI and may play an important role as a ''docking receptor'' for HDL in connection with selective uptake of cholesterol esters, An additional role in recognition of damaged cells is suggested by these studies.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 14197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BADIMON JJ, 1992, CIRCULATION, V86, P86; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FADOK VA, 1992, J IMMUNOL, V148, P2207; FRANCESCHINI G, 1991, ATHEROSCLEROSIS, V88, P99, DOI 10.1016/0021-9150(91)90073-C; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENWALT DE, 1992, BLOOD, V80, P1105; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEIDER JG, 1978, J LIPID RES, V19, P514; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huh HY, 1996, BLOOD, V87, P2020; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCNALLY AK, 1990, J IMMUNOL, V145, P254; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MIZOBUCHI M, 1994, J NEUROCHEM, V62, P322; MORRE DJ, 1989, BIOTECHNIQUES, V7, P946; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1994, ATHEROSCLEROSIS, V105, P145, DOI 10.1016/0021-9150(94)90044-2; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001	46	288	299	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17551	17557		10.1074/jbc.272.28.17551	http://dx.doi.org/10.1074/jbc.272.28.17551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211901	hybrid			2022-12-25	WOS:A1997XK16500044
J	Pettitt, TR; Martin, A; Horton, T; Liossis, C; Lord, JM; Wakelam, MJO				Pettitt, TR; Martin, A; Horton, T; Liossis, C; Lord, JM; Wakelam, MJO			Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions - Phospholipase D-derived diacylglycerol does not activate protein kinase C in porcine aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; THYROTROPIN-RELEASING-HORMONE; MOLECULAR-SPECIES ANALYSIS; CANINE KIDNEY-CELLS; ALPHA-THROMBIN; CULTURED FIBROBLASTS; SN-1,2-DIACYLGLYCEROL; 1,2-DIGLYCERIDES; HYDROLYSIS	Stimulation of cells with certain agonists often activates both phospholipases C and D. These generate diacylglycerol and phosphatidate, respectively, although the two lipids are also apparently interconvertable through the actions of phosphatidate phosphohydrolase and diacylglycerol kinase. Diacylglycerol activates protein kinase C while one role for phosphatidate is the activation of actin stress fiber formation, Therefore, if the two lipids are interconvertable, it is theoretically possible that an uncontrolled signaling loop could arise. To address this issue structural analysis of diacylglycerol, phosphatidate, and phosphatidylbutanol (formed in the presence of butan-1-ol) from both Swiss 3T3 and porcine aortic endothelial cells was performed. This demonstrated that phospholipase C activation generates primarily polyunsaturated species while phospholipase D activation generates saturated/monounsaturated species. in the endothelial cells, where phospholipase D was activated by lysophosphatidic acid independently of phospholipase C, there was no activation of protein kinase C. Thus we propose that only poly-unsaturated diacylglycerols and saturated/monounsaturated phosphatidates function as intracellular messengers and that their interconversion products are inactive.	UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham				Wakelam, Michael/0000-0003-4059-9276; Lord, Janet/0000-0003-1030-6786	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALBOA MA, 1995, J BIOL CHEM, V270, P29843; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; COOK SJ, 1992, REV PHYSL BIOCH PHAR, V119, P14; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DRUMMOND AH, 1984, BIOCHEM J, V224, P129, DOI 10.1042/bj2240129; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HA KS, 1993, J BIOL CHEM, V268, P10534; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEE C, 1991, J BIOL CHEM, V266, P22837; MONACO ME, 1991, BIOCHEM J, V279, P337, DOI 10.1042/bj2790337; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Olivier AR, 1996, BIOCHEM J, V318, P519, DOI 10.1042/bj3180519; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PETTITT TR, 1993, BIOCHEM J, V289, P487, DOI 10.1042/bj2890487; PETTITT TR, 1994, BIOCHEM J, V298, P655, DOI 10.1042/bj2980655; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; RODRIGUEZ R, 1987, MOL ENDOCRINOL, V1, P802, DOI 10.1210/mend-1-11-802; Sawai H, 1997, J BIOL CHEM, V272, P2452; WAKELAM MJO, 1988, CURRENT TOPICS MEMBR, V32, P87; WAKELAM MJO, 1995, RECEPTOR TRANSDUCTIO, P271; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	28	171	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17354	17359		10.1074/jbc.272.28.17354	http://dx.doi.org/10.1074/jbc.272.28.17354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211874	hybrid			2022-12-25	WOS:A1997XK16500017
J	Barbier, CS; Short, SA; Senear, DF				Barbier, CS; Short, SA; Senear, DF			Allosteric mechanism of induction of CytR-regulated gene expression - CytR repressor-cytidine interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; PURINE REPRESSOR; INDUCER BINDING; RNA-POLYMERASE; DNA-BINDING; PROMOTER; COREPRESSOR; IDENTIFICATION; CONSTRUCTION	Transcription from cistrons of the Escherichia coli CytR regulon is activated by E. coli cAMP receptor protein (CRP) and repressed by a multiprotein complex composed elf CRP and CytR. De-repression results when CytR binds cytidine. CytR is a homodimer and a LacI family member, A central question for all LacI family proteins concerns the allosteric mechanism that couples ligand binding to the protein-DNA and protein-protein interactions that regulate transcription. To explore this mechanism for CytR, we analyzed nucleoside binding in vitro and its coupling to cooperative CytR binding to operator DNA, Analysis of the thermodynamic linkage between sequential cytidine binding to dimeric CytR and cooperative binding of CytR to deoP2 indicates that de-repression results from just one of the two cytidine binding steps. go test this conclusion in vivo, CytR mutants that have wild-type repressor function but are cytidine induction-deficient (CID) were identified, Each has a substitution for Asp(281) or neighboring residue. CID CytR281N was found to bind cytidine with three orders of magnitude lower affinity than wild-type CytR. Other CytR mutants that do not exhibit the CID phenotype were: found to bind cytidine with affinity similar to wild-type CytR. The rate of transcription regulated by heterodimeric CytR composed of one CytR281N and one wild-type subunit was compared with that regulated by wild-type CytR under inducing conditions. The data support the conclusion that the first cytidine binding step alone is sufficient to induce.	GLAXO WELLCOME INC, MOL SCI, RES TRIANGLE PK, NC 27709 USA; UNIV CALIF IRVINE, DEPT MOL BIOL & BIOCHEM, IRVINE, CA 92697 USA	GlaxoSmithKline; University of California System; University of California Irvine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041465] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBIER CS, 1992, J BACTERIOL, V174, P2881, DOI 10.1128/JB.174.9.2881-2890.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENOWITZ M, 1989, CURRENT PROTOCOLS S7, V2; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHANG WI, 1994, BIOCHEMISTRY-US, V33, P3607, DOI 10.1021/bi00178a018; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; COZZARELLI NR, 1968, P NATL ACAD SCI USA, V60, P992, DOI 10.1073/pnas.60.3.992; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GERLACH P, 1990, MOL MICROBIOL, V4, P479, DOI 10.1111/j.1365-2958.1990.tb00614.x; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HAMMERJE, 1971, EUR J BIOCHEM, V19, P533; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HSIEH M, 1994, J BIOL CHEM, V269, P13825; HUTCHISON CA, 1991, METHOD ENZYMOL, V202, P356; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; Kristensen HH, 1996, J MOL BIOL, V260, P113, DOI 10.1006/jmbi.1996.0385; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEATHERBARROW RG, 1990, GRAFIT VERSION 2 0; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Maniatis T, 1989, MOL CLONING; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PEDERSEN H, 1995, MOL MICROBIOL, V17, P843, DOI 10.1111/j.1365-2958.1995.mmi_17050843.x; PERINI L, 1995, BIOPHYS J, V68, pA295; Perini LT, 1996, J BIOL CHEM, V271, P33242, DOI 10.1074/jbc.271.52.33242; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P155, DOI 10.1111/j.1432-1033.1986.tb09652.x; RAZZELL WE, 1964, J BIOL CHEM, V239, P1789; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAUNDERS PP, 1969, J BIOL CHEM, V244, P3691; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SENEAR DF, 1992, METHOD ENZYMOL, V210, P463; SHORT SA, 1984, GENE, V31, P205, DOI 10.1016/0378-1119(84)90211-7; SINGER JT, 1985, J BACTERIOL, V163, P1095, DOI 10.1128/JB.163.3.1095-1100.1985; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAXMAN E, 1993, ANAL BIOCHEM, V210, P425, DOI 10.1006/abio.1993.1220; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985	48	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16962	16971		10.1074/jbc.272.27.16962	http://dx.doi.org/10.1074/jbc.272.27.16962			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202008	hybrid			2022-12-25	WOS:A1997XH44600040
J	Deissler, H; Wilm, M; Genc, B; Schmitz, B; Ternes, T; Naumann, F; Mann, M; Doerfler, W				Deissler, H; Wilm, M; Genc, B; Schmitz, B; Ternes, T; Naumann, F; Mann, M; Doerfler, W			Rapid protein sequencing by tandem mass spectrometry and cDNA cloning of p20-CGGBP - A novel protein that binds to the unstable triplet repeat 5'-d(CGG)(n)-3' in the human FMR1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; IN-VITRO; TRINUCLEOTIDE REPEATS; METHYLATION ANALYSIS; CGG REPEAT; DNA; IDENTIFICATION; INSTABILITY; RESOLUTION; EXPANSION	The autonomous expansion of the unstable 5'-d(CGG)(n)-3' repeat in the 5'-untranslated region of the human FMR1 gene leads to the fragile X syndrome, one of the most frequent causes of mental retardation in human males, We have recently described the isolation of a protein p20-CGGBP that binds sequence-specifically to the double stranded trinucleotide repeat 5'-d(CGG)-3' (Deissler, H., Behn-Krappa, A., and Doerfler, W. (1996) J. Biol. Chem. 271, 4327-4334), We demonstrate now that the p20-CGGBP can also bind to an interrupted repeat sequence, Peptide sequence tags of p20-CGGBP obtained by nanoelectrospray mass spectrometry were screened against an expressed sequence tag data base, retrieving a clone that contained the full-length coding sequence for p20-CGGBP. A bacterially expressed fusion protein p20-CGGBP-6xHis exhibits a binding pattern to the double-stranded 5'-d(CGG),-3' repeat similar to that of the authentic p20-CGGBP, This novel protein lacks any overall homology to other known proteins but carries a putative nuclear localization signal, The p20-CGGBP gene is conserved among mammals but shows no homology to non-vertebrate species, The gene encoding the sequence for the new protein has been mapped to human chromosome 3.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY; EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69117 HEIDELBERG,GERMANY	University of Cologne; European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Deissler, Heidrun/0000-0003-0086-7811; Wilm, Matthias/0000-0002-5461-6834				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; Deissler H, 1996, J BIOL CHEM, V271, P4327; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; ILM M, 1996, ANAL CHEM, V66, P1; IMAGAWA M, 1995, J BIOL CHEM, V270, P20898, DOI 10.1074/jbc.270.36.20898; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mann M, 1996, TRENDS BIOCHEM SCI, V21, P494, DOI 10.1016/S0968-0004(96)30042-X; MCMURRAY CT, 1995, CHROMOSOMA, V104, P2; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PEREVOZCHIKOV AP, 1994, DOKL AKAD NAUK+, V338, P411; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SMEETS HJM, 1995, HUM MOL GENET, V4, P2103, DOI 10.1093/hmg/4.11.2103; THOMSON BA, 1995, ANAL CHEM, V67, P1696, DOI 10.1021/ac00106a008; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; YANOYANAGISAWA H, 1995, NUCLEIC ACIDS RES, V23, P2654, DOI 10.1093/nar/23.14.2654; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706	47	40	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16761	16768		10.1074/jbc.272.27.16761	http://dx.doi.org/10.1074/jbc.272.27.16761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201980	hybrid			2022-12-25	WOS:A1997XH44600012
J	Franklin, CC; Kraft, AS				Franklin, CC; Kraft, AS			Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE CELLS; C-JUN; TYROSINE-PHOSPHATASE; IN-VIVO; PHOSPHORYLATION; GROWTH; DOMAIN; 3CH134	Phorbol ester tumor promoters, such as phorbol 12-myristate 13-acetate (PMA), are potent activators of extracellular signal-regulated kinase 2 (ERK2), stress-activated protein kinase (SAPK), and p38 mitogen-activated protein kinase (MAPK) in U937 human leukemic cells, These kinases are regulated by the reversible dual phosphorylation of conserved threonine and tyrosine residues, The dual specificity protein phosphatase MAPK phosphatase-l (MKP-1) has been shown to dephosphorylate and inactivate ERK2, SAPK, and p38 MAPK in transient transfection studies. Here we demonstrate that PMA treatment induces MKP-1 protein expression in U937 cells, which is detectable within 30 min with maximal levels attained after 4 h, This time course coincides with the rapid inactivation of PMA-induced SAPK activity, but not ERK2 phosphorylation, which remains elevated for up to 6 h, To examine directly the role of MKP-1 in the regulation of these protein kinases in vivo, we established a U937 cell line that conditionally expresses MKP-1 from the human metallothionein IIa promoter, Conditional expression of MKP-1 inhibited PMA-induced ERK2, SAPK, and p38 MAPK activity, By titrating the levels of MKP-1 expression from the human metallothionein IIa promoter, however, it was found that p38 MAPK and SAPK were much more sensitive to inhibition by MKP-1 than ERK2, This differential substrate specificity of MKP-1 can be functionally extended to nuclear transcriptional events in that PMA-induced c-Jun transcriptional activity was more sensitive to inhibition by MKP-1 than either Elk-l or c-Myc. Conditional expression of MKP-1 also abolished the induction of endogenous MKP-1 protein expression in response to PMA treatment, This negative feedback regulatory mechanism is likely due to MKP-1-mediated inhibition of ERK2, as studies utilizing the MEK1/2 inhibitor PD98059 suggest that ERK2 activation is required for PMA-induced MKP-1 expression, These findings suggest that ERK2-mediated induction of MKP-1 may play an important role in preferentially attenuating signaling through the p38 MAPK and SAPK signal transduction pathways.			Franklin, CC (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV MED ONCOL,DENVER,CO 80262, USA.				NCI NIH HHS [CA42533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADUNYAH SE, 1992, J CELL PHYSIOL, V151, P415, DOI 10.1002/jcp.1041510223; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dorfman K, 1996, ONCOGENE, V13, P925; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; Franklin CC, 1995, ONCOGENE, V11, P2365; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SETH A, 1992, J BIOL CHEM, V267, P24796; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	48	387	392	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16917	16923		10.1074/jbc.272.27.16917	http://dx.doi.org/10.1074/jbc.272.27.16917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202001	hybrid			2022-12-25	WOS:A1997XH44600033
J	Rivers, RL; Dean, RM; Chandy, G; Hall, JE; Roberts, DM; Zeidel, ML				Rivers, RL; Dean, RM; Chandy, G; Hall, JE; Roberts, DM; Zeidel, ML			Functional analysis of nodulin 26, an aquaporin in soybean root nodule symbiosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; CELL CHIP28 PROTEIN; WATER CHANNEL; PERIBACTEROID MEMBRANE; LENS; PHOSPHORYLATION; PERMEABILITY; LIPOSOMES; PROTEOLIPOSOMES; RECONSTITUTION	Upon infection of soybean roots, nitrogen-fixing bacteria become enclosed in a specific organelle known as the symbiosome. The symbiosome membrane (SM) is a selectively permeable barrier that controls metabolite flux between the plant cytosol and the symbiotic bacterium inside; Nodulin 26 (NOD 26), a member of the aquaporin (AQP) water channel family, is a major protein component of the SM. Expression of NOD 26 in Xenopus oocytes gave a mercury-sensitive increase in osmotic water permeability (P-f). To define the biophysical properties of NOD 26 water channels in their native membranes, symbiosomes were isolated from soybean root nodules and the SM separated as vesicles from the bacteria. Permeabilities were measured using stopped-flow fluorimetry in SM vesicles with entrapped carboxyfluorescein. Osmotic water permeability (P-f) of SM was high, with a value of 0.05 +/- 0.003 cm/s observed at 20 degrees C (mean +/- S.E.; n = 15). Water flow exhibited a low activation energy, was inhibited by HgCl2 (0.1 mM), and exhibited a unit conductance of 3.2 +/- 1.3 x 10(-15) cm(3)/s, a value 30-fold lower than that of AQP 1, the red blood cell water channel. Diffusive water permeability (P-d) was 0.0024 +/- 0.0002 cm/s, and the resulting P-f to P-d ratio was 18.3, indicating that water crosses the SM in single file fashion via the NOD 26 water channel. In addition to high water permeability, SM vesicles also show high mercury-sensitive permeability to glycerol and formamide, but not urea, suggesting that NOD 26 also fluxes these solutes. Overall, we conclude that NOD 26 acts as a water channel with a single channel conductance that is 30-fold lower than AQP 1. Because the solutes that permeate NOD 26 are far larger than water, and water appears to cross the channel via a single file pathway, solute flux across NOD 26 appears to occur by a pathway that is distinct from that for water.	UNIV PITTSBURGH,MED CTR,LAB EPITHELIAL CELL BIOL,RENAL ELECTROLYTE DIV,PITTSBURGH,PA 15213; UNIV TENNESSEE,DEPT BIOCHEM CELLULAR & MOL BIOL,KNOXVILLE,TN 37996; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tennessee System; University of Tennessee Knoxville; University of California System; University of California Irvine			Hall, James E/K-6306-2012	Roberts, Daniel/0000-0002-0780-7056	NEI NIH HHS [EY05661] Funding Source: Medline; NIDDK NIH HHS [DK 43955] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1995, CURR OPIN CELL BIOL, V7, P72; CHANDY G, 1997, IN PRESS J MEMBR BIO, V178; DAY DA, 1993, SYMBIOSIS, V14, P175; DENISON RF, 1995, PLANT PHYSIOL, V108, P235, DOI 10.1104/pp.108.1.235; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; EHRING GR, 1991, J MEMBRANE BIOL, V126, P75; FINKELSTEIN A, 1986, WATER MOVEMENT LIPID; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; GIRSCH SJ, 1985, J MEMBRANE BIOL, V83, P217, DOI 10.1007/BF01868696; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; HUNT S, 1993, ANNU REV PLANT PHYS, V44, P483, DOI 10.1146/annurev.pp.44.060193.002411; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KUYPERS FA, 1984, J CELL BIOL, V99, P2260, DOI 10.1083/jcb.99.6.2260; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; LEE JW, 1995, J BIOL CHEM, V270, P27051, DOI 10.1074/jbc.270.45.27051; MAGGI CA, 1986, J AUTON PHARMACOL, V6, P133, DOI 10.1111/j.1474-8673.1986.tb00640.x; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; Negrete HO, 1996, J BIOL CHEM, V271, P11627, DOI 10.1074/jbc.271.20.11627; NIKAIDO H, 1985, J MEMBRANE BIOL, V85, P87, DOI 10.1007/BF01872008; OUYANG LJ, 1991, FEBS LETT, V293, P188, DOI 10.1016/0014-5793(91)81183-9; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PURCELL LC, 1994, PLANT CELL ENVIRON, V17, P837, DOI 10.1111/j.1365-3040.1994.tb00178.x; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Roth L.E., 1988, MOL GENETICS PLANT M, P220; STEIN WD, 1990, CHANNELS CARRIERS PU, P66; Streeter JG, 1995, SYMBIOSIS, V19, P175; STREETER JG, 1992, PHYSIOL PLANTARUM, V84, P584, DOI 10.1111/j.1399-3054.1992.tb04708.x; WEAVER CD, 1991, PLANT PHYSIOL, V95, P222, DOI 10.1104/pp.95.1.222; WEAVER CD, 1994, J BIOL CHEM, V269, P17858; WEAVER CD, 1992, BIOCHEMISTRY-US, V31, P8954, DOI 10.1021/bi00152a035; Whitehead LF, 1995, SYMBIOSIS, V19, P141; YE RG, 1989, BIOCHEMISTRY-US, V28, P824, DOI 10.1021/bi00428a062; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZAMPIGHI GA, 1985, P NATL ACAD SCI USA, V82, P8468, DOI 10.1073/pnas.82.24.8468; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65; ZEIDEL ML, 1994, BIOCHEMISTRY-US, V33, P1606, DOI 10.1021/bi00172a042; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG YX, 1995, MOL BIOL CELL, V6, P109, DOI 10.1091/mbc.6.1.109	41	144	156	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16256	16261		10.1074/jbc.272.26.16256	http://dx.doi.org/10.1074/jbc.272.26.16256			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195927	hybrid			2022-12-25	WOS:A1997XG01900031
J	SawkaVerhelle, D; Baron, V; Mothe, I; Filloux, C; White, MF; VanObberghen, E				SawkaVerhelle, D; Baron, V; Mothe, I; Filloux, C; White, MF; VanObberghen, E			Tyr(624) and Tyr(628) in insulin receptor substrate-2 mediate its association with the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; KINASE DOMAIN AUTOPHOSPHORYLATION; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GROWTH-HORMONE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; 2-HYBRID SYSTEM; NPEY MOTIF	In addition to the pleckstrin homology domain and the phosphotyrosine binding domain in insulin receptor substrate (IRS)-1 and IRS-2, a region between amino acids 591 and 786 in IRS-2 (IRS-2-(591-786)) binds to the insulin receptor. Based on peptide competition studies, this region interacts with the phosphorylated regulatory loop of the insulin receptor; we designate this region the kinase regulatory loop binding (KRLB) domain. Two tyrosine residues in the KRLB domain at positions 624 and 628 are crucial for this interaction. Phosphorylation of tyrosine residues in the KRLB domain by the insulin receptor inhibits the binding to the receptor. These results reveal a novel mechanism regulating the interaction of the insulin receptor and IRS-2 that may distinguish the signal of IRS-2 from IRS-1.	FAC MED NICE,INSERM,U145,F-06107 NICE 2,FRANCE; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			MOTHE-SATNEY, ISABELLE/Q-6377-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385	NIDDK NIH HHS [DK 38712, DK 43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808, R55DK038712, R01DK038712, R29DK038712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; ECK MJ, 1996, CELL, V85, P1; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARPER JW, 1993, CELL, V75, P805; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HOLGADOMADRUGA M, 1995, NATURE, V379, P590; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Miller J.H., 1972, EXPT MOL GENETICS; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PONS S, 1995, MOL CELL BIOL, V15, P4453; PONZIO G, 1988, EMBO J, V7, P4111, DOI 10.1002/j.1460-2075.1988.tb03305.x; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719	40	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16414	16420		10.1074/jbc.272.26.16414	http://dx.doi.org/10.1074/jbc.272.26.16414			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195949	hybrid, Green Submitted			2022-12-25	WOS:A1997XG01900053
J	Sato, S; Roberts, K; Gambino, G; Cook, A; Kouzarides, T; Goding, CR				Sato, S; Roberts, K; Gambino, G; Cook, A; Kouzarides, T; Goding, CR			CBP/p300 as a co-factor for the Microphthalmia transcription factor	ONCOGENE			English	Article						microphthalmia; transcription activation; E1A; CBP; melanocytes	MELANOCYTE-SPECIFIC TRANSCRIPTION; NUCLEAR-PROTEIN CBP; ACTIVATION DOMAINS; TYROSINASE GENE; E1A; DIFFERENTIATION; MUTATIONS; P300; EXPRESSION; MYOBLASTS	The Microphthalmia basic-Helix-loop-Helix-Leucine Zipper (bHLH-LZ) transcription factor (Mi) plays a crucial role in the genesis of melanocytes; mice deficient for a functional (Microphthalmia) gene product lack all pigment cells, We show here that the Mi activation domain resides N-terminal to the DNA-binding domain and that as little as 18 amino acids are sufficient to mediate transcription activation, The minimal activation region of Mi is highly conserved in the related transcription factor TFE3 and is predicted to adopt an amphipathic alphahelical conformation, This region of Mi is also highly conserved with a region of E1A known to be essential for binding the CBP/p300 transcription cofactor, Consistent with these observations, the Mi activation domain can interact in vitro with CBP specifically through a region of CBP required for complex formation with E1A, P/CAF and c-Fos, and anti p300 antibodies can co-immunoprecipitate Mi from both melanocyte and melanoma cell lines, In addition, co-transfection of a vector expressing CBP2 (aas 1621-1891) fused to the VP16 activation domain potentiated the ability of Mi to activate transcription, confirming the significance of the CBP-Mi interaction observed in vitro. These data suggest that transcription activation by Mi is achieved at least in part by recruitment of CBP, The parallels between transcription regulation by Microphthalmia in melanocytes and MyoD in muscle cells are discussed.	MARIE CURIE RES INST,EUKARYOT TRANSCRIPT LAB,OXTED RH8 0TL,SURREY,ENGLAND; CRC,WELLCOME INST,CAMBRIDGE CB2 1QR,ENGLAND	Wellcome Trust Sanger Institute			Sato, Shigeru/ABE-2090-2020	Kouzarides, Tony/0000-0002-8918-4162; Goding, Colin/0000-0002-1614-3909	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BANERJEE AC, 1994, ONCOGENE, V9, P1733; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BATTACHARYA S, 1996, NATURE, V383, P344; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARUSO M, 1993, ONCOGENE, V8, P267; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FITZPATRICK TB, 1979, BIOL MELANIN PIGMENT; GANSS R, 1994, J BIOL CHEM, V269, P29808; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; OELGESCHLAGER M, 1996, EMBO J, V15, P1227; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; PERKINS ND, 1997, SCIENCE, V275, P451; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STEEL KP, 1989, DEVELOPMENT, V107, P453; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; YACUIK P, 1991, MOL CELL BIOL, V11, P5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YAVUZER U, 1995, ONCOGENE, V10, P123; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	57	147	151	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3083	3092		10.1038/sj.onc.1201298	http://dx.doi.org/10.1038/sj.onc.1201298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223672				2022-12-25	WOS:A1997XG10000011
J	Kawasaki, H; Morooka, T; Shimohama, S; Kimura, J; Hirano, T; Gotoh, Y; Nishida, E				Kawasaki, H; Morooka, T; Shimohama, S; Kimura, J; Hirano, T; Gotoh, Y; Nishida, E			Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATORY AMINO-ACIDS; METHYL-D-ASPARTATE; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; NITRIC-OXIDE; MAMMALIAN-CELLS; NEURONAL DEATH; MESSENGER-RNA; NEUROTOXICITY; PHOSPHORYLATION	In the mammalian central nervous system glutamate is the major excitatory neurotransmitter and plays a crucial role in plasticity and toxicity of certain neural cells. We found that glutamate stimulated activation of p38 and stress-activated protein kinase (SAPK, also known as c-Jun N-terminal kinase (JNK)), two subgroup members of the mitogen-activated protein kinase superfamily in matured cerebellar granule cells. The p38 activation was largely mediated by N-methyl-D-aspartate receptors. Furthermore, we have revealed a novel signaling pathway, that is, Ca2+-mediated activation of p38 in glutamate-treated granule cells. The glutamate concentration effective for inducing apoptosis correlated with that for inducing p38 activation, SB203580, a specific inhibitor for p38, inhibited glutamate-induced apoptosis. Thus p38 might be involved in glutamate-induced apoptosis in cerebellar granule cells.	KYOTO UNIV,FAC MED,DEPT GENET & MOL BIOL,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT BIOPHYS,GRAD SCH SCI,BUNKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT NEUROL,BUNKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT PHYSIOL,BUNKYO KU,KYOTO 60601,JAPAN	Kyoto University; Kyoto University; Kyoto University; Kyoto University			KAWASAKI, Hiroshi/L-3736-2015; Kawasaki, Hiroshi/C-4404-2015	Kawasaki, Hiroshi/0000-0002-2514-1497				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; BESSHO Y, 1993, J NEUROCHEM, V60, P253, DOI 10.1111/j.1471-4159.1993.tb05845.x; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COX JA, 1990, NEURON, V4, P941, DOI 10.1016/0896-6273(90)90147-8; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FINKBEINER S, 1988, P NATL ACAD SCI USA, V85, P4071, DOI 10.1073/pnas.85.11.4071; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gotoh Y, 1995, Prog Cell Cycle Res, V1, P287; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDENREICH A, 1996, J BIOL CHEM, V271, P9891; HEISENBERG CP, 1992, NEUROREPORT, V3, P685, DOI 10.1097/00001756-199208000-00008; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MANEV H, 1989, MOL PHARMACOL, V36, P106; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Olney J.W., 1978, KAINIC ACID TOOL NEU, P95; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RESINK A, 1994, BRAIN RES, V655, P222, DOI 10.1016/0006-8993(94)91617-9; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	54	363	372	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18518	18521		10.1074/jbc.272.30.18518	http://dx.doi.org/10.1074/jbc.272.30.18518			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228012	hybrid			2022-12-25	WOS:A1997XM34200003
J	Peterson, BZ; Johnson, BD; Hockerman, GH; Acheson, M; Scheuer, T; Catterall, WA				Peterson, BZ; Johnson, BD; Hockerman, GH; Acheson, M; Scheuer, T; Catterall, WA			Analysis of the dihydropyridine receptor site of L-type calcium channels by alanine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ALPHA-1 SUBUNIT; FUNCTIONAL EXPRESSION; ALLOSTERIC TRANSITION; CA2+ CHANNELS; BINDING DOMAINS; MOLECULAR-BASIS; SMOOTH-MUSCLE; H-3 AZIDOPINE; BETA-SUBUNIT	The dihydropyridine Ca2+ antagonist drugs used in the therapy of cardiovacular disorders inhibit L-type Ca2+ channels by binding to a single high affinity site, Photoaffinity labeling and analysis of mutant Ca2+ channels implicate the IIIS6 and IVS6 segments in high affinity binding, The amino acid residues that are required for high affinity binding of dihydropyridine Ca2+ channel antagonists were probed by alanine scanning mutagenesis of the alpha(1C) subunit, transient expression in mammalian cells, and analysis by measurements of ligand binding and block of Ba2+ currents through expressed Ca2+ channels, Eleven amino acid residues in transmembrane segments IIIS6 and IVS6 were identified whose mutation reduced the affinity for the Ca2+ antagonist PN200-110 by 2-25-fold. Both amino acid residues conserved among Ca2+ channels and those specific to L-type Ca2+ channels were found to be required for high affinity dihydropyridine binding, In addition, mutation F1462A increased the affinity for the dihydropyridine Ca2+ antagonist PN200-110 by 416-fold with no effect on the affinity for the Ca2+ agonist Bay K8644. The residues in transmembrane segments IIIS6 and IVS6 that are required for high affinity binding are primarily aligned on single faces of these two alpha helices, supporting a ''domain interface model'' of dihydropyridine binding and action in which the IIIS6 and IVS6 interact to form a high affinity dihydropyridine receptor site on L-type Ca2+ channels.			Peterson, BZ (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312, P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07312, P01 HL44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGALORE R, 1994, MOL PHARMACOL, V46, P660; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BECHEM M, 1987, J MOL CELL CARDIOL, V19, P63, DOI 10.1016/S0022-2828(87)80005-6; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; DIOCHOT S, 1995, PFLUG ARCH EUR J PHY, V431, P10, DOI 10.1007/BF00374372; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; FERRY DR, 1984, FEBS LETT, V169, P112, DOI 10.1016/0014-5793(84)80299-9; GALIZZI JP, 1986, J BIOL CHEM, V261, P1393; GLOSSMANN H, 1984, J CARDIOVASC PHARM S, V6, P508; GOULD RJ, 1983, COLD SPRING HARB SYM, V48, P355, DOI 10.1101/SQB.1983.048.01.039; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HERING S, 1993, MOL PHARMACOL, V43, P820; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HOSEY MM, 1987, BIOCHEM BIOPH RES CO, V147, P1137; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KASS RS, 1989, J GEN PHYSIOL, V93, P1109, DOI 10.1085/jgp.93.6.1109; KASS RS, 1991, J GEN PHYSIOL, V98, P63, DOI 10.1085/jgp.98.1.63; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MITTERDORFER J, 1995, BIOCHEMISTRY-US, V34, P9350, DOI 10.1021/bi00029a010; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SEDYL K, 1993, PFLUGERS ARCH, V424, P552; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SIEBER M, 1987, EUR J BIOCHEM, V167, P117, DOI 10.1111/j.1432-1033.1987.tb13311.x; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; VAGHY PL, 1987, J BIOL CHEM, V262, P14337; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	59	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18752	18758		10.1074/jbc.272.30.18752	http://dx.doi.org/10.1074/jbc.272.30.18752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228048	hybrid			2022-12-25	WOS:A1997XM34200039
J	Yabe, D; Nakamura, T; Kanazawa, N; Tashiro, K; Honjo, T				Yabe, D; Nakamura, T; Kanazawa, N; Tashiro, K; Honjo, T			Calumenin, a Ca2+-binding protein retained in the endoplasmic reticulum with a novel carboxyl-terminal sequence, HDEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; GLUCOSE-REGULATED PROTEIN; LUMINAL ER PROTEINS; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; RECEPTOR; CALRETICULIN; RETENTION; MEMBRANE; SIGNAL	We have identified and characterized a cDNA encoding a novel Ca2+-binding protein named calumenin from mouse heart by the signal sequence trap method, The deduced amino acid sequence (315 residues) of calumenin contains an amino-terminal signal sequence and sis Ca2+-binding (EF-hand) motifs and shows homology with reticulocalbin, Erc-55, and Cab45. These proteins seem to form a new subset of the EF-hand protein family expressed in the lumen of the endoplasmic reticulum (ER) and Golgi apparatus. Purified calumenin had Ca2+-binding ability. The carboxyl-terminal tetrapeptide His-Asp-Glu-Phe was shown to be responsible far retention of calumenin in ER by the retention assay, immunostaining with a confocal laser microscope, and the deglycosylation assay, This is the first report indicating that the Phe residue is included in the ER retention signal, Calumenin is expressed most strongly in heart of adult and 18.5-day embryos. The calumenin gene (Calu) was mapped at the proximal portion of mouse chromosome 7.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Yabe, Daisuke/J-6682-2014; Honjo, Tasuku/N-4470-2016; Nakamura, Tomoyuki/AAX-9340-2020; Kanazawa, Nobuo/AAM-7353-2021	Yabe, Daisuke/0000-0002-5334-7687; Kanazawa, Nobuo/0000-0003-3000-9711				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRILLIANT MH, 1994, MAMM GENOME, V5, pS104; BRINK PA, 1995, CIRCULATION, V91, P1633, DOI 10.1161/01.CIR.91.6.1633; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHIESI M, 1981, J CELL BIOL, V91, P728, DOI 10.1083/jcb.91.3.728; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DANG CV, 1985, J BIOL CHEM, V260, P9713; DODDS D, 1995, J NEUROCHEM, V64, P2339; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; JACOBS K, 1996, Patent No. 5536637; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P47; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKAMURA T, 1995, GENOMICS, V30, P312, DOI 10.1006/geno.1995.9872; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OBRIG TG, 1971, J BIOL CHEM, V246, P174; OHTA T, 1995, J BIOL CHEM, V270, P15571, DOI 10.1074/jbc.270.26.15571; OZAWA M, 1993, J BIOL CHEM, V268, P699; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SEMENZA JC, 1992, J MOL BIOL, V224, P1, DOI 10.1016/0022-2836(92)90571-Z; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WEIS K, 1994, J BIOL CHEM, V269, P19142; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WILEMAN T, 1991, J BIOL CHEM, V266, P4500	54	91	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18232	18239		10.1074/jbc.272.29.18232	http://dx.doi.org/10.1074/jbc.272.29.18232			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218460	hybrid			2022-12-25	WOS:A1997XL73500050
J	Chen, Q; EngelbergKulka, H; AmsterChoder, O				Chen, Q; EngelbergKulka, H; AmsterChoder, O			The localization of the phosphorylation site of BglG, the response regulator of the Escherichia coli bgl sensory system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDE UTILIZATION; PHOSPHOTRANSFERASE SYSTEM; BACILLUS-SUBTILIS; TRANSCRIPTIONAL ANTITERMINATOR; PROTEIN-PHOSPHORYLATION; OPERON; FAMILY; GENES; PHOSPHOENOLPYRUVATE; EXPRESSION	BglG, the response regulator of the bgl sensory system, was recently shown to be phosphorylated on a histidine residue, We report here the localization of the phosphorylation site to histidine 208, Localization of the phosphorylated histidine was carried out in two steps, We first engineered BglG derivatives with a specific protease (factor Xa) cleavage site that allowed asymmetric splitting of each prephosphorylated protein to well defined peptides, of which only one was labeled by radioactive phosphate, This allowed the localization of the phosphorylation site to the last 111 residues, Subsequently, we identified the phosphorylated histidine by mutating each of the three histidines located in this region to an arginine and following the ability of the resulting mutants to be in vivo regulated and in vitro phosphorylated by BglF, the bgl system sensor, Histidine 208 was the only histidine which failed both tests, The use of simple techniques to map the phosphorylation site should make this protocol applicable for the localization of phosphorylation sites in other proteins, The bgl system represents a new family of sensory systems, Thus, the mapping reported here is an important step toward the definition of the functional domains involved in the transduction of a signal by the components that constitute systems of this novel family.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOL BIOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, 1993, J CELL BIOCHEM, V51, P83, DOI 10.1002/jcb.240510115; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; AYMERICH S, 1992, P NATL ACAD SCI USA, V89, P10410, DOI 10.1073/pnas.89.21.10410; BARDOWSKI J, 1994, J BACTERIOL, V176, P5681, DOI 10.1128/JB.176.18.5681-5685.1994; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; BENHAR I, 1991, GENE, V103, P79, DOI 10.1016/0378-1119(91)90394-Q; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; ELHASSOUNI M, 1992, J BACTERIOL, V174, P765, DOI 10.1128/jb.174.3.765-777.1992; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; KRUGER S, 1995, J BACTERIOL, V177, P5590; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOQ D, 1995, J BACTERIOL, V177, P1527, DOI 10.1128/jb.177.6.1527-1535.1995; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; Miller J.H., 1972, EXPT MOL GENETICS; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PRASAD I, 1974, J BACTERIOL, V120, P638, DOI 10.1128/JB.120.2.638-650.1974; Russo F D, 1993, Trends Microbiol, V1, P306, DOI 10.1016/0966-842X(93)90007-E; SAIER MH, 1975, J BIOL CHEM, V250, P7078; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFLER S, 1967, J BACTERIOL, V93, P254, DOI 10.1128/JB.93.1.254-263.1967; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	32	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17263	17268		10.1074/jbc.272.28.17263	http://dx.doi.org/10.1074/jbc.272.28.17263			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211862	hybrid			2022-12-25	WOS:A1997XK16500005
J	Deprez, J; Vertommen, D; Alessi, DR; Hue, L; Rider, MH				Deprez, J; Vertommen, D; Alessi, DR; Hue, L; Rider, MH			Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; BOVINE HEART; S6 KINASE; FRUCTOSE 2,6-BISPHOSPHATE; RAT-LIVER; FRUCTOSE-2,6-BISPHOSPHATASE; IDENTIFICATION; PURIFICATION; MUTAGENESIS; GLYCOLYSIS	To understand the insulin induced activation of 6-phosphofructo-2-kinase (PFK-S) of the bifunctional enzyme PFK-2/fructose-2,6-bisphosphatase in heart, the effect of phosphorylation by protein kinases of the insulin signaling pathways on PFK-2 activity was studied. Purified PFK-2/fructose-2,6-bisphosphatase from bovine heart is a mixture of two isoforms (M-r 58,000 and 54,000 on SDS-polyacrylamide gels). The M-r 54,000 protein is an alternatively spliced form, lacking phosphorylation sites for protein kinases, Recombinant enzymes corresponding to the M-r 58,000 (Bill) and M-r 54,000 (BH3) forms were expressed and used as substrates for phosphorylation. The recombinant BH1 isoform was phosphorylated by p70 ribosomal S6 kinase (p70(s6k)), mitogen activated protein kinase activated protein kinase-l, and protein kinase B (PKB), whereas the recombinant BH3 isoform was a poor substrate for these protein kinases. Treatment with all protein kinases activated PFK-P in the recombinant Bill preparation. Phosphorylation of the recombinant BH1 isoform correlated with PFK-S activation and was reversed by treatment with protein phosphatase 2A. All the protein kinases phosphorylated Ser-466 and Ser-483 in the BH1 isoform, but to different extents: p70(s6k) preferentially phosphorylated Ser-466, whereas mitogen-activated protein kinase-activated protein kinase-l and PKB phosphorylated Ser 466 and Ser-483 to a similar extent, We propose that PKB is part of the insulin signaling cascade for PFK-S activation in heart.	INT INST CELLULAR & MOL PATHOL,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Dundee				Vertommen, Didier/0000-0001-7648-8282; Alessi, Dario/0000-0002-2140-9185				ABE Y, 1995, BIOCHEMISTRY-US, V34, P2553, DOI 10.1021/bi00008a020; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALLEN G, 1989, SEQUENCING PROTEINS, P140; BELACOSSA A, 1991, SCIENCE, V254, P244; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHIKRI M, 1995, BIOCHEMISTRY-US, V34, P8876, DOI 10.1021/bi00027a040; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CREPIN KM, 1993, J BIOL CHEM, V268, P15277; CROSS DAE, 1995, NATURE, V378, P229; DARVILLE MI, 1991, FEBS LETT, V288, P91, DOI 10.1016/0014-5793(91)81009-W; DEPRE C, 1993, J BIOL CHEM, V268, P13274; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Gevaert K, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P15; HUE L, 1982, J BIOL CHEM, V257, P4308; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1990, FRUCTOSE 2 6 BISPHOS, P173; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KITAMURA K, 1988, J BIOL CHEM, V263, P1696; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; RIDER MH, 1984, FEBS LETT, V176, P484, DOI 10.1016/0014-5793(84)81223-5; RIDER MH, 1992, FEBS LETT, V310, P139, DOI 10.1016/0014-5793(92)81315-D; RIDER MH, 1986, BIOCHEM J, V240, P57, DOI 10.1042/bj2400057; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAKATA J, 1991, BIOCHEM BIOPH RES CO, V180, P470, DOI 10.1016/S0006-291X(05)81088-5; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Vertommen D, 1996, J BIOL CHEM, V271, P17875, DOI 10.1074/jbc.271.30.17875; VIDAL H, 1993, FEBS LETT, V330, P329, DOI 10.1016/0014-5793(93)80898-5	41	333	350	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17269	17275		10.1074/jbc.272.28.17269	http://dx.doi.org/10.1074/jbc.272.28.17269			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211863	hybrid			2022-12-25	WOS:A1997XK16500006
J	Hargrove, MS; Whitaker, T; Olson, JS; Vali, RJ; Mathews, AJ				Hargrove, MS; Whitaker, T; Olson, JS; Vali, RJ; Mathews, AJ			Quaternary structure regulates hemin dissociation from human hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXPRESSION; ASSOCIATION; STABILITY; MYOGLOBIN; BINDING; GLOBIN	Rate constants for hemin dissociation from the alpha and beta subunits of native and recombinant human hemoglobins were measured as a function of protein concentration at pH 7.0, 37 degrees C, using H64Y/V68F apomyoglobin as a hemin acceptor reagent, Hemin dissociation rates were also measured for native isolated alpha and beta chains and for recombinant hemoglobin tetramers stabilized by alpha subunit fusion, The rate constant for hemin dissociation from beta subunits in native hemoglobin increases from 1.5 h(-1) in tetramers at high protein concentration to 15 h(-1) in dimers at low concentrations, The rate of hemin dissociation from alpha subunits in native hemoglobin is significantly smaller (0.3-0.6 h(-1)) and shows little dependence on protein concentration, Recombinant hemoglobins containing a fused di-alpha subunit remain tetrameric under all concentrations and show rates of hemin loss similar to those observed for wild-type and native hemoglobin at high protein concentration, Rates of hemin dissociation from monomeric alpha and beta chains are much greater, 12 and 40 h(-1), respectively, at pH 7, 37 degrees C, Aggregation of monomers to form alpha(1) beta(1) dimers greatly stabilizes bound hemin in cu chains, decreasing its rate of hemin loss similar to 20-fold. In contrast, dimer formation has little stabilizing effect on hemin binding to beta subunits, A significant reduction in the rate of hemin loss from beta subunits does occur after formation of the alpha(1) beta(2) interface in tetrameric hemoglobin, These results suggest that native human hemoglobin may have evolved to lose heme rapidly after red cell lysis, allowing the prosthetic group to be removed by serum albumin and apohemopexin.	RICE UNIV,WM KECK CTR COMPUTAT BIOL,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005; SOMATOGEN INC,BOULDER,CO 80301	Rice University				Olson, John/0000-0002-0760-5403	NHLBI NIH HHS [HL-47020] Funding Source: Medline; NIGMS NIH HHS [GM-08280, GM-35649] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, R01GM035649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN ME, 1971, J BIOL CHEM, V246, P2796; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; Bucci E, 1981, Methods Enzymol, V76, P97; BUNN HF, 1968, J BIOL CHEM, V243, P465; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P634; EDELSTEI.SJ, 1970, J BIOL CHEM, V245, P4372; GIBSON QH, 1948, BIOCHEM J, V42, P113; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11293, DOI 10.1021/bi960371l; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11310, DOI 10.1021/bi9603736; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11300, DOI 10.1021/bi960372d; HARGROVE MS, 1994, BIOCHEMISTRY-US, V33, P11767, DOI 10.1021/bi00205a012; HENSLEY P, 1975, J BIOL CHEM, V250, P952; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; LOOKER D, 1994, METHOD ENZYMOL, V231, P364; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MCGOVERN P, 1976, J BIOL CHEM, V251, P7871; NAGEL RL, 1971, J BIOL CHEM, V246, P69; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; WIEDERMANN BL, 1975, J BIOL CHEM, V250, P5273; ZHANG L, 1991, J BIOL CHEM, V266, P24698	24	122	125	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17385	17389		10.1074/jbc.272.28.17385	http://dx.doi.org/10.1074/jbc.272.28.17385			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211878	hybrid			2022-12-25	WOS:A1997XK16500021
J	Kollar, R; Reinhold, BB; Petrakova, E; Yeh, HJC; Ashwell, G; Drgonova, J; Kapteyn, JC; Klis, FM; Cabib, E				Kollar, R; Reinhold, BB; Petrakova, E; Yeh, HJC; Ashwell, G; Drgonova, J; Kapteyn, JC; Klis, FM; Cabib, E			Architecture of the yeast cell wall - beta(1->6)-glucan interconnects mannoprotein, beta(1-3)-glucan, and chitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; NUCLEAR MAGNETIC-RESONANCE; SACCHAROMYCES-CEREVISIAE; SIDE-CHAIN; ENDOPLASMIC-RETICULUM; PATHOGENIC YEAST; CANDIDA-ALBICANS; BETA-GLUCAN; MANNAN; PROTEINS	In a previous study (Kollar, R., Petrakova, E., Ashwell, G,, Robbins, P, W,, and Cabib, E, (1995) J, Biol, Chem. 270, 1170-1178), the linkage region between chitin and beta(1-->3)-glucan was solubilized and isolated in the form of oligosaccharides, after digestion of yeast cell walls with beta(1-->3)-glucanase, reduction with borotritide, and subsequent incubation with chitinase. In addition to the oligosaccharides, the solubilized fraction contained tritium-labeled high molecular weight material, We have now investigated the nature of this material and found that it represents areas in which all four structural components of the cell wall, beta(1-->)-glucan, beta(1-->6)-glucan, chitin, and mannoprotein are linked together, Mannoprotein, with a protein moiety about 100 kDa in apparent size, is attached to beta(1-->6)-glucan through a remnant of a glycosylphosphatidylinositol anchor containing five iv-linked mannosyl residues, The beta(1-->6)-glucan has some beta(1-->)-linked branches, and it is to these branches that the reducing terminus of chitin chains appears to be attached in a beta(1-->4) or beta(1-->2) linkage, Finally, the reducing end of beta(1-->6)-glucan is connected to the nonreducing terminal glucose of beta(1-->3)-glucan through a linkage that remains to be established, A fraction of the isolated material has three of the main components but lacks mannoprotein, From these results and previous findings on the linkage between mannoproteins and beta(1-->6)-glucan, it is concluded that the latter polysaccharide has a central role in the organization of the yeast cell wall, The possible mechanism of synthesis and physiological significance of the cross-links is discussed.	NIDDK,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892; NIDDK,LAB CELL BIOCHEM & BIOL,BETHESDA,MD 20892; BOSTON UNIV,SCH MED,BOSTON,MA 02118; US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; UNIV AMSTERDAM,INST MOL CELL BIOL,NL-1098 SM AMSTERDAM,NETHERLANDS	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Boston University; US Food & Drug Administration (FDA); University of Amsterdam			Drgonova, Jana/B-2903-2008; Klis, Frans M/B-9085-2008	Klis, Frans M/0000-0003-0079-9492; Drgonova, Jana/0000-0002-4623-8466				ALTONA C, 1980, ORG MAGN RESONANCE, V13, P417, DOI 10.1002/mrc.1270130606; ANGEL AS, 1980, MEHTODS ENZYMOL, V193, P587; Ballou C, 1976, Adv Microb Physiol, V14, P93, DOI 10.1016/S0065-2911(08)60227-1; BASSIEUX D, 1977, CARBOHYD RES, V56, P19, DOI 10.1016/S0008-6215(00)84233-0; BOCK K, 1984, ADV CARBOHYD CHEM BI, V42, P193, DOI 10.1016/S0065-2318(08)60125-0; BOCK K, 1973, TETRAHEDRON LETT, V13, P1037; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, 1988, MICROBIOL SCI, V5, P370; CABIB E, 1996, MYCOTA, V3, P243; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COLSON P, 1974, J AM CHEM SOC, V96, P8081, DOI 10.1021/ja00833a038; DEBRUYN A, 1975, B SOC CHIM BELG, V84, P721; DENOBEL JG, 1990, YEAST, V6, P491, DOI 10.1002/yea.320060606; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FLEET GH, 1974, J BACTERIOL, V119, P207, DOI 10.1128/JB.119.1.207-219.1974; Frankhauser C., 1993, J BIOL CHEM, V268, P26365; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HARTLAND RP, 1994, YEAST, V10, P1591, DOI 10.1002/yea.320101208; JIMENEZBARBERO J, 1993, CARBOHYD RES, V250, P289, DOI 10.1016/0008-6215(93)84007-S; KEPTEYN JC, 1996, GLYCOBIOLOGY, V6, P337; KITAMURA K, 1974, J GEN APPL MICROBIOL, V20, P323, DOI 10.2323/jgam.20.323; KOBAYASHI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P662, DOI 10.1016/0003-9861(92)90739-J; KOCOUREK J, 1969, J BACTERIOL, V100, P1175, DOI 10.1128/JB.100.3.1175-1181.1969; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMOINE J, 1993, J AM SOC MASS SPECTR, V4, P197, DOI 10.1016/1044-0305(93)85081-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; MANNERS DJ, 1973, BIOCHEM J, V135, P31, DOI 10.1042/bj1350031; MEADEN P, 1990, MOL CELL BIOL, V10, P3013, DOI 10.1128/MCB.10.6.3013; MILLER MW, 1994, J BIOL CHEM, V269, P9289; MOLANO J, 1980, J CELL BIOL, V85, P199, DOI 10.1083/jcb.85.2.199; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; NOVICK P, 1983, J CELL BIOL, V96, P541, DOI 10.1083/jcb.96.2.541; OGAWA T, 1982, CARBOHYD RES, V104, P271, DOI 10.1016/S0008-6215(00)82588-4; REINHOLD BB, 1992, J AM SOC MASS SPECTR, V3, P207, DOI 10.1016/1044-0305(92)87004-I; REINHOLD VN, 1995, ANAL CHEM, V67, P1772, DOI 10.1021/ac00107a005; REISSIG JL, 1955, J BIOL CHEM, V217, P959; ROBERTS RL, 1982, ANAL BIOCHEM, V127, P402, DOI 10.1016/0003-2697(82)90194-4; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; Ruiz-Herrera J., 1991, FUNGAL CELL WALL STR; SAITO H, 1987, CARBOHYD RES, V58, P293; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; Shibata N, 1996, J BIOL CHEM, V271, P9259, DOI 10.1074/jbc.271.16.9259; SHIBATA N, 1993, EUR J BIOCHEM, V217, P1, DOI 10.1111/j.1432-1033.1993.tb18211.x; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SIPOS G, 1995, J BIOL CHEM, V270, P19709, DOI 10.1074/jbc.270.34.19709; TRAYER IP, 1971, J BIOL CHEM, V246, P6666; TREVELYAN WE, 1952, BIOCHEM J, V50, P298, DOI 10.1042/bj0500298; VANBERKEL MAA, 1994, FEBS LETT, V349, P135, DOI 10.1016/0014-5793(94)00631-8; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12104; YOSHIOKA Y, 1985, CARBOHYD RES, V140, P93, DOI 10.1016/0008-6215(85)85052-7; ZLOTNIK H, 1984, J BACTERIOL, V159, P1018, DOI 10.1128/JB.159.3.1018-1026.1984	59	466	478	1	81	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17762	17775		10.1074/jbc.272.28.17762	http://dx.doi.org/10.1074/jbc.272.28.17762			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211929	Green Submitted, hybrid			2022-12-25	WOS:A1997XK16500072
J	Shulman, T; Sauer, FG; Jackman, RM; Chang, CN; Landolfi, NF				Shulman, T; Sauer, FG; Jackman, RM; Chang, CN; Landolfi, NF			An antibody reactive with domain 4 of the platelet-derived growth factor beta receptor allows BB binding while inhibiting proliferation by impairing receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL FACTOR; HUMANIZED ANTIBODIES; SIGNAL-TRANSDUCTION; LIGAND-BINDING; FACTOR PDGF; ACTIVATION	A panel of murine monoclonal antibodies was generated against the extracellular domain of the human platelet-derived growth factor (PDGF) beta receptor (PDGFR beta). These antibodies were assayed for both the ability to inhibit binding of PDGF BB 60 PDGFR beta(+) cells as well as the capacity to inhibit PDGF BB-mediated mitogenesis, As expected, all antibodies that could pre vent PDGF BB binding also inhibited mitogenesis. However one antibody (M4TS.11), with no detectable ability to inhibit PDGF BE binding, was a potent inhibitor of proliferation induced by PDGF EB. Further characterization indicated that M4TS.11 impaired PDGFR beta dimerization, revealing the mechanism by which it prevented PDGF EB-mediated mitogenesis, Using domain deletion mutants of the extracellular portion of PDGFR beta, the determinant recognized by this antibody was localized to the fourth extracellular domain of PDGFR beta, indicating that this domain, which is not involved in ligand binding, actively participates in receptor dimerization and signal transduction. The M4TS.11 antibody could also inhibit PDGF BB-mediated proliferation of responsive cells from both the baboon and the rabbit, indicating the determinant recognized by the antibody is not limited to humans and making it possible to use this antibody to evaluate the therapeutic benefit of interfering with PDGF in animal models of human disease.	PROT DESIGN LABS INC,MT VIEW,CA 94043									BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLAESSONWELSH L, 1993, CYTOKINES, V5, P31; Co MS, 1996, CANCER RES, V56, P1118; CO MS, 1992, J IMMUNOL, V148, P1149; CO MS, 1991, NATURE, V351, P501, DOI 10.1038/351501a0; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KNORR M, 1992, INVEST OPHTH VIS SCI, V33, P2207; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; KOYOMA N, 1994, CIRC RES, V75, P682; LOWENTHAL JW, 1996, CURRENT PROTOCOLS IM; RAMAKRISHNAN V, 1993, GROWTH FACTORS, V8, P253, DOI 10.3109/08977199308991571; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; WESTERMARK B, 1993, BIOL PLATELET DERIVE, V5, P146	25	19	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17400	17404		10.1074/jbc.272.28.17400	http://dx.doi.org/10.1074/jbc.272.28.17400			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211881	hybrid			2022-12-25	WOS:A1997XK16500024
J	Yamaoka, T; Kondo, M; Honda, S; Iwahana, H; Moritani, M; Ii, S; Yoshimoto, K; Itakura, M				Yamaoka, T; Kondo, M; Honda, S; Iwahana, H; Moritani, M; Ii, S; Yoshimoto, K; Itakura, M			Amidophosphoribosyltransferase limits the rate of cell growth-linked de novo purine biosynthesis in the presence of constant capacity of salvage purine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE SYNTHESIS; HUMAN-FIBROBLASTS; SYNTHESIS DENOVO; PHOSPHORIBOSYLPYROPHOSPHATE; HYPOXANTHINE; METABOLISM; HEPATOCYTES; LYMPHOCYTES; EXPRESSION; REPRESSOR	Factors controlling relative flux rates of the de novo and salvage pathways of purine nucleotide biosynthesis during animal cell growth are not fully understood, To examine the relative role of each pathway for cell. growth, three cell lines including CHO K1 (a wild-type Chinese hamster ovary fibroblast cell line), CHO ade (-)A (an auxotrophic cell line deficient of amidophosphoribosyltransferase (ATase), a presumed rate-limiting enzyme of the de novo pathway), and CHO ade (-)A transfected with human ATase cDNA ((-)A+hATase) resulting in 30-350% of the ATase activity of CHO K1, were cultured in purine-rich or purine-free media, Based on the enzyme activities of ATase and hypoxanthine phosphoribosyltransferase, the metabolic rate of the de novo and salvage pathways, the rate of cell growth (growth rate) in three cell lines under various culture conditions, and the effect of hypoxanthine infusion on the metabolic rate of the de novo pathway in rat liver, we concluded the following, 1) In (-)A+hATase transfectants, ATase activity limits the rate of the de novo pathway, which is closely linked with the growth rate, 2) Purine nucleotides are synthesized preferentially by the salvage path way as long as hypoxanthine, the most essential source of purine salvage, can be utilized, which was confirmed in rat liver in vivo by hypoxanthine infusion, The preferential usage of the salvage pathway results in sparing the energy expenditure required for de novo synthesis, 3) The regulatory capacity of the de novo pathway (about 200%) was larger than that of the salvage pathway (about 20%) with constant hypoxanthine phosphoribosyltransferase activity.	UNIV TOKUSHIMA, SCH MED, OTSUKA DEPT CLIN & MOL NUTR, TOKUSHIMA 770, JAPAN	Tokushima University								AHMED N, 1994, LEUKEMIA RES, V18, P441, DOI 10.1016/0145-2126(94)90080-9; ALEXIOU M, 1992, DEVELOPMENT, V114, P185; ALLISON AC, 1975, LANCET, V2, P1179; BARDOT V, 1994, BRIT J CANCER, V70, P212, DOI 10.1038/bjc.1994.282; BECKER MA, 1987, J BIOL CHEM, V262, P5596; BECKER MA, 1987, J BIOL CHEM, V262, P14531; BOSS GR, 1982, J BIOL CHEM, V257, P4242; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSH S, 1976, J CLIN INVEST, V58, P289, DOI 10.1172/JCI108471; DESROSIERS C, 1980, CAN J BIOCHEM CELL B, V58, P599; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; HERSHFIELD MS, 1977, SCIENCE, V197, P1284, DOI 10.1126/science.197600; ITAKURA M, 1987, AM J PHYSIOL, V253, pE684, DOI 10.1152/ajpendo.1987.253.6.E684; ITAKURA M, 1979, J BIOL CHEM, V333, P999; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; IWAHANA H, 1994, BIOCHIM BIOPHYS ACTA, V1261, P369; IWAMAHANA H, 1993, BIOCHEM BIOPH RES CO, V190, P192; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KING ME, 1983, J CLIN INVEST, V72, P965, DOI 10.1172/JCI111068; LILIEMARK J, 1992, LEUKEMIA RES, V16, P275, DOI 10.1016/0145-2126(92)90065-F; NATSUMEDA Y, 1985, CANCER RES, V45, P2556; NATSUMEDA Y, 1984, CANCER RES, V44, P2475; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OATES DC, 1977, SOMAT CELL GENET, V3, P561, DOI 10.1007/BF01539066; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; ROWE PB, 1983, P NATL ACAD SCI-BIOL, V80, P7333, DOI 10.1073/pnas.80.23.7333; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; STEEN AM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P77, DOI 10.1016/0167-4781(91)90155-F; THOMPSON LF, 1985, J IMMUNOL, V134, P3794; TSUCHIYA M, 1990, AM J PHYSIOL, V258, pC841, DOI 10.1152/ajpcell.1990.258.5.C841; UEMURA N, 1992, BLOOD, V80, P3198; WEBER G, 1987, ADV ENZYME REGUL, V26, P335, DOI 10.1016/0065-2571(87)90022-7; WEBER G, 1983, ADV ENZYME REGUL, V21, P53, DOI 10.1016/0065-2571(83)90008-0; ZOREFSHANI E, 1980, ENZYME, V25, P413, DOI 10.1159/000459290	35	52	54	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17719	17725		10.1074/jbc.272.28.17719	http://dx.doi.org/10.1074/jbc.272.28.17719			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211923	hybrid			2022-12-25	WOS:A1997XK16500066
J	Zhang, XL; Loijens, JC; Boronenkov, IV; Parker, GJ; Norris, FA; Chen, J; Thum, O; Prestwich, GD; Majerus, PW; Anderson, RA				Zhang, XL; Loijens, JC; Boronenkov, IV; Parker, GJ; Norris, FA; Chen, J; Thum, O; Prestwich, GD; Majerus, PW; Anderson, RA			Phosphatidylinositol-4-phosphate 5-kinase isozymes catalyze the synthesis of 3-phosphate-containing phosphatidylinositol signaling molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHOLIPIDS; 4-PHOSPHATE 5-KINASE; HUMAN PLATELETS; PATHWAY; 3,4-BISPHOSPHATE; CELLS; PHOSPHORYLATION; HYDROLYSIS; SEQUENCE; KINASES	Phosphatidylinositol-4-phosphate 5-kinases (PIP5Ks) utilize phosphatidylinositols containing D-3-position phosphates as substrates to form phosphatidylinositol 3,4-bisphosphate, In addition, type I PIP5Ks phosphorylate phosphatidylinositol a,4-bisphosphate to phosphatidylinositol 3,4,5-trisphosphate, while type IT kinases have less activity toward this substrate. Remarkably, these kinases can convert phosphatidylinositol 3-phosphate to phosphatidylinositol 3,4,5-trisphosphate in a concerted reaction, Kinase activities toward the 3-position phosphoinositides are comparable with those seen with phosphatidylinositol 4-phosphate as the substrate. Therefore, the PIP5Ks can synthesize phosphatidyl-inositol 4,5-bisphosphate and two 3-phosphate-containing polyphosphoinositides. These unexpected activities position the PIP5Ks as potential participants in the generation of all polyphosphoinositide signaling molecules.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63100; WASHINGTON UNIV,SCH MED,DEPT BIOL CHEM & MOL BIOPHYS,DIV HEMATOL ONCOL,ST LOUIS,MO 63100; UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT BIOMOL CHEM,MADISON,WI 53706; UNIV WISCONSIN,PROGRAM MOL & CELLULAR BIOL,MADISON,WI 53706; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; University of Utah			Thum, Oliver/F-2201-2010	Thum, Oliver/0000-0002-2568-1450; Anderson, Richard/0000-0001-6265-8359	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R37HL016634, R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051968] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55672, HL 16634] Funding Source: Medline; NIGMS NIH HHS [GM 51968] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BREARLEY CA, 1993, BIOCHEM J, V290, P145, DOI 10.1042/bj2900145; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Harlow E., 1988, ANTIBODIES LAB MANUA; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LING LE, 1989, J BIOL CHEM, V264, P5080; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Thum O, 1996, TETRAHEDRON LETT, V37, P9017, DOI 10.1016/S0040-4039(96)02117-X; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	33	104	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17756	17761		10.1074/jbc.272.28.17756	http://dx.doi.org/10.1074/jbc.272.28.17756			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211928	hybrid			2022-12-25	WOS:A1997XK16500071
J	Azad, AK; Sirakova, TD; Fernandes, ND; Kolattukudy, PE				Azad, AK; Sirakova, TD; Fernandes, ND; Kolattukudy, PE			Gene knockout reveals a novel gene cluster for the synthesis of a class of cell wall lipids unique to pathogenic mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; MYCOCEROSIC ACID SYNTHASE; PHTHIOCEROL DIESTER; TUBERCULOSIS; LEPRAE; BIOSYNTHESIS; SUPPRESSION; GLYCOLIPIDS; LEPROSY; ENZYME	Surface-exposed unusual lipids containing phthiocerol and phenolphthiocerol are found only in the cell wall of slow-growing pathogenic mycobacteria and are thought to play important roles in host-pathogen interaction, The enzymology and molecular genetics of biosynthesis of phthiocerol and phenolphthiocerol are unknown, We postulate the domain organization of a set of multifunctional enzymes and a cluster of genes (pps) that would encode these enzymes for the biosynthesis of phthiocerol and phenolphthiocerol, A cosmid containing the postulated pps gene cluster was identified by screening a genomic library of Mycobacterium bovis BCG with the postulated homologous domains from mycocerosic acid synthase and fatty acid synthase genes as probes, Homologous cosmids were also identified in the genomic libraries of Mycobacterium tuberculosis and Mycobacterium leprae, M. bovis BCG was transformed with a pps disruption construct, made from the BCG cosmid by introducing the hygromycin resistance gene as the positive-selectable marker and the sacB gene as the counter-selectable marker, Gene disruption by homologous recombination with double crossover was confirmed by polymerase chain reaction and Southern hybridization, Chromatographic analysis showed that the phenolphthiocerol derivative, mycoside B, and phthiocerol dimycocerosates were not produced by the gene knockout mutants, This result confirms the identity of the pps genes, With the identification of the pps gene clusters in both M. tuberculosis and M. leprae, it should be possible to test the postulated roles of these unique lipids in tuberculosis and leprosy.	OHIO STATE UNIV, NEUROBIOTECHNOL CTR, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM MED, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			kolattukudy, pappachan e/A-1350-2012		NCI NIH HHS [CA66029] Funding Source: Medline; NIAID NIH HHS [R01 AI35272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1996, WORLD HLTH REP; Asselineau C, 1984, MYCOBACTERIA SOURC A, P345; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; Balasubramanian V, 1996, J BACTERIOL, V178, P273, DOI 10.1128/jb.178.1.273-279.1996; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DAFFE M, 1989, BIOCHIM BIOPHYS ACTA, V1002, P333, DOI 10.1016/0005-2760(89)90347-0; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Fernandes ND, 1996, GENE, V170, P95, DOI 10.1016/0378-1119(95)00842-X; FOLCH J, 1957, J BIOL CHEM, V226, P497; GASTAMBIDEODIER M, 1967, B SOC CHIM BIOL, V49, P849; GASTAMBIDEODIER M, 1966, CR ACAD SCI C CHIM, V262, P1401; GASTAMBIDEODIER M, 1963, CHEM IND-LONDON, P1285; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; LAUNOIS P, 1989, RES IMMUNOL, V140, P847, DOI 10.1016/0923-2494(89)90044-8; LYDIATE DJ, 1989, J GEN MICROBIOL, V135, P941; MATHUR M, 1992, J BIOL CHEM, V267, P19388; McFadden J, 1996, MOL MICROBIOL, V21, P205, DOI 10.1046/j.1365-2958.1996.6271345.x; MEHRA V, 1984, NATURE, V308, P194, DOI 10.1038/308194a0; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; Pelicic V, 1996, J BACTERIOL, V178, P1197, DOI 10.1128/jb.178.4.1197-1199.1996; PUZO G, 1990, CRIT REV MICROBIOL, V17, P305, DOI 10.3109/10408419009105730; RAINWATER DL, 1985, J BIOL CHEM, V260, P616; REYRAT JM, 1995, P NATL ACAD SCI USA, V92, P8768, DOI 10.1073/pnas.92.19.8768; STEINMETZ M, 1985, MOL GEN GENET, V200, P220, DOI 10.1007/BF00425427; TAKAYAMA K, 1984, MYCOBACTERIA SOURC A, P315; Thurman P, 1989, Acta Leprol, V7 Suppl 1, P74; VACHULA M, 1989, J IMMUNOL, V142, P1696; YOUNG DB, 1993, J BACTERIOL, V175, P1, DOI 10.1128/JB.175.1.1-6.1993; Young Douglas B., 1994, P559	34	116	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16741	16745		10.1074/jbc.272.27.16741	http://dx.doi.org/10.1074/jbc.272.27.16741			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201977	hybrid			2022-12-25	WOS:A1997XH44600009
J	Gerst, JE				Gerst, JE			Conserved alpha-helical segments on yeast homologs of the synaptobrevin/VAMP family of V-SNAREs mediate exocytic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEINS; INTEGRAL MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; VAMP FAMILY; COMPLEX; FUSION; SYNAPTOPHYSIN; GENES; COMPONENT	We are studying yeast homologs of the synaptobrevin/VAMP family of vesicle-associated membrane proteins, which act as vesicular compartment-soluble N-ethylmaleimide-sensitive factor attachment protein receptors (v-SNAREs) in cells having a capacity for stimulus-coupled secretion, as well as in other cell types. The yeast homologs, Snc1 and Snc2, localize to secretory vesicles and are required for normal bulk secretion in Saccharomyces cerevisiae. Here we have used Snc deletion mutants and chimeric Snc-VAMP proteins to demonstrate that these v-SNAREs can be dissected into regions that are either indispensable or dispensable for exocytic function in vivo. We have found that a region encompassing two predicted amphipathic alpha-helices (helix 1 and helix 2) (residues 32-85), which are thought to form coiled-coil structures, is essential for conferring exocytosis in yeast. Deletions in either the helix 1 or helix 2 segments result in a complete loss in the ability of the protein to confer secretion competence to snc cells and to interact genetically with components of the proposed fusion complex: the Sec9 and Sso2 t-SNAREs and the Sec17 alpha-SNAP homolog. In contrast, deletions in either the variable (residues 2-27) or putative intravesicular (residues 115-117) regions have no deleterious effect upon v-SNARE function. This makes it unlikely that sequences in either the amino or carboxyl terminus act in an exocytic capacity. Along with additional studies utilizing chimeric Snc-VAMP proteins, we suggest that although the Snc and synaptobrevin/VAMP proteins have evolved to mediate vastly different exocytic programs, their structural requirements and actions have remained remarkably well-conserved in evolution.			Gerst, JE (corresponding author), WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL.							AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; COUVE A, 1994, J BIOL CHEM, V269, P23391; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; Goldstein A, 1975, Methods Enzymol, V42, P504; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INOUE A, 1992, J BIOL CHEM, V267, P10613; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OYLER GA, 1989, J CELL BIOL, V109, P3030; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Regazzi R, 1996, EMBO J, V15, P6951, DOI 10.1002/j.1460-2075.1996.tb01087.x; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1993, J PHYSIOLOGY-PARIS, V87, P107, DOI 10.1016/0928-4257(93)90004-D; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; Zelicof A, 1996, J BIOL CHEM, V271, P18243, DOI 10.1074/jbc.271.30.18243	39	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16591	16598		10.1074/jbc.272.26.16591	http://dx.doi.org/10.1074/jbc.272.26.16591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195971	hybrid			2022-12-25	WOS:A1997XG01900075
J	Kobayashi, M; Nagata, S; Kita, Y; Nakatsu, N; Ihara, S; Kaibuchi, K; Kuroda, S; Ui, M; Iba, H; Konishi, H; Kikkawa, U; Saitoh, I; Fukui, Y				Kobayashi, M; Nagata, S; Kita, Y; Nakatsu, N; Ihara, S; Kaibuchi, K; Kuroda, S; Ui, M; Iba, H; Konishi, H; Kikkawa, U; Saitoh, I; Fukui, Y			Expression of a constitutively active phosphatidylinositol 3-kinase induces process formation in rat PC12 cells - Use of Cre/loxP recombination system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; MAP KINASE; ACTIVATION; GAP-43; WORTMANNIN; INHIBITION	It has been shown that inhibition of phosphatidylinositol (PI) S-kinase blocks neurite outgrowth of PC12 cells stimulated with nerve growth factor. To further assess the role of PI S-kinase, the active form of PI 3-kinase was expressed in PC12 cells by the adenovirus mediated introduction of a site-specific recombinase, Cre. After expression of the active PI S-kinase, elevation of the levels of PI 3,4-diphosphate and PI 3,4,5-trisphosphate as well as formation of neurite-like processes was observed. The process formation was inhibited by wortmannin, a selective inhibitor of PI 3-kinase, which suggests that a high activity of PI 3-kinase was responsible for the formation of these processes. The processes lacked accumulation of F-actin and GAP43 at the growth cone, which suggests that the processes were incomplete compared with neurites. Instead, the bundling of microtubules was enhanced, which suggests that organization of the microtubules might be driving the process of elongation in the cells expressing the active PI 3-kinase. Induction of active PI 3-kinase resulted in activation of Jun N-terminal kinase but not of mitogen-activated protein kinase or protein kinase B/Rac protein kinase/Akt. These results suggest that PI 3-kinase is involved in neurite outgrowth in PC12 cells and that activation of Jun N-terminal kinase cascade may be involved in the cell response.	UNIV TOKYO, BIOL CHEM LAB,DEPT APPL BIOL CHEM, FAC AGR & LIFE SCI,BUNKYO KU, TOKYO 113, JAPAN; NARA INST SCI & TECHNOL, DIV SIGNAL TRANSDUCT, NARA 63001, JAPAN; KOBE UNIV, BIOSIGNAL RES CTR, NADA KU, KOBE, HYOGO 657, JAPAN; UNIV TOKYO, DEPT GENE REGULAT, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, MOL GENET LAB, TOKYO 108, JAPAN	University of Tokyo; Nara Institute of Science & Technology; Kobe University; University of Tokyo; University of Tokyo			Fukui, Yasuhisa/E-8806-2010	Nagata, Satoshi/0000-0001-9156-5215				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1991, ONCOGENE, V6, P407; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GOSLIN K, 1990, J NEUROSCI, V10, P588; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI M, 1997, IN PRESS P NATL ACAD; MEIRI KF, 1988, J NEUROSCI, V8, P2571; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OKADA T, 1994, J BIOL CHEM, V269, P3563; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; YANO H, 1993, J BIOL CHEM, V268, P25846	36	118	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16089	16092		10.1074/jbc.272.26.16089	http://dx.doi.org/10.1074/jbc.272.26.16089			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195902	hybrid			2022-12-25	WOS:A1997XG01900006
J	Jiang, JG; Chen, QY; Bell, A; Zarnegar, R				Jiang, JG; Chen, QY; Bell, A; Zarnegar, R			Transcriptional regulation of the hepatocyte growth factor (HGF) gene by the Sp family of transcription factors	ONCOGENE			English	Article						hepatocyte growth factor (HGF); transcription; promoter; SP1; SP3	FACTOR-SCATTER-FACTOR; C-MET PROTOONCOGENE; FACTOR/SCATTER FACTOR; EPITHELIAL-CELLS; HEPATOPOIETIN-A; MESSENGER-RNA; EXPRESSION; RECEPTOR; PROMOTER; ACTIVATION	In this study, we have localized an enhancer element in the 5'-flanking region of the HGF gene promoter and have identified its functional transcriptional factors. Through transient transfection of NIH3T3 fibroblast cells and gel mobility shift assays, the functional binding site was localized to a short region (-318 to -303 bp from the transcription start site) which has a CTCCC sequence. This motif is also conserved in the human HGF promoter and acts as a binding site for the Sp family of transcription factors. In the presence of NIH3T3 nuclear protein extracts, this enhancer region formed specific DNA-protein complexes which were totally abrogated by excess amounts of consensus Spl oligonucleotide. In gel mobility supershift assays, anti-Sp1 and anti-Sp3 antibodies specifically recognized these complexes as was evident by their slower migration. Site-specific mutation of this binding motif resulted in total loss of Sp1 and Sp3 binding and a concomitant loss of enhancer function within the context of the HGF promoter. Furthermore, in transient cotransfection assays, overexpression of Sp1 and/or Sp3 stimulated HGF promoter activity independently and additively through binding to the Sp1 binding site in the HGF gene promoter region. DNaseI hypersensitive analysis of freshly isolated nuclei from NIH3T3 cells revealed that five hypersensitive sites (HSS) are present within the 2 kb region immediately upstream of the HGF promoter. One of these sites was mapped to position -0.3 kb from the transcription start site. These data show that both Sp1 and Sp3 transcription factors upregulate HGF promoter activity by binding to the Sp1 binding site at position -318 to -303 bp in the HGF gene promoter.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,DIV CELLULAR & MOL PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Jiang, Jie-Gen/K-3845-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAVAMUDAN B, 1993, BIOCHEM BIOPH RES CO, V195, P346, DOI 10.1006/bbrc.1993.2050; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; BURKOWITZ EA, 1996, ONCOGENE, V12, P1991; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P388; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; EBERT M, 1994, CANCER RES, V54, P5775; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOLDBERG ID, 1995, EPITHELIAL MESENCHYM; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hino M, 1996, BRIT J CANCER, V73, P119, DOI 10.1038/bjc.1996.22; Jeffers M, 1996, ONCOGENE, V13, P853; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LIU YH, 1994, J BIOL CHEM, V269, P4152; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOKER M, 1991, FEBS LETT, V291, P229; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WAGNER S, 1994, CURR OPIN CELL BIOL, V6, P410, DOI 10.1016/0955-0674(94)90034-5; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zarnegar R., 1995, V74, P33	60	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3039	3049		10.1038/sj.onc.1201152	http://dx.doi.org/10.1038/sj.onc.1201152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223667				2022-12-25	WOS:A1997XG10000006
J	Nagai, H; Pineau, P; Tiollais, P; Buendia, MA; Dejean, A				Nagai, H; Pineau, P; Tiollais, P; Buendia, MA; Dejean, A			Comprehensive allelotyping of human hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; hepatitis; loss of heterozygosity; microsatellite markers; tumor suppressor genes	TUMOR-SUPPRESSOR GENE; B VIRUS INTEGRATION; FREQUENT LOSS; P53 GENE; HETEROZYGOSITY; CANCER; RETINOBLASTOMA; PROGRESSION; DNA; IDENTIFICATION	Hepatocellular carcinoma (HCC) is one of the most common cancers in many parts of the world, however the molecular mechanisms underlying liver cell transformation remain obscure. A genome-wide scan of loss of heterozygosity (LOH) in tumors provides a powerful tool to search for genes involved in neoplastic processes, To identify recurrent genetic alterations in liver tumors, we examined DNAs isolated from 120 HCCs and their adjacent non tumorous parts for LOH using a collection of 195 microsatellite markers located roughly every 20cM throughout 39 autosomal arms, The mean heterozygosity was 73%, Our findings provide additional support that LOH for loci on chromosomal arms 1p, 4q, 6q, 8p, 13q and 16p is significantly elevated in HCC. The highest percentage of LOH is found for a locus in 8p23 (42% of informative csaes), This corresponds to one of the most common genetic abnormalities reported to date in these tumors. In addition, high ratio of LOH (greater than or equal to 35%) is observed on chromosome arms which had not been implicated in previous studies, notably on 1q, 2q and 9q, No correlation was found between LOH of specific chromosomal regions and etiologic factors such as chronic infections with hepatitis B or C viruses. This first report of an extensive allelotypic analysis of HCC should help in identifying new genes whose loss of function contributes to the development of liver cancer.	INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,INSERM U163,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Dejean, Anne/L-5145-2018; Pineau, Pascal/AAP-5614-2020	Pineau, Pascal/0000-0002-9407-1592				BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 1995, DNA TUMOR VIRUSES ON, P171; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COX DW, 1995, CYTOGENET CELL GENET, V69, P160; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIMORI M, 1991, CANCER RES, V51, P89; FUJIWARA Y, 1993, CANCER RES, V53, P857; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEARLY E, 1995, GENE CHROMOSOME CANC, V12, P152; Hermanek P, 1987, TNM CLASSIFICATION M; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; MATSUBARA K, 1991, MOL BIOL HEPATITIS B, P245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAGAI H, 1994, CANCER RES, V54, P1545; RANFORD DM, 1995, CANCER RES, V55, P3399; SLAGLE BL, 1991, CANCER RES, V51, P49; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TAKITA J, 1995, ONCOGENE, V11, P1829; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; VIGNAL A, 1993, METHODS MOL GENETICS, V1; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YEH SH, 1994, CANCER RES, V54, P4188; ZHANG X, 1994, CANCER RES, V54, P4177	39	270	284	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2927	2933		10.1038/sj.onc.1201136	http://dx.doi.org/10.1038/sj.onc.1201136			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205099				2022-12-25	WOS:A1997XF55500006
J	Acton, D; Jacobs, H; Domen, J; Berns, A				Acton, D; Jacobs, H; Domen, J; Berns, A			Bcl2 reduces lymphomagenesis in Delta V-TCR beta transgenic mice	ONCOGENE			English	Article						Bcl-2; T-cell receptor; T-cell development; lymphomagenesis; tumor suppression	CELLS; INHIBITION; EXPRESSION; CLONING; GROWTH; IL-7	Overexpression of the bcl-2 oncogene in the lymphoid compartment of transgenic mice prolongs the lifespan of lymphocytes and leads to a low incidence of lymphomas at later age. Transgenic mice carrying a mutated T-cell receptor lacking the variable domain (Delta V-TCR beta) suffer from lymphocyte depletion and are highly predisposed to lymphoma development. We intercrossed Bcl-2-Ig and Delta V-TCR beta transgenic mice to assess whether Bcl-2 could synergize with Delta V-TCR beta in tumorigenesis as reported previously for other oncogenes. Surprisingly, bitransgenic Delta V-TCR beta; bcl-2-Ig mice showed a reduction in the incidence of lymphomas. Analyses of prelymphomatous mice showed that Bcl-2 restored some of the phenotypic aberrations caused by the Delta V-TCR beta transgene in the lymphoid compartment. The inhibitory activity of Bcl-2 on Delta VTCR beta-induced lymphomagenesis was not observed when both transgenes were crossed into the RAG-1(-/-) background suggesting an important role for more mature lymphocytes in this phenomenon. These results show that, depending on the specific conditions, overexpression of Bcl-2 can both promote as well as impair lymphoma development.	NETHERLANDS CANC INST,DIV MOL GENET,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Jacobs, Heinz/0000-0001-6227-9850				Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CARROZZA ML, IN PRESS ONCOGENE; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Jacobs H, 1996, ONCOGENE, V12, P2089; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; LEE G, 1989, J IMMUNOL, V142, P3875; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; SMETS LA, 1994, BLOOD, V84, P1613; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vairo G, 1996, ONCOGENE, V13, P1511	25	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2497	2501		10.1038/sj.onc.1201089	http://dx.doi.org/10.1038/sj.onc.1201089			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191049				2022-12-25	WOS:A1997XA94900001
J	Moriyama, M; Yamochi, T; Semba, K; Akiyama, T; Mori, S				Moriyama, M; Yamochi, T; Semba, K; Akiyama, T; Mori, S			BCL-6 is phosphorylated at multiple sites in its serine- and proline-clustered region by mitogen-activated protein kinase (MAPK) in vivo	ONCOGENE			English	Article						BCL-6; MAP kinase; transcription factor; zinc finger; BTB/POZ; phosphorylation	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; DNA-BINDING ACTIVITY; LARGE-CELL LYMPHOMA; C-FOS PROMOTER; CENTER B-CELLS; TRANSCRIPTION FACTOR; GROWTH-FACTOR; ZINC FINGERS; DOMAIN	BCL-6 gene alterations have been observed in 27-45% of diffuse large B-cell lymphomas (DLBs) with chromosomal translocations at 3q27. The deregulated expression of normal BCL-6 protein caused by this chromosomal translocation is believed to be responsible for lymphomagenesis. Recently, we demonstrated that BCL-6 is expressed at high levels in germinal center B-cells as a 92-98 kDa nuclear protein in a constitutively phosphorylated form. In this study, we show that BCL-6 is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro at the sites phosphorylated in vivo. These numerous phosphorylation sites were found to be located in its serine- and proline-clustered (SPC) region (amino acids-250-483). BCL-6 phosphorylation significantly increased in Ramos cells following stimulation with 12-o-tetradecanoylphorbol-13-acetate (TPA) or BCL-6- and erk1-transfected COS-7 cells stimulated with epidermal growth factor (EGF), and the increase of phosphorylation was inhibited by MEK1 inhibitor, PD98059. Furthermore, we observed that BCL-6 was associated with MAPK in vivo and its SPC region was important for this association. These results suggest that the functions of BCL-6 are regulated by phosphorylation mediated by the MAPK signaling pathway.	UNIV TOKYO, INST MED SCI, DEPT CELLULAR & MOL BIOL, TOKYO 108, JAPAN; OSAKA UNIV, INST MICROBIAL DIS, DEPT ONCOGENE RES, OSAKA 565, JAPAN	University of Tokyo; Osaka University	Moriyama, M (corresponding author), UNIV TOKYO, INST MED SCI, DEPT PATHOL, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.							AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhordain P, 1995, ONCOGENE, V11, P2689; DIBELLO PR, 1991, GENETICS, V129, P385; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIKI T, 1994, BLOOD, V83, P26; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO VN, 1994, ONCOGENE, V9, P1855; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SETH A, 1991, J BIOL CHEM, V266, P23521; Seyfert VL, 1996, ONCOGENE, V12, P2331; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; YAMOCHI T, IN PRESS LEUKEMIA; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	55	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2465	2474		10.1038/sj.onc.1201084	http://dx.doi.org/10.1038/sj.onc.1201084			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188861	Bronze			2022-12-25	WOS:A1997WZ68000010
J	Ammit, AJ; ONeill, C				Ammit, AJ; ONeill, C			Studies of the nature of the binding by albumin of platelet-activating factor released from cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; HUMAN-SERUM ALBUMIN; FACTOR PAF; LIMITED PROTEOLYSIS; CULTURE; RADIOIMMUNOASSAY; PROSTACYCLIN; THIOREDOXIN; SYNTHESIZE; MODULATION	This report confirms that human umbilical vein endothelial cells activated by A23187 produce platelet-activating factor (PAF) (22.4 +/- 9.9 ng/10(6) cells/h; mean +/- S.E.). A proportion of the PAF produced (56%) was released by cells into the medium, The PAF released, however, was not detected without prior organic extraction, and the method of organic extraction was critical for detection, Extraction with 80% ethanol was not successful, but a modified methanol/chloroform extraction method was, These observations may explain some of the conflicting reports in the literature on release of PAF by activated endothelial cells, The requirements for organic extraction may reflect the nature of cell-released PAF's binding by albumin; it was observed that PAF added to identical media could be detected in a bioassay without the requirement for extraction, Such PAF was also readily degraded by PAF-acetylhydrolase added to media, while PAF released from cells was resistant to such degradation, suggesting that it was released in a ''protected'' configuration, Stimulation of cells was performed in media with albumin as the only extracellular macromolecule. Limited proteolytic digestion of the albumin with trypsin and pepsin showed that PAF released by cells was located exclusively between amino acids 240 and 386 (domain II), while no synthetic PAF added to media was located on this region, These results are identical to those described for the release of PAF by the early embryo, Albumin exposed to embryos had a higher thiol concentration (0.77 +/- 0.04 mu mol of thiol/mu mol of albumin; mean +/- S.E.) than control media to which an equivalent amount of synthetic PAF was added (0.59 +/- 0.02 mu mol of thiol/mu mol of albumin) (measured with Ellman's reagent), Furthermore, albumin from conditioned media was more susceptible to reduction by 10 mM dithiothreitol than control albumin, as assessed by its mobility on PAGE. The protected configuration of released PAF was caused by cell-dependent conformational changes to albumin involving cysteine-cysteine disulfide bonds, Partial reduction with dithiothreitol of albumin exposed to cells resulted in released PAF being able to be detected directly in a bioassay without the requirement for prior organic extraction.	UNIV SYDNEY,ROYAL N SHORE HOSP,HUMAN REPROD UNIT,DEPT PHYSIOL,ST LEONARDS,NSW 2065,AUSTRALIA; UNIV SYDNEY,ROYAL N SHORE HOSP,HUMAN REPROD UNIT,DEPT OBSTET & GYNAECOL,ST LEONARDS,NSW 2065,AUSTRALIA	Royal North Shore Hospital; University of Sydney; Royal North Shore Hospital; University of Sydney				O'Neill, Christopher/0000-0003-4003-8727; Ammit, Alaina/0000-0003-0555-2544				Ammit AJ, 1997, J REPROD FERTIL, V109, P309, DOI 10.1530/jrf.0.1090309; AMMIT AJ, 1991, J PHARMACOL METHOD, V29, P7; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bratton D, 1989, PLATELET ACTIVATING, P23; BRODERSEN R, 1990, EUROPEAN J BIOCH, V189, P339; BROWN JR, 1976, FED PROC, V35, P2141; BROWN JR, 1974, FED PROC, V33, P1389; BROWN JR, 1982, LIPID PROTEIN INTERA, V1, P25; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; BUSSOLINO F, 1987, BIOCHIM BIOPHYS ACTA, V927, P43, DOI 10.1016/0167-4889(87)90064-4; CABRE F, 1993, AGENTS ACTIONS, V38, P212, DOI 10.1007/BF01976213; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CARAMELO C, 1987, EUR J CLIN INVEST, V17, P7, DOI 10.1111/j.1365-2362.1987.tb01218.x; CARAMELO C, 1984, BIOCHEM BIOPH RES CO, V120, P789, DOI 10.1016/S0006-291X(84)80176-X; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; CLAY KL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P309, DOI 10.1016/0005-2760(90)90246-T; COLLIER M, 1990, HUM REPROD, V5, P323, DOI 10.1093/oxfordjournals.humrep.a137098; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; DEAN MF, 1994, BIOCHEM J, V304, P861, DOI 10.1042/bj3040861; DEMPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DENT G, 1990, PLATELET ACTIVATING, P23; FELDHOFF RC, 1975, BIOCHEMISTRY-US, V14, P4508, DOI 10.1021/bi00691a027; FOUNTOULAKIS M, 1992, J BIOL CHEM, V267, P7095; GHIGGERI GM, 1983, CLIN CHIM ACTA, V130, P257, DOI 10.1016/0009-8981(83)90124-9; HIRAFUJI M, 1987, BIOCHIM BIOPHYS ACTA, V930, P359, DOI 10.1016/0167-4889(87)90009-7; HOLTZMAN MJ, 1991, BIOCHEM BIOPH RES CO, V177, P357, DOI 10.1016/0006-291X(91)91991-K; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; KING TP, 1961, J BIOL CHEM, V236, pPC5; LUDWIG JC, 1985, ARCH BIOCHEM BIOPHYS, V241, P337, DOI 10.1016/0003-9861(85)90555-7; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MONTRUCCHIO G, 1993, CIRCULATION, V88, P1479; ONEILL C, 1985, J REPROD FERTIL, V75, P375; PETERS T, 1975, BIOCHEMISTRY-US, V14, P3384, DOI 10.1021/bi00686a015; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; QUINN P, 1985, FERTIL STERIL, V44, P493; REED RG, 1989, J BIOL CHEM, V264, P9867; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; SALARI H, 1986, J CHROMATOGR, V382, P89, DOI 10.1016/S0378-4347(00)83507-0; SMAL MA, 1990, J IMMUNOL METHODS, V128, P183, DOI 10.1016/0022-1759(90)90209-E; SMAL MA, 1990, J MOL RECOGNITION, V3, P168; STEWART AG, 1989, BRIT J PHARMACOL, V96, P503, DOI 10.1111/j.1476-5381.1989.tb11845.x; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; SUGATANI J, 1990, LIFE SCI, V46, P1443, DOI 10.1016/0024-3205(90)90460-9; WARDLOW ML, 1986, J IMMUNOL, V136, P3441; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; ZIMMERMAN GA, 1985, CIRCULATION, V72, P718, DOI 10.1161/01.CIR.72.4.718; ZIMMERMAN GA, 1987, AM REV RESPIR DIS, V136, P204, DOI 10.1164/ajrccm/136.1.204	55	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18772	18778		10.1074/jbc.272.30.18772	http://dx.doi.org/10.1074/jbc.272.30.18772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228051	hybrid			2022-12-25	WOS:A1997XM34200042
J	Lutsenko, S; Petrukhin, K; Cooper, MJ; Gilliam, CT; Kaplan, JH				Lutsenko, S; Petrukhin, K; Cooper, MJ; Gilliam, CT; Kaplan, JH			N-terminal domains of human copper-transporting adenosine triphosphatases (the Wilson's and Menkes disease proteins) bind copper selectively in vivo and in vitro with stoichiometry of one copper per metal-binding repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CADMIUM-RESISTANCE; ESCHERICHIA-COLI; CANDIDATE GENE; ATPASE; ORGANIZATION; SITE; CDNA	N-terminal domains of the Wilson's and Menkes disease proteins (N-WND and N-MNK) were overexpressed in a soluble form in Escherichia coli as fusions;vith maltose-binding protein, purified, and their metal-binding properties were characterized, Both N-MNK and N-WND bind copper specifically as indicated by the results of metal-chelate chromatography, direct copper-binding measurements, and chemical modification of Cys residues hi the presence of different heavy metals. When E. coli cells are grown in the presence of copper, N-MNK and N-WND bind copper in vivo with stoichiometry of 5-6 nmol of copper/nmol of protein. Copper released from the copper-N-MNK and copper-N-WND complexes reacts with the Cu(I)-selective chelator bicinchoninic acid in the absence of reducing agents. This suggests that in proteins, it is bound in reduced Cu(I) form, in agreement with the spectroscopic properties of the copper-bound domains. Copper bound to the domains in vivo or in vitro specifically protects the N-MNK and N-WND against labeling with the cysteine-directed probe; this indicates that Cys residues in the repetitive motifs GMTCXPCXXXIE are involved in coordination of copper. Direct involvement of the N-terminal domains in the binding of copper suggests their important role in copper-dependent functions of human copper-transporting adenosine triphosphatases (Wilson's and Menkes disease proteins).	MERCK RES LABS, DEPT HUMAN GENET, W POINT, PA 19486 USA; COLUMBIA UNIV, DEPT GENET, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT DEV, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT PSYCHIAT, NEW YORK, NY 10032 USA; NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA	Merck & Company; Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute	Lutsenko, S (corresponding author), OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA.			Petrukhin, Konstantin/0000-0002-5545-6924; Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL 30315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Danks DM, 1989, METABOLIC BASIS INHE, P1411; HARRIS TJR, 1986, MOL BIOL MED, V3, P279; KALER SG, 1994, NAT GENET, V8, P195, DOI 10.1038/ng1094-195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; LUTSENKO S, 1997, IN PRESS ANN REV ACA; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; SILVER S, 1993, MOL MICROBIOL, V10, P7, DOI 10.1111/j.1365-2958.1993.tb00898.x; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; SPENO H, 1995, J BIOL CHEM, V270, P25363, DOI 10.1074/jbc.270.43.25363; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TOMAS GR, 1995, NAT GENET, V9, P210; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WALSH CT, 1988, FASEB J, V2, P124, DOI 10.1096/fasebj.2.2.3277886; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	22	205	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18939	18944		10.1074/jbc.272.30.18939	http://dx.doi.org/10.1074/jbc.272.30.18939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228074	hybrid			2022-12-25	WOS:A1997XM34200065
J	Pietila, M; Alhonen, L; Halmekyto, M; Kanter, P; Janne, J; Porter, CW				Pietila, M; Alhonen, L; Halmekyto, M; Kanter, P; Janne, J; Porter, CW			Activation of polyamine catabolism profoundly alters tissue polyamine pools and affects hair growth and female fertility in transgenic mice overexpressing spermidine/spermine N-1-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE GENE; SPERMINE N1-ACETYLTRANSFERASE; CELL-TRANSFORMATION; C-MYC; EXPRESSION; METABOLISM; ONCOGENE; MUTATION; ANALOGS; ODC	We have generated a transgenic mouse line that overexpresses the rate controlling enzyme of polyamine catabolism, spermidine/spermine N-1-acetyltransferase. Tissues of these mice showed markedly distorted polyamine pools, which in most cases were characterized by the appearance of N-1-acetylspermidine, not normally found in mouse tissues, a massive accumulation of putrescine, and decreases in spermidine and/or spermine pools. The most striking phenotypic change was permanent hair loss at the age of 3 to 4 weeks which was typified histologically by the appearance of extensive follicular cysts in the dermis, The effect seemed attributable to putrescine interference with hair development, possibly with differentiation/proliferation of epidermal cells located in hair follicles, Female members of the transgenic line were found to be infertile apparently due to ovarian hypofunction and hypoplastic uteri, The findings demonstrate the utility of spermidine/spermine N-1-acetyltransferase overexpression as an effective means for genetically modulating total tissue polyamine pools in transgenic animals and examining the developmental and oncogenic consequences.	ROSWELL PK CANC INST,GRACE CANC DRUG CTR,BUFFALO,NY 14263; UNIV KUOPIO,AI VIRTANEN INST,FIN-70211 KUOPIO,FINLAND	Roswell Park Cancer Institute; University of Eastern Finland					NATIONAL CANCER INSTITUTE [R01CA022153, R01CA065942] Funding Source: NIH RePORTER; NCI NIH HHS [CA-65942, CA-22153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALHONEN L, 1995, INT J CANCER, V63, P402, DOI 10.1002/ijc.2910630317; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FOGELPETROVIC M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P255, DOI 10.1016/0167-4781(93)90152-4; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; HAKOVIRTA H, 1993, MOL ENDOCRINOL, V7, P1430, DOI 10.1210/me.7.11.1430; HALMEKYTO M, 1993, BIOCHEM J, V291, P505, DOI 10.1042/bj2910505; HALMEKYTO M, 1991, J BIOL CHEM, V266, P19746; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; Hogan B, 1986, MANIPULATING MOUSE E, P1; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; JONES JM, 1993, MAMM GENOME, V4, P639, DOI 10.1007/BF00360900; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; Lutz W, 1996, ONCOGENE, V13, P803; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MEGOSH L, 1995, CANCER RES, V55, P4205; MOSHIER JA, 1993, CANCER RES, V53, P2618; PARRY L, 1995, BIOCHEMISTRY-US, V34, P2701, DOI 10.1021/bi00008a038; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PENA A, 1993, J BIOL CHEM, V268, P27277; PERALTASOLER A, 1996, J INVEST DERMATOL, V106, P1108; PILZ RB, 1990, J BIOL CHEM, V265, P8880; POLVINEN K, 1988, BIOCHEM BIOPH RES CO, V155, P373, DOI 10.1016/S0006-291X(88)81095-7; Porter C. W., 1992, V62, P301; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; VARGIU C, 1994, FEBS LETT, V355, P163, DOI 10.1016/0014-5793(94)01183-4; VOGELPETROVIC M, 1996, BIOCHEMISTRY-US, V35, P14436; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879	39	107	109	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18746	18751		10.1074/jbc.272.30.18746	http://dx.doi.org/10.1074/jbc.272.30.18746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228047	hybrid			2022-12-25	WOS:A1997XM34200038
J	Antoine, B; LefranoisMartinez, AM; LeGuillou, G; Leturque, A; Vandewalle, A; Kahn, A				Antoine, B; LefranoisMartinez, AM; LeGuillou, G; Leturque, A; Vandewalle, A; Kahn, A			Role of the GLUT 2 glucose transporter in the response of the L-type pyruvate kinase gene to glucose in liver-derived cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; TRANSGENIC MICE; MESSENGER-RNA; BETA-CELLS; ISLET CELLS; EXPRESSION; GLUCOKINASE; PROMOTER; LINES; CARCINOGENESIS	Twenty-six different hepatoma cell lines established from cancer-prone transgenic mice exhibited a close correlation between expression of the GLUT 2 glucose transporter and activation of the L-type pyruvate kinase (L-PK) gene by glucose, as judged by Northern blot analyses and transient transfection assays. The L-PK gene and a transfected L-PK construct were silent in GLUT 2(+) cells and active in GLUT 2(-) cells cultured in glucose-free medium, Transfection of GLUT 2(-) cells with a GLUT 2 expression vector restored the inducibility of the L-PK promoter by glucose, mainly by suppressing the glucose-independent activity of this promoter, Culture of GLUT 2(-) cells, in which the L-PK gene is constitutively expressed, in a culture medium using fructose as fuel selected GLUT 2(+) clones in which the L-PK gene responded to glucose. The expression of the L-PKgene in GLUT 2(-) cells cultured in the absence of glucose was correlated with a high intracellular glucose B-phosphate (Glu-6-P) concentration while under similar culture conditions Glu-6-P concentration was very low in GLUT 2(+) cells, Consequently, a role of GLUT 2 in the glucose responsiveness of glucose-sensitive genes in cultured hepatoma cells could be to allow for Glu-6-P depletion under gluconeogenic culture conditions. In the absence of GLUT 2, glucose endogeneously produced might be unable to be exported from the cells and would be phosphorylated again to Glu-6-P by constitutively expressed hexokinase isoforms, continuously generating the glycolytic intermediates active on the L-PK gene transcription.	CNRS,CTR RECH ENDOCRINOL MOL & DEV,F-92190 MEUDON,FRANCE; UNIV PARIS 07,INST FEDERAT RECH,INSERM U246,F-75018 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Antoine, B (corresponding author), UNIV PARIS 05,INST COCHIN GENET MOL,INSERM U129,F-75014 PARIS,FRANCE.		Leturque, Armelle/Q-9437-2017	Leturque, Armelle/0000-0001-6570-6387				ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; ANTOINE B, 1997, IN PRESS EXP CELL RE; ARORA KK, 1988, J BIOL CHEM, V263, P17422; ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CARTIER N, 1992, ONCOGENE, V7, P1413; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; FERRER J, 1995, DIABETES, V44, P1369, DOI 10.2337/diabetes.44.12.1369; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; LACHAAL M, 1993, AM J PHYSIOL, V265, pE914, DOI 10.1152/ajpendo.1993.265.6.E914; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; MARIE S, 1993, J BIOL CHEM, V268, P23881; MEIENHOFER MC, 1987, EUR J BIOCHEM, V169, P237, DOI 10.1111/j.1432-1033.1987.tb13603.x; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; NEWGARD CB, 1994, DIABETES, V43, P341, DOI 10.2337/diabetes.43.3.341; POSTIC C, 1993, BIOCHEM J, V293, P119, DOI 10.1042/bj2930119; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; SHAPIRA F, 1961, ENZYMOL BIOL CLIN, V7, P170; SLEIN MW, 1963, METHOD ENZYMAT AN, P1238; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; VALERA A, 1994, J BIOL CHEM, V269, P28543; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	37	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					17937	17943		10.1074/jbc.272.29.17937	http://dx.doi.org/10.1074/jbc.272.29.17937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218418	hybrid			2022-12-25	WOS:A1997XL73500008
J	Devos, R; Guisez, Y; VanderHeyden, J; White, DW; Kalai, M; Fountoulakis, M; Plaetinck, G				Devos, R; Guisez, Y; VanderHeyden, J; White, DW; Kalai, M; Fountoulakis, M; Plaetinck, G			Ligand-independent dimerization of the extracellular domain of the leptin receptor and determination of the stoichiometry of leptin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE-PRODUCT; PROTEIN; LINKING	The leptin receptor is a class I transmembrane protein with either a short or a long cytoplasmic domain. Using chemical cross-linking we have analyzed the binding of leptin to its receptor. Cross-linking of radiolabeled leptin to different isoforms of the leptin receptor expressed on COS-l cells reveals leptin receptor monomer, homodimer, and oligomer complexes. Cotransfection of the long and short form of She leptin receptor did not provide any evidence for the formation of heterodimer complexes, Soluble forms consisting of either the entire extracellular domain or the two cytokine receptor homologous domains of the leptin receptor were purified to homogeneity from recombinant baculovirus-infected insect cells by leptin affinity chromatography, Gel filtration chromatography showed that these proteins exist in a dimeric form. Analysis of the complex formed between soluble leptin receptor and leptin by native polyacrylamide gel electrophoresis, and data obtained from the amino acid composition of the complex provide direct evidence that the extracellular domain of the leptin receptor binds leptin in a I:I ratio.	F HOFFMANN LA ROCHE & CO LTD, GENE TECHNOL, CH-4002 BASEL, SWITZERLAND; MILLENIUM PHARMACEUT INC, CAMBRIDGE, MA 02139 USA	Roche Holding; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Devos, R (corresponding author), F HOFFMANN LA ROCHE & CO LTD, ROCHE RES GENT, J PLATEAUSTR 22, B-9000 GHENT, BELGIUM.							Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; DEVOS R, 1993, J BIOL CHEM, V268, P6581; Devos R, 1996, P NATL ACAD SCI USA, V93, P5668, DOI 10.1073/pnas.93.11.5668; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; GHILARDI N, 1996, P NATL ACAD SCI USA, V93, P9231; Glaum SR, 1996, MOL PHARMACOL, V50, P230; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Iida M, 1996, BIOCHEM BIOPH RES CO, V222, P19, DOI 10.1006/bbrc.1996.0691; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lynn RB, 1996, BIOCHEM BIOPH RES CO, V219, P884, DOI 10.1006/bbrc.1996.0328; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; Malik KF, 1996, ENDOCRINOLOGY, V137, P1497, DOI 10.1210/en.137.4.1497; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	139	147	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18304	18310		10.1074/jbc.272.29.18304	http://dx.doi.org/10.1074/jbc.272.29.18304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218470	hybrid			2022-12-25	WOS:A1997XL73500060
J	Pilcher, BK; GaitherGanim, J; Parks, WC; Welgus, HG				Pilcher, BK; GaitherGanim, J; Parks, WC; Welgus, HG			Cell type-specific inhibition of keratinocyte collagenase-1 expression by basic fibroblast growth factor and keratinocyte growth factor - A common receptor pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; PROTEIN-KINASE-C; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; 92-KDA GELATINASE; IMMUNOGLOBULIN DOMAIN; LIGAND SPECIFICITY; EPITHELIAL-CELLS; GENE-EXPRESSION	Collagenase-1 is invariantly expressed by migrating basal keratinocytes in all forms of human skin wounds, and its expression is induced by contact with native type I collagen, However, net differences in enzyme production between acute and chronic wounds may be modulated by soluble factors present within the tissue environment, Basic fibroblast growth factor (bFGF, FGF-2;) and keratinocyte growth factor (KGF, FGF-9), which are produced during wound healing, inhibited collagenase-1 expression by keratinocytes in a dose dependent manner, However, KGF was >100-fold more effective than bFGF at inhibiting collagenase-1 expression, suggesting that this differential signaling is transduced via an FGF receptor that binds these ligands with different affinities, Reverse transcriptase-polymerase chain reaction analysis of human keratinocyte mRNA for fibroblast growth factor receptors (FGFRs) revealed expression of only FGFR-2 IIIb, the KGF-specific receptor, which also binds bFGF with low affinity, and FGFR-3 IIIb, which does not bind bFGF or KGF, FGFRs that bind bFGF with high affinity were not detected, Our results suggest that bFGF and KGF inhibit collagenase-1 expression through the KGF cell-surface receptor (FG;FR-P IIIb), Because bFGF induces collagenase-1 in most cell types, cell-specific expression of FGFR family members may dictate the regulation of matrix metalloproteinases in a tissue-specific manner.	WASHINGTON UNIV, SCH MED,DIV DERMATOL,DEPT MED,BARNES JEWISH HOSP, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805, F32AR008339] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR08339, AR35805] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUA CC, 1991, CONNECT TISSUE RES, V26, P271, DOI 10.3109/03008209109152444; Chubinskaya S, 1996, LAB INVEST, V74, P232; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170, DOI 10.1111/1523-1747.ep12317080; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FIRESTEIN G S, 1992, Current Opinion in Rheumatology, V4, P348, DOI 10.1097/00002281-199206000-00012; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Garlick JA, 1996, J DENT RES, V75, P912, DOI 10.1177/00220345960750030801; GARLICK JA, 1993, IN PRESS J INVEST DE; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HURLEY MM, 1995, BIOCHEM BIOPH RES CO, V214, P331, DOI 10.1006/bbrc.1995.2292; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KENNEDY SH, 1995, AM J PATHOL, V146, P764; KURITA Y, 1992, ARCH DERMATOL RES, V284, P193, DOI 10.1007/BF00375792; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LAMBERT CA, 1993, BIOCHEM J, V290, P135, DOI 10.1042/bj2900135; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; McEwen DG, 1997, BIOTECHNIQUES, V22, P1068, DOI 10.2144/97226bm12; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; OKEEFE EJ, 1988, J INVEST DERMATOL, V90, P767, DOI 10.1111/1523-1747.ep12560956; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PEKONEN F, 1993, MOL CELL ENDOCRINOL, V95, P43, DOI 10.1016/0303-7207(93)90027-H; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V104, P982, DOI 10.1111/1523-1747.ep12606231; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SAARIALHOKERE UK, 1993, J INVEST DERMATOL, V100, P335, DOI 10.1111/1523-1747.ep12470032; Sasaki Tetsuo, 1992, Journal of Dermatology (Tokyo), V19, P664; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHIPLEY GD, 1989, J CELL PHYSIOL, V138, P511, DOI 10.1002/jcp.1041380310; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; STRICKLIN GP, 1993, AM J PATHOL, V143, P1657; Sudbeck BD, 1997, MOL BIOL CELL, V8, P811, DOI 10.1091/mbc.8.5.811; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; TAMAI K, 1995, J INVEST DERMATOL, V104, P384, DOI 10.1111/1523-1747.ep12665857; TSUBOI R, 1990, J EXP MED, V172, P245, DOI 10.1084/jem.172.1.245; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; VARGHESE S, 1995, ENDOCRINOLOGY, V136, P2156, DOI 10.1210/en.136.5.2156; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	76	32	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18147	18154		10.1074/jbc.272.29.18147	http://dx.doi.org/10.1074/jbc.272.29.18147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218449	hybrid			2022-12-25	WOS:A1997XL73500039
J	Oda, H; Nakabeppu, Y; Furuichi, M; Sekiguchi, M				Oda, H; Nakabeppu, Y; Furuichi, M; Sekiguchi, M			Regulation of expression of the human MTH1 gene encoding 8-oxo-dGTPase - Alternative splicing of transcription products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; G.C->T.A TRANSVERSIONS; DNA GLYCOSYLASE; MUTT PROTEIN; 8-HYDROXYGUANINE; 8-OXOGUANINE; MUTAGENESIS; NUCLEOTIDE; OXIDATION; SUBSTRATE	The enzyme 8-oxo-7,8-dihydrodeoxyguanosine triphosphatase (8-oxo-dGTPase) hydrolyzes 8-oxo-dGTP to 8-oxo-dGMP, thereby preventing misincorporation of 8-oxo-dGTP into DNA. We investigated expression of MTH1 gene encoding 8-oxo-dGTPase. Large amounts of MTH1 mRNA were present in thymus and testis, embryonic tissues, and certain cell lines. In peripheral blood lymphocytes, the level of MTH1 mRNA was significantly increased after concomitant treatment with phytohemagglutinin and interleukin-a. Analyses of the 5' regions of the MTH1 transcripts revealed that 7 types of MTH1 mRNAs, which may be produced by transcription initiation at different sites and/or alternative splicing. The MTH1 gene consists of 5 major exons, some of which are composed of differentially processed segments. All types of MTH1 mRNAs carry the entire coding region, and may be functional. Three ATG initiation codons in-frame were found in the 5' regions of some of the MTH1 mRNAs, There is a polymorphic alteration at the 5' splicing site (GT to GC) located in exon 2, an event which affects splicing patterns of the MTH1 transcript. Allele frequency of this polymorphism is about 20% among healthy volunteers.	FUKUOKA DENT COLL,DEPT BIOL,SAWARA KU,FUKUOKA 81401,JAPAN; KYUSHU UNIV,MED INST BIOREGULAT,DEPT BIOCHEM,FUKUOKA 81282,JAPAN	Fukuoka Dental College (FDC); Kyushu University			Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAPTISTE J, 1993, PCR PROTOCOLS CURREN, P365; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N; FARRELL RE, 1993, RNA METHODOLOGIES LA, P158; FINANCSEK I, 1982, GENE, V18, P115; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Igarashi H, 1997, J BIOL CHEM, V272, P3766, DOI 10.1074/jbc.272.6.3766; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KANG D, 1995, J BIOL CHEM, V270, P25942; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; NGHEIM Y, 1988, P NATL ACAD SCI USA, V85, P2709; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; SAKUMI K, 1993, J BIOL CHEM, V268, P14659; Sambrook J., 2002, MOL CLONING LAB MANU; Sekiguchi M, 1996, GENES CELLS, V1, P139, DOI 10.1046/j.1365-2443.1996.d01-232.x; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	43	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17843	17850		10.1074/jbc.272.28.17843	http://dx.doi.org/10.1074/jbc.272.28.17843			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211940	hybrid			2022-12-25	WOS:A1997XK16500083
J	Ruby, SW				Ruby, SW			Dynamics of the U1 small nuclear ribonucleoprotein during yeast spliceosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; U2 SNRNP ADDITION; SPLICING FACTOR; PREMESSENGER RNA; SITE SELECTION; 5' END; PROTEIN; COMPLEXES; PATHWAY; PRP9	U1 small nuclear ribonucleoprotein (snRNP) may function during several steps of spliceosome assembly. Most spliceosome assembly assays, however, fail to detect the U1 snRNP. Here, I used a new native gel electrophoretic assay to find the yeast U1 snRNP in three pre-splicing complexes (delta, beta(1), alpha(2)) formed in vitro. The order of complex formation is deduced to be delta --> beta(1) --> alpha(2) --> alpha(1) --> beta(2), the active spliceosome, The delta complex is formed when U1 snRNP binds to pre-mRNA in the absence of ATP. There are two forms of delta: a major one, delta(un), unstable to competitor RNA; and a minor one, delta(commit), committed to the splicing pathway. The other complexes are formed in the presence of ATP and contain the following snRNPs: beta(1), the pre-spliceosome, has both U1 and U2; alpha(2) has all five, however, U1 is reduced compared with the others; and alpha(1) and beta(2) have U2, U5, and U6. Prior work by others suggests that U1 is ''handing off'' the 5' splice site region to the U5 and U6 snRNPs before splicing begins. The reduced levels of U1 snRNP in the alpha(2) complex suggests that the handoff occurs during formation of this complex.			Ruby, SW (corresponding author), UNIV NEW MEXICO,CTR HLTH SCI,CANC RES & TREATMENT CTR,DEPT CELL BIOL,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131, USA.							ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; Ast G, 1997, RNA, V3, P371; Ast G, 1996, SCIENCE, V272, P881, DOI 10.1126/science.272.5263.881; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BEHRENS SE, 1993, P NATL ACAD SCI USA, V90, P8229, DOI 10.1073/pnas.90.17.8229; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BENNETT M, 1993, SCIENCE, V262, P105, DOI 10.1126/science.8211113; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; CHAMPIONARNAUD P, 1995, MOL CELL BIOL, V15, P5750; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Colot HV, 1996, GENE DEV, V10, P1699, DOI 10.1101/gad.10.13.1699; DAUGERON MC, 1992, NUCLEIC ACIDS RES, V20, P3625, DOI 10.1093/nar/20.14.3625; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURMAN E, 1995, J BIOL CHEM, V270, P15515, DOI 10.1074/jbc.270.26.15515; GALISSON F, 1993, NUCLEIC ACIDS RES, V21, P1555, DOI 10.1093/nar/21.7.1555; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; HOROWITZ DS, 1993, GENE DEV, V7, P320, DOI 10.1101/gad.7.2.320; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRETZNER L, 1987, CELL, V50, P593, DOI 10.1016/0092-8674(87)90032-8; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Lewis JD, 1996, NUCLEIC ACIDS RES, V24, P3332, DOI 10.1093/nar/24.17.3332; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; NEWMAN A, 1994, CURR BIOL, V4, P462, DOI 10.1016/S0960-9822(00)00104-4; NEWMAN AJ, 1994, CURR OPIN GENET DEV, V4, P298, DOI 10.1016/S0959-437X(05)80057-7; PIKIELNY CW, 1986, CELL, V45, P869, DOI 10.1016/0092-8674(86)90561-1; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P143; Sambrook J., 2002, MOL CLONING LAB MANU; Schwer B, 1996, RNA, V2, P574; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; Wiest DK, 1996, J BIOL CHEM, V271, P33268, DOI 10.1074/jbc.271.52.33268; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yean SL, 1996, GENE EXPRESSION, V5, P301; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	59	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17333	17341		10.1074/jbc.272.28.17333	http://dx.doi.org/10.1074/jbc.272.28.17333			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211871	hybrid			2022-12-25	WOS:A1997XK16500014
J	Kruip, J; Chitnis, PR; Lagoutte, B; Rogner, M; Boekema, EJ				Kruip, J; Chitnis, PR; Lagoutte, B; Rogner, M; Boekema, EJ			Structural organization of the major subunits in cyanobacterial photosystem 1 - Localization of subunits PsaC, -D, -E, -F, and -J	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I REACTION-CENTER; SYNECHOCYSTIS SP PCC-6803; CHEMICAL CROSS-LINKING; SYNECHOCOCCUS-SP PCC-6301; SP PCC 6803; PERFUSION CHROMATOGRAPHY; TARGETED INACTIVATION; CORE COMPLEXES; PSI-E; POLYPEPTIDES	Based on an improved isolation procedure using perfusion chromatography, trimeric Photosystem 1 (PS1) complexes have been isolated from various deletion mutants of the mesophilic cyanobacterium Synechocystis PCC 6803. These mutants are only deficient in the deleted subunits, which was carefully checked by high resolution gel electrophoresis in combination with immunoblotting. These highly purified and well characterized PS1 particles were then examined by electron microscopy, followed by computer-aided image processing with single particle averaging techniques as described earlier (Kruip, J., Boekema, E. J., Bald, D., Boonstra, A. F., and Rogner, M. (1993) J. Biol. Chem. 268, 23353-23360). This precise methodological approach allowed a confident localization of the PS1 subunits PsaC, -D, -E, -F, and -J; it also shows shape and size of these subunits once integrated in the PS1 complex. Subunits PsaC, -D, and -E form a ridge on the stromal site, with PsaE toward the edge of each monomer within the trimer and PsaD extending toward the trimeric center, leaving PsaC in between. PsaF (near PsaE) and PsaJ are close together on the outer edge of each monomer; their proximity is also supported by chemical cross-linking, using the zero-length cross-linker EDC. This localization of PsaF contradicts the position suggested by the published low resolution x-ray analysis and shows for the first time the existence of at least one transmembrane cu-helix for PsaF. A topographic three-dimensional map has been drawn from this set of results showing the location of the major PS1 subunits (besides PsaA and PsaB). These data also led to the assignment of electron density in the recent medium resolution x-ray structure for PS1 (Krauss, N., Schubert, W.-D., Klukas, O., Fromme, P., Witt, H. T., Saenger, W. (1996) Nat. Struct. Biol. 3, 965-973).	UNIV MUNSTER, INST BOT, D-48149 MUNSTER, GERMANY; UNIV GRONINGEN, DEPT BIOPHYS CHEM, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9747 AG GRONINGEN, NETHERLANDS; CEA, DEPT BIOL CELLULAIRE & MOL, SERV BIOENERGET, F-91191 GIF SUR YVETTE, FRANCE; IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	University of Munster; University of Groningen; CEA; UDICE-French Research Universities; Universite Paris Saclay; Iowa State University								ALMOG O, 1991, P NATL ACAD SCI USA, V88, P5312, DOI 10.1073/pnas.88.12.5312; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BRYANT DA, 1992, PHOTOSYSTEMS STRUCTU, P501; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; FORD RC, 1987, EMBO J, V6, P1581, DOI 10.1002/j.1460-2075.1987.tb02403.x; Fromme P, 1996, BBA-BIOENERGETICS, V1275, P76, DOI 10.1016/0005-2728(96)00053-9; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; Hanley J, 1996, BIOCHEMISTRY-US, V35, P8563, DOI 10.1021/bi960399x; HARAUZ G, 1988, METHOD ENZYMOL, V164, P35; HARAUZ G, 1991, IMAGE ANAL BIOL, P196; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KRUIP J, 1993, J BIOL CHEM, V268, P23353; LAGOUTTE B, 1992, EUR J BIOCHEM, V205, P1175, DOI 10.1111/j.1432-1033.1992.tb16888.x; LELONG C, 1994, J BIOL CHEM, V269, P10034; Lelong C, 1996, EMBO J, V15, P2160, DOI 10.1002/j.1460-2075.1996.tb00569.x; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LUNEBERG J, 1994, FEBS LETT, V338, P197, DOI 10.1016/0014-5793(94)80364-1; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; Muhlenhoff U, 1996, EUR J BIOCHEM, V235, P324, DOI 10.1111/j.1432-1033.1996.00324.x; OHOKA H, 1989, PLANT CELL PHYSIOL, V30, P869, DOI 10.1093/oxfordjournals.pcp.a077818; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; REGNIER FE, 1991, NATURE, V350, P634, DOI 10.1038/350634a0; ROGNER M, 1990, J BIOL CHEM, V265, P6189; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; SONOIKE K, 1993, BIOCHIM BIOPHYS ACTA, V1141, P52, DOI 10.1016/0005-2728(93)90188-L; TJUS SE, 1995, PHOTOSYNTH RES, V45, P41, DOI 10.1007/BF00032234; TJUS SE, 1991, PHOTOSYNTH RES, V27, P209, DOI 10.1007/BF00035842; VALLON O, 1993, EUR J BIOCHEM, V214, P907, DOI 10.1111/j.1432-1033.1993.tb17994.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WITT I, 1987, FEBS LETT, V221, P260, DOI 10.1016/0014-5793(87)80937-7; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; XU Q, 1994, PLANT PHYSIOL, V106, P1057, DOI 10.1104/pp.106.3.1057; XU Q, 1994, PLANT MOL BIOL, V26, P291, DOI 10.1007/BF00039540; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU Q, 1995, PLANT PHYSIOL, V108, P1067, DOI 10.1104/pp.108.3.1067; XU QA, 1994, J BIOL CHEM, V269, P3205; XU QA, 1994, PLANT PHYSIOL, V106, P617, DOI 10.1104/pp.106.2.617; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656; YU L, 1993, PLANT PHYSIOL, V103, P171, DOI 10.1104/pp.103.1.171; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZHAO JD, 1990, FEBS LETT, V276, P175, DOI 10.1016/0014-5793(90)80536-R; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	57	75	80	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17061	17069		10.1074/jbc.272.27.17061	http://dx.doi.org/10.1074/jbc.272.27.17061			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202022	hybrid, Green Published			2022-12-25	WOS:A1997XH44600054
J	Yoshida, A; Suzuki, M; Ikenaga, H; Takeuchi, M				Yoshida, A; Suzuki, M; Ikenaga, H; Takeuchi, M			Discovery of the shortest sequence motif for high level mucin-type O-glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; BOVINE UDP-GALNAC; STRUCTURAL CHARACTERIZATION; SUBMAXILLARY MUCIN; D-GALACTOSAMINE; KAPPA-CASEIN; PURIFICATION; TRANSFERASE; CLONING; ERYTHROPOIETIN	The consensus primary amino acid sequence for mucin-type O-glycosylation sites Has not beers identified, To determine the shortest motif sequence required for high level mucin-type O-glycosylation, we prepared more than 100 synthetic peptides and assayed in vitro O-GalNAc transfer to serine or threonine in these peptides using a bovine colostrum UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyl transferase (O-GalNAcT). We chose the sequence PDAASAAP from human erythropoietin (hEPO) for further systematic substitutions because it accepted GalNAc and was a fairly simple sequence consisting only of four kinds of amino acids, Several substitutions showed that threonine is similar to 40-fold better than serine as the glycosylated amino acid and a proline at position +3 on the C-terminal side is very important, go define the effect of proline residues around the glycosylation site, we analyzed a series of peptides containing one to three proline residues in;a parent peptide AAATAAA. The results clearly indicated that pralines at positions +1 and +3 had a positive effect. The O-GalNAc transfer level of AAATPAP was increased approximately 90-fold from AAATAAA. The deletion of amino acids from the N-terminal side of the glycosylation site suggested that five amino acids from position -1 to +3 were especially important for glycosylation. Moreover, the influence of all 20 amino acids at positions -1, +2, and +4 was analyzed. Uncharged amino acids were preferred at position -1, and small or positively charged amino acids were preferred at position +2. No preference was observed at position +4. We propose a mucin-type O-glycosylation motif, XTPXP, which may be suitable as a signal for protein O-glycosylation. The features observed in this study also appear to he very useful for prediction of mucin-type O-glycosylation sites in glycoproteins.	KIRIN BREWERY CO LTD, CENT LABS KEY TECHNOL, GLYCOTECHNOL GRP, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	Kirin Brewery Company Limited								Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; DELORME E, 1992, BIOCHEMISTRY-US, V31, P9871, DOI 10.1021/bi00156a003; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; ELLIOTT S, 1994, BIOCHEMISTRY-US, V33, P11237, DOI 10.1021/bi00203a020; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HILL HD, 1977, J BIOL CHEM, V252, P3799; HOMA FL, 1993, J BIOL CHEM, V268, P12609; KUBOTA N, 1990, J BIOCHEM, V107, P486, DOI 10.1093/oxfordjournals.jbchem.a123072; LAI PH, 1986, J BIOL CHEM, V261, P3116; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TAKEUCHI M, 1985, AGR BIOL CHEM TOKYO, V49, P1059, DOI 10.1080/00021369.1985.10866844; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; YOSHIDA A, 1995, GLYCOCONJUGATE J, V12, P824, DOI 10.1007/BF00731244; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	31	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16884	16888		10.1074/jbc.272.27.16884	http://dx.doi.org/10.1074/jbc.272.27.16884			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201996	hybrid			2022-12-25	WOS:A1997XH44600028
J	Lebowitz, PF; Du, W; Prendergast, GC				Lebowitz, PF; Du, W; Prendergast, GC			Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS TRANSFORMATION; GROWTH-FACTOR; FARNESYLTRANSFERASE INHIBITORS; PROTEIN; MORPHOLOGY; MEMBRANE; RAC1; P21; GDI	Rho regulates cytoskeletal actin structure and integrin-mediated cell adhesion. Rho also has a role in cell growth regulation and is required for cell transformation by oncogenic Ras. Recently, it has been demonstrated that Rho can activate transcription from the c-fos serum response element (SRE). This raised the possibility that functions required for Rho-mediated cell transformation might overlap with those involved in transcriptional regulation. Here we show that RhoB can activate the SRE and can synergize in cell transformation with constitutively activated Raf-CAAX. Significantly, unprenylated forms of RhoB that are biologically inert and unable to transform cells can still activate SRE-dependent transcription. This finding suggests that transcriptional activation by Rho may be separable from its cell transforming functions.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,CELL & MOL BIOL GRAD GRP,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania					NCI NIH HHS [CA65892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA065892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Harlow E., 1988, ANTIBODIES LAB MANUA; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MIURA Y, 1993, J BIOL CHEM, V268, P510; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; ZALCMAN G, 1995, ONCOGENE, V1085, P1935	27	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16093	16095		10.1074/jbc.272.26.16093	http://dx.doi.org/10.1074/jbc.272.26.16093			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195903	hybrid			2022-12-25	WOS:A1997XG01900007
J	Strobel, T; Swanson, L; Korsmeyer, S; Cannistra, SA				Strobel, T; Swanson, L; Korsmeyer, S; Cannistra, SA			Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells	ONCOGENE			English	Article						apoptosis; p53; BAX; radiation; ovarian; cancer	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; IN-VIVO; BCL-2; DEATH; GENE; RADIOSENSITIVITY; CHECKPOINT; INDUCTION	The p53 protein is known to play a central role in mediating G(1) arrest or apoptosis in response to ionizing radiation in some cell types, It has been proposed that the Link between p53 and induction of apoptosis is provided in part by p53-mediated upregulation of BAX. In this study, we used the human SW626 ovarian cancer cell line, which lacks functional p53, to further investigate the relationship between wildtype p53, BAX, and apoptosis, SW626 cells expressing a temperature sensitive (ts) p53 mutant did not undergo G(1) arrest or apoptosis and did not exhibit enhanced sensitivity to radiation at the permissive temperature of 32 degrees C, The tsp53 protein was functional in these cells as evidenced by rapid induction of p21 at 32 degrees C, but not at 37 degrees C, Interestingly, restoration of wildtype p53 function at 32 degrees C was not associated with BAS upregulation. In addition, stable overexpression of BAX in SW626 cells was not capable of enhancing apoptotic cell death in response to radiation, Thus, failure of p53 to upregulate BAS is not the sole reason for its inability to promote radiation-induced apoptosis in SW626 cells, Taken together, our data suggest that neither p53 nor BAX upregulation is sufficient for the induction of apoptosis in response to genotoxic damage in some cell types.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,DIV MOL ONCOL,ST LOUIS,MO	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA060670] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1995, ONCOGENE, V11, P1921; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; HALDAR S, 1994, CANCER RES, V54, P2095; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1995, ONCOGENE, V11, P2311; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU TJ, 1994, CANCER RES, V54, P3662; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	22	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2753	2758		10.1038/sj.onc.1201132	http://dx.doi.org/10.1038/sj.onc.1201132			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190890				2022-12-25	WOS:A1997XD64300002
J	Tjandrawinata, RR; Vincent, VL; HughesFulford, M				Tjandrawinata, RR; Vincent, VL; HughesFulford, M			Vibrational force alters mRNA expression in osteoblasts	FASEB JOURNAL			English	Article						vibration; shear force; mRNA expression; mechanical stress	HUMAN-ENDOTHELIAL-CELLS; MECHANICAL STRAIN; GENES; PATHWAY	Serum-deprived mouse osteoblastic (MC3T3E1) cells were subjected to a vibrational force modeled by NASA to simulate a space shuttle launch (7.83 G rms). The mRNA levels for eight genes were investigated to determine the effect of vibrational force on mRNA expression. The mRNA levels of two growth-related protooncogenes, c-fos and c-myc, were up-regulated significantly within 30 min after vibration, whereas those of osteocalcin as well as transforming growth factor-beta 1 were decreased significantly within 3 h after vibration. No changes were detected in the levels of beta-actin, histone H4, or cytoplasmic phospholipase A2 after vibration. No basal levels of cyclooxygenase-2 expression were detected. Zn addition, the extracellular concentrations of prostaglandin E-2 (PGE(2)), a potent autocrine/paracrine growth factor in bone, were not significantly altered after vibration most likely due to the serum deprivation state of the osteoblasts. In comparison with the gravitational launch profile, vibrational-induced changes in gene expression were greater both in magnitude and number of genes activated. Taken together, these data suggest that the changes in mRNA expression are due to a direct mechanical effect of the vibrational force on the osteoblast cells and not to changes in the local PGE(2) concentrations. The finding that launch forces induce gene expression is of utmost importance since many of the biological experiments do not dampen vibrational loads on experimental samples. This lack of dampening of vibrational forces may partially explain why l-G onboard controls sometimes do not reflect l-G ground controls. These data may also suggest that scientists use extra ground controls that are exposed to launch forces, have these forces dampened on launched samples, or use facilities such as Biorack that provide an onboard 1-G centrufuge in order to control for space shuttle launch forces.	VET AFFAIRS MED CTR,LAB CELL GROWTH 151F,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco			Tjandrawinata, Raymond R/F-1889-2013	Tjandrawinata, Raymond R/0000-0003-0461-9874; Hughes-Fulford, Millie/0000-0002-0756-068X				BACKUP P, 1994, AM J PHYSIOL, V266, pE567, DOI 10.1152/ajpendo.1994.266.4.E567; BANES AJ, 1990, AM BIOTECHNOL LAB, V8, P12; BIRCH MA, 1993, J BONE MINER RES, V8, P1155; BRIGHTON CT, 1992, J ORTHOPAED RES, V10, P385, DOI 10.1002/jor.1100100311; CARTER DR, 1987, J BIOMECH, V20, P1095, DOI 10.1016/0021-9290(87)90027-3; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; HUGHESFULFORD M, 1992, EXP CELL RES, V203, P150, DOI 10.1016/0014-4827(92)90050-I; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; IRVING J, 1992, EXP CELL RES, V202, P161, DOI 10.1016/0014-4827(92)90415-5; MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796; MURRAY DW, 1990, CALCIFIED TISSUE INT, V47, P35, DOI 10.1007/BF02555863; NOSE K, 1994, EXP CELL RES, V211, P168, DOI 10.1006/excr.1994.1073; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Sambrook J., 2002, MOL CLONING LAB MANU; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; WIERSBITZKY M, 1994, EXP CELL RES, V210, P52, DOI 10.1006/excr.1994.1008; WIRZ HRW, 1990, SCIENCE, V250, P1266	20	54	60	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1997	11	6					493	497		10.1096/fasebj.11.6.9194530	http://dx.doi.org/10.1096/fasebj.11.6.9194530			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XE404	9194530				2022-12-25	WOS:A1997XE40400012
J	Ponnampalam, SN; Bauer, CE				Ponnampalam, SN; Bauer, CE			DNA binding characteristics of CrtJ - A redox-responding repressor of bacteriochlorophyll, carotenoid, and light harvesting-II gene expression in Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN REPRESSOR; ESCHERICHIA-COLI; CORYNEBACTERIUM-DIPHTHERIAE; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; BIOSYNTHESIS GENE; RNA-POLYMERASE; CLONED GENES; PROTEIN; SPHAEROIDES	Previous genetic analysis indicated that the photosynthesis gene cluster from Rhodobacter capsulatus coded for the transcription factor, CrtJ, that is responsible for aerobic repression of bacteriochlorophyll, carotenoid, and light harvesting-II gene expression. In this study, we have heterologously overexpressed and purified CrtJ to homogeneity and shown by gel mobility shift assays that CrtJ is biologically active. DNase I footprint analysis confirms molecular genetic studies by showing that CrtJ binds to conserved palindromic sequences that overlap the -10 and -35 promoter regions of the bchC operon. Graphs of the percentage of DNA bound versus protein concentration show sigmoidal curves, which is highly indicative of cooperative binding of CrtJ to the two palindromic sites. A binding constant for interaction of CrtJ with the palindrome that spans the -10 region was calculated to be 4.8 x 10(-9) M, whereas affinity for the palindrome that spans the -35 region was found to be 2.9 x 10(-9) hi. Binding of CrtJ to the bchC promoter region was also found to be redox-sensitive, with CrtJ exhibiting a 4.5-fold higher binding affinity under oxidizing versus reducing conditions.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,DEPT CHEM,BIOCHEM PROGRAM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [R01 GM040941, GM 539040, R37 GM040941, GM 00618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040941, K04GM000618, R37GM040941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1986, J MOL BIOL, V192, P513, DOI 10.1016/0022-2836(86)90273-1; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BRENOWITZ M, 1986, P NATL ACAD SCI USA, V83, P8462, DOI 10.1073/pnas.83.22.8462; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; GOMELSKY M, 1995, J BACTERIOL, V177, P1634, DOI 10.1128/jb.177.6.1634-1637.1995; Gomelsky M, 1997, J BACTERIOL, V179, P128, DOI 10.1128/jb.179.1.128-134.1997; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Johnson A D, 1980, Methods Enzymol, V65, P839; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; MA D, 1993, J BACTERIOL, V175, P2037, DOI 10.1128/JB.175.7.2037-2045.1993; MARRS B, 1981, J BACTERIOL, V146, P1003, DOI 10.1128/JB.146.3.1003-1012.1981; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGLYNN P, 1993, MOL GEN GENET, V236, P227, DOI 10.1007/BF00277117; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; PENFOLD RJ, 1991, CURR MICROBIOL, V23, P259, DOI 10.1007/BF02092027; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; PTASHNE M, 1986, GENETIC SWITCH GENE, P87; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER R, 1979, THESIS HARVARD U; SCHMITT MP, 1993, MOL MICROBIOL, V9, P173, DOI 10.1111/j.1365-2958.1993.tb01679.x; SCHMITT MP, 1994, J BACTERIOL, V176, P1141, DOI 10.1128/JB.176.4.1141-1149.1994; SCHMITT MP, 1992, P NATL ACAD SCI USA, V89, P7576, DOI 10.1073/pnas.89.16.7576; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; SILVERSTEIN T, 1993, BIOCHIM BIOPHYS ACTA, V1183, P215, DOI 10.1016/0005-2728(93)90022-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TADROS MH, 1993, EUR J BIOCHEM, V217, P867, DOI 10.1111/j.1432-1033.1993.tb18315.x; TAO X, 1993, P NATL ACAD SCI USA, V90, P8524, DOI 10.1073/pnas.90.18.8524; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WANG ZO, 1994, INFECT IMMUN, V62, P1600, DOI 10.1128/IAI.62.5.1600-1608.1994; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WELLINGTON CL, 1989, GENE, V83, P251, DOI 10.1016/0378-1119(89)90111-X; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	46	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18391	18396		10.1074/jbc.272.29.18391	http://dx.doi.org/10.1074/jbc.272.29.18391			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218481	hybrid			2022-12-25	WOS:A1997XL73500071
J	Sato, A; Perlas, E; BenMenahem, D; Kudo, M; Pixley, MR; Furuhashi, M; Hsueh, AJW; Boime, I				Sato, A; Perlas, E; BenMenahem, D; Kudo, M; Pixley, MR; Furuhashi, M; Hsueh, AJW; Boime, I			Cystine knot of the gonadotropin alpha subunit is critical for intracellular behavior but not for in vitro biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SITE-DIRECTED MUTAGENESIS; HAMSTER OVARY CELLS; BETA-SUBUNIT; GLYCOPROTEIN HORMONES; MONOCLONAL-ANTIBODIES; LUTEINIZING-HORMONE; CYSTEINE RESIDUES; DISULFIDE BONDS; FUNCTIONAL EXPRESSION	The common alpha subunit of glycoprotein hormones contains five disulfide bonds. Based on the published crystal structure, the assignments are 7-31, 59-87, 10-60, 25-82, and 32-84; the last three comprise the cystine knot, a structure also seen in a variety of growth factors, Previously, we demonstrated that the efficiency of secretion and the ability to form heterodimers by alpha subunits hearing single cysteine residue mutants in the cystine knot were significantly reduced. These results suggested that the cystine knot is critical for the intracellular integrity of the subunit, To assess if the presence of the free thiol. affected the secretion kinetics, we constructed paired cysteine mutants of each disulfide bond of the alpha subunit. The secretion rate for these monomers was comparable with mild type except for the alpha-10-60 mutant, which was 40% lower. The recovery of the alpha 7-31 and alpha 59-87 mutants was greater than 95%, whereas for the cystine knot mutants, it was 20-40%. Co-expression of the wild-type chorionic gonadotropin beta subunit with double cysteine mutants did not enhance the recovery of alpha mutants in the media, Moreover, compared with wild-type, the efficiency of heterodimer formation of the alpha 10-60 or alpha 32-84 mutants was less than 5%. Because subunit assembly is required for biological activity, steadies oil the role of these disulfide bonds in signal transduction mere not possible. To bypass the assembly step, we exploited the single chain model, where the alpha and beta subunits are genetically fused. The recovery of secreted tethered gonadotropins bearing mutations in the cystine knot was increased significantly. Although dimer-specific monoclonal antibodies discriminated the conformation of single chain alpha 10-60 and alpha 32-84 mutants from the native heterodimer, these mutants were nevertheless biologically active. Thus, individual bonds of cystine knot are important for secretion and heteradimer formation but not for in vitro bioactivity. Moreover, the data suggest that the native heterodimer configuration is not a prerequisite for receptor binding or signal transduction.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; STANFORD UNIV, MED CTR, DIV REPROD BIOL, DEPT OBSTET GYNECOL, STANFORD, CA 94305 USA	Washington University (WUSTL); Stanford University				Ben-Menahem, David/0000-0002-8985-0591	NICHD NIH HHS [N01-HD67922] Funding Source: Medline; NIDDK NIH HHS [5 P60 DK20579] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; BENKIRANE MM, 1987, ENDOCRINOLOGY, V121, P1171, DOI 10.1210/endo-121-3-1171; BIELINSKA M, 1990, Journal of Cell Biology, V111, p330A; BIELINSKA M, 1992, MOL ENDOCRINOL, V6, P267; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CHEN F, 1991, J BIOL CHEM, V266, P6904; CORLESS CL, 1987, J BIOL CHEM, V262, P14197; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; EHRLICH PH, 1985, AM J REPROD IM MIC, V8, P48; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; Garnier J., 1978, STRUCTURE FUNCTION G, P381; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; HOJO H, 1985, ENDOCRINOLOGY, V117, P2428, DOI 10.1210/endo-117-6-2428; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; KEENE JL, 1989, J BIOL CHEM, V264, P4769; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; KIM P, 1997, IN PRESS ENDOCR REV; KRICHEVSKY A, 1988, ENDOCRINOLOGY, V123, P584, DOI 10.1210/endo-123-1-584; KRICHEVSKY A, 1994, ENDOCRINE, V2, P511; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; ZENG HW, 1995, ENDOCRINOLOGY, V136, P2948, DOI 10.1210/en.136.7.2948	43	38	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	1997	272	29					18098	18103		10.1074/jbc.272.29.18098	http://dx.doi.org/10.1074/jbc.272.29.18098			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XL735	9218442	hybrid			2022-12-25	WOS:A1997XL73500032
J	Hall, JA; Gehring, K; Nikaido, H				Hall, JA; Gehring, K; Nikaido, H			Two modes of ligand binding in maltose-binding protein of Escherichia coli - Correlation with the structure of ligands and the structure of binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-TRANSPORT; MALTODEXTRIN TRANSPORT; CHEMOTAXIS; SPECTROSCOPY; MUTANTS	Ligands that are transported by the maltose transport system of Escherichia coli must first bind to the periplasmic maltose-binding protein (MBP). However, binding of a ligand does not always lead to its transport. As reported earlier, reduced or oxidized maltodextrins bind tightly to MBP but are not transported; some mutant MBPs, such as MalE254, bind maltodextrins tightly but cannot produce their transport, In this study, UV differential spectroscopy and fluorescence emission spectroscopy were used to study the modes by which various ligands bind to MBP, Maltose binding produced a red shift in the fluorescence emission spectrum of wild type MBP and a sharp hypochromatic trend below 265 nm in its UV spectrum (R mode (for red)), On the other hand, binding of reduced, oxidized, or cyclic maltodextrins produced a pronounced blue shift in the fluorescence emission spectrum of wild type MBP and a peak at about 250 nm in its UV difference spectrum (B mode (for blue), Binding of reducing maltodextrins to wild type MBP produced spectral changes that seemed to be a mixture of predominantly R mode binding and some B mode binding, whereas their binding to mutant MBP MalE254 produced changes indicative of pure B mode binding, Thus, the ligands that are bound exclusively via the B mode to either the wild type or MalE254 MBP are not transported.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	University of California System; University of California Berkeley; McGill University			Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184	NIAID NIH HHS [AI-09644] Funding Source: Medline; NIGMS NIH HHS [GM-07232] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1986, BIOCHIM BIOPHYS ACTA, V860, P44, DOI 10.1016/0005-2736(86)90496-7; FERENCI T, 1978, FEBS LETT, V94, P212; GEHRING K, 1992, FEBS LETT, V300, P33, DOI 10.1016/0014-5793(92)80159-E; GEHRING K, 1991, BIOCHEMISTRY-US, V30, P5524, DOI 10.1021/bi00236a027; Hall JA, 1997, J BIOL CHEM, V272, P17615, DOI 10.1074/jbc.272.28.17615; Hall JA, 1997, J BIOL CHEM, V272, P17610, DOI 10.1074/jbc.272.28.17610; MILLER DM, 1983, J BIOL CHEM, V258, P3665; PARK JT, 1949, J BIOL CHEM, V181, P149; SCHAFFER R, 1963, METHODS CARBOHYDR CH, V2, P11; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WANDERSMAN C, 1979, J BACTERIOL, V140, P1; Wolfrom M. L., 1963, METHODS CARBOHYDR CH, V2, P65	20	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17605	17609		10.1074/jbc.272.28.17605	http://dx.doi.org/10.1074/jbc.272.28.17605			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211908	hybrid			2022-12-25	WOS:A1997XK16500051
J	Ram, PA; Waxman, DJ				Ram, PA; Waxman, DJ			Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC CYTOCHROME-P450; GENE-TRANSCRIPTION; IN-VIVO; PHOSPHORYLATION; RECEPTOR; PROTEIN; TRANSLOCATION; RECRUITMENT; EXPRESSION; TARGET	Growth hormone (GH) rapidly stimulates tyrosine phosphorylation followed by serine/threonine phosphorylation of multiple cytoplasmic STAT transcription factors, including one, STAT5b, that is uniquely responsive to the temporal pattern of plasma GH stimulation in rat liver and is proposed to play a central role in the activation of male-expressed liver genes by GH pulses in vivo (Waxman, D, J,, Bam, P. A., Park, S. H., and Choi, H. K. (1995) J. Biol. Chem. 270, 13262-13270). We now show that JAK2, the GH receptor-associated tyrosine kinase, is present both in the cytosol and in the nucleus in cultured liver cells and in rat liver in vivo and that GH-activated STAT3 but not STAT5b becomes associated with nuclear JAK2. GH is also shown to activate by 3-4-fold SHP-1, a phosphotyrosine phosphatase that contains two src homology 2 (SH2) domains. GI-I also induces nuclear translocation and binding of SHP-1 to tyrosine-phosphorylated STAT5b, suggesting that this GH-activated phosphatase may play a role in dephosphorylation leading to deactivation of nuclear STAT5b following the termination of a plasma GH pulse in male rat Liver in vivo, No such association of SHP-1 with GH-activated STATE was detected, a finding that could help explain the marked desensitization of STAT3, but not STAT5b, to subsequent GH pulses following an initial GH activation event.	BOSTON UNIV,DEPT BIOL,DIV CELL & MOL BIOL,BOSTON,MA 02215	Boston University				Waxman, David/0000-0001-7982-9206				Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Goffin V, 1996, CLIN ENDOCRINOL, V45, P247, DOI 10.1046/j.1365-2265.1996.00799.x; GOUILLEUX F, 1994, EMBO J, V13, P1361; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JANSSON JO, 1982, ACTA PHYSIOL SCAND, V114, P261, DOI 10.1111/j.1748-1716.1982.tb06980.x; KEMPE KC, 1995, BIOCHEM PHARMACOL, V49, P1091, DOI 10.1016/0006-2952(95)98506-5; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Lobie PE, 1996, ENDOCRINOLOGY, V137, P4037, DOI 10.1210/en.137.9.4037; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425	43	159	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	1997	272	28					17694	17702		10.1074/jbc.272.28.17694	http://dx.doi.org/10.1074/jbc.272.28.17694			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XK165	9211920	hybrid			2022-12-25	WOS:A1997XK16500063
J	ElBenna, J; Dang, PMC; Gaudry, M; Fay, M; Morel, F; Hakim, J; GougerotPocidalo, MA				ElBenna, J; Dang, PMC; Gaudry, M; Fay, M; Morel, F; Hakim, J; GougerotPocidalo, MA			Phosphorylation of the respiratory burst oxidase subunit p67(phox) during human neutrophil activation - Regulation by protein kinase C-dependent and independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHORBOL-MYRISTATE ACETATE; NADPH OXIDASE; FORMYL PEPTIDES; COMPONENTS; TRANSLOCATION; P47(PHOX); MEMBRANE; REDISTRIBUTION; STIMULATION	The respiratory burst oxidase of phagocytes and B lymphocytes catalyzes the reduction of oxygen to superoxide anion (O-2(radical anion) at the expense of NADPH. This multicomponent enzyme is dormant in resting cells but is activated on exposure to an appropriate stimulus, The phosphorylation-dependent mechanisms regulating the activation of the respiratory burst oxidase are unclear, particularly the phosphorylation status of the cytosolic component p67(phox). In this study, we found that activation of human neutrophils with formyl-methionyl-leucyl-phenylalanine (fMLP), a chemotactic peptide, or phorbol myristate acetate (PMA), a stimulator of protein kinase C (PKC), resulted in the phosphorylation of p67(phox). Using an anti-p67(phox) antibody or all anti-p47(phox) antibody, we showed that phosphorylated p67(phox) and p47(phox) form a complex, Phosphoamino acid analysis of the phosphorylated p67(phox) revealed only P-32-labeled serine residues, Two-dimensional tryptic peptide mapping analysis showed that p67(phox) is phosphorylated at the same peptide whether fMLP or PMA is used as a stimulus, In addition, PHC induced the phosphorylation of recombinant GST-p67(phox) in vitro, at the same peptide as that phosphorylated in intact cells, PMA-induced phosphorylation of p67(phox) was strongly inhibited by the PKC inhibitor GF109203X. In contrast, fMLP-induced phosphorylation was minimally affected by this PKC inhibitor. Taken together, these results show that p67(phox) is phosphorylated in human neutrophils by different pathways, one of which involves protein kinase C.	CHU GRENOBLE, ENZYMOL LAB, F-38043 GRENOBLE, FRANCE	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	ElBenna, J (corresponding author), CHU XAVIER BICHAT, INSERM U294, SERV HEMATOL & IMMUNOL BIOL, 46 RUE HENRI HUCHARD, F-75018 PARIS, FRANCE.			Gaudry, Murielle/0000-0002-9281-2334				BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COMBADIERE C, 1993, BLOOD, V82, P2890; CURNUTTE J T, 1992, Immunodeficiency Reviews, V3, P149; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; Heyworth PG, 1996, BLOOD, V87, P4404, DOI 10.1182/blood.V87.10.4404.bloodjournal87104404; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1991, J BIOL CHEM, V266, P19812; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; TANUGICHOLLEY LC, 1995, BLOOD, V85, P242, DOI 10.1182/blood.V85.1.242.bloodjournal851242; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; WOLFSON M, 1985, J IMMUNOL, V135, P2057	32	132	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17204	17208		10.1074/jbc.272.27.17204	http://dx.doi.org/10.1074/jbc.272.27.17204			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202043	hybrid			2022-12-25	WOS:A1997XH44600075
J	Machado, AK; Morgan, BA; Merrill, GF				Machado, AK; Morgan, BA; Merrill, GF			Thioredoxin reductase-dependent inhibition of MCB cell cycle box activity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST HO GENE; DISULFIDE BOND FORMATION; DNA-BINDING ACTIVITY; BUDDING YEAST; S-CEREVISIAE; TRANSCRIPTION; PROTEIN; IDENTIFICATION; ELEMENTS; START	Mlu1 cell cycle box (MCB) elements are found near the start site of yeast genes expressed at G(1)/S. Basal promoters dependent on the elements for upstream activating sequence activity are inactive in Delta swi6 yeast, Yeast were screened for mutations that activated MCB reporter genes in the absence of Swi6, The mutations identified a single complementation group, Functional cloning revealed the mutations were alleles of the TRR1 gene encoding thioredoxin reductase, Although deletion of TRR1 activated RICE reporter genes, high copy expression did not suppress reporter gene activity;. The trr1 mutations strongly (20 fold) stimulated MCB- and SCB (Swi4/Swi6 cell cycle box)-containing reporter genes, but also weakly (3-fold) stimulated reporter genes that lacked these elements, The trr1 mutations did not affect the level or periodicity of three endogenous MCB gene mRNAs (TMP1, RNR1, and SW14). Deletion of thioredoxin genes TRX1 and TRX2 recapitulated the stimulatory effect of trr1 mutations on MCB reporter gene activity, Conditions expected to oxidize thioredoxin (exposure to H2O2) induced MCB gene expression, whereas conditions expected to conserve thioredoxin (exposure to hydroxyurea) inhibited MCB gene expression, The results suggest that thioredoxin oxidation contributes to MCB element activation and suggest a link between thioredoxin-oxidizing processes such as ribonucleotide reduction and cell cycle-specific gene transcription.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR GENE RES & BIOTECHNOL,CORVALLIS,OR 97331; NATL INST MED RES,LAB YEAST GENET,LONDON NW7 1AA,ENGLAND	Oregon State University; Oregon State University; MRC National Institute for Medical Research								ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3328; BENEZRA R, 1994, CELL, V79, P1257; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1994, GENETICS, V138, P1015; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; FOSTER R, 1993, MOL CELL BIOL, V13, P3792, DOI 10.1128/MCB.13.6.3792; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; PIZZAGALLI A, 1992, CURR GENET, V21, P183, DOI 10.1007/BF00336839; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; Rose MD., 1990, METHODS YEAST GENETI; SCHMIDT EE, 1989, J BIOL CHEM, V264, P21247; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1067; SIDOROVA J, 1994, YEAST GEN MOL BIOL M, P8; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVA CM, 1989, J BIOL CHEM, V264, P6638; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; VEMU S, 1995, J BIOL CHEM, V270, P20724, DOI 10.1074/jbc.270.35.20724; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	41	47	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17045	17054		10.1074/jbc.272.27.17045	http://dx.doi.org/10.1074/jbc.272.27.17045			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202020	hybrid			2022-12-25	WOS:A1997XH44600052
J	Sumiyoshi, H; Inoguchi, K; Khaleduzzaman, M; Ninomiya, Y; Yoshioka, H				Sumiyoshi, H; Inoguchi, K; Khaleduzzaman, M; Ninomiya, Y; Yoshioka, H			Ubiquitous expression of the alpha 1(XIX) collagen gene (Col19a1) during mouse embryogenesis becomes restricted to a few tissues in the adult organism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PRO-ALPHA-2(XI) COLLAGEN; DIFFERENTIAL EXPRESSION; 5' END; CHAIN; PROTEINS; REGION; PROPEPTIDE; SEQUENCE; VARIANTS	Type XIX collagen is a poorly characterized member of the fibril-associated collagens with an interrupted triple helices (FACIT) class of collagen molecules, As a first step toward elucidating its function, we have isolated full size cDNA clones from the mouse alpha 1(XIX) collagen gene (Col19 alpha 1) and established its pattern of expression in the developing embryo and adult organism, Col19 alpha 1 transcripts can be detected as early as II days of gestation and in all embryonic tissues, except the liver, of an Is-day postcoitum mouse, in contrast, only a few adult tissues, brain, eye, and testis, seem to accumulate Col19 alpha 1 mRNA, Col19 alpha 1 transcripts are at least 10 times more abundant in adult than fetal brain and significantly less in adult than fetal muscle and skin, Consistent with the RNA data, polyclonal antibodies for alpha 1(XIX) collagen reacted with a 150-kDa protein in the neutral salt extraction of adult mouse brain tissues. We therefore propose that type XIX collagen plays a distinct role from the other FACIT molecules, particularly in the assembly of embryonic matrices and in the maintenance of specific adult tissues.	OKAYAMA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,OKAYAMA 700,JAPAN	Okayama University			Khaledian, Hossein/S-7707-2016	Khaledian, Hossein/0000-0002-4082-2987				Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; DUBLET B, 1989, J BIOL CHEM, V264, P13150; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; INOGUCHI K, 1995, J BIOCHEM-TOKYO, V117, P137, DOI 10.1093/oxfordjournals.jbchem.a124700; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MYERS JC, 1993, GENE, V123, P211, DOI 10.1016/0378-1119(93)90126-N; MYERS JC, 1994, J BIOL CHEM, V269, P18549; OH SP, 1992, GENOMICS, V14, P225, DOI 10.1016/S0888-7543(05)80210-1; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; RENNARD SI, 1980, ANAL BIOCHEM, V104, P205, DOI 10.1016/0003-2697(80)90300-0; Sambrook J., 2002, MOL CLONING LAB MANU; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; STROKES DG, 1991, J BIOL CHEM, V266, P8626; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEB J, 1992, BIOCHIM BIOPHYS ACTA, V1171, P97, DOI 10.1016/0167-4781(92)90145-P; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S; YOSHIOKA H, 1995, GENOMICS, V28, P337, DOI 10.1006/geno.1995.1151; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	24	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					17104	17111		10.1074/jbc.272.27.17104	http://dx.doi.org/10.1074/jbc.272.27.17104			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9202028	hybrid, Green Submitted			2022-12-25	WOS:A1997XH44600060
J	Burton, EA; Hunter, S; Wu, SC; Anderson, SM				Burton, EA; Hunter, S; Wu, SC; Anderson, SM			Binding of src-like kinases to the beta-subunit of the interleukin-3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; PHOSPHORYLATED IG-ALPHA; GENE FAMILY; MEMBRANE-BINDING; CELL LINES; GM-CSF; CLONING; EXPRESSION; ACTIVATION	We have previously shown that stimulation of 32D c13 cells with interleukin (IL)-3 results in the activation of three src-like tyrosine kinase's, fyn, hck, and lyn. The beta subunit of the IL-3 receptor co-immunoprecipitated with hck in lysates of both unstimulated and IL-3-stimulated cells; however, the beta subunit did not precipitate with either fyn or lyn, The association of these three kinases with the beta subunit of the IL-3 receptor was further investigated using bacterial fusion proteins encoding the unique, SH3, and SH2 domains of these three kinases. Fusion proteins of both hck and fyn bound to a 150-kDa tyrosine-phosphorylated protein present in lysates of IL-3-stimulated cells. This protein was identified as the beta subunit of the IL-3 receptor by immunoblotting with an anti-beta antibody. Glutathione S-transferase (GST) fusion proteins containing the SH2 domain of hck. bound to the beta subunit although the amount of beta subunit that bound to the SH2 domain alone was only 30% of that which bound to the fusion protein containing the unique, SH3, and SH2 domains. This indicates that the SH2 domain is one of the motifs involved in binding hck. to the beta subunit, A GST fusion protein encoding a 236-amino acid region of the cytoplasmic tail of the beta subunit, which contained four tyrosine residues, bound to hck and fyn, Binding to both proteins was dramatically increased when the GST-beta fusion protein was tyrosine-phosphorylated, Far Western blot analysis was used to demonstrate the binding of the unique, SH3, and SH2 domains of hck to this 236-amino acid region of the beta subunit; tyrosine phosphorylation of this protein increased the binding of both the unique region and the SH2 domain probes, These data indicate that binding of hck to the beta subunit is mediated by both phosphotyrosine-dependent and -independent mechanisms.	UNIV COLORADO, HLTH SCI CTR, DEPT PATHOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; APPLEBY MW, 1995, J EXP MED, V182, P811, DOI 10.1084/jem.182.3.811; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BOULET I, 1992, ONCOGENE, V7, P703; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; TORIGOE T, 1992, BLOOD, V80, P617; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16189	16195		10.1074/jbc.272.26.16189	http://dx.doi.org/10.1074/jbc.272.26.16189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195918	hybrid			2022-12-25	WOS:A1997XG01900022
J	Kirito, K; Uchida, M; Yamada, M; Miura, Y; Komatsu, N				Kirito, K; Uchida, M; Yamada, M; Miura, Y; Komatsu, N			A distinct function of STAT proteins in erythropoietin signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; LEUKEMIC-CELL LINE; TRANSCRIPTION FACTOR; SERINE PHOSPHORYLATION; INTERFERON-ALPHA; TYROSINE KINASE; INTERLEUKIN-3 IL-3; GROWTH-HORMONE; GENE FAMILY	The Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway is an important signaling pathway of interferons and cytokines. We examined the activation of STAT proteins induced by interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM CSP), or erythropoietin (EPO) using the human leukemia cell line, UT-7, which requires these cytokines for growth. IL-3, GM-CSF, and EPO induced DNA-binding activity to the oligonucleotides corresponding to the sis-inducible elements (SIE) of c-fos, in addition to the beta-casein promoter (beta-CAP), SIE- and beta-CAP-binding proteins were identical to Stat1 alpha and Stat3 complex and to Stat5 protein, respectively. This indicates that IL-3, GM CSF, and EPO commonly activated Stat1 alpha, Stat3, and Stat5 proteins in UT-7. However, EPO hardly activated Stat1 alpha and Stat3 in UT-7/GM, which is a subline of UT-7 that grows slightly in response to EPO. Transfection studies revealed that UT7/GM cells constitutively expressing Stat1 alpha, but not Stat3, can grow as well in response to EPO as GM-CSF, suggesting that Stat1 alpha is involved in the EPO-induced proliferation of UT-7. Thus, although Stat1 alpha, Stat3, and Stat5 proteins are activated by GM-CSF, IL-3, and EPO, our data suggest that each STAT protein has a distinctive role in the actions of cytokines.	JICHI MED SCH,DEPT MED,DIV HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University			Kirito, Keita/AEO-6802-2022					AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BRUGGEN TVD, 1995, BLOOD, V85, P1442; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHIBA S, 1991, BLOOD, V78, P2261; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1996, P NATL ACAD SCI USA, V93, P6221, DOI 10.1073/pnas.93.13.6221; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EILERS A, 1995, MOL CELL BIOL, V15, P3579; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOTHO A, 1996, BLOOD, V88, P138; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; KOMATSU N, 1997, IN PRESS BLOOD; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIURA O, 1994, BLOOD, V84, P1501; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MORELLA KK, 1995, BLOOD, V86, P557, DOI 10.1182/blood.V86.2.557.bloodjournal862557; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORIGOE T, 1992, BLOOD, V80, P617; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	58	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16507	16513		10.1074/jbc.272.26.16507	http://dx.doi.org/10.1074/jbc.272.26.16507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195960	hybrid			2022-12-25	WOS:A1997XG01900064
J	Maheo, K; AntrasFerry, J; Morel, F; Langouet, S; Guillouzo, A				Maheo, K; AntrasFerry, J; Morel, F; Langouet, S; Guillouzo, A			Modulation of glutathione S-transferase subunits A2, M1, and P1 expression by interleukin-1 beta in rat hepatocytes in primary culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT HUMAN HEPATOCYTES; TRANSFORMING GROWTH-FACTOR-BETA-1; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY; GENE-EXPRESSION; LIVER; CYTOKINES; INDUCTION; ACID; CYTOCHROME-P-450	The influence of various cytokines on the expression of glutathione S-transferases (GSTs) was investigated in rat hepatocytes in primary culture. Only treatment of hepatocytes with interleukin-1 beta (IL-1) was effective, resulting in a marked decrease in GSTs. Steady-state mRNA levels of rGSTA2 and M1 were strongly downregulated by IL-1 in a dose-dependent manner after a 24-h exposure while rGSTP1 mRNA level was increased by a 48-h treatment. Similar effects of IL-1 were observed at the protein level. The response to IL-1 appeared to be specific for each subunit within GST gene families. In addition, IL-1 strongly suppressed the induction of rGSTA2 by 3-methylcholanthrene, oltipraz (a synthetic derivative of 1,2-dithiole-3-thione), and phenobarbital and that of rGSTM1 by oltipraz and phenobarbital, whereas it was ineffective on rGSTP1 induction by these compounds. Using in vitro nuclear run-on transcription assay and Northern blot analysis of or-amanitin treated cells, IL-1-mediated rGSTM1 mRNA decrease was found to result from mRNA destabilization. These results provide the first demonstration that IL-1 regulates some major GST subunits in hepatocytes by a post-transcriptional mechanism.	UNIV RENNES 1,FAC SCI PHARMACEUT & BIOL,UNITE DETOXICAT & REPARAT TISSULAIRE,INSERM,U456,F-35043 RENNES,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes			Maheo, Karine/AAC-3259-2022; GUILLOUZO, Andre/Z-2373-2019; Langouet, Sophie A/I-2776-2015	Langouet, Sophie/0000-0002-0016-5425				ABDELRAZZAK Z, 1994, MOL PHARMACOL, V46, P1100; ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; ABDELRAZZAK Z, 1995, FEBS LETT, V366, P159, DOI 10.1016/0014-5793(95)00513-9; ADAMS DJ, 1987, J BIOL CHEM, V262, P4888; ANDUS T, 1991, HEPATOLOGY, V13, P364, DOI 10.1016/0270-9139(91)92454-G; ANTRASFERRY J, 1995, EUR J BIOCHEM, V234, P390, DOI 10.1111/j.1432-1033.1995.390_b.x; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BOLLAG W, 1994, J CELL BIOCHEM, V56, P427, DOI 10.1002/jcb.240560402; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DING GJF, 1985, J BIOL CHEM, V260, P3268; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GANTER G, 1989, EMBO J, V8, P3373; GUGUEN C, 1975, BIOL GASTRO-ENTEROL, V8, P223; GUILLOUZO A, 1992, COLLOQ INSE, V216, P61; Habig W H, 1981, Methods Enzymol, V77, P218; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KENSLER TW, 1987, CANCER RES, V47, P4271; KISPERT A, 1989, BIOCHEM J, V260, P789, DOI 10.1042/bj2600789; LANGOUET S, 1995, BIOCHEM BIOPH RES CO, V216, P793, DOI 10.1006/bbrc.1995.2691; Langouet S, 1996, HEPATOLOGY, V23, P881; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MEYER DJ, 1993, CARCINOGENESIS, V14, P567, DOI 10.1093/carcin/14.4.567; MORROW CS, 1992, J BIOL CHEM, V267, P10544; MOSIALOU E, 1993, BIOCHEM PHARMACOL, V45, P1645, DOI 10.1016/0006-2952(93)90305-G; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; PEMBLE SE, 1986, BIOCHEM J, V240, P885, DOI 10.1042/bj2400885; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; PROCHASKA HJ, 1992, P NATL ACAD SCI USA, V89, P2394, DOI 10.1073/pnas.89.6.2394; RENTON KW, 1990, CAN J PHYSIOL PHARM, V68, P777, DOI 10.1139/y90-119; RENTON KW, 1983, BIOL BASIS DETOXICAT, P307; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STENBERG G, 1992, BIOCHEM J, V284, P313, DOI 10.1042/bj2840313; TELAKOWSKIHOPKI.CA, 1985, P NATL ACAD SCI USA, V83, P9393; VANDENBERGHE Y, 1990, MOL PHARMACOL, V37, P372; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; WILLIAMS RT, 1967, FED PROC, V26, P1029; YEH FS, 1989, CANCER RES, V49, P2506	46	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16125	16132		10.1074/jbc.272.26.16125	http://dx.doi.org/10.1074/jbc.272.26.16125			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195908	hybrid			2022-12-25	WOS:A1997XG01900012
J	Marini, MG; Chan, K; Casula, L; Kan, YW; Cao, A; Moi, P				Marini, MG; Chan, K; Casula, L; Kan, YW; Cao, A; Moi, P			hMAF, a small human transcription factor that heterodimerizes specifically with Nrf1 and Nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BETA-GLOBIN LOCUS; DOMINANT CONTROL REGION; PORPHOBILINOGEN DEAMINASE GENE; LEUCINE ZIPPER PROTEIN; 3' UNTRANSLATED REGION; I HYPERSENSITIVE SITE; SMALL MAF PROTEINS; TRANSGENIC MICE; FACTOR NF-E2	A 1.6-kilobase pair full-length cDNA encoding a transcription factor homologous to the Maf family of proteins was isolated by screening a K562 cDNA library with the NFE2 tandem repeat probe derived from the globin locus control region. The protein, which was designated hMAF, contains a basic DNA binding domain and an extended leucine zipper but lacks any recognizable activation domain. Expressed in vitro, the hMAF protein is able to homodimerize in solution and bandshift the NFE2 tandem repeat probe. In addition to homodimers, hMAF can also form high affinity heterodimers with two members of the NFE2/CNC-bZip family (Nrf1 and Nrf2) but not with a third family member, p45-NFE2. Although hMAF/hMAF homodimers and hMAF/Nrf1 and hMAF/Nrf2 heterodimers bind to the same NFE2 site, they exert functionally opposite effects on the activity of a linked gamma-globin gene. In fact, whereas all hMAF/CNC-bZip heterodimers stimulate the activity of a gamma-promoter reporter construct in K562 cells, the association into homodimers that is induced by overexpressing hMAF inhibits the activity of the same construct. Thus variations in the expression of hMAF may account for the modulation in the activity of the genes that bear NFE2 recognition sites.	UNIV CAGLIARI,IST CLIN & BIOL ETA EVOLUT,I-09121 CAGLIARI,ITALY; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of Cagliari; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Moi, Paolo/AAC-3161-2019; Marini, Maria Giuseppina/AAC-9384-2021	Marini, Maria Giuseppina/0000-0003-0371-9398; MOI, Paolo/0000-0001-7879-8057; Marini, Maria Giuseppina/0000-0002-2359-2892	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050267, R01DK016666, R37DK016666] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16666, DK50267] Funding Source: Medline; Telethon [E.0356] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1995, HUM GENET, V95, P265; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CURTIN PT, 1989, P NATL ACAD SCI USA, V86, P7082, DOI 10.1073/pnas.86.18.7082; DOMEN J, 1987, ONCOGENE RES, V1, P103; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HOPPE J, 1987, FEBS LETT, V223, P243, DOI 10.1016/0014-5793(87)80297-1; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KEAVENEY M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P289, DOI 10.1016/0167-4781(89)90150-4; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KOTKOW KJ, 1996, P NATL ACAD SCI USA, V93, P35314; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI QL, 1994, BLOOD, V84, P1399; LU DL, 1994, EUR J BIOCHEM, V222, P753, DOI 10.1111/j.1432-1033.1994.tb18921.x; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; LUTHMAN H, 1989, EUR J BIOCHEM, V180, P259, DOI 10.1111/j.1432-1033.1989.tb14641.x; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRUZINA S, 1994, BBA-GENE STRUCT EXPR, V1219, P351, DOI 10.1016/0167-4781(94)90059-0; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RAICH N, 1992, BLOOD, V79, P861; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; WADAKIYAMA Y, 1992, J BIOL CHEM, V267, P11532	61	108	111	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16490	16497		10.1074/jbc.272.26.16490	http://dx.doi.org/10.1074/jbc.272.26.16490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195958	hybrid			2022-12-25	WOS:A1997XG01900062
J	Schneider, H; ScheinerBobis, G				Schneider, H; ScheinerBobis, G			Involvement of the M7/M8 extracellular loop of the sodium pump alpha subunit in ion transport - Structural and functional homology to P-loops of ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE BETA-SUBUNIT; RAT-KIDNEY NA+,K+-ATPASE; AMINO-ACID-SEQUENCE; (NA+ + K+)-ATPASE; CATALYTIC SUBUNIT; ATP-BINDING; ESSENTIAL RESIDUE; POTASSIUM-IONS; EXPRESSION; TOPOLOGY	Mutations were introduced in the motif (DDRW887)-D-884 from an extracellular peptide of the sodium pump alpha subunit localized between M7 and M8 membrane spans to investigate a possible role of this structure in ion recognition. A homologous sequence (399)QDCW(402) that occurs in the P-loops of Na+ channels was shown earlier to be important for ion gating. Mutant sodium pumps were expressed in yeast and subsequently investigated for their behavior toward ouabain, Na+, K+, and ATP. Native enzyme and D884A, D884R, D885A, D885E, or D885R mutants all bind ouabain in the presence of phosphate and Mg2+. The K-D values determined from Scatchard analysis are in the range 5-8 nM for the native enzyme and the D884A, D885E, or D885A mutants, and 15.7 +/- 2.04 and 30.1 +/- 4.32 nM for mutants D884R and D885R, respectively. This ouabain binding is reduced in the presence of K+ in a similar way for both native or mutant sodium pumps with relative affinities (K-0.5) for K+ ranging from 1.4 to 3.7 mM. Ouabain binding in the presence of 100 mu M ATP is promoted by Na+ with K-0.5 = 1.64 +/- 0.01 mM for the native enzyme and K-0.5 = 8.6 +/- 1.35 mM for the D884R mutant. The K-0.5 values of the two enzymes for ATP are 0.66 +/- 0.16 mu M and 1.1 +/- 0.12 mu M, respectively. Ouabain binding as a function of Na+ concentration, on the other hand, is very low for the D885R mutant, even at an ATP concentration of 2 mM. Phosphate or eosin, however, are recognized by this mutant enzyme, so that a major conformational change within the ATP-binding site appears unlikely. The inability of the D885R mutant to bind ouabain in the presence of Na+ and ATP could be explained by assuming that the M7/M8 connecting extracellular loop, which also contains the mutated amino acids, is invaginated within the plane of the plasma membrane and possibly involved in acceptance and/or release of Na+ ions coming from cytosolic areas of the protein. In this case, the placement of an additional positive charge might repel Na+ ions and interrupt their flow, thus not allowing the enzyme to assume the proper conformational state for ouabain binding. Such invaginated hydrophilic protein structures, such as the P-loops of Na+ and K+ channels, are already known and have been shown to participate in ion conduction.	UNIV GIESSEN,INST BIOCH & ENDOKRINOL,FACHBEREICH VET MED,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen								ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; CHEN CY, 1984, NUCLEIC ACIDS RES, V12, P8951, DOI 10.1093/nar/12.23.8951; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GUY HR, 1995, SOC GEN PHY, V50, P1; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HANSEN O, 1984, PHARMACOL REV, V36, P143; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; INAGAKI C, 1974, J BIOL CHEM, V249, P5135; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KIRSCH GE, 1995, BIOPHYS J, V68, P1804, DOI 10.1016/S0006-3495(95)80357-7; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; POST RL, 1965, J BIOL CHEM, V240, P1437; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEINERBOBIS G, 1989, EUR J BIOCHEM, V183, P173, DOI 10.1111/j.1432-1033.1989.tb14910.x; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHEINERBOBIS G, 1987, EUR J BIOCHEM, V168, P123, DOI 10.1111/j.1432-1033.1987.tb13396.x; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SKOU JC, 1988, METHOD ENZYMOL, V156, P278; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; SKOU JC, 1981, BIOCHIM BIOPHYS ACTA, V647, P232, DOI 10.1016/0005-2736(81)90251-0; SKOU JC, 1973, BIOCHIM BIOPHYS ACTA, V311, P51; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WANG JZ, 1992, BIOCHEM BIOPH RES CO, V182, P794, DOI 10.1016/0006-291X(92)91802-W; WANG K, 1992, J BIOL CHEM, V267, P3577; Yamagishi T., 1997, Biophysical Journal, V72, pA262; YOON KL, 1994, J BIOL CHEM, V269, P28249	46	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16158	16165		10.1074/jbc.272.26.16158	http://dx.doi.org/10.1074/jbc.272.26.16158			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195913	hybrid			2022-12-25	WOS:A1997XG01900017
J	Walker, G; Pfeilschifter, J; Kunz, D				Walker, G; Pfeilschifter, J; Kunz, D			Mechanisms of suppression of inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-gamma-stimulated RAW 264.7 cells by dexamethasone - Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in post-transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL MESANGIAL CELLS; MOLECULAR MECHANISMS; MESSENGER-RNA; INDUCTION; MACROPHAGES; INHIBIT; INTERLEUKIN-1; ACTIVATION; CALMODULIN; STEROIDS	The murine macrophage cell line RAW 264.7 expresses inducible nitric-oxide synthase (iNOS) activity upon stimulation with interferon (IFN)-gamma and/or bacterial lipopolysaccharide. We have studied the mechanisms by which the synthetic glucocorticoid dexamethasone suppresses IFN-gamma stimulated NOS expression in RAW 264.7 cells. Treatment of cells with dexamethasone reduces the formation of nitrite, one of the stable end products of NO production measured in culture supernatants with an IC50 of 9 nM. The reduction of iNOS activity is caused by decreased NOS protein levels as assessed by immunoblotting using a specific anti-iNOS antibody. Dexamethasone treatment also reduces the formation of iNOS mRNA steady state levels to about 50% in IFN-gamma-stimulated cells. This is due to decreased iNOS gene transcription and iNOS mRNA stability. More importantly, dexamethasone reduces the amount of iNOS protein by two additional mechanisms: reduction of the translation of iNOS mRNA and increased degradation of the NOS protein. Using a specific protease inhibitor for the cysteine protease calpain I, N-acetyl-Leu-Leu-norleucinal (calpain inhibitor I), the enhanced proteolysis of the iNOS protein can efficiently be blocked, whereas other protease inhibitors such as tosyl-L-lysine chloromethyl ketone have no effect. Dexamethasone does not significantly alter calpain gene expression, Northern blot analyses reveal that calpain mRNA steady state levels are virtually not affected upon incubation of the cells with IFN-gamma and dexamethasone. Immunoprecipitation using a polyclonal anti-calpain antibody reveals that calpain protein levels are also not affected by the glucocorticoid. This is the first evidence that the iNOS protein is a molecular target for the cysteine protease calpain.	UNIV FRANKFURT KLINIKUM,ZENTRUM PHARMAKOL,D-60590 FRANKFURT,GERMANY; UNIV BASEL,BIOZENTRUM,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Basel								BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; CETKOVICCVRLJE M, 1993, ENDOCRINOLOGY, V133, P1739, DOI 10.1210/en.133.4.1739; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DESHPANDE RV, 1995, J BIOL CHEM, V270, P2497, DOI 10.1074/jbc.270.6.2497; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; GELLER DA, 1994, ARCH SURG-CHICAGO, V129, P165; GILBERT RS, 1993, J CELL PHYSIOL, V157, P128, DOI 10.1002/jcp.1041570117; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HONG DH, 1995, MOL CELL ENDOCRINOL, V108, P199, DOI 10.1016/0303-7207(95)03476-N; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KLEIMERT H, 1996, MOL PHARMACOL, V19, P15; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KUNZ D, 1994, BIOCHEM J, V304, P337, DOI 10.1042/bj3040337; Kunz D, 1996, P NATL ACAD SCI USA, V93, P255, DOI 10.1073/pnas.93.1.255; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; MONCADA S, 1991, PHARMACOL REV, V43, P119; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Pfeilschifter J, 1996, CELL BIOL INT, V20, P51, DOI 10.1006/cbir.1996.0008; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; PFEILSCHIFTER J, 1991, EUR J PHARMACOL, V195, P179, DOI 10.1016/0014-2999(91)90399-B; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RINGHEIM GE, 1995, BIOCHEM BIOPH RES CO, V210, P711, DOI 10.1006/bbrc.1995.1717; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKAKOMI SC, 1994, FASEB J, V8, P814; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914	38	94	96	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16679	16687		10.1074/jbc.272.26.16679	http://dx.doi.org/10.1074/jbc.272.26.16679			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195984	hybrid			2022-12-25	WOS:A1997XG01900088
J	Ueno, H; Honda, H; Nakamoto, T; Yamagata, T; Sasaki, K; Miyagawa, K; Mitani, K; Yazaki, Y; Hirai, H				Ueno, H; Honda, H; Nakamoto, T; Yamagata, T; Sasaki, K; Miyagawa, K; Mitani, K; Yazaki, Y; Hirai, H			The phosphatidylinositol 3' kinase pathway is required for the survival signal of leukocyte tyrosine kinase	ONCOGENE			English	Article						leukocyte tyrosine kinase; phosphatydylinositol 3' kinase; c-Cbl; signal transduction	INSULIN-RECEPTOR SUBSTRATE-1; GROWTH-FACTOR-I; PHOSPHOTYROSINE-DEPENDENT INTERACTION; HEMATOPOIETIC-CELLS; SH2 DOMAINS; NPEY MOTIF; HUMAN LTK; C-CBL; PROTEIN; 3'-KINASE	Leukocyte tyrosine kinase (LTK) is a receptor tyrosine kinase which belongs to the insulin receptor superfamily and is mainly expressed in pre-B lymphocytes and neuronal tissues, Recently, we demonstrated that LTK utilizes She and IRS-1 as two major substrates and while both equally activate the Ras pathway, only IRS-1 suppresses apoptosis of hematopoietic cells, suggesting the existence of another unidentified signaling pathway downstream of IRS-1, which is relevant to the anti-apoptotic activity, In the present study, we found that wortmannin, a specific inhibitor of phosphatidylinositol 3' (PI3)-kinase, abolished the survival effects of LTK. Although c-Cbl is found to be phosphorylated by LTK and therefore is a second candidate linking LTK with the P13-kinase pathway along with IRS-1, we found that the p85 subunit of PI3 kinase directly binds to tyrosine 753 of LTK, which is located within a YXXM motif, a consensus binding amino acid sequence for the SH2 domain of p85, but fails to bind to IRS-1 or c-Cbl. Ba/F3 cells which stably express the EGF receptor-LTK chimeric receptor carrying a mutation at tyrosine 753 fell into apoptotic death even in the presence of EGF, indicating that the PI3 kinase pathway is required for the survival effects of LTK.	UNIV TOKYO, DEPT INTERNAL MED 3, FAC MED, TOKYO 113, JAPAN	University of Tokyo								BACKER JM, 1993, J BIOL CHEM, V268, P8204; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; MARU Y, 1990, ONCOGENE RES, V5, P199; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	26	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	1997	14	25					3067	3072		10.1038/sj.onc.1201153	http://dx.doi.org/10.1038/sj.onc.1201153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223670				2022-12-25	WOS:A1997XG10000009
J	Kapoun, AM; Shackleford, GM				Kapoun, AM; Shackleford, GM			Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice	ONCOGENE			English	Article						Fgf8; Wnt1; MMTV; oncogene cooperation; Fgf3; Fgf4; multistep tumorigenesis; growth factors	MESSENGER-RNA; GENE FAMILY; VIRUS; INT-2; EXPRESSION; ONCOGENE; CARCINOGENESIS; TUMORIGENESIS; INT-2/FGF-3; OUTGROWTH	Mouse mammary tumor virus (MMTV) is an insertional mutagen that has been demonstrated to transcriptionally activate flanking cellular proto-oncogenes. Previously we have used MMTV infection to accelerate mammary tumorigenesis in Wnt1 transgenic mice in order to identify genes that cooperate with the Wnt1 oncogene, Initial investigations into the resulting tumor collection, screened primarily by Southern analysis, showed that three fibroblast growth factor genes, Fgf8, Fgf3 and Fgf4, sustain activating insertion mutations in 10%, 42% and 6% of the tumors, respectively, Here, in an examination of the tumors from MMTV-infected Wnt1 transgenic mice that emphasizes Northern analysis, we report transcriptional activation of Fgf8 in 30 additional tumors (increasing the percentage of activations to 50%), while no significant changes in the activation frequency of Fgf3 or Fgf4 were found, To determine the frequency of insertional activation in normal mice, we examined tumors from MMTV-infected nontransgenic Littermates of the Wnt1 transgenics and from MMTV-infected BALB/c mice, Fgf8, Fgf3 and Fgf4 were found to be activated in 11%, 80% and 5%, respectively, of the tumors in the combined nontransgenic groups, Thus, there appears to be an increased predisposition for Fgf8 activations in Wnt1 transgenic mice versus normal mice, suggesting that cells expressing Wnt1 are especially sensitized to stimulation by FGF8 compared with FGF3 or FGF4, In contrast, the activation frequency of Fgf3 in tumors from MMTV-infected Wnt1 transgenic mice was approximately one-half that of normal mice, Our results show that this in vivo model of multistep tumorigenesis reveals significant differences in the activation rates of Fgf3 and Fgf8 depending upon the status of Wnt1 expression in the mammary gland, The differential activation of these Fgfs may relate to differences in their signaling pathways.	CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California; University of Southern California					NCI NIH HHS [CA58412, CA65104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065104, R01CA058412] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MACARTHUR CA, 1997, IN PRESS GENOMICS; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARCHETTI A, 1991, J VIROL, V65, P4550, DOI 10.1128/JVI.65.8.4550-4554.1991; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PETERS G, 1989, J VIROL, V63, P1448, DOI 10.1128/JVI.63.3.1448-1450.1989; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X	28	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2985	2989		10.1038/sj.onc.1201146	http://dx.doi.org/10.1038/sj.onc.1201146			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205106	Green Published			2022-12-25	WOS:A1997XF55500013
J	Fichter, M; Hinrichs, R; Eissner, G; Scheffer, B; Classen, S; Ueffing, M				Fichter, M; Hinrichs, R; Eissner, G; Scheffer, B; Classen, S; Ueffing, M			Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C	ONCOGENE			English	Article						CD44; PI 3-kinase; PKC	PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR PROGRESSION; VARIANT ISOFORMS; GROWTH-FACTOR; RAS GENE; METASTASIS; DIFFERENTIATION; HYALURONATE; ACTIVATION; BINDING	With respect to a potential role for CD44 in neuronal tumors, we investigated the regulation of variant CD44 exon containing isoforms (CD44V) in the human neuroblastoma cell line SR-N-SH in response to treatment with differentiation-inducing and mitogenic factors, While the standard form of CD44 was expressed at high levels in both treated and untreated cells, variant isoforms were strongly upregulated in response to treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), insulinlike growth factor-1 (IGF-1) and platelet-derived growth factor (PDGF) as shown by RT-PCR and immunofluorescence. One of the CD44 isoforms contains sequences encoded by variant exon v6 (CD44V6), which was originally described as a metastasis-associated antigen, Using specific inhibitors, me explored the signal transduction pathways involved in the expression of variant CD44, GF-109203X, a specific inhibitor of protein kinase C effectively blocked TPA- and IGF-1-upregulated expression of CD44v6, Wortmannin, a specific inhibitor of phosphoinositide 3-kinase (PI 3-kinase) partly reduced IGF-1 and PDGF induced CD44v6 expression, The induction of CD44V by TPA, IGF-1 or PDGF was correlated with an increased cellular binding to hyaluronic acid, a major counter receptor for CD44. The increased binding caused by TPA or IGF-1 could specifically be blocked by the above inhibitors, Thus, PKC and PI 3-kinase are likely to transduce growth factor induced signals that upregulate specific CD44 splice variants.	GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GMBH, NATL RES CTR ENVIRONM & HLTH, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich								ALLEN RW, 1987, J BIOL CHEM, V262, P649; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; BLOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN H, 1995, EUR J CANCER, V31A, P541, DOI 10.1016/0959-8049(95)00030-M; CHRISTIANSEN H, 1995, KLIN PADIATR, V207, P219, DOI 10.1055/s-2008-1046543; COMBARET V, 1995, EUR J CANCER, V31A, P545, DOI 10.1016/0959-8049(95)00027-G; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; GROSS N, 1995, EUR J CANCER, V31A, P471, DOI 10.1016/0959-8049(95)00029-I; GROSS N, 1994, CANCER RES, V54, P4238; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1993, CANCER RES, V53, P1516; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KODAKI T, 1995, BIOCHEM SOC T, V23, pS195, DOI 10.1042/bst023195s; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; PAHLMAN S, 1992, CELL GROWTH DIFFER, V3, P783; PONTA H, 1994, INVAS METAST, V14, P82; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SADEE W, 1987, CANCER RES, V47, P5207; Sherman L, 1996, CURR TOP MICROBIOL, V213, P249; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SHTIVELMAN E, 1991, MOL CELL BIOL, V11, P5446, DOI 10.1128/MCB.11.11.5446; Sleeman JP, 1996, CANCER RES, V56, P3134; SOZERI O, 1992, ONCOGENE, V7, P2259; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; STAUDER R, 1995, IMMUNOLOGIST, V3, P78; TANABE KK, 1994, CRIT REV ONCOGENESIS, V5, P201, DOI 10.1615/CritRevOncog.v5.i2-3.50; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TERPE HJ, 1994, HISTOCHEMISTRY, V101, P79, DOI 10.1007/BF00269353; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UEFFING M, 1996, 3 HON KONG INT CANC, P80; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; WIELENGA VJM, 1993, CANCER RES, V53, P4754; Zhu D, 1996, ONCOGENE, V12, P2309	49	40	40	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2817	2824		10.1038/sj.onc.1201127	http://dx.doi.org/10.1038/sj.onc.1201127			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190898				2022-12-25	WOS:A1997XD64300010
J	Takahashi, A; Hirata, H; Yonehara, S; Imai, Y; Lee, KK; Moyer, RW; Turner, PC; Mesner, PW; Okazaki, T; Sawai, H; Kishi, S; Yamamoto, K; Okuma, M; Sasada, M				Takahashi, A; Hirata, H; Yonehara, S; Imai, Y; Lee, KK; Moyer, RW; Turner, PC; Mesner, PW; Okazaki, T; Sawai, H; Kishi, S; Yamamoto, K; Okuma, M; Sasada, M			Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8	ONCOGENE			English	Article						apoptosis; apoptotic cell death; YV(bio)KD-aomk; serpin; Jurkat T cells	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TUMOR NECROSIS FACTOR; POLY(ADP-RIBOSE) POLYMERASE; CELL-DEATH; MEDIATED APOPTOSIS; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; MOLECULAR-CLONING; INHIBITION; CLEAVAGE	The activation of multiple interleukin-1 beta converting enzyme-related proteases (caspases) in apoptotic mammalian cells raises questions as to whether the multiple active caspases have distinct roles in apoptotic execution as well as how these proteases are organized in apoptotic signaling pathways. Here we used an affinity-labeling agent, YV(bio)KD-aomk, to investigate the caspases activated during apoptotic cell death, YV(bio))KD-aomk identified sis distinct polypeptides corresponding to active caspases in Fas-stimulated Jurkat T cells, On staurosporine treatment, four polypeptides were detected, Competition experiments showed that the labelled caspases have distinct substrate preferences, Stepwise appearance of the labelled caspases in each cell death event was consistent with the view that the activated caspases are organized into protease cascades, Moreover, me found that stepwise activation of caspases similar to that induced by Fas ligation is triggered by exposing non-apoptotic Jurkat cell extracts to caspase-8 (MACH/FLICE/Mch5). Conversely, CrmA protein, a viral suppressor of Fas-induced apoptosis, inhibited the protease activity of caspase-8, Overall, these findings provide evidence that caspase-8, a CrmA-sensitive protease, is responsible for initiating the stepwise activation of multiple caspases in Fas-stimulated cells.	KYOTO UNIV,DEPT HEMATOL & ONCOL,GRAD SCH MED,KYOTO 606,JAPAN; KYOTO UNIV,DEPT VIRAL ONCOL,INST VIRUS RES,KYOTO 606,JAPAN; UNIV FLORIDA,COLL MED,DEPT MOL GENET & MICROBIOL,GAINESVILLE,FL 32610; MAYO CLIN & MAYO FDN,DIV ONCOL RES,ROCHESTER,MN 55905; JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,YOKOHAMA,KANAGAWA 236,JAPAN; KYOTO UNIV,COLL MED TECHNOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University; State University System of Florida; University of Florida; Mayo Clinic; Japan Tobacco Inc.; Kyoto University			Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Turner, Peter/0000-0002-7706-4593; Takahashi, Atsushi/0000-0003-3340-432X				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Henderson Peter J.F., 1993, P277; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KIKUCHI H, 1995, J BIOCHEM-TOKYO, V117, P936, DOI 10.1093/oxfordjournals.jbchem.a124823; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; NETT MA, 1992, J IMMUNOL, V149, P3254; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; Takahashi A, 1997, EXP CELL RES, V231, P123, DOI 10.1006/excr.1996.3459; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAKAHASHI A, 1997, CELL CYCLE REGULATIO; TAKAHASHI A, 1997, APOPTOSIS PHARM THER; Tatsuta T, 1996, J IMMUNOL, V157, P3949; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; THORNBERRY NA, 1997, IN PRESS APOPTOSIS P; Turner PC, 1995, VIROCEPTORS VIROKINE, P67; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	76	104	106	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2741	2752		10.1038/sj.onc.1201131	http://dx.doi.org/10.1038/sj.onc.1201131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190889	Bronze			2022-12-25	WOS:A1997XD64300001
J	Aspnes, LE; Lee, CM; Weindruch, R; Chung, SS; Roecker, EB; Aiken, JM				Aspnes, LE; Lee, CM; Weindruch, R; Chung, SS; Roecker, EB; Aiken, JM			Caloric restriction reduces fiber loss and mitochondrial abnormalities in aged rat muscle	FASEB JOURNAL			English	Article						aging; sarcopenia; mitochondria; skeletal muscle	CYTOCHROME-C-OXIDASE; ANTIOXIDANT ENZYME-ACTIVITIES; DNA OXIDATIVE DAMAGE; SKELETAL-MUSCLE; DIETARY RESTRICTION; FOOD RESTRICTION; MULTIPLE DELETIONS; RHESUS-MONKEYS; LIFE-SPAN; ATROPHY	The influence of caloric restriction (CR) initiated at 17 months of age was investigated on selected age-associated measures in skeletal muscle. Tissue from young (3-4 months) ad libitum-fed, old (30-32 months) restricted (35% and 50% CR, designated CR35 and CR50, respectively), and old ad libitum-fed rats (29 months) was studied. CR preserved fiber number and fiber type composition in the vastus lateralis muscle of the CR50 rats. In the old rats from all groups, individual fibers were found with either no detectable cytochrome c oxidase activity (COX-), hyperreactivity for succinate dehydrogenase activity (SDH++; also known as ragged red fibers [RRF]), or both COX- and SDH++. Muscle from the CR50 rats contained significantly fewer COX- and SDH++ fibers than did the muscle from CR35 rats. CR50 rats also had significantly lower numbers of mtDNA deletion products in two (adductor longus and soleus) of the four muscles examined compared to CR35 rats. These data indicate that CR begun in late middle age can retard age-associated fiber loss and fiber type changes, as well as increases in the number of skeletal muscle fibers showing mitochondrial enzyme abnormalities. CR also decreased the accumulation of mtDNA deletions.	UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOSTAT,MADISON,WI 53706; WILLIAM S MIDDLETON MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Aspnes, LE (corresponding author), UNIV WISCONSIN,DEPT ANIM HLTH & BIOMED SCI,1655 LINDEN DR,MADISON,WI 53706, USA.			Aiken, Judd/0000-0001-6119-4521	NATIONAL INSTITUTE ON AGING [P01AG011915, R01AG011604, R01AG010536] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG10536, P01 AG11915, R01 AG11604] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; ATTARDI G, 1986, BIOESSAYS, V5, P34, DOI 10.1002/bies.950050111; BASS A, 1975, GERONTOLOGY, V21, P31, DOI 10.1159/000212028; BAUMER A, 1994, AM J HUM GENET, V54, P618; BOREHAM CAG, 1988, J ANAT, V157, P111; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BROSSAS JY, 1994, BIOCHEM BIOPH RES CO, V202, P654, DOI 10.1006/bbrc.1994.1980; CACCIA MR, 1979, MUSCLE NERVE, V2, P202, DOI 10.1002/mus.880020308; CARLSON BM, 1995, J GERONTOL A-BIOL, V50, P96; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHUNG SS, 1994, AGING-CLIN EXP RES, V6, P193, DOI 10.1007/BF03324239; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; COGGAN AR, 1992, J GERONTOL, V47, pB71, DOI 10.1093/geronj/47.3.B71; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DAW CK, 1988, J APPL PHYSIOL, V64, P2428, DOI 10.1152/jappl.1988.64.6.2428; Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375; DiMauro S, 1993, MOL GENETIC BASIS NE, P665; Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, P19; EDRIS W, 1994, MUTAT RES-DNAGING G, V316, P69, DOI 10.1016/0921-8734(94)90009-4; Eimon PM, 1996, DEV GENET, V18, P107, DOI 10.1002/(SICI)1520-6408(1996)18:2&lt;107::AID-DVG3&gt;3.0.CO;2-D; ELHAJ AJ, 1986, COMP BIOCHEM PHYS A, V85, P281, DOI 10.1016/0300-9629(86)90251-3; ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919; FAULKNER JA, 1995, J GERONTOL A-BIOL, V50, P124; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; GARTHWAITE SM, 1986, MECH AGEING DEV, V36, P187, DOI 10.1016/0047-6374(86)90019-9; GUTMANN E, 1972, AGE CHANGES NEUROMUS; HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I; HAVENITH MG, 1990, HISTOCHEMISTRY, V93, P497, DOI 10.1007/BF00266407; HIGAMI Y, 1994, J GERONTOL, V49, pB239, DOI 10.1093/geronj/49.5.B239; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; HOLLOSZY JO, 1995, J GERONTOL A, V50; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106; LARSSON L, 1986, J NEUROL SCI, V76, P69, DOI 10.1016/0022-510X(86)90143-7; LARSSON L, 1995, J GERONTOL A-BIOL, V50, P91; LARSSON L, 1978, ACTA PHYSIOL SCAND, V103, P31, DOI 10.1111/j.1748-1716.1978.tb06187.x; LEE CM, 1993, J GERONTOL, V48, pB201, DOI 10.1093/geronj/48.6.B201; LEXELL J, 1983, MUSCLE NERVE, V6, P588, DOI 10.1002/mus.880060809; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LUHTALA TA, 1994, J GERONTOL, V49, pB231, DOI 10.1093/geronj/49.5.B231; MCCARTER R, 1987, J GERONTOL, V42, P432, DOI 10.1093/geronj/42.4.432; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MORAES CT, 1992, AM J HUM GENET, V50, P934; MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127; MullerHocker J, 1996, MECH AGEING DEV, V86, P197, DOI 10.1016/0047-6374(95)01692-9; NOY N, 1985, MECH AGEING DEV, V29, P63, DOI 10.1016/0047-6374(85)90047-8; OhIshi S, 1995, MECH AGEING DEV, V84, P65, DOI 10.1016/0047-6374(95)01637-F; PRELLE A, 1994, ACTA NEUROPATHOL, V87, P371; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107; Sambrook J., 2002, MOL CLONING LAB MANU; Sanderson JP, 1997, J GERONTOL A-BIOL, V52, pB20, DOI 10.1093/gerona/52A.1.B20; SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; SNECEDOR GW, 1980, STAT METHODS; SNYDER DL, 1990, J GERONTOL, V45, pB52, DOI 10.1093/geronj/45.2.B52; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1992, MUTAT RES, V275, P295, DOI 10.1016/0921-8734(92)90033-L; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SUGIYAMA S, 1993, BIOCHEM MOL BIOL INT, V30, P937; TAKASAWA M, 1993, EXP GERONTOL, V28, P269, DOI 10.1016/0531-5565(93)90034-B; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; TAUCHI H, 1971, GERONTOLOGY, V17, P219, DOI 10.1159/000211826; TORRI K, 1992, AM J RESP CELL MOL B, V6, P543; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; VanTuyle GC, 1996, MUTAT RES-FUND MOL M, V349, P95, DOI 10.1016/0027-5107(95)00165-4; VERTECHY M, 1989, EXP GERONTOL, V24, P211, DOI 10.1016/0531-5565(89)90012-0; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1995, J GERONTOL A-BIOL, V50, P157; WEINDRUCH R, 1988, RETARDATION AGING DI; WEINDRUCH RH, 1980, MECH AGEING DEV, V12, P375, DOI 10.1016/0047-6374(80)90070-6; Yu BP, 1993, FREE RADICALS AGING; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	82	129	129	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1997	11	7					573	581		10.1096/fasebj.11.7.9212081	http://dx.doi.org/10.1096/fasebj.11.7.9212081			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XH342	9212081				2022-12-25	WOS:A1997XH34200009
J	Plet, A; Huet, X; Algarte, M; Rech, J; Imbert, J; Philips, A; Blanchard, JM				Plet, A; Huet, X; Algarte, M; Rech, J; Imbert, J; Philips, A; Blanchard, JM			Relief of cyclin A gene transcriptional inhibition during activation of human primary T lymphocytes via CD2 and CD28 adhesion molecules	ONCOGENE			English	Article						cyclin A; primary T lymphocytes adhesion	DNA-BINDING ACTIVITY; CELL-CYCLE; A GENE; RETINOBLASTOMA PROTEIN; S-PHASE; EXPRESSION; KINASE; REPLICATION; FAMILY; E2F	Cyclin A transcription is cell cycle regulated and induced by cell proliferative signals. To understand the mechanisms underlined in this regulation in normal human cells, we have analysed in vivo protein-DNA interactions at the Cyclin A locus in primary T lymphocytes. Stimulation of purified T lymphocytes by a combination of monoclonal antibodies directed at CD2 and CD28 adhesion molecules gives rise to a long lasting proliferation in the absence of accessory cells. Cyclin A was observed after 4 days of costimulation with anti CD2+ CD28 whereas stimulation by anti CD2 or anti CD28 alone was not effective. In vivo genomic DMS footprinting revealed upstream of the major transcription initiation sites, the presence of at least three protein binding sites, two of which were constitutively occupied. They bind in vitro respectively ATF-1 and NF-Y proteins. The third site was occupied in quiescent cells or in cells stimulated by anti CD2 or anti CD28 alone. The mitogenic combination of anti CD2+ anti CD28 released the footprint as cells were committed to proliferation. Consistent with theses results, nuclear extracts prepared from quiescent cells formed a specific complex with this element, whereas extracts prepared from cells treated with anti CD2+ anti CD28 failed to do so after cells entered-a proliferative state.	CNRS, UMR 5535, INST GENET MOL MONTPELLIER, F-34033 MONTPELLIER 1, FRANCE; INSERM, U119, F-13009 MARSEILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)			Imbert, Jean/G-3248-2013; Imbert, Jean/AAG-1165-2020; PHILIPS, Alexandre/AAB-6047-2020	Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; 				ALGARTE M, 1995, EMBO J, V14, P5060, DOI 10.1002/j.1460-2075.1995.tb00188.x; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CERDAN C, 1991, J IMMUNOL, V146, P560; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HORI T, 1987, BLOOD, V70, P1069; Huet X, 1996, MOL CELL BIOL, V16, P3789; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; NEVINS JR, 1992, SCIENCE, V258, P424; OLIVE D, 1994, FUND CLIN IMMUNOL, V2, P185; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER RA, 1995, CELL, V354, P314; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	41	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2575	2583		10.1038/sj.onc.1201103	http://dx.doi.org/10.1038/sj.onc.1201103			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191057				2022-12-25	WOS:A1997XA94900009
